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Allergic diseases are still steadily  rising and affecting a large number of individuals who are also 
facing an overall worsening of their clinical manifestations at any point during their life-time.
Many children suffer from severe food allergy and anaphylaxis, many adolescents and young adults 
are underperforming due to asthma and allergic rhinitis and many adults are missing work due 
to co-morbidities of allergic diseases.  Allergy is currently a public health issue although hugely 
underestimated and under -recognized. There is a need to improve the care of allergic patients 
through better education of health professionals and the public. As part of its Mission the European 
Academy of Allergy and Clinical Immunology –EAACI has started a project aimed to translate best 
knowledge into best practice. Atlases and Guidelines represent a comprehensive set of documents 
that are distributed for improving appraisal and proper management of allergy. 
This User’s Guide for Molecular Allergology will be another breakthrough in this regard.
Recombinant technology in the field of allergology has brought tremendous advances in allergen 
characterization as well as in the knowledge of immune mechanisms involved in allergic diseases. 
Molecular allergology takes diagnostics one-step further. It can enable you to get better perspectives 
on the risk connected with sensitization. Sensitization to the components is measured individually 
helping to pinpoint on an exact molecular level which component the patient is sensitized to. In 
light of this, allergen extracts are being step-by-step replaced by molecule-based products. The 
new developments will allow clinicians to obtain detailed information on sensitization patterns 
and more accurate interpretation of allergic symptoms.  This information provides the basis for 
a refined , earlier ,  diagnosis of the allergic reactions and ultimately for a tailored individualized 
management of the patient, including opportunities for prevention.
In this regard, molecular allergology is a further, excellent example of how allergy is linked to 
precision medicine and drives precision health forward. 
Moreover, this book is also the culmination of the EAACI spirit of team working. It comes from an 
outstanding effort from many: the EAACI Board of Officers, the Executive Committee and the 100 
contributors who have volunteered in this activity to get it finalized. Without their enthusiasm and 
continuous support this achievement would not have been accomplished. 
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Preface from the EAACI President
However, a special thank you must go to the leadership of the Interest Group of Allergy Diagnosis, 
Paolo Matricardi, Hans-Jurgen Hoffman, Markus Ollert, Jorg Kleine –Tebbe, Rudolph Valenta. They 
have been the key drivers of the initiative and their vision and commitment has helped in tackling 
many issues.
This User’s guide is supposed to be a straightforward guide on molecular allergology describing 
what are components, the clinical benefits of testing for components as well as how to interpret 
results including understanding cross-reactions. Our hope is that it will be an essential daily pocket 
guide for allergists and for all those health professionals who are dealing everyday with allergic 
patients 
I am confident that the dissemination of this User’s Guide will positively impact the perception of 
allergy at the global level changing significantly the approach to patients world-wide.
Antonella Muraro
President of the European Academy of Allergy and Clinical Immunology-EAACI
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Allergology is experiencing a technological revolution, which is transforming into a rapid clinical 
practice “evolution”.  Our knowledge as “traditional” allergists, inherited since the first years of 1900, 
is progressively challenged by new concepts. Our tools, based on sometimes poorly standardized 
and highly variable allergenic preparations, become clearly defined and allow more analyses in 
depth. Similar to other areas of Medicine, these changes are facilitated by a new era of biosiences 
and technologies, including advanced molecular and structural biology. This process is part of 
a broader concept, coined “Precision Medicine” promoting personalized treatments based on a 
detailed patient’s disease phenotype. Thanks to this technological revolution, a growing number 
of allergenic molecules and their isoforms have been purified, sequenced, cloned, and produced 
in large quantities. They allowed to study the immunological reactivity of these molecules, their 
degree of cross-reactivity and to define complex IgE repertoires. New diagnostic methods have 
been made available for clinicians and improved therapeutic strategies will be further developed 
in the future. 
The results of these studies are regularly published in medical journals with high impact factors. Up 
to now more than one thousand molecules from diverse allergen sources have been characterized; 
many others will be identified, purified and cloned in the future. Over 100 of these molecules have 
already been developed as diagnostic reagents for routine use in clinical practice.  Many more will 
be introduced not far from today. Altogether, this knowledge has created a new branch establishing 
novel “allergomics” or “allergologic proteomics”. The main information on physico-chemical and 
biological features of allergenic molecules, their sources, abundance, regional distribution and 
nomenclature are accessible in several web-based databanks. Symposia and Congresses are 
nowadays providing and promoting exiting topics regarding Molecular Allergology. 
However, this “scientific revolution” has not yet fully translated into an improved management of 
the allergic patient. The main reason for this “gap” between science and routine clinical practice is 
in part the complexity of the new subject, hampering instant utilization and interpretation of these 
new diagnostic tools by an average physician. Based on this scientific revolution in allergy practice, 
the medical education programs as well as the training programs for allergy specialists should be 
re-written and adapted accordingly.
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Nevertheless, molecular tests are already available and clinicians need guidance for proper use. 
For this purpose, the EAACI has established a Task Force to compose a handbook on molecular 
allergology for clinicians. This document will introduce the current position of the EAACI on in 
vitro methods of Molecular Allergology, their advantages and limitations and how they can be 
used in an up-to-date diagnostic work-up of the allergic patients. With this perspective, most 
immediate hypersensitivity reactions and allergic diseases are taken into account, including allergic 
rhinoconjunctivitis and asthma to pollens, mites and other airborne allergens, food allergies, atopic 
eczema, insect venom hypersensitivity and occupational allergies. For each of these diseases the 
most important allergenic molecules and their potential role in our diagnostic work-up will be 
discussed, providing a unique EAACI position on their current use.  Molecular Allergology is rapidly 
evolving. Therefore this text will regularly be updated, approximately every three years, to monitor 
technological and scientific progress, as well as new evidence coming from clinical studies.
The idea of a Task Force on Molecular Allergology was originally proposed in 2011 by Dr Adriano 
Mari, a visionary initiator in this field, and then re-vitalized by Markus Ollert and Paolo Matricardi. 
The goal of a handbook has been established after an constructive and articulate debate within 
the EAACI. The workplan has been further shaped during a meeting in London in November 2014 
among the five editors. More than 50 authors from over 15 countries and five continents have 
drafted the 40 chapters composing this first edition of the Handbook. These drafts have been 
discussed in a three day workshop in Berlin (15-17 April 2015) and further elaborated by their 
contributors. A long reviewing process has involved all the authors and, at a second stage, six 
additional reviewers that had not participated in the Berlin meeting. The final draft of the text 
has subsequently been presented to the EAACI Executive Committee, approved and released for 
publication. 
We are all grateful to the former EAACI President Nikos Papadopoulos (2013-2015), who has 
moderated and guided our initiative during its infancy including delicate debates on the proper 
orientation and structure of the Handbook. We also thank our current EAACI President Antonella 
Muraro, who has not only contributed as an author, but has strongly supported our Task Force 
activities. The Handbook would have never been produced without the constant assistance of 
Dr. Stephanie Hofmaier, who has not only contributed to the scientific content of the Handbook 
(PART-D, appendices), but also coordinated the Berlin team in the organization of meetings, 
telephone conferences and the long and difficult peer-reviewing and publication process. We are 
also particularly grateful to Dr. Christiane Hilger who has not only contributed various chapters 
of the User´s Guide, but has also provided clear examples of the editorial style with her first 
contribution, being followed by many other authors. Last but not least we are of course grateful 
to all the authors, opinion leaders in their own area, who have all enthusiastically accepted to 
join us in this ambitious project and have dedicated so much of their time to share, discuss and 
elaborate their knowledge and expertise in such a broad area. We do really hope that this group 
of experts will continue to work together in the next years to develop updates of the Handbook, 
to transform it into a novel informatics platform, to foster translation in several languages and to 
develop didactic tools for the dissemination of this new tool for doctors and their patients.  
Paolo Maria Matricardi
Jörg Kleine-Tebbe
Hans Jürgen Hoffmann
Rudolf Valenta
Markus Ollert
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The transition from allergen extracts to 
molecules for the diagnostic work-up of 
IgE mediated reactions/diseases has great 
potential, but requires detailed knowledge 
and intelligent interpretation
Diagnostic algorithms traditionally start 
with the history (“top-down”), followed by 
skin tests, then IgE assays adding allergen 
molecules for “component-resolved 
diagnosis” (CRD)
Novel diagnostics invert the test order 
(“bottom-up”) and start with a multiplex 
(i.e. microarray-based) IgE assay and many 
components. Then the history is reviewed 
for concordance to establish a broad CRD
Combining both strategies, “top-down” and 
“bottom-up”, creates a “U-shaped” sequence. 
Traditional diagnostic work-up can thus be 
expanded by a broad screening for IgE-binding 
molecules unfolding missing details and 
feeding back to a molecular allergy diagnosis 
Immunoglobulin E (IgE) antibodies are both a marker 
and major contributor in immediate hypersensitivity 
reactions and atopic diseases (1). Since the late sixties 
serological tests for allergen-specific IgE antibodies 
were used to identify triggers of IgE-mediated allergic 
symptoms (2). Notably, the composition and amount 
of an allergenic extract strongly affects the result of 
traditional extract-based IgE assays (3). Therefore, 
IgE assays produced by different companies generate 
often various quantitative levels and sometimes 
nonconcordant qualitative results (positive versus 
negative).
The following rationales support the targeted use 
of allergen molecules and improve test properties: 
(I) increased test sensitivity (“analytical sensitivity”), 
particularly when important allergens are under-
represented or lacking in the extract; (II) improved 
test selectivity (analytical specificity), particularly 
when the selected IgE repertoire against an allergen 
yields additional information on: (a) potential 
risks, (b) possible cross-reactivity, or (c) primary 
(species-specific) sensitization. Allergen-specific 
IgE tests utilizing individual allergenic molecules 
are subsequently considered a more precise and 
informative option, particularly in polysensitized 
A01
Paolo Matricardi, Jörg Kleine-Tebbe, Hans 
Jürgen Hoffmann, Rudolf Valenta, Markus 
Ollert
ALLERGOLOGY 
FROM EXTRACTS 
TO MOLECULES: 
INTEGRATING 
TRADITION WITH 
INNOVATION
 EAACI Molecular Allergology User´s GuideEAACI Molecular Allergology User´s Guide2016 Part  A:  Molecular Al lergology:  General  Concepts
4 Allergology from extracts to molecules: integrating tradition with innovation
patients compared to those tests based on allergenic 
extracts (4). A growing spectrum of molecules, 
representing single allergens of clinical relevance 
have been identified, characterized and produced for 
commercial in vitro assays. This “component resolved 
diagnosis” (CRD) thus allows a detailed molecular 
profiling of the polyclonal IgE repertoire of the 
allergic patient (5).
CRD is pushing Allergology in the coming Era of 
“Precision Medicine”, an approach integrating novel 
individual genetic or molecular data for improved 
geno-/phenotyping and proper selection of personal 
treatments (6). Accordingly, the need of learning 
to handle and interpret “allergomics” data is a true 
challenge for the practicing allergist (7). Several 
databases of allergenic molecules and advanced web-
platforms are already available for this purpose (8).
The list of important allergenic molecules, cloned 
or purified and introduced for diagnostic purposes, 
is still incomplete. Moreover, the costs of IgE assays 
using individual allergens are about 10% higher 
compared to extract-based tests; microarrayed 
multiple allergenic molecules will produce even 
higher costs. It is therefore conceivable that the use 
of molecular assays in allergology will be balanced 
by a general need of careful stewarding the scarce 
resources of public health systems (9). This may be 
particular relevant for IgE microarrays testing of more 
than 100 individual allergenic molecules in a single 
analysis (10). In other words, “Precision Allergology” 
will progressively grow, but confined in a “Choosing 
Wisely” scenario. Given these premises, both, the 
in vitro IgE assays based on allergenic extracts and 
those based on allergenic molecules, will probably 
co-exist in clinical practice for many years to come.
DISCREPANCIES BETWEEN ALLERGEN 
EXTRACT AND ALLERGEN MOLECULE- 
BASED IGE ASSAY RESULTS (11)*
The coexistence of two laboratory strategies to 
test serum IgE antibodies to allergens (extracts 
vs molecules) will inevitably lead to discrepancies 
between their outcomes. In an ideal world, a “positive” 
IgE-extract assay result should always be paralleled by 
a “positive” outcome in one or more of the IgE assays 
utilizing the extract’s individual molecules. Similarly, a 
“negative” IgE-extract assay should always correspond 
to “negative” outcomes in molecular based IgE assays 
covering all the extract’s components.
Nonconcordant outcomes among extract- and 
molecular-based IgE assays can have several 
characteristics and explanations (Table 1):
A. Allergen extract positive but its molecules negative 
- The serum IgE antibodies might recognize one/
several particular molecules in the extract, which 
is/are simply not available in corresponding 
molecular assay/s. Another explanation would 
be a lower Limit of Quantitation (LoQ) of the 
extract assay compared to the molecular one in 
case of rather low specific IgE levels. In other 
words, the serum IgE antibodies levels to the 
implicated molecules could be below the LoQ 
of the molecular-assay but above the LoQ of the 
extract-assay.
B. Allergen extract negative but its molecules 
positive - The serum might carry IgE to 
components recognized in a molecular assay, but 
missing or underrepresented in the corresponding 
allergen extract. The same discrepancy can also 
be explained if the extract assay is analytically 
less sensitive (higher LoQ) than the molecular 
one and specific IgE levels are low. In other 
words, the level of serum IgE antibodies to the 
implicated molecules could be above the LoQ of 
the molecular-assay but below the LoQ of the 
extract-assay.
C. Allergen extract positive but its genuine 
components are negative - In this case the serum’s 
IgE might recognize only minor, highly cross-
reactive components of an allergenic extract, 
but not its genuine, species-specific (major) 
components. Patients sensitized to panallergens 
frequently show positive IgE results to many 
different allergenic extracts containing a member 
of that highly cross-reactive family and falsely 
appear to be highly “polysensitised”. Similarly, 
patients sensitized to cross-reactiv carbohydrate 
determinants (CCD) only, show positive result 
to extracts but not to corresponding molecules 
produced as recombinant proteins lacking 
posttranslational modifications like CCDs.
D. Allergen extract less positive than the added 
molecular assay levels - The level of serum IgE to 
(*this paragraph is reprinted with permission from the publisher 
from: Matricardi PM, Kleine-Tebbe J. Molecular Allergology between 
Precision Medicine and the Choosing Wisely initiative. Clin Exp Allergy 
2016; in press.)
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an allergenic extract could be much lower than the 
sum of the IgE levels to all its components. Extracts-
based IgE assays tend to underestimate the IgE 
levels of highly sensitized patients, as they might 
miss or contain only limited amounts of particular 
molecules recognized by the patient’s IgE. As a 
consequence, the sum of IgE levels obtained by 
testing individual molecules is often higher than 
the level measured by testing the corresponding 
allergenic extract. An additional explanation 
is potential (partial) cross-reactivity between 
structurally non-related allergens (i.e. Ara h 1, 2 
and 3) from different protein families, leading to 
arbitrarily high sum values after adding molecular 
assay results in comparison to the extract result.
In summary, studying discrepancies between 
outcomes of allergen extract-based vs molecular 
IgE assays is of crucial relevance for improving our 
capability to screen for IgE sensitizations in allergic 
patients with high precision in a cost-effective way, 
as recently reviewed elsewhere (6). In other words, 
the use of “customized”, properly balanced selection 
of allergenic molecules in IgE assays will be a valuable 
compromise between “tradition” and “modernity” in 
serological in vitro allergy testing and the best strategy 
to harmonize “Precision Medicine” with a “Choosing 
Wisely” approach in the field of allergology.
INTEGRATING TRADITION AND 
INNOVATION: EXTRACTS AND MOLECULES
How should a molecular approach be integrated in the 
diagnostic work-up of the allergic patient? There is no 
conclusive answer to this question. New technologies 
require years before being fully integrated in the routine 
clinical practice. Moreover, only daily clinical practice 
can ultimately disclose their advantages and limitations 
in different settings. Currently, doctors practicing a 
molecular approach as part of their allergy diagnosis can 
be roughly divided into those pursuing an integration of 
allergy molecular tests in a traditional diagnostic work-
up which includes the use of allergen extracts, and 
those that prefer to generally omit the use of allergenic 
extracts and conceive a systematic molecular diagnosis. 
The first ones privilege the use of singleplex tests, i.e. 
an inductive method based on the doctor´s choice 
which allergen should be used. This approach has been 
termed ”TOP-DOWN” diagnostic approach, including 
first clinical history with SPT or IgE assays to extracts 
and then the molecular step. The others prefer to use 
microarrays providing a broad and analytical vision 
of the sensitization profile of the patient. This can be 
defined as ”BOTTOM-UP” approach, moving from 
a microarray test to the clinical history (Fig. 1). In the 
following section seven arguments for the first and the 
second approach are listed:
Table 1
Discrepancies between allergen extract and allergen molecular IgE assay results
Extracts Molecular Explanations
Absolute Disagreement (qualitative differences)
A positive negative
a) serum IgE binds only to extract’s molecules that are not (yet) 
available in molecular assays;
b) molecular assays less analytically sensitive than the extract based 
assay
B negative positive
c) serum IgE binds to molecules tested as components which 
missing or of low abundance in the extract;
d) extract assay less analytically sensitive than the molecular assay
Relative Disagreement (quantitative differences)
C positive negative to major components
serum IgE binds only to highly cross reactive, minor allergenic 
molecules or CCD determinants
D lower levels higher levels serum IgE binds to molecules tested as components being of low abundance in the extract
modified from (11) with permission
 EAACI Molecular Allergology User´s GuideEAACI Molecular Allergology User´s Guide2016 Part  A:  Molecular Al lergology:  General  Concepts
6 Allergology from extracts to molecules: integrating tradition with innovation
Arguments raised pro a TOP-DOWN approach 
or against a BOTTOM-UP approach.
1. Extracts are essential screening tools that most 
doctors are accustomed to; they cannot be 
removed as routine diagnostics since doctors 
would loose basic tools for proper allergy work-up.
2. Microarrays are too complex and detailed; 
doctors are not yet prepared to interpret them 
properly.
3. Microarrays offer useful information – if linked to 
individual clinical symptoms - but also information 
on sensitizations not being linked to any symptoms. 
This extra information can generate conceptual, 
ethical and legal problems and it is difficult to be 
communicated to the patient.
4. The use of individually selected reagents, 
covering extracts and molecules for testing, 
facilitates the use of the singleplex approach to 
molecular diagnosis, which is inductive and less 
expensive than the use of microarrays.
5. Extract-based reagents contain more molecules 
than those included in a microarray or in 
catalogues for singleplex tests. Some of these 
missing molecules are essential for a diagnosis.
6. SPT based on extracts offer information on 
biological function of IgE antibodies, not only 
their presence/absence.
7. Degranulating cells in polysensitized patients (the 
vast majority) react to complex protein mixtures 
in the allergen extract and not only to individual 
molecules.
Arguments raised pro a BOTTOM-UP approach 
or against a TOP-DOWN approach
1. Patients should be examined with a multiplexed 
approach (microarray) to get a global evaluation 
of their individual IgE repertoire
2. Any step or approach using extracts is outdated 
and unreliable, because extracts are not always 
properly characterized and standardized; different 
extracts tend to give different results leading to 
different decisions in the same patients.
3. Patients should be examined with a multiplexed 
approach (microarray) for a global evaluation of 
the entire sensitization profile, then the physician 
should properly address the clinical history, and 
make a comprehensive evaluation of the atopic 
conditions.
4. Positive results in a microarray, even if not 
clinically relevant at present, may predict future 
allergic symptoms.
5. The bottom-up approach, performed with a 
microarray, would reduce the number of contacts 
patient-doctor-lab while a singleplex ”reflex” 
approach would require several consultations 
(and therefore higher costs) before all the 
molecules relevant for a final diagnosis are tested.
6. Broader use of microarrays will induce 
companies to reduce the prices in view of a 
broader distribution and increase the likelihood 
of reimbursement from insurance companies and 
public health systems.
7. The resistance of allergists to the progress of 
molecular allergology, which may reduce their 
earnings based on SPT, should be overcome.
THE EAACI PROPOSAL: A ”U-SHAPED” 
APPROACH
The debate between the two diagnostic approaches 
to molecular allergology is still open. Nevertheless, 
the Task Force of EAACI suggests to integrate both of 
them in a so called “U-SHAPED” approach (Fig. 1). The 
patient undergoes, as in usual care, clinical history, 
physical examination, skin test or IgE assay with 
extracts and selected molecules, chosen according 
to the clinical history and results of the tests with 
extracts. Then IgE responses to allergenic molecules 
of those allergen sources to which clinical relevant 
sensitizations have been detected by the previous 
two diagnostic steps [“top-down” approach (part II)]. 
In some patients, IgE sensitization to highly cross-
reacting molecules belonging to the allergenic source 
may have been demonstrated. Here comes the advice 
of further investigating the patient for potential 
clinical consequences of cross-reactive sensitization: 
(1) by testing IgE sensitization to other molecules of 
the same family, but limited cross-reactivity (i.e. seed 
storage proteins); (2) by expanding the clinical history 
with questions related to symptoms triggered by 
other allergen sources containing the other molecules 
of the same family [“bottom-up” approach (part III)]. 
Arguments in favour of this “U-SHAPED” approach 
are listed below:
1. An ”exclusive” bottom-up approach would not be 
cost-effective. In addition, the microarray test is 
not reimbursed in most countries. The bottom-
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Figure 1
The combined “U-shaped” approach. 
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(e.g. LTP) with potentially no clinical relevance (e.g. 
in south Europe) but always tested in a microarray, 
independently from the patient’s diagnostic 
question. The handling of occasional or bystander 
results in medicine (e.g. those obtained in total 
body CT or NMR) is always difficult.
THE HANDBOOK OF MOLECULAR 
ALLERGOLOGY: GENERAL CONCEPTS, 
ALLERGEN SOURCES, AND ALLERGEN 
FAMILIES
In keeping with the concepts expressed above, the 
Handbook is divided in three parts:
up approach, based on a microarray, is a visionary 
one, but only the traditional diagnostic algorithm 
using extracts and singleplex approach is the one 
presently reimbursed.
2. Most doctors will continue using extracts and 
working with a top-down approach. A subsequent 
”U-shaped” approach should make molecular 
allergolgy accessible to more allergists and not 
only to the very few ”enthusiasts” of molecular 
allergology and microarrays.
3. The new way of thinking should be introduced 
step-by-step. The use of microarrays will become 
easier after doctors have learnt to use individual 
molecules (singleplex).
4. We should prevent the legal/QoL problems 
generated by knowing sensitization to molecules 
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A INTRODUCTION TO MOLECULAR 
ALLERGOLOGY – this part is dedicated to 
introduce the reader to basic scientific and 
clinical concepts of molecular allergology. 
Five sections describe (A02) the major 
properties of an allergenic molecule, including 
structural characteristics; biological functions; 
immunological and allergenic features are 
described; (A03) the use of a molecular approach 
in the clinical practice; (A04) the essentials 
of in vitro IgE assays and the most important 
performance characteristics and parameters 
of reliability; specific features, advantages and 
limitations, of singleplex assays and multiplex 
assay; (A05) how information obtained with skin 
prick tests, challenge tests and basophil activation 
tests can be interpreted in the framework of a 
molecular approach to allergy diagnosis and 
(A06) the concept of cross-reactivity and how 
the complex diversity of shapes are shared at 
different degrees by molecules belonging to 
similar or unrelated species (allergen families).
B MOLECULAR DIAGNOSIS BY ALLERGENIC 
SOURCE – This part describes systematically 
how to use and integrate a molecular assay in a 
classical allergy diagnostic work-up, which starts 
with clinical history, physical examination and 
extract-based assays. 23 Sections (B01-B23) 
are dedicated to all major allergenic sources, 
including pollens, mites and cockroaches, animals, 
molds, occupational allergens, major food 
allergens, insect venoms. In each section, general 
information on the characteristics of the allergen 
source: nature, classification, allergenic tissues, 
cross-reacting species, exposure, are given as in a 
“traditional” textbook. Then some characteristics 
of major and relevant minor allergenic molecules 
are described (e.g. MW, functions, biochemical 
properties, localization, isoforms, etc).
The clinical relevance of a sensitization to 
individual molecules is discussed providing 
information on
  the frequency and intensity of IgE 
sensitizations,
  the potential role in triggering and shaping 
the patient´s symptoms, and
  the relevance for prognosis or response to 
therapy.
When appropriate, a diagnostic algorithm is 
proposed by the authors, i.e. when a patient is 
consistently positive to the allergenic source. 
These diagnostic algorithms are also based on 
expert opinion and not necessarily backed up by 
various studies or meta-analyses. They can be 
useful to orient the doctor in the use of molecular 
diagnostic tests but they are not intended to 
provide a fixed, rigid approach to diagnosis. One 
or more index clinical cases are then presented 
to provide examples of how molecular diagnosis 
may help understanding the patient’s allergy and 
assist clinical decisions.
C FAMILIES OF HIGHLY CROSS-REACTIVE 
MOLECULES – This part is dedicated to present 
major allergen families, their clinical relevance 
and how to use this information to improve 
the management of the allergic patient in the 
daily clinical practice. The families taken into 
consideration are: Profilins, PR-10-like molecules, 
nsLTP, Serum Albumins, Tropomysins, Polcalcins, 
Lipocalins, Parvalbumins (section C01-C08). 
Each section describes features of members from 
that protein family: MW, functions, biochemical 
characteristics, distribution, tertiary structure; a 
list of major members of the family is given, with 
the range of homogeneity, and a phylogenetic 
tree. When appropriate, the routes of exposure, 
the symptoms triggered, aggravating and 
protecting features, cofactors, frequency, 
epidemiology of sensitization are also discussed. 
Then the impact of sensitization to members of 
the allergen family is discussed with the respect 
to clinical decision and the management of the 
patient. Finally, one or more index clinical cases 
are then presented to provide examples of how 
molecular diagnosis may help understanding the 
patient’s allergy and assist clinical decisions.
D APPENDICES – Four appendixes are given at the 
end oft he text, including a list summarizing the 
characteristics of 100 relevant allergenic molecules 
(“the “100 VIM”, [D01]) and a list of a few definitions, 
which are relevant especially for molecular in vitro 
diagnostic tests (“Glossary” [D02]).
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A02
Many different types of proteins are 
allergenic.
The context of a protein may be a major 
determinant for its allergenicity.
Some IgE inducers are not really allergens at 
all because they don’t induce symptoms. This 
negatively impacts specificity of diagnostic 
tests, certainly of extract-based tests but 
also still of molecular tests.
Allergen extracts are imperfect but not yet 
obsolete.
Molecular sensitization profiles: potential 
biomarkers for disease phenotypes and 
progression
The initial response to an allergen source is 
possibly characterized by IgE antibodies to 
one or two “initiator” allergens.
Allergenic sources can vary from biological sources 
with very complex composition such as pollen, house 
dust mites (inhalant allergy) or foods (food allergy), 
to single molecules such as chemicals (occupational 
allergy) or drugs (drug allergy). In this chapter we will 
focus on the molecular composition of more complex 
biological allergen sources that are implicated in 
causing hay fever, allergic asthma and food allergy. 
Around the late sixties and early seventies of last 
century the first reports were published in which 
individual molecules were identified that were 
responsible for binding IgE within different allergen 
sources such as grass pollen (1), ragweed pollen (2), 
cod fish (3) and house dust mite (4). By now probably 
the most important allergens of the most relevant 
allergen sources have been identified (www.allergen.
org; www.allergenonline.org; www.allergome.org).
Before we can discuss the allergens, we have to 
introduce the nomenclature of molecularly defined 
allergens (Textbox 1).
Ronald van Ree, Rob C. Aalberse
ALLERGENS AND 
THE ALLERGENIC 
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WHAT IS AN ALLERGEN?
The broadest definition of an allergen is that it is 
any molecule that binds IgE antibodies (7). Allergens 
can differ in several ways (Textboxes 2 and 3). In this 
introduction, the practical consequences of four of 
these differences will be discussed.
SENSITIZING VERSUS NON-SENSITIZING 
ALLERGENS
Most, but not all, allergens are sensitizing which is 
defined as the ability to induce allergen-specific IgE 
antibodies. Non-sensitizing allergens can only cause 
allergic symptoms if previous contact with a related 
(cross-reactive) allergen has caused sensitization. A 
prototypic example of a sensitizer is birch allergen 
Bet v 1 and a cross-reactive non-sensitizer is the 
homologous apple allergen Mal d 1 (8).
AIRBORNE VERSUS FOOD ALLERGENS: 
CROSSING DIFFERENT BARRIERS
The two most common sites of entry into the body 
are the mucosal surfaces of the airways in which the 
allergen is delivered as part of an airborne particle 
or aerosol droplet and the digestive tract which 
includes the oral cavity where it is introduced as part 
of a food or drink (Textbox 4). Also the skin has been 
proposed as a route for sensitization, a hypothesis 
that gained significance since the discovery of 
filaggrin SNPs associated the development of allergy. 
Prototypic examples of true food allergens include 
the shrimp muscle protein tropomyosin that varies in 
nomenclature depending on the type of shrimp (Pen 
a 1, Cra c 1, Met e 1, Lit v 1 etc). All these are highly 
cross-reactive allergens, see the official IUIS website 
[www.allergen.org] or the Allergome website [www.
Textbox 1
Allergen nomenclature
Allergen names are based on the scientific (Latin) 
name of the plant or animal species from which the 
allergen originates (5, 6). For example, the major 
allergen from birch pollen Bet v 1 is named after 
the scientific name of the tree Betula verrucosa, in 
which Betula is the genus and verrucosa the spe-
cies. The first three letters of the genus (Bet) and 
the first letter of the species (v) together form the 
basis of the allergen name, followed by a number. In 
principle the number is given in order of discovery, 
so Bet v 1 was the first allergen from birch pollen 
that was discovered. Related (often cross-reactive) 
allergens from different species, genus, family or 
even order, get the same number, if still available. 
So, the homologue of Bet v 1 in hazel is Cor a 1 and 
in apple is Mal d 1, but in peanut is Ara h 8 because 
numbers 1 to 7 were already occupied by peanut 
allergens described earlier.
Many allergens have molecular variants (isoforms). 
One example is Cor a 1. One isoform is mainly 
found in hazel pollen (Cor a 1.01), the other main-
ly in hazelnut (Cor a 1.04). Some isoforms are so 
closely related (>90% sequence identity) that they 
can usually be considered identical. If they need to 
be distinguished, two more digits are added to the 
name, e.g. Cor a 1.0101 and Cor a 1.0102.
Textbox 2
The long road from allergen-coding DNA to a mol-
ecule interacting with IgE on the mast cell surface
Much of our information on allergen structure comes 
from proteins that are produced with recombinant 
DNA technologies (conveniently, but scientifically 
incorrectly, referred to as “recombinant allergens”). 
Most currently available recombinant allergens are 
prepared based on a direct translation of their ge-
nomic information. In the real world, the allergen 
that is knocking at the mast cell’s door is often mod-
ified. Some of the modifications are well-character-
ized intra-cellular biochemical processes known as 
co-translational or post-translational modifications, 
such as homo-and hetero-oligomerization, glyco-
sylation, cleavage of a leader peptide, propeptide 
and other proteolytic events, binding of metallic 
cofactors or organic ligands and oxidation of pro-
line to hydroxyproline. Others are due to more 
random extracellular processes often influenced 
by environmental conditions (humidity, UV, ozone). 
Examples are nitration, methionine oxidation, de-
amidation and cross-linking by transglutaminases 
and glycation (a non-enzymatic process also known 
as the Maillard reaction). Upon water loss, excret-
ed proteins attach to various substrates, both on 
a nano-scale (homo- and hetero-aggregation) and 
on a micro-scale (attachment to fibers and dusty 
particles). The effect of these modifications of the 
structure of the allergen on allergenicity has only 
just started to be investigated (9).
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allergome.org]); other invertebrate allergens, such 
as hemocyanin and hemoglobin, are more likely to 
sensitize via the airways or via skin contact in an 
occupational setting (seafood preparation, fish food 
production) (14).
INITIATOR ALLERGENS VERSUS SECONDARY 
RESPONDING ALLERGENS
The initial response to an allergen source is 
possibly characterized by IgE antibodies to one or 
two “initiator” allergens, which tend to dominate 
the subsequent more complex IgE response to 
the allergen source in question. It is therefore an 
attractive hypothesis that within an allergen source 
some allergens are more important than others. It 
might be tempting to call these “major” allergens, 
but traditionally, an allergen is referred to as “major” 
if it is recognized by >50% of the patients that are 
sensitized to the source (Textbox 5). Not all these 
“major” allergens seem to act as “initiator” allergens.
Textbox 3
The exception: some allergens are NOT proteins
Examples of non-protein allergens are drugs such as penicillin, chlorhexidine and other pharmacological com-
pounds such as rocuronium. It is generally assumed that these compounds depend for their allergenicity on a 
strong (covalent) interaction with a carrier protein, but this has not always been demonstrated convincingly. 
One explanation might be that a metabolite is the allergologically active substance.
The above-mentioned allergic drug-protein complexes are often referred to as hapten-carrier complexes. Sub-
stances other than pharmacological compounds can also act as hapten. An important category of hapten-like 
structures are naturally occurring chains of simple sugars, referred to as glycans. The role of glycans as IgE-reac-
tive structure is a source of some confusion. It is generally assumed that pure glycans are unable to induce IgE 
antibodies. This fits with the general scheme of IgE antibody production as a process that depends on signals 
provided by TH2 cells, as described above. Classical MHC-II molecules are very efficient at interacting with 
peptides, but are unable to combine with pure glycans. However, for glycans coupled to a protein carrier, the 
situation is different. The cell-anchored antibody on some B cells can interact with the glycan. These B cells 
bind the glycoprotein via the antibody-glycan interaction. Next, the B cell ingests and digests the glycoprotein 
and presents the peptides in its MHCII to the T cell. The T cell receptor interacts with the peptide-MHC-II 
complex on the B cell, which results in activation of the T cell. The T cell activates the B cell, which results in 
differentiation of the B cell to an antibody-secreting plasma cell. The important point is that the conventional 
TH2 cell does not recognize the glycan and yet it can induce the B cell to produce anti-glycan antibodies. It is 
possible that glycans can be allergenic not only as glycoprotein, but also as glycolipid, potentially via sources of 
IL-4 other than TH2 cells. This is presumably mostly relevant for immune responses to invertebrate parasites 
such as helminths and ticks.
Two prototypic glycans with well-established IgE-binding activity are known as CCD (10) and the alpha-Gal epi-
tope (11). CCD (cross-reactive carbohydrate determinant) refers to a group of related glycans that are character-
ized by a fucose and/or a xylose that are linked in a specific way to the core of the glycan. Such glycans are pro-
duced by invertebrates and plants, but not by vertebrates. Because of the widespread presence of such structures 
in plant foods, patients with such IgE antibodies demonstrate cross-reactivity to virtually all plant foods (12). In 
contrast, alpha-Gal (in full: the Gal-α1-3Gal-β1-3GlcNAc epitope) is produced by non-primate mammals, but not 
by humans. This structure, now commonly referred to as alpha-Gal, has been associated with allergy to red meat. 
For yet unknown reasons, the onset of systemic (skin) symptoms observed upon consumption of meat is not im-
mediate but delayed. Where induction of IgE antibodies against CCD is thought to be driven by pollen exposure 
and/or insect stings, IgE antibodies against aGAL most likely occur in response to tick bites.
A convenient way to distinguish peptide-based epitopes from glycan-based epitopes is the use of proteolytic 
enzymes or glycan-destroying chemicals (periodate). Some IgE antibodies show dual recognition towards a 
glycoprotein allergen: their epitope consists of a combination of part of the glycan and part of the protein (13).
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relevant that some relatively innocuous sensitizers 
are associated with relatively high IgG/IgE ratios. 
A prototypic example is tetanus toxoid (15). The 
allergenic risk spectrum is further discussed below.
WHAT MAKES AN ANTIGEN AN ALLERGEN?
Some, but not all, antigens that pass through our 
epithelial barrier trigger an IgE response (Textbox 
6). There is an ongoing debate on the features of 
allergenic proteins (if any) that distinguish these from 
the more mundane, only IgG-inducing, antigens. It has 
been proposed that there are few restrictions on the 
properties of antigens that can induce IgE antibodies 
(6, 12). On the other hand, it has been argued that 
only a very restricted set of antigens has been found 
to induce IgE antibodies. This view has been promoted 
among others by Breiteneder et al. (16).
It is clear that many different types of proteins are 
allergenic. Some features are not an intrinsic to the 
protein itself, but rather a consequence of an extrinsic 
feature: the context of the protein. One such extrinsic 
feature is its introduction of the protein in the 
presence of bacterial cell wall components. If a protein 
enters our body as part of a bacterium, the cytokine 
response induced by this bacterial infection usually 
evokes the production of TH1-type cytokines (such 
as gamma interferon) that are needed to efficiently 
fight the infection. Gamma interferon prevents the 
INNOCENT VERSUS DANGEROUS 
ALLERGENS
As expected, a close association is often found 
between allergen exposure and allergic symptoms. 
However, for some sensitizers this association is very 
weak. Several factors may explain the position of an 
allergen in the allergenicity risk spectrum. In addition 
to all 3 above-mentioned features, it is presumably 
Textbox 4
Allergens have to get into our body to sensitize and 
to do harm
Allergenic proteins have to be in solution in order 
to get into our tissues, both for the sensitization 
phase (the interaction reaction with a profession-
al antigen-presenting cell, T cell and B cell) and for 
elicitation phase (the interaction with the IgE-anti-
body on the surface of the mast cell or basophilic 
leukocyte). For inhaled allergens the allergen will be 
attached to a particle (pollen grain, mold spore, mite 
fecal particle, a skin flake, hair, a textile fiber or a 
fluid droplet) The size of the allergen-carrying par-
ticle (typically 5-20 micron) is important, because 
this determines the most likely site of deposition 
(upper or lower airways). The allergen has to be re-
leased into the mucosal fluid to pass through the 
airway epithelial barrier. For this passage also a size 
limit exists. The diameter of a typical globular aller-
gen molecule is some 1000 times smaller than the 
allergen-carrying particle (2-10 nm, in molecular 
mass units: 5-50 kDa).
For food allergens the biophysical requirements for 
allergenicity are different in at least 2 ways. First-
ly food processing can substantially change the 
solubility of some proteins and in some cases also 
change allergenicity. In addition to the destructive 
effects of cooking on many allergens, another well-
known example is the loss of allergenicity following 
the mincing of apples, due to oxidative browning 
of apple polyphenols. This results in denaturation 
of apple proteins by the tannin-like structures. 
Secondly, the digestive system could increase al-
lergenicity by releasing small soluble allergenic 
fragments from poorly soluble conglomerates, or 
decrease allergenicity by more extensive fragmen-
tation. In addition to proteases, also the low pH in 
the stomach and the detergent action of bile salts 
are important in modifying the allergenicity of in-
gested proteins.
Textbox 5
What are major and minor allergens?
Officially a major allergen is an allergen that is 
recognized by IgE antibodies of > 50% of patients 
allergic to the allergen source. A minor allergen is 
recognized by by < 50% of the allergic population. 
Although the terminology “major” and “minor” may 
suggest major and minor clinical relevance, this is 
not necessarily automatically true. Some allergens 
may be recognized by > 50% of patients, but bind 
only a small fraction of the overall IgE response 
against the allergen source. However, in most cas-
es, major allergens bind a large fraction of the al-
lergen-source specific IgE and are (most likely) of 
dominant clinical importance. Most major allergens 
also occupy the lower numbers in the nomenclature 
system, simply because researchers tended to iden-
tify the most dominant allergens first.
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production of TH2-type cytokines (particularly IL-4) 
that are needed for the switch to IgE.
Regarding intrinsic features, the situation is not so 
clear-cut. While there is good evidence to support 
the claim that proteolytic activity may enhance the 
allergenicity of a protein (example: the mite allergen 
Der p 1), most allergens are not proteases. Some 
allergens have enzymatic activities that are unlikely to 
have an effect on human pathophysiology (example: 
pectinase activity of pollen allergens). Similarly, many 
allergens can bind small ligands, but the type of ligand 
varies considerably. It is not uncommon to find more 
than 10 different allergenic proteins in a single allergen 
source material (mite, pollen, peanut, shrimp etc).
It has been suggested that proteins that have close 
homologues to human proteins are intrinsically more 
likely to be allergenic. Proteins of the lipocalin family 
are taken as an example (17). It is clear that some 
proteins are more allergenic than others. Many factors 
are known that contribute to these differences, but 
prediction of the allergenicity (i.e. sensitization risk of 
a protein not cross-reactive with a known allergen) of 
a novel protein is as uncertain as next week’s weather 
forecast. The allergenicity debate will undoubtedly 
go on. From a practical point of view it is relevant 
that some source materials are more allergenic than 
others. Illustrative examples include allergens from 
cooked legumes that are less allergenic than those 
from roasted peanuts and the lipocalins from dogs 
(Can f 1, Can f 2 and Can f 4 as major allergens) are 
less allergenic than the major allergen from cats (Fel 
d 1), which is a NOT a lipocalin.
CLINICAL RELEVANCE OF INDIVIDUAL 
ALLERGENIC PROTEINS
Some inhalant allergen sources contain a single 
dominant major allergen. The clearest example is Bet 
v 1 in birch pollen, which is responsible for most of 
the IgE binding to the allergen source. For tree pollen 
allergic patients in Northwestern and Central Europe, 
Bet v 1 is of decisive clinical importance because there 
is no “competing” major allergen. In contrast, multiple 
major allergens have been described for grass pollen 
[i.e. group 1 (e.g. Phl p 1) and group 5 (e.g. Phl p 5)] 
and house dust mite [group 1 (e.g. Der p 1) and group 
2 (e.g. Der p 2)]. Currently, it is assumed that in these 
cases both allergens clinically play an important role. 
Whether individually they play a role in determining 
clinical phenotypes is still unknown. Future studies 
will have to elucidate whether specific molecules are 
associated with different clinical presentations such as 
allergic rhinitis or asthma, or with severity phenotypes.
For food allergy, individual allergen molecules have 
clearly been associated with both defined clinical 
phenotypes and the severity of allergic symptoms 
(20). There are three ways one can become allergic 
to a specific food, (a) by direct exposure to that food 
Textbox 6
Short introduction on the production of IgE anti-
bodies to conventional protein allergens
A cardinal feature of an allergen is the ability to in-
duce the production of IgE antibodies. The first step 
to initial IgE antibody production is the activation 
and expansion of naïve allergen-reactive IgM-pro-
ducing B cells. This process depends on the inter-
action between various cells (in particular dendritic 
antigen presenting cells and T helper cells) and the 
production of many cytokines.
IgE antibody production is a process that depends 
on signals provided by TH2 cells. Major Histocom-
patibility Complex-II or MHC-II molecules present 
peptides derived from the protein to TH2 cells. The 
T cell receptor interacts with the peptide-MHC-II 
complex, which results in activation of the T cell. 
This activated T cell can activate B cells, but only 
if these B cells have the same peptide in their 
surface-anchored MHC-II. In contrast to the anti-
gen-presenting cell, the B cell can only ingest an-
tigens if the antigen binds to the surface-anchored 
unique antibody of that B cell. These B cells ingest 
and digest the protein and present the peptides 
in its MHC-II to the T cell. The B cell further ac-
tivates the T cell, which results in the production 
of cytokines by the T cell. The T cell activates the 
B cell, which results in differentiation of the B cell 
to an antibody-secreting plasma cell. The activated 
IgM-producing B cells can differentiate to change 
their isotype by a process called class-switch re-
combination (which results in a change in isotype 
production from IgM to IgG1, IgG4, IgA1 etc, and 
sometimes to IgE) and to increase their affinity by 
a process called somatic hypermutation. Both pro-
cesses result in irreversible changes in the DNA of 
the B cell. The discovery of the crucial role of IL-4 
produced by TH2-cells (and other cells) in the gen-
eration of IgE responses is a milestone in the history 
of allergy (18, 19).
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most likely via the oral route, but the skin has also 
been proposed, (b) by cross-reactivity between foods, 
and (c) by cross-reactivity between respiratory allergen 
sources and foods. The best-known example of the 
latter is fruit and tree nut allergy as comorbidity with 
birch pollen allergy (27). The mechanism behind this 
association is cross-reactivity of Bet v 1-specific IgE with 
structurally homologous allergens in foods like apple, 
peach, hazelnut and peanut (Textbox 7). The clinical 
phenotype observed in such patients is characterized 
by mild to moderate symptoms restricted to the oral 
cavity. The explanation for the lack of (severe) systemic 
symptoms is thought to reside in the labile nature of the 
Bet v 1-related food allergens that are readily digested 
in the gastro-intestinal tract (28). This characteristic 
also explains why sensitization to these Bet v 1-related 
food allergens is never seen in patients without birch 
pollen allergy. Apple Mal d 1 or peach Pru p 1, the Bet 
v 1 homologues of these fruits, are completely digested 
before they can directly sensitize.
This does not mean that a fruit like peach cannot 
directly sensitize atopic subjects. For yet unknown 
reasons this is mainly observed in patients living 
around the Mediterranean Sea (29). The implicated 
allergen for peach allergy in countries like, Spain, Italy 
and Greece is the non-specific lipid transfer protein 
(LTP), i.e. Pru p 3. IgE antibodies against Pru p 3 can 
cross-react quite broadly to other fruits, as well as 
to tree nuts, legumes and some vegetables (30), and 
they are associated with an increased risk for severe 
systemic reactions (31). This more “dangerous” profile 
of LTPs has been attributed to their high degree of 
protease (and food-processing) resistance (32).
In addition to Bet v 1-related allergens and LTPs, tree 
nuts, legumes and seeds contain far more abundant 
seed storage proteins, such as 2S albumins, and 7S 
and 11S globulins. These proteins are involved in 
direct sensitization, which often occurs at younger 
ages. As reported for LTPs, IgE antibodies against 
these seed storage proteins are remarkably stable 
and thus better markers for predicting a positive 
double-blind placebo-controlled food challenge, i.e. 
for clinical allergy. They are also associated with more 
severe symptoms. Hazelnut 2S (Cor a 14) and 11S (Cor 
a 9) play such a role (33), however for hazelnut allergy 
as a whole they would not qualify as major allergens 
because birch pollen-associated hazelnut allergy is 
the dominant phenotype (34). This illustrates that 
minor allergens can be of major clinical relevance.
Textbox 7
Allergen cross-reactivity and its assessment
Two allergens are cross-reactive if antibodies exist that recognize both allergens. The antibody will usually have 
a preference for one allergen over the other. This preferential recognition provides a clue as to identify of the 
more relevant of the two allergens. A single allergen molecule has several IgE-binding regions (called epitopes). 
Among IgE antibodies to the birch allergen, Bet v 1, that are induced by inhaling birch pollen, two types of anti-
body populations can be distinguished based on their reactivity with Mal d 1, the homologous protein of apple. 
Some IgE anti-Bet v 1 antibodies will not react with Mal d 1, because they are directed to a non-conserved part 
of Bet v 1. Other IgE antibodies will react not only with Bet v 1, but also with Mal d 1. The latter reaction will 
usually be of lower affinity. In this example, Bet v 1 can be shown to be a more complete allergen than Mal d 
1. Grass pollen extract does not at all inhibit the binding between IgE anti Bet v 1 to Mal d 1 (because grass 
pollen extract does not contain a cross-reactive Bet v 1 homologue). In this way it is possible to rank allergen 
source materials (such as birch, apple, celery and peanut) in a cross-reactivity hierarchy. This is most reliably 
done by using a quantitative bi-directional cross-inhibition protocol (21), but less demanding protocols may 
also be informative. Some cross-reactions are relatively restricted (example: cross-reactivity among grasses). 
Others are broader (example: Bet v 1/Mal d 1, with much lower cross-reactivity to the homologous protein 
in peanut, celery and potato and no cross-reactivity with grasses). Others cross wider phylogenetic barriers 
(examples: cross-reactivity between pollen from birch and grass due to profilin (22, 23) and cross-reactivity 
between shrimp and mites due to tropomyosin (24)). Among the glycan epitopes, CCDs tend to be even more 
cross-reactive (example: cross-reactivity between bee venom and potato (10). Glycan-based cross-reactivity is 
different from protein-based cross-reactivity, because the degree and fine structure of glycosylation is variable 
among glycoproteins, even at the single-cell level (25). It is not unusual to find that 2 allergen source materials 
share several distinct cross-reactive molecules. An example is the cross-reactivity among birch pollen, vegeta-
bles and fruits, which was found to be due to at least 3 cross-reactive structures (26).
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THE ALLERGENIC RISK SPECTRUM
Some allergens are considered more dangerous 
than others in that they elicit more severe allergic 
symptoms. In contrast, some IgE inducers are not really 
allergens at all because they don’t induce symptoms. 
The prevalence of such cases has often been 
underestimated, because they are rarely detected 
in the doctor’s office. They used to be identified 
mostly in population surveys and birth cohort 
studies. This situation is changing, particularly since 
the introduction of the large allergen microarrays, 
as discussed in Section A04. Peanut is a prototypic 
example of an allergenic source material to which 
many people have IgE antibodies, but they can freely 
consume peanuts. Finding IgE to peanuts in peanut-
tolerant subjects is particularly common among 
pollen-sensitized patients (46). This association is 
due to IgE cross-reactivity between allergens from 
pollen and (glyco-) proteins in peanut and many 
other vegetable sources. Bet v 1-related cross-
reactivity has been discussed above. Peanut contains 
a cross-reactive homologue, Ara h 8. However, cross-
reactivity has also been evident between peanut and 
grasses, which don’t have a cross-reactive Bet v 1 
homologue. Profilin and CCD have been found to be 
the most likely additional cross-reactive substances 
(35). It has been convincingly demonstrated that 
CCD-specific IgE antibodies are of limited if any 
clinical relevance (36).
It is tempting to assume that all non-sensitizing 
cross-reactive allergens are relatively safe. While 
this is true in many cases, severe reactions caused 
by exposure to such presumed non-sensitizing cross-
reactive allergens have been reported.
The often relatively low biological activity of cross-
reacting allergens may reflect lower epitope density 
and lower affinity of the IgE-allergen interaction, 
but it has been disappointingly difficult to predict 
biological activity on the basis of immunochemical 
characteristics in individual cases.
The use of a bioassay such as the basophil-activation 
test is a promising alternative. Allergen sources are 
complex, heterogeneous mixtures of proteins. They 
contain harmless IgE-binding structures such as 
CCD, molecules that induce mild symptoms only and 
molecules that are associated with severe symptoms 
including food or insect venom-induced anaphylaxis. 
Moreover, molecules can inform us about the origin 
and route of sensitization, sometimes reflected in 
clear geographic differences. Dissection of these 
molecular characteristics of allergen sources is of 
the utmost importance to improve allergy diagnosis, 
prevention and therapy.
MOLECULAR SENSITIZATION PROFILES: 
BIOMARKERS FOR DISEASE PROGRESSION?
A relatively unexplored area is whether IgE recognition 
profiles have predictive value for disease progression. 
This field will most likely develop rapidly in the near 
future. Some evidence from the field of food allergy 
suggests that recognition profiles of specific epitopes 
on major food allergens, using short synthetic 
peptides, can predict outgrowth or persistence (37). 
Another study reported that persistence of peanut 
allergy is associated with the number of peanut 
allergens recognized (38). These studies are just the 
beginning and illustrate the importance of carefully 
dissecting molecular composition of allergen sources.
ALLERGEN EXTRACTS: IMPERFECT BUT NOT 
YET OBSOLETE
Both allergy diagnostics and allergen immunotherapy 
(AIT) still heavily depend on extracts of the allergen 
sources. In particular in diagnostics, molecular 
approaches are gaining ground rapidly (39), but 
extracts can certainly not be dismissed (40). Usually, 
allergen extracts are simple aqueous extracts of the 
crude allergen source. In most cases, extraction is 
carried out at neutral or close to neutral pH, followed 
by a defatting step, and dialysis. In the case of food 
extracts the source material may sometimes be 
partially processed before extraction, e.g. peanut 
meal of mildly roasted peanuts.
What are the potential shortcomings of allergen 
extracts? Allergen sources are biological products 
with inherent variability of composition. Extraction 
with aqueous buffers at neutral pH may not optimally 
extract all possible allergens, especially those that 
are lipid soluble. This is particularly relevant for 
food extracts because the natural route of exposure 
through the stomach includes exposure to low pH. A 
good example of a food allergen that is not optimally 
extracted at neutral pH is LTP from legumes such 
as peanut and lentils (41). This phenomenon may 
also be the explanation for the huge variability in 
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LTP content reported for a series of commercially 
available skin test reagents for hazelnut allergy (42). 
Extraction at low pH has proven to be the solution. 
Another problem encountered when preparing 
diagnostic food extracts, in particular of fruits and 
vegetables, is that enzymatic oxidative processes 
are initiated when the food tissue is disrupted. In 
particular Bet v 1-related food allergens such as Mal 
d 1 in apple, Pru p 1 in peach or Cor a 1 in hazelnut 
are sensitive to these processes and they lose their 
IgE-binding capacity. Finally, the defatting step has 
been implicated in loss of lipophilic allergens such as 
oleosins in legumes, nuts and seeds (43). Together, 
these shortcomings are probably the main reason 
that skin testing for many foods is done using the 
poorly standardized but more sensitive prick-to-
prick method with fresh foods. To overcome the 
loss of sensitivity for detecting IgE antibodies 
against hazelnut Cor a 1, the extract can effectively 
be improved by spiking with recombinant Cor a 1. 
Although GMP-requirements do not facilitate broad 
in vivo application of recombinant allergens, e.g. 
recombinant Mal d 1 has been successfully used in 
skin testing and oral challenges (44, 45).
CONCLUSION
Overall, one can conclude that the multitude of factors 
influencing extract composition results in batch-
to-batch and company-to-company differences, 
which may lead to differences in the diagnostic and 
therapeutic management of patients. For several 
reasons, this is particularly true for skin test reagents. 
Traditionally, these products are provided for free 
by allergen manufacturers to support the selection 
and subsequent sales of immunotherapy products. 
Regulatory pressure now requires skin test reagents 
to be registered. This development that has resulted 
in many “less important” allergen specificities being 
removed from the market, because they would 
require too big an investment in documentation of 
their clinical performance. Potential solutions such 
as spiking with recombinant allergens are not really 
an option either, because recombinant allergens used 
in vivo need to be produced under GMP conditions 
and tested in toxicity studies. Again, this is too large 
an investment. In the future the number of skin test 
reagents available will therefore be rather limited, 
and extracts for in vitro diagnosis will continue to be 
improved by the use of different extraction methods 
and/or spiking. Increasingly, molecular diagnostics 
will supplement and partly replace extract-based 
tests, to overcome the imperfections of extracts 
and this should also lead to allow improved risk 
assessment and subsequent advice to patients.
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Diagnostic work-up for IgE mediated allergic 
reactions/diseases starts with the history, 
followed by sensitization tests (skin, IgE and 
basophil tests) and optional challenge tests 
(Top-down approach) 
Molecular allergens for IgE testing provide 
additional information, particularly in 
polysensitized patients and with allergens of 
low abundance, low stability or associated risks
IgE reactivity to members of the same allergen 
family reflect the degree of protein homology 
and IgE cross-reactivity. If it is high, the 
relevance needs to be sorted out clinically. 
In case it is low, selected IgE testing of other 
family members can provide additional 
information.  
Proper interpretation should complete 
diagnostic testing: Positive sensitizations to 
allergen extracts or molecules are only clinically 
relevant in case of corresponding symptoms
Conventional allergy diagnostics are based on 
detecting specific IgE antibodies in the blood or skin 
with reactivity for allergen extracts obtained from 
various allergen sources such as pollen grains, house 
dust mite, or cat dander. These extracts contain 
many components (glycosylated and unglycosylated 
proteins lipids etc.) the majority of which are irrelevant 
for the allergic reaction and allergy diagnostics.
Progress in molecular biology over the last 3 decades 
has allowed us to identify and characterize single 
allergens in detail at a molecular level. Large allergen 
data banks have been established (e.g. www.allergen.
org, www.allergome.org) in which information on 
identified allergens is accessible for the scientific and 
medical community. Currently as of June 2015, more 
than 3000 different allergens (plus approx. 1400 
isoforms) have been described (www.allergome.
org), almost 1500 of which have been expressed 
as recombinant proteins. Some of these allergens 
have already and will become available for in vitro 
allergy diagnostics, either as highly purified native or 
recombinant proteins.
The use of single allergenic molecules (instead of 
extracts) has introduced a new area of high-resolution 
molecular allergy diagnostics (also designated 
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“component-resolved diagnostics”, CRD (1)) and 
changed our understanding of sensitization profiles 
and cross-reactivity (2). Daily routine molecular 
allergy diagnostics offers a number of benefits that 
give us a higher diagnostic precision and allow for 
better management of the patient. To utilize the full 
potential in clinical practice, an in-depth general 
knowledge of molecular allergology as well as a clear 
rationale for its use are needed as it relates to when 
and how allergenic molecules are to be used for 
diagnostic purposes (“always think molecular - use 
molecules, when needed”).
This section
  summarizes general considerations for the 
diagnostic work-up of allergic patients in the age 
of molecular allergology,
   provides a number of universal reasons to utilize 
molecular diagnostics, and
   describes the rationale behind different 
approaches (“from symptoms to molecules”; 
“from molecules to symptoms”)
that allow us to make the optimal use of molecular 
allergy diagnostics in clinical practice.
GENERAL CONSIDERATIONS FOR THE 
DIAGNOSTIC WORK-UP OF ALLERGY 
PATIENTS
In patients with suspected IgE-mediated reactions 
and/or diseases, the diagnostic algorithm should 
include the following sequential steps (Fig. 1 and 2):
A. Clinical evaluation and examination
a. allergy-related history including information 
on co-morbidities, differential diagnoses
b. clinical examination
B1. Sensitization test(s) with allergen extracts, like skin 
prick tests (SPT) (3), IgE tests (4), and basophil 
activation tests (BAT) (5) if needed, providing 
information on the allergic sensitization, that is 
“the risk for allergy”
B1. indirect or direct evidence of allergen-
specific IgE
B3. interpretation of sensitization test result(s) 
(clinical relevance or not?)
B2. Sensitization test with allergenic molecules 
(applying allergen-specific IgE tests)
B2. direct evidence of present or absent 
allergen-specific IgE to defined allergens?
B3. interpretation of sensitization test result(s) 
(clinical relevance or not?)
C. Challenge test (optional, depending on the allergen 
source in question)
a. demonstration of clinical symptoms upon 
allergen exposure
b. interpretation (qualitative conclusion: 
positive or negative?)
For each of these steps certain general considerations 
may be helpful to make the best out of our expanding 
knowledge of the molecular nature of allergens. 
These considerations are listed below and combined 
with examples from clinical practice (italic font).
A. Some history-related information might 
immediately suggest certain underlying allergenic 
molecules (“think molecular”), due to
  temporal relationship of symptoms with particular 
exposures (i.e. pollen, furry animals, house dust, 
certain food items)
  patient´s observation of certain triggers 
representing particular pattern (related triggers, 
i.e. indicative selection of food items),
  degree and variety of symptoms indicating 
involvement of certain molecules (either mild 
oropharyngeal or severe systemic symptoms to 
i.e. legumes, tree nuts or seeds)
Examples:
Oropharyngeal symptoms after eating raw apples, 
hazelnuts, carrots and/or soy AND symptoms of allergic 
rhinoconjunctivitis during the birch pollen season: 
Suggestive for the presence of IgE to major birch pollen 
allergen Bet v 1-specific with subsequent serological 
(and clinical) cross reactions (primary inhalant 
sensitization, but due to structural similarity of Bet v 1 
and its homologs secondary symptoms in the oral cavity 
upon exposure).
Oropharyngeal symptoms after eating various (non-
related) fruits and vegetables, including melon, citrus 
fruits, banana, avocado, peanuts AND symptoms of 
allergic rhinoconjunctivitis during the grass pollen 
season: Suggestive for IgE to minor (grass) pollen 
allergen profilin (i.e. timothy profilin Phl p 12) with 
subsequent serological (and clinical?) cross reactions.
Anaphylaxis in the context of exercise after consumption 
of wheat containing food stuff, which is suggestive for 
IgE to omega-5 gliadin Tri a 19.
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B1. Some sensitization test results with extracts, 
either by SPT or serology, might immediately suggest 
certain underlying allergenic molecules, i.e.:
  particular pattern of sensitization, pointing to 
cross-reactive molecules
  unusual pattern or magnitude of sensitization 
test results (i.e. to non-related allergen sources)
Examples:
Positive reactions to fagales tree (hazel, alder, birch, 
beech, oak) pollen, potentially with symptoms during the 
tree pollen season:
Suggestive for the presence of IgE to major birch pollen 
allergen Bet v 1 with subsequent serological (and 
potential clinical) cross reactions to related fagales trees.
Positive reactions to non-related pollen plants, 
sometimes all pollen sources, with various, not 
necessarily corresponding symptoms:
Suggestive for the presence of IgE to pan-pollen allergens 
(profilins, i.e. Bet v 2 or Phl p 12 and/or polcalcins, i.e. 
Bet v 4 or Phl p 7) with subsequent serological (and 
clinical?) cross reactions to profilin-containing pollen 
and plant foods as well as polcalcin-containing pollen. 
In case of double sensitization to profilin AND polcalcin: 
commonly positive reactions to ALL pollen species can 
be expected and it is not possible to define the precise 
sensitization specificity with allergen extracts.
Multiple sensitization to different furry animals which is 
suggestive of IgE reactivity to the animal pan allergen 
serum albumin or certain lipocalins
B2. Tests for allergen-specific IgE to molecules (Fig. 
2) can be applied with one reagent as single test 
(singleplex) (4) or with many reagents (multiplex) 
(6) for i.e. screening purposes (see section A04 for 
more technical information). Reasons for molecular 
Figure 1
General diagnostic work-up of IgE-mediated allergic reactions and diseases. After collecting the aller-
gy history and performing a physical examination (A) appropriate sensitization tests are applied (B1). 
IgE-sensitizations are directly demonstrated by serological allergen-specific IgE determination (4) and/or 
indirectly by skin prick tests (SPT) (3) or basophil activation tests (BAT) (5), if indicated. Sensitization tests 
should be completed by careful interpretation (B3), validating the agreement with the history to ultimately 
evaluate the clinical relevance of the obtained results. In case of uncertainty (B3), i.e. due to a non-con-
clusive history, challenge test are applied (C) to induce allergic symptoms under controlled conditions (7, 
8). A clear outcome will support the decision on the clinical relevance of suspected allergen triggers and 
provide the basis for potential therapeutic consequences (D). 
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IgE testing, either singleplex or multiplex, will be 
summarized below (see also section 5).
Following options will be extensively discussed in the 
following sections:
  “Classical” diagnostic work-up (Fig. 1) with extract-
based sensitization test(s), before employing 
allergen-specific IgE-testing with molecules (Fig. 
2) (“top-down approach”, section 3)
  Novel diagnostic work-up with primarily allergen 
molecule-related information, i.e. allergen-
specific IgE to a panel of related molecules to 
explain diverse clinical reactions or diseases 
(“bottom-up approach”, section 4)
  Integrated use of both approaches, first working 
from the history, applying extract-based 
sensitization tests (SPT, IgE) before exploring the 
entire individual IgE repertoire with an extended 
panel of allergen molecules (“U-shape approach”, 
section 5).
C. Finally, if the information provided by the patient’s 
history and/or their sensitization test results is 
inconclusive and does not allow for a clear decision 
on the clinical relevance of the suspected allergen 
source, additional challenge tests should be applied. 
They should ultimately demonstrate or rule out 
clinical symptoms following allergen exposure.
In case of inhalants (pollen, mites, molds, furry 
animals) standardized extracts of the suspected 
allergen source are applied on the mucosal surface 
(i.e. conjunctiva, nose) (7). In case of food allergy 
(plant foods, i.e. fruits, vegetables, legumes) 
increasing doses of the suspected allergen are given 
orally, ideally in a double-blind, placebo-controlled 
fashion (8, 9).
Subsequent immediate or delayed (i.e. exacerbation 
of an atopic eczema) type allergic symptoms would 
prove current clinical relevance; in contrast, a 
lack of any objective clinical reaction would rule 
out a previously suspected allergy (provided that 
no additional co-factors are required to elicit the 
allergic reaction, as exemplified by all forms of food-
dependent, exercise induced anaphylaxis (10)).
Figure 2
Diagnostic work-up with targeted (singleplex) molecular-based IgE-testing. After sensitization testing (B1) 
with allergen extracts, more detailed information regarding the IgE-repertoire is obtained with molecu-
lar-based testing (B2). This diagnostic approach, coined “top-down” is followed by a thorough interpreta-
tion (B3) including challenge tests (C), if needed. 
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Subsequently, interpretation needs to be integral part 
of any suspected sensitization (i.e. demonstrated by 
SPT, IgE, BAT) as well of a challenge test outcome 
(Fig. 1).
  A positive test result is only clinically relevant in 
the case of corresponding allergic symptoms that 
are temporally associated with a defined allergen 
exposure.
  A negative test (i.e. allergen-specific IgE) result 
against one recombinant allergen molecule or a 
mixture of natural isoforms of one single allergen 
can indicate exclusion of allergic sensitization 
or risk of allergy to the allergen specificity in 
question (see section 5 for details), provided that
a) the total IgE is high enough (i.e. > 20 kUA/l)
b) the allergen reagent is of sufficient 
abundance, fully intact, and presenting all its 
epitopes
c) the analytical performance of the IgE 
antibody assay has been optimized for a low 
limit of quantitation (i.e. 0.1 kUA/L).
In conclusion, the clinical relevance of an allergic 
sensitization (i.e. presence of allergen-specific 
IgE, independent of the use of allergen extracts or 
molecules for diagnostic purposes) can ultimately 
only be determined by the physician and not by the 
test. Therefore, the complete diagnostic results of 
sensitizations as well as challenge test results will 
always have to be interpreted within the clinical 
context and on the basis of the individual´s case 
history.
COMMON REASONS TO UTILIZE 
MOLECULAR DIAGNOSTICS AND THEIR 
LIMITATIONS
There are a number of general reasons that speak in 
favor of using single allergens as compared to allergen 
extracts (Fig. 3). They are principally related to an 
improved assay performance (i.e. assay sensitivity 
and analytical specificity) and/or to additional 
levels of interpretation such as risk assessment 
or differentiation between genuine (“primary”) 
sensitization and cross reactivity, particularly in 
presumed polysensitizations.
While these arguments clearly support the use of 
single allergens in clinical routine, we need to be 
careful not to over interpret results of molecular 
allergy diagnostics, which have clear limitations 
when it comes to predicting clinical outcomes. sIgE 
test results – regardless of using extracts or single 
molecules - only reflect the status of sensitization 
and always have to be interpreted in the context 
of the clinical data. The benefits and limitations of 
molecular allergy diagnostics are outlined below.
Factors improving assay performance are able 
to warrant the use of allergenic molecules 
instead of extracts:
1. Molecules of low abundance and/or weak 
stability
If allergen molecules, being of low abundance or 
missing in the extract, are able to improve the 
assay’s analytical sensitivity (LoQ) of an IgE test, 
their use is meaningful and important (i.e. Gly m 
4 vs soy extract, omega-5-gliadin vs wheat extract).
2. Risk- or severity-associated molecules
If allergen molecules provide improved analytical 
specificity (“selectivity”) and allow additional 
clinical assumption(s) (i.e. increased risk 
association, clinical severity or other associated 
clinical features of an IgE-sensitization), their 
use is again meaningful and recommended (i.e. 
storage proteins Ara h 1, 2, 3, 6 vs whole peanut 
extract).
3. Indicator of cross reactivity
Certain allergen molecules can serve as indicators 
for serological cross sensitizations through 
the binding of cross-reactive IgE. In case of a 
positive result they can demonstrate the lack of 
analytical specificity of an IgE test with allergen 
extracts (in affected subjects with potential cross 
reactions) (e.g. profilin or polcalcin, members of 
plant panallergen families),
4. Marker of genuine (species-specific) sensitization
Particular allergen molecules (often major 
allergens) can serve as markers for a primary, 
“genuine”, family- or species-specific sensitization. 
They provide improved analytical specificity 
compared to allergen extracts (particularly in 
affected subjects with potential cross reactions) 
(e.g. marker allergens Ves v 1 and Ves v 5 from yellow 
jacket venom and marker allergens Api m 1, Api m 3, 
Api m 10 from honey bee venom vs hymenoptera 
whole venom preparations from the corresponding 
species).
 EAACI Molecular Allergology User´s GuideEAACI Molecular Allergology User´s Guide2016 Part  A:  Molecular Al lergology:  General  Concepts
26 Molecular allergy diagnostics in clinical practice
The above rationale is primarily based on the status 
of sensitization (presence or absence of IgE antibody) 
and not on the clinical manifestations of the subjects. 
Examples are given in more detail below in Section 2.
Limitations in improving predictions on clinical 
outcome from (isolated) molecular based 
sensitization test results
In contrast to parameters that describe the analytical 
assay performance (analytical sensitivity, analytical 
specificity, see above), clinical diagnostic criteria are 
required when it comes to making predictions on the 
clinical outcome. General clinical diagnostic criteria 
in the field of (molecular) allergology include:
I. diagnostic sensitivity (proportion of positive IgE 
antibody tests in patients with allergic symptoms/
disease)
II. diagnostic specificity (proportion of negative IgE 
antibody tests in asymptomatic/healthy individuals)
III. indicator of clinical cross reactivity (allergic 
symptoms to allergenic sources that did not elicit 
the primary sensitization)
IV. prediction of clinical reactions (positive predictive 
value, PPV, negative predictive value, NPV, 
thresholds, likelihood ratio etc.)
All of the above criteria require a thorough individual 
interpretation of each test result based on the 
previous history and if needed additional proof of 
Figure 3
Utility of allergen extracts and allergenic molecules for diagnostic work-up Mono-/limited oligo-sensi-
tizations (A) and/or minor clinical risks (B) as well as high abundance allergen molecules in the allergen 
source suspected (C) and/or allergens of high stability (D) indicate suitability of allergen extracts for proper 
diagnostic work-up. In case of polysensitizations and/or allergen triggers associated with high clinical risks 
as well as low abundant and/or labile allergenic molecules in the extract, the diagnostic work-up should 
consider the use of molecular components for IgE detection.
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reproducible and objective symptoms in the affected 
allergic subject upon exposure (i.e. challenge test). 
Subsequently, these clinical criteria will go beyond the 
essential (“raw”) assay result of an allergen-specific IgE 
test (IgE-sensitization in question: yes or no).
In general, clinical diagnostic criteria are
  less suitable and sometimes misleading for a 
proper assay evaluation of sensitization tests
  largely not needed to demonstrate the advantage 
of single allergenic molecules in IgE assays and
   often burdened with unsatisfactory study 
results due to the per se limited and imperfect 
prediction of clinical outcomes (clinical reactivity) 
by sensitization tests.
In conclusion, the above listed advantages of 
molecular allergy diagnostics mostly refer to an 
improved detection and discrimination of allergic 
sensitization. Molecular allergy diagnostics, however, 
have clear limitations for improving predictions of 
the clinical outcome. After all, the detection of sIgE is 
primarily an indicator of “sensitization” and - despite 
various attempts to integrate clinical data and results 
of challenge tests - not a decisive predictor of clinical 
reactivity.
FROM SYMPTOMS TO MOLECULES: THE 
“TOP-DOWN APPROACH”
Based on the experience that detection of allergen 
specific IgE does not equal clinical relevance, current 
guidelines on allergy diagnostics (4) recommend that 
the diagnostic workup should be primarily guided 
by the clinical symptoms. Random screening for IgE 
sensitization is discouraged since the number of 
positive IgE results to a certain allergen source usually 
exceeds by far the number of clinical relevant allergies 
(11). This “top-down” approach – from the symptoms 
to the allergen source also applies to molecular allergy 
diagnostics and can be defined as follows:
Definition: Diagnostic work-up from symptoms to 
molecules (“top-down approach”, (Fig. 2) aims for more 
detailed characterization of the IgE-repertoire unfolding 
important molecular IgE-sensitizations that provide 
information beyond the extract based test results.
In practice, taking the case history and performing 
a symptom guided diagnostic work-up with extract-
based SPT and/or IgE-testing usually allows the 
identification (or exclusion) of IgE-sensitizations to 
potentially involved allergen sources (Fig. 1). Here 
two main scenarios are usually encountered:
Figure 4
Diagnostic work-up with broad (multiplex) molecular-based IgE-testing: In complex cases and/or incon-
clusive diagnostic outcomes after previous testing (A) a panel of molecular allergens might be applied for 
subsequent (multiplex) IgE testing (B2). After final interpretation (B3) with an optional challenge (C) this 
approach, coined “bottom-up”, might facilitate superior decisions on therapeutic consequences. 
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A) Limited numbers of positive extract based 
sensitization test results
In case of rather restricted IgE antibody responses 
with only few positive results to inhalants like 
tree or grass or weed pollen, certain molds, one 
or two furry animals, only a single insect venom 
(bee or wasp venom) or only selected food 
items, the analytical specificity of an extract-
based sensitization test might be sufficient 
to identify the underlying allergen source. No 
further testing would be required, if the extract-
based sensitization test permits a proper and 
specific diagnostic work-up. The exceptions are 
potentially false negative sensitization tests in 
case of underrepresented or unstable single 
allergens.
B) Broad panel of positive extract based sensitization 
test results
More frequently we encounter the scenario 
in which rather broad IgE antibody responses 
occur with many positive results to extracts from 
inhalants or reported symptoms to many (plant) 
foods. This indicates possible cross-reactivities 
and a lack of analytical specificity of the extract 
based test approach.
In this setting, further work-up (“top-down 
approach”, (Fig. 2)) with allergen molecules 
may allow a more detailed and meaningful 
characterization of the IgE-repertoire, identifying 
important molecular IgE-sensitizations. 
Examples of situations in which molecular allergy 
diagnostics provide additional information 
beyond the extract-based tests are listed below:
Examples of situations for further molecular 
diagnostic work-up
A) Allergen source with potentially competing 
clinically relevant allergen sources
  Multiple sensitizations to (non-related) pollen 
species (i.e. from trees, grasses, weeds) with 
overlapping seasons
Examples: pollinating plants (trees, grasses, 
weeds) with overlapping seasons. Here the use 
of marker allergens and pan allergens allows 
discrimination between genuine sensitization 
and cross reactivity.
  Symptoms to multiple (non-related) plant 
foods due to potential cross-reactivity
Examples:
a. apples, hazelnuts, cherries, plums, peaches, 
carrots, soy (suggesting Bet v 1-cluster, 
predominantly in the northern hemisphere 
with birch trees)
b. melon, banana, apples, nuts, peanut, citrus 
and others (suggesting profilin-cluster, often 
due to high regional grass pollen exposure)
c. peaches, other fruits of the Rosacea family, 
grapes, berries (black, blue), citrus and 
others (suggesting LTP-cluster, mainly in the 
mediterranean region)
  Multiple sensitizations to furry animals (with 
potential clinical consequences)
Examples: i.e. cats, dogs, horses, furry animals 
(suggesting serum albumin or certain lipocalins 
as cross reacting allergens)
B) Allergen source with a variety of different single 
allergens, either resembling cross reactive or 
genuine molecules.
  Anaphylactic Hymenoptera sting reaction 
and sensitization to both honey bee and 
yellow jacket venom.
Both allergen sources contain potentially 
crossreactive allergens such as Api m 2, 
Ves v 2 (hyaluronidases), Api m 5, Ves v 3 
(Dipetidylpepitdases), Api m 12, Ves v 6 
(vitellogenins), and marker allergens that are 
specific for honey bee venom (Api m 1, Api m 3, Api 
m 4, Api m 10) or yellow jacket venom (Ves v 1, Ves 
v 5). Use of marker allergens allows discrimination 
between genuine sensitization and cross reactivity.
  Variable symptoms to certain plant foods
Examples: fruits, vegetables
  Severe reactions to plant foods
Examples: peanut, soy, tree nuts, seeds
Criteria for selecting appropriate molecules 
(from an allergen source) (Fig. 5)
The general reasons given in section 2.a provide 
criteria to select certain molecules for further 
diagnostic work-up:
1. molecules of low abundance and/or weak stability
Examples: use major birch pollen allergen Bet v 1 
as a representative to demonstrate potential cross-
reactivities to low abundant, labile Bet v 1-homologs 
i.e. Cor a 1.04 (hazelnut), Act d 8 (kiwi), Pru p 1 
(peach), Gly m 4 (soy) and others
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Other examples of not well represented allergens 
are the peanut allergens Ara h 10, Ara h 11, Ara h 
14, Ara h 15 (oleosins), the wheat allergen Tri a 19 
(omega-5-gliadin), and natural rubber latex allergen 
(Hev b 5 (acidic structural protein).
2. risk- or severity-associated molecules
Examples: 2S albumins, i.e. Ara h 2, Ara h 6/7 
(peanut), Cor a 14 (hazelnut), Gly m 8 (soy),
other seed storage proteins Ara h 1, Ara h 3, Cor a 9, 
Cor a 11, Gly m 5, Gly m 6,
nsLTP, i.e. Pru p 3 (LTP marker in peach, 
mediterranean), Cor a 8 (hazelnut, mediterranean), 
Ara h 9 (peanut, mediterranean),
other examples: alpha-GAL (delayed type red meat 
allergy)
3.  indicators of cross reactivity
Examples: Fel d 2, Can f 3, Equ c 3 (serum albumins); 
Bet v 1, Act d 8, Ara h 8, Pru p 1, (Bet v 1-homologs); 
Amb a 8, Ara h 5, Art v 4, Bet v 2, Ole e 2*, Phl p 
12, Pru p 4 (profilins, pan-allergen in pollen and 
plant foods); Amb a 10, Art v 5, Bet v 4, Ole e 3, 
Phl p 7 (polcalcins, pan-allergen in pollen); CCD 
(crossreactive carbohydrate determinants)
4.  markers of genuine (species-specific) sensitization
Examples: Fel d 1 (cat), Api m 1, Api m 3, Api m 
4, Api m 10 (honey bee venom), Ves v 1, Ves v 5 
(Vespula species), Bet v 1 (fagales), Ole e 1 (olive tree, 
plantane), Phl p 1, Phl p 5 (grass) Art v 1 (mugwort), 
Amb a 1(ragweed)
bold letters indicate availability as reagents mainly 
non-USA, (eg. Europe, Japan); regular letters: not (yet) 
available as reagents,
See also section 2.a for explanations.
In summary, after taking the history and performing 
extract-based sensitization tests a diagnostic work-
up including specific IgE to allergenic molecules is 
useful to increase assay sensitivity for single allergens 
of low abundance (in extracts) or weak stability. An 
increased analytical specificity will help to identify 
risk- or severity-associated allergens, indicators for 
2S album
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Figure 5
Allergen-specific IgE concentrations to various 
allergen molecules depending on structural sim-
ilarity within one allergen family.
A. Variable, limited cross reactions (illustrated by 
circles with limited overlap) between different 
2S-albumins (stabile seed storage proteins in 
nuts, legumes and seeds) and corresponding IgE 
values (bars of various sizes)
B. Cross reactions of moderately limited variabil-
ity (illustrated by circles with moderately limited 
overlap) between different Bet v 1-homologous 
food allergens
C. High degree of cross reactivity (illustrated by 
largely overlapping circles) between highly con-
served, similar stuctures and epitopes of profi-
lins (in pollen, foods and natural rubber latex) 
with corresponding IgE concentrations (bars of 
almost identical size) 
(Adapted from (13) with kind permission of 
Springer Science and Business Media).
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cross-reactivity and marker allergens of genuine 
(primary) sensitization.
Interpretation is an integral part of each sensitization 
test: Positive results are only clinically relevant in case 
of corresponding symptoms; negative results can 
ideally rule out an allergic sensitization and subsequent 
clinical reaction to the tested allergen specificity.
FROM MOLECULES TO SYMPTOMS: THE 
“BOTTOM-UP APPROACH”
Instead of performing symptom-oriented focused 
molecular allergy diagnostics (“top-down approach”, 
see above), one can simply turn this approach around 
and start from the bottom i.e. with the molecules (12). 
In an ideal scenario, diagnostic tools would allow us to 
characterize the entire IgE repertoire to all potential 
allergens that a patient has been exposed to. It would 
then be conceivable that we first analyze the entire 
IgE repertoire and then start talking to the patient to 
find out which of the detected IgE sensitizations are 
clinically relevant. This would be a “broad bottom up 
approach” i.e. turning the diagnostic pyramid upside 
down. However, a number of reasons suggest that in 
real life this is not appropriate:
a) We are far from being able to characterize the 
entire IgE repertoire, i.e. the individual IgE 
response to the entire allergome – currently only 
approx. 200 of the 3000 known allergens are 
available for diagnostic purposes.
b) An entire IgE repertoire characterization would 
be exceedingly expensive and yield enormous 
amounts of information that require processing 
and interpretation.
c) At present molecular allergy research attempts 
and multiplex technologies still depend on the 
availability of allergens for diagnosis. Many 
research projects have so far focused on certain 
molecules, i.e. Bet v 1-homologous proteins in 
various sources, leading to a broad spectrum 
of available proteins. However, this does not 
mean that this group is more relevant than other 
allergens to which less attention was paid in the 
past or which are more difficult to be produced as 
recombinant allergens.
d) Finally, the number of positive IgE results to a 
certain allergen source usually exceeds by far the 
number of clinical relevant allergies. Screening 
the IgE response to the entire allergome thus 
would most likely result in generation of large 
proportions of positive test results that have no 
clinical relevance.
In conclusion, screening of IgE sensitization profiles 
to large panels of allergens irrespective of the clinical 
history (“broad bottom up approach”) is of limited 
value for the management of the allergy patient. 
However, there are a number of situations, in which 
a “targeted bottom up approach”, i.e. using molecular 
information and asking for corresponding symptoms 
can be helpful for patient management and 
consultation in clinical practice as outlined below:
Definition: Diagnostic work-up from (cross-reactive=) 
molecules to clinical implications (“targeted bottom-
up approach “, (Fig. 4)) aims for more detailed 
characterization of the IgE-repertoire or clinical 
reaction pattern unfolding important hints from a 
panel of potential molecular IgE-mediated cross-
reactions.
This diagnostic algorithm “targeted bottom-up 
approach” (Fig. 4) is designated for molecular work-
up in case of positive IgE to a certain, potentially 
clinically relevant cross-reactive molecule (protein 
family). The finding might explain broad cross-
reactivities to other allergen sources, if the candidate 
belongs to a protein family with many members of 
similar structure and a high degree of cross-reactive 
IgE-recognition.
In clinical practice, the diagnostic work up in such 
cases (IgE to potentially clinically relevant cross-
reactive molecules) can be based purely on clinical 
assessment to determine the relevance of potential 
symptom driving cross reactivities, extending the 
clinical history or applying optional challenge tests 
with the allergen source in question.
Alternatively or in addition, molecular IgE serology 
using the “targeted bottom up approach” i.e. 
screening for sIgE to corresponding cross-reactive 
allergens, may provide useful information on the 
presence or absence of cross-sensitizations.
The decision on which allergenic molecules have 
to be tested in this context should be based on the 
known degree of cross reactivity. Here, two different 
pattern emerge:
1. Protein families with highly cross-reactive 
allergens do not require further IgE-testing, but 
thorough clinical work-up to identify relevant 
clinical cross-reactions.
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  A single IgE test is sufficient to demonstrate 
cross-reactivity to a prominent (most IgE-
binding) member of an allergen family with 
broad cross-reactivity.
  Additional tests would only demonstrate 
more cross reactions (Fig. 5 B, C) without 
addressing the clinical consequences (i.e. 
symptoms, clinical reactions)
  Subsequently, detailed clinical work-up is 
required to clarify potential clinically relevant 
cross-reactivities.
Reasoning: Further IgE tests would potentially 
create many (more) positive results with 
questionable clinical relevance. Therefore, the 
physician should sort out potential clinically 
relevant cross-reactions to related allergen 
sources in questions containing a cross-reactive 
member of the same allergen family. In conclusion, 
it is commonly sufficient to test only one member 
of a highly cross-reactive allergen family.
Examples:
Bet v 1 and its homologs, nsLTPs , profilins, polcalcins 
(Ca++-binding proteins), serum albumins, grass 
pollen major group 1 and 5 allergens, parvalbumins, 
tropomyosins
2. Protein families with allergens of limited cross 
reactivity are an option for further IgE-testing, 
if an IgE test to a member of the same allergen 
family has been positive.
  In general, the highest IgE concentration to 
a member of the same family might indicate 
the primary sensitizer (Fig. 4.5 A). A negative 
result would generally exclude an IgE-
sensitization and make subsequent clinical 
reactions highly unlikely.
  However, in the case of a positive IgE result, 
only a thorough clinical work-up would be 
able to clarify potential clinically relevant 
cross-reactivities and subsequent reactions.
  If the case history is not informative, a 
challenge test with the allergen source in 
question has to be applied to ultimately 
address the question of potential clinical 
relevance.
Reasoning: In case of allergens of limited cross 
reactivity (Fig. 5 A) an appropriate panel of related 
allergens (from the same protein family) could 
be used to demonstrate or exclude subsequent 
(serological) cross-reactivities. Therefore, 
additional IgE testing with related allergen 
molecules of the same family might establish a 
hierarchy of allergen-specific IgE values (Fig. 5): 
Ideally the one with the highest IgE antibody level 
will represent the primary sensitizer. A negative 
result could exclude serological (and subsequently 
clinical) cross-reactivity. A positive result, however, 
would indicate serological cross-reactivity which 
should be addressed with the patient according 
to his individual symptoms. Only in the case of 
corresponding symptoms, sometimes backed by an 
oral challenge, these cross reactivities have to be 
considered in terms of present clinical relevance.
Examples:
Seed storage proteins like 2S-albumins, 7S-globulins 
(vicilins), 11S-globulins (legumins);
lipocalin subfamilies
In conclusion, dissecting the relevance of a panel 
of related, cross-reactive allergens can be obtained 
by a) a purely clinical work-up and/or b) a further 
introduction of related, cross-reactive molecules. 
In case of negative IgE-tests, serological as well as 
clinical cross-reactions can be ruled out with certainty. 
Positive IgE results would confirm serological 
cross-reactivity, the clinical relevance needs to be 
addressed with the patient according to his individual 
symptoms. This approach is only recommended for 
protein families with a low or limited degree of cross-
reactivity (i.e. seed storage proteins, nsLTP), where 
the individual’s IgE repertoire is highly variable and 
its binding to related molecules cannot be predicted.
“U-SHAPED” MOLECULAR DIAGNOSTICS IN 
IGE-MEDIATED DISEASES
Definition: A previous diagnostic work-up from 
symptoms to molecules (“top-down approach”, (Fig. 2) 
is combined with a subsequent diagnostic sequence 
from molecules to clinical implications (“targeted 
bottom-up approach”, (Fig. 4)), coined “U-shaped 
molecular diagnosis” (Fig. 6), dissecting the relevance 
of potential molecular IgE-mediated cross-reactions.
Satisfactory diagnostic conclusions after applying 
selected molecules (“top-down approach) for IgE-
testing would end with appropriate advice to the 
patient without the need of further work-up (i.e. 
“bottom-up approach).
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However, if open questions remain, regarding the 
implications of potentially cross-reactive allergens 
after identification of one key allergen, the U-shaped 
molecular diagnosis (Fig. 7) might help to solve the 
diagnostic problem. Subsequently, criteria for further 
molecular work-up after a previous “top-down 
approach” with the “bottom-up approach” have to 
be applied on an individual basis depending on the 
diagnostic outcome after the initial diagnostic steps.
The question remains if singleplex or multiplex 
testing should be applied:
  if possibly a large number of allergens from one 
family are involved, multiplex testing might carry 
some advantages;
  singleplex testing, however, offers an enhanced 
assay sensitivity, allowing the ultimate exclusion 
of IgE-mediated sensitization to the allergen 
in question if the allergen-specific IgE does not 
exceed the cut-off of 0.1 kUA/l;
  therefore, the decision of singleplex or multiplex 
testing should take into account the number of 
allergens to be tested and the preferred test 
sensitivity (very low or not as low).
Examples: seed storage proteins like 2S-albumins, 
7S-globulins (vicilins), 11S-globulins (legumins). Note of 
caution: The number of storage proteins of different nuts, 
legumes and seeds that are available for diagnostics 
is still limited. This does not allow one to check for the 
presence of allergen-specific IgE to a full panel of these 
stable and risk-associated allergens. Therefore, allergen 
extracts are still needed, to indirectly get information on 
the potential relevance of the risk-associated storage 
proteins.
In conclusion, certain scenarios require a complete 
molecular diagnostic work-up after taking the history 
and performing focused extract- and molecule-based 
sensitization tests. This approach explores the degree 
and potential clinical relevance of further cross-
reactivities to related molecules of a protein family. 
Singleplex assays would guarantee maximum assay 
sensitivity; multiplex assays would rather provide a 
broad panel of related, cross-reactive molecules for 
Figure 6
Combined diagnostic work-up with “top-down” and “bottom-up” aproach. The diagnostic flow chart 
starts with the history, extract diagnostics, molecular diagnostics and subsequent application of extended 
molecular panels for further differentiation of the allergen-specific IgE repertoire. The approach, coined 
“U-shape”, has been proposed for complex cases. 
individual history, examination
(clinical symptoms?) 
 SPT and/or IgE test and/or BAT 
(with extracts) 
2nd IgE testing 
(selected molecules, CRD)
interpretation 
(optional challenge)
certain uncertain
a) multi-sensitization and/or  
b) broad cross-reactivity
molecular-based IgE testing 
(panel of i.e. cross-reactive allergens)
interpretation (optional challenge)
to determine clinical relevance
certain uncertain
therapeutic consequences(i.e. allergen 
avoidance, allergen immunotherapy)
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further definition of the IgE-repertoire. The clinical 
relevance has to be determined by the physician 
and not by the test, based on patient´s history and 
outcome of challenge tests if needed. 
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MOLECULAR 
ALLERGOLOGY: 
GENERAL 
CONCEPTS
PART A
A04
IgE antibody tests are run as singleplex 
(one), multi-allergen (<10) and multiplex 
(>100 allergen specificities) assays, all with 
particular design and performance features.
Allergen extracts remain the principal 
reagents for IgE assays; allergenic molecules 
supplement labile or missing allergens in 
extracts or are analyzed individually.
Allergenic molecules enhance the IgE 
assay’s analytical sensitivity, and improve 
its analytical specificity by separating 
serological cross-reactivity from primary 
(genuine) sensitization to an allergen source 
or by identifying risk-associated allergens.
The relevance of positive allergen-specific 
IgE antibody responses, either to extracts 
or molecules, can only be determined by 
the physician based on the clinical context 
(history, challenge) and not by the test itself.
INTRODUCTION
The serological measurement of IgE antibodies 
provides the clinician with a measure of a patient’s 
allergic sensitization profile. Two fundamental types 
of IgE antibody assays are performed in the clinical 
immunology laboratory. “Singleplex“ or “monoplex” 
assays refer to laboratory methods in which one 
analyte is measured per analysis. “Multiplex” assays 
permit more than one analyte to be detected 
and quantified in a single assay analysis (1). This 
report examines the technology, performance and 
application of singleplex and multiplex IgE antibody 
assays that utilize allergen extracts and allergenic 
molecules (components) in the diagnosis and 
subsequent management of human allergic disease.
IMMUNOCHEMISTRY DESIGN 
CONSIDERATIONS
Two fundamental assay chemistries that have been 
referred to as “classical’ or “reverse” assay formats 
have been used to detect IgE antibody (Table 1).
Robert G. Hamilton, Jörg Kleine-Tebbe
METHODS FOR IgE 
ANTIBODY TESTING: 
SINGLEPLEX AND 
MULTIPLEX ASSAYS
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“Classical” IgE assay format: Basis of most 
current singleplex and multiplex assays
The noncompetitive, heterogeneous (separation of 
free and bound), immunometric (labeled antibody) 
assay that employs allergen immobilized on a solid 
phase “allergosorbent” to bind specific antibodies of 
all isotypes from serum is the design that has endured 
in both singleplex and multiplex assays that are used 
in clinical laboratories (Fig. 1). Following a buffer 
wash to separate free and bound human antibody, 
radionuclide-, enzyme- or fluorescence-labeled anti-
human IgE is added to detect IgE antibodies that have 
bound to immobilized allergen. The magnitude of the 
response (counts per minute-radioactivity, optical 
density, chemiluminescence, or fluorescence) after 
the final buffer wash is proportional to the quantity of 
allergen-specific IgE antibody in the original test serum.
Reverse IgE assay format: Basis of certain 
singleplex assays
A reverse or capture anti-IgE assay design uses a 
second step liquid-phase allergen to detect allergen-
specific IgE antibody. In this assay (Fig. 1-bottom panel], 
all IgE (in theory) is initially captured from serum by a 
paramagnetic particle solid-phase anti-IgE in molar 
excess to the amount of IgE in most test sera. Following 
the capture of human IgE, allergen-specific IgE antibody 
is detected with limited quantities of labeled allergen. 
The reverse phase assay format has been used for IgE 
antibody quantitation in the ADVIA Centaur (4, 5).
The principal advantage of the reverse phase assay 
over the classical allergosorbent-based singleplex 
assay is its tendency to measure principally high 
affinity IgE antibody that is assumed to be “more” 
clinically relevant (Table 1). In contrast, assays that 
use molar excess amounts of allergen that have 
been immobilized on an allergosorbent tend to more 
broadly detect both low as well as high affinity IgE 
antibody. The reverse assay format also addresses 
the concern of competitive inhibition caused by 
allergen-specific antibodies of non-IgE isotypes 
origin such as IgG anti-allergen that can achieve 
microgram per ml levels in sera from individuals 
receiving immunotherapy. This reverse assay format 
is, however, less amenable to use in multiplex assays 
where multiple labeled allergens would have to be 
added to the same reaction vessel. It suffers from 
a requirement for large amounts of anti-IgE capture 
Table 1
Different formats and features of allergen-specific IgE-assays 
“classical” IgE assay format “reverse” IgE assay format
1st assay step
allergen-specific IgE and other antibody 
isotypes (e.g., IgG) bind allergen reagent
Immobilized Anti-IgE ideally binds entire (total) IgE in 
the reaction vessel
2nd assay step
Labeled anti-IgE binds only allergen-
specific IgE
Labeled allergen reagent binds only allergen-specific 
IgE
Advantages 
(pro)
Detection of the entire allergen-specific 
IgE-repertoire (low and high affinity)
detection of allergen-specific IgE principally of higher 
affinity
no competitive inhibition through allergen-specific 
immunoglobulins other than IgE, (i.e. IgG)
Limitations 
(con)
competitive inhibition by allergen-
specific immunoglobulins other than IgE, 
(i.e. IgG antibody after subcutaneous 
immunotherapy or natural exposure)
large amounts of anti-IgE needed for sera with high 
total IgE levels
biased results (lower values) in samples with a low 
specific to total IgE-ratio 6
Potential use 
in multiplex 
assay formats
micronization of binding chemistry and 
limited amounts of allergen reagents 
required
less useful due to the need of multiple labeled 
allergens (to be put into one reaction vessel)
References Wide et al. (2); Ekins (3) Ricci et al. (4); Petersen et al. (5)
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Total IgE
1st Anti-IgE
2nd Anti-IgE
with label
IgE
Allergen-specific IgE
„classical“ assay format
solid phase
solid phase
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IgE
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Fluid phase Solid phase
Particles
with Allergen
extract or
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Anti-IgE
IgE
IgE
Allergen-specific IgE
Enzyme-
allergen
„reverse“ assay formatfluid phase format
A
B
Figure 1
A. General principle of “classical” IgE assay formats for total and allergen-specific IgE quantification. B. 
General principle of the “reverse” IgE assay format for allergen-specific IgE quantification.
antibody to insure the binding of all IgE molecules 
from the test serum. The reverse assay design can also 
show a major bias because its performance depends 
on the fraction of the total IgE that is specific for the 
allergen of interest. These assay design constraints 
have resulted in the disappearance of the reverse 
assay format from use in clinical laboratories in the 
USA and elsewhere.
Heterologous calibration based on total IgE for 
singleplex allergen-specific IgE systems
Consensus has been established that a single generic 
total serum IgE calibration system is the only workable 
calibration strategy for use in clinical IgE antibody 
assays (Figure 1, top panel) (1). It allows interpolation 
of IgE antibody results from any of the hundreds of 
allergen specificities as long as the total serum IgE 
and allergen-specific IgE portions of the assay dilute 
out in parallel with each other. The total serum IgE 
“heterologous” calibration system that is used in all 
regulatory cleared singleplex assays is traceable to 
the World Health Organization’s recently depleted 
75/502 and currently used third 11/234 human IgE 
Reference Preparations (6). This calibration system 
allows interpolation of IgE antibody results from 
a limit of quantitation of 0.1 kUA/L to 100 kUA/L 
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levels of IgE antibody. While rarely performed in 
clinical testing, serum levels of IgE antibody greater 
than 100 kUA/L can be accurately determined by re-
analysis of the serum at a dilution and subsequent 
mathematical correction for the dilution factor. The 
alternative to the total serum IgE-based heterologous 
interpolation scheme is the use of individual allergen-
specific calibrations, one for each allergen specificity. 
Early attempts as the use of this approach exposed 
its major limitation which involved a demand for liter 
quantities of IgE positive sera for each specificity 
(7). This made the multiple specific IgE antibody 
calibration strategy impractical, especially since there 
are no internationally recognized polyclonal human 
IgE antibody reference preparations.
Multi-allergen versus Multiplex Assays
A true multiplex antibody assay allows many 
specificities of a single antibody isotype (e.g. IgE) 
to be individually detected and semi-quantified 
in a single analysis (1). This assay design can be 
distinguished from a “multi-allergen” screening assay 
in which many allergen specificities from a common 
group (aeroallergens or food allergens) are mixed and 
immobilized as extracts or components on a single 
solid phase. This multi-allergen reagent is typically 
used in a singleplex assay format to simultaneously 
detect specific IgE to multiple antibody specificities 
in a single reaction. A single qualitative (positive or 
negative) result is generated for each specimen based 
on a positive/negative cutpoint. However, the actual 
allergen specificities that produce a positive IgE 
antibody response in the multi-allergen screen cannot 
be definitively identified by the requesting physician 
without further analysis using additional singleplex 
assay analyses, one for each of the individual 
allergen specificities on the multi-allergosorbent. 
One widely used multi-aeroallergen screening assay 
measures IgE antibody to 10 or more aeroallergens 
(8). The allergen specificities immobilized on a 
single solid phase are carefully selected because 
they are known to be unique or cross-reactive with 
the major specificities that induce the majority of 
aeroallergen-related allergic symptoms. Due to its 
high negative predictive value, this particular multi-
aeroallergen assay serves as a cost-effective screen 
to rule out allergic sensitization in an individual with 
a questionable respiratory allergy history and to 
define the atopic status of individuals enrolling in 
asthma studies (9).
Heterogeneity in IgE Antibody Measurements 
from Different Assay Types and Manufacturers
In most multiplex assays, the small quantities of the 
individual allergens bound to a solid phase contrast 
with the higher IgE antibody binding capacity 
present on individual hydrophilic polymer and bead-
based allergosorbents that are used clinically. Law 
of Mass Action constraints cause these assays to 
detect different distributions of allergen-specific IgE 
antibody in any given serum. The amount of antibody 
detected in the assay is dependent on multiple factors 
including the IgE antibody’s concentration, affinity, 
epitope specificity, IgE specific activity (specific to 
total IgE ratio) (10) and level of non-IgE antibody 
specific for the allergen (1). The more antigen-
limiting multiplex allergosorbents tend to bind more 
allergen-specific IgE antibody when it is higher in 
concentration, has a higher affinity, the serum has a 
higher specific IgE antibody to total IgE ratio and a 
lower concentration of competing allergen-specific 
non-IgE (typically IgG) antibody. These mass action 
considerations have important assay performance 
consequences, especially when analyzing sera with 
nanogram quantities of IgE antibody that are present 
with high microgram/ml levels of allergen-specific 
IgG antibody. Such high IgG anti-allergen levels can 
result from inadvertent natural exposure to high 
levels of allergen or hyper-immunization through 
allergen immunotherapy. IgG antibody competes 
with the lower nanogram/ml levels of IgE antibody 
for limited allergen binding sites on the multiplex chip 
allergosorbent (11). This constraint has been cited as 
an advantage of the multiplex assay format in that its 
lower level of detected allergen-specific IgE antibody 
in the presence of high allergen specific IgG may more 
closely reflect the true biological consequence of IgG 
interference with allergen binding to IgE attached to 
effector cells.
Advantages and Limitations of Multiplex Assays
Table 2 summarizes commonly cited performance 
and assay design advantages and limitations of a 
multiplex assay in comparison with the singleplex 
assay. Multiplex assays are attractive because they 
tend to have a shorter turn-around time for result 
generation. They tend to use less specimen volume 
by simultaneously testing multiple IgE antibody 
specificities in a small surface area on the solid 
phase. Their assay design tends to be simpler, with 
fewer reagents and less technician time that reduces 
overall costs. Multiplex assays, especially in a hand-
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held cassette format, are attractive for use as point 
of care tests (12). These advantages are offset 
by the multiplex assays’ potentially lower limit of 
quantitation, reduced ability to provide quantitative 
levels of antibody for each respective IgE specificity, 
and an increased challenge in optimizing the assay 
which involves simultaneous quality control of many 
immobilized allergens. There is the potential for 
greater inter-lot variability as a result of the need 
to balance multiple reagents in different spots on a 
single allergosorbent. The fixed allergen menus of 
the multiplex assay encourages the testing of IgE 
antibody for unwanted or unnecessary specificities. 
Finally, there can be additional expense associated 
with the need to purchase new equipment to perform 
a multiplex assay.
Table 2
Advantages and Limitations of Singleplex and Multiplex Assay Technology for Allergen-specific IgE Testing 
that Utilizes Allergenic Molecules (Components)
Singleplex IgE Antibody Assay Multiplex IgE Antibody Assay
Performance Related Advantages (pro)
* Increased assay analytical sensitivity (lower Limit of 
Quantitation, LoQ)
* Potentially more precise quantification and precision, 
facilitating comparisons between different allergen 
reagents (extracts versus molecules)
* More established internal and external quality control 
measures (proficiency testing)
* Increased speed of analysis and reduced result turn-
around time
* Conservation of sample volume facilitating pediatric 
testing
Assay Design and Cost Related Advantages (pro)
* Traceable of allergen-specific IgE values to a total 
human IgE International Reference Preparation
* Similar units for total IgE and allergen-specific IgE due 
to heterologous calibration (permits calculation of 
allergen-specific IgE/total IgE-ratio)
* Global availability in many countries
* In case of limited number of samples more cost efficient
* Minimizes unneeded testing 
* Greater simplicity
* Reduced cost due to fewer required reagents
* Reduced technician intervention
* Optimal design applications for point of care tests
Performance Limitations (con)
More costly due to increased need for reagents
More technical intervention
Limited answers in case of few samples per subject
Expensive in case of large scale screening (i.e. multi-
sensitized subjects)
* Potentially lower analytical sensitivity for each analyte 
specificity measured (higher limit of detection, LoD)
* Reduced ability to accurately quantify each IgE 
antibody
* Encouragement of abusive testing which involves the 
measurement of unwanted or unneeded IgE antibody 
specificities
Assay Design and Cost Related Limitations (con)
* More serum required, particularly in case of many 
samples
* Potentially slower analysis
* Likely more sophisticated assay format
* Less global availability
* Cost of the new instrumentation and reagents
* Greater challenge in managing different levels of non-
specific binding
* Enhanced challenges in optimizing, balancing and 
standardizing assay reagents and assay quality control
* Potential greater inter-lot variability
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CURRENT ASSAY TECHNOLOGY
Common IgE assay systems based on singleplex 
technology
Many versions of the “classical” IgE assay format have 
been cleared by governmental regulators over the 
years. Worldwide, three singleplex autoanalyzers that 
use the “classical” allergosorbent design dominate 
the current clinical laboratory market. These are 
the ImmunoCAP (Thermofisher Scientific/Phadia); 
Immulite (Siemens Healthcare Diagnostics) and the 
HyTEC88 (Hycor Biomedical). The latter Hycor assay 
is being replaced with a new autoanalyzer called 
the Falcon. In Europe, there are additional assays 
with the EU mark that use a similar assay design but 
that are not available worldwide for use in clinical 
laboratories. The performance characteristics of the 
three predominant singleplex autoanalyzers have 
been assessed using masked patient specimens 
and inter-laboratory proficiency data (13). All three 
singleplex autoanalyzers use an analogous total 
IgE calibration curve. They display good precision, 
reproducibility and they report down to the same 
0.1 kUA/L limit of quantitation. Multiple studies 
have confirmed, however, that they report different 
levels of IgE antibody for any given specificity, which 
indicates that they detect different distributions 
of allergen-specific IgE antibody (13-15). This is 
most probably due to the use of different allergen-
containing reagents and possibly a result of slightly 
different procedures for assay calibration and data 
computation.
Introduction of single molecules (components) 
into singleplex and multiplex assays
The single most important scientific advance to 
impact on the use of multiplex assays in the diagnostic 
allergy laboratory has been the identification since 
2000 and purification of allergenic components 
from principal aero-, food and venom allergens 
as discussed extensively throughout this book. 
Molecular biology techniques have been employed 
to generate recombinant forms of many of the 
allergens and others are isolated from extracted 
native sources using various purification procedures. 
Allergen libraries have been created as illustrated 
by the food allergen library from the EuroPrevall 
project that has established rigorous verification 
and purity requirements for allergenic molecules. 
Well-characterized allergenic components from 
cow’s and goat’s milk, chicken egg, fish, shrimp, 
hazelnut, peanut, celery and fruits from the Rosaceae 
family (apple and peach) have been produced. 
Documentation of these allergenic components has 
involved extensive analytical, immunochemical and 
3-dimensional structural analyses.
The availability of unlimited quantities of the 
molecular allergens has allowed multiplex chip 
microarray based assay methods to be used for 
rapid simultaneous evaluation of human sera for IgE 
antibodies to multiple allergen specificities. The most 
important illustration of technology transition from 
singleplex to multiplex assays has involved the chip-
based multiplex IgE antibody assay initially reported 
by Hiller et al. (16). The original chip-based microarray 
utilized 94 purified allergen molecules, which were 
covalently immobilized in fixed microdot arrays on 
a pre-activated glass slide. IgE antibody profiles 
of allergic individuals were evaluated to disease-
causing allergens in a single multiplex analysis 
using 40 microliters of undiluted serum. With this 
report, serious clinical application of both allergenic 
components and multiplex assay methods because 
available to evaluate individuals for allergic disease. 
From this initial proof of concept, the repertoire of 
allergens has increased and the assays’ lower limit of 
quantitation and reproducibility have continued to 
improve. The commercially available version of this 
assay is the immune solid phase allergen chip or ISAC 
(Thermofisher Scientific/Phadia) which requires 40 
microliters of serum to detect IgE antibody to 112 
individual allergenic molecules that are in a static or 
planar array on a glass slide (17-19). The ISAC reports 
IgE antibody levels in ISU units, which are considered 
semi-quantitative (18). A good correlation exists 
between the summed IgE anti-cow’s milk components 
levels (Bos d 4, 5, 6, 8 and lactoferrin, r2=0.66) as 
measured in 44 sera from clinically milk allergic 
individuals by the singleplex ImmunoCAP (x-axis) 
and multiplex ISAC (y axis) (Fig. 2 upper panel). The 
correlation remains impressive when one compares 
the individual IgE anti-cow’s milk components (Bos 
d 4, 5, 6, 8 and lactoferrin, r2=0.77) as measured in 
the same sera by ImmunoCAP and ISAC (Fig. 2 lower 
panel). The lower analytical sensitivity of the ISAC, 
however, depends on the allergen in question (18, 
19) and is evident with many strongly positive IgE 
antibody levels as detected in the ImmunoCAP that 
are undetectable in the same sera when analyzed in 
the ISAC.
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Figure 2
Correlation between the summed IgE anti-cow’s 
milk (Bos domesticus [Bos d]) components as 
measured in the ImmunoCAP and ISAC (Bos d 
4:alpha lactalbumin + Bos d 5: beta lactoglob-
ulin + Bos d 6: bovine serum albumin; Bos d 8: 
casein + Bos d lactoferrin). (Lower Panel) Cor-
relation between individual IgE anti-cow’s milk 
(Bos domesticus [Bos d]) molecules as mea-
sured in the ImmunoCAP and ISAC (Bos d 4:al-
pha lactalbumin; Bos d 5: beta lactoglobulin; 
Bos d 6: bovine serum albumin; Bos d 8: casein; 
Bos d lactoferrin) The dashed lines indicate the 
positive negative cutoff for each assay: Immu-
noCAP 0.1 kUA/L; ISAC: 0.3 ISU. Reproduced 
from Reference 20.
Additional multiplex IgE assays used in research 
or in development
While the ISAC has been designed and thoroughly 
evaluated (18) for use with purified recombinant 
and native allergenic molecules, other assays have 
employed allergen extracts immobilized in chip 
microarrays and multiplex assay modifications.
A. A research version of the ISAC called the 
“Mechanisms for the Development of ALLergy” 
or MeDALL allergen chip has been produced with 
170 allergen molecules to more broadly study 
IgE and IgG antibody development in children 
(11) Using defined concentrations of chimeric IgE 
and IgG antibodies specific for Bet v 1, the study 
demonstrated that the simultaneous presence 
of IgG blocking antibodies can effectively inhibit 
IgE antibody binding to Bet v 1 allergen that 
has been immobilized on the multiplex chip. 
In contrast, the same levels of IgG anti-Bet v1 
produce minimal competitive interference in 
the more antigen laden singleplex ImmunoCAP. 
The authors suggest that the inhibition of IgE 
binding by IgG antibodies of the same specificity 
to limited allergen immobilized on the chip 
may more closely reflect biological responses 
under conditions of natural allergen exposure. 
However, the clinical relevance of this inhibition 
needs further investigation. The smaller amount 
of allergen on the chip also reduces the working 
range of the IgE antibody assay in comparison to 
the singleplex ImmunoCAP, whose allergosorbent 
has 10,000,000 times more allergen coupled (11).
B. In 2015, Williams et al. (21) reported comparative 
testing with ISAC, ImmunoCAP and puncture skin 
testing of a chip-based multiplex autoanalyzer called 
the MicrotestDx In contrast to the ISAC, it uses 
100 microliters of serum and employs 19 allergen 
extracts and 16 allergenic molecules covering a 
total of 26 aero- and food-allergen specificities that 
are covalently immobilized onto a precoated chip in 
triplicate. This is a scaled down version of a proof 
of concept assay that used 95 allergen extracts and 
8 recombinant proteins which were immobilized 
on aldehyde-activated glass microscope slides 
(22). These initial IgE antibody comparative data 
are encouraging as qualitative positive/negative 
agreement between the methods ranged from 
81% to 87% and semi-quantitative (negative, 
low, moderate and high) agreement among the 4 
methods ranged from 60% to 77% (86).
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C. Wiltshire et al. spotted a small number of allergen 
extracts on activated microarray slides and used 
an interesting rolling DNA circle amplification 
strategy to detect IgE antibody bound to 
immobilized allergen (23). Feyzkhanova et al. (24) 
photo-induced copolymerization of 21 allergens 
[15 extracts and 6 molecular allergens] into a 
hydrogel covered chip and used 60 microliters 
of serum to perform IgE antibody microarray 
analyses. Renault et al. (25) reported a microarray 
assay in which 350 defatted and extracted foods 
were imprinted on slides (4800 dots per slide) 
and human IgG, IgA, IgM and IgE antibodies 
were simultaneously detected in serum using a 
4 laser scanner. Joshi et al. (26) reported on an 
ultrasensitive carbohydrate-peptide surface 
plasmon resonance imaging microarray in which 
they immobilized peptide and xylosyl glycoside of 
Ara h 2 onto carboxylated gold slides and amplified 
the response with 1 micron diameter magnetic 
beads coated with ~60,000 polyclonal anti-IgE 
molecules. These proof of concept microarrays 
that have used novel imaging systems and 
allergen extracts bound to chips raise theoretical 
concerns about the analytical sensitivity of the 
assays and whether the limited binding capacity 
of microdot surface on an activated glass chip 
can immobilize sufficient molar concentrations 
of allergen (especially from allergen extracts) to 
quantitatively bind IgE antibody in the presence 
of other antibody isotypes.
D. Alternative multiplex technologies are capable 
of detecting IgE antibody in human serum. The 
Luminex bead based suspension array assay 
uses fluorescent microspheres are coupled with 
allergen, one specificity per bead type. Each 
bead type emits a different internal fluorescence 
that allows them to be distinguished from each 
other in a flow cytometer when they are mixed 
together. Each well of a microtiter plate is loaded 
with a mixture of bead types (50 microliters; 2000 
beads) and serum (50 microliters at 1:4). Following 
an incubation and wash, bound IgE antibody is 
detected with biotinylated anti-IgE and avidin-
phycoerythrin. The fluorescence intensity on the 
surface of the individual bead types is quantified 
and interpolated from a (fluorescent intensity vs 
total serum IgE) calibration curve. In a proof of 
concept study, this assay was able to measure IgE 
antibody specific for 6 aeroallergen components 
from dust mites (Der p 1, Der p 2), cat dander (Fel 
d 1), dog dander (Can f 1), birch tree pollen (Bet v 
1) and Timothy grass pollen (Phl p 5) (27).
E. A different multi-array approach has been employed 
by Meso-Scale Discovery (28). In an unpublished 
proof of concept analysis, α-lactalbumin, 
β-lactoglobulin A/B, α- β- ĸ-casein, lactoferrin and 
BSA proteins were individually biodotted onto 
separate spots in NPT 9-spot plates. Each spot 
within the same reaction well permitted a separate 
antibody specificity to bind. Following reaction 
with milk allergic sera, bound IgE antibody was 
detected with Sulfo-Tag-labeled anti-human IgE 
antibody. Bound labeled antibody when exposed 
to an electrical pulse generated chemiluminescence 
through an oxidation-reduction reaction that was 
measured in an automated reader. Response levels 
were interpolated from a calibration curve into 
IgE antibody units. In unpublished pilot studies, 
significant correlations have been shown between 
the NPT9-spot plate assay and the singleplex 
ImmunoCAP generated estimates of IgE antibody 
levels.
F. A proof of concept study investigated a vertical 
flow allergen microarray assay with 10 purified 
allergenic molecules at 3 concentrations 
that were immobilized on 0.1 um pore size 
nitrocellulose membranes (29). Bound IgE 
antibodies from human sera were detected 
with gold nanoparticle bound anti-IgE using a 
colorimetric readout. Its precision and relative 
concordance with the singleplex ImmunoCAP 
were encouraging. However, to apply the vertical 
flow strategy, additional verification analyses 
are needed to further validate the technique 
using direct comparison studies with clinical 
specimens that have been analyzed in parallel 
with established single and multiplex IgE assays.
G. A novel nanotechnology biosensor point of care 
test reported by Abionic has been developed in 
which serum is mixed with fluorescently labeled 
anti-IgE and the mixture added to a capsule 
containing 10 allergenic molecules coupled 
to a biosensor surface. Capillary action drives 
allergen-specific IgE to bind to immobilized 
allergen and fluorescent molecular complexes 
are then optically measured by the abioSCOPE 
reading unit. The fluorescent response is finally 
translated to an IgE antibody dose. This is 
graphically overviewed by Chapman et al. (30).
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RATIONALE FOR THE INTRODUCTION OF 
ALLERGENIC MOLECULES INTO CLINICAL 
IGE ANTIBODY ASSAYS
The use of single allergens (molecules/components) 
that have been prepared by purification from native 
sources or molecular recombinant methods can 
enhance the clinical performance of serological IgE-
assays in different ways (Fig. 3 and 4). Recombinant 
allergens can be generated with or without cross-
reactive carbohydrate determinants while allergenic 
molecules purified from native sources will have a 
mixture of isoforms and carbohydrate determinants. 
All available allergenic molecules of one allergen 
source can be used as a mixture in place of a complex 
natural allergen extract mixture (Fig. 3A). While this 
approach is theoretically feasible, so far it has not been 
considered as a serious option since it is considered 
cumbersome, possibly not all inclusive of relevant 
allergens, expensive and thus of questionable benefit. 
A second approach is to use allergenic molecules 
individually as single reagents in a singleplex or as 
individual replicate spots in multiplex microarray 
assays for targeted allergen-specific IgE detection (Fig. 
3B-1 component). This is at present the most common 
use of molecular allergens. Third, selected single 
molecular allergens of a given allergen specificity can 
be combined and used as single molecular mixtures for 
allergen-specific IgE detection (Fig. 3B-2 component). 
To illustrate this approach, an equal molar mixture of 
the unique marker allergens Phl p 1 and Phl p 5 for 
Timothy grass sensitization are also representative 
of sweet vernal grasses. Alternatively, a combination 
of highly cross reactive allergenic molecules like Phl 
p 7 and Phl p 12 which are the polcalcin and profilin 
representatives of Timothy grass pollen can be used to 
identify a patient’s sensitization to other cross-reactive 
polcalcin and/or profilin pan-allergen specificities. 
Fourth, single components can be added to allergenic 
extracts (“spiked”) to increase assay sensitivity. This 
has been particularly useful for Hevea brasiliensis latex 
where Hev b 5 is underrepresented as a result of being 
in low abundance or missing from certain extracts 
(Figures 3C and 4A). While, spiking physiological 
allergen extracts can enhance the assay’s limit of 
quantitation and increase its analytical sensitivity, it 
can lead to problems. For instance, supplementation of 
hazelnut ImmunoCAP (F17) with recombinant Cor a 1 
caused Bet v 1-specific IgE to be increasingly detected. 
This led unsuspecting clinicians to puzzle over the 
elevated values of IgE anti-hazelnut in the serum of 
their patients who subsequently were confirmed to 
have birch pollen allergy (32). The use of all available 
components (Figure 3A) in a microarray format can 
allow targeted and more precise differentiation of the 
individual’s sensitization profile from their allergen-
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Figure 3
Use of allergenic molecules in singleplex and multiplex IgE antibody assays. Modified from (37) with kind 
permission of Dustri-Verlag, Deisenhofen-Munich, Germany.
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Figure 4
Reagent patterns based on allergen sources/extracts (upper row), with typical reasons why it is valuable 
to use allergen molecules as reagents in allergen-specific singleplex IgE assays (middle row) and how IgE 
anti-allergenic molecule results can enhance the final analytical sensitivity and specificity of the generated 
assay results. Table 3 provides specific examples that correspond with the conditions depicted in depicted 
in this figure (adapted from (31) with kind permission of Springer Science and Business Media).
Table 3
Utility of allergen molecules as reagents from various allergen sources/extracts (left column), reasons and improved 
assay performance (upper row) will vary due to the individual diagnostic question and the specific allergen applied. 
Variants 1 2 3 4
Examples  
(allergen source, 
allergen carrier)
Increased analytic 
sensitivity
Increased analytical 
specificity/selectivity
Cross-reactive 
allergens
Species/family-
specific major 
allergens
cat Fel d 2 Fel d 2 Fel d 1
hazelnut Cor a 1  (Bet v 1-homologue)
Cor a 14 (2S albumin)
Cor a 9 (11S globulin)
Cor a 8 (LTP, mediterranean)
kiwi Act d 8  (Bet v 1-homologue)
Act d 8 (Bet v 
1-homolog)
peach Pru p 1  (Bet v 1-homologue)
Pru p 3 (LTP, marker, 
mediterranean)
Pru p 1 (Bet v 
1-homolog), 
Pru p 4 (Profilin)
peanut Ara h 10, Ara h 11 (oleosins)
Ara h 1 (7S globulin)
Ara h 2 (2S albumin)
Ara h 3 (11S globulin)
Ara h 6/7 (2S albumin)
Ara h 9 (LTP, mediterranean)
Ara h 8 (Bet v 
1-homolog)  
Ara h 5*
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specific IgE response. This approach has been coined 
“Component-Resolved-Diagnostic” (CRD) (31) and it 
represents the most important option in molecular 
allergy diagnosis.
The utility of single allergenic molecules can be 
justified by four conditions (Fig. 4 and Table 3)(4). 
First, the assay’s sensitivity can be improved by 
lowering its limit of quantification (LoQ, Textbox 1) 
while increasing its analytical specificity. Second, if 
allergen molecules are in low abundance or missing in 
the extract such as Cor a 1 in hazelnut or Gly m 4 in 
soy, supplementation improves the assay’s sensitivity 
(LoQ). Third, if allergen molecules are unique to 
a specificity such as Fel d 1 for cat or Bet v 1 for 
birch, their use can improve the analytical specificity 
(“selectivity”) of the assay. This allows additional 
clinical assumption(s) such as assessing increased 
risk for severe symptoms. Finally, certain allergenic 
molecules such as Ara h 8 (Bet v 1 homologue) for 
peanut and Phl p 7 and 12, the polcalcin and profilin 
representatives in Timothy grass, can serve as 
indicators for serological cross sensitizations through 
the binding of cross reactive IgE. In case of a positive 
result, they can demonstrate the lack of analytical 
specificity of an IgE test with allergen extracts in 
affected subjects with potential cross-reactions.
ASSAY PERFORMANCE EVALUATION: ASSAY 
SENSITIVITY AND ANALYTICAL SPECIFICITY 
(SELECTIVITY)
The analytical performance characteristics of 
laboratory tests and their predictive value in defining 
Table 3 (continued)
Variants 1 2 3 4
Examples 
(allergen source, 
allergen carrier)
Increased analytic 
sensitivity
Increased analytical 
specificity/selectivity
Cross-reactive 
allergens
Species/family-
specific major 
allergens
soy Gly m 4  (Bet v 1- homolog) Glym 5, Gly m 6
wheat Tri a 19 (omega-5-gliadin)
meat alpha-GAL alpha-GAL
honeybee venom Api m 3, Api m 4, Api m 10
Api m 1, Api m 3, Api m 4, 
Api m 10
Api m 1, Api m 3, 
Api m 4, Api m 10
yellow jacket venom Ves v 5 Ves v 1, Ves v 5 Ves v 1, Ves v 5
birch (hazel, alder, birch 
pollen) and beech trees 
(beech, oak pollen)
Bet v 1 Bet v 2*,Bet v 4** Bet v 1
oleaceae (ash, olive 
pollen) Ole e 1
Ole e 2* 
Ole e 3** Ole e 1
poaceae (pollen  
from moderate climate 
grasses) 
Phl p 1 
Phl p 5
Phl p 12*  
Phl p 7**
Phl p 1,  
Phl p 5
mugwort pollen Art v 1 Art v 4*,  Art v 5** Art v 1
ragweed pollen Amb a 1 Amb a 8* Amb a 10** Amb a 1
bolded letters indicate availability as reagents mainly non-USA, (eg Europe, Japan); regular letters: not (yet) available as reagents, * profilin (pan-
allergen in pollen and plant foods), **polcalcin (pan-allergen in pollen); (adapted from (31) with kind permission of Springer Science and Business 
Media)
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Textbox 1
Common definitions to describe performance characteristics of a laboratory test (i.e. allergen-specific IgE 
assay)
Analytical sensitivity is equivalent to the slope of the calibration curve of an (immuno)assay. In contrast assay 
sensitivity in real terms (=lowest test “cut-off”) is currently calculated and provided with following, internation-
ally harmonized variables: 
  limit of blank, LoB (i.e. signal of a serum sample without allergen-specific IgE)
  limit of detection, LoD (i.e. signal of a serum sample with the lowest detectable allergen-specific IgE)
  limit of quantitation, LoQ (i.e. signal of a serum sample with the lowest allergen-specific IgE at a predefined 
assay precision)
Analytical specificity of an allergen-specific IgE assay can, first, be related to the specificity of the detected Im-
munoglobulin class, meaning the test will indeed measure IgE and not immunoglobulins of other classes (IgA, 
IgD, IgG or IgM) 6. 
A second definition relates analytical specificity to a targeted, more selective IgE-detection against single al-
lergenic molecules.  While an allergen extract, consisting of complex protein mixtures, ideally binds the entire 
IgE-repertoire to a specific allergen source, the use of single allergen molecules will only detect a part of the 
IgE-repertoire.  Thus, the analytical specificity (selectivity) will be increased. 
the presence and severity clinical disease have been 
internationally defined by variables such as sensitivity 
and specificity (Textbox 1) (1). Two pairs of definitions 
separate the IgE antibody test’s analytical sensitivity 
and specificity (Table 4, left column, 1-4) from its 
diagnostic sensitivity and specificity (Table 5, right 
column, I-IV) that discriminate among the various 
clinical allergy phenotypes. These definitions have 
been adopted as part of international guidelines for 
IgE antibody assays through the Clinical Laboratory 
Standards Institute (CLSI) (1). They are particularly 
important to consider when allergenic molecules 
are substituted into an IgE antibody assay (31). 
Their importance stems from the observation that 
introducing single allergenic molecules into an IgE 
antibody assay frequently improves the analytical 
variables in the left column of Table 4 and this has 
a direct effect on changing the diagnostic clinical 
discrimination of disease as defined by the parameters 
in the right column of Table 4.
The extent to which an assay performance 
improvement translates into improved diagnostic 
clinical discrimination of disease depends on (a) the 
cohort of individuals being evaluated in terms of their 
age, disease spectrum and severity, (b) the availability 
and selection of the specific allergenic molecules 
used in the IgE assay, and (c) the preselected study 
endpoints defined by the clinician (33). This means that 
the diagnostic-clinical criteria [right column, I-IV, Table 
4] need a thorough individual interpretation based 
on each IgE antibody test result using the patient’s 
previous history and if needed, additional proof of 
reproducible and objective symptoms in the affected 
allergic subject upon allergen exposure (i.e., challenge 
test). As a consequence, these clinical criteria extend 
beyond the essential “raw” allergen-specific IgE 
antibody assay result (e.g., IgE sensitization in question: 
yes or no). Together these facts support the conclusion 
that it can be misleading to use sensitization test 
results to define the diagnostic clinical criteria of an 
IgE antibody test (31, 34).
One example is enhancement of the analytical 
sensitivity of an IgE antibody assay by supplementing 
an extract with a labile allergen molecule (Hev b 5 
into the Hevea brasiliensis extract) prior to use in 
preparing the allergosorbent. The additional Hev 
b 5 improves the analytical sensitivity by lowering 
the assay’s limit of quantitation (LoQ), and thus 
increasing the test’s diagnostic sensitivity without 
compromising the analytical specificity of the test. 
Alternatively, in patients with wheat-dependent, 
exercise-induced anaphylaxis (WDEIA), only 20-30% 
of the subjects have IgE-mediated sensitization to 
wheat flour extract. However, 80-90% of these cases 
demonstrate allergen-specific IgE to Tri a 19 (Omega-
5-gliadin). This gliadin is often responsible for WDEIA, 
however, it suffers from a poor aqueous solubility and 
is therefore not well represented in wheat extracts. 
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Table 4
Potential criteria for assessing assay improvement of sensitization tests following the replacement of aller-
gen extracts with allergenic molecules 
analytical criteria
(potential assay improvement)
diagnostic-clinical criteria
(potential clinical advantages)
1. >”analytical” sensitivity<limit of quantitation (LoQ) I.
>diagnostic sensitivity (proportion of positive IgE antibody 
tests in patients with allergic disease)
2. >analytical specificity II. >diagnostic specificity (proportion negative IgE antibody tests in healthy individuals )
3. indicator of serologicalcross reactivity III.
indicator of clinical crossreactivity (allergic symptoms to 
allergenic sources that did not elicit the primary sensitization)
4. marker of primary/genuine sensitization IV.
prediction of clinical reactions (PPV, NPV, thresholds, 
likelihood ratio etc.)
(adapted from (31) with kind permission of Springer Science and Business Media)
By using recombinant Tri a 19 as a reagent in the IgE 
antibody assay, the assay’s sensitivity (lowered LoQ) 
is immediately improved.
Another asset of the use of defined allergenic 
molecules is the restriction that it provides to 
the assay. This is especially important when IgE 
immune responses need to be detected to allergenic 
specificities that are highly stable or in relatively high 
abundance (i.e. Ara h 2 or Cor a 14). Their use makes 
the measurement of IgE antibody more targeted or 
analytically specific. Identification of IgE immune 
response patterns to the 2S albumins, Ara h 2 and 
Cor a 14 (Table 3), have been repeatedly associated 
with an increased risk for severe reactions to foods 
and they can facilitate decisions about the possible 
elimination of an oral food challenge. Alternatively, 
in a non-selected population study, more than 10% 
of German children and adolescents demonstrate 
allergen-specific IgE to peanut extract that is 
predominantly linked to serological pollen-associated 
cross reactions (35). Moreover, diagnostic tests with 
the stable and risk-associated peanut storage allergen 
(Ara h 2) show elevated allergen-specific IgE in only 
a small proportion of the general children/adolescent 
population (approximately 0.2% to 0.4%) (Kirsten 
Beyer, personal communication). Thus IgE anti-Ara 
h 2 provides a much higher analytical specificity 
(“selectivity”) than the use of a peanut extract based 
allergosorbent.
CLINICAL EVALUATION: DIAGNOSTIC 
SENSITIVITY AND SPECIFICITY
Diagnostic sensitivity and specificity are related 
to a clinical history and physical examination 
based assessment of affected and non-affected 
subjects. Requirements for proper calculation and 
interpretation of the diagnostic sensitivity and 
specificity of IgE antibody tests of sensitization 
require sound clinical data from the subject´s case 
history and in some cases additional challenge 
tests to back up the clinical diagnosis (Table 4, right 
column). However, the presence of allergen-specific 
IgE is strictly a marker for allergic sensitization 
(risk for allergy) and it alone cannot predict the 
probability of a clinical reaction per se (31, 34). Thus, 
concordant results (case history and allergen-specific 
IgE with a positive clinical or challenge outcome) are 
effectively considered as clinically relevant (rather 
than being labeled as true positive). The same applies 
for concordant negative results, which are used to 
exclude a clinical state of allergy and an underlying 
state of allergic sensitization. In case of positive 
allergen-specific IgE results and a negative case 
history or provocation test, however, consideration 
should be given to labeling these discordant results 
as clinically irrelevant (rather than false positive). 
Labeling clinically irrelevant as false positive results 
actually misses the key point of the analysis, since the 
presence of allergen-specific IgE itself should not be 
disputed, but rather considered valid in its own right 
as a marker for atopy and IgE-sensitization.
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A number of clinical studies have explored diagnostic 
sensitivity and specificity of IgE tests with single 
allergens from a particular allergen source. The use 
of previously missing or less represented allergens 
in IgE antibody assays was able to increase its 
diagnostic sensitivity through the improvement 
of assay sensitivity, usually by lowering the assay’s 
limit of assay quantitation (Tables 3 and 4). As a 
consequence, higher rates of sensitization were 
found, in general, even among subjects without 
clinically relevant reactions or disease.
The reciprocity of diagnostic sensitivity and specificity 
is a general feature of diagnostic tests. It is usually 
depicted as Receiver Operating Characteristics (ROC) 
curves (general example see Figure 5B). Some single 
allergens like Ara h 2 or other risk-associated allergens 
belonging to the seed storage protein family of 
2S-albumins have been found to increase diagnostic 
sensitivity and specificity of a patient’s evaluation by 
assessing the risk of severe clinical reactions. Using 
risk-associated 2S-albumins, predictive allergen-
specific IgE-thresholds (“decision points”) have been 
defined to forecast a positive or negative oral challenge 
in children with peanut or hazelnut allergy (35).
Despite the performance of elaborate and elegant 
clinical studies, they have produced rather variable 
outcomes with group effects, displaying considerable 
overlap between i.e. clinically affected and non-
affected (tolerant) individuals (Fig. 5C). Presenting 
data with smoothed probability plots (Fig. 5D) 
suggests a close relationship, suitable for individual 
prediction with the collected data. However, results 
of sensitization tests like the allergen-specific 
IgE assays cannot yet (and presumably never will) 
reliably predict clinical reactions (or their non-
appearance) (36). Therefore, future studies on the 
diagnostic value of allergenic molecules should 
establish as their primarily goal, the improvement of 
well-defined methodological variables (Table 3, left 
column) that are linked to the analytical performance 
characteristics of the assay. This should be done 
even without a complete clinical evaluation of the 
assay which includes the assessment of the assay’s 
diagnostic sensitivity and specificity, predictive 
values and likelihood ratio (Table 3, right column), 
the analytical performance of IgE assays can be 
substantially improved in many cases by the use of 
allergenic molecules that are used in parallel with or 
in place of allergen extracts. This conceptual view 
has already been adopted by international guidelines 
on allergen-specific IgE assays (1). It should further 
Figure 5
Typical data analysis of IgE antibody laborato-
ry data with single allergenic molecules. A: As-
sociation of log distributed allergen-specific 
IgE concentrations to a natural (x axis) versus 
recombinant (y-axis) allergen molecules. B: Di-
agnostic efficacy (Receiver Operating Charac-
teristics, ROC) displaying performance of IgE 
antibody assays with allergen molecules as com-
pared to extracts; C. Single values of allergen 
molecule-specific IgE antibody with the median, 
25% and 75% percentiles that are presented to 
compare groups. D: Threshold levels of IgE an-
tibody that are used to predict the probability 
of a clinical reaction (i.e. 95% probability of a 
positive oral food challenge). (Reproduced from 
(37) with kind permission of Dustri-Verlag, Dei-
senhofen-Munich, Germany).
facilitate and possibly accelerate the evaluation and 
clinical acceptance of allergenic molecules into the 
diagnostic algorithm for human allergic disease.
Determination of the Clinical Relevance of an 
IgE Antibody Assay
 The ultimate and essential question with diagnostic 
allergy testing is “what is the clinical relevance of an 
allergen-specific IgE measurement”? Even in this era 
with the availability of molecular allergens, the basic 
rule still applies. Namely, a positive allergen-specific 
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IgE result represents a state of allergic sensitization 
(risk for allergic disease), but not proof of allergic 
disease (31, 36). A positive IgE antibody response 
is only clinically relevant in the case that there are 
objectively defined corresponding allergic symptoms 
that are temporally associated with a known allergen 
exposure. A negative allergen-specific IgE result 
against one recombinant allergen molecule or a 
mixture of natural isoforms of one single allergen 
can generally exclude an allergic sensitization or 
risk of allergy to that allergen specificity in question. 
This is, however, only possible if the total IgE is high 
enough (i.e. >20 kUA/L), the allergen reagent is in 
sufficient abundance, fully intact, and presenting all 
its epitopes and the analytical performance of the IgE 
antibody assay has been optimized for a low limit of 
quantitation (i.e. 0.1 kUA/L).
In conclusion, the clinical relevance of an allergic 
sensitization (i.e. presence of allergen-specific 
IgE) independent of the use of allergen extracts or 
molecules for diagnostic purposes can ultimately only 
be determined by the physician and not by the test 
(1, 31, 34, 36). Therefore, the complete diagnostic 
results of sensitizations tests, including allergen-
specific IgE assays that have been improved by the 
use of allergenic molecules, will always have to be 
interpreted in the clinical context and on the basis of 
the individual´s case history.
SUMMARY
For the foreseeable future, several clinically validated 
singleplex assays that use allergen extract-based 
reagents will remain the principal assays employed 
worldwide by clinical immunology laboratories to 
serologically document sensitization (IgE antibody) in 
patients with a positive history of allergic disease. Novel 
molecular allergen-based multiplex assays will remain 
invaluable research assays. Allergen extract-based 
reagents used in the singleplex assays will currently be 
judiciously supplemented with an increasing number 
of allergenic molecule-based reagents. Principal 
among these are molecular allergens from peanut 
and hazelnut that (a) improve analytical sensitivity by 
providing molar excess of missing or low abundant 
allergens (e.g. Ara h 8 in the peanut extract; Cor a 1 in 
the hazelnut extract), (b) enhance the assay’s analytical 
specificity by defining a clinical risk for systemic 
reactions (Ara h 1,2,3 [severe] versus Ara h 8 [more 
mild]) and (c) distinguish cross-reactivity versus (d) 
genuine (primary) sensitization (Cor a 9,14 [genuine] 
versus Cor a 1 [Bet v 1 cross-reactive] sensitization 
to hazelnut). The clinical relevance of allergen-specific 
IgE detection in a patient’s serum is strictly as a marker 
for allergic sensitization (risk for allergy) and it alone 
cannot predict the probability of an allergic reaction. 
The determination of the diagnostic sensitivity and 
specificity of IgE antibody assays will thus remain 
difficult to definitively determine because of the lack 
of an absolute method of defining the presence of 
allergic disease. This means that the clinical relevance 
of an allergic sensitization (i.e. presence of allergen-
specific IgE) independent of the use of allergen extracts 
or molecules for diagnostic purposes will ultimately be 
determined only by the physician and not by the test.
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Skin and other provocation testing with 
molecular allergens is safe and may provide 
important information beyond extract 
testing.
Basophil activation testing of molecular 
allergens is a good alternative prior to skin or 
other provocation testing
INTRODUCTION
The issues covered in this section (in vivo testing with 
recombinant allergens (1) and basophil activation (2) 
have recently been reviewed.
Think molecular when taking clinical history
The first line approach to the diagnosis of allergic 
disease is with a thorough clinical history and 
physical examination of the patient. When allergic 
symptoms appear on exposure to a relevant allergen, 
specific IgE sensitization is confirmed with second 
line investigation, i.e. with allergen- extract-based 
in vivo skin prick tests and /or serology. If there is 
a mismatch between the history and these primary 
diagnostic tests, basophil activation testing could 
assess the allergenic activity ex vivo. When required, 
a third line provocation test (conjunctival, nasal or 
bronchial allergen challenge, placebo controlled food 
challenge) may confirm the diagnosis.
However, an increasing proportion of patients have 
inconclusive clinical history, symptoms profile and 
allergen extract testing, which may be solved by 
including component resolved diagnosis. These are 
Nikos Douladiris, Peter Korosec, Hans 
Jürgen Hoffmann
SKIN TEST, BASOPHIL 
ACTIVATION 
TEST (BAT) AND 
PROVOCATION TESTS
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patients with complex symptomatology that mainly 
originates from:
a) Poly-sensitization to three or more inhalant 
allergens with overlapping exposure periods 
to natural and work environment, with graded 
symptoms. Molecular allergens can contribute to 
efficient identification of genuine sensitization 
to eliciting allergens and reveal co-sensitization 
and/or cross-sensitization of closely related or 
widely different allergen sources.
b) Sensitization to one or more food allergens 
with graded severity of symptoms that appears 
on ingestion of graded quantity and/or degree 
of processing of food (raw, cooked, baked). 
Molecular allergens can be used to characterize 
the severity and assess the future risk of the 
reaction in relation to stability and any process of 
the offending (food) allergen.
c) Co-sensitization to inhalant and food allergens 
present with symptoms of known or obscure 
aetiology. Molecular allergens can be used to 
optimize the decision process of provocation 
tests, avoiding costly, time consuming, and 
potentially life-threatening reactions and improve 
allergen avoidance recommendations.
d) Sensitization to more than one insect venom 
allergen in patients with anaphylactic sting 
reaction, but confused culprit history of insect 
stings. Molecular allergens can contribute to 
efficient identification of genuine sensitization 
to culprit venom and reveal co-sensitization and/
or cross sensitization of different insect venoms 
and can facilitate accurate prescription of venom 
immunotherapy.
e) In case of suspecting idiopathic anaphylaxis 
allergen microarrays allow the simultaneous 
detection of patients’ antibody reactivity profiles 
towards a large variety of each of the molecular 
allergens, and this information is very helpful in 
establishing reactivity profiles and identifying of 
possible trigger.
Integrating component resolved diagnosis in first and 
second line investigations solves a number of difficult 
diagnoses.
SKIN TESTS
The usefulness of commercial whole-allergen 
extracts for skin testing is limited by the variation 
in the content of major and minor allergens, as 
well as by non-allergenic compounds they contain. 
Recombinant allergens or natural purified allergen 
molecules (referred to as: molecular allergens or 
allergen components or components) have been 
produced from all major allergen sources (e.g. pollens, 
mites, fungi, Hymenoptera venom, and food) and 
may be used for diagnosis and provocation testing; 
they were reviewed recently in detail (1).
Current evidence suggests skin allergy testing as a 
safe procedure, although in extremely rare occasions, 
fatalities have been observed with both skin 
provocation tests and - with a slightly higher rate 
with intradermal tests (3). No such reaction has been 
reported so far with molecular allergens. Allergen 
components are well defined and highly purified 
molecules with a narrow concentration range for 
optimal sensitivity and specificity. A comparison of 
possible advantages vs. disadvantages of available 
biological tests with allergen components is listed in 
Table 1.
Molecular allergens can promote diagnosis in skin 
testing significantly, contributing to both a more 
precise determination of sensitization pattern and 
a more targeted therapeutic approach. To that end, 
components could be used according to algorithms 
either complementary to, or instead of whole extracts, 
as they are proposed for in vitro use, in other sections 
of this handbook. The inclusion of recombinant or 
natural purified allergen molecules in current in vivo 
diagnostic methodology of allergic disease is a very 
promising task. Recent application of Molecular 
allergens in skin testing are listed in Table 2. Current 
high demands set by EU-imposed GMP and GCP may 
make this impossible, or at best an option for the 
distant future (4).
BASOPHIL ACTIVATION TESTING
Serum IgE reactivity to allergens informs about the 
concentration of specific IgE but not the individual 
allergenic activity of the measured specific IgE 
antibodies. As basophil activity depends on both 
reactivity and sensitivity, a basophil activation test 
(BAT) with molecular allergens not only identifies the 
allergen the patient is IgE sensitized to, but also the 
allergenic activity of these specific IgE antibodies.
Basophil activation is based on the fact that mast 
cells and basophil granulocytes share the pathway 
 EAACI Molecular Allergology User´s GuideEAACI Molecular Allergology User´s Guide Part  A:  Molecular Al lergology:  General  Concepts 2016
53Skin test, basophil activation test (BAT) and provocation tests
Table 1
Advantages and disadvantages of allergen extract vs. molecular allergens in allergy diagnostics
Allergen extracts Molecular allergens
Advantages Easy preparation
Inexpensive
Contain many allergenic proteins
Easy market authorisation
Detection of genuine sensitization.
Identification of cross reactivity as cause of a 
s-IgE measurement
Highly defined proteins
Highly purified proteins
Structure – amount of protein precisely known
More safe
Disadvantages Difficult standardization
Unknown allergen composition
Contains undefined components, i.e. endotoxins
Endogenous degradation – low sensitivity
Proteins mixture complexity – low specificity 
Laborious preparation (first set up)
Expensive (first set up)
Uncompleted yet panel of allergens for some 
allergen sources
Difficult market authorization
Table 2
An update of provocation and BAT assessment of recombinant allergens since 2013
Allergen Source Molecular allergen Modification Test
Nr 
Patients
Nr 
controls Conc
Ref 
(PMID)
Peanut Ara h 1, 2, 3 Hypo-allergenic
Rectral 
provocation 10 5 10-3063 mg (15)
Dermatophagoides 
farinae Der f 27 - SPT 19 . 10 mg/ml (16)
Dermatophagoides 
farinae Der f 29 - SPT 14 - Not listed (17)
Chenopodium 
album
Che a 1, 
Che a 2 and 
Che a 3
Hypo-
allergenic, 
natural
SPT 17 4 1 mg/ml (18)
Dog  
Canis familiaris
Can f 1, Can 
f 2, Can f 4 
and Can f 6
Fusion protein, BAT (19)
Grass  
Phleum partense Phl p 4
Natural, non-
glycosylated BAT (20)
Cockroach Per a 10 - Basophil histamine release (21)
Siberian hamster Pho s 1, 2, 3 - BAT 2 2 0-.1 – 10 mg/ml (22)
Felix domesticus Fel d 1, 2, 3 Fusion protein, mosaic protein BAT 21 1
0.1 – 100 
ng/ml (23)
Dermatophagoides 
pterinussinus Der p 2 - BAT 10 12
100 fg/ml – 
100 ng/ml (24)
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for anaphylactic degranulation after crosslinking of 
the high affinity receptor for the IgE (FcεRI) by IgE 
and allergen on the cell surface. Individual basophils 
with anaphylactic degranulation can be identified and 
distinguished from marginally activated basophils by 
upregulation of CD63 on activated basophils (2).
An allergen induces response in basophils through 
FcεRI (this is basophil reactivity), in concentrations 
where non-allergic patients would not react (this is 
basophil sensitivity). Basophil reactivity has been 
shown to correlate with symptoms. Once reactivity is 
documented, it could be useful to know the sensitivity 
of blood basophils to allergen - this requires testing 
at a broad range of allergen concentrations (typically 
in 3- or 10-fold steps of dilution). On the basis of this 
series of tests, basophil sensitivity can be determined 
from a non-linear line of regression. The sensitivity 
has been associated with patients’ threshold in 
allergen provocation (2). For example, diagnosis 
of peanut allergy usually requires a provocation 
as follow up on a positive skin prick test. Basophil 
sensitivity of sensitised patients was assessed before 
provocation testing. Basophil sensitivity with Ara 
h 2 gave the same clinical outcome as testing with 
peanut allergen (2). All patients tested negative in the 
basophil sensitivity test also passed a provocation 
test.
Insect venom allergy can be life threatening and is 
treated with a long course of AIT. The diagnostic 
process starts with measurement of specific IgE 
that often is positive for both bee and wasp whole 
allergen extracts. In contrast, in certain cases (e.g. 
mastocytosis) both tests may be negative. Assessment 
of reactivity to allergen components such as Api 
m1 (honey bee) and/or Ves v5/Ves v1 (wasp) has 
better diagnostic performance than measurement of 
serum IgE to whole extracts (5). Upgrading of those 
tests with component BAT demonstrates a further 
diagnostic improvement (6).
Basophil reactivity with olive pollen extracts and 
nOle e 1 was useful in the diagnosis of local allergic 
rhinitis (7).
Basophil testing is useful in the evaluation of the 
biological relevance of newly described molecular 
allergens. Reactivity to the recently discovered pan-
allergen Der p 23 was demonstrated, and the lack of 
response of a modified hypoallergenic form of Der p 
23 was confirmed by basophil testing (7). In the last 
few years all novel allergen components developed 
for diagnostic use or constructed as hypoallergenic 
vaccine (Table 2) were characterized by BAT for their 
allergenic activity (1, 2, 9, 10).
There are three major advantages of basophils testing 
compared with provocation testing:
a. The patient is not exposed to allergen. This saves 
both the patient and the health care system for 
resources, and requires only good manufacturing 
and laboratory procedures.
b. A number of single allergen molecules can be 
tested simultaneously as 75-100 μl blood is 
required for a single test, and allergen components 
can be combined to mirror a real life exposure.
c. CD63 upregulation is a precise marker of 
anaphylactic degranulation, and thus has a 
potential to reflect the severity of allergic 
reaction (2).
PROVOCATION TESTS
Allergen provocation testing has been among the 
finest tools in the allergologist’s quiver, setting 
the golden standard in certain conditions or being 
neglected due to standardization or safety issues 
in many others (11). Used mostly when observing 
discrepancies between clinical history and test results, 
provocation tests can provide critical information in 
clinical practice, along with serving for research (12).
Nasal allergen provocation testing is important 
when there are inconsistencies between clinical 
history and sensitization patterns. An important 
condition diagnosed by BAT or nasal provocation is 
the subgroup of patients suffering from local allergic 
rhinitis, with negative serum specific IgE and skin 
test results. Provocation with olive pollen extracts 
detected more sensitised patients with LAR than 
provocation with nOle e 1, but provocation with 
nOle e1 may be more specific (7). Nasal provocation 
should comply with EAACI guidelines. It is the 
provocation modality first and most frequently used 
for in vivo testing of molecular allergens (1) because 
the nose is accessible, and symptoms are easily 
standardised. Nasal provocation with component Bet 
v 1 and Art v 1 results in similar effects as provocation 
with natural pollen extracts (1) and skin testing with 
molecular allergens (Bet v1, Bet v 2 and Phl p 1, 
Phl p 2, Phl p 5) reflects the nasal response better 
than concentrations of serum IgE (13). The only trial 
with bronchial provocation of asthmatic patients 
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found comparable reactivity of component Bet v 
1 and natural allergen in skin prick tests, nasal and 
bronchial allergen provocation testing (14). Similarly, 
conjunctival provocation with component Bet v1 and 
birch extract found comparable allergenic reactivity 
of recombinant and natural products (1).
CONCLUSION
Molecular allergens may develop into a useful 
supplement in the clinic. Testing with allergen 
components is a part of the development of 
novel allergy vaccines and identification of non-
allergenic isoforms. Development of recombinant 
allergen products has been delayed by the large 
difference in requirements for marketing natural 
extracts and recombinant products. Due to those 
requirements it seems unlikely to have recombinant 
allergen molecules for in vivo test in near future. 
However, we expect dissemination of recombinant 
allergen molecules in BAT testing. CRD is useful in 
identification of patients genuinely sensitised to 
allergen sources and identification of patients cross-
reacting to pan allergens. These groups need to be 
treated differently. For now however, CRD need to 
be accompanied by clear explanation of the relevance 
and implication of positive and negative tests.
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ALLERGOLOGY: 
GENERAL 
CONCEPTS
PART A
A06
Proteins that share a common evolutionary 
origin - which is reflected first and foremost by 
their similar overall structure and topology - are 
grouped into families. Families with a common 
origin are grouped into superfamilies.
Very few of the almost 16,300 protein families as 
described by the protein family database Pfam 
families harbour allergens.
Proteins that are described worldwide as allergens 
can be classified roughly into 30 to 40 protein 
families.
Based on their molecular, biologic and biochemical 
properties, allergenic proteins are able to initiate 
both innate and adaptive immune responses 
during the sensitization process that ultimately 
result in the production of allergen-specific IgE.
Allergen databases make curated information 
available on the allergen nomenclature, allergen 
structures, allergen protein families, and the risk 
of allergenic cross-reactivity, or offer an uncurated 
extensive collection of information on allergens.
INTRODUCTION
The current version 29.0 of the Pfam (protein 
family) database (http://pfam.xfam.org/) describes 
16,295 protein families (1). Families are grouped 
together into superfamilies - called clans in Pfam - 
(e.g. the prolamin superfamily), and some families 
are further divided into subfamilies (e.g. the PR-10-
like proteins are a subfamily of the Bet v 1 family). 
A protein family is a group of proteins that share 
a common evolutionary origin, which is reflected 
first and foremost by their similar overall structure 
and topology (Fig. 1). Members of a protein family 
may also possess related biological functions and 
immunological characteristics as well as similar amino 
acid sequences.
The allergenicity of proteins is determined by a small 
number of protein architectures and thus are found 
in a rather limited number of protein families. The 
SDAP (https://fermi.utmb.edu/; accessed on March 
7, 2015) database of structures of allergenic proteins 
assigns all presently known allergens to 130 of the 
16,230 Pfam families. Proteins that are described 
worldwide as the most important allergens can be 
classified into roughly 30 to 40 protein families. 
Heimo Breiteneder
ALLERGEN FAMILIES 
AND DATABASES
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The most important families and selected allergenic 
member proteins are discussed here (Table 1).
Our understanding why exactly these types of 
proteins are able to trigger Th2-dominated immune 
responses is incomplete. Allergenic proteins that are 
able to sensitize predisposed individuals initiate both 
innate and adaptive immune responses. Such proteins 
are recognized by epithelial cells and dendritic cells 
that produce signals to polarize the immune response 
towards a Th2 phenotype. It has been clearly shown 
that the decision whether a protein will be treated 
as an allergen by the organism is made by the innate 
immune system (2-4). It is highly likely that allergenic 
proteins possess molecular features that enable 
them to activate the pattern recognition receptors 
of innate immune cells to induce a Th2 polarization 
of the ensuing immune response. These features 
include (i) the ability to bind lipids and to activate Toll-
like receptors - shown for Der p 2 from house dust 
mite (5) and for Fel d 1 from cat (6), (ii) the presence 
of glycosylation and thus the ability to bind to C-type 
lectin receptors – shown for allergens from house dust 
mite, pollen and peanut (7-9), or (iii) the presence of 
protease activity which allows the activation of the 
protease-activated receptor PAR-2 – shown for Der p 
3 and Der p 9 from house dust mite (10).
PROLAMIN SUPERFAMILY
The prolamin superfamily derives its name from 
the alcohol-soluble proline- and glutamine-rich 
storage proteins of cereal grains. Members of this 
superfamily are characterized by the presence of an 
alpha-helical globular domain. This domain contains 
Bet v 1 Pru av 1 Api g 1 Ara h 8
a conserved pattern of cysteine residues that form 
three to five intra-molecular disulfide bonds. Apart 
from the conserved cysteine pattern, only little 
sequence similarities exist between the members 
of different families. Members of the prolamin 
superfamily include the cereal prolamin seed storage 
proteins (gliadins and glutenins) and several families 
of disulfide-rich small proteins belonging to the 
bifunctional inhibitors, the 2S albumin seed storage 
proteins, and the non-specific lipid transfer proteins.
Cereal prolamins
Cereal prolamins are seed storage proteins that are 
exclusively found in the grains of cereal grasses. In 
contrast to the low molecular weight members of 
the superfamily, the α-helical domain of the cereal 
prolamins has been disrupted by an insertion of 
repetitive sequences (11). Gliadins and glutenins 
represent the members of the cereal prolamin family. 
Gliadins are soluble in alcohol and they are classified 
into α/β-, γ- and ω-gliadins. Glutenins are polymeric 
proteins that are held together by interchain disulfide 
bonds. They are divided into high and low molecular 
weight groups (Fig. 2) (12).
Wheat (Triticum aestivum) contains several allergenic 
cereal prolamins. Tri a 19 is an ω-5-gliadine, Tri a 21 
an α/β-gliadine, and Tri a 26 a high molecular weight 
glutenine from wheat.
Bifunctional inhibitors
Like the cereal prolamins, the bifunctional inhibitors 
are only present in cereal grains. These allergens 
sensitize either via the respiratory tract by inhalation 
of the flour or via the gastro-intestinal tract by 
eating foods that contain wheat, barley or rice. The 
Figure 1
Four representative members of the Bet v 1 family of proteins. Bet v 1 is from birch pollen, Pru av 1 from 
cherry, Api g 1 from celery and Ara h 8 from peanut.
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Hor v 15 is a monomeric α-amylase inhibitor from 
barley. Tri a 28 is a dimeric and Tri a 29 a tetrameric 
α-amylase inhibitor from wheat.
2S albumins
The 2S albumins are a major group of plant seed 
storage proteins. Most 2S albumins are synthesized 
as single-chain proteins that are subsequently cleaved 
into a small and a large subunit. Both subunits are 
held together as compact α-helical molecules by 4 to 
5 disulfide bonds (15). Many of the important seed 
and tree nut allergens are 2S albumins (Fig. 3).
  Allergenic 2S albumins include Ara h 2 and Ara h 
6 from peanut, Ber e 1 from Brazil nut, Cor a 14 
from hazelnut, Jug r 1 from English walnut, Ses 
i 1 from sesame seeds, and Sin a 1 from yellow 
mustard.
Non-specific lipid transfer proteins (nsLTPs)
nsLTPs have been suggested to mediate the transfer 
of phospholipids between vesicles and membranes. 
Table 1
Overview of the most important allergen super-
families and families with their corresponding 
sources
Superfamily Family Allergen sources
Prolamin
Cereal 
prolamins
Grains of cereal 
grasses
Bifunctional 
inhibitors
Grains of cereal 
grasses
2S albumins Tree nuts, peanuts, legumes, seeds
Non-specific 
lipid-transfer 
proteins
Fruits, tree nuts, 
peanuts, vegetables, 
tree and weed 
pollen, latex
EF-hand
Polcalcins Tree, grass, and weed pollen
Parvalbumins Fish
Profilin-like Profilin
Tree, grass, and 
weed pollen, fruits, 
vegetables, latex
Tropomyosin-
like Tropomyosin
Crustaceans, 
mollusks, fish 
parasite Anisaki 
simplex, mites, 
cockroaches
Cupin
Vicilins Tree nuts, peanuts, legumes, seeds
Legumins Tree nuts, peanuts, legumes, seeds
Bet v 1-like Bet v 1
Fagales tree pollen, 
fruits, vegetables, 
legumes, tree nuts
Calycin Lipocalins Mammals, mites, cockroaches
Double-psi 
beta-barrel
DPBB_1 Grass pollen
Pollen_
allerg_1 Grass pollen
Figure 2
Dimeric Tri a 28 from wheat.
bifunctional inhibitors are 12- to 16 kDa proteins 
that are held together by 4 to 6 disulfide bonds (13). 
Monomeric, heterodimeric and heterotetrameric 
forms are distinguished according to the degree of 
aggregation of their subunits. They are the major 
cause of baker’s asthma but also play a role as plant 
food allergens (14).
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However, plants have use the three-dimensional 
scaffold of the nsLTPs in various ways and many 
nsLTPs play a role in plant defense against fungi 
and bacteria. Allergenic nsLTPs are a large group of 
proteins that are resistant to heat and digestion (16). 
nsLTPs are found in high concentrations in epidermal 
tissues of fruits. They are major allergens of fruits 
from the Rosaceae family. In addition, allergenic 
nsLTPs are present in nuts, seeds, vegetables, and 
Hevea brasiliensis latex. Besides their presence in 
plant foods, nsLTPs are also expressed in pollen of 
weeds, olive, and plane (Fig. 4).
   Roseacea fruit nsLTP include Mal d 3 from apple 
and Pru p 3 from peach. Representative allergenic 
nsLTPs from tree nuts are Cor a 8 from hazelnut 
and Jug r 3 from walnut. Pollen nsLTPs include 
Pla a 3 from plane tree and Art v 3 from mugwort. 
Zea m 14 is the nsLTP from maize.
EF-HAND SUPERFAMILY
A wide range of calcium-binding proteins share a 
conserved domain consisting of a 12 residue calcium-
binding loop flanked on both sides by α-helices of 12 
residues in length (17). The biological functions of 
these proteins include signaling and calcium buffering 
or transport.
Polcalcins
Polcalcins are 9 kDa calcium-binding pollen proteins of 
unknown biological function. While regular polcalcins 
contain two EF hand domains, several polcalcin-
related allergens with three or four EF hand domains 
were described (18). Polcalcins were shown to be 
minor albeit highly cross-reactive allergens identified 
in pollen from diverse plant families (Fig. 5).
Figure 3
Ara h 6 from peanut and other sources of aller-
genic 2S albumins: Brazil nut, hazelnut, walnut, 
sesame seeds, and yellow mustard.
Figure 4
Zea m 14 from maize and other sources of al-
lergenic nsLTPs: apple, peach, hazelnut, maize, 
and walnut.
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   Allergenic polcalcins include the monomeric 
Bet v 4 from birch, the dimeric Phl p 7 from 
timothy grass, and the tetrameric Che a 3 from 
Chenopodium album.
Parvalbumins
Parvalbumins are 12 kDa proteins that contain two 
EF hand domains. They are found in fast-twitch 
muscle fibers of vertebrates and bind calcium ions 
during muscle relaxation. Parvalbumins from fishes 
and amphibians are major food allergens eliciting IgE 
responses in most fish-allergic individuals (Fig. 6) (19).
   Allergenic parvalbumins include Gad m 1 from 
Atlantic cod, Sal s 1 from Atlantic salmon, and 
Cyp c 1 from carp
PROFILIN-LIKE SUPERFAMILY
Profilins are small cytosolic proteins that are found in 
all eukaryotic cells. Profilins bind to monomeric actin 
and various other muscle proteins, thus regulating the 
dynamics of actin polymerization during processes 
such as cell movement, cytokinesis, and signaling. 
Profilins from higher plants constitute a family of 
highly conserved proteins that show sequence 
identities of at least 75% even between members 
from distantly related organisms (20). Since profilin-
specific IgE usually cross-reacts with homologues 
from virtually every plant source, sensitization to 
these allergens has been considered a risk factor 
for pollen-associated food allergy (21). However, 
no substantial cross-reactivity between plant and 
human profilins has been shown so far (Fig. 7).
  Allergenic profilins include Art v 4 from mugwort 
pollen, Bet v 2 from birch pollen, Ole e 2 from 
olive pollen, Cit s 2 from oranges, Cuc m 2 from 
melons, and Mus a 1 from bananas.
TROPOMYOSIN-LIKE SUPERFAMILY
Tropomyosins are present in muscle and non-
muscle cells. In striated muscle, they mediate the 
interactions between the troponin complex and actin 
to regulate muscle contraction. Tropomyosin is an 
α-helical protein that forms a coiled-coil structure 
of two parallel helices containing two sets of seven 
alternating actin binding sites. Tropomyosins were 
identified as animal food allergens in crustaceans, 
Figure 5
Phl p 7 dimer with bound calcium ions.
Figure 6
Gad m 1 from cod with bound calcium ions 
(green spheres) and a young carp (picture kindly 
provided by Clinical Unit of Fish Medicine, Uni-
versity of Veterinary Medicine, Vienna, Austria), 
a source of Cyp c 1.
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mollusks, and the fish parasite Anisakis simplex 
(22). Tropomyosins were also identified as inhalant 
allergens in arthropods (mites, cockroaches). 
Tropomyosin sequences are highly conserved, which 
explains the frequent cross-sensitization among 
tropomyosin-containing allergen sources (Fig. 8) (23).
   Pen i 1 from the Indian prawn, Bla g 1 from the 
German cockroach, and Der p 10 from house dust 
mite are well-known allergenic tropomyosins.
CUPIN SUPERFAMILY
The cupins are a large and functionally immensely 
diverse superfamily of proteins that have a common 
origin and whose evolution can be followed from 
bacteria to eukaryotes including animals and higher 
plants. Cupin proteins are currently classified into 
57 protein families of this superfamily. The largest 
families of bicupins are the 7/8S and 11S seed 
storage globulins that are the major components of 
plant seeds and are not only important sources of 
proteins for the human diet and but also of allergens 
(24, 25).
Vicilins
These are homotrimeric proteins of about 150 
to 190 kDa. Their detailed subunit compositions 
vary considerably due to differences in proteolytic 
processing and glycosylation of the monomers (Fig. 9).
   Allergenic vicilins include Ara h 1 from peanut, 
Gly m 5 from soybean, Jug r 2 from walnut, and 
Ses i 3 from sesame.
Legumins
In mature legumins, two trimers associate to form 
hexameric proteins (Fig. 10).
   Allergenic legumins include the peanut allergen 
Ara h 3, Gly m 6 from soybean, Ber e 2 from 
Brazil nut, and Fag e 1 from buckwheat.
BET V 1-LIKE SUPERFAMILY
The Bet v 1-like superfamily currently harbors 103,375 
proteins from 1,452 species with sequences related to 
the major birch (Betula verrucosa) pollen allergen Bet v 
1. These proteins are distributed between 14 families. 
The members of all 14 families (one of which is the Bet 
v 1 family) in this superfamily share the same structure 
Figure 7
Bet v 2 from birch pollen and other sources of 
allergenic profilins.
Figure 8
Examples for sources of allergenic tropomy-
osins: Indian prawn, German cockroach, and 
house dust mite.
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which is composed of 7 antiparallel β-sheets and 3 
α-helices (26). There is a cavity between the β-sheet 
and a long C terminal α-helix. The cavity appears to 
be able to bind a variety of lipid and bioflavonoid 
molecules. So far, allergens were identified in 3 of the 
11 subfamilies of the Bet v 1 family.
Pathogenesis-related protein subfamily 10 (PR-
10)
The PR-10 proteins are actually one of the 11 
subfamilies of the Bet v 1 family. The expression of 
these proteins is either induced by pathogen attack 
or abiotic stress, or it is developmentally regulated. 
PR-10 proteins are expressed in high concentrations 
in reproductive tissues such as pollen, seeds and 
fruits. Many birch pollen-allergic patients show 
allergic reactions to various fruits and vegetables, 
which are caused by IgE cross-reactivity between 
Bet v 1 and homologous allergens from plant foods. 
Most Bet v 1-related food allergens have been found 
in members of certain plant families: Rosaceae (apple, 
pear, stone fruits), Apiaceae (celery, carrot), and 
Fabaceae (soybean, peanut; Fig. 11).
RRP (ripening-related proteins)/MLP (major 
latex proteins) family
The RRP/MLP group of proteins is another subfamily 
of the Bet v 1 family. Act d 11 is the first described 
Bet v 1-related allergen from kiwi from the RRP/MLP 
subfamily (Fig. 12) (27).
Figure 9
Ara h 1 homotrimer from peanut and other 
sources of allergenic vicilins: soybean, walnut, 
sesame seeds.
Figure 10
Ara h 3 from peanut and other sources of aller-
genic legumins: soybean, Brazil nut, and buck-
wheat.
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Figure 11
Bet v 1 from birch pollen and other sources of 
allergens belonging to the pathogenesis-related 
protein subfamily 10: celery, soybean, and pea-
nut.
Figure 12
Act d 11 from kiwi.
Figure 13
Vig r 6 from mungbean.
CSBP (cytokinin-specific binding proteins) 
subfamily
Vig r 6 from the mung bean is the first described Bet 
v 1-related allergen from the CSBP subfamily of the 
Bet v 1 family Bet v 1 family (Fig. 13) (28).
CALYCIN SUPERFAMILY
The calycin superfamily comprises 16 families. 
Although structurally similar, calycins have rather 
low sequence similarities. The calycin architecture is 
based on an eight-stranded β-barrel which can bind a 
variety of different ligands (29).
Lipocalins
Lipocalins are transporters for small hydrophobic 
molecules, such as lipids, steroid hormones, bilins, and 
retinoids. Lipocalins fold into an eight-stranded anti-
parallel β-barrel. Allergens from this protein family 
include β-lactoglobulin, mammalian dander allergens, 
and cytoplasmic fatty acid binding proteins (30, 31). 
β-lactoglobulin is the major whey protein of ruminant 
species. Bos d 5 is a major cow’s milk allergen. Cross-
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reactions to milk proteins from other species have 
also been described. Lipocalins constitute the vast 
majority of mammalian dander allergens (Fig. 14). 
Cytoplasmic fatty acid binding proteins are distantly 
related to extracellular lipocalins and β-lactoglubulins. 
They were identified as minor allergens in mites 
(group 13) and cockraoches.
   Examples for mammalian allergenic lipocalins are 
Equ c 1 from horse, Bos d 2 from cattle, Can f 1 
and Can f 2 from dog, and Fel d 4 from cat.
Figure 14
Equ c 1 from horse and other sources of aller-
genic lipocalins: dog, cow, and cat.
DPBB (DOUBLE-PSI BETA BARREL) 
SUPERFAMILY
β-barrels are frequently found structural elements of 
proteins. Barrels of a given number of strands can have 
different strand connections, or topologies. One such 
topology consisting of a certain arrangement of six 
β-strands is called a double-psi β-barrel (32). Group 
1 grass pollen allergens are found in the DPBB_1 
family of the DPBB superfamily. They are most 
closely related to the β-expansins and - like them - 
contain two domains. Domain 1, which assumes the 
six-stranded double-psi β-barrel topology, is distantly 
related to glycoside hydrolase family 45 proteins, and 
domain 2, which consists of two stacked β-sheets 
with an immunoglobulin-like fold, is also called group 
2 grass pollen allergen domain (33). Expansin activity 
is often associated with cell wall loosening activity in 
growing cells including penetration of pollen tubes 
through the stigma and style (34). Group 2 and 3 
grass pollen allergens belong to the Pollen_allerg_1 
family and are related to the domain 2 of β-expansins. 
As they lack the domain 1, it is assumed that these 
allergenic proteins evolved from a truncated copy of 
a β-expansin gene (Fig. 15) (33).
   Examples for group 1, grass pollen allergens are 
Lol p 1 from rye grass, Phl p 1 from timothy grass, 
and Poa p 1 from Kentucky bluegrass. Group 2/3 
grass pollen allergens include Dac g 2 and Dac g 
3 from orchard grass, Lol p 2 and Lol p 3 from rye 
grass, and Phl p 2 and Phl p 3 from timothy grass.
 DATABASES
1. WHO/IUIS allergen nomenclature database 
(http://www.allergen.org/)
The allergen nomenclature database is a repository 
of allergens that underwent a submission and 
evaluation process and were accepted by a panel 
of experts in allergen characterization, structure 
and function. This is the only body officially able 
to assign allergen designations. The database 
contains links for each allergen to the nucleotide 
and protein databases of the NCBI (National 
Center for Biotechnology Information; http://
www.ncbi.nlm.nih.gov/), the UniProt database 
(http://www.uniprot.org/), and the Protein 
Databank (PDB) of macromolecular structures 
(http://www.rcsb.org/pdb/).
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2. SDAP (structural database of allergenic proteins, 
https://fermi.utmb.edu/)
The SDAP is a repository of allergen sequences, 
IgE epitopes, structures and models. It offers 
various computational tools onsite that can assist 
structural biology studies related to allergens. The 
SDAP is curated by host scientists with oversight 
by an international review panel. The SDAP was 
developed based on the allergen list from the 
WHO/IUIS allergen nomenclature database.
3. AllFam (allergen protein families, http://www.
meduniwien.ac.at/allergens/allfam/)
The AllFam database is a resource for classifying 
allergens into protein families. AllFam groups 
allergens according to the protein family 
classification from the Pfam database. AllFam 
is curated by the host scientists and provides 
a good overview on allergen families and their 
most important member proteins. A new version 
of the Allfam database will become available in 
June 2016.
4. AllergenOnline (http://www.allergenonline.org/)
AllergenOnline provides access to a peer-
reviewed allergen list and sequence searchable 
database intended for the identification of 
proteins that may present a potential risk of 
allergenic cross-reactivity. The website was 
designed to help in assessing the safety of 
proteins that may be introduced into foods 
through genetic engineering or through food 
processing methods.
5. Allergome (http://www.allergome.org/)
Allergome a non peer-reviewed database has 
the most extensive collection of information on 
allergens. It is based on the literature published 
since the early sixties and is continuously 
updated. Allergome lists all allergens that have 
been identified and characterized in the literature 
including those that are not present on the 
WHO/IUIS allergen nomenclature website.
6. Pfam (http://pfam.xfam.org/)
Pfam is the most extensive database of manually 
curated protein families. The current release of 
Pfam, version 29.0, contains 16,295 families. The 
Pfam database was used to classify allergens into 
protein families.
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Cup a 1 reactivity is the specific marker 
allergen for a sensitization to the 
Cupressaceae family.
PR-10 molecules (i.e. Bet v 1) are the major 
allergens in Fagales pollen, often associated 
with an oral allergy syndrome.
Ole e 1 is the most common sensitizing 
molecule in olive pollen.
Pla a 1 and Pla a 2 may serve as a marker of 
primary sensitization to plane tree pollen.
THE ALLERGEN SOURCES
Among over 400,000 plant species (1), about 
100 flowering (Angiospermae) and non-flowering 
(Gymnospermae) trees can induce specific 
sensitization in predisposed individuals. Besides grass 
pollen and house dust mites, tree pollens belong to 
the most important respiratory allergen sources. The 
knowledge of the taxonomical relationship between 
different tree species allows the prediction of cross 
reactivity between closely related plants, which share 
homologous molecules not found in unrelated plants. 
The trees most commonly causing allergy belong to 
the orders Fagales (alder, beech, birch, hazelnut, oak), 
Lamiales (ash, privet, olive, lilac), Pinales (cypress, 
Japanese cedar, juniper), and Proteales (plane tree, 
sycamore) (2).
The geographical distribution of allergenic 
plants drives patients’ sensitization profiles, as a 
consequence of different local pollen exposure. For 
instance in the Mediterranean area, as well as in 
regions with a Mediterranean climate such as North 
and South Africa, North and South America and 
Australia, trees belonging to the order Lamiales (i.e. 
olive tree) or Pinales (i.e. cypress tree) are mainly 
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found, whilst Fagales trees play a role as allergen 
sources mostly in temperate climate regions such as 
Northern and Central Europe, North America, East 
Asia and Northwest Africa (3).
The order Fagales encompasses two main families 
most frequently implicated in allergies: (i) Betulaceae 
including the genera Alnus (alder), Betula (birch), 
Carpinus (hornbeam), Corylus (hazel), and Ostrya (hop 
hornbeam), and (ii) Fagaceae, comprising the genera 
Castanea (chestnut), Fagus (beech), and Quercus (oak) 
(Fig. 1). A high degree of allergenic cross-reactivity 
among allergens from these plants distributed all over 
the world has been demonstrated. Birch, followed by 
alder and hazel, represents the most potent cause of 
tree pollen allergy within this order. The flowering 
period of birch begins at the end of March in Western 
Europe, from the beginning to mid April in central 
and Eastern Europe and from late April to late May 
in northern Europe. From 1 to 3 weeks after the 
beginning of the season higher amounts of pollen in 
the atmosphere are recorded, and the extent of the 
pollen season is extremely dependent on weather 
conditions and thus ranges from 2 to 8 weeks. An 
alternation of low and high pollen production years 
has been detected. Hazel and alder florescence starts 
early from December to April, is followed by birch, 
hornbeam and hop hornbeam and then by oak and 
beech in spring. Chestnuts shed pollens in June and 
July in western and central Europe.
Trees from the family Oleaceae, order Lamilaes, grow 
on all 5 continents and are among the most important 
causes of respiratory allergy in the Mediterranean area 
as well as in some areas of North America, Australia, 
Japan and North and South Africa, where these 
trees are intensively cultivated (4). The Oleaceae 
family comprises 4 main genera: olive (Olea europea), 
European ash (Fraxinus excelsior), lilac (Syringa vulgaris), 
and common privet (Ligustrum vulgare), all able to 
cause IgE sensitization (5) (Fig. 1). The pollination 
period ranges from April to June in warmer regions, 
and the occurrence of olive tree allergy is about 30-
40% in Italy and over 80% in southern Spain. Ash 
pollen season is during wintertime, rather similar to 
the birch pollen season, and is very relevant in central 
Europe (Austria, North and East of France, Switzerland 
up to 30% prevalence of pollen allergic patients).
In Mediterranean regions trees of the Cupressaceae 
family (Fig. 1) from the order Pinales are widely 
spread. Wind pollination of cypress trees occurs 
during the winter season, when no other allergenic 
plants flower, and accounts for up to 40% of the 
total pollen count in Mediterranean countries (160). 
Cypress tree inflorescence covers about 30-40 days, 
from January to April, showing a high variability 
from year to year, depending on weather conditions, 
causing difficulty in identifying the beginning and 
length of pollen season. The high degree of cross-
reactivity found among Cupressaceae trees (cypress, 
juniper and cedar), which have somewhat different 
but overlapping pollination periods, could extend the 
cypress pollen season from December to March.
Trees of the Plane-tree familty, from the order 
Proteales are common species widely spread in 
southern Europe, with a short but intense pollen 
season from March to April, characterized by high 
pollen counts, reaching one hundred billion pollen 
grains per tree only few days after the florescence 
time. Clinical surveys have acknowledged plane trees 
as a major cause of pollen with sensitization rates 
ranging from 8 to 17% in exposed populations. Annual 
airborne pollen counts differ on the basis of weather 
conditions but also as a function of human activity, 
mainly pruning, since plane trees or sycamores are 
widely used for ornamental purposes (7). Temperature, 
but not rainfall, is the weather parameter mainly 
affecting the Platanus pollen season, affecting both 
start-date and daily pollen counts.
MAJOR AND RELEVANT MINOR 
ALLERGENIC MOLECULES
Pollen from Fagales trees are one of the most 
frequent causes of winter/spring respiratory allergy 
in the temperate areas of the Northern hemisphere. 
This order includes two main families (Betulaceae and 
Fagaceae) comprising different trees characterized 
by a rather limited number of homologous, cross-
reacting allergens (8) (Table 1).
Pathogenesis-related-protein group 10 (PR-10) 
molecules (i.e., Bet v 1 and homologous allergens) (9) are 
the major allergens in Fagales pollen and are recognized 
by virtually all allergic patients, thus representing the 
major cause of clinical allergy (see also section C02). 
Several PR-10 family members have been described to 
date within tree pollen belonging to Fagales order ([i] 
Betulaceae: Aln g 1 from alder, Bet v 1 from birch, Car 
b 1 from hornbeam, Cas s 1 from chestnut and Cor a 1 
from hazel, [ii] Fagaceae: Fag s 1 from European beech, 
Ost c 1 from hop hornbeam, and Que a 1 from oak).
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Figure 1
Tree pollen related allergen families. 
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Table 1
Allergenic molecules of the two main families (Betulaceae and Fagaceae) of the order Fagales 
Species  
(English name)
Allergenic
molecule Biochemical name
IUIS
code
Prevalence 
among patients MW
Betulaceae
Alnus glutinosa 
(Alder)
Aln g 1 PR-10, Bet v 1 family member 19 100% 18
Aln g 4 Polcalcin 20 18% 6
Betula verrucosa  
(Betula pendula)  
(European white birch)
Bet v 1 PR-10, Bet v 1 family member 129 95% 17
Bet v 2 Profilin 130 22% 15
Bet v 3 "Polcalcin-like protein  (4 EF-hand)" 131 10% 24
Bet v 4 Polcalcin 132 5% 7
Bet v 6 "Isoflavone reductase-like and  phenylcoumaran benzylic ether reductase" 133 32% 35
Bet v 7 Cyclophilin 134 21% 18
Carpinus betulus 
(Hornbeam) Car b 1 PR-10, Bet v 1 family member 182 17
Corylus avellana 
(Hazel)
Cor a 1 PR-10, Bet v 1 family member 228 100% 17
Cor a 2 Profilin 234 14
Cor a 6 Isoflavone reductase homologue 778 35
Cor a 8 Non-specific lipid transfer protein type 1 235 9
Cor a 9 11S seed storage globulin (legumin-like) 236 86% 40
Cor a 10 Luminal binding protein 229 70
Cor a 11 7S seed storage globulin (vicilin-like) 230 48
Cor a 12 17 kDa oelosin 231 63% 17
Cor a 13 14-16 kDa oleosin 232 63% 14
Cor a 14 2S albumin 233 33% 15
Ostrya carpinifolia 
(European hophornbeam) Ost c 1 PR-10, Bet v 1 family member 697
Fagaceae
Castanea sativa 
(Chestnut)
Cas s 1 PR-10, Bet v 1 family member 185 100% 22
Cas s 5 Chitinase 186
Cas s 8 Non-specific lipid transfer protein type 1 187 12
Cas s 9 Cytosolic class I small heat shock protein 666 17
Fagus sylvatica 
(European beech) Fag s 1 PR-10, Bet v 1 family member 696
Quercus alba 
(White oak) Que a 1 PR-10, Bet v 1 family member 566 64% 17
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In addition to PR-10 proteins, several other allergens 
have been described. (i) Profilins (e.g. Bet v 2 from 
birch pollen or Cor a 2 from hazel pollen) (10) are plant-
pan allergens (see section C01) present in the whole 
plant kingdom. Profilins are recognized by 10-20% 
of patients primarily sensitized to birch pollen, but 
this proportion is higher in areas where grass pollen 
represents the primary sensitizer. Clinical relevance 
of profilin as a respiratory allergen is variable (11). 
Profilins may cause secondary plant food allergy to 
various fruits and vegetables (see section C01).
(ii) Polcalcin-like proteins (calcium binding proteins; 
e.g. Bet v 3 and Bet v 4 from birch, and Aln g 4 from 
alder) are pollen pan-allergens, which generally 
sensitize less than 10% of pollen-allergic individuals. 
They cross-react with homologous allergens from 
pollen from botanically unrelated species. The 
clinical relevance is variable and often limited (165); 
(iii) phenyl-coumaran benzylic ether reductased and 
isoflavone reductases (e.g. Bet v 6 from birch, Cor a 
6 from hazel, Ole e 12 from olive) are minor allergens 
which are involved in plant defence reactions, 
showing a sensitization rate of about 32% among 
birch allergic people (12); (iv) cyclophilin (Bet v 7 from 
birch) is a minor, potentially cross-reactive, allergen; 
(v) pectin methylesterase (Bet v 8 from birch) (13); 
(vi) glucanase; (vii) thaumatin-like protein; and (viii) 
Glutathione-S-transferase (GST).
Olive pollen allergy is caused by Ole e 1 in the majority 
of cases (about 70%), (Table 2). The Ole e 1-like 
protein family comprises several other allergenic 
glycosylated proteins from tree pollen (Fra e 1, Lig 
v 1, and Syr v 1), whose glycan moieties are involved 
in the allergenic properties of these molecules (14).
Besides Ole e 1, several other molecules have been 
identified, and a biological function can be associated 
Table 2
Allergenic molecules of the olive family 
Species  
(English name)
Allergenic
molecule Biochemical name
IUIS
code
Prevalence 
among patients MW
Oleaceae
Fraxinus excelsior  
(Ash) Fra e 1 Ole e 1-like protein family member 331 87% 20
Ligustrum vulgare 
(Privet) Lig v 1 Ole e 1-like protein family member 409 58% 20
Olea europaea 
(Olive)
Ole e 1 Common olive group 1 454 90% 16
Ole e 2 Profilin 456 50% 15
Ole e 3 Polcalcin-like protein (4 EF-hands) 457 9
Ole e 4 N.A. 458 80% 32
Ole e 5 Superoxide dismutase [Cu-Zn] 459 35% 16
Ole e 6 460 15% 10
Ole e 7 putative non-specific lipid transfer protein 461 47% 9
Ole e 8 "Polcalcin-like protein  (4 EF-hands)" 462 21
Ole e 9 1 3-beta glucanase 463 68% 46
Ole e 10 X8 domain containing protein 455 90% 11
Ole e 11 Pectin methylesterase 685 39.4
Ole e 12 Isoflavone reductase 4-33% 36
Syringa vulgaris 
(Lilac) Syr v 1 Ole e 1-like protein family member 612 90% 20
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with most of these molecules, such as actin-binding 
protein (the profilin Ole e 2), polcalcin (Ole e 3 and Ole 
e 8), glucanase (Ole e 9 and its probable degradation 
product Ole e 4), superoxide dismutase (Ole e 5) 
and lipid transfer protein (Ole e 7). Olive tree Ole e 
7, shares less than 20% of amino acid sequence with 
Pru p 3. Even though the homology at the primary 
sequence level is low, the tertiary structure of nsLTP 
is rather similar. Immunologically they seem to be 
distinct, which is also true for Par j 2, the nsLTP from 
pellitory that does not cross-react with e.g. Pru p 
3., Ole e 7 is suspected to be the possible cause of 
adverse reactions in patients undergoing allergen 
specific immunotherapy.
The glucanase Ole e 9, despite representing less than 
0.3% of crude olive pollen content, induces sensitization 
in about 50% of patients in some Mediterranean regions 
with high olive pollen counts during pollen season. As 
previously described for Ole e 7, sensitized patients are 
at higher risk of suffering adverse side reactions during 
immunotherapy. Ole e 7 and Ole e 9 IgE recognition 
have been recently associated with local or systemic 
reactions to food and Atopic dermatitis, respectively 
(15). Ole e 10 (X8 domain containing protein) and the 
pectin methylesterase Ole e 11 are two other major 
olive pollen allergens.
In the Cypress family two main groups of proteins 
have been identified: the pectate lyases and the 
polygalacturonases (16) (Table 3). The highly related, 
(95.1% sequence identity) pectate lyases Cup a 1 
(57) and Cup s 1 are found In the Mediterranean 
area, whilst Cry j 1 and Cha o 1 are mainly found 
in Japan, sharing 78.6% sequence identity. The 
polygalacturonases, Cha o 2, Cry j 2, and Jun a 2 are 
also major allergens of Pinales pollen, showing high 
levels sequence identities (71%-82%).
The most important allergen from London plane 
tree (Platanus acerifolia) pollen is Pla a 1 (17), which 
has an invertase inhibitor function as has the 
homologous Pla or 1 from Platanus orientalis (Table 
4). Pla a 2 and Pla or 2 are major allergens displaying 
a polygalacturonase activity. The plane tree Pla a 3 
belongs to the family of non-specific lipid transfer 
proteins, showing 58.3% sequence identity with the 
nsLTP Pru p 3 from peach (18).
Table 3
Allergenic molecules of the cypress family
Species  
(English name)
Allergenic
molecule Biochemical name
IUIS
code
Prevalence 
among patients MW
Cupressaceae
Chamaecyparis obtusa 
(Japanese cypress)
Cha o 1 Pectate lyase 193 97.50% 40.2
Cha o 2 Polygalacturonase 194 82.50% 45
Cryptomeria japonica  
(Sugi)
Cry j 1 Pectate lyase 245 >90% 41-45
Cry j 2 Polygalacturonase 246 >90% 45
Cupressus arizonica 
(Cypress) Cup a 1 Pectate lyase 253 100% 43
Cupressus sempervirens 
(Common cypress)
Cup s 1 Pectate lyase 254 43
Cup s 3 Thaumatin-like protein 255 34
Juniperus ashei 
(Mountain cedar)
Jun a 1 Pectate lyase 392 71.40% 43
Jun a 2 Polygalacturonase 393 100% 43
Jun a 3 Thaumatin-like protein 394 42.95 30
Juniperus oxycedrus 
(Prickly juniper) Jun o 4
Polcalcin-like protein (4 EF hand 
domains) 395 14.65 29
Juniperus virginiana 
(Eastern red cedar)
Jun v 1 Pectate lyase 397 46.15 43
Jun v 3 Thaumatin-like protein 398 34
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SENSITIZATION TO INDIVIDUAL 
MOLECULES AND THEIR CLINICAL 
RELEVANCE
Epidemiology and sensitization/cross reactivity 
rates
In Europe, the prevalence of positive skin prick 
test to birch pollen allergens ranges from 5% in 
The Netherlands to 54% in Switzerland, while 
Scandinavian countries have the highest number of 
patients with exclusive sensitization to Bet v 1 (19). 
Bet v 1-specific IgE levels are not predictive for the 
development of pollen-related bronchial asthma. PR-
10 proteins defend plants against fungi and other 
microorganisms. Their homologs are also present 
in a large number of plant-derived foods, and thus 
frequently cause cross-sensitization and consequently 
plant-food allergy (oral allergy syndrome, in most 
cases). For this reason, up to 70% of patients with 
sensitization to PR-10 proteins complain about oral 
symptoms following the ingestion of certain plant-
foods (e.g., apples, carrots, hazel nuts and stone 
fruit, see section C02). No more than 38% identity is 
found comparing the sequences of PR-10 tree pollen 
members belonging to either the Betulaceae or the 
Fagaceae family (31 identical positions and 57 similar 
positions). When the sequences of PR-10 proteins 
from tree pollen of the Betulaceae and Fagaceae 
families were compared separately, the identity 
doubled up to 63.75% and 63.125%, respectively. 
This indicates from a clinical point of view the need 
to check at least one representative allergen from 
both the Betulaceae family (i.e. Bet v 1 from birch) 
and the Fagaceae family (i.e. Que a 1 from oak) in all 
patients. 
Also Olea europaea reactivity seems to be clinically 
characterized by rhino-conjunctivitis more than 
bronchial asthma. Moreover, in olive pollen patients 
a polysensitization is more common than mono-
sensitization. Reactivity to other genera belonging to 
the Oleaceae family, i.e. Fraxinus excelsior or Ligustrum 
vulgare, is relevant in several regions in central and 
southern Europe (20). Olive tree Ole e 1 is a 145 amino 
acid protein sharing both significant sequence identity 
(82.76% of identity with 120 Identical positions and 
19 similar positions) and IgE cross-reactivity with all 
the other related trees belonging to the Olive family 
(Fra e 1 from ash, Lig v 1 from privet and Syr v 1 from 
lilac) (21). Several Ole e 1-like molecules have been 
described in goosefoot (Chenopodium album, Che 
a 1), timothy (Phleum pretense, Phl p 11), rye-grass 
(Lolium perenne, Lol p 11), English plantain (Plantago 
lanceolata Pla l 1) and prickly saltwort (Salsola kali, 
Sal k 5), but the real clinical cross-reactivity of these 
molecules not belonging to the Olive family with Ole 
e 1 is somewhat questioned (20).
Patients allergic to Cypress pollen show a 30% 
sensitization rate in some areas (22) and 42% in 
central and southern Italy (23). Cypress pectate lyases 
allergy generally causes seasonal allergic rhinitis, and a 
very low occurrence of bronchial asthma in sensitized 
patients has been reported in the literature (24), but 
since asthma is a genetically determined condition, 
it depends more on the degree of sensitization and 
exposure rather than on the intrinsic characteristics of 
the allergens. High sequence identity and IgE cross-
Table 4
Allergenic molecules of the plane-tree family
Species  
(English name)
Allergenic
molecule Biochemical name
IUIS
code
Prevalence 
among patients MW
Platanaceae
Platanus acerifolia 
(London plane 
tree)
Pla a 1 Putative invertase inhibitor 520 87.50% 18
Pla a 2 Polygalacturonase 521 83% 43
Pla a 3 N on-specific lipid transfer protein 1 522 45% 10
Platanus orientalis 
(Oriental plane)
Pla or 1 Putative invertase inhibitor 524 15.80% 18
Pla or 2 Polygalacturonase 525 26.30% 42
Pla or 3 nsLTP1 526 26.30% 11
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reactivity among the pectate lyases belonging to the 
Cupressaceae family (Cha o 1, Cry j 1, Cup a 1, Cup 
s 1, Jun a 1, Jun c 1, Jun o 1 and Jun v 1) is observed, 
with an overall 70% of similarity (262 identical and 74 
similar amino acid positions).
A 50% sequence identity with the ragweed allergenic 
pectate lyase Amb a 1 without evidence of cross-
reactivity has been described (25).
In the case of Polygalacturonases an IgE cross reactivity 
among the homologous allergens belonging to 
Cupressaceae families (Cri y 2, Cha o 2, Cup a 2, Cup s 2 
and Jun a 2) has been observed (26). Polygalacturonase 
belonging to timothy grass (Phl p 13) showed also 
considerable (up to 40%) sequence identity with Cri j 2, 
without measurable cross-reactivity (27).
Plane tree Pla a 1 has a 98% sequence identity with 
Pla or 1. Pla a 2 and Pla or 2 are other major allergens 
displaying a polygalacturonase activity with only 35% 
of sequence identity and no cross reactivity with 
Cryptomera japonica Cry j 2. The plane tree Pla a 3 
exhibits approximately 50% sequence identity with 
peach Pru p 3, and thus is possibly implicated in plant 
food-pollen co-sensitization, although this role has 
been recently questioned (18).
Clinical relevance and clinical patterns
Certain proteins are restricted to a given allergenic 
biological source, and therefore can be considered 
as a “marker allergens” or the genuine “signature” 
clinically useful for the identification of patients for 
whom immunotherapy with a given allergen extract 
Figure 2
Genuine markers of sensitization (green) and panallergens (red) in the different pollens.
Platanaceae Cupressaceae
Betulaceae Oleaceae
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is appropriate. For instance, in the tree pollen model, 
the major birch pollen, Bet v 1, can identify individuals 
allergic to the Betulaceae family. The olive tree major 
allergen, Ole e 1, detects sensitization to the Oleaceae 
family, the cypress pollen major allergen, Cup a 1, 
reveals sensitization to the Cupressaceae family, and 
Pla a 1 detects sensitization to the Platanaceae family.
Other allergens exhibit a large cross-reactivity 
and their distribution is not restricted to a given 
taxonomical order, but they are rather distributed 
throughout the entire plant kingdom and are 
therefore found in all tree pollen families (the so-
called panallergens). Polcalcin-like proteins (4 EF-
hand) and the profilins are typical examples of 
panallergens. In the case of polcalcin-like proteins, 
also known as EF-hand calcium-binding allergens 
(i.e. alder Aln g 4, hornbeam Car b 4, birch Bet v 4, 
beech Fag s 4, and oak Que a 4), IgE recognition is 
often associated with a multiple pollen (grass, weed 
and tree) sensitization (28) and a lower response 
to immunotherapy. Patients sensitized to profilins 
(e.g., Aln g 2 from alder, Bet v 2 from birch, Car b 2 
from hornbeam, Cas s 2 from chestnut, Cor a 2 from 
hazel, Fag s 2 from beech and Que a 2 from oak) are 
not only reactors to a panallergen found in distinct 
sources but also true plant food multi-sensitized 
patients (29). Panallergens reactivity could therefore 
bring to a misleading interpretation if allergy testing 
is carried out only using allergenic extracts. A given 
patient could have positive extract-based tests to 
several tree pollen extracts, due to IgE recognition 
of both genuine and/or panallergens, or as a result 
of an IgE recognition of panallergens in the absence 
of a genuine reactivity to the marker allergens. 
Despite the high sequence identity observed among 
Textbox  1
Clinical relevance
  Molecular allergens markers of genuine re-
activity: Cry j 1 (pectate lyase); Cup a 1 (pec-
tate lyase); Aln g 1.0101 (PR-10 protein); Bet v 
1.0101 (PR-10 protein); Cor a 1.0101 (PR-10 
protein); Ole e 1 (common olive group 1); Ole 
e 9.0101 (beta-1,3-glucanase); Pla a 1.0101 
(putative invertase inhibitor); Pla a 2 (polygalac-
turonase)
  Panallergens: Profilin (Bet v 2.0101), Polcal-
cin (Bet v 4.0101) and nsLTP (Ole e 7 and Pla a 
3.0101). Check also bromelain (Ana c 2) or the 
purified N-glycan from bromelain MUXF3 in the 
case of multiple tree pollen IgE reactivity, to rule 
out the possibility of CCD reactivity.
  Tree pollen allergy is associated with a low inci-
dence of respiratory symptoms and asthma.
Figure 3
Algorithms to complete the diagnostic work-up of tree pollen allergic patients.
Monoreactivity
Polyreactivity to all extracts 
(Cypress, Olive, Birch 
and Plane tree)
Polyreactivity to  
Plane tree and/or Olive tree No reactivity
Tree pollen AIT 
for the culprit 
allergen can be 
considered
Tree pollen AIT 
for culprit 
allergen mixed 
together can be 
considered
No AIT 
suggested
Check for 
other genuine 
sensitizations
Tree pollen AIT 
for culprit 
allergen mixed 
together can be 
considered
No AIT 
suggested 
Check for 
nsLTP 
 reactivity
No AIT 
suggested
No Tree pollen 
allergy
No AIT 
suggested
Genuine 
sensitization to 
all tree pollen 
sources 
(Cup a 1, Bet 
v 1.0101, Ole e 
1, Pla a 1.0101)
Profilin 
(Bet v 2.0101) 
or Polcalcin 
(Bet v 4.0101, 
Phl p 7.0101) 
reactivity
Genuine 
sensitization 
both biological 
sources 
(Ole e 1 and 
Pla a 1.0101)
IgE recognition 
of LTP 
molecules 
(Pla a 3 and/or 
Ole e 7)
No Reactivity
Reactivity to 
all tree pollen 
sources due 
to a CCD IgE 
recognition
 Diagnosis 
confirmed after 
specific IgE 
evaluation
SP
T
Ig
E
M
an
ag
em
en
t
 EAACI Molecular Allergology User´s GuideEAACI Molecular Allergology User´s Guide2016 Part  B:  Using Molecular Al lergology In The Cl inical  Practice 
80 Tree Pollen Allergy
constituents of every single group of panallergens, 
testing of several panallergens could possibly 
increase assay reliability and the identification of 
interesting clinical phenotypes (30), albeit in daily 
clinical practice a less expensive approach may often 
be necessary (31). IgE reactivity due to cross-reacting 
carbohydrate determinants (CCDs) should also be 
ruled out, since all plant extracts can be weakly 
recognized by patients’ IgE specific for CCDs, with no 
clinical significance (32).
In Fig. 2, genuine markers of sensitization are 
indicated in green and panallergens found in the 
different pollens are colored in red.
CLINICAL MANAGEMENT
Allergen specific Immunotherapy (AIT) should be 
prescribed only when clinical relevance of a given 
allergen source has been reliably demonstrated (33). 
In the presence of a multiple IgE-sensitization the first 
goal is to distinguish patients genuinely reactive from 
those misrecognizing a given biological source due to 
a reactivity to polcalcin, profilin or nsLTPs. Another 
difficulty in identifying the primary sensitizing 
source occurs in several countries (i.e. southern 
Europe) where an overlapping of tree, weed or grass 
pollination periods takes place. Several molecules 
have been proposed as markers for the prediction of 
a better response to AIT: Ole e 1, Cup a 1, Bet v 1, Cor 
a 1 or Pla a 1 reactivity can be considered as specific 
signatures for a genuine tree pollen allergy.
Cup a 1 reactivity is the specific marker allergen for 
a sensitization to pollen of trees of the Cupressaceae 
family. Also in this case the high sequence identity, 
associated to a high degree of cross-reactivity among 
Cupressaceae family members, suggest the use of 
Cup a 1 as a representative marker of the entire 
family for both diagnostic testing and therapeutic 
approaches (Fig. 1 and 2).
Bet v 1 sensitized individuals often experience 
an oral allergy syndrome due to the intake of food 
containing PR-10 proteins. It has been suggested 
that birch pollen AIT can improve not only pollen-
related respiratory symptoms but also-food related 
adverse reactions (34), but different outcomes 
without benefit are reported in other studies (35) 
(see section C02).
Ole e 1 is the most common sensitizing molecule 
in olive pollen. It is utilized in both diagnostic and 
therapeutic extracts for standardization purposes 
and can determine immunological changes after olive 
pollen AIT. On the other hand, due to the high degree 
of cross-reactivity among the Ole e 1-like proteins 
of the Oleaceae family, in olive-free areas, Ole e 1 
reactivity could help to identify individuals reacting 
with ash or privet pollen as suitable for AIT (36). In 
areas with heavy olive pollen exposure, Ole e 7 and 
Ole e 9 should be tested to identify patients with a 
more severe allergic phenotype (15).
Pla a 1 and Pla a 2 may serve as a marker of primary 
sensitization to plane tree pollen, therefore useful 
for AIT selection, whilst the nsLTP Pla a 3 has been 
linked with sensitization to plant-food LTPs (37).
Profilin and polcalcin represent the major causes 
of cross-reactivity due to their highly conserved 
structure and ubiquitous distribution (38). Profilin 
or polcalcin-reactors score positive to all tree pollen 
after an extract based diagnostic testing (29). Several 
allergens that are currently available for routine 
testing (profilins from birch, Bet v 2, and grass, Phl 
p 12, and polcalcins from birch, rBet v 4, and grass, 
rPhl p 7), are marker molecules for the entire group 
of panallergens, excluding cypress and Parietaria 
profilins (39). IgE-sensitization to panallergens, 
despite the ability to induce symptoms in sensitized 
patients, could affect AIT efficacy in the absence 
of species-specific molecules reactivity (33) (Fig. 
3). Interestingly, panallergens reactors in the vast 
majority of cases are also co-sensitized to species-
specific genuine molecules from different pollen 
(23), thus ideally requiring a multiple pollen AIT to be 
successful.
Cross-reactive carbohydrate determinants (CCDs) 
do not behave as allergens in vivo and are therefore 
clinically insignificant (40), but the presence of 
IgE to CCDs could lead to a misleading in vitro 
reactivity also in the case of extract-based testing 
orwhen using CCD-containing natural purified 
glycoproteins such as nCyn d 1, nOle e 1, nCup a 
1, nSal k 1, nPla a 2 or nArt v 1 (41). Recombinant 
proteins produced in Escherichia coli bacteria are not 
affected by CCD recognition, because of the lack of 
the posttranslational glycosylation of proteins (42). 
Bromelain (Ana c 2) or the purified N-glycan from 
bromelain MUXF3 are available to detect CCDs 
in vitro in the vast majority of pollen sources, with 
the exception of nArt v 1 where CCD reactivity is 
driven by O-glycans and not N-glycans measurable 
with bromelain or MUXF3. A positive skin prick test 
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or in vivo (i.e. nasal, or conjunctival) challenge with 
the biological source can prove the genuine protein 
epitopes IgE recognition (40). In Fig. 3 we suggest 
several algorithms possibly useful to complete the 
diagnostic work-up in tree pollen allergic patients.
CLINICAL CASES
Case 1 (original)
Clinical History: Austria, patient (female, 27y) suffers 
from allergic rhinitis and conjunctivitis in April, 
the flowering period of birch and ash. Oral allergy 
syndrome does not occur.
Test with extracts (A) SPT: A skin prick test is not 
possible because the patient has dermographism; 
(B) in-vitro testing: Birch: 8 kUA/L; Ash: 2 kUA/L
Test with molecules: Bet v 1: 7 kUA/L; Bet v 2: 3 
kUA/L; Bet v 4: negative; Ole e 1*: negative
*Ole e 1 is used here to substitute for Fra e 1, 
which is highly cross-reactive with Ole e 1 and is 
not available in the CAP system.
Conclusion: The serology clearly identifies the 
patient as genuinely sensitized to birch; elevated 
IgE to ash is caused by cross-reactive pan-
allergens. Immunotherapy with birch pollen 
extract is possible because the patient is mainly 
sensitized to the major allergen Bet v 1 and should 
be performed if symptomatic treatment does not 
sufficiently reduce the symptoms of allergy.
Case 2 (original)
Clinical History: Male, Italy, born 1994. Patient 
suffering from a perennial allergic rhinitis. 
Because of concurrent antihistaminic therapy, 
patient underwent a routine specific extract IgE 
evaluation.
Test with extracts: (A) In-vitro testing: birch: 25 
kUA/L; olive tree: 18 kUA/L; plane tree; 14 kUA/L; 
Cypress: 30 kUA/L; D. pteronyssinus: 44 kUA/L. 
(B) SPT: After discontinuation of antihistaminic 
therapy, the patient went through cutaneous 
allergic evaluation that gave negative results for all 
the four tree pollen tested and mono-reactivity to 
D. pteronyssinus and D. farinae.
Test with molecules: ImmunoCAP ISAC: Der p 2: 35 
ISU-E; Der f 2: 42 ISU-E; Lep d 2: 2.3 ISU-E; rBet 
v 1: Negative; nCry j 1: 1.2 ISU-E; nCup a 1: 3.3 
ISU-E; nOle e 1: 2.8 ISU-E; rPla a 1: Negative; nPla 
a 2: 4 ISU-E; rPla a 3: Negative; MUXF3: 18 ISU-E
Conclusion: The serology clearly identifies the 
patient as genuinely sensitized only to house dust 
mite. The presence of MUXF3 reactivity indicates 
a CCD recognition further confirmed by the 
reactivity to native tree pollen molecules (Ole e 1, 
Pla a 2, Cup a 1 and Cry j 1) in the presence of 
negative result considering recombinant (not CCD 
bringing) molecules (rBet v 1, rPla a 1, rPla a 3) and 
in the absence of skin test reactivity to tree pollen 
extracts (CCD IgE reactivity is never followed by a 
positive skin test result).
Case 3 (original)
Clinical History: Female, Italy, born 1973. Patient has 
been suffering from a seasonal allergic rhinitis and 
asthma since 2000. After ingestion of 2 walnuts, 
anaphylactic reaction (abdominal pain, dyspnea, 
generalized flushing and swelling, low blood 
pressure), subsequent emergency treatment and 
hospitalization overnight. No food allergy to peach 
or other food item known so far.
Test with extracts: (A) SPT: Environmental allergens: 
Pellitory (Parietaria j): 9mmx5mm; plane tree 
(Platanus a.): 6mmx7mm; olive tree (Olea e): 
7mmx10mm; Mugwort (Artemisia v.): 3mmx4mm. 
Food allergens: all negative except walnut (Juglans 
regia nut): 15mmx10mm (peach negative). (B) In-
vitro testing: (2014) Total IgE 49.3 kU/l, specific 
IgE to pellitory (Parietaria j): 2.5 kUA/l; plane tree 
(Platanus a.): 0.56 kUA/l; Olive tree (olea e): 0.78 
kUA/l; Mugwort (Artemisia v.): 0.42 kUA/l; Walnut 
3.82 kUA/l; rPru p 3: 0.76 kUA/l
Test with molecules: (ImmunoCAP ISAC): Par j 2: 1.56 
ISU-E; Jug r 3: 1.15 ISU-E; Ole e 7: 9.82 ISU-E; Pla 
a 3: 1.98 ISU-E, (Pru p 3: negative)
Conclusion: Strict avoidance of walnut. AIT prescribed 
only for Pellitory.
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PART B
IgE to group 1 allergens (eg Phl p 1) is a marker of 
true grass pollen sensitisation.
Whilst IgE to other major grass pollen allergens are 
rarely observed in the absence of IgE to Phl p 1, IgE 
to Phl p 5 or Phl p 2 can serve as a markers of true 
grass pollen sensitisation.
A number of allergen families exist in grass pollens, 
but IgE reactivity to Phl p 4, Phl p7, Phl p 11 or 
Phl 12 may be due to cross-reactivity (CCD or 
panallergenicity).
Early onset of IgE sensitisation to grass pollen 
allergens, particularly Phl p 1, and a high number of 
sensitisations (Phl p 5, 7 and 12) may be prognostic 
markers of disease progression but further studies 
are needed.
In temperate climates, patient serum IgE shows 
broad cross-reactivity between similar allergen 
components from different temperate grass pollens.
Group 1 allergens of subtropical grass pollens (Pas n 
1, Sor h 1 and Cyn d 1) are more relevant allergens 
for patients in subtropical regions.
Janet M. Davies, Paolo M. Matricardi, 
Johannes Schmid
THE ALLERGEN SOURCES
Grasses are ubiquitous throughout the entire world. 
In places with a temperate climate, members of the 
Pooideae subfamily (1) like Timothy grass (Phleum 
pratense), Orchard grass (Dactylus glomerata), Perennial 
ryegrass (Lolium perenne) and bluegrass (Poa pratensis) 
are the most common pollen sources. The pollen of 
this Pooideae subfamily shows extensive IgE cross-
reactivity. Grasses have a pollinating season from May to 
August in Central Europe, peaking in June. In Northern 
Europe, the grass pollen season starts later, while 
pollination lasts for a longer period in Mediterranean 
Europe. The grass pollen season overlaps with weed 
pollen (mugwort, ragweed) in most parts of Europe 
and with tree pollen (olive, plane) in Southern Europe. 
In subtropical and tropical regions of the world, grass 
pollen seasons can be perennial (2). Subtropical 
sources of allergenic grass pollens include those of the 
Panicoideae subfamily; Bahia grass (Paspalum notatum) 
and the prolific weed Johnson grass (Sorghum halepense), 
as well as the Chloridoideae subfamily; Bermuda grass 
(Cynodon dactylon) (3). Timothy grass is originally native 
to Europe and adjacent regions in Africa and Asia. It is 
widely cultivated throughout most temperate regions 
of the world for pasture and hay production. Despite 
GRASS POLLEN 
ALLERGY 
B02
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of substantial geographical variations, grass pollen is 
the most prevalent sensitizing pollen in Europe with a 
median prevalence of 16.5 % (4).
MAJOR AND RELEVANT MINOR 
ALLERGENIC MOLECULES
At present, nine allergenic molecules from Timothy 
grass pollen have been officially listed by the IUIS 
Allergen Nomenclature Sub-Committee. Phl p 2, p 5 
and p 6 are specific for grasses from the Pooideae 
subfamily. Orthologues of the group 1 grass pollen 
allergens represented by Phl p 1 of Timothy grass 
are present in all grass pollens thus being specific for 
grasses from the Poaceae family. Phl p 3 is another 
Pooideae specific allergen molecule with similarities 
to Phl p 2 (5) not yet listed in the IUIS list. Phl p 13, 
a polygalacturonase protein, is a grass pollen-specific 
allergen molecule as well.
Sensitization to Phl p 1 usually precedes other grass 
pollen sensitizations and is the most prevalent 
component sensitization in grass pollen allergic 
patients (6). It is a useful marker for primary grass 
pollen sensitization. Phl p 1 is a beta-expansin, 
bound to the cell wall and important for pollen tube 
penetration. Phl p 1 is a major grass pollen allergen, 
with more than 80% homology to group 1 allergens 
from other members of the Pooideae subfamily (7). 
Phl p 1 shares epitopes with group 1 allergens from 
other grasses and shows IgE cross-reactivity to most 
other group 1 allergens from grasses, corns and 
monocots (8).
Phl p 5 is another major pollen allergen of temperate 
grasses with a lower sensitization prevalence, but 
often with high IgE-levels. Phl p 5 is a cytoplasmatic 
ribonuclease, important in the enzymatic degradation 
of RNA. It shows broad IgE cross reactivity with other 
group 5 allergens from the Pooideae subfamily of 
temperate grasses.
Figure 1
Clinically important examples of common temperate (Pooideae) and subtropical (Panicoideae and Chlori-
doideae) grass pollen allergen sources. Species origin, geographical distribution and peak pollinating pe-
riods in common regions are included. Timing of pollination of Pooideae species refers to the northern 
hemisphere.
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The Phl p 2 and Phl p 3 allergens are proteins with 
homology to the C terminal domain of the beta-
expansin protein family. They show substantial 
similarities and are specific for the Pooideae subfamily. 
Their biochemical function is not yet known.
Phl p 6 is another major grass pollen allergen, specific 
for the Pooideae subfamily. Its function has not yet 
been described.
Phl p 13 is a polygalactorunase which is a hydrolytic 
enzyme, degrading parts of the pectin network in 
plant cell walls. It is a major allergen, specific for the 
Pooideae subfamily.
Phl p 4 is a tryptase-resistant glycoprotein, berberine 
bridge enzyme, involved in the synthesis of alkaloids. 
It can be classified as a major allergen. It shows 
IgE cross reactivity with other group 4 grass pollen 
allergens, including with Cyn 4 to some extent. 
Moreover, cross-reactivity to the major ragweed 
allergen Amb a 1 and to Oilseed Rape pollen has 
been demonstrated. Natural Phl p 4 contains CCD, 
which may lead to IgE cross-reactivity with a wide 
range of plants and plant products.
Phl p 11 belongs to the Ole e 1 related proteins and 
hence exhibits a broad range of cross-reactivities 
to pollen from different plants as olive, ash, privet, 
saffron crocus, thistle, plantain and corn. It is an 
acidic polypeptide with homology to the tryptase 
inhibitor of soybean.
Phl p 7 and Phl p 12 are minor allergens, representing 
pan-allergens from the plant world. Phl p 7, polcalcin, 
is a calcium binding protein present in many different 
pollens, hence representing a broad cross-reacting 
allergen: birch, alder, juniper, ragweed, mugwort, 
olive, goosefoot etc. Phl p 7 sensitization can be used 
as a marker for a more general pollen sensitization.
Phl p 12 is a member of the profilin family, an actin-
binding protein that is present throughout the whole 
plant world. As profilins are ubiquitous in plant cells, 
profilin sensitization gives rise to a long range of 
cross-reacting plants and plant products as birch, 
soybean, corn, latex and plant foods.
Subtropical grass pollens of Bahia grass (Paspalum 
notatum) and Bermuda grass (Cynodon dactylon) show 
only limited IgE cross-reactivity with the pollens from 
the Pooideae subfamily (9). Patterns of IgE cross-
Figure 2
Left panel: A Venn diagram showing allergens of different sources that are similar to temperate and/or 
subtropical grass pollen allergens. Major allergens are in bold. Allergens of the same biochemical family are 
shown in boxes of the same color. Panallergens including profilins (brown boxes e.g. Phl p12) and polcalins 
(pink boxes e.g. Phl p 7) are in small font. Right panel: Relationship between the major group 1 allergen 
components of temperate (Pooideae) and subtropical grass pollens of Chloridoideae and Panicoideae 
subfamily (Unrooted phylogentic tree generated by multiple sequence alignment with ClustalW2 using 
sequences published in Davies et al., 2008 (20).
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Table 1
Allergenic molecules of timothy grass (205-207)
Allergen Allergenicity Code Biochemical name Function MW Iso-forms
Structure 
(14)
Phleum pratense (temperate grasses)
Phl p 1 83-95 % 549-551
CCD-bearing 
protein Beta-expansin 27 2
Phl p 2 55-65 % 555 Grass group 2 Unknown 10-12 1
Phl p 3 60 % 556 Grass group 3 unknown 2
Phl p 4 70-75 % 557 CCD-bearing protein
Berberine-bridge 
enzyme 55 6
Phl p 5 50-95 5 558 Grass group 5 Ribonuclease 32 16
Phl p 6 44-75 % 569 Grass group 6 unknown 11 2
Phl p 7 7-10 % 570 Polcalcin Calcium-binding protein 6 1
Phl p 11 32-43 % 552 Ole e 1-related protein Trypsin inhibitor 20 1
Phl p 12 15 % 553 Profilin Actin-binding protein 14 3
Phl p 13 50 % 554 Grass group 13 Polygalacturonase 55 1
Subtropical grasses
Cyn d 1 76-100% Yes Glycoprotein Beta-expansin 32 12
Cyn d 4 100% Yes Glycoprotein Berberine bridge enzyme 60 1
Pas n 1 85-92% Yes Glycoprotein Beta-expansin 29-30 2
Pas n 13 48% No Glycoprotein Polygalacturonase 55 4
Sor h 1 76% Yes Glycoprotein Beta-expansin 30 2
 EAACI Molecular Allergology User´s GuideEAACI Molecular Allergology User´s Guide Part  B:  Using Molecular Al lergology In The Cl inical  Practice 2016
89Grass Pollen Allergy 
reactivity between subtropical and temperate grass 
pollen appear to depend of the geographical region 
of the patient population being investigated.
Subtropical grass pollens contain the major beta 
expansin group 1 allergen family; Pas n 1 of Bahia 
grass, multiple isoforms of Sor h 1 of Johnson grass 
and Cyn d 1 of Bermuda grass. The polygalacturonase 
components Pas n 13 of Bahia and Sor h 13 of 
Johnson grasses, are the second most abundant 
protein and frequently recognized allergens 
from pollen of Panicoideae family of subtropical 
subtropical regions. A number of allergens have been 
described from Bermuda grass pollen including the 
berberine bridge enzyme orthologue Cyn d 4 that is 
a major allergen. IgE reactivity with a group 2 allergen 
Sor h 2 of Johnson grass pollen has recently been 
discovered (19). Notably, however to date no allergen 
with significant homology with the Pooideae group 
5 allergen has been discovered by proteomic or 
transcriptomic analysis of subtropical grass pollens.
As mentioned above allergen molecules from 
different members of the Pooideae subfamily are 
highly IgE cross-reactive (10). As both wild and 
cultivated grasses in the temperate climate zones 
belong to the Pooideae subfamily, Phleum pratense 
allergens can be used for diagnostic and therapeutic 
purposes in grass pollen allergic patients living in the 
temperate parts of the world.
SENSITIZATION TO INDIVIDUAL 
MOLECULES AND ITS CLINICAL RELEVANCE
The IgE response against grass pollen (e.g. 
Phleum pratense) usually evolves from a simple, 
monomolecular stage to an oligomolecular stage and 
eventually to a polymolecular sensitization stage (6). 
This phenomenon has been defined as ‘molecular 
spreading’, that is, “The sequential development of 
antibody (IgE) response to distinct non-cross-reacting 
molecules from the same antigenic (allergenic) source, 
starting with an “initiator” (allergenic) molecule.” (15). Phl 
p 1 is the probable ‘initiator’ molecule in most patients, 
and the response involves then Phl p 4 or Phl p 5, 
thereafter also Phl p 2 and Phl p 11 and at a later stage 
Phl p 12 or Phl p 7. This has been confirmed in other 
birth cohort studies (16). The practical consequence of 
this phenomenon is that the longer is the duration of 
disease, the broader is the repertoire of IgE against the 
different molecules of a single pollen.
This has also led to the consideration that AIT should 
be started earlier in a patient’s clinical care, possibly 
even immediately after the first season in which the 
allergic respiratory symptoms are initiated (“early-
AIT”) (15). Interestingly, the molecular spreading 
process follows different pathways in different 
children: some patients remain sensitized only to 
the “initiator” molecule (Fig. 3) while a few patients 
become sensitized to most or all allergenic molecules. 
Consequently, a population of grass-pollen allergic 
patients “apparently” homogeneous if examined 
with an allergen extract is remarkably heterogeneous 
when examined with allergenic molecules (Fig. 4) 
(16, 17). The clinical relevance of individual profile 
of sensitizaion is being tested in large populations 
both in cross-sectional, observational studies and 
in longitudinal intervention studies. However, only 
few data have yet been published; in a recent study 
a higher risk of asthma at 11 years was observed in 
children being sensitized at 5 years to almost all grass 
pollen allergen molecules in comparison with those 
who had a late onset of sensitization (16).
IgE to Phl p 1 - Clinical relevance – Phl p 1 (or others of 
the “group 1” antigens of grass pollen, such as Lol p 1, 
from Lolium perenne) is in most patients the “initiator” 
molecule. Moreover, even in the few grass-pollen 
allergic patients who start their sensitization process 
with other molecules, IgE against Phl p 1 are produced 
quite soon. Therefore, IgE to Phl p 1 is an essential 
marker in grass pollen allergic patients to establish “true 
sensitization”. The presence of IgE to Phl p 1 confirms 
that the patient with a positive skin test or IgE assay to 
grass pollen extract is truly sensitized to grass pollen. 
The absence of IgE to Phl p 1 does not exclude “true” 
sensitization to grass pollen, which might be due (in a 
few cases) to isolated IgE sensitization to other major 
allergenic proteins (e.g. Phl p 5) but makes it rather 
Textbox 1
Advices for use of molecule diagnostics for grass 
pollen
IgE to Phl p 1 is a marker of “true sensitization” to 
grass pollen.
Exceptions:
In a few rare cases with skin test positivity to a 
grass pollen extract but no detectible IgE to Phl p 
1, IgE to Phl p 5, may confirm the diagnosis of grass 
pollen allergy.
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unlikely. Then patients with skin test-IgE positivity 
to a grass pollen extract but lacking IgE to Phl p 1 
should be tested for IgE to all other Phl p molecules. 
The group 1 allergens are the major and most clinically 
important allergen of subtropical Panicoideae grass 
pollens. Whilst other allergen components are present 
in subtropical grass pollens, IgE to Pas n 1 of Bahia 
grass pollens accounts for nearly all of the detectible 
IgE reactivity to the whole extract (18) similarly, IgE 
reactivity with Sor h 1 of Johnson grass pollen is highly 
Figure 3
Molecular spreading of the IgE response to Timothy grass and potential implications for allergen-specif-
ic immunological intervention in a child with seasonal allergic rhinitis to grass pollen (SARg). Molecular 
spreading of the IgE response to Timothy grass and potential implications for allergen-specific immunolog-
ic intervention in a child with seasonal allergic rhinitis to grass pollen (SARg). Molecular spreading of the 
IgE response to Phleum pratense and implications for allergen-specific immunological intervention in one 
child with hay fever (case from the MAS birth cohort). Numbers refer to serum concentrations of IgE anti-
bodies measured by ISAC (ISU). This child started suffering from hay fever symptoms at the age of 6 years. 
IgE response against Phleum pratense started 3 years before with a weak, monomolecular sensitization 
to Phl p 1. This IgE response was stronger and directed also to Phl p 2 and Phl p 4 at disease onset. After 
disease onset, the IgE response was much stronger and directed also to Phl p 5, Phl p 6, and Phl p 11. In 
clinical practice, allergen-specific immunotherapy (SIT) would be ‘normally’ prescribed at this advanced 
stage, after some years of symptoms (age 10 yrs). An interesting hypothesis is that SIT would be more 
efficient if started much earlier, ideally ‘at’ disease onset (age 6 yrs) (early SIT). Moreover, it could be inves-
tigated whether an immune intervention at the earliest, preclinical stages (age 3 yrs) of disease could even 
better change the natural history of the sensitization and prevent or delay diseases onset (allergen-specific 
immunoprohpylaxis, SIP). The use of recombinant allergens would be easier at this stage, as less molecules 
should be used (component-resolved immune prophylaxis (CRP)). Reprinted with permission from (15).
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correlated with IgE reactivity with the whole pollen 
(19). For Bermuda grass pollen, Cyn d 1 is the major 
allergen but the complexity of described allergen 
components is broad (3).
IgE to Phl p 5 - Clinical relevance – Phl p 5 is rarely 
the only molecule inducing grass pollen sensitization 
and the presence of IgE antibodies to this Phl p 5 
– observed in around 50% of the European grass 
pollen allergic patients - confirms that a positive SPT 
reaction is the expression of true sensitization to 
grass pollen. However, although IgE to Phl p 5 usually 
appear later than those to Phl p 1 in the sensitization 
process, their concentration grows in many patients 
rapidly and higher and their contribution to patients’ 
symptoms has been demonstrated. Testing IgE to 
Phl p 5 can be useful as a second line test and has 
been shown to be useful for distinguishing between 
allergy to grass and olive pollen in Southern Europe. 
Phl p 5 specific IgE may have some prognostic value 
for indicating disease severity or likely progression 
from allergic rhinitis to asthma, but this needs to be 
confirmed with well-designed studies. As group 5 
allergens have not been found in subtropical grass 
pollens, Phl p 5 specific IgE may indicate sensitization 
to temperate grass pollens in particular. This needs to 
be investigated in relevant patient populations.
IgE to Phl p 12 - Clinical relevance (see also Section 
C01) – Phl p 12, is the highly cross-reacting profilin 
of Phleum pratense. As a heat-labile, relatively weak 
allergenic molecule, IgE sensitization to profilin comes 
later in the molecular spreading process, reaches 
only moderate levels of IgE antibodies and only in a 
minority of patients. Hence, IgE to Phl p 12 mark in 
general patients with a higher atopic background and/
or longer disease duration. Patients with a positive 
skin test/IgE to grass pollen extract but no IgE to Phl 
p 1 and Phl p 5 must be tested for IgE to Phl p 12 
as these antibodies – that can be induced by other 
pollens containing profilin, is the first cause of “false” 
positivity to assays based on grass pollen extract. In 
the presence of IgE to Phl p 12, patients should be 
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Figure 4
Profiles of IgE sensitization to eight Phleum 
pratense molecules in 176 sensitized children. 
Profiles of IgE sensitization to eight Phleum 
pratense molecules in 176-sensitized children. 
Profiles of IgE sensitization to eight Phleum 
pratense moleculesin 176 children with an IgE 
reaction to Phleum pratense and complete da-
ta-set. The Allergen Profile Codification System 
(APCS) code and the absolute and cumulative 
frequency are shown. The profiles are ordered 
by declining frequency and the point at which 
the arbitrary threshold of 80% of the patient 
population has been reached is marked in red. 
Reprinted with permission from (17).
Textbox 2
Highlights
The major allergen Phl p 1 serves as a specific diag-
nostic marker for grass pollen allergy in temperate 
regions. Phl p 5 and Phl p 2 may also serve as diag-
nostic or prognostic markers for some patients.
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asked about Oral Allergic Syndrome triggered by the 
ingestion of fruit and vegetables containing profilin, 
with a focus on apple, celery and birch.
IgE to Phl p 7 - Clinical relevance (see also Section 
C06) – Phl p 7, is the highly cross-reacting polcalcin 
of Phleum pratense. This is a heat-stabile, relatively 
potent allergen that can induce quite high IgE 
antibody levels. An IgE response to Phl p 7 is observed 
only infrequently among grass pollen allergic patients 
and usually many years after the disease onset. IgE to 
Phl p 7 marks a relatively distinct category of grass 
pollen allergic patients, with more severe symptoms, 
a higher prevalence of asthma, and a higher frequency 
of additional allergic comorbidities. Moreover, many 
other pollens and allergenic sources contain polcalcin 
so that the origin sensitization to polcalcin in a grass-
pollen allergic patient must be carefully searched. 
These allergenic sources could be indeed responsible 
of a more severe disease.
IgE to Phl p 4 - Clinical relevance (see also Section 
A03) – Phl p 4 is a major allergenic protein of grass 
Figure 5
Diagnostic algorithm for AIT prescription in grass pollen allergic patients. Patients with AR symptoms 
during the grass pollen-season and a positive SPT/IgE assay to grass pollen extracts are further inves-
tigated to detect serum IgE antibodies to Phl p 1, Phl p 2, Phl p 5, Phl p 7, Phl p 11, and Phl p 12. The 
identification of one or more of IgE antibodies to Phl p 1, Phl p 2, Phl p 5 and/or Phl p 11 is followed by 
the prescription of grass pollen AIT. The identification of IgE to Phl p 12 (profilin) is followed by further 
investigation of OAS and influences is relevant to better interpret results of SPT/IgE assays with other 
pollen extracts or vegetables. The identification of IgE to Phl p 7 alerts the doctor of a worse prognosis 
and greater severity of the disease.
Partient with AR symptoms in grass pollen 
season and positive to SPT or IgE 
assay with grass pollen extracts
Phl p 1 pos Phl p 1 neg
Q1b) Is the patient
already sensitized also
to highly cross-reacting
molecules?
Phl p 12 pos Phl p 12 neg
Phl p 2/5/11 pos Phl p 2/5/11 neg
Phl p 7 pos Phl p 7 neg
Consider AIT
with  Grass 
pollen extract
Check sensitization 
to other pollens
Careful investigation 
of symptoms 
compatible with OAS 
Worse prognosis, & 
comorbidities 
(e.g. asthma)
Monitor next 
season both 
symptoms 
and 
sensitization
Systemic IgE 
sensitization to grass 
pollen species-specific 
not detected
Unexplained 
SPT/IgE positivity to 
grass pollen extracts
Q1a) 
Is the patient really
sensitized to grass pollen?
(test for IgE to Phl p 1, 
Phl p 7, Phl p 12)
Q2)  Is the patient really
sensitized to grass pollen?
(test for Phl p 2,  
Phl p 5, Phl p 11)
 EAACI Molecular Allergology User´s GuideEAACI Molecular Allergology User´s Guide Part  B:  Using Molecular Al lergology In The Cl inical  Practice 2016
93Grass Pollen Allergy 
pollen. In its native form, the one still used in most 
commercial available assays, Phl p 4 contains extremely 
highly cross-reactive carbohydrate determinants 
(CCD). This explains why in several epidemiological 
studies IgE positivity to Phl p 4 scores over 90% of 
the grass pollen allergic patients. However, when 
the recombinant version of the molecules is used for 
assays, over 50% of the positivity is not confirmed 
anymore. As extracts contain native Phl p 4, a weak 
positivity to SPT/IgE test based on grass pollen 
extracts can in some patients be “false” and simply 
explained by IgE recognizing CCD determinants. Phl 
p 4 may also serve as a marker for sensitization to 
Bermuda grass pollen due to its similarity with Cyn 
d 4, a major allergen of Bermuda grass pollen, but 
this needs to be investigated in relevant patient 
populations.
IgE to Phl p 2, 6, 11 – Phl p 2 and Phl p 11 are 
both rarely the only molecule inducing grass pollen 
sensitization and the presence of IgE antibodies to 
this Phl p 2 – observed in around 60-80%% of the 
European grass pollen allergic patients - just confirms 
that a positive SPT reaction is the expression of true 
sensitization to grass. Phl p 6 is highly cross-reacting 
with Phl p 5 and does not add a lot of diagnostic 
information, once IgE to Phl p 5 has been tested.
CLINICAL MANAGEMENT
In patients allergic to grass pollens IgE tests should 
be oriented to answer the following questions:
A) is the patient really sensitized to grass pollen 
major allergenic proteins? (test Phl p 1, if negative 
also Phl p 5 and the other molecules);
B) is the patient sensitized also to highly cross-
reacting molecules? (test Phl p 12 and Phl p 7);
C) in the case of negativity to Phl p 1 and other 
species-specific allergenic molecules and 
positivity to Phl p 12 and/or Phl p 7), which is the 
pollen inducing a “false” IgE sensitization to grass 
pollen extracts?
After having answered these questions the doctor 
should be able to decide whether the patients’ 
symptoms are consistent or not to IgE sensitization 
to grass-pollen and consequently can decide whether 
to prescribe an AIT based on grass-pollen extract. 
Whilst orthologues such as Cyn d 7 and Sor h 12 
have been reported in subtropical grasses, there is 
currently limited evidence available of IgE reactivity 
in relevant patients primarily sensitized to subtropical 
grass pollens. A diagnostic algorithm for a decision 
making process which summarizes the information 
provided in the previous section is proposed (Fig. 5).
CLINICAL CASES
Case 1
Step 1 - History: A 35 year old male from Central 
Italy patient presented with allergic rhinitis from 
April to July but not in September or October. The 
patient had experienced conjunctival and nasal 
symptoms that did not respond to antihistamines 
and were only partly controlled with nasal steroids. 
He reported the condition was steadily increasing 
each season and that he, occasionally, experienced 
a tight chest after spending time outside. Since 
the last year, he had experienced oral symptoms 
(pruritus, swelling) after eating either melon or 
watermelon.
Step 2 - Testing: SPT positive for birch (5mm), timothy 
grass (8mm), pellitory (4mm), olive (3mm) pollens. 
Serum IgE antibody levels were 7.1 kU/L to birch, 
17.3 kU/L to timothy grass, 6.7 kU/l to pellitory, 
3.2 kU/l to olive extracts.
Step 3 - Treatment: No AIT was started as the doctor 
was not sure which pollen(s) was/were responsible 
of the patient’s symptoms.
Added CRD value: positive response to Phl p 1 (12.2 
kU/l), Phl p 5 (6.5 kU/l), and Phl p 12 (4.3 kU/l) 
but not to Bet v 1, Ole e 1, and Par j 2. The patient 
commenced SLIT with grass pollen and responded 
well to this treatment. OAS was also explained by 
IgE sensitization to profilin (Phl p 12).  
Case 2
Step 1 - History: A 26 year old Danish woman with 
a 10 year history of persistent severe seasonal 
rhinoconjunctivitis during birch and grass pollen 
season. Symptoms most severe in early summer, 
with persistent conjunctival (redness, itching, 
watering, light sensitivity) and nasal (blocked nose, 
itching and secretion) symptoms. Very poor effect 
of systemic antihistamines and local antihistamine 
(eyes and nose) and local corticosteroid (nose). 
Had some benefit from systemic corticosteroid. 
Good symptom control during birch pollen season.
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Step 2 - Testing: SPT positive for birch and grass 
pollen 7 mm diameter. IgE to grass pollen 10.9 
kU/l, birch pollen 3.9 kU/l
Step 3 - Treatment: Starts standard SCIT with natural 
grass pollen extract´. Poor clinical effect after 2 
years of treatment.
Added CRD value = Missing Step 2b - In vitro 
testing: We found a sensitizations to Phl p 4 in the 
grass pollen panel, as well as Bet v 1. She was not 
sensitized to typical other CCD reactive natural 
molecules. The conclusion was that she truly was 
grass pollen allergic, and she received anti-IgE 
treatment during grass pollen season with good 
clinical outcome
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Common invasive weeds like ragweed, 
mugwort and plantain, are frequently 
important allergen sources typically flowering 
in summer through to autumn.  
The biogeographical range and pollination 
periods of allergenic weeds can overlap 
confounding accurate allergy diagnosis.
Specific IgE to Amb a 1 can be a useful marker 
for ragweed sensitization but it shows cross-
reactivity with Art v 6 from mugwort.  Likewise 
specific IgE to Art v 1 can be a useful marker 
for mugwort sensitization, but its shows partial 
cross-reactivity with Amb a 4 from ragweed.
Art v 3 reactivity is frequently associated with 
LTP sensitization in Mediterranean patients 
but is rare in patients with mugwort pollen-
related symptoms in non-Mediterranean 
regions.
Par j 2 is a highly specific marker allergen for 
pellitory sensitization while Pla l 1 is a useful 
marker for genuine plantain sensitization.
B03
THE ALLERGEN SOURCES
The term weed does not constitute a botanical 
family, but rather refers to diverse plants used 
sometimes as culinary culinary and medicinal herbs, 
that are ecologically adaptive and invasive segetal 
plants. Pollen of weeds mediating IgE-related 
allergic reactions are found in monocot (Poaceae) 
and dicot (Asteraceae, Urticaceae, Plantaginaceae, 
Euphorbiaceae, and Amaranthaceae) plant families 
(1). This section will focus on dicot weeds. Pollen of 
ragweed, mugwort, sunflower, feverfew, pellitory, 
English plantain, Annual mercury, goosefoot, Russian 
thistle and amaranth are considered important allergy 
eliciting sources (Fig. 1). Poaceae weeds like Johnson 
grass can be found in section B02.
The impact of climate change on pollen load, 
allergenicity, distribution, and flowering season is well 
acknowledged and is of particular interest in regards 
to weeds since they can dominate groundcover, 
adapt to various environmental conditions or reside 
in ecologic niches. Due to globalization, neophytes 
such as ragweed have been imported to Europe as 
ballast grain, spreading readily with predictions to 
reach Northern Europe (2). Furthermore, significant 
WEED POLLEN 
ALLERGY
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increases in duration of pollen season of ragweed 
and pellitory were recorded over the last 20 years. 
Additional influence on the allergenicity might arise 
from environmental pollution, as was shown for 
ragweed pollen collected along high-traffic roads 
presenting elevated IgE reactivity. Weeds are often 
considered non-desired invasive species and thus 
combated using herbicides. However, there are some 
species actively cultivated for economic purposes, 
e.g. sunflower for birdseed or Artemisia annua to 
obtain the anti-malaria drug artemisinin.
Plants of the genus Ambrosia comprise around 50 
species native to northern and central America. In 
the past decades, the neophyte is rapidly spreading 
in Europe due to the pollen´s ability to travel long 
distances. The genus Artemisia comprises around 
350 species and representatives can be found 
throughout the Northern hemisphere and Australia. 
Mugwort is frequently used as herb in traditional 
Chinese medicine and A. annua is cultivated for 
harvest of artemisinin. There are parts of Europe and 
America where the range and pollination of mugwort 
and ragweed overlap (www.discoverlife.org; Atlas of 
living Australia and US Department of Agriculture), 
confounding accurate allergy diagnosis. Common 
sunflower is primarily grown for commercial use of its 
oil and birdseed. Parthenium spp are predominately 
found in Southern US, Central and South America 
and invasive in India, Australia and parts of Africa. 
Allergenic members of the Parietaria genus are 
frequently found in southern and central Europe 
showing a long pollination season with recurrent 
flowering periods. The genus Plantago includes 
around 250 species and was spreading from Europe 
throughout the world. Mercurialis annua is a highly 
prevalent weed throughout Europe. Chenopodium 
album, Salsola kali and Amaranthus retroflexus can be 
Figure 1
Important allergenic weeds. Figure adapted from Stemeseder et al. (215). Flowering periods given refer 
to the Northern Hemisphere.
 EAACI Molecular Allergology User´s GuideEAACI Molecular Allergology User´s Guide Part  B:  Using Molecular Al lergology In The Cl inical  Practice 2016
97Weed Pollen Allergy 
found in arid regions of the Northern hemisphere 
and Australia. Due to use in greening programs or as 
ornamental flowers, these weeds are highly abundant 
in Iran, Kuwait or Saudi Arabia.
MAJOR AND RELEVANT MINOR 
ALLERGENIC MOLECULES
The most relevant weed pollen allergens belong to 
the families of pectate lyases, defensin-like proteins, 
non-specific lipid transfer proteins (nsLTP) and Ole e 
1-like proteins (Table 1). Additionally, the panallergens 
profilin and polcalcin have been identified as cross-
reactive molecules present in weed pollen (see C01 
and C04 of this handbook). Currently, 36 weed 
pollen allergens are listed as allergens by the IUIS 
Allergen Nomenclature Sub-Committee. In addition, 
a 60 kDa acidic glycoprotein from mugwort and 
Par h 1, a defensin-like protein from feverfew 
pollen were described to be major allergens in the 
respective sources. Comprehensive information and 
characteristics on molecules and derivatives as well 
as functions are reviewed in Gadermaier et al and 
Villalba et al (3, 4).
SENSITIZATION TO INDIVIDUAL 
MOLECULES AND THEIR CLINICAL 
RELEVANCE
Epidemiology and sensitization
Ambrosia spp are major elicitors of type I pollen 
allergies in Northern America and 15.3% adults from 
Canada were tested positive with ragweed extract. 
Data from the GA2LEN study showed sensitization 
rates of 8.7% (US), while in European countries 
SPT reactivity was typically lower than 2.6% in the 
general population (6). Among allergic patients 
from Germany, 19.5% were ragweed sensitized as 
determined by SPT (7). Sensitization frequencies to 
mugwort of more than 10% were found in a German 
general population cohort. Amongst patients with 
allergic rhinitis in Korea, the sensitization rate to 
ragweed was low (2.2%) but increasing over time 
(2.8%). In China, 3.7-6.5% of asthma and/or rhinitis 
patients were sensitized to ragweed while reactivity 
to mugwort was around 11% (8). There was a markedly 
higher frequency of specific IgE to Artemisia (58.3%) 
correlating to Art v 1 reactivity (49%). In contrast, 
specific IgE to Ambrosia (14.7%) and Amb a 1 (11.2%) 
was lower in frequency and level, not correlated with 
each other, and uncommon in the absence of specific 
IgE to Art v 1 suggesting primary sensitization with 
Artemisia species (9). Epidemiological studies on 
pollen allergic patients performed in Spain identified 
a frequency of sensitization to Art v 1 of 13% (10). 
In Adelaide, South Australia, 37% and 25% of over 
3000 patients presenting to a respiratory clinic 
showed SPT to plantain and ragweed respectively 
(Dr Frank Kett, personal communication). Similar 
sensitization frequencies for ragweed were found in 
other regions of Australia ranging from 34-38% (11). 
Among sunflower processing workers, a sensitization 
rate of 23.5% to sunflower extract was reported (12). 
Thirty-five percent of autumn pollinosis patients in 
US were reactive to feverfew extract and among type 
IV atopic dermatitis patients in India, 35.7% showed 
positive type I reactions in skin prick tests (13).
Parietaria is one of the most relevant causes of pollen 
allergy in people living in the Mediterranean basin. 
About 30% of all allergic subjects living in southern 
Italy are SPT positive to Parietaria judaica pollen 
extract, with local sensitization rates up to 60%. 
Although the weed is highly prevalent throughout 
Europe, sensitization in the non-Mediterranean 
population is marginal (14). Epidemiological studies on 
pollen allergic patients performed with Pla l 1 in Spain 
identified plantain as the second cause of pollinosis in 
some northern areas, frequently associated to grass 
sensitization. Recent studies also demonstrated the 
relevance of Plantago in central/northern European 
patients (10, 15). High levels of reactivity to Mercurialis 
annua pollen ranging from 28-56% were observed in 
several areas of Spain (3).
Due to use of Chenopodium album in greening 
programs, the weed gained relevance in countries 
with desert and semi-desert areas accounting for up 
to 70.7% sensitization in asthmatic patients. Clinical 
incidences have been reported in southern Spain 
and Saudi Arabia, while they even represent the main 
sensitizer for allergic rhinitis and asthma in Kuweit and 
Iran (4). The ornamental plant Amaranthus retroflexus 
is also described as major trigger of allergic reactions 
in Iran, with a sensitization frequency up to 69% in 
SPT (4). Salsola allergy, as determined by specific 
sensitization to Sal k 1, the major Salsola allergen 
(homologous molecule absent in Chenopodiaceae), is 
the overall third cause of pollinosis in Spain. In some of 
the dryer areas of the south, up to 80% of the patients 
suffering from seasonal allergy are sensitized to Sal k 
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Table 1
Relevant weed pollen allergens
Species 
(English name)
Allergenic 
molecule
Biochemical name Prevalence 
among patients 
MW 
(kDa)
Ambrosia artemisiifolia 
(ragweed)
Amb a 1 Pectate lyase >95% 38
Amb a 4 Defensin-like protein 20-40% 13-15
Amb a 6 Non-specific lipid transfer protein 20% 10
Amb a 8 Profilin 35-50% 14
Amb a 9 Polcalcin (2 EF-hand calcium binding protein) 10-15% 9
Amb a 10 Polcalcin (3 EF-hand calcium binding protein) 10-15% 17
Amb a 11 Cysteine protease 66% 37
Artemisia vulgaris 
(mugwort)
Art v 1 Defensin-like protein 95% 13-15
Art v 3 Non-specific lipid transfer protein 22-70% 10
Art v 4 Profilin 35% 14
Art v 5 Polcalcin (2 EF-hand calcium binding protein) 10-28% 10
Art v 6 Pectate lyase, Amb a 1-homolog 26% 38
Helianthus annuus 
(sunflower)
Hel a 1 Defensin-like protein (potentially SF18 from sunflower) 65% 34
Hel a 2 Profilin 31% 14
Parietaria judaica 
(pellitory)
Par j 1 Non-specific lipid transfer protein 95% 15
Par j 2 Non-specific lipid transfer protein 80% 11
Par j 3 Profilin nd 14
Par j 4 Polcalcin (2 EF-hand calcium binding protein) 6% 9
Plantago lanceolata 
(English plantain) Pla l 1 Ole e 1-like protein 86% 15
Mercurialis annua 
(Annual mercury) Mer a 1 Profilin 50-60% 14
Chenopodium album 
(goosefoot)
Che a 1 Ole e 1-like protein 70% 18
Che a 2 Profilin 55% 14
Che a 3 Polcalcin (2 EF-hand calcium binding protein) 46% 10
Salsola kali (Russian 
thistle)
Sal k 1 Pectin methylesterase family 65% 37
Sal k 4 Profilin 46% 14
Sal k 5 Ole e 1-like protein 30-60% 18
Amaranthus retroflexus 
(Amaranth) Ama r 2 Profilin 33% 14
Data on sensitization frequency according to Gadermaier et al. (3), except for Amb a 11 (5); the sensitization prevalence to each allergenic 
molecule among patients sensitized to the natural extract may vary in different geographic regions.
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1, and are frequently monosensitized. In other areas 
such as the Ebro river valley it is the second cause 
of pollinosis after grasses (10, 16) This allergy is also 
very prevalent in other dry areas like Iran where up 
to 72.5% of pollen allergic patients are sensitized to 
Salsola (3, 4).
Cross-reactivity
A high degree of IgE cross-reactivity is typically 
observed among different Artemisia or Ambrosia 
species and is extendable to allergenic plants of the 
Asteraceae family (3, 17). Frequent levels of moderate 
IgE cross-reactivity are observed between pectate 
lyases (Amb a 1 and Art v 6) and defensin-like proteins 
(Art v 1, Amb a 4, Par h 1, and potentially Hel a 1) (Fig. 
2A and 2B) (3, 18). Art v 3, the nsLTP from mugwort 
pollen demonstrates frequent cross-reactivity to 
homologous molecules in plant food, i. e. Pru p 3 
(Fig. 2C). Sensitization to Art v 3 in the absence of 
pollinosis can indicate primary sensitization to LTP in 
case of food allergy. In contrast, source constrained 
sensitizations are observed for the nsLTP Par j 2 and 
Amb a 6 (19). The Ole e 1-like protein Pla l 1 from 
plantain presents low sequence identity to other 
family members and thus presents limited cross-
reactivity. In contrast, substantial cross-reactivity is 
Amb a 1
Ragweed
Art v 6
Mugwort
Cup a 1
Cypress
Cry j 1
Japanese cedar
Art v 1
Mugwort
Amb a 4
Ragweed
Par h 1
Feverfew
Hel a 1
Sunflower
Art v 3
Mugwort
Amb a 6
Ragweed
Par j 2
Pellitory
Pru p 3
Peach fruit
Pla l 1
plantain
Che a 1
Goosefoot
Sal k 5 
Russian thistle
Ole e 1
Olive
A) Pectate lyases B) Defensin-like proteins
C) Lipid transfer proteins D) Ole e 1-like family
Figure 2
A) Model Amb a 1.0101 (template 1PXZ), B) Structure Art v 1.0101 defensin-domain (2KYP), C) Mod-
el Art v 3.0201 (template 2B5S), and D) Structure Pla l 1.0101 (4Z8W). Models were generated using 
Swiss-Model (www.swissmodel.expasy.org) and ribbon cartons are shown using UCSF Chimera (www.cgl.
ucsf.edu/chimera). Lines represent documented IgE cross-reactivity, dotted lines represent potential IgE 
cross-reactivity based on high sequence identity. 
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observed for Che a 1 and Sal k 5 due to 74% sequence 
identity (Fig. 2D) (4, 15). As anticipated, pan-allergens 
like profilins or polcalcins also present in weed pollen 
frequently give rise to IgE cross-reactivity beyond 
close botanical relations.
Pollen-food syndromes mediated by weeds are mainly 
involving mugwort and ragweed allergic patients (for 
review see (20). In addition to oral allergy syndromes, 
more severe clinical pictures as observed e.g. in 
the celery-mugwort-spice syndrome are reported. 
Underlying cross-reactive molecules can be found 
within the family of nsLTP (Art v 3), profilins, and high-
molecular weight allergens with CCDs (20).
CLINICAL MANAGEMENT
Clinical relevance and clinical pattern
A) Exposure to weed pollen and primary sensitization 
to major as well as minor allergens predominately 
leads to rhino-conjunctivitis and/or asthma. 
Occupational allergies, i. e. to sunflower pollen 
are observed in workers and citizens in close 
vicinity.
B) Clinically relevant IgE cross-reactivity to weeds 
due to primary sensitization to pollen from 
botanically related sources, i) sunflower or 
feverfew allergy as a consequence of primary 
mugwort pollen allergy since the major allergen 
Art v 1 demonstrates high sequence similarity, 
ii) IgE cross-reactivity between Salsola and 
Chenopodium is observed due to highly 
homologous Ole e 1-like molecules.
Clinical diagnosis
Diagnosis of weed pollen allergy can be difficult 
due to frequent polysensitization and inconclusive 
anamnesis owing to overlapping flowering seasons 
with other pollen. Thus molecule-based allergy 
diagnosis is particularly advantageous and work-ups 
facilitating diagnosis of some weed pollen allergies 
are presented in Figure 3.
Case history
Weed pollen allergic patients typically present 
seasonal respiratory symptoms (rhinitis and/
or conjunctivitis and/or asthmatic symptoms, 
sometimes also itching of the throat and/or contact 
urticaria). Since clinical symptoms coincide with 
flowering periods of the respective weeds (Fig. 1), 
principal information can be obtained by narrowing 
down the eliciting allergen source(s).
Skin prick test (SPT)
The choice of commercially available weed pollen 
extracts for SPT is highly depending on pollen 
exposure and clinical references. Based on current 
GA2LEN recommendations for harmonization of skin 
prick tests in Europe, mugwort, ragweed and pellitory 
are included in routine diagnostic panels, while 
plantain and allergenic pollen of the Amaranthaceae 
family are not considered. Since the allergological 
relevance can considerably vary among regions, local 
modifications are however useful and necessary. 
Since Parietaria extracts are virtually missing profilin, 
a positive SPT with this weed is generally indicative of 
primary sensitization unless the patient is sensitized 
to the pollen pan-allergen polcalcin (21).
IgE testing
Apart from in vitro testing using weed pollen extracts, 
molecule-based approaches offer a valuable tool for 
refined diagnosis limiting unspecific results due to 
polysensitization (Fig. 2). All major allergens of weed 
pollen are commercially available for diagnosis using 
single components or multiplex assays, except for Che 
a 1 which is solely present on a multiplex platform. 
Components are available as recombinant molecules 
(rPla l 1, rChe a 1, rPar j 2) or CCD (N-glycan)-free, 
natural molecules like nAmb a 1 (non-glycosylated) 
and nArt v 1 (O-glycosylated). To discriminate ragweed 
and mugwort primary sensitization, Art v 6 and Amb 
a 4 would be additional useful diagnostic markers as 
they are homologs of the respective major allergens; 
however these components are not yet available 
for routine diagnosis. In the case of Sal k 1, false-
positive results might arise due to N-glycosylation. 
Mer a 1 is so far the only allergen identified from 
annual mercury and owing to expected broad IgE 
cross-reactivity with other profilins should not be 
considered a marker allergen for the source (see C01).
Clinical management
Besides recommendations to generally limit exposure 
during pollen season, symptomatic treatment is 
considered a first line of defense for weed pollen 
allergic patients. In addition, allergen immunotherapy 
(AIT) is recommended based on the identification 
of the primary sensitizer using highly specific 
marker allergens. Weed allergic patients frequently 
present multiple sensitizations, and thus typically 
allergen sources triggering most profound symptoms 
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B) Pellitory C) English plantain
Case history: pollen related rhinitis and/or
conjunctivitis from May-September 
Skin prick test using relevant allergen panel
sIgE Pla l 1
sIgE plantain
sIgE grass
Follow protocol
for grass diagnosis
Plantain allergy unlinkely,
extract reactivity due to
panallergens
Plantain allergy with/
without concomitant
grass pollen allergy
Case history: pollen related rhinitis and/or conjunctivitis in 
the Mediterranean area during pellitory flowering season
Skin prick test using relevant allergen panel
sIgE pellitory
sIgE to other pollen
Follow protocol
for pollen diagnosis sIgE Par j 2
Pellitory allergy unlinkely, extract
reactivity due to polcalcin sensitization
Pellitory
allergy
A) Ragweed and mugwort
Case history: pollen related rhino-conjunctival and/or asthmatic symptoms
from late summer to autumn
Skin prick test using ragweed and mugwort pollen extract
sIgE ragweed
sIgE mugwort
Primary mugwort
pollen allergy
sIgE Amb a 1
Ragweed and mugwort co-sensitization
Primary ragweed
pollen allergy
sIgE Art v 1
sIgE Art v 6
(  )
(  )
Figure 3
Diagnostic work-up for A) ragweed and mugwort pollen allergy, B) pellitory allergy and C) English plantain 
allergy. 
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are selected for therapeutic interventions. For 
subcutaneous immunization, 5 single extracts and 9 
combination products are available and registered for 
the German market (www.pei.de).
However, economic considerations, regulation and 
standardisation requirements are prompting some 
providers to withdraw their weed pollen products. 
Various weed pollen solutions (mainly combination 
products) and recently also a tablet for sublingual 
immunotherapy of ragweed allergy are available in the 
U.S. (www.fda.gov).
CLINICAL CASES
Case 1 (educational)
Clinical history: A 42-year old man from Central 
Europe with increasing rhino-conjunctival 
Table 2
Molecular components for diagnosis of weed pollen allergy 
Allergen source Specific IgE component Protein family Diagnostic use
Ragweed Amb a 1 Pectate lyase Marker for ragweed, IgE cross-reactivity with Art v 6 from mugwort
Ragweed Amb a 4* Defensin-like protein
Minor ragweed allergen with partial IgE cross-
reactivity to Art v 1
Mugwort Art v 1 Defensin-like protein
Marker for mugwort, partial cross-reactivity 
with Amb a 4
Mugwort Art v 3 nsLTP Cross-reactive with nsLTP from food e.g. Pru p 3 from peach or Cor a 8 from hazelnut
Mugwort Art v 6* Pectate lyase Amb a 1 cross-reactive allergen 
Pellitory Par j 2 nsLTP Highly specific marker allergen for pellitory sensitization
English plantain Pla l 1 Ole e 1-like protein Highly specific marker allergen for English plantain
Goosefoot Che a 1§ Ole e 1-like protein Marker for goosefoot, partial IgE cross-reactivity with minor Russian thistle allergen Sal k 5 
Russian thistle Sal k 1 Pectin methylesterase
Marker allergen for Russian thistle allergy, 
contains N-glycans (result might be false 
positive if patient is CCD reactive)
nsLTP, non-specific lipid transfer protein. Marker allergens shown bold, *not commercially available, §available only in multiplex analysis
symptoms from February to September for 12 
years; additionally asthmatic symptoms for 2 years 
occurring only between May and September.
Test with extracts: Histamine-equivalent 
sensitization to tree pollen (hazel, alder, birch, 
ash) and to mugwort; weak skin prick reactivity 
to ragweed and goosefoot; strong sensitization 
to grass pollen. Specific IgE to birch (10.7 kU/L), 
ash (1.31 kU/L), grass (17.7 kU/L), mugwort (10.4 
kU/L) and ragweed pollen (1.26 kU/L).
Test with molecules: The patient had positive IgE 
results to Bet v 1 (13.2 kU/L), Ole e 1 (2.56 kU/L), 
Phl p 1 (9.26 kU/L), Phl p 5 (3.58 kU/L), Art v 1 
(12.8 kU/L), Art v 3 (10.8 kU/L) and Amb a 1 (0.68 
kU/L).
Conclusion: The patient presents a complex pollen 
sensitization profile involving tree, grass and weed 
pollen. Symptoms in autumn are mainly caused by 
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to Cyn d 1 (6.20 ISU), Phl p 1 (29.2 ISU), Phl p 2 
(10.2 ISU), Phl p 11 (5.25 ISU) and Pla l 1 27.2 ISU.
Conclusion: In addition to grass pollen, the patient 
presents a weed pollen allergy to English plantain 
which explains symptoms observed in autumn 
after the grass pollen season.
Case 3 (educational)
Clinical history: A 36-year-old male living in northern 
Italy with a long lasting history of mild seasonal 
rhinitis from the beginning of May to the end 
of June experiences severe rhino-conjunctivitis 
associated with asthma at the beginning of 
March as he moves to Sicily. Gradual worsening 
symtpoms force the man to ask for assistance 
at an Emergency Department where systemic 
corticosteroids were administered.
Test with extracts: Strong skin reactivity to pellitory 
pollen was observed (12 mm mean wheal diameter) 
along with a weak sensitivity to grass pollen (3 
mm).
Test with molecules: The patient had positive IgE 
results to Par j 2 (37.3 kU/L), Phl p 1 (0.88 kU/L) 
and Phl p 5 (0.41 kU/L).
Conclusion: Allergy to pellitory pollen is diagnosed 
which was caused by high pollen exposure in 
Southern Italy.
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House dust allergy is an important risk factor 
for asthma and rhinitis
Most recognized house dust mites are 
Dermatophagoides pteronyssinus, 
Dermatophagoides farinae and Blomia 
tropicalis
In the majority of cases skin test with mite 
extracts is able to detect sensitization and 
define the specificity of immunotherapy in 
asthmatic patients
The use of species specific components 
might be necessary in places like the Tropics 
where coexposure to non-crossreacting mites 
genera is common
Thomas Platts-Mills, Luis Caraballo
THE ALLERGEN SOURCES
Arthropods are divided into five major classes of 
which three play an important role in allergic disease. 
Thus both insects and arachnids play important roles, 
as inhalant allergens while the crustacean are an 
important source of food allergens. The arthropods 
separated from other animals approximately 600 
million years ago and the major classes were 
established within 100 million years (Fig. 1). Thus dust 
mites and cockroaches have been separated for at 
least 400 million years and it is no surprise that most 
of these allergens are so different in their primary 
sequences that they do not cross react. This should 
be compared to the mammals, which separated 
approximately 65 million years ago (MYA) and still 
have extensive similarity between proteins. Of the 
hundreds of thousands of arthropod species only a 
few have been recognized as significant sources of 
indoor allergens. Indeed greater than 90% of the 
literature relates to five genera: Dermatophagoides, 
Blomia, Euroglyphus, Blatella and Periplaneta.
Since this and the next section (Cockroach Allergens) 
have several points in common a brief introduction is 
pertinent. The important parallel between mites and 
DUST MITE 
ALLERGY
 EAACI Molecular Allergology User´s GuideEAACI Molecular Allergology User´s Guide2016 Part  B:  Using Molecular Al lergology In The Cl inical  Practice 
106 Dust Mite Allergy
cockroaches is that they each can play a very important 
role in asthma, without their role being obvious to the 
patients. While there are many possible explanations 
for this the most obvious are that exposure is perennial, 
that the organisms are small and often not noticed 
and that the particles that carry these allergens are 
sufficiently large that they do not remain airborne 
for more than a few minutes after disturbance (1, 2). 
Because the role of exposure to mite or cockroach 
allergens was not obvious to the patients these 
species have been central to the arguments about 
the causal role of allergen exposure in asthma. The 
relevance of particle size became obvious shortly after 
the purification of Der p 1 and the development of 
accurate assays for this allergen (3). For D. pteronyssinus 
and D. farinae the faecal particles are the cardinal 
form in which the allergens became airborne (1, 4). 
For cockroach, the dynamics of airborne exposure 
are similar but the particle is not so well defined (2). 
The faeces of cockroaches are usually too large being 
visible like ground pepper i.e. > 100 micron in diameter. 
Because the particles are not well defined, there is 
less detailed information about the elements that are 
inhaled together with cockroach allergens.
The focus on particles carrying allergens is because 
of the awareness that due to protein molecule size 
of most allergens, that is, 15,000-50.000 Da, they 
are not volatile, so that significant exposure can only 
occur on particles. The nature of these particles is 
relevant to both the induction of the IgE response 
and the subsequent contribution to inflammation 
of the nose and lungs. For dust mite particles, it is 
clear that they not only carry a high concentration 
of several allergens but also are an important source 
of other substances both nucleic acids and proteins 
that act as toll receptor ligands or PAMPS. While this 
has been well recognized for mites, it may be just as 
important for cockroach allergens.
A significant feature of the epidemiology of these two 
sources of allergens is that there are areas of the world 
where one, both or neither of these two sources are 
important (Table 1). Both climate and housing conditions 
play a major role in these differences. However, there 
Figure 1
Clinically relevant members of Arthropoda, including storage and house dust mites.
Phylum Arthropoda
Class
Subclass
Order
Family Species
Storage and house dust mites
Glycyphagus domesticus
Lepidoglyphus destructor
Blomia tropicalis
Chortoglyphus arcauatus
Tyrophagus putrescentiae
Acarus siro
Aleuroglyphus ovatus
D. pteronyssinus
D. farinae
Euroglyphus maynei
Glycyphagidae
Echimyopodidae
Chortoglyphidae
Acaridae
Pyroglyphidae
Insects Arachnida Crustaceans
Cockroaches
Asian Lady Beetles
Mosquitoes
(Food Allergens)
Acari Scorpiones
(Scorpions)
Araneae
(Spiders)
AstigmataIxodes
Dog Tick
Deer Tick
Lone Star Tick
Tarseonemidae
(Bee Parasite)
Prostigmata
Chiggers
Cheyletidae
Demodex
160 MYA 580 MYA 440 MYA
460 MYA
390 MYA
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is also a significant biological difference between the 
two groups of arthropods. Cockroaches can search for 
a water source in a building and will find a leaking tap or 
drip pan behind a refrigerator. By contrast, mites absorb 
moisture from their environment and are absolutely 
dependent on the level of humidity in the air or on 
either carpets or upholstered material, which will retain 
humidity for long periods of time.
Before 1960, it was well recognized that house dust 
contained allergens other than those derived from 
domestic or pet animals as well as pollens or fungi; 
indeed several groups had attempted to identify a house 
dust atopen by immunochemical analysis of house dust 
extracts. However, the breakthrough was made by 
microscopic identification of dust mites’ in house dust. 
It was fitting that these observations were made in the 
Netherlands since Van Leeuwenhoek had first described 
mites in 1693. In addition, to demonstrating that mites 
of the genus Dermatophagoides were the major source 
of allergens in house dust Spieksma and Voorhorst also 
developed the technique for culturing these organisms 
(5). This in turn made it possible to manufacture dust 
mite extracts for commercial use and subsequently 
facilitated the purification of mite allergen (3).
Dust mites belong to the order Astigmata, which 
is part of the Arachnids (Fig. 1). This order includes 
not only the Pyroglyphidae and at least four families 
of storage mites (Echimyopodidae, Acaridae, 
Glycyphagidae and Chortoglyphidae) but also 
Sarcoptes scabiei (the scabies mite). Many different 
mites have been identified in house dust but only a 
limited number have been related to allergic disease. 
The mites generally recognized as house dust mites 
are: D. pteronyssinus, D. farinae, Euroglyphus maynei, 
and Blomia tropicalis. However, four species of 
storage mites, which are best recognized as pests on 
farms or in food storage have also been recognized in 
house dust (Table 2). In addition, mites of the family 
Tarsonemidae may be found in significant numbers 
in house dust. The best evidence that a given mite 
species is relevant to allergic disease comes from 
studies in an area where a given species dominates 
all other mites in the house dust. This is true for D. 
pteronyssinus in the UK, and New Zealand, for D. 
farinae in some areas of the United States, and for 
Blomia tropicalis in areas of South America and other 
tropical areas (6, 7). In high altitude location such as 
the Alpes, specific species (Euroglyphus manei) are 
found. Representative allergens from B. tropicalis and 
D. pteronyssinus are shown in Fig. 2.
Table 1
Environments Where Mites and Cockroaches Play 
Dramatically Different Roles in Relation to Asthma
I. Dominant Dust Mite: New Zealand, Australia, 
Europe (West and Central) England, Scotland 
have temperate climates with damp houses 
in a climate where because of the climate 
cockroaches do not flourish outside and most 
families live in separate homes.
II. Dominant Cockroach Allergens: United States 
inner city apartments in the North e.g. Chicago 
or New York, where buildings are heated and 
very dry so that cockroaches can thrive but 
mites do not. Many areas of South Asia
III. Both Cockroach and Mite Allergens: United 
States inner city apartments or houses e.g. 
New Orleans or Atlanta, but also many areas 
of South America where homes are both warm 
and damp so that both species thrive; 
IV. either of these arthropods are relevant: 
Northern areas of Europe e.g. Norbotten where 
the climate is extremely dry so that mites 
cannot survive the winter and the outside is 
too cold for cockroaches.
Table 2
The Best Recognized Mites Found in House Dust 
Mite Species Defined 
Allergens
House Dust Mites
Dermatophagoides pteronyssinus 17
Dermatophagoides farinae 27
Euroglyphus maynei 5
Blomia tropicalis 13
Storage Mites
Acarus siro 1
Glycyphagus domesticus 1
Lepidoglyphus destructor 5
Tyrophagus putrescentior 5
Number of specific allergens from each species recognized in  
www.allergen.org
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MAJOR AND RELEVANT MINOR 
ALLERGENIC MOLECULES
The first dust mite allergens were purified in 1980 
and 1982 using classical immunochemical techniques 
without the benefit of monoclonal antibodies, cloning 
or modern sequencing techniques (3, 8). By contrast 
the purification of the Group 2 allergens Der p 2 and 
Der f 2 in 1989 was aided by the development of a 
monoclonal antibody (9, 10). Considerable effort has 
been made to keep the nomenclature of mite allergens 
consistent within groups so that Groups 1, 2, 3, 4, 5 
and 10 include similar molecules purified from each 
of these species (Table 3). Over the last 20 years, the 
techniques for cloning and sequencing proteins have 
become well defined and much simpler. As a result 
many mite derived proteins have been described with 
convincing data about their amino acid sequence and 
in many cases about their tertiary structure. However, 
the evidence about allergenicity is less robust, and in 
some cases is limited to non-quantitative immunoblots 
on a small series of sera. Given the large number of 
allergens that have been described it is not possible to 
give a realistic assessment of the clinical significance 
of the allergens such as Der f 13-22, and Der f 24-33 
(see www.allergen.org).
For the major allergens in Group 1 and Group 2, 
we have evidence from random cohorts and birth 
cohorts as well as measurements of airborne and 
dust allergens (11, 12). Der p 1 and Der p 2 are 
present in fecal particles and are strongly associated 
with asthma. In addition, for Der p 1, there is specific 
evidence about the effects of reducing exposure from 
13 µg/g to 0.2 µg/g on symptoms among mite allergic 
individuals (13, 14). Thus for these allergens there is 
good evidence that they have an important role in the 
symptoms of rhinitis and asthma. For other allergens 
there may be excellent evidence about the prevalence 
of sensitization but less complete basis for judging 
their role in disease. Clearly, it is not possible to have 
an accurate assessment of the relative importance 
of more than ten different proteins derived from 
mites. Interestingly, there are two relatively recent 
identifications, which may have significance. Der p 
11 was defined several years ago and is distinctive 
because of the high molecular weight i.e. ~95-100 
kDA (15). However in 2014, it was reported that IgE 
antibodies to Der p 11 are more common in sera 
from patients with Atopic Dermatitis (AD). Thus 
sensitization to this allergen may reflect the fact 
that the eczematous skin allows easy penetration 
of allergens even with molecular weight as high as 
100,000 (15). Blo t 12 is an interesting allergen that 
has different isoforms in Colombia and Singapore 
(16). Der p 21 and Blo t 21 have high prevalence of 
sensitization in allergic children. The other recently 
described mite allergen is Der p 23, which appears to 
be a major allergen associated with asthma and has 
a molecular weight of 8 KD. The sequence of Der p 
23 identifies it as a peritrophin-like protein and it is 
found in the peritrophic lining of the gut as well as in 
fecal particles (17).
Figure 2
Clinically relevant house dust mite allergens. Those with experimentally detected cross-reactivity are 
shown in orange.
Blo t 8
Blo t 10
Blo t 21
Blo t 5
Blo t 2
Blo t 12
Blomia tropicalis
Der p 1
Der p 2
Der p 5
Der p 3
Der p 7
Der p 10
Der p 21
Der p 23Der p 8
Dermatophagoides pteronyssinus
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SENSITIZATION TO INDIVIDUAL 
MOLECULES AND ITS CLINICAL 
SIGNIFICANCE
Fecal particles as the major airborne form of 
mite allergens
Mite fecal particles consist of an amorphous mass of 
partially digested skin scales and other food materials 
surrounded by a chitinous peritrophic membrane. 
These particles contain mite DNA, bacteria, bacterial 
DNA, bacterial products such as endotoxin as well 
Group I and Group II allergens and in the case of D. 
pteronyssinus Der p 23. Airborne measurements of 
particle size in homes suggest that these particles 
maintain a size of > 10 microns and microscopic 
examination suggest that in general they maintain 
the structure due to the strength of the peritrophic 
membrane (4). Thus the diameter of these particles 
ranges from 15-30 microns, which is in keeping with 
the fact that most dust mite allergen falls within 20 
minutes after a vigorous domestic disturbance (1). In 
turn, this is in keeping with the fact that very few mite 
allergic patients report onset of symptoms occurring 
within minutes of entering a house, which is infested 
with mites.
The biological and immunological significance of the 
mite particles includes both the properties of mite 
allergens and the associated constituents. Not only 
do the particles contain a very high concentration 
of mite allergen e.g. Der p 1, Der p 2, and Der p 23 
but they also contain ligands for TLR 4, TLR 9 and 
Dectin I. Given that Der p 1 is an active cysteine 
protease and has been shown to cleave CD 25 and 
CD 23, while Der p 2 has activity comparable to 
MD2, it is obvious that these particles have different 
constituents that can contribute to the allergenicity. 
Furthermore, it is obvious that the constituents of 
the particle are released rapidly after contact with a 
liquid milieu such as the mucosal membrane of the 
nose or the lung lining fluid (1).
CLINICAL MANAGEMENT
Diagnosis of Sensitization
As was stated in the introduction the role of dust 
mite allergy in asthma is generally not obvious to 
the patients. Indeed histories of specific allergy to 
mites are not usually clear. Many patients will report 
sneezing on awakening or sneezing during house 
cleaning. During vigorous cleaning they may also 
Table 3
Major and relevant minor mite-allergens for D. pteronyssinus, D. farinae and B. tropicalis species
Allergenic molecule Biochemical name Prevalence among patients (%)
Molecular 
Weight (kDa)
Der p 1, Der f 1, Blo t 1 Cysteine protease 70 - 100 24-27
Der p 2, Der f 2, Blo t 2 NPC2 protein family (epidermal 
secretory proteins)
80 - 100 15-26 
Der p 3, Der f 3, Blo t 3 Trypsin-like protein 16 - 100 29-31 
Der p 4, Blo t 4 Alpha-amylase 25 - 46 60 
Der p 5, Blo t 5 50 - 70 14 
Der p 7, Der f 7 Lipid binding protein 50 26-31
Der p 8, Der f 8, Blo t 8 Glutathione S-transferase 40 27 
Der p 10, Der f 10, Blo t 10 Tropomyosin 5-18, 50-95 36 
Der p 11 Paramyosin 80 103 
Blo t 12 Chitin binding protein 50 14
Der p 21, Blo t 21 13.2 
Der p 23 Peritrophin-like protein 74 8
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notice eye irritation or wheezing, but conjunctivitis 
is not a common symptom of dust mite allergy. Skin 
prick testing is the primary means of diagnosis, and 
dust mite extracts are included in all inhalant panels. 
Most authorities would regard a wheal of 3 mm 
greater than the negative control as positive. The 
common practice is to test with both D. pteronyssinus 
and D. farinae. In some areas one mite or the other is 
the dominant cause of sensitization, but in general 
the results of the two provide convincing positive or 
negative results. However, D. pteronyssinus extracts 
might lack important allergens and often show great 
variability regarding allergen composition (18). Also, 
testing with B. tropicalis has become a very useful 
routine in the tropics. In vitro assays for IgE to dust 
mite are well established and the units are given in 
IU/ml or kUnits /L. In vitro testing for specific IgE 
can be done using extracts of D. pteronyssinus (Dp), 
D. farinae (Df) and B. tropicalis (Bt). Assays for IgE to 
components (Der p 1, Der p 2, Der p 10, Blo t 5) are 
also available. There is good evidence that the units 
used for IgE ab are the same as the units used for IgE 
i.e. ~2.4 ng. Serum assays can provide a wide range of 
positive results from 0.1 IU/ml to > 300 IU/ml. There 
is also good evidence that the size of the wheal or the 
titer of IgE is a useful predictor of the risk of allergic 
disease and also of the scale of the added risk with 
rhinovirus infection (19).
Although the criteria for judging sensitization can 
be defined convincingly, it is not so easy to define 
criteria for judging the role of dust mite in individual 
cases. There are several things that can help. If the 
patient is only allergic to mite, or the skin tests or 
IgE assays are much stronger for mite than for 
those other allergens, which could be relevant for 
perennial symptoms. Although not widely accepted 
as a diagnostic procedure nasal provocation test with 
mite extracts is other important tool for defining the 
clinical relevance of sensitization and detecting cases 
of local rhinitis associated to negative skin tests. A 
measurement of mite allergens in dust from the 
house can be very helpful. However, the criteria of 
>2 µg Der p 1 per gram of dust for sensitization and 
>10 µg Der p 1 per gram of dust for severe symptoms 
should not be regarded as more than a guide. It is a 
major advantage to know what the average levels of 
mite allergen are in homes or apartments in the areas 
where the patient lives (Table 1).
Cross reactivity between D. pteronyssinus and D. 
farinae extracts is high but between Dermatophagoides 
and Blomia tropicalis is low. The use of species-
specific components might be necessary in places 
like the tropics where co exposure to both genera 
is common. Tropomyosin is the main cause of cross 
reactivity among mites, cockroaches, shellfish and 
helminths (e.g. Ascaris lumbricoides), but Glutathione 
Transferase may also be involved (Fig. 3).
In the majority of cases skin test with mite extracts is 
able to detect sensitization and define the specificity 
of immunotherapy in asthmatic patients. However, 
the use of component resolved diagnosis could be 
useful in especial circumstances where genuine 
sensitization is not clear and has to be defined. 
Figures 4 and 5 represent algorithms that could be 
applied for diagnosing mite allergy in temperate and 
tropical countries. Not all suggested components are 
commercially available.
Management
The management of allergic disease in patients who 
are allergic to dust mites consists of several different 
phases most of which are similar to those for many 
other inhalant allergens (Table 4). However education 
and allergen avoidance require extra care because of 
the complex biology of dust mites, the fact that their 
presence in the home is not visible to the patients 
and the need for significant education in relation to 
avoidance.
Figure 3
Clinically relecat cross-reactivity of mite aller-
gens. Species-specific components are shown in 
green.
Bla g 1, Bla g 2
Blot t 5, Blo t 12
Blot t 10, Blo t 8
Bla g 7,   Bla g 5
Der p 1
Der f 1
Der p 2
Der f 2
Der p 10
Der f 10
Der p 8
Der f 8
ABA-1
Asc l 3
Asc l 13
 EAACI Molecular Allergology User´s GuideEAACI Molecular Allergology User´s Guide Part  B:  Using Molecular Al lergology In The Cl inical  Practice 2016
111Dust Mite Allergy
Figure 4
Possible decision algorithm for mite allergy in temperate countries. SPT: Skin Prick Test. CRD: Component 
Resolved Diagnosis. CR: Cross-reactivity. EC: Environmental Control. AIT: Allergen Immunotherapy.
There is a wide range of evidence that dramatically 
decreasing exposure to dust mite allergens can help 
both asthma and rhinitis related to dust mites. This 
comes both from controlled trials of avoidance and 
from moving patients to a sanatorium or to a hospital 
based allergen “free” unit (13, 14, 20, 21). Some of the 
most dramatic results have come from Sanatoria in the 
Alps, but these are complicated to interpret because 
exposure to animal dander and fungi as well as mites 
will be reduced (21-23). In addition, most of these 
Sanatoria have regular exercise regimes, which may 
also contribute to the improved lung function and to 
the decrease in non-specific bronchial hyper-reactivity 
(BHR) (21). Following the initial study in Davos further 
studies were carried out in Briancon in France and 
Misurina in Italy. The studies in Misurina provided 
compelling evidence that there was a progressive 
decrease in inflammatory markers in parallel with 
decreases in BHR among mite allergic children who 
spent 3 months in the sanatorium. In order to study the 
role of mite allergens, mite allergic asthmatics in London 
spent 3 or more months living in a hospital room which 
had filtered air and was designed to have no sites where 
Table 4
Management of Allergic Disease Related to Dust Mite
A. Skin tests or serum assays for IgE antibodies 
using dust mite extract. CRD could be helpful 
to define allergen immunotherapy
B. Education about the role these allergens can 
play in both acute and chronic symptoms
C. Advice about avoidance including a written 
plan and in some cases measurement of mite 
allergen in houses
D. A plan for pharmaceutical management both 
for the nose and the lungs
E. Subcutaneous or sublingual Immunotherapy 
using dust mite allergen
F. In cases of asthma that are poorly controlled 
treatment with Anti-IgE (omalizumab) may also 
be recommended
Asthma/Rhinitis 
symptoms
Dp/Df 
Positive
Dp/Df 
Negarive
Der p 1/Der p 2/  
Der p 10
Der p 1/Der p 2 Negative  
Der p 10 Positive
Der p 1 and/or 
Der p 2 Positive
Der p 1/Der p 2 Negative 
Der p 10 Positive
EC + AIT
Possible CR
No AIT
Positive Negative
EC + AIT Explore other allergens
SPT
CRD
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mites could live. The level of mite allergen in dust from 
their homes was 13.6 µg Der p 1/g, while dust from the 
hospital room had less than 0.2 µg/g dust. The patients 
not only improved their symptoms but also experienced 
a major decrease in BHR (13).
CLINICAL CASES
Case 1
Clinical history: A 32-year old male faculty member 
in cardiology presented to clinic because of 
increasing episodes of shortness of breath (SOB) 
during exercise. He was an enthusiastic runner (up 
to 10 miles) and had only developed symptoms 
since moving into a basement apartment one 
year earlier. His history did not include seasonal 
nasal symptoms or reactions on exposure to 
animals. When seen in clinic, his examination and 
spirometry were normal.
Test with extracts: Prick skin tests were strongly 
positive for D. pteronyssinus and D. farinae 
with 8x8 and 7x6 mm wheals. Blood count was 
unremarkable with AEC of 350. Total IgE 230 
kUA/L; IgE to D. pteronyssinus was 32 UA/ml. 
He was given a peak flow meter (Mini Wright) 
and instructed to record values before and after 
running, in addition, we arranged to collect 
samples from his apartment.
Test with molecules: Serum assayed for components 
using ISAC chip showed Der p 1 IgE 28 ISU/ml; 
Der p 2 33 ISU/ml ; Der p 10 (tropomyosin) <0.5 
ISU/ml. Peak flow values mean of 3 values, before 
running was 510 +20. Liters/min and fell to 400 
+40/ µ Liters/min and 320 +20, Liters/min 2 
minutes and 4 minutes after running for 6 minutes.
Dust samples from his apartment: 8.4 µg Der p 1/g 
carpet dust, 10.6 µg Der p 1/g sofa dust and 4.6 
µg Der p 1/g bedding dust
Figure 5
Possible decision algorithm for mite allergy in the tropics. SPT: Skin Prick Test. CRD: Component Resolved 
Diagnosis. CR: Cross-reactivity. EC: Environmental Control. AIT: Allergen Immunotherapy.
Asthma/Rhinitis 
symptoms
SPT: Bt/Dp/Df
AIT 
Bt/Dp
Bt Positive 
Dp/Df Negative All Positive
Bt Negative 
Dp Positive
CRD: Blo t 12/ Blo t 5/  
Der p 1/ Der p 2/ 
Der p10/Blo t 10
All Positive Blo t 12/ Blo t 5 Positive 
Der p 1/ Der p 2 Negative
Blo t 12/ Blo t 5 Negative 
Der p 1/ Der p 2 Positive
All Negative  
Der p 10/Blot 10 Positive
EC + AIT
AIT 
Bt
EC + AIT
AIT 
Dp
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Treatment Advice and Outcome: Initially he was 
treated with albuterol inhaler, two puffs 10 min. 
prior to exercise and inhaled Fluticasone 100 
µg bid. In addition, he was advised to move to a 
second floor apartment without carpeting and 
with minimal upholstered furniture. He was given 
routine advice about controlling mites in his 
bedding. He moved one month later and within 3 
months his exercise breathing returned to normal. 
When seen 1 year later, he was no longer using 
inhalers and was without significant symptoms.
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B05
Cockroach allergens are strong inducers of 
sensitization and asthma.
Clinically important species include 
American, German, Oriental, Asian, brown-
banded and smoky-brown cockroaches.
Bla g 2 and Bla g 5 have the higher 
frequency of IgE positivity among cockroach 
allergens but there are important differences 
among individual patients and populations.
Currently, diagnosis is performed by skin 
testing and/or measurement of specific IgE 
to cockroach, using crude extracts.
THE ALLERGEN SOURCES
Cockroaches belong to the phylum Arthropoda; 
class Insecta, Order Blattaria. Species causing allergy 
symptoms such as asthma are listed in Table 1. These 
ubiquitous scavenger organisms have inhabited 
the planet long ago and domiciliary species are 
currently a serious problem for humans. Those 
that live in human dwellings (around 25 species) 
include American, German, Oriental, and Asian, 
which, together with the brown-banded and the 
smoky-brown cockroaches are sources of important 
allergens, inducers of allergic asthma (1).
Sensitization to cockroach usually occurs by 
inhalation. Potential sources of relevant allergens in 
the environment include whole bodies, cast skins, 
secretions, egg casings, and fecal material. Level of 
exposure for increased risk of asthma symptoms is 
8 U/g of dust and a US national study found that 
10% of living rooms were above this point. There is 
inter-species cross reactivity (e.g. American, German, 
Asian and Oriental) and extra-species cross reactivity 
(“pan allergy”) with a number of other arthropods 
such as crustaceans (shrimp, crab, and lobster), 
insects (silverfish, butterflies), arachnids (dust mites) 
Luis Caraballo, Thomas Platts-Mills
COCKROACH 
ALLERGY 
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and mollusks (oysters, mussels, scallops, clams). Since 
both exposure and allergy to cockroach are very 
common, patients with asthma or rhinitis should be 
routinely evaluated for this type of allergy.
MAJOR AND RELEVANT MINOR 
ALLERGENIC MOLECULES
Based in their molecular and biological properties 
cockroach allergens have been distributed in several 
groups, most of them are shown in Fig. 1 and Table 2 
(2).
Group 1 Bla g 1 is composed by multiple consecutive 
amino acid repeats originated by gene duplication of 
an original 100 amino acid domain (3). There is cross 
reactivity between Bla g 1 and homologous proteins 
(such as Per a 1, Per f 1 and Bla o 1) from other 
cockroach species, and allergens from other insects. 
The protein is most prevalent in the midgut, probably 
because the Bla g 1 gene is exclusively expressed by 
midgut cells. The presence of Bla g 1 in fecal particles 
makes this molecule, together with Bla g 2, a good 
marker of cockroach allergen exposure. Three epitopes 
of Bla g 1 have been described (www.iedb.org).
Group 2 Bla g 2 is an unusual (inactive) aspartic protease 
with strong allergenic properties. It is the most frequent 
IgE binding molecule among cockroach allergens (4). 
The crystal structure (5) and antigenic structure of 
this allergen was analyzed by X ray crystallography 
and site directed mutagenesis, providing important 
information about key residues determining epitopes 
and antigen antibody interactions (6, 7). There is three 
times more Bla g 2 in cockroach feces compared with 
the whole extract. Ten epitopes of this allergen have 
been described.
Group 3 Allergens of this group show high homology 
to insect hemolymph proteins. Per a 3 induces IL-4 
expression in PBMC from allergic patients and this 
correlates with skin reactivity and clinical symptoms 
(8).
Group 4 Bla g 4 is a lipocalin. These molecules 
are very stable and their structure consists of a 
C-terminal α-helix and a β-barrel enclosing an 
internal hydrophobic cavity that binds small ligands 
such as retinoids, glucocorticoids and pheromones. 
Four epitopes of Bla g 4 have been described. The 
structure and possible epitopes of other homologous 
molecule (Per a 4) have been described.
Group 5 Bla g 5 is a sigma class glutathione 
S-transferase (GST), a major cockroach allergen which 
has a high IgE response in the cockroach sensitized 
individuals. Thirty nine epitopes of Bla g 5 have been 
described and cross reactivity with GSTs of several 
sources is known.
Group 6 The allergens of this group are homologues 
to insect troponin C and vertebrate calmodulins 
(61% to 78% and 42% to 44% amino acid identity, 
respectively) and have 2 EF-hand calcium binding 
domains. Interestingly, IgE binding to Bla g 6 has 
proven to be calcium dependent indicating that IgE 
preferably binds to one of the conformers.
Table 1
Clinically relevant cockroach species
Family Genus/species Common name Geographic distribution
Blaberidae Leucophaea maderae Madeira Asia, Africa, America, Oceania
Blattellidae Blatella germanica German Mainly temperate dry zones, Europe and USA
Blatella asahinai Asian Japan, tropical and subtropical
Supella longipalpa Brown-banded Tropical
Blattidae Periplaneta americana American Mainly tropical and subtropical
Periplaneta australasiae Australian Cosmopolitan
Periplaneta brunnea Brown Mainly tropical
Periplaneta fuliginosa Smoky brown China, Russia, Korea, Japan, Australia and USA
Blatta orientalis Oriental America, United Kindom, Germany
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Table 2
Major and relevant minor Cockroach Allergens
Allergenic molecule Biochemical name Prevalence of Allergen-specific IgE among patients (%) MW  (kDa)
B. germanica
Bla g 1 Midgut microvilli protein-homolog 20-50 21-90
Bla g 2 Unusual aspartic protease 40-70 36
Bla g 3 Arylphorin/hemocyanin 78.9
Bla g 4 Lipocalin 17-60 21
Bla g 5 Glutathione S-transferase 35-73 23
Bla g 6 Troponin C 14 17
Bla g 7 Tropomyosin 18 33
Bla g 8 Myosin light chain 14 21
Bla g 11 Alpha-amylase 57
P. americana
Per a 1 Midgut microvilli protein-homolog 30 - 50, 100 26-51
Per a 2 Aspartic protease-like 42
Per a 3 Arylphorin/hemocyanin 26-95 46-79
Per a 6 Troponin C 17 17
Per a 7 Tropomyosin 13-54 33
Per a 9 Arginine kinase 80-100 43
Per a 10 Serine protease 80 28
Figure 1
Allergen components from American and German Cockroaches. Homologous molecules have the same 
colour.
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Group 7 Invertebrate tropomyosins are important 
pan-allergens among dust mites, chironomids, 
silverfish, crustaceans, nematodes and mollusks. 
Tropomyosins from B. germanica and P. americana 
have been described. IgE binding frequency to 
cockroach tropomyosins are very different in some 
populations and this may reflect differences in 
environmental conditions.
Group 8 Bla g 8 shares 81-84% amino acid sequence 
identity with the myosin light chain of several insects 
and the shrimp Litopenaeus vannamei. The myosin 
regulatory light chains are small acidic polypeptides 
non-covalently bound to the neck region of the 
myosin head, which regulate the interaction of the 
myosin head with actin.
Group 9 Per a 9 was identified as a major allergen 
of P. americana in Thai patients (9). Arginine 
kinase homologues have also been reported in B. 
germanica, the shrimp Penaeus monodon (Pen m 
2), D. pteronyssinus (Der p 20) and the Indian meal 
moth Plodia interpunctella (Plo i 1). There is evidence 
suggesting that arginine kinase is an invertebrate 
pan-allergen (10).
Group 10 Per a 10 isolated from P. americana is a 
major allergen in Indian allergic patients (11). Other 
important allergens are also serine protease (Der f 
3, Der p 3, Der p 6 and Der p 9). Cross reactivity is 
expected among these molecules.
Group 11 Bla g 11 shares 55.8% sequence identity 
with pig α-amylase and with group 4 mite allergens 
Blo t 4 (50.4%), Der p 4 (49.8%) and Eur m 4 (47.4%). 
Bla g 11 seems to be an important novel allergen 
because the recombinant α-amylase inhibited 55% 
of specific IgE of German cockroach extract.
SENSITIZATION TO INDIVIDUAL 
MOLECULES AND ITS CLINICAL RELEVANCE
Cockroach allergens are strong inducers of 
sensitization and asthma (12, 13) and cockroach 
allergy is an important risk factor for emergency 
room visits and hospital admissions. Special clinical 
characteristics have been described for cockroach-
induced allergic asthma; it might be more severe 
and associated to higher total IgE levels than pollen 
induced asthma. Most characterized allergens 
are from B. germanica and P. americana, although 
homologous from other species have been purified. 
Satinover S et al. found that Bla g 2 and Bla g 5 
have the higher frequency of IgE positivity among 
cockroach allergens in US patients (4) but there are 
important differences in the profiles of IgE reactivity 
among individual patients and populations.
In a study performed in Taiwan to determine whether 
sensitization to different cockroach allergenic 
components correlates with different clinical 
manifestations and severities, eight P. americana 
allergens (Per a 1 through Per a 7 and Per a 9) were 
evaluated. IgE binding to Per a 2 was more frequent 
in patients with persistent asthma than in patients 
with rhinitis only, suggesting that this allergen could 
be a marker for more severe airway disease.
Also, IgE to Per a 9 was strongly associated with rhinitis 
(14). The availability of cloned, purified allergens will 
allow furthering investigating their particular effects on 
the immune responses and the possibilities to be used 
as reagents for Component resolved diagnosis (CRD) 
and markers of severity and response to treatment. 
For example, results of a study on cockroach allergen 
epitopes showed that T cell cytokine responses were 
different for Bla g 2, Bla g 5 and Bla g 6; in addition, 
analysis of the IgE response in the same patients 
suggested that T cell responses to these allergens 
appear uncorrelated with IgE responses.
Groups 1 and 7, and possibly 6, are cross reactive. 
Some P. americana molecules share homology with 
mite allergens of group 2, 3 and 13. Since mite and 
cockroach co-exposure is common a differential 
CDR of sensitization might be necessary. In some 
populations there is cross reactivity between Bla g 
5 and other Glutathione-transferases (GST), such as 
Der p 8 and Wuchereria bancrofti GST. In addition, the 
high correlation between IgE antibodies to Bla g 5 
and Ascaris lumbricoides GST (Asc l 13) suggests the 
presence of cross reactivity between these molecules. 
However, the frequency of sensitization to Asc l 13 
and Bla g 5 in a tropical Caribbean population is 
around 23% and, in comparison to that of the mite 
allergen Der p 2, the strength of the IgE response to 
these allergens was low (15). The clinical importance 
of potential cross sensitization between helminth 
and cockroach GSTs should be further investigated.
Bla g 7 and Per a 7, two of the cockroaches’ 
tropomyosins, are pan allergens and positive 
correlation between shrimp, cockroach, and dust 
mite IgE levels have been described. In this study, 
high exposure to cockroach in the home showed 
significant correlation to higher IgE levels to cockroach 
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and shrimp, but no to mite. Sensitization rates to 
tropomyosins, including mite and cockroaches, are 
low in the US and Europe and high in tropical countries 
(16, 17), more likely because of cross reactivity with 
helminth tropomyosins (2, 18, 19). Arginine kinases 
have been described as allergens not only in seafood 
and other sources but also in cockroaches (Per a 9) 
and mites (Der p 20). Fig. 2 shows predicted (dotted 
lines) and experimentally confirmed (solid lines) cross 
reactivity of B. germanica. Potential species specific 
components are also shown (no lines).
CLINICAL MANAGEMENT
Cockroach allergy should be investigated in all 
patients with respiratory allergy (Fig. 3). Diagnosis 
is performed by skin testing and/or measurement 
of specific IgE to cockroach, using crude extracts. 
However, inconsistent protein contents and relative 
potencies have been reported in the commercially 
available cockroach extracts. In vitro testing for 
sensitization to components (CRD) is commercially 
available for Bla g 1, Bla g 2, Bla g 5 and Bla g 7. Since 
Bla g 5 (GST) and Bla g 7 (tropomyosin) are cross 
reactive allergens, Bla g 1 and Bla g 2 are useful for 
detecting genuine sensitization to cockroaches in 
patients co exposed to mites and cockroaches. The 
effectiveness of recombinant Bla g 2, Bla g 4, Bla g 
5, Per a 1 and Per a 7 for skin testing was evaluated 
in cockroach allergic patients living in Brazil (17). In 
this study, sensitization to Per a 7 was dominant with 
a frequency of 42%, in contrast with results from 
other places where a heterogeneous IgE reactivity 
profile among cockroach-allergic patients has been 
found. In the US a panel of 5 recombinant allergens 
(rBla g 1, rBla g 2, rBla g 4, rBla g 5, and rPer a 7) 
could identify 64 % of cockroach-allergic patients (4). 
A larger battery of recombinant allergens was tested 
in cockroach allergic patients in Taiwan showing 
that all patients reacted to at least one allergen and 
discovering that vitellogenin is an important allergen 
of B. germanica (20). Together, these studies suggest 
that a cocktail of five cockroach allergens Bla g 1 
and/or Per a 1, Bla g 2, Bla g 4, Bla g 5, Bla g 7, and/or 
Per a 7, would be expected to diagnose 50–64 % of 
cockroach allergic patients worldwide (21).
Bla g 1 and Bla g 2 allergens are secreted in the 
digestive system and excreted in fecal particles, 
being good markers of cockroach allergen exposure. 
Threshold levels of exposure for sensitization and 
asthma symptoms in the susceptible population 
are 2 and 8 U/g of dust; however, sensitization by 
chronic exposure of very low levels (1 – 10 µg/g of 
dust) of Bla g 2 is associated with asthma; also is a 
risk factor for wheezing in children (22). Reducing 
the environmental allergen exposure in homes of 
patients with cockroach-induced asthma, could 
lead to improvement of symptoms. However, 
cockroach allergens may persist for months following 
eradication of the insects. A controlled intervention 
including professional cleaning, bait traps, 
insecticides, and HEPA filters, decreased allergen 
levels, which correlated with decreased asthma 
symptoms, suggesting that allergen reduction is 
possible but difficult because continuous efforts 
and non-accessible equipment might be necessary; 
Textbox 1
Clinical relevance
  Cockroach allergens are strong inducers of sen-
sitization and asthma
  Sensitization to cockroach allergens should be 
investigated in asthmatic patients
  In some places, co-exposure to cockroach and 
mite allergens occurs
  CRD could help to detect genuine sensitization 
to mite and cockroach allergens
Figure 2
Clinically relevant cross-reactivity of B. germanica, 
D. pteronyssinus, shrimp and Ascaris allergens.
Bla g 1, Bla g 2
Pen a 1
Bla g 7,   Bla g 5
Der p 1
Der p 2
Der p 10
Der p 8
ABA-1
Asc l 3
Asc l 13
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also, the level of expertise that would be required to 
achieve significant cockroach extermination should 
be determined.
Immunotherapy (IT) is currently performed with 
crude extracts and there are reports supporting 
its effectiveness (23). In a work including four pilot 
studies of IT with B. germanica extract, subcutaneous 
IT was more effective modifying immune parameters 
than sublingual IT, although both types proved to be 
safe. Potential cockroach allergen immunotherapy 
has been tested in mouse models for prophylaxis (Bla 
g 2 DNA vaccine) or control (liposome-entrapped Per 
a 9) of airway inflammation (24). 
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B06
Mammalian furry animals are an important 
indoor allergen source
Sensitisation to mammalian furry animals 
is common and a risk factor for the 
development of allergic rhinitis and asthma
Cat, dog and horse contain cross-reactive 
molecules such as serum albumins and some 
lipocalins
Co-sensitization to furry animals can be 
distinguished from cross-sensitization by 
allergen component testing
THE ALLERGEN SOURCES
Mammalian furry animals are an important source of 
indoor allergens (1). They are considered as risk factors 
for the development of allergic rhinitis and asthma 
in the domestic and occupational environment. 
Pets are present in up to 60% of European and US 
households, with cats and dogs being the most 
popular pets. Horse riding is a favorite leisure activity 
among young people. Animal allergens are present 
in urine and saliva dander and above all, and are 
dispersed. They stick to animal hair and dander and 
are dispersed indoors (Fig. 1). They also adhere to 
human clothes and are easily transported to public 
places. Exposure measurement studies have shown 
their presence in schools, day-care centres, public 
transport and households of non-pet owners (2).
Allergic reaction have been described upon
  Inhalation by direct contact with the animal
  Inhalation by indirect contact in a contaminated 
environment
  Animal bites
  Ingestion of raw or medium cooked meat
Marianne van Hage, Christiane Hilger
ALLERGY 
TO CAT, DOG 
AND HORSE 
 EAACI Molecular Allergology User´s GuideEAACI Molecular Allergology User´s Guide2016 Part  B:  Using Molecular Al lergology In The Cl inical  Practice 
124 Allergy to Cat, Dog and Horse 
Most sensitised patients experience allergic 
symptoms like rhinits or asthma upon direct 
exposure to the animal. As animal allergens are easily 
transported by human clothes, they are ubiquitous. 
There is evidence that exposure to cat allergens in 
schools may lead to asthma exaberations in cat-
sensitized students (3). In classrooms with a high 
number of cat-owners, allergen levels measured are 
considered to be high enough to induce sensitization 
to cat (4). Animal bites are also capable of provoking 
anaphylactic reactions. Several cases of anaphylaxis 
upon rodent bites have been described in the literature 
(5). Anaphylaxis to cat, dog or horse bites does not 
to seem common. Only one case of anaphylaxis to 
cat bite has been reported in the literature (6). Serum 
albumins present in meat are easily inactivated by 
heat, but they can induce symptoms in sensitized 
patients upon ingestion of raw meat such as ham or 
sausages (7).
MAJOR AND RELEVANT MINOR 
ALLERGENIC MOLECULES
A number of cat, dog and horse allergens have been 
described. Lipocalins constitute the most important 
allergen protein family (8). Most of them are major 
allergens: Equ c 1, Can f 1, Can f 6 and Fel d 4. Lipocalins 
are characterized by a common three-dimensional 
structure and a low sequence identity (see C07). They 
are synthezised in salivary glands and are dispersed 
into the environment by saliva and dander. Serum 
albumins are highly cross-reactive molecules generally 
considered as minor allergens. They are abundant in 
saliva and dander. Fel d 1, the major cat allergen, is 
an uteroglobin expressed in salivary glands and skin. 
The production of Fel d 1 is related to sexual homones 
(9). Three allergens are known to have surfactant 
properties, Equ c 1, Equ c 4 and Fel d 8. The latter two 
Figure 1
Animal allergen sources.
Figure 2
Molecular structures of animal allergens. The 
uteroglobin family is represented by Fel d 1, li-
pocalins by Equ c 1, serum albumins by Equ c 3, 
cystatins by human cystatin A and latherins by 
Equ c 4. 
saliva urine fur/dander
Cat & dog
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Table 1
Major and relevant minor allergenic molecules from dog, horse and cat
Allergen Biochemical name MW Glycosylation Isoforms 
Dog (Canis familiaris)
Can f 1 lipocalin 23-25 yes 1
Can f 2 lipocalin 19 yes 1
Can f 3 serum albumin 69 no 1
Can f 4 lipocalin 18 noa 1
Can f 5 kallikrein 28 yes 1
Can f 6 lipocalin 27-29 yesa 1
Horse (Equus caballus)
Equ c 1 lipocalin 25 yes 1
Equ c 2 lipocalin 17 no 2
Equ c 3 serum albumin 67 no 1
Equ c 4 latherin 17, 20.5 noa 1
Cat (Felis domesticus)
Fel d 1 uteroglobin 18 yes 1
Fel d 2 serum albumin 69 no 1
Fel d 3 cystatin 11 yesa 1
Fel d 4 lipocalin 22 yesa 1
Fel d 5 immunoglobulin A 400 yes 1
Fel d 6 immunoglobulin M 800-1000 yes 1
Fel d 7 lipocalin 17.5 noa 1
Fel d 8 latherin-like protein 24 noa 1
aPresence or absence of glycosylation deduced from sequence analysis, not based on experimental evidence.
are considered as latherins. Fel d 3 is a minor allergen 
belonging to the cystatin protein family. Can f 5, a 
prostatic kallikrein was isolated from urine of male 
dogs. It is considered as major allergen.
SENSITIZATION TO INDIVIDUAL 
MOLECULES AND THEIR CLINICAL 
RELEVANCE
Large epidemiology studies are based on skin prick 
test results and determination of specific IgE to 
animal dander. These studies are hampered by the 
fact that cross-reactive molecules such as serum 
albumins are present in the extracts used and this 
may lead to an overestimation of sensitzation 
rates to a particular animal. A recent German study 
analysed sensitization rates to 50 allergen sources in 
more than 7000 healthy adults (10) Seven percent 
were found to have specific IgE against cat and dog, 
3.5 % were sensitized against horse. Another study 
reported sensitization rates of 9.7% to dog, 8.1% 
to cat and 4.4% to horse dander in about 13 000 
German children and adolescents (11). Interestingly, 
animal sensitization prevalence raised from 5.7% in 
the age group 3-6 years to 17.2% in the 14-17 years 
old adolescents. The Swedish BAMSE study, which 
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is an unselected population-based birth cohort of 
more than 4000 children with data from childhood 
up to adolescence, recently reported an increase in 
sensitization to cat (from 6.4% to 19.0%), dog (from 
4.8% to 22.6%) and horse (from 3.1%-10.6%) in 
1699 children followed from 4 to 16 years (12). The 
GA2LEN skin test study revealed striking geographic 
sensitization pattern among 14 European countries 
(288). Among patients presenting at allergy centres 
with suspected allergic reaction to inhalant allergens, 
prevalence to cats and dogs was highest in Denmark 
and lowest in Austria. Sensitization to animals tended 
to be higher in Nordic countries which probably 
depends on the fact that e.g. cats are kept indoors 
in a higher frequency in the Northern part of Europe.
As not all pet allergen molecules are commercially 
available has only been adressed for specific IgE 
diagnosis, their clinical relevance have only been 
adressed in a few studies. Using an allergen chip 
based (MeDALL chip) containing several individual 
pet allergens (Table 2), sera from nearly 800 randomly 
collected children from the BAMSE birth cohort 
at 4, 8 and 16 years were analyzed in relation to 
symptoms to these animals up to 16 yrs. The auhtors 
reported that IgE to Fel d 1 and Can f 1 in childhood 
and polysensitization to either cat or dog allergen 
molecules, are predicitve markers of allergy to cat or 
dog, respectively, at 16 years. IgE to Fel d 1 was as 
good as IgE to cat extract for diagnosing cat allergy. 
Furthermore, IgE to Can f 1 was the most important 
prognostic marker of dog allergy and superior to IgE 
to dog allergen extract. IgE to Can f 5 was to a lower 
extent associated with allergy to dog than IgE to Can 
f 1 (14).
Furthermore, multiple sensitizations towards 
lipocalins, kallikrein and uteroglobin components 
have been associated with increased bronchial 
inflammation in severe asthmatics (15). In addition, 
in children with severe asthma and allergy towards 
furry animals sensitization to Can f 2 (22% vs. 0%, 
p = 0.009) and Equ c 1 (51% vs. 25%, p = 0.03) was 
shown to be more common than in children with 
controlled asthma (16). Moreover, children with 
asthma due to cat have also been reported to have 
higher IgE antibody levels to Fel d 1 than compared 
to children with rhinoconjunctivitis (17).
Figure 3
Known allergens of cat, dog and horse. Proteins belonging to the lipocalin family are depicted in blue, 
serum albumins are shown in orange, latherins in green, immunoglobulins in light grey, cystatin in light 
orange, uteroglobin in dark red and kallikrein in dark grey.
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A single case of a cat-induced anaphylactic reaction 
in a child sensitized exclusively to Fel d 1 was 
recently reported (18). Elevated IgE levels of cat and 
dog-specific IgG4 antibodies seem to be protective 
as increasing ratios of specific IgG4/IgE have been 
associated with a lower likelihood of reporting allergic 
symptoms (19). However, a dissociation of allergen-
specific IgE and IgG responses in animal allergy 
has also been reported, indicating that IgG can be 
directed against other allergens/epitopes than IgE, 
which may explain why naturally occurring allergen-
specific IgG is not always protective (20). Commercial 
skin prick test extracts for dog allergy diagnosis 
have been evaluated for their content of major and 
minor allergens (21). The contents of Can f 1, 2 and 
3 showed marked variations between companies and 
this is likely to have an impact of patient diagnosis.
Epidemiological studies have shown that the presence 
of animal allergens in the indoor environment 
has been associated with an increased risk of 
developing allergic symptoms. Monitoring of allergen 
contamination allows to dermine allergen levels and 
to assess eviction strategies. Different methods 
of dust collection and antibody based allergen 
quantification assays allow to measure allergen levels 
of Fel d 1, Can f 1 and Equ c 4 in settled dust and 
ambiant air (2). Currently, there are no detection 
systems available for other major and minor cat, dog 
and horse allergens.
CLINICAL RELEVANCE, DIAGNOSIS AND 
MANAGEMENT
A careful record of the clinical history such as the 
presence of pets at home or regular pet contact is 
of great value. Skin prick test or allergen-specific IgE 
using extracts from cat, dog or horse will confirm furry 
animal sensitization. As cat, dog and horse contain 
cross-reactive molecules such as serum albumins, 
some of the cross-reactive lipocalins and potentially 
other cross-reactive molecules, it is important to 
define the primary allergenic source, especially if a 
specific immunotherapy is intended. Co-sensitization 
has to be distinguished from cross-sensitization. It is 
important to acknowledge that IgE-cross-reactivity 
may not always imply clinical cross-reactivity. Exposure 
to furry animals can lead to different sensitization 
patterns with different clinical implication. In this 
context the dose of exposure is also of importance.
Table 2
Major and minor relevant allergenic molecules from 
dog, horse and cat
Allergen Degree of cross-reactivity Sensitiza-tion rate
Can f 1 high risk of cross-reactivity 
with Fel d 7
50-76
Can f 2 22-35
Can f 3 high risk of cross-reactivity 
with other serum albumins
25-59
Can f 4 35-59
Can f 5 71
Can f 6 moderate risk of cross-reactivity 
with Fel d 4 and Equ c 1
23-61
Equ c 1 moderate risk of cross-reactivity 
with Fel d 4 and Can f 6
27-100
Equ c 2 50
Equ c 3 high risk of cross-reactivity 
with other serum albumins
36
Equ c 4 77
Fel d 1 response to Fel d 1 higher 
among children with asthma
60-100
Fel d 2 high risk of cross-reactivity 
with other serum albumins
14-54
Fel d 3 10
Fel d 4 moderate risk of cross-reactivity 
with Equ c 1 and Can f 6
63
Fel d 5 38
Fel d 6 ?
Fel d 7 high risk of cross-reactivity 
with Can f 1
38
Fel d 8 19
A)  Sensitization to major cat/dog/horse allergens 
(e.g. Fel d 1/Can f 1/Can f 2/Can f 5/Equ c 1) are 
specific markers of cat/dog/horse sensitization. 
Patients may experience symptoms from the 
upper and/or lower airways to cat/dog/horse. IgE 
to Fel d 1 and Can f 1 in childhood have shown 
to be predictive markers of cat or dog allergy in 
adolescence (14). For further information, please 
see section C07 on Lipocalins.
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B)  Sensitization to cross-reactive animal allergens 
with high sequence homology, e.g. serum 
albumins from cat/dog/horse. There is very 
limited data on sensitization to serum albumins 
and symptoms. High levels of IgE to Fel d 2 have 
been associated with atopic dermatitis in children 
with cat allergy (22). Serum albumins are involved 
in pork-cat syndrome, where sensitization to cat 
serum albumin represents the primary event in 
the development of the cross-reactive IgE (23). 
For further information, please see section C04 
on Serum albumins.
If the cross reactive IgE is against allergens with low 
to moderate degree of sequence homology, which is 
the case for many of the lipocalins, the patient may 
not experience symptoms to these allergen sources. 
However, if the cross-reacting lipocalin allergens 
have high sequence homology, patients may 
experience symptoms to all these allergen sources. 
There are few data on symptoms clearly related to 
cross-reactive molecules, as monosensitization to 
these components seems to be rare.
Clinical diagnosis
Proper interpretation of sensitisation results and case 
history (which allergen source causes symptoms? 
Which organ/s are affected? Progression? In case of 
polyallergies investigation of genuine sensitization to 
the different furry animals is needed (please see Fig. 
4-5 (C07). The description of the chronology of onset 
of symptoms to each animal may also help to identify 
the primary sensitization source. Additional atopic 
diseases (atopic eczema).
Skin prick test (SPT)
Commercial cat extract can be used, but dog extract 
has shown marked variations between companies in 
their content of major dog allergens. There is no data 
available on the usefulness of horse extract.
IgE-Testing
Total IgE has no added value in this context.
IgE to Fel d 1 is equally good as IgE to cat extract in 
predicting cat allergy
IgE to Can f 1 has shown to be the most important 
prognostic marker of dog allergy and superior to dog 
allergen extract IgE (14)
Different sensitization patterns are discussed in the 
sections on Lipocalins and serum albumins.
Challenge tests
Challenge tests using natural cat extracts are usually 
not needed, but may be indicated in selected cases 
such as polysensitization or when discordances 
are observed between skin tests and IgE results. 
Challenge tests using a cat challenge chamber are only 
performed in clinical trials to evaluate efficacy of new 
molecules used for immunotherapy or pharmacological 
treatment.
Clinical management
Advices and avoidance
1.  If the patient experiences asthma symptoms 
at exposure to dog or cat even after proper 
medication the patient should be informed that 
such direct and continous exposure may have 
detrimental effects on health
2.  If the patient experiences asthma at indirect 
exposure to cat or dog, allergen-specific 
immunotherapy is recommended.
3.  Patients who are sensitised to Can f 5 only may 
tolerate female or castrated dogs. Furthermore, 
patients sensitized to Can f 5 may show allergic 
reactions to seminal fluid (24).
Pharmacotherapy (emergency kit)
1. Symptomatic treatment as required.
Allergen-specific immunotherapy
Allergen-specific immunotherapy is especially 
recommended for cat if the patient experiences 
asthma at indirect cat exposure and is primarily 
sensitized to cat.
Other domestic animals
Bovine allergens are important inducers of occupational 
allergic airway diseases in cattle-exposed farmers 
(302). The European Farmers’ Project Study Group 
has determined that the prevalence of work-related 
respiratory symptoms was 21.8% among cattle farmers. 
The main sources of bovine allergens are cow hair and 
dander, but allergens are also found in urine, saliva, milk 
and beef. Early investigations of bovine dander extracts 
have identified 17 different antigenic components. 
Three of these, having molecular weights of 24, 22 and 
20 kDa, have been characterised as major allergens. 
Subsequent studies have shown that the 20-kDa 
protein, designated as Bos d 2, is the most important 
allergen in cow antigen extracts and belongs to the 
lipocalin family of proteins (Section C07: Lipocalins). 
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ELISA is available to quantify Bos d 2 or cow hair 
proteins (25) in the air and dust samples to monitor the 
allergen load in occupational and home environment.
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USING 
MOLECULAR 
ALLERGOLOGY 
IN THE CLINICAL 
PRACTICE
PART B
B07
Aspergillus fumigatus is the causative agent 
involved in allergic bronchopulmonary 
aspergillosis, an intense inflammatory 
response of the lung to A. fumigatus 
allergens.
Twenty-tree allergens from the fungus have 
been cloned, produced as recombinant 
proteins, and characterized.
Component resolved serologic investigations 
of patient’s sera with the recombinant A. 
fumigatus allergens of the fungus can aid to 
confirm a diagnosis of ABPA suspected from 
clinical signs.
THE ALLERGEN SOURCE
Aspergillus fumigatus (A. fumigatus) is a ubiquitous 
mould perennially present in the indoor and 
outdoor environment (1) being both, a primary 
and opportunistic pathogen associated with many 
pathologic conditions (2) as well as a major allergenic 
source. With 23 cloned allergens officially approved 
by the World Health Organization and International 
Union of Immunological Species (WHO/IUIS) 
Allergen Nomenclature Subcommittee (3) and more 
than 80 putative IgE-binding proteins described (4). 
A. fumigatus represents the most complex allergenic 
source described so far.
MAJOR AND RELEVANT MINOR 
ALLERGENIC MOLECULES
The spectrum of allergens produced by the fungus 
spans a wide variety of different molecular structures 
covering enzymes, secreted, intracellular, and 
structural proteins (Table 1). A subdivision into 
major and minor allergens is difficult because the 
sensitization to a very variable pattern of allergens 
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Figure 1
Picture of Aspergillus fumigatus showing the major secreted allergen Asp f 1 (red) and the ABPA-related 
intracellular allergen s Asp f 2, Asp f 4 and Asp f 6 (blue).
Figure 2
Ribbon diagram showing the assembly of the A. 
fumigatus MnSOD (Asp f 6). The four identical 
subunits are indicated by different colours.
Figure 3
Ribbon diagram showing the dimer formation 
of A. fumigatus cyclophilin (Asp f 11). The two 
identical subunits form a dimer through swap-
ping of a central domain involving the -sheets 
5 and 6 of the cyclophilin monomeric unit.
Asp f 1
Asp f 6
Asp f 4
Asp f 2
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Table 1
Officially recognized Aspergillus fumigatus allergens
Allergen Biochemical function MW (kDa)
Accession 
Number
% IgE-positive among  
(n) patients tested with Ref.
ABPA A. fumigatus Allergy
Asp f 1 Ribotoxin 18 M83781 83% (60) 45% (40) 5
Asp f 2 Unknown 27 U56938 100% (10)  0% (10) 6
Asp f 3 Peroxisomal protein 19 U58050 88% (60) 52% (40) 5
Asp f 4 Unknown 30 AJ001732  80% (60) 0% (40) 5
Asp f 5 Metalloprotease 40 Z30424  93% (54) 74% (35) 7
Asp f 6 MnSOD 26.5 U53561  55% (60)  0% (40) 5
Asp f 7 Unknown 12 AJ223315  46% (64) 29% (35) 7
Asp f 8 P2 ribosomal protein 11 AJ224333  15% (92) 8% (75) 8
Asp f 9 Unknown 34 AJ223327  89% (54) 31% (35) 7
Asp f 10 Aspartate protease 34 X85092  28% (54) 3% (35) 7
Asp f 11 Cyclophilin 24 AJ006689  ND* 90% (30) 9
Asp f 12 Heat shock protein P90 90 U92465  ND ND
Asp f 13 Alkaline serine protease 34 Z11580  ND ND
Asp f 15 Unknown 16 AJ002026  ND ND
Asp f 16 Unknown 43 AF062651  70% (26) ND 10
Asp f 17 Unknown AJ224865  ND ND
Asp f 18 Vacuolar serine protease 34 Y13338  ND 79% (33) 11
Asp f 22 Enolase 46 AF284645  ND  86% (7) 12
Asp f 23 L3 ribosomal protein 44 AF464911  ND ND
Asp f 27 Cyclophilin 18 AJ937743  75% (40) ND 13
Asp f 28 Thioredoxin 13 AJ937744  30% (40) ND 14
Asp f 29 Thioredoxin 13 AJ937745  50% (40) ND 14
Asp f 34 PhiA cell wall protein 20 AM496018  93% (40) 46% (24) 15
*ND: not determined
strongly depends on the pathologic background of 
the single individual. Aspergillus allergy rarely affects 
atopic individuals without asthma or cystic fibrosis 
(2) which are as such heterogeneous diseases with 
many phenotypes.  
Interestingly the phylogenetically highly conserved 
allergens Asp f 6 (MnSOD), Asp f 8 (P2 ribosomal 
protein), Asp f 11 and Asp f 27 (cyclophilins), as well 
as Asp f 28 and Asp f 29 (thioredoxins) show a high 
degree of in vitro and in vivo cross-reactivity with 
other fungal proteins belonging to the same families 
and also with the corresponding human proteins 
due to the presence of conserved epitopes on the 
surface of the proteins. The clinical relevance of 
these reactions is, however, still unclear.
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Table 2
Criteria for a clinical diagnosis of classical ABPA
Clinical and laboratory findings Importance Ref
Asthma or CF with deterioration 
of the lung function
Required 16, 20
Immediate cutaneous reactivity 
to A. fumigatus extracts
Required 16, 20
Elevated total serum IgE (>416 
IU/ml) or Elevated serum IgE 
and IgG to A. fumigatus
Required 16, 20
Chest graphic infiltrates Required 16, 20
Serum precipitating antibodies 
to A. fumigatus
Additional 16, 20
Central bronchiectasis on chest 
CT
Additional 16, 20
Peripheral blood eosinophilia Additional 16, 20
A. fumigatus containing mucus 
plugs
Additional 16, 20
SENSITIZATION TO INDIVIDUAL 
MOLECULES AND ITS CLINICAL RELEVANCE
As shown in Table 1 the incidence of sensitization 
to individual A. fumigatus allergens strongly depends 
from the status of the patient. Asthmatic, as well 
as cystic fibrosis (CF) patients (16) suffering from 
ABPA, show a higher sensitization to all investigated 
allergens then asthmatic or CF patients suffering 
from a simple A. fumigatus allergy. Interestingly the 
allergens like Asp f 2, 4 and 6 seem to be exclusively 
recognized by patients with ABPA both, in asthma (5) 
and CF (17) although large confirmatory studies are 
still lacking (16). At cDNA level only two A. fumigatus 
allergens, Asp f 1 and Asp f 5 did not have homologues 
in both A. nidulans and A. oryzae although Asp f 5 
did, and has a closely related homologue in A. oryzae 
indicating a high degree of cross-reactivity among 
Aspergillus species (19). The clinical significance of this 
observation awaits experimental elucidation.
CLINICAL MANAGEMENT
ABPA, an intense inflammatory reaction to Aspergillus 
in the lung, is considered a complex clinical syndrome 
with defined serological, pathological, radiological, and 
clinical features. The diagnosis of ABPA in asthmatic and 
CF patients sensitized to A. fumigatus is complicated 
by interfering laboratory and clinical findings shared 
between the diseases. The criteria for the diagnosis of 
ABPA are summarized in Table 2, and when all criteria 
are present the diagnosis is readily made.
However, all criteria are rarely present simultaneously 
even in classical ABPA patients because their 
presence depends on the stage of the disease 
(20), and therefore the correct diagnosis of ABPA 
suspected from clinical signs remains challenging. 
Nevertheless, because an untreated ABPA lead to a 
lethal end stage lung fibrosis, the disease should be 
ruled out in all patients sensitized to A. fumigatus.
Because A. fumigatus is ubiquitously present in our 
environment (1), allergen avoidance is not an option 
for the management of the disease, and allergen-
specific immunotherapy with recombinant fungal 
allergens has never been reported.
The overall goals for the management of ABPA are: 
i) to control symptoms of asthma or CF, ii) prevent 
or treat pulmonary exacerbations, iii) reduce or 
remit pulmonary inflammation, and iv) mitigating 
or preventing progression to end-stage fibrotic 
lung diseases (20). The treatment of choice for 
ABPA still remains the administration of systemic 
corticosteroids, with itraconazole or omalizumab as 
adjunctive treatments in severe cases (18).
Despite the availability of the recombinant allergens 
Asp f 1, 2, 3, 4, and 6 on ImmunoCAP’s, the “gold 
standard” for the determination of allergen-specific 
IgE in serum and experimental evidence that these 
allergens could help to discriminate between A. 
fumigatus sensitization and ABPA, large multicentre 
studies (5, 6, 17, 21) validating the utility of these 
allergens for the discrimination between the two 
diseases are still lacking.
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Figure 4
Decision algorithm for the diagnosis of ABPA. Allergen-specific IgE against rAsp f 2, rAsp f 4, and rAsp f 6 
might be used to corroborate the diagnosis made based on clinical signs.
Case history Asthma or Cystic Fibrosis
Skin test reactivity and/or specific IgE to Aspergillus fumigatus extract
ABPA excluded ABPA possible
Work out classical criteria for the diagnosis of ABPA
ABPA excluded ABPA confirmed
_ +
_ +
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The best-characterized molecular allergens in 
atopic dermatitis are fungal allergens of the 
skin-colonizing yeast Malassezia spp.
Fourteen allergens from 3 Malassezia species 
have been characterized to date.
The well characterized allergens Mala s 
11 and Mala s13 from M. sympodialis 
can induce auto-reactive T cells against 
homologeous proteins in human skin.
Non-fungal allergens of supposed relevance 
in atopic dermatitis are Der p 11 from the 
mite Dermatophagoides pteronyssinus 
and enterotoxin B from the bacterium 
Staphylococcus aureus.
INTRODUCTION
Atopic dermatitis (AD) is a chronic relapsing 
inflammatory skin disorder, characterized by 
intensely itchy skin eczema. The prevalence of AD 
in industrialized countries has tripled during the past 
30 years (1), affecting 15-30% of children and up 
to 10% of adults (2). The pathogenesis of AD is not 
fully understood. Several factors seem to contribute 
to the development of AD including an impaired 
barrier function of atopic skin with higher skin pH 
and higher transepidermal water loss than healthy 
skin (3), and an altered skin immune system with 
the altered production of antimicrobial peptides and 
cytokines (4). It can be speculated that the impaired 
barrier function and the altered immune system in 
atopic skin play intertwining roles and contribute to 
a colonization and growth of microorganisms on the 
skin of AD patients (3).
The skin is a complex ecosystem that harbors diverse 
and body site-specific microbial communities, which 
have been termed skin microbiome. The phylogenetic 
profiling of the skin microbiome in healthy individuals 
revealed that most body sites predominantly harbor 
bacteria (5). Notably, fungi are part of the normal 
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skin flora at all body sites and comprise 1-22% of the 
phylogenetic composition of the skin microbiome 
(5). The fungal flora of healthy skin harbors almost 
exclusively Malassezia spp. (5) Recent investigations 
suggested a significant role of the skin microbiome 
in the development and course of AD (3, 6). Some 
species of skin microbial communities or their 
immunogenic components such as allergens may 
interact with the altered immune system in atopic 
skin and so contribute to skin inflammation in AD. 
In the following we will discuss the significance of 
skin microbes in AD from an immunologic point of 
view, and we will overview the possible interactions 
between microbial allergens with the immune system 
in atopic skin. We will focus on fungal allergens 
because recent investigations particularly suggested 
a possible role of Malassezia allergens in AD, but we 
will also briefly discuss the role of allergens from 
other microorganisms,
THE ALLERGEN SOURCE
Malassezia is a genus of lipophilic yeasts that 
belongs to the phylum Basidiomycota and currently 
encompasses 14 species. Nine of them are 
frequently isolated from human skin, while five are 
usually isolated from animal skin (Table 1). Most 
Malassezia species lack the genes for the fatty acid 
synthase and therefore rely on exogenous fatty 
acid sources, for example skin lipids, to satisfy their 
nutritive requirement (7). Their need for exogenous 
lipids explains the predilection of Malassezia spp. for 
seborrhoeic skin sites, such as the head and neck (8).
Several studies investigated the colonization of 
healthy and atopic skin with Malassezia spp. (Table 2). 
Interestingly, these studies did not reveal a consistent 
difference in the frequency of skin colonization with 
particular Malassezia spp. between healthy individuals 
and AD patients. This inconsistency might be due to 
different methods used in these studies, for example 
the use of different culture media that might favor 
the growth of a particular species (9). Despite these 
methodical considerations, some epidemiological 
studies postulated a geographic variation in the 
distribution of particular Malassezia spp., presumably 
due to climate factors. However, no study directly 
compared the prevalence of Malassezia spp. in skin 
samples from different geographic areas.
MAJOR AND RELEVANT MINOR 
ALLERGENIC MOLECULES
Currently 14 immunogenic allergens are characterized 
that are produced by three Malassezia species, namely 
M. furfur, M. sympodialis and M. globosa (Table 3). 
The crystal structure of some of these allergens 
are known and two examples are shown in Fig. 1. 
Thirteen allergens, all of which are produced by 
M. furfur or M. sympodialis, are listed in the official 
allergen nomenclature list of the International Union 
of Immunological Societies (IUIS, http://www.allergen.
org). Two Malassezia allergens have raised special 
attention, namely Mala s 11 and Mala s 13. Mala s 11 
is 50% homologous in its amino acid sequence with 
human MnSOD (10) and 56% homologous to the 
MnSOD from Aspergillus fumigatus (Asp f 6) (11). Mala s 
13 belongs to the family of thioredoxins. Both allergens 
can induce auto-reactive T cells, which react against 
the human homologous proteins, hence contributing 
to skin inflammation in AD (12, 13). Recently, an 
allergen (MGL_1304) derived from M. globosa was 
described. In vitro experiments have shown that this 
Table 1
Currently identified Malassezia species 
Malassezia 
species
Isolated 
from  
human skin
Isolated 
from  
animal skin
Description 
as species 
(year)
M. caprae X 2007
M. cuniculi X 2011
M. dermatis X 2002
M. equina X 2007
 M. furfur X X 1889
M. globosa X X 1996
M. japonica X 2003
M. nana X 2004
M. obtusa X 1996
M. pachydermatis X 1925
M. restricta X 1996
M. slooffiae X X 1996
M. sympodialis X X 1990
M. yamatoensis X 2004
modified from (8)
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Table 2
Frequency of skin colonization with Malassezia species
Malassezia 
species
Identification by PCR (%) Geographic 
region
Identification by culture (%) Geographic  
regionHealthy skin Atopic skin Healthy skin Atopic skin
M. dermatis 4-34 29-43 Japan, South Korea 7 South Korea
M. furfur 5-27 6-29 Japan, South Korea 6-21 4-21
Iran, Bosnia, Canada, 
Tunisia
M. globosa 28-100 100 Japan, South Korea 32-78 16-28
Iran, Bosnia, Canada, 
Tunisia, South Korea, 
Sweden
M. japonica 10-13 6-19 Japan
M. obtusa 1-13 12-24 Japan, South Korea 10-30 Canada, Sweden
M. restricta 32-100 100 Japan, South Korea 1-8 3-22
Iran, Canada, Tunisia, 
South Korea, Sweden
M. slooffiae 1-17 12-24 Japan, South Korea 2-3 3-7
Bosnia, Canada, 
Tunisia, South Korea
M. sympodialis 29-63 59-62 Japan, South Korea 7-78 32-100
Iran, Bosnia, Canada, 
Tunisia, Poland
M. yamatoensis 7-16 24 Japan
references are with the authors
Figure 1
Crystal structure of two Malassezia spp. allergens.
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allergen induces mast cell degranulation and the 
release of IL-4 by basophils (14).
SENSITIZATION TO INDIVIDUAL 
MOLECULES AND ITS CLINICAL RELEVANCE
Malassezia spp. are part of the healthy skin flora 
and Malassezia-specific IgG and IgM antibodies are 
therefore regularly detected in healthy individuals 
(7). However, healthy individuals usually do not have 
detectable levels of Malassezia-specific IgE antibodies. 
In contrast, 30-80% of adult AD patients are sensitized 
to Malassezia spp. as demonstrated by positive atopy 
patch tests, skin prick tests (SPT) or detectable serum 
levels of specific IgE antibodies (15, 16). Malassezia-
specific IgE are found in 5 - 27% of children and 29 - 
65% of adults with AD (17, 18), which is consistent to 
the rates found by SPT. The sensitization rate against 
particular allergens from Malassezia spp. (as far as 
known) is shown in Table 3.
Clinical relevance of sensitization
M. sympodialis produces higher amounts of the 
allergen Mala s 12 (Table 3) when cultured under 
Table 3
Allergens from Malassezia species and their relevance in atopic dermatitis
Allergen Source Mass (kDa) Function
Sensitization 
(%) Comment
Mala f 2 M. furfur 21 Peroxysomal membrane protein 72
Mala f 3 M. furfur 20 Peroxysomal membrane protein 70
Mala f 4 M. furfur 35 Mitochondrial malate dehydrogenase 83
Mala s 1 M. sympodialis 36 unknown
Mala s 5 M. sympodialis 19 unknown
Mala s 6 M. sympodialis 18 Cyclophilin 92%
Mala s 7 M. sympodialis 22 40-60
Mala s 8 M. sympodialis 16 40-72
Mala s 9 M. sympodialis 11 24-36
Mala s 10 M. sympodialis 86 Heat shock protein70 69
Mala s 11 M. sympodialis 23 Manganese superoxide dismutase 43-75
Sensitization correlates to disease 
severity
Induces dendritic cell maturation,
Induces release of IL-6, IL-8, IL-
12p70, TNF-α by dendritic cells
Induces auto-reactive T cells against 
human homologue
Mala s 12 M. sympodialis 67 Glucose-methanol-choline oxidoreduktase 62
Increased production under higher 
pH, which is typical for atopic skin
Mala s 13 M. sympodialis 13 Thioredoxin 50 Induces auto-reactive T cells against human homologue
MGL_1304 M. globosa 17 62 Induces degranulation of mast cellsInduces IL-4 release by basophils
references are with the authors
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high pH conditions reflecting the higher pH of atopic 
compared to normal skin. This might contribute to 
Malassezia-related skin inflammation in AD (19). The 
currently proposed role of Malassezia allergens in the 
pathogenesis of AD are depicted in Fig. 2.
Some studies found a significant correlation between 
the severity of AD and serum levels of Malassezia 
spp.-specific IgE, usually in adults but not in children 
(18). The lower frequency of Malassezia sensitization 
in children compared to adults might be related to 
the poor growth conditions for Malassezia spp. in 
children compared to adults. The lipid content of 
sebum, which is a prerequisite for skin colonization 
for most Malassezia spp. is low in children but rises 
during puberty and is high until the age of 50 (20). 
Accordingly, sensitization to Malassezia spp. seems to 
occur preferably in adulthood, and therefore later than 
the sensitization to food allergens and aeroallergens, 
which frequently occurs during childhood (18).
Figure 2
Proposed mechanisms of Malassezia spp. allergen-induced skin inflammation in atopic dermatitis (AD). 
Increased skin pH in AD induces increased allergen release by Malassezia spp. These allergens penetrate 
the epidermis through the disturbed skin barrier typically found in atopic skin. Allergens may be recog-
nized by toll-like receptor 2 on keratinocytes and dendritic cells and elicit the release of pro-inflammatory 
cytokines by these cells, or induce the production of specific IgE antibodies. Autoreactive T cells can cross 
react between fungal and human manganese-dependent superoxide dismutase (MgSOD) or thioredoxin, 
hence sustaining skin inflammation.
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CLINICAL MANAGEMENT
Diagnosis
Standardized skin test extracts for Malassezia spp. are 
not yet commercially available. Malassezia -specific 
serum IgE can be measured using a commercially 
available standardized test (ImmunoCAP® m70, 
Phadia, Thermo Scientific, Uppsala, Sweden; www.
phadia.com) based on M. sympodialis (ATCC strain 
42132) extracts. Recently, a new kit containing 
several species of Malassezia has been introduced 
(ImmunoCAP® m227) with a slightly increased 
sensitivity compared to the single species test 
according to our experience (17). Cultivation 
of Malassezia spp. from the skin is feasible but 
challenging, and this method is usually not implicated 
in the clinical routine care of AD patients.
Due to its sequence homology, Asp f 6 is highly 
cross-reacting to Mala s 11 (11). It might therefore 
be hypothesized, that serum levels of Asp f 6-specific 
IgE are a marker for auto-reactivity. This could be 
of clinical relevance, because, in contrast to Mala s 
11, a test using recombinant Asp f 6 to determine 
allergen-specific IgE is available in clinical routine 
(ImmunoCAP® m222).
Treatment
The benefit of topical or systemic antifungal treatment 
for the clinical improvement of human AD is still 
debated. Azole antifungals are the most common 
class of antifungal drugs prescribed for AD patients. 
In vitro, azole antifungals are effective against 
Malassezia spp (20). They have anti-inflammatory 
properties through inhibition of the IL-4 and IL-5 
production by T cells, which might reduce skin 
inflammation contributing to the improvement of AD 
during antifungal treatment (21).
In clinical routine, the topical application of 
ketoconazole on the face of patients with AD of the 
head and neck type frequently improves eczema, 
presumably due to a partial overlap with seborrhoeic 
dermatitis in some cases (personal communication and 
own experience). The benefit of a systemic antifungal 
treatment for AD patients has been assessed in several 
randomized, placebo-controlled trials. One study 
compared 36 AD patients treated with ketoconazole 
with 39 AD patients treated with placebo. AD severity 
improved significantly in the ketoconazole group but 
not in the placebo group (22). In another trial, a total 
of 53 AD patients were treated with itraconazole 
or placebo. The improvement of AD severity was 
significantly higher in itraconazole treated patients 
than in the placebo group (23).
A different therapeutic approach for AD patients 
specifically against Malassezia spp. might be 
photodynamic therapy. For example, irradiation 
with a 670-nm diode laser significantly reduces the 
viability of M. furfur cultures that were grown in the 
presence of a cationic photosensitizer (24). However, 
the relevance of these results in clinical routine still 
needs to be proved.
OTHER MOLECULAR ALLERGENS RELEVANT 
IN ATOPIC DERMATITIS
House dust mites are one of the most relevant 
allergen sources worldwide. About 50% of allergic 
individuals in Central Europe are sensitized to house 
dust mites (25) and the severity of AD correlates 
with the indoor concentration of house dust mite 
allergens such as Der f 1 (26). Another AD-relevant 
allergen of house dust mite is the 104 kD protein 
Der p 11 (27). Der p 11 is a paramyosin, a family of 
muscle-associated high molecular weight proteins in 
invertebrates such as ticks, lice and insects (28). The 
IgE-mediated sensitization to Der p 11 is relatively 
low in house dust mite-allergic individuals in Europe 
(7-16%), while the sensitization in AD patients is 
much higher (55-67%) (28). Therefore, Der p 11 may 
be a marker allergen for house dust mite-allergic AD 
patients (28). Another AD-relevant microbial allergen 
source may be cockroaches. Cockroach allergens, as 
well as house dust mite allergens, may exacerbate AD 
via activation of the protease-activated receptor-2 
(PAR-2) on human keratinocytes. This impairs the 
skin barrier function via delayed lamellar body 
secretion by keratinocytes and decreased neutral 
lipid deposition in the stratum corneum of the 
epidermis (29).
A pathogenic role in AD is attributed to the Gram-
positive bacterium Staphylococcus aureus, because 
it more frequently colonizes lesional and non-
lesional skin of AD patients (91-100% and 31-78%, 
respectively) than the skin of healthy individuals 
(10%) (30), and its relative abundance on the skin 
increases with the development of AD flares (6). S. 
aureus allergen-specific IgE might be relevant for the 
pathogenetic role of this bacterium in AD as 29-45% 
of AD patients have specific IgE against S. aureus 
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enterotoxin B, and 10-18% against enterotoxin 
A (31), although sensitization rates to S. aureus 
allergens appear lower than for Malassezia spp. 
allergens (18). Furthermore, the sensitization rate 
to S. aureus allergens correlates with the severity 
of AD (31), and the serum levels of enterotoxin 
B-specific IgE correlate with serum IL-18 levels in 
AD patients (32). S. aureus enterotoxin B belongs 
to the family of superantigens, and therefore also 
induces an IgE-independent cytokine release from 
T cells and macrophages via cross-linking the major 
histocompatibility complex II on antigen-presenting 
cells and the beta-chains of T cell receptors. Some 
S. aureus strains isolated from AD patients produce 
up to 23 superantigens, and the cytokine release 
induced by these antigens may contribute to skin 
inflammation in AD (33).
Also, autoreactivity induced by microbial sources 
other than Malassezia spp have been postulated 
as a pathogenic or exacerbating factor in AD (34). 
For instance, five IgE-reactive autoallergens from 
keratinocytes named Hom s 1 through Hom s 5 have 
officially been named by WHO-IUIS (www.allergen.
org) and are supposed to trigger skin inflammation 
in AD, particularly as a late stage phenomenon in 
severe AD (35, 36).
CASE
A 37-years-old men with long-lasting generalized AD 
predominantly on the head and neck presented with 
severe relapses of the eczema (maximum EASI score 
51) due to unknown causes except worsening during 
strong sweating and physical exercise. No other 
trigger factors such as seasonal influences, food or 
topical contacts were identified. Topical treatment 
with steroids and emollients was not sufficient during 
AD flares, therefore the patient sometimes received 
systemic steroids. Also phototherapy and short-time 
Cyclosporin A have been used.
Skin prick test with common inhalant and food 
allergens was negative, as well as patch testing with 
standard series, topical steroids and antibiotics/
disinfectants. Testing for fungi-specific IgE in serum 
and patch testing with Malassezia spp. extract and 
fungal allergens was positive (Table 4).
This patient demonstrated strong IgE-mediated 
sensitization to M. sympodialis and fungal MnSOD 
and also T-cell mediated reactivity and eczematous 
reaction to fungal and recombinant human MnSOD 
by patch testing. In addition to emollients and topical 
steroids the patient received a peroral anti-fungal 
treatment (itraconazole 100 mg bid for two weeks) 
what led to a fast but only temporary improvement 
of his AD (EASI 23 after two weeks therapy, EASI 35 
three weeks later). The patient currently uses topical 
antifungal agents in the face and neck region and 
an antifungal shampoo every six weeks resulting in 
significant improvement of eczema and decrease of 
AD flare frequency.
This case demonstrates that AD patients with a 
significant sensitization to Malassezia spp. may 
benefit from a systemic and topical anti-fungal 
treatment.
TOOLS
There is not enough data available for 
recommendations of molecular-based allergy 
diagnosis in the diagnostic work-up of AD. However, 
assessment of some allergen-specific IgE might be 
useful to determine the sensitization to fungal and 
human autologous antigens (Fig. 3).
Table 4
Test results of the patient
Serum IgE titer Value (kU/l) Interpretation
Total IgE 523 Elevated
Inhalant allergen 
screening
0.2 CAP–Class 0
Food Screening (Fx5) 0.3 CAP–Class 0
IgE Malassezia spp (m227) 53.2 CAP–Class 5
IgE Aspergillus fumigatus 
(m3)
12.4 CAP–Class 3
IgE Asp f 6 (m222) 22.4 CAP–Class 4
IgE Mold mix (mx2) 24.1 CAP–Class 4
Patch testing (assessment after 48 hours)
Malassezia spp. extract +++ Highly pos
Fungal MnSOD (r Asp f 6) ++++ Highly pos
Human MnSOD ++ Highly pos
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Total IgE IgE Inhalant allergens
IgE food allergens
IgE House dust mite
Der p 1 / Der f 1
Der p 11 *
IgE Malassezia spp
(m227)
IgE Asp fum MnSOD **
Asp f 6 (m222)
*  not yet fully proved, only one 1st publication
**  sign of possible autoreactivity
Figure 3
Possible use of molecular allergy diagnosis in atopic dermatitis.
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B09
 Molecular diagnosis (MD) provides a major 
step in improving the accuracy of diagnosing 
IgE-mediated food allergy.
Use of MD in combination with conventional 
sensitization testing improves analytical and 
diagnostic performance and can lead to a 
reduction in the need for diagnostic oral food 
challenges
 New component allergen / pattern of 
component allergens for a food should be 
evaluated against conventional allergy 
testing against whole allergens (both SPT 
and sIgE) as well as against the gold standard 
oral food challenge to determine their 
diagnostic performance.
Food allergy has increased particularly in children 
and is an increasing public health concern (1). Clinical 
practice guidelines covering general diagnosis and 
management of food allergies have recently been 
published and disseminated by the EAACI Food 
Allergy Diagnosis Systematic Review and Guidelines 
(2, 3). Correct diagnosis of food allergy is of great 
importance so as to avoid falsely labelling the patient 
as food allergic or not allergic:
A false positive food allergy diagnosis will lead to 
unnecessary food exclusions and potential impact 
on nutrition and growth (4), heightened anxiety 
and inappropriate recommendation of emergency 
medication (5).
  A false negative food allergy diagnosis will lead 
to unexpected allergic reactions to the food in 
question and risk of potentially severe symptoms 
without the availability of rescue medication 
- thus the need to continuously improve and 
evaluate our approach on the diagnosis of food 
allergy.
Helen A. Brough, Gideon Lack, Jörg Kleine-
Tebbe, Antonella Muraro
MOLECULAR 
DIAGNOSTICS 
IN THE MANAGEMENT 
OF FOOD ALLERGY 
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POTENTIAL ADVANTAGES AND 
LIMITATIONS OF MOLECULAR DIAGNOSIS
Molecular diagnosis (MD) provides a major step in 
improving the accuracy of diagnosing IgE-mediated 
sensitizations in food allergy. The ability to identify and 
characterize single allergens at a molecular level has 
added a significant body of understanding as to the 
mechanism of sensitization to foods. The increasing 
number of available single allergens, particularly for 
peanut protein allows for a comprehensive review 
of the pattern of sensitization (e.g. entire allergen-
specific IgE repertoire) (see section A05). Research 
into the structural similarity between allergens 
and the amino acid sequence homology between 
food allergens also helps to explain cross-reactivity 
between allergens, which may be clinically relevant or 
irrelevant. Certain panallergen molecules can indicate 
broad cross-sensitization and unfold particular pollen-
food or plant food syndromes (6) (see Sections on 
Cross-reactivity C01-C08).
Natural extracts used for conventional allergy testing 
(commercial extracts for skin test and serum specific 
IgE) contain a complex mixture of proteins. Some of 
these proteins are relevant for clinical reactivity and 
some are not but still result in IgE binding and thus 
positive allergy tests (e.g. positive IgE results due to 
cross-reactive carbohydrate determinants, (CCDs). 
Therefore it is assumed that conventional allergy tests 
(i.e. extract-based peanut IgE) are more likely than 
molecular allergen testing to lead to clinically irrelevant 
results with the negative implications described above 
(see also Section B18 on peanut allergy).
The specific context in which MD can improve on total 
allergen IgE testing include where there are 1) low 
abundant and or labile food proteins in conventional 
allergy tests, 2) MD provides information on risk- 
or severity associated molecules, 3) MD provides 
indicators of food-related cross-reactivity or 4) 
markers of genuine (species-specific) sensitization. 
These scenarios are discussed in further depth in 
Sections A04 and A05.
The performance of any test can be assessed based 
on metrics such as sensitivity, specificity and negative 
predictive value (NPV), positive predictive value (PPV), 
likelihood ratio (LR) with optimum cut-off values being 
determined on the receiver operating characteristics 
(ROC) curve. Using these metrics, predictions on the 
likelihood of clinical reactivity, severity and course 
provided by MD, go beyond the detection of allergen-
specific IgE sensitization. However, these tests are still 
tests for IgE sensitization and are not synonymous 
with allergy. Following this line of reasoning one could 
argue that they should not be called “allergy tests”, but 
rather viewed and termed as “sensitization tests” (see 
terminology in numerous chapters of this book as well 
as international guidelines on assays for human IgE) (7).
Numerous clinical studies have produced variable 
performances of the above metrics for IgE assay 
results including MD testing. Thus, these tests require 
thorough individual clinical interpretation and the 
expectations from MD to predict clinical reactivity 
should be restrained and valued with caution. 
The strength of MD is related to the level of IgE-
sensitizations, providing more detailed and precise 
profiles of the allergen-specific IgE repertoire. In the 
end, the physician has to define the clinical relevance 
of the diagnostic test result, not the test by itself.
ATTEMPTS TO PREDICT CLINICAL 
REACTIVITY WITH SENSITIZATION TESTS 
USING EXTRACTS OR MOLECULES
Clinical allergist have always been interested in 
evaluating the potential of sensitization test outcomes 
i.e. skin prick test (SPT), allergen-specific IgE (sIgE), 
basophil activation test (BAT) for the prediction of 
clinically relevant food allergic reactions. 
In the Healthnuts Australian based study, peanut SPT 
had a similar area under the curve (AUC) on ROC curve 
analysis of 0.94 to Ara h 2 (AUC: 0.95) for predicting 
challenge proven peanut allergy (364). In a UK based 
study, peanut SPT had a similar AUC (0.93) than Ara 
h 2 (AUC: 0.91) using optimal cut-off points of 5 mm 
and 0.53 kUA/l respectively (9). Furthermore, SPT and 
sIgE to whole allergens for cow’s milk, egg and peanut 
have robust, but variable 95% PPV in the published 
literature (8, 10). The specific cut-offs for 95% PPV 
for cow’s milk, egg and peanut usually vary between 
populations depending on the prevalence of disease in 
that population, inclusion criteria and study protocols. 
This is also the case for molecular allergens such as 
Ara h 2 where the 90-95% cut-offs range from 0.35 
kUA/l to 42.2 kUA/l in the published literature (11, 
12). Subsequently, no general recommended cut-off 
level is available for Ara h 2, indicating the difficulty 
to precisely predict clinical food reactions with pure 
sensitization test levels, regardless of using extracts 
or molecules. It is, common practice that as each new 
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component allergen becomes available, its diagnostic 
performance is compared against SPT and sIgE to the 
whole allergen.
GENERAL VALUE OF DIAGNOSTIC TESTS IN 
FOOD ALLERGY, INDICATING IgE ALLERGY 
(SPT, BAT)
Conventional sensitization tests with whole protein 
allergens have the advantage that they include the 
majority of relevant, mainly stable and highly abundant 
allergens, particularly where these molecular 
allergens are not yet commercially available (which is 
the case for the majority of foods). In this case SPTs 
with extracts are less likely to lead to false negative 
results. Exceptions are indeed allergens missing (i.e. 
lipophilic food allergens like oleosins in aqueous 
extracts or defensins) or of low abundance and 
stability (i.e. pollen-food-syndromes based on Bet v 
1-homologs or profilins). SPT confers the benefit of 
immediate interpretation allowing for a ‘one-stop-
shop’ approach to the allergy consultation, which has 
innumerable benefits for the patient and family (13) 
Additionally, the BAT is another diagnostic method, 
which is increasing in popularity and, although still 
mainly used as a research tool, its combination with 
MD could represent a powerful tool. Advantages 
and disadvantages of the various testing options are 
described in Table 1.
There is growing evidence that the use of MD in 
combination with conventional sensitization testing 
improves analytical and diagnostic performance and 
can lead to a reduction in the need for diagnostic 
oral food challenges in selected cases (8). Therefore, 
rather than replace conventional testing, MD 
should be added to our existing armamentarium of 
diagnostic testing.
The chapter below will summarize the following in the 
evaluation of patients with a suspected food allergy:
1. Considerations for the diagnostic work-up of 
patients with a suspected food allergy
2. Circumstances in which MD is not necessary and 
circumstances when it improves the diagnostic 
work-up and management of food allergy
3. At which stage in the diagnostic algorithm for 
food allergy does MD provide the most benefit
4. Future perspectives in the diagnosis and 
management of food allergy in the age of MD
CONSIDERATIONS FOR THE DIAGNOSTIC 
WORK-UP OF PATIENTS WITH A 
SUSPECTED FOOD ALLERGY
When evaluating a patient with a suspected food 
allergy, performing a wide range of allergy tests 
without corresponding history of symptoms is 
likely to lead to unnecessary food elimination due 
to clinically irrelevant tests. The ‘molecules to 
symptoms’ approach, where a battery of tests are 
performed without first assessing clinical symptoms 
(as described in Section A03 (Molecular allergy 
diagnostics in clinical practice) is therefore generally 
not recommended and at this point is mainly used 
for research purposes. Allergy testing should 
be performed where there is a clear history of a 
convincing IgE-mediated allergic reaction in relation 
to a particular food/substance. Anticipatory allergy 
testing may also be considered where there is a 
known risk of co-reactivity (for example testing for 
peanut allergy in a child with egg allergy and eczema 
as per the LEAP study findings) (14). In cases where 
the allergen is not clearly elucidated from the history, 
such as in the case of food dependent exercise 
induced anaphylaxis or idiopathic anaphylaxis, 
multiple allergen testing (both component and whole 
allergens) may elucidate the responsible allergen; 
often this will be omega-5-gliadin, LTPs (in the 
mediterranean) or tropomyosins (15), or may be due 
to other, sometimes unusual allergen sources (e.g. 
lupine or buckwheat).
Whatever diagnostic tests are performed, history 
forms the cornerstone of our diagnosis thus one must 
not forget the basic questions outlined in Table 2.
CIRCUMSTANCES IN WHICH MOLECULAR 
ALLERGOLOGY IS NOT NECESSARY AND 
CIRCUMSTANCES WHEN IT IMPROVES 
THE DIAGNOSTIC WORK-UP AND 
MANAGEMENT OF FOOD ALLERGY
In patients where there is a convincing history of 
IgE-mediated allergy (not delayed gastrointestinal or 
eczematous reactions) a positive SPT or sIgE to the 
relevant whole food allergen may be sufficient to 
confirm the diagnosis (Fig. 1). Ninety-five percent PPV 
values for SPT and sIgE that have been documented 
in the past for peanut, cow’s milk and egg, however 
they are highly dependent on the specific clinical 
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Table 1
Testing modalities for a suspected food allergy (advantages and disadvantages)
Advantages Disadvantages
Allergen 
extracts 
in SPT
  Inexpensive
  Contain many allergenic proteins
  Immediate results in clinic (one-stop shop 
clinic)
  Modified (prick to prick) SPT allows for any 
allergen source to be evaluated
  Patient is exposed to the allergen
  Difficult characterization and standardization
  Unknown allergen composition
  Contains undefined components, i.e. 
endotoxins
  Low abundance or degradation may lead to 
low analytic and diagnostic sensitivity
  Proteins mixture complexity may lead to low 
specificity 
Allergen 
extracts 
in sIgE
  Contain many allergenic proteins
  Patient not exposed to the allergen
  Large allergen source panel
  Delay in obtaining results
  Higher costs
  Unknown allergen composition
  Contains undefined components, i.e. 
endotoxins
  Low abundance may lead to low sensitivity
  Proteins mixture complexity may lead to low 
specificity
Molecular 
allergens 
for sIgE
  Detection of sensitization to relevant allergens.
  Identification of cross reactivity as cause of a 
s-IgE measurement
  Highly defined proteins
  Highly purified proteins
  Structure – amount of protein precisely known
  Patient not exposed to the allergen
  Number of allergen molecules can be tested 
simultaneously
  Results not immediately available during 
consultation
  Technical challenges (first set up)
  Higher costs
  Identification of IgE only to a limited number 
of component allergens 
Basophil 
activation 
test
  Reflects reactivity and sensitivity to allergen
  Will pick up sensitizations in case of extremely 
low total IgE (<10 kU/l)
  May relate to threshold reactivity and severity 
of reaction
  May use molecular allergens in culture
  Patient not exposed to the allergen
  Limited number of allergen molecules could be 
tested simultaneously 
  Higher costs
  Significant manpower requirements
  Fresh blood sample must be used
  Results not available in clinic
setting (prevalence, geographical region, clinical 
phenotype, inclusion criteria, procedures, etc.) and 
cannot be extrapolated and transformed into general 
recommendations (16, 17). Due to a high NPV (91% 
for SPT <3 mm) a negative SPT can be helpful in ruling 
out an IgE mediated egg allergy (18). Similarly fresh 
cow’s milk SPT <3 mm has been reported with a NPV 
of 98% (19). The NPV of peanut SPT is also good (29). 
Thus a negative SPT to the natural extract may be 
used to rule out IgE-sensitization without the need 
for MD. The NPV of sIgE to whole allergen cow’s milk, 
egg white and peanut have been shown reliable in 
excluding an IgE mediated food allergy. Whole peanut 
allergen sIgE appears to be sometimes diagnostically 
more sensitive test than Ara h 2 depending on the 
population and clinical settings (21). In addition, new 
peanut allergens (www.allergen.org) indicate gaps in 
our present molecular peanut allergen panel, being 
likely available in the future as reagents for allergen-
specific IgE assays. This will fill the gap, increasing 
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the repertoire and general analytical sensitivity by 
applying MD-based allergy tests.
There are, however, other whole allergen tests with 
poor predictive values for clinical reactivity, such as 
soy, wheat and hazelnut (16). In these cases, MD may 
outperform whole allergen testing providing more 
detailed information on the sensitization profile and 
within limits on the clinical outcome. For example Cor 
a 9 and Cor a 14 have been shown to outperform 
hazelnut SPT and sIgE tests for objective symptoms 
on oral food challenge (12, 22, 23), predominantly 
due to hazelnut cross-reactivity with birch leading to 
frequently occurring and clinically irrelevant extract-
based results. The component allergen Tri a 19 
(omega-5 Gliadin) to diagnose IgE-mediated clinical 
reactivity to wheat has had encouraging results in 
Japan (24), but these results were not reproduced in 
America/Germany (25). Focusing on the assay level, 
Tri a 19 has, however, dramatically increased analytical 
sensitivity and specificity compared to whole wheat 
extracts, providing a powerful tool to accurately 
identify omega-5 Gliadin sensitized individuals.
There are situations where MD can differentiate 
between severity of clinical phenotypes but its role 
in adding to the clinical history need to be carefully 
thought through. For example, if the patient has 
symptoms suggestive of oral allergy syndrome (OAS) 
after eating apple in the context of birch pollen allergy 
then doing SPT to a birch pollen extract or to raw and 
cooked apple is one way to confirm this diagnosis; 
molecular testing to the underlying primary sensitizer 
(e.g. Bet v 1) would be another option. If the patient 
Table 2
Questions and considerations in the evaluation of food allergy
Question Considerations
What is the suspected food allergy? Consider whether the allergen is typical for the patient’s age and 
population
Was the suspected food allergen 
ingested, inhaled or touched?
A proportion of patients have a reaction after inhalation of or contact 
with the allergen
Does the patient have an aversion to 
the suspected food allergen?
Generally patients dislike and refuse food containing the allergen
How soon after exposure to the food 
allergen did the symptoms occur?
IgE-mediated allergic reactions usually occur within 20 minutes and 
certainly within 2 hours
What are the specific symptoms and 
how severe are they?
If the symptoms are not typical of IgE-mediated food allergy, consider a 
differential diagnosis (which may be delayed food allergy). If the symptoms 
are severe an emergency plan and rescue medication will be necessary
How long did it take for the 
symptoms to resolve?
The typical time to symptom resolution after reaction is 4-12 hours
How reproducible are the symptoms 
with previous or subsequent 
ingestion
A patient is unlikely to have a reaction to a food on just a few occasions, 
although reactivity may vary depending on factors such as processing 
and heating and co-factors.
Does exercise precipitate the 
symptoms?
Exercise that precipitates symptoms may suggest a diagnosis such as 
food dependent, exercise-induced anaphylaxis (see chapter B16 on 
wheat dependent, exercise-induced anaphylaxis).
Does the child have early onset 
severe eczema?
Children with early onset severe eczema have an increased risk of IgE-
mediated food allergy, particularly to milk, egg and peanut.
Is the child birch or grass pollen 
allergic?
Children with birch or grass pollen allergy are more likely to demonstrate 
cross-reactivity with legumes, fruits, peanut and tree-nuts leading to 
false positive allergy testing.
See also: Chapter B16 on wheat wheat dependent, exercise induced anaphylaxis
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has more ambiguous symptoms which could suggest 
a more severe clinical phenotype then molecular 
diagnosis to Mal d 1 (PR-10 protein) or Mal d 3 (LTP) 
will contribute significantly to the diagnostic algorithm 
(Fig. 58). This is particularly relevant for apple allergy 
in the case of a patient of Mediterranean origin where 
lipid transfer protein allergy (LTP) is more common. 
This scenario is also relevant for ambiguous histories 
related to raw or roasted hazelnut (see Section B19 
on Tree Nuts and Seeds Allergy) and has important 
implications in management especially regarding the 
prescription of self-injectable adrenaline. Soy allergy is 
often also confusing due to the overlap between OAS 
symptoms versus more significant clinical reactions. 
Previously soy components Gly m 5 and 6 were shown 
to predict more systemic allergic reactions to soy (with 
both positive Gly m 5 and 6 giving an Odds Ratio of 
12 for severe reactions) (26). More recently the 2S 
albumin Gly m 8 was found to be a better marker for 
systemic reactions to soy than Gly m 5 and 6 (and soy 
extract) but it still misclassified many patients (27, 28). 
With MD testing for soya there is also the caveat that 
sole reactivity to the PR-10 protein Gly m 4 has been 
responsible for anaphylaxis following consumption of 
unprocessed soya (29) (see Section B17).
In summary, can add value in cases where there is 
the possibility of clinically irrelevant sensitization 
(for example in children with moderate to severe 
eczema), sensitization due to cross-reactivity (for 
example in birch pollen allergic patients tested for 
peanut allergy) or symptoms consistent with either 
mild allergic phenomenon (OAS) versus potentially 
more severe allergic phenomenon (with LTP or seed 
storage protein allergy).
AT WHICH STAGE IN THE DIAGNOSTIC 
ALGORITHM FOR FOOD ALLERGY DOES 
MOLECULAR DIAGNOSIS PROVIDES THE 
MOST BENEFIT?
The classical top-down approach to testing in a 
patient with suspected food allergy (as discussed in 
section A04) combines extract based testing with 
subsequent targeted allergen specific molecule 
testing. This approach, from ‘symptoms to molecules’ 
provides a pragmatic, yet thorough approach to 
allergy testing in patients with a suspected food 
allergy. A proposed algorithm for the use of molecular 
diagnosis in combination with conventional testing is 
outlined in Fig. 1 and 2. For general recommendations 
about food allergy diagnosis, the reader may also 
refer to the “EAACI Food Allergy Guidelines” (2).
FUTURE PERSPECTIVES IN THE DIAGNOSIS 
AND MANAGEMENT OF FOOD ALLERGY IN 
THE AGE OF MOLECULAR ALLERGOLOGY
Only a small proportion of relevant molecular 
allergens to foods have been fully characterized. 
Such a process should involve:
  thorough technical evaluation (e.g. molecular 
characterization, appropriateness of an isoform, 
stability) of the chosen molecule/component
  scientific information on its analytical 
performance (assay features like analytical 
sensitivity, analytical specificity, potential as a 
marker for serological cross-reactivity or indicator 
for primary, genuine sensitization), and ideally
  additional information on diagnostic-clinical 
performance (diagnostic sensitivity, diagnostic 
specificity, PPV, NPV, etc).
In order to increase the performance characteristics 
of MD full characterization is required particularly 
for seed storage proteins for tree nuts, legumes and 
seeds. As with all diagnostic tests discussed MD 
require validation in large populations both in the 
hospital and at a community level using the double-
blind placebo-controlled food challenge (DBPCFC) 
as the gold standard for validation. The value of 
combination testing using all the tests that have 
been assessed also needs to be validated as has been 
performed for peanut component allergens (8, 9).
MD has become synonymous with sIgE to clinical 
relevant food allergens but it could be used for 
SPT to the relevant allergen or BAT to the relevant 
allergen. Given the benefit of bed-side testing 
towards the running of a one-stop shop allergy clinic 
it would be of great value to have SPTs containing 
the major component allergens. Such SPT materials 
have been commercialized for certain allergens (e.g. 
LTP (Pru p 3), profilin (Pho d 2) and Bet v 1 homologs 
(Mal d 1) (30, 31) but not for seed storage proteins 
such as Ara h 2. Similarly, bed-side molecular allergen 
testing with quantitative assessments would improve 
the diagnostic experience for patients. Results of 
the LEAP study now recommend testing in high risk 
infants to peanut; having bed-side molecular testing 
would greatly improve the diagnostic efficiency and 
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facilitate the decision as to whether peanut can be 
safely introduced into the patient’s diet (32).
A progression of MD could be linear epitope mapping 
which appears to have been useful in certain contexts 
such as determining transient versus persistent egg 
allergy at a research level (33). However, it is unclear 
whether this would be an improvement over MD, 
which relies on the 3 dimensional structure of the 
allergen. There should be emphasis in bringing both 
BAT using molecular allergen and epitope mapping 
assays into clinical practice by validating simple 
methods that could be applied to the laboratory 
equipment already in use to run sIgE tests.
CONCLUSIONS
MD is a very useful adjunct to conventional allergy 
testing with whole allergens (SPT and sIgE testing). 
We are just at the beginning of getting comprehensive 
analysis of all food allergens but already at this early 
stage the fruits of this labour are apparent for primary 
Self-reported IgE-mediated 
allergic symptoms to known food allergen
History and examination
Skin prick test < 3mm* Skin prick test ≥ 3mm
Specific IgE < 0.35kU/L* Specific IgE ≥ 0.35kU/L
Molecular diagnostics Convincing  documented symptoms
Incomplete history  
or atypical history
IgE mediated 
allergy confirmed 
Recommend oral food  
challenge (open or DBPCFC)
food allergies such as peanut allergy and secondary food 
allergies due pollen–food or plant-food syndromes. 
Allergy testing should only be performed in the context 
of the clinical history as history provides the cornerstone 
of diagnosis. Multiple allergy tests (especially in children 
with eczema) often give rise to false positive results 
(this is more the case for sIgE testing to whole allergens 
than SPT to whole allergens) and thus can lead to 
unnecessary avoidance or delay in introduction of 
foods. A ‘molecule to symptom’ approach is therefore 
not recommended as this will lead to confusion and 
potential avoidance of foods to which the child or adult 
is not allergic. However, the progress achieved so far 
is paving the way to exciting developments. A proper 
methodological approach should be implemented any 
time there is a new component allergen / pattern of 
component allergens available for a food. Evaluation 
against conventional allergy testing against whole 
allergens (both SPT and sIgE) as well as validation 
against the gold standard DBPCFC to determine their 
diagnostic performance should be carried out for that 
component allergen before ultimately guidance is put 
in place for daily clinical practice.
Figure 1
Simplified algorithm for diagnostic approach for IgE-mediated allergic symptoms to a known food allergen. 
*Exactly the same algorithm can be used using specific IgE first and SPT second depending on the practice 
of the allergy clinician.
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storage proteins/thaumatins)
Clear differentiation Clear differentiation
OAS confirmed OFC to cooked and raw food (optional)
Figure 2
Algorithm for diagnostic approach for possible OAS / systemic reaction to known food allergen*. 
*The gold standard for the evaluation of food allergy is the double blind placebo controlled food challenge. 
** If no SPT facilities available further differentiation using MD for clinical relevance of other food stuffs 
containing similar proteins Bet v 1-homologs, profilins, thaumatins or LTPs (unlikely given history) may be 
considered.
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Cow milk caseins and whey proteins are type I 
food allergens inducing allergic sensitization via 
gastrointestinal tract.
The majority of cow milk allergic subjects are 
polysensitized to several casein and whey 
proteins.
Natural history is favorable with majority of the 
milk allergic children becoming tolerant with 
age; those with cow milk-specific IgE serum 
levels exceeding 60 kIU/L are more likely to have 
persistent milk allergy.
Extensive heating e.g., baking, affects the 
allergenicity of CM protein, with caseins being 
more resistant to heating compared to whey 
proteins that are susceptible to heating.
Majority of cow milk allergic children can tolerate 
extensively heated (baked) products with milk; 
reactivity to baked milk is a marker of a more 
severe and more persistent cow milk allergy.
ALLERGEN SOURCES
Cow’s milk (CM) is a liquid product of the mammary 
glands of cows (Bos domesticus). It is commonly 
consumed in large quantities by children and adults 
in a liquid form, as well as in a form of various dairy 
products, such as cheeses, butter, yoghurt, and 
cream. CM is a base source for the majority of infant 
formulas, including hypoallergenic hydrolyzed and 
amino acid-based formulas. CM is commonly the first 
protein introduced into the diet of infants who are 
not exclusively breast-fed. CM and dairy products are 
the major source of protein, calories, and calcium in 
a diet of infants and young children under the age of 
2 years. CM proteins are among the most common 
food allergens in infant and children with IgE and 
non-IgE mediated food allergy, and among adults 
with eosinophilic esophagitis. The frequency of CM 
allergy (CMA) has been estimated to range from 
0.5 to 7.5% in westernized countries (1, 2, 3, 4-6). 
Nevertheless, the perceived prevalence of reactions 
to CM milk is much higher than the actual number of 
cases.
CM proteins are classified as class I food allergens, 
due to their resistance to digestion and heating. They 
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do induce sensitization via gastrointestinal tract. 
Proteins in CM have a high sequence homology 
(>80%) with proteins from goat and sheep and are 
highly clinically cross-reactive (>90%) with these 
species. In contrast, the laboratory and clinical cross-
reactivity is very low (<5%) with milks from donkey, 
mare, buffalo, or camel (7).
MAJOR AND RELEVANT MINOR 
ALLERGENIC MOLECULES
CM contains approximately 30 to 35 g of proteins 
per liter. Under the influence of rennin or upon 
acidification of the milk to pH 4.6, proteins segregate 
into 2 fractions: curd (coagulum) which contains 
approximately 80% of the CM proteins and whey 
(lactoserum) which contains approximately 20% 
of the CM proteins (Table 1). All of the proteins 
present in cow’s milk are also present in human 
breast milk, with an exception of beta-lactoglobulin. 
Caseins, beta-lactoglobulin and alpha-lactalbumin 
are considered major allergens, i. e. more than 50% 
of the individuals with CMA are sensitized to these 
proteins. Most of the patients are polysensitized to 
several proteins (8, 9).
Casein supplies amino acids, carbohydrates, and the 
two inorganic elements calcium and phosphorus. 
Casein fraction is very resistant to high temperatures, 
retaining strong IgE binding after 90 minutes of 
boiling at >90°C (10). Except for short alpha-helical 
regions, caseins have little secondary or tertiary 
structure. The caseins of milk exist in the form of 
colloidal complexes called micelles. The micelles 
contain an amorphous micellar calcium phosphate 
core, surrounded by a casein shell (11,12).
Alphas1-casein is the most abundant protein of 
bovine milk. It exists as a major and minor form and is 
highly phosphorylated.
Alphas2-casein is also highly phosphorylated and has 
four isoforms.
Beta-casein has one isoform. Limited hydrolysis of 
beta-casein by endogenous peptides (e.g., plasmin) 
present in milk produces gamma-caseins 1, 2, and 3.
Kappa-casein is the only casein soluble in the 
presence of calcium ions. It also has the smallest 
amount of phosphate, with phosphorylation sites 
being present only in the C-terminal region. Kappa-
casein is the only casein to contain carbohydrate 
moieties.
Whey is a mixture of beta-lactoglobulin (~65%), 
alpha-lactalbumin (~25%), bovine serum albumin 
(~8%) and immunoglobulins (390). These are soluble 
in their native forms, independent of pH. Whey 
proteins are more sensitive to heating than caseins 
and lose IgE binding following 15-20 minutes of 
boiling at >90°C (10).
Alpha-lactalbumin is a protein present in the milk of 
almost all mammals. In primates, alpha-lactalbumin 
expression is upregulated in response to the hormone 
prolactin and increases the production of lactose (5). 
Alpha-lactalbumin forms the regulatory subunit of 
the lactose synthase (LS) heterodimer and beta-1,4-
galactosyltransferase forms the catalytic component. 
Together, these proteins enable LS to produce lactose 
by transferring galactose moieties to glucose. As a 
multimer, alpha-lactalbumin strongly binds calcium 
and zinc ions and may possess bactericidal and / or 
antitumor activity.
Beta-lactoglobulin under physiological conditions 
forms dimers but dissociates to a monomer below pH 
3. Beta-lactoglobulin solutions form gels in various 
conditions, when the native structure is sufficiently 
destabilized to allow aggregation (6). No clear function 
has been identified for beta-lactoglobulin, although it 
binds to several hydrophobic molecules, suggesting 
potential role in their transport. Beta-lactoglobulin is 
the only CM protein that is not present in the human 
breast milk.
Bovine serum albumin (BSA) is a globular, water-
soluble, un-glycosylated serum protein. Albumin 
functions primarily as a carrier protein for steroids, 
fatty acids, and thyroid hormones in the blood and 
plays a major role in stabilizing extracellular fluid 
Figure 1
Casein micelles (from ref 10).
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Table 1
Allergens in Cow’s Milk 
Protein name Allergen name Molecular 
mass (kDa)
AA # Tertiary structure
Curd (coagulum)-Casein family
Caseins Bos d 8 20-30 Caseins don’t have a 
rigid tertiary structure 
but develop a random 
coil conformation 
stabilized by 
hydrophobic interactions
Alpha s1-casein Bos d 9 23.6 199
Alpha s2-casein Bos d 10 25.2 207
Beta-casein Bos d 11 24 209
Kappa-casein Bos d 12 19 169
Whey (lactoserum)
Alpha-
lactalbumin Bos d 4 14.2
123; 4 disulphide bridges, 
70% homology with human 
alpha-lactalbumin
Beta-
lactoglobulin
Protein family:
lipocalins
Bos d 5
18.3; 
exists as a 
dimer
162; 2 disulphide bridges, 
one free cysteine; exist as 
isoforms A and B;  binds and 
carries hydrophobic molecules
Bovine serum 
albumin; 
Family: Serum 
albumins
Bos d 6 67 583
Immunoglobulins 
(mostly IgG)
Family: 
Immunoglobulins
Bos d 7 160
Lactoferrin
Family: 
Transferrins
800
703; forms two homologous 
globular domains named 
N-and C-lobes
Lactoferrin exists in various 
polymeric forms: monomers 
to tetramers
source: IUIS Allergen Database, July 2015
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volume by contributing to oncotic pressure of 
plasma. BSA is highly homologous with human serum 
albumin and albumins of other species, e.g. cow 
(beef), cat, and dog. BSA has been identified as one of 
the major beef allergens and is responsible for clinical 
cross reactivity between CM and raw beef (13-16).
Immunoglobulins present in CM are predominantly 
of the G class. Immunoglobulins may play a role in 
cross-reactivity with beef (14).
Lactoferrin is a multifunctional protein of the 
transferrin family. Lactoferrin is a globular glycoprotein 
with a molecular mass of about 80 kDa that is widely 
represented in various secretory fluids, such as milk, 
saliva, tears, and nasal secretions. Lactoferrin is one 
of the transferrin proteins that transfer iron to the 
cells and control the level of free iron in the blood 
and external secretions. Lactoferrin is one of the 
components of the immune system of the body; it 
has antimicrobial activity (bactericide, fungicide) 
and is part of the innate immune defense, mainly at 
mucosal surfaces. In particular, lactoferrin provides 
antibacterial activity to human infants. Lactoferrin 
interacts with DNA and RNA, polysaccharides and 
heparin. Lactoferrin is a minor allergen in CM (9).
SENSITIZATION TO INDIVIDUAL 
MOLECULES AND ITS CLINICAL RELEVANCE
The patterns of sensitization to the individual CM 
proteins vary significantly by study population 
and age of the affected individuals. In general, the 
majority of the affected subjects are polysensitized 
to several casein and whey proteins (17-20). Caseins, 
beta-lactoglobulin and alpha-lactalbumin are the 
major allergens, with over 50% of CM-allergic 
subjects having evidence of IgE-antibodies directed 
at these proteins. IgE-sensitization to caseins, beta-
lactoglobulin and alpha-lactalbumin is closely related, 
whereas IgE-sensitization to BSA is independent of 
other CM proteins, and may reflect cross-reactivity 
with beef (14) (Table 2).
Natural history of CMA: Molecular diagnosis may 
be useful for monitoring for natural spontaneous) 
tolerance development in CMA (20). In a prospective 
follow up study of 66 infants, lower serum levels of 
casein-IgE were associated with higher chances of 
resolution of CMA (21). In another prospective study 
in which CMA diagnosis was confirmed with DBPCFC 
to CM, children with lower serum levels of specific 
Table 2
Sensitization and cross-reactivity patterns of the CM proteins
Allergen name Allergenicity
Sensitization rate 
% among those 
reactive to CM
Laboratory 
cross-reactivity Clinical cross-reactivity
Curd fraction (coagulum)
Caseins (Bos d 8) Major 63
>85% with sheep 
and goat milk 
caseins
>90% with other 
mammalian milks (27)
20% with mare’s 
milk29 and donkey 
milk 30
Alpha s1-casein (Bos d 9) Major 98 *
Alpha s2-casein (Bos d 10) Major 94 *
Beta-casein (Bos d 11) Major 91 *
Kappa-casein (Bos d12) Major 91 *
Whey fraction (lactoserum)
Alpha-lactalbumin (Bos d 4) Major 51
Beta-lactoglobulin (Bos d 5) Major 61
Bovine serum albumin (Bos d 6) Minor 43 80% with beef 15-20% with raw beef
Immunoglobulins (Bos d 7) Minor 36
Lactoferrin Minor 35
* Percentage of those sensitized to casein Bos d 8
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IgE to CM, alpha-lactalbumin, beta-lactoglobulin, 
kappa-casein and alpha s1 casein had better odds 
of outgrowing CMA over 80 month period (19). On 
an individual epitope levels, children with persistent 
milk allergy have been shown to predominantly 
generate IgE antibodies directed against sequential 
casein epitopes (22-24). IgE epitope-binding patterns 
were stable over time in patients with persisting 
CMA, whereas binding decreased in patients who 
recovered early. Binding patterns of IgE and IgG4 
overlapped. Among patients who recovered early, 
the signal of IgG4 binding increased and that of IgE 
decreased over time. IgE and IgG4 binding to a panel 
of alpha(s1)-, alpha(s2)-, beta-, and kappa-casein 
regions predicted outcome with significant accuracy 
(25).
Effect of heating on CM protein allergenicity
CM proteins contain both conformational and 
sequential IgE-binding epitopes. Children with 
persistent milk allergy have been shown to 
predominantly generate IgE antibodies directed 
against sequential casein epitopes (22-24). Extensive 
heating e.g., baking, affects the allergenicity of CM 
protein, with caseins being more resistant to heating 
compared to whey proteins that are susceptible to 
heating. Heating of beta-lactoglobulin results in 
formation of the intermolecular disulphide bonds 
and binding to other food proteins that result in 
a reduced allergenicity of beta-lactoglobulin (30). 
The majority (70-80%) of the CM-allergic children 
tolerate CM as an ingredient in the baked products 
(31, 32). Reactivity to baked milk is a marker of 
a more severe and more persistent CM allergy. 
Inclusion of the baked products containing CM 
into the diet of children with CM allergy appears to 
accelerate development of tolerance to unheated CM 
(33). High levels of specific IgE antibodies directed 
against casein are predictive of clinical reactivity to 
baked milk (32, 34). In a peptide microarray assay, 
subjects with persistent milk allergy had increased 
epitope diversity to caseins and beta-lactoglobulin 
compared with those who outgrew their CM allergy 
(24, 35). Baked milk-tolerant subjects had IgE-
binding patterns similar to those who had outgrown 
CM allergy, but IgG4-binding patterns that were 
more similar to those of the allergic group. Binding 
to higher numbers of IgE peptides was associated 
with more severe allergic reactions during an oral CM 
challenge. There was no association between IgG4 
peptides and clinical features of milk allergy. Using 
a competitive peptide microarray assay, CM-allergic 
patients had a combination of high- and low-affinity 
IgE binding, whereas baked milk-tolerant subjects 
and those who had outgrown their CM allergy had 
primarily low-affinity binding.
CLINICAL MANAGEMENT
Diagnosis of CM allergy begins with an assessment 
of clinical history and an assessment of the potential 
immunologic mechanism involved in the reactions.
Suspected IgE-mediated CM allergy
Laboratory testing: Routine testing involves skin 
prick (SPT) and/or serologic testing with complete 
CM extract. Molecular diagnosis is not recommended 
for standard evaluation of suspected CM allergy. 
Diagnostic decision points have been proposed; 
they vary by population studied and age. Negative 
SPT and undetectable serum level of CM-specific 
IgE antibodies have a very high negative predictive 
value >90% for IgE-mediated CM allergy. The 
positive predictive value of the test increases with 
an increased size of the wheal of the SPT and serum 
level of the specific CM-IgE antibody (Table 3).
Molecular diagnosis may be helpful for evaluation 
of reactivity to baked milk, based on the differential 
resistance to heating among the CM protein. As 
caseins are more resistant to extensive heating, 
higher levels of casein-specific IgE are associated 
with increased likelihood of reactivity to baked 
milk. Basophil activation test with CM proteins has 
been utilized in a research setting but it is not yet 
recommended for a routine diagnosis of CM allergy 
(32, 36). Several studies indicated that molecular 
diagnosis may be useful for monitoring and predicting 
the resolution of CMA (17, 19, 21, 24, 25).
Not recommended: Testing for CM- specific IgG / 
IgG4 antibodies is not recommended in the diagnosis 
of CM allergy as these antibodies reflect the presence 
of CM in the diet, not an allergy.
Elimination-Challenge testing: In general, the 
conclusive diagnosis of CM allergy requires 
elimination of CM proteins from the diet followed 
by a supervised oral food challenge. Double-blind 
placebo controlled oral food challenge (DBPCFC) 
remains the gold standard for food allergy diagnosis. 
Open controlled challenge can replace DBPCFC 
in the children younger than 2 years of age. The 
initial assessment of reactivity to baked milk is also 
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recommended to be conducted under the physician-
supervised food challenge condition because children 
reactive to baked milk may experience anaphylaxis.
Suspected non IgE-mediated CM allergy
Laboratory testing: There is no reliable laboratory 
diagnostic testing for non-IgE mediated CM allergy (4, 
9). Atopy patch testing may be considered in selected 
cases of Eosinophilic Esophagitis (EoE) but not as a 
routine diagnostic test (4). Lymphocyte transformation 
test, serum CM- specific IgG / IgG4 antibodies, or 
stool measurements of pro-inflammatory mediators 
(e.g., calprotectin, eosinophilic cationic protein, 
eosinophil-derived neurotoxin) are not recommended 
(1). As some non-IgE-mediated disorders may be 
associated with a concomitant IgE-mediated food 
allergy, testing for CM-specific IgE antibodies may 
be utilized in such cases, e.g., EoE and food protein-
induced enterocolitis syndrome (FPIES) to diagnose 
IgE-mediated CM allergy. The ultimate confirmation 
of diagnosis in non-IgE-mediated CM allergy requires 
an elimination of CM proteins from the diet followed 
by an oral CM challenge.
Management of CM allergy
Management relies on dietary avoidance of CM 
proteins. In infants and young children, substituting 
alternative sources of protein, calories, and calcium 
with a specialized hypoallergenic formula may be 
necessary. The alternative formula choices include: 
soy-based, rice hydrolysate, casein-hydrolysate, 
whey-hydrolysate and amino-acid based formulas 
(37).
Nutritional consultation is recommended for 
those with severe form of CM allergy, multiple 
food allergies and poor growth. Education about 
recognition of allergic symptoms and prompt 
treatment of anaphylaxis is crucial in the patients 
at risk for anaphylaxis. As most children outgrow 
CM by school age, periodic re-evaluations every 
6-12 months with laboratory testing and oral food 
challenges are recommended. A drop in the CM level 
by 50% or more over 12-24 months is a favorable 
prognostic indicator of developing tolerance (38). 
Children with peak lifetime CM-IgE >50 kUA/L are 
more likely to retain milk allergy until teenage years 
and may need less frequent testing (39). Introduction 
of baked products with CM should be attempted 
under physician supervision for patients with IgE-
mediated CMA. Baked milk products may be tolerated 
by a subset of patient with EoE (40). It is unknown if 
children with FPIES can tolerate baked milk products 
and therefore strict avoidance is recommended.
Novel therapies for CM allergy
Oral (OIT), sublingual (SLIT) and epicutaneous (EPIT) 
immunotherapy routes have been evaluated for 
CMA with promising results in clinical trials (41). OIT, 
SLIT, and EPIT utilize native CM proteins in a form 
of a CM powder. In a trial comparing CM OIT and 
SLIT, 10% receiving SLIT (maintenance daily dose 7 
mg CM) were desensitized, 60% receiving SLIT/low 
dose OIT (maintenance daily dose 1000 mg CM) 
were desensitized, and 80% receiving SLIT/high dose 
OIT (maintenance daily dose 2000 mg CM) were 
desensitized (42). In general, CM SLIT was associated 
with very mild side effects mostly oro-pharyngeal 
pruritus, whereas CM OIT was associated with more 
systemic side effects, involving gastrointestinal tract 
(nausea, vomiting, abdominal pain, diarrhoea), or 
respiratory system (rhinorrhea, sneezing, congestion, 
cough, wheezing). CM OIT has been associated with 
cases of EoE. More studies are needed to determine 
the potential of inducing permanent oral tolerance to 
milk with CM OIT.
In a small pilot study, after 90 days, CM EPIT treatment 
tended to increase the cumulative tolerated dose, 
from a mean ± SD of 1.77 ± 2.98 mL at day 0 to 
23.61 ± 28.61 mL at day 90 (43). Large international 
clinical trial of CM EPIT is ongoing and will provide 
more evidence regarding safety and efficacy of CM 
EPIT. Molecular diagnosis may be utilized to identify 
subjects at higher risk to experience side effects from 
milk OIT and to monitor evolution of immunologic 
parameters during milk OIT and to correlate it with 
desensitization and tolerance. Children with at high 
risk for adverse reactions to milk OIT recognized a 
statistically significant higher number of IgE peptides 
in caseins at all the time, before and during milk 
OIT (44). IgE binding to CM peptides decreased and 
IgG4 binding increased following the OIT in children 
who attained desensitization (45). Compared with 
children who successfully completed OIT, those who 
discontinued OIT due to adverse reactions developed 
increased quantities and affinity of epitope-specific 
IgE antibodies and a broader diversity of IgE and 
IgG4 binding, but less overlap in IgE and IgG4 binding 
to CM peptides. Thus, detailed analysis of IgE and 
IgG4 binding to CM peptides may help in predicting 
whether CM OIT will be tolerated successfully and 
may thus improve the safety of milk OIT (44, 45).
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Table 3
Proposed specific IgE diagnostic decision points for CM allergy diagnosis derived from 
studies in children, majority of whom had atopic dermatitis. 
OFC to regular [non-heated milk]
SPT to CM, mean wheal diameter (mm) CM-IgE [kUA/L]
Defer
>95% PPV >8 
47 >15 46
> 5 if less than 1 year old 17
Perform
<50% PPV Not done <5
OFC to baked milk
SPT to CM, mean wheal diameter (mm) CM-sIgE [kUA/L]
Defer 
>95% PPV Not done >24.5 
34
Perform
>90 NPV <12 
48 <9.97
SPT to Casein, mean wheal diameter (mm) Casein-sIgE [kUA/L]
Defer 
>95% PPV Not done >10 
34
Perform
>90 NPV <9 
48
<50% PPV <5 34
This might be a practical guidance for the clinical ambulatory setting, aiming to identify the optimal candidates for OFC and 
to limit unnecessary OFC. It is important to recognize that OFC can always be performed at the discretion of the treating 
physician despite the elevated results of the serologic tests. In the research setting, OFC are recommended regardless of 
the sIgE level.
CLINICAL CASES
Case 1
Parents of a 2-year old child with atopic dermatitis 
and history of milk-induced generalized urticaria at 
the age 6 months inquire about the likelihood of their 
child outgrowing milk allergy. There are no additional 
allergic reactions to milk or milk products. Skin prick 
test with a commercial cow milk extract is positive at 
a mean wheal diameter at 10 mm. Serum CM- specific 
IgE antibody level is 17 kIU/L. Based on these results, 
the child has more than 95% chances of reacting to 
liquid milk. However, considering that about 70-80% 
of milk allergic children tolerate milk in the baked 
products, further diagnostic testing is performed. 
Serum specific IgE antibodies directed against casein 
level is 4.5 kIU/L and beta-lactoglobulin IgE is 25 
kIU/L. Based on the level of the casein-specific IgE, 
it is estimated that the likelihood of tolerating baked 
milk products in form of a muffin is approximately 
50%. A physician-supervised oral challenge with 
baked milk in a form of a muffin is performed in the 
office and the child tolerates it without an adverse 
reaction. Baked milk products are incorporated into 
the diet.
Case 2
A 10-year-old asthmatic male has history of severe 
anaphylaxis to trace amounts of milk in a cookie. He 
wants to know what his chances of outgrowing his 
milk allergy are. His CM-IgE is 75 kUA/L, casein IgE 
is 90 kUA/L; SPT to CM extract is 20 mm diameter. 
Based on his past history of anaphylaxis to baked 
milk and the current test results highly predictive of 
clinical reactivity to both baked and unheated milk, 
it is likely that he will remain-milk allergic until his 
teenage years.
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Egg allergy is one of the most frequent food 
allergies in children around the world
The use of egg white components is 
clinically helpful for distinguishing between 
sensitization and clinical allergy
The use of egg white components is 
clinically helpful for distinguishing 
between allergy to cooked and raw egg, or 
exclusively to raw egg
The result of an IgE test can only be 
validated when corresponding to the 
clinical history, if necessary after a 
standardized egg challenge
THE ALLERGEN SOURCES
Hen’s egg is an ubiquitous food eaten in most parts 
of the world. It is a cheap and easily accessible food 
source, used in many home-made dishes, but also 
widely used by the food industry in processed foods.
Individuals are mostly exposed to hen’s egg proteins 
in foods. Nevertheless, hen’s egg proteins can be 
found in aerosolized particles produced by cooking. In 
a clinical report, respiratory symptoms to aerosolized 
egg proteins have been reported in bakery workers 
(1). It can be suspected that these may also contribute 
to primary sensitization to egg, similarly to what has 
been shown for peanut proteins (2).
MAJOR AND RELEVANT MINOR 
ALLERGENIC MOLECULES AND THEIR 
CLINICAL RELEVANCE
Five proteins most commonly involved in allergic 
reactions to hen’s egg have been identified and 
characterized (Gal d 1 to 5, see Table 1). Despite being 
present in a lower quantity in hen’s egg white than 
Philippe A. Eigenmann, Jean-Christoph 
Caubet, and Antonella Muraro
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ovalbumin, it has been shown that ovomucoid is most 
probably the immunodominant hen’s egg allergen (3). 
Among the various physico-chemical characteristics, 
resistance to chemical denaturation has a direct 
clinical significance as structural modification of egg 
allergens can allow safe consumption of cooked/
baked egg containing foods.
CLINICAL RELEVANCE, DIAGNOSIS AND 
MANAGEMENT
According to the IgE sensitivity of a given patient, 3 
different clinical scenarios should be distinguished in a 
patient with a positive test to egg proteins (5, 6).
1.  Sensitized to hen’s egg, but clinically tolerant. 
Can eat all forms of eggs. Such patients will 
present a positive serum IgE test to hen’s egg 
white, in general in a low to mid range value, 
as well as a negative or low serum IgE test to 
ovomucoid.
2.  Allergic to raw, or partially raw eggs only. Tolerant 
to cooked eggs, or processed foods containing 
cooked eggs. These patients will present similarly 
to scenario one, with a positive serum IgE test to 
hen’s egg white, in general in a low to mid range 
value, as well as a negative or low serum IgE test 
to ovomucoid. Serum specific IgE to ovalbumin 
might be elevated in a similar range than the test 
to egg white.
3.  Allergic to all forms of eggs. These patients 
have often serum specific IgE to egg white in 
the middle to upper range. They might also have 
elevated serum specific IgE to ovomucoid and 
well as to ovalbumin.
Case history
The case history is decisive. It needs to be assessed 
if the child has a concomitant atopic disease (e.g. 
atopic eczema), which might predispose to a positive 
test to egg white. If the child has a history of an 
allergic reaction after eating eggs, the history needs 
to specify to which form of egg the child reacted 
(cooked, partially cooked, or raw eggs).
Skin prick testing (SPT)
SPT can be done with commercial egg white extracts 
or with raw eggs. Both have a good accuracy for 
showing IgE sensitization. Extracts of major egg 
allergens (ovomucoid, ovalbumin or others) are not 
commercially available, and are not used in routine 
diagnostic testing. In absence of standardization 
of SPT procedure, cut-off values for prediction of 
clinical reactivity cannot be provided.
IgE-testing
Following tests are commercially available: Egg; Egg 
white; Egg yolk; Ovomucoid (Gal d 1); Ovalbumin (Gal 
d 2); Conalbumin (Gal d 3); Egg lysozyme (Gal d 4)
Egg white IgE testing is in general mostly 
recommended for primary diagnosis of egg allergy 
in children (most common age of sensitization and 
clinical allergy to eggs). In particular, egg white 
extract combines the most common major allergens 
recognized in egg allergy (ovomucoid and ovalbumin) 
and therefore constitutes the most accurate test 
for the initial diagnostic step (7). Egg white specific 
IgE levels have been studied in order to determine 
cut-off values indicative of true clinical egg allergy. 
Nevertheless, the published studies done in patient 
populations of different ages, or with various clinical 
pictures (e.g. presence or absence of eczema) have 
clearly shown cut-off value limitations to populations 
with similar characteristics (8-12). In addition, levels 
of specific IgE to egg white might be indicative of the 
severity of egg allergy.
Molecular diagnosis has been shown to be helpful in a 
more fine-tuned diagnosis of egg allergy, in particular 
for answering the following clinical questions: (1) 
sensitization vs clinical allergy to egg, (2) allergy to 
raw or partially cooked eggs, (3) allergy to all forms of 
egg (raw and cooked).
Major egg 
allergens:
  ovomucoid
  ovalbumin
  ovotransferrin
  egg lysozyme
  livetin
Figure 1
Major egg allergens.
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Table 1
Allergenic molecules of hen’s egg and clinical relevance of specific proteins
Protein name Mr 
(kDa)
protein family biological function(s) Resistance 
to heating 
and chemical 
denaturation
Clinical relevance
Egg White Proteins
ovomucoid 
(Gal d 1)
28 Kazal-type 
serine protease 
inhibitor
serine protease 
inhibition activity
high Heat-stable and highly 
allergenic
Risk for reaction to all 
forms of egg
High levels of specific IgE 
may indicate sustained 
egg allergy
ovalbumin 
(Gal d 2)
45 serine protease 
inhibitor
storage protein? low Heat-labile
Most abundant egg white 
protein
Risk for clinical reaction to 
raw or slightly heated egg 
and certain vaccines
ovotransferrin or 
conalbumin 
Heat-labile
Risk for clinical reaction to 
raw or slightly heated egg
(Gal d 3) 76−77 transferrin iron-binding capacity 
with antimicrobial 
activity
low Risk for clinical reaction to 
raw or slightly heated egg
egg lysozyme 
(Gal d 4)
14.3 glycoside 
hydrolase family 
22
antibacterial activity moderate
ovomucin 165 contains trypsin 
inhibitor-like 
domains
heavily glycosylated 
protein with potent 
antiviral activities
n.a.
Egg Yolk Proteins
phosvitin 35 transferase? metal-chelating agent n.a. n.a.
α-livetin (Gal 
d 5)
65−70 serum albumin bind ions, fatty 
acids, hormones 
in physiological 
conditions
n.a. n.a.
apovitellenins I 9.5 very low density 
lipoprotein
potent lipoprotein 
lipase inhibitor
n.a. n.a.
apovitellenins VI 
(orapoprotein B)
170 unknown lipid-binding activity n.a.
Adapted from (4)
 EAACI Molecular Allergology User´s GuideEAACI Molecular Allergology User´s Guide2016 Part  B:  Using Molecular Al lergology In The Cl inical  Practice 
170 Allergy to Egg
Ando et al. have defined a positive decision point for 
95% diagnostic accuracy for allergy to heated egg at 
10.8 kU/L for ovomucoid (13). In a similar study, but 
with different patient characteristics, we have found 
a cut-off value of 6.9 kU/L with a 95% specificity (14). 
Also in this study, a cut-off of 4.1 kU/L can be used 
for egg white in order to distinguish between allergy 
to all forms of egg, and sensitization in absence of 
allergy. Cut-off differences between different studies 
clearly limit the application of cut-off values to well 
defined patient populations (12).
Similarly, the heat-labile egg white allergen ovalbumin 
can help distinguishing between the various patterns 
of clinical reactivity to egg. We have shown that 
sequential testing starting with IgE measurement to 
egg white, followed by measuring IgE to ovomucoid 
will significantly increase the sensitivity of diagnostic 
testing compared to testing egg white only, although 
with a decrease in specificity (14).
We postulated that egg extracts modified by 
denaturation for mimicking heating of eggs, or egg 
digestion in the gut might provide more accurate 
proteins for clinical diagnosis. For distinguishing 
between egg sensitized subjects and patients allergic 
to all forms of eggs, native egg proteins provide 
reliable extracts for diagnosis as determined by 
ROC curves. For more fine tuned diagnosis, i.e. for 
distinguishing between patients allergic to eggs but 
tolerating cooked egg, denatured egg white or egg 
white allergens might be helpful (14). Nevertheless 
clinical utility of such tests need to be confirmed in 
various other patient populations.
Food challenge tests
Egg can be challenged in an open, or double-blind, 
placebo-controlled way. Patients with subjective 
symptoms or active atopic eczema should preferably 
be challenged with placebo phase. In addition, and 
according to the clinical question, egg might be 
given raw or in a cooked form. Routine testing does 
not include challenges with isolated egg proteins. 
Food challenges are useful in cases with a doubtful 
diagnosis, as well as for the follow-up of food allergy 
(at intervals defined according to the type of food, as 
well as the IgE test results, but not more frequently 
than every 1 to 2 years), in order to determine natural 
tolerance acquisition.
Clinical management
The food avoidance diet should be restricted only to 
the form of egg not tolerated by the patient. All other 
forms should be regularly consumed. The diagnosis 
should aim to properly identify forms of eggs to 
which the patient is tolerant.
Pharmacotherapy
Similarly to other foods, is not available for cure, but 
for treatment of acute symptoms due to accidental 
ingestions.
Immunotherapy
Various studies have shown a clinical efficacy for 
specific oral tolerance induction protocols (SOTI) 
(15). Nevertheless, this procedure is not yet routinely 
applicable.
CLINICAL CASES
Case 1 (original)
History: girl, 8 months old, severe atopic eczema. 
Allergy testing is done for ruling out food allergy 
as a triggering factor of her severe atopic eczema. 
Has never eaten eggs, neither isolated or in 
processed foods.
SPT: Positive to egg white, negative to milk, wheat, 
soy, fish, peanut and hazelnut.
In-vitro testing: Total IgE: 1825 kU/l, specific IgE to 
hen’s egg white: 5.02 kUA/l, ovomucoid: 0.82 kU/L.
Oral challenge: Egg is progressively introduced at 
home in baked goods as well as in pasta with eggs. 
Well tolerated, without immediate reactions or 
flaring of atopic eczema
Diagnosis: Sensitization to egg white in the context 
of moderate atopic eczema.
Recommendation: Continue eggs in cooked form, 
retesting and possibly a food challenge before 
introducing egg in partially cooked or raw forms.
Case 2 (original)
History: girl, 13 months old, in good health. Eats 
cooked eggs, either isolated or in processed foods 
without any symptoms since 8 months of age. Is 
given for the first time a chocolate mousse made 
with raw beaten egg white. Present within minutes 
a facial rash spreading to the upper thorax, a dry 
cough and several episodes of sneezing. The 
symptoms rapidly disappear after administration 
of an oral antihistamine.
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SPT: Positive to egg white.
In-vitro testing: specific IgE to hen’s egg white 3.65 
kUA/l, ovomucoid 0.78 kU/L. Interpretation: a 
low ovomucoid allergen-specific IgE (relative to 
the specific IgE to hen´s egg white) is indicative of 
probable tolerance to cooked eggs.
Diagnosis: Allergy to raw eggs only.
Recommendation: Eggs well tolerated in baked 
goods or hard boiled can be eaten. Elimination diet 
of incompletely cooked, or raw eggs in any form. 
Follow-up at 2 years of age with measurement of 
sIgE to egg white and ovomucoid, assess clinical 
reactivity with oral food challenge if there is a 
reasonable chance of tolerance acquisition.
Case 3 (original)
History: boy, 9 months old, history of moderate 
atopic eczema. Eats for the first time a hardboiled 
egg. Present within minutes a urticarial rash over 
the thorax, followed by an episode of vomiting. The 
symptoms rapidly disappear after administration 
of an oral antihistamine.
SPT: Positive to egg white.
In-vitro testing: specific IgE to hen’s egg white 18.23 
kUA/l, ovomucoid 8.56 kU/L.
Interpretation: a high ovomucoid-specific IgE 
concentration is indicative of probable allergy to 
all forms of eggs.
Diagnosis: Allergy to all forms of egg.
Recommendation: Eggs in all forms and foods 
containing eggs need to be avoided. Follow-up at 
2 years of age with measurement of sIgE to egg 
white and ovomucoid, assess clinical reactivity with 
oral food challenge first to cooked egg if there is 
a reasonable chance of tolerance acquisition. Not 
completely cooked eggs and raw egg will probably 
need to be continued to be avoided
CONCLUSION
At the present stage, the measurement of serum IgE 
or skin prick testing to egg white should represent 
the first diagnostic test which should be available 
also to primary care physician. Using tests with egg 
white components is most helpful for fine tuning 
of the diagnosis in order to define tolerance or not 
to cooked eggs, and the follow-up of egg allergy. 
Nevertheless, the use of these tests is still subject of 
research and their interpretation might be subjected 
to knowledge by the allergy specialist. The definite 
diagnosis should always be done in relation to the 
clinical outcome, if necessary by a standardized food 
challenge. For general recommendations about food 
allergy diagnosis, the reader might also refer to the 
“EAACI Food Allergy Guidelines” (16).
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Fish species may differ by their allergenic 
potency.
Allergy can be elicited by proteins present in 
fish muscle, roe, skin or blood.
Allergens from fish and shellfish (e.g. 
crustaceans, molluscs) are not the same.
Less than 1 % of the general population 
suffer from a fish allergy.
Parvalbumin is the major fish allergen 
(prevalence rates 70-95 %).
Most patients have sIgE to new fish 
allergens, enolases and aldolases.
THE ALLERGEN SOURCES
Fish together with egg, milk and crustaceans 
represent the animal kingdom in the “big eight” 
group of food allergens, to which the majority of food 
allergic patients reacts. As fish is both an important 
food component and a potent source of food 
allergens, fish has been included in the European 
Union regulation of food labelling (1).
Despite the broad biodiversity among fishes 
(more than 30,000 individual species have been 
described), the most frequently consumed species 
belong to a limited number of orders, the salmon-
like (Salmoniformes), cod-like (Gadiformes), perch-
like (Perciformes), herring-like (Clupeiformes), carp-
like (Cypriniformes), catfish-like (Siluriformes) and 
platfishes (Pleuronectiformes) (Fig. 1).
Globally, a much higher number of fish species is 
commercially available (2). The market share of these 
species varies in different countries according to 
regional availability and eating habits. While cod and 
salmon are important food fishes in Europe, other 
low-value freshwater species are popular in Asia (e.g. 
grass carp and Asian carp). Fish allergens have been 
described in around 40 species but detailed analysis 
Lars K. Poulsen, Martine Morisset, Annette 
Kuehn
ALLERGY
TO FISH 
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of the allergy-eliciting molecules was performed 
mainly for fish which are commonly consumed in 
Europe such as carp, cod, salmon, trout and tuna. A 
large and clinically relevant cross-reactivity seems to 
exist between parvalbumins of different fish species 
(see chapter ‘Parvalbumins’). This has probably 
limited the research and willingness to experiment 
with other species for both patients and doctors.
The following fish products can be elicitors of severe 
allergic reactions in sensitized patients.
  Fish meat - The largest allergenic activity resides 
in the muscle of the fish (2). Fish is consumed as a 
cooked, fried, pickled or raw food product. Food 
processing does not seem to affect the allergenic 
potency of the fish but rather the allergen 
content which varies in different species (3). 
Parvalbumins are the major fish allergens. With 
a serving size of 200 g carp or herring filet, the 
consumer ingests up to 1 g of parvalbumin per 
meal. Other fish allergens present in the muscle 
are enolases and aldolases. As a food ingredient, 
fish has to be listed specifically on a product label 
regardless of the percentage of content.
  Eggs, roe, caviar - There are case reports that 
caviar has elicited allergic reactions (4). Typically, 
roe is consumed in its raw form. Vitellogenin has 
been identified as an important fish egg allergen. 
This protein and its metabolites represent nearly 
the total protein content of roe. The knowledge 
about fish egg allergens is still limited. However, 
parvalbumins are not present in fish eggs.
  Fish gelatin, isinglass and similar products - 
Recently, concern has been raised as to whether 
fish-derived products such as fish gelatin 
may contain allergenic activity. Fish gelatin, 
hydrolysed collagen, is made from fish skins 
and bones (5). Isinglass is derived from fish 
swim bladders and mainly contains collagen. 
Food (beverages, candy), pharmaceutical (gel 
capsules and coatings) or biological (vaccines, 
sublingual immunotherapy) products may 
contain these ingredients. Allergenicity might 
be inherent to collagen-like products or it might 
stem from contaminations by fish meat residues. 
Consumers are not aware of these fish-derived 
food ingredients as they are exempted from the 
food labelling regulation.
  Fish blood - Fish hemin (fish blood) or individual 
blood proteins have been used by the food 
industry as additives or processing aids but they 
seem to be relevant as an allergen source only in 
the fish-processing environment. Occupational 
asthma has been linked to the aerosolization of 
blood-derived allergens during processing of fish. 
Serum albumin has been suggested as a potential 
allergen but this could not be confirmed so far.
Figure 1
Most important food fishes are members of seven taxonomic orders.
Bony fishes
Salmoniformes Gadiformes Perciformes Clupeiformes Cypriniformes Siluriformes Pleuronectiformes
Salmon Cod Tuna Herring Carp Pangasius Sole
Trout Hake Mackerel Pilchard Anchovy Catfish Whiff
Char Pollock Barramundi
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The term seafood comprises both fish and shellfish 
(e.g. shrimps, crabs, lobsters, mussels, oysters, 
octopus, squid). Considering the large phylogenetic 
distance between fish and these other organisms it 
is not surprising that little cross-reactivity occurs. 
Therefore, seafood other than fish as allergenic food 
will not be discussed further in the context of this 
chapter (see Section B13).
An increasing number of studies reports on IgE-
mediated allergy which is caused by the parasite 
Anisakis simplex found in contaminated raw or 
undercooked fish (6). Since it is not a proper fish 
allergen, it will not be discussed further in this chapter. 
However, it is important to keep it in consideration 
when diagnosing patients experiencing allergic 
reactions following the ingestion of fish.
PARVALBUMIN AND MINOR ALLERGENIC 
MOLECULES
A search in the WHO/IUIS database reveals currently 
29 entries while the database Allergen Online (www.
allergenonline.org, version 15) comprises 65 fish 
allergens of known sequence. Nineteen and 55, 
respectively, of these belong to the parvalbumin family 
(Table 1). The others are enolases (n=4), aldolases 
(n=4), tropomyosin (n=1) and vitellogenin from salmon 
roe (n=1). These are discussed further below.
  Fish meat - The dominating major allergen in 
fish muscle is parvalbumin of which the codfish 
Gad c 1 was the first to be identified (see chapter 
‘Parvalbumins’) (2). Subsequently, studies were 
performed with a number of homologous proteins 
such as Gad m 1 from Atlantic cod, Cyp c 1 from 
Common carp and Sal s 1 from Atlantic salmon 
(Fig. 2). Parvalbumins are small muscle proteins 
(10-12 kDa) of remarkable stability towards 
physicochemical effects by food processing. 
During fish preparation, they can even become 
airborne. Because of specific characteristics of 
their protein structure, these calcium-binding 
allergens belong to the so-called EF-hand family 
(Fig. 3) (7). Parvalbumin levels vary considerably 
in different fish tissues and species (3, 8). Carp 
and herring muscle contain about 100-times 
more parvalbumin than mackerel and tuna. Most 
fish-allergic patients have specific IgE to these 
allergens (Table 1). Highly conserved parvalbumin 
epitopes have been used to explain not only IgE- 
Figure 2
Most important allergens from Atlantic salmon 
muscle and fish roe.
Figure 3
Protein structure of parvalbumin Cyp c 1 from 
carp (pdb 4CPV). Two EF-hand motifs each bind 
a Ca2+-ion.
Sal s 1
Sal s 2
Sal s 3
Onc k 1
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Table 1
Major and relevant minor fish allergenic molecules
Order English name (Species) Allergenic molecule
Biochemical 
name
IUIS rec-
ognized
Preva-
lence (%)
MW 
(kDa)
Clupeiformes
Herring (Clupea harengus) Clu h 1 parvalbumin X 45 12
Pilchard (Sardinops sagax) Sar sa 1 parvalbumin X 80 12
Cypriniformes Carp (Cyprinus carpio) Cyp c 1 parvalbumin X 100 12
Gadiformes
Baltic cod (Gadus callarias) Gad c 1 parvalbumin X 100 12
Atlantic cod (Gadus morhua)
Gad m 1 parvalbumin X 100 12
Gad m 2 enolase X 56 50
Gad m 3 aldolase X 37 40
Perciformes Tuna (Thunnus albacares)
Thu a 1 parvalbumin X 95 11
Thu a 2 enolase X 19 50
Thu a 3 aldolase X 13 40
Pleuronecti-
formes
Megrim, whiff (Lepidorhombus 
whiffiagonis) Lep w 1 parvalbumin X 100 11.5
Salmoni-
formes
Pacific salmon (Oncorhynchus keta) Onc k 5 vitellogenin X nd 18
Rainbow trout (Oncorhynchus mykiss) Onc m 1 parvalbumin X 95 12
Salmon (Salmo salar)
Sal s 1 parvalbumin X 64 12
Sal s 2 enolase X 24 50
Sal s 3 aldolase X 16 40
Scorpaeni-
formes Redfish (Sebastes marinus) Seb m 1 parvalbumin X 95 11
Other parvalbumins: Sco s 1 (mackerel), Sol so 1 (sole), Lat c 1 (barramundi), Xip g 1 (swordfish); nd, not determined.
but also clinical cross-reactivity among various 
fish species. More recently, new fish allergens 
were identified, namely 50 kDa-enolases and 
40 kDa-aldolases from cod, salmon and tuna (9). 
These glycolytic enzymes are highly expressed in 
the fish muscle. Their potency as food allergens 
still needs to be defined as they are less stable 
than parvalbumins. However, a considerable 
number of fish-allergic subjects seem to have IgE 
against these allergens (Table 1). In-vitro cross-
reactivity has been reported for homologues 
from cod, salmon and tuna.
  Fish gelatin - Collagen consists of three individual 
polypeptide chains corresponding to two alpha-
subunits (α1, α2; each 110 kDa) and one beta-
subunit (210 kDa). These chains are wound around 
one another in a confirmation of a triple helix. 
Fish gelatin is a heterogeneous product, which is 
obtained from acidic acid extraction of collagen 
followed by chemical hydrolysis. According to the 
molecular weight of fish gelatin components, it 
is available at different hydrolysation grades. The 
allergenic potency of fish gelatin is not yet well 
understood. IgE-binding to fish collagen has been 
shown using sera from fish-allergic patients. 
Skin testing was positive in two studies (10, 
11). Severe anaphylaxis has been only reported 
in a single patient following ingestion of several 
grams of fish gelatin (12). Fish gelatin differs 
considerably by its amino acid composition from 
their mammalian counterparts so that there is no 
cross-reactivity among these molecules.
  Eggs, roe, caviar - The allergens of roe are different 
from those of fish meat. Patients with roe allergy 
often tolerate fish meat and vice versa. Vitellogenins 
are glycolipoproteins of high molecular weight 
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(>150 kDa) belonging to the family of lipid-
transport proteins. Studies of allergens from 
salmonid roe have led to the identification of a 35 
kDa vitellogenin fragment consisting of two partly 
identical subunits (18 and 16 kDa) named Onc k 5 
(Fig. 2) (13). Cross-reactivity has been proven for 
roe allergens from different fish species by IgE- 
and skin testing. However, no cross-reactivity was 
found to homologues from chicken egg yolk.
SENSITIZATION TO INDIVIDUAL 
MOLECULES AND ITS CLINICAL RELEVANCE
So far, epidemiological studies on fish allergy are 
missing to present consistent data of sensitization to 
fish and fish allergens. Prevalence rates to fish have 
been determined in studies of variable design and 
methodology (2, 14, 15). Overall, it seems that less 
than 1 % of the global population is affected by allergy 
to fish. A higher percentage is observed in paediatric 
cohorts (up to 10 %) and in countries with long coast 
lines which have a high fish consumption as well as in 
regions with fish-processing industries (up to 3 %) (2). 
Patients get sensitized to fish not only upon ingestion 
but also by skin contact and inhalation of fish steam 
during processing of this food. Occupational asthma 
has been reported in 7-36 % of workers in industrial 
fish production lines.
Parvalbumins have been defined as the panallergens 
in fish. Sensitization rates for parvalbumins were 
determined based on studies during allergen 
characterization (2, 16-18). It was concluded that 90-
95% of the patients had specific IgE to these muscle 
proteins. Recent studies showed that the fish-allergic 
population might be subdivided into the following 
clinical clusters, (i) highly sensitized patients reacting to 
all fish, (ii) oligo-sensitized patients reacting to several, 
specific fishes, and (iii) patients with ‘selective reactions’ 
to individual fish species only (9, 19, 20). Patients of these 
clinical clusters vary by their IgE-recognition profiles. 
It was shown that the prevalence of IgE-binding to 
parvalbumin was lower than assumed. The sensitization 
rate to this major allergen might be rather around 70 %, 
which would need to be confirmed in future studies. 
A single study demonstrated that fish-allergic patients 
with specific IgE to cod parvalbumin might be co-
sensitized to cod enolases (81 %) and aldolases (58 %). 
The clinical origin and relevance of this co-sensitization 
is not yet resolved. However, specific parvalbumin-
negative patients seem to develop IgE-antibodies to fish 
enolase (47 %) and aldolase (41 %) which is rather linked 
to species-specific fish allergies (20).
It is important to note that there are still limited data 
available to delineate how many patients can be 
categorized in each proposed clinical cluster. Also, it 
has to be taken into consideration that a geographical 
and/or a temporal gradient might be relevant for such 
a prevalence data collection.
CLINICAL MANAGEMENT
Diagnosis is mostly based on clinical history, skin tests 
and IgE tests, followed (if needed) by a an oral food 
challenge (ideally, double-blind placebo-controlled 
challenge) with the fish that has elicited the reaction 
(15, 21). Level of serum IgE antibodies have been 
correlated with the clinical reactivity to predict 
allergy to fish. In a US population, a diagnostic serum 
IgE level of 20 kUA/L to cod (ImmunoCAP, Thermo 
Fisher) has been established to predict an allergy to 
this fish with 95 % certainty (22). However, clinical 
reactions have been indicated for patients with much 
lower IgE-titers. Therefore, the significance of this 
diagnostic indicator using fish extract is doubtful and 
needs to be further evaluated.
The availability of individual allergens for IgE-testing 
is still limited and thus, not of much help in predicting 
whether the patient is allergic to other fish species. 
However, an outline of the future diagnosis using 
single allergens is presented in the ‘Clinical cases’ and 
in the chapter ‘Parvalbumins’.
Two important questions should be addressed if the 
initial suspicion of fish allergy is confirmed by the 
challenge procedure (Fig. 4): first, how sensitive is 
the patient? This can normally be deduced from the 
titrated challenge procedure, and the patient should 
be advised for future dietary precautions based on 
his or her individual threshold.
The second question relates to the degree of cross-
reactivity between fish species (Fig. 5). If the patient 
reacts with IgE of similar magnitude and reacts to a 
parvalbumin it is likely that there is a broad cross-
reactivity. If the sensitization pattern suggests a more 
“selective” reaction to a single fish species, an open 
challenge may be tried to confirm this tolerance.
History of exposure
As for diagnosis of fish-allergic patients, it should be 
remembered that most people are aware of ingesting 
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fish, and thus the patient history is often quite reliable 
as for the exposure (which does of course not exclude 
other ingredients in a meal). While probably extremely 
rare, there are examples of patients - mentioned 
above - reacting to fish allergens that are hidden in 
foods (23). It is obviously difficult to demonstrate 
a 100% safety level, but a number of studies have 
suggested that some fish-derived food additives 
seem to have a quite low risk of causing reactions in 
previously sensitized fish-allergic persons.
Figure 4
Diagnostic algorithm in patients with suspected fish allergy.
Figure 5
Diagnostic algorithm in patients with suspected allergy to single or specific fishes.
+
Case history: Immediate reaction after potential consumption of fish (product)
Regular consumption of fish or recent exposure without symptoms
Skin prick test and/or IgE to fish extracts (cod, salmon, 
suspected species) and Gad c 1 
Oral challenge with fish
Fish allergy unlikely - 
may be confirmed by 
open challenge
Fish allergy confirmed
Fish allergy unlikely: 
test IgE to Anisakis 
extract and Ani s 1
+_
_
No Yes
Case history: Immediate reaction after consumption of SPECIFIC fish
Regular consumption of ANOTHER fish species or recent exposure without symptoms
Skin prick test and/or IgE of similar result/level 
as with suspected fish species
Clinical cross-reaction 
unlikely – consider 
open challenge
Clinical cross-reaction 
highly probable – 
exclude by challenge
Clinical cross-reaction 
unlikely - test also for 
Anisakis allergy
Yes No
YesNo
Quantitative risk assessment
As relating to the dose of fish producing food allergic 
symptoms only data for fish meat are available in the 
published literature. According to the literature the 
lowest provoking dose of fish is in the low milligram 
range (24). A larger population was tested in the 
EuroPrevall project, an EU-funded project addressing 
the prevalence, cost and basis of food allergy across 
Europe, and an ED10 of 27.3 mg of protein was 
found (25).
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Other risk factors
It is important to notice that parvalbumins, the 
major fish allergens, are extremely heat-stable (26). 
Thus, their allergenicity cannot be expected to be 
reduced by food processing. However, its proteolytic 
resistance seem to be less, e.g. to pepsin at low pH 
(27). Accordingly, maintenance of a well-functioning 
digestive system with low ventricular pH may be of 
importance for avoiding fish allergy (28).
CLINICAL CASES
Most cases of fish allergy present with classical 
food allergic symptoms short after intake of fish. 
Symptoms may include oral allergy syndrome, 
rhinitis/conjunctivitis, bronchospasm, urticaria, 
gastro-intestinal symptoms and anaphylaxis.
Case 1 (published (9))
Clinical History: A woman, 21 years, with a clinical 
history of fish allergy presenting with angioedema 
and urticaria after eating fish (cod, salmon, herring) 
at several episodes.
Test with extracts: Skin testing was positive for cod 
and pollock extract. Specific IgE were positive for 
cod extract (7.3 kUA/L), salmon (5.7 kUA/L) and 
tuna (3.5 kUA/L).
Food challenge: The patient refused a food challenge.
Test with molecules: Specific IgE were found for cod, 
carp, salmon and tuna parvalbumins (5.0 kUA/L, 
45.0 kUA/L, 5.1 kUA/L and 5.3 kUA/L, respectively).
Conclusion: In this case, the clinical cross-reactivity 
to several fishes was confirmed by the detection 
of specific IgE to fish allergens Gad m 1, Cyp c 1, 
Sal s 1, and Thu a 1 (Fig. 6).
Case 2 (published (20))
Clinical History: A male child, 10 years, with a clinical 
history of fish allergy presenting with swelling 
of the lips and tongue, throat discomfort and 
conjunctivitis after eating cod.
Test with extracts: Skin testing was positive for cod 
extract only. Specific IgE were positive for cod 
extract (0.4 kUA/L) but negative for other extracts 
(salmon, tuna).
Food challenge: The parents of the child refused a 
food challenge.
Test with molecules: Cod, salmon and tuna 
parvalbumins were negative in IgE ELISA. Only 
new cod allergens, enolase and aldolase were 
positive (Gad m 2, 0.5 kUA/L; Gad m 3, 0.4 kUA/L). 
No cross-inhibition was performed because IgE-
testing was negative for other fish parvalbumins.
Conclusion: In this case, the monosensitivity to cod 
was confirmed by the detection of specific IgE 
recognizing the newly identified allergens Gad m 
2 and Gad m 3 (Fig. 7).
Figure 6
Diagnostic procedure Case 1.
Cod extract 
Gad m 1 +
Gad m 1 –
Gad m 2, Gad m 3 +
Potentially cross-/ 
co-sensitization to other fishes
Primary sensitization and 
clinical monosensitivity to cod
Cyp c 1, Sal s 1 + Allergy to various fishes
Cod extract 
Gad m 1 +
Gad m 1 –
Gad m 2, Gad m 3 +
Potentially cross-/ 
co-sensitization to other fishes
Primary sensitization and
clinical monosensitivity to cod
Cyp c 1, Sal s 1, Thu a 1 + Allergy to various 
fishes
Figure 7
Diagnostic procedure Case 2.
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Over 2% of the world population are affected 
by allergy to shellfish (crustaceans and 
molluscs), with one of the highest rates of 
food-induced anaphylaxis.
Food allergy to shellfish may cause cross-
sensitisation and clinical reactivity to dust 
mites, insects and arachnids.
The major shellfish allergens are highly heat-
stable proteins, which also cause inhalational 
exposure and sensitisation among workers 
in the shellfish processing industry leading 
to asthma and subsequently food-induced 
allergy.
THE ALLERGEN SOURCES
The shellfish group is included among the “Big Eight” 
food groups, which are responsible for more than 
90% of all food allergy cases. In general, 2% of the 
population are affected by food allergy to shellfish, 
including the crustacean and mollusk groups. Shellfish 
allergy, particularly to prawns, has one of the highest 
rates of food-induced anaphylaxis with nearly 42% 
among affected adults and 12% in children (1). It is 
noteworthy that although shellfish, along with fish 
are commonly termed as seafood, these two groups 
are very distinct in evolutionary terms and contain 
different molecular repertoires of food allergens. 
All shellfish species are invertebrate animals, in 
comparison to fish, which are lower vertebrates. 
Comparing evolutionary distance, crustaceans are 
placed closer to insects and arachnids, and this 
seems to be the major factor for molecular cross-
sensitization and clinical cross-reactivity between 
crustacean, house dust-mites and insects.
Edible shellfish consists of more than 300 different 
species. These should be further grouped into 
crustaceans (prawns, crabs, lobsters, krill etc.) and 
mollusks (mussels, oysters, abalone, squid, octopus, 
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snail, limpets etc.). This classification is important 
from the clinical and immunological cross-reactivity 
point-of-view. The allergenic proteins present in these 
shellfish species have variable primary structures and 
often present a challenge in allergen detection as 
well as accurate allergy diagnosis and management. 
In addition, the availability and consumption of 
different shellfish species varies to a high degree in 
different parts of the world.
Shellfish are a rich source of proteins and omega-3 
fatty acids. An increased awareness of the nutritional 
value has resulted in increased consumption of 
shellfish, and this has been accompanied by more 
frequent reporting of allergic health problems. The 
following types of consumption and exposure can be 
potent elicitors of severe allergic reactions to shellfish.
A)  Fresh and cooked meat – Allergenic proteins are 
found in high concentrations in the edible muscle 
regions of the shellfish. In crustaceans, it is found 
in the abdominal, tail and pincer meat. Food 
processing methods such as thermal or pressure 
treatment does not seem to destroy most of the 
allergens, but may enhance their allergenic activity 
(2, 3). The tropomyosin family represent the major 
heat-stable allergen present in all shellfish species, 
and may constitute up to 20% of the total protein 
content. For food safety, products containing 
shellfish have to be indicated on the label. Moreover, 
the European Union has mandated separate food 
allergen labelling for crustaceans and mollusks, 
however appropriate tests for mollusks are not 
yet available (4). A recent study has demonstrated 
that at least 0.1-1.0 g of meat has to be ingested to 
trigger an allergic response (5).
B)  Food additives – Shellfish products such as 
dried shrimp or shrimp paste are widely used 
as flavouring agents in various packaged and 
processed food products such as instant noodles 
and soups. This may be a potential source and 
cause of accidental consumption and exposure to 
shellfish allergens (see Table 1 for food products 
indicating the presence of shellfish groups).
C)  Occupational exposure – In the seafood industry, 
workers are constantly exposed to air-borne 
Figure 1
Classification of crustacean and mollusk species, comprising the shellfish group.
Invertebrates
Shellfish
Crustaceans (Arthropods) Mollusks
Prawn Crab Lobster Bivalve Gastropod Cephalopod
Squid (calamari)
(Sepioteuthis 
lessoniana)
Green mussel
(Perna viridis)
Snail
(Helix aspersa)
Brown prawn
(Penaeus aztecus)
King crab
(Paralithodes 
camtschaticus)
American lobster
(Homarus  
americanus)
Octopus
(Octopus australis)
Scallop
(Pecten fumatus)
Abalone
(Haliotis rubra)
Black tiger prawn
(Penaeus monodon)
Mud crab
(Scylla serrata)
Southern rock lobster
(Jasus edwardsii)
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shellfish particulate matter arising from different 
processing activities that results in the inhalation 
of air-borne allergens and cooking fumes (6). Such 
occupational exposure to shellfish allergens elicit 
upper and lower respiratory tract symptoms such 
as asthma, rhinitis and even result in skin symptoms 
(7). Workers with occupational asthma have been 
shown to develop ingestion induced food allergies 
to the same shellfish species.
D) Fish parasites –The food-borne parasite 
Anisakis or herring worm is an important food 
allergen. Anisakis is a parasitic nematode which 
mainly infects fish, but has also been reported 
for crustacean and squid, and the ingestion 
of contaminated fish or shellfish can result in 
severe allergic reactions (8). More importantly, 
the tropomyosin family of allergens are thought 
to be primarily responsible for cross-reactivity 
between anisakis and other invertebrates such 
as insects, mites and crustaceans. However, it 
is difficult to estimate the prevalence data of 
anisakis and shellfish cross-reactivity due to the 
lack of population-based studies.
MAJOR AND RELEVANT MINOR 
ALLERGENIC MOLECULES
At least 6 shellfish allergens have been identified 
displaying mainly metabolic or structural functions. 
They belong to diverse protein families characterized 
by conserved three-dimensional structures leading 
to possible broad immunochemical IgE mediated 
cross-reactions among different members of the 
crustacean or mollusk group. Due to complexity and 
heterogeneity of proteins among crustaceans and 
mollusks the relationship between their structure 
and subsequent allergenicity has only partly been 
addressed. In the past, mainly tropomyosin from 
many crustacean and few mollusks had been 
characterized in detail. In the past 10 years five 
additional allergenic proteins have been identified 
to induce IgE-mediated hypersensitivity through 
ingestion and inhalation and are officially accepted 
by the IUIS Allergen Nomenclature Sub-Committee 
(Table 2 and 4). The major allergen, tropomyosin was 
first identified in 1993 as the major shrimp allergen 
(9). Subsequently, arginine kinase (10) myosin light 
chain (11) and sarcoplasmic calcium binding protein 
(12) were identified as minor crustacean allergens.
SENSITIZATION TO INDIVIDUAL 
MOLECULES AND ITS CLINICAL RELEVANCE
Epidemiology and sensitization/cross reactivity 
rates
Previous sensitization rates were mainly based on 
skin or IgE testing to whole shellfish extracts (13, 14). 
Previous studies have identified the prevalence of 
shellfish allergy to be 2% for the general population 
and 0.1%-0.9% for children (15-17).
Allergen-specific IgE sensitization to various shellfish 
allergens have been demonstrated (Table 4). On an 
average, 60% of individuals with confirmed allergy to 
shellfish elicit specific IgE binding to tropomyosin. More 
importantly, it has been demonstrated that serum-
specific IgE to tropomyosin is a better predictor of 
shrimp allergy than shrimp SPT or IgE to whole shrimp 
extract. Tropomyosin (Pen m 1) and sarcoplasmic 
calcium binding protein (Pen m 4) sensitization has been 
associated with clinical reactivity to shrimp allergy (18).
Notably, conclusions on true sensitization rates are 
hampered due to the highly cross-reactive nature 
of some shellfish allergens. The allergen group of 
tropomyosin among the crustacean group seems to 
demonstrate very strong clinical cross-reactivity (Fig. 
3), possible due to the high amino acid homology with 
Table 1
List of ingredients, which may contain Crustacean 
or Mollusk proteins
Crustaceans species that may be included as food 
ingredients
Barnacle, Crab, Crawfish, Krill, Lobster, Moreton bay 
bugs, Prawns, Shrimp (Crevette, Scampi)
Mollusk species that may be included as food 
ingredients
Abalone, Clam, Cockle, Cuttlefish, Limpet, Mussel, 
Octopus, Oyster, Periwinkle, Sea cucumber, Sea 
urchin, Scallop, Snail, Squid (calamari), Whelk
Food preparations that may contain shellfish
Bouillabaisse, Cuttlefish Ink, Glucosamine, Fish 
stock, Seafood flavouring, Surimi, Condiments and 
spices, Fish stock (shells of shrimp), Clam broth 
base powder, Crab extract powder, Shrimp powder, 
Scallop extract powder, Oyster juice powder, Lobster 
extract powder
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Figure 2
Three dimensional ribbon models of major and minor shellfish allergens in native conformation.
Figure 3
Clinically relevant cross-reactivity between shellfish and invertebrate allergens.
Tropomyosin
(dimeric, coiled coil)
Arginine kinase
(monomeric)
Myosin light chain
(monomeric)
Sarcoplasmic calcium binding 
protein (dimeric)
Troponin C 
(dimeric)
Myosin light chain
(monomeric)
Pen m 1
Cha f 1
Hom a 1
Der p 10
Fer f 10
Ani s 3
Top p 1
Hel as 1
Per v 1
Parasites
(Nematodes)
Mollusks
Crustaceans
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Table 2
Allergenic molecules present in crustacean species
Species frequently 
implicated
Allergen name 
(IUIS)
Biochemical 
name
Molecular 
weight kDa
Heat 
stability
Physiological 
function
Route of 
exposure
Penaeus monodon 
(Black tiger prawn)
Cha f 1, Cra c 
1, Hom a 1, Lit 
v 1, Mel l 1
Tropomyosin 34-38
Highly 
heat 
stable
Muscle 
contraction
Ingestion
Inhalation
Litopenaeus vannamei 
(White leg shrimp)
Met e 1, Pan b 1, 
Pen m 1, Por p 1
Penaeus aztecus 
(Brown shrimp)
Cra c 2, Lit v 2, 
Pen m 2 Arginine kinase 40-45 Stable 
Energy metabolism 
in muscles
Ingestion
Inhalation
Homarusamericanus 
(American lobster)
Hom a 3, Lit v 
3, Pen m 3
Myosin light 
chain 17-20 Stable
Muscle 
contraction Ingestion
Crangoncrangon 
(Sand shrimp)
Cra c 4, Lit v 4, 
Pen m 4, Pon 
I 4
Sarcoplasmic 
calcium binding 
protein
20-25 Stable Muscle contrac-tion regulation Ingestion
Charybdis feriatus 
(Crucifix crab)
Cra c 6, Hom a 
6, Pen m 6 Troponin C 20-21 Unknown
Calcium depen-
dent activation of 
muscle contraction
Ingestion
Portunuspelagicus 
(Blueswimmer crab) Arc s 8, Cra c 8
Triose-Phosphate 
isomerase 28 Labile
Glycolysis (energy 
metabolism)
Ingestion
Inhalation
Registered allergen names are stated in accordance with WHO/IUIS Allergen Nomenclature
Table 3
Allergenic molecules present in mollusk species. 
Species frequently 
implicated
Allergen name 
(IUIS)
Biochemical 
name
Molecular 
weight kDa
Heat 
stability
Physiological 
function
Route of 
exposure
Haliotismidae (Abalone) Hal m1, Tod p 1 Tropomyosin 34-49 kDa Highly 
heat 
stable
Muscle 
contraction
Ingestion
Inhalation
Helix aspersa (Garden 
snail)
Hel as 1 Arginine 
kinase
40-45 kDa Stable Energy 
metabolism in 
muscles
Ingestion
Inhalation
Todarodespaci ficus 
(Flying squid)
Amphioctopus fangsiao 
(Octopus)
Crassostreagig as 
(Pacific oyster)
Fulviamutica (Cockle)
Un-assigned Actin 42 kDa Heat-
labile
Muscle 
contraction
Ingestion
Registered allergen names are stated in accordance with WHO/IUIS Allergen Nomenclature
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over 95% among all currently analyzed prawns, crabs 
and lobsters. For example 75% of shrimp allergic 
patients elicited immunological IgE cross-reactivity 
to crab tropomyosin Por p 1 (19).
In contrast, there is very limited information about 
tropomyosin among the mollusk group. The major 
allergens from various mollusk species such as 
abalone, mussel, oysters, squid and cockle share 
rather low amino acid homology between 65-99%. 
This can result in limited clinical cross-reactivity of 
patients as demonstrated in a study where 54% of the 
recruited patients with anaphylaxis to crustaceans 
were tolerant to mollusks (20). Sensitization rates 
to recently identified allergens including triose 
phosphate and troponin c are still lacking.
CLINICAL RELEVANCE, DIAGNOSIS AND 
MANAGEMENT
Clinical relevance and clinical pattern
Due to different routes and exposure to different 
allergen quantities, degree of shellfish processing and 
physicochemical properties of the involved allergenic 
shellfish proteins, three distinct developments (Table 
5) can prompt IgE-mediated sensitizations and clinical 
symptoms of mainly immediate Type I hypersensitivity:
A) Early and presumably gastro-intestinal 
sensitization to rather stable shellfish allergens 
(e.g. tropomyosin and arginine kinase) in highly 
atopic individuals are the basis of subsequent 
Table 4
Clinical relevance and IgE sensitisation to allergenic molecules in crustaceans.
Allergen IgE Sensitisation Allergenicity (FC and SPT) Risk factors
Tropomyosin (TM)
Pen a 1 51% (total 45 subjects) 61% (24 subjects)
37% (45 subjects)
sIgE to tropomyosin is 
a better predictor of 
shrimp allergy than 
shrimp SPT or sIgE to 
whole shrimp
Ingestion
Inhalation
Occupational 
exposure
Lit v 1 94% (34 children) 61% (19 adults)
Pen m 1 62% (16 subjects)
Cra c 1
68% (31 subjects)
71% (35 subjects)
Arginine kinase 
(AK)
Pen m 2 50% (16 subjects)
Not known
Ingestion
Inhalation
Occupational 
exposure
Lit v 2 67% (34 children) 21% (19 adults)
Cra c 2 29% (31 subjects)
Myosin light chain 
(MLC)
Pen m 3 31% (16 subjects)
Not known IngestionLit v 3 70% (34 children) 31% (19 adults)
Cra c 3 19% (31 subjects)
Sarcoplasmic 
calcium binding 
protein (SCBP)
Pen m 4 19% (16 subjects)
sIgE to SCBP may be 
a better predictor of 
shrimp allergy in children
IngestionLit v 4 59% (34 children) 21% (19 adults)
Cra c 4 35% (31 subjects)
Troponin C (TnC) Cra c 6 29% (31 subjects) Not known Ingestion
Triose phosphate 
isomerase (TIM)
Pen m 8 19% (16 subjects)
Not known IngestionInhalationCra c 8 23% (31 subjects)
SPT - skin prick test, FC - Food challenge
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severe systemic reactions after ingestion of 
small amounts of (processed) shellfish products. 
IgE-sensitizations (e.g to structural protein 
tropomyosin and enzyme arginine kinase) could 
also evolve from exposure to different crustacean 
or mollusk species (e.g. prawn and lobster or 
abalone and squid) with various degrees of cross-
reactivity, prompting occasionally severe clinical 
symptoms after ingestion of shellfish products. 
These reactions have mainly been described in 
adults but also reported for children.
B) Exposure to inhaled shellfish allergens is 
frequently reported in atopic individuals working 
in the seafood processing industry. Sensitizing 
allergens have to be heat stable (e.g. tropomyosin 
and arginine kinase) to endure the heat 
processing. Cross-reactivity among members 
of the crustacean group is more common than 
among mollusks. Reactions to inhaled shellfish 
allergens subsequent to ingestion sensitization 
have also been reported.
C) Skin exposure to heated as well as unprocessed 
shellfish induce IgE-mediated sensitization to 
shellfish allergens with subsequent inhalant and 
ingestion allergies in exposed individuals.
CLINICAL MANAGEMENT
Specific questions, interpretation of sensitization tests 
(e.g. SPT, IgE) and optional food challenges help to 
establish the diagnosis of shellfish allergy. Following 
work-up (Fig. 4) might facilitate correct diagnosis.
Case history
Previous reaction(s) to crustacean or mollusk, 
symptoms, affected organ system(s), onset and 
course (progression), shellfish containing food items 
(highly-, mildly-, non-processed grade), co-factors 
(exercise, NSAID, alcohol etc.), previous reactions 
after shellfish allergen sources, additional (allergic) 
features, e.g.house dust-mite or insect (e.g cockroach, 
moth) allergy, reactions to seafood poisoning (e.g. 
histamine from Scombroid poisoning (fish) or marine 
biotoxins from filter feeders (mussels), additional 
atopic diseases, i.e. atopic eczema, asthma.
Skin prick test (SPT)
  Commercial shellfish extracts (reasonable results in 
case of highly abundant allergens (e.g tropomyosin), 
but limited value due to false negative responses 
in case of heat sensitive allergens (e.g. MLC) 
or weak- or non-cross-reactive allergens (e.g. 
arginine kinase) or commercial extracts do not 
represent the specific shellfish species consumed 
by the patient (e.g. Southern hemisphere).
  Prick-prick test with offending shellfish product 
(in case of severe anaphylactic reaction, preferably 
titrated testing with diluted shellfish product; 
primary IgE-testing before SPT; potentially false 
negative, depending on the abundance and stability 
of the shellfish allergen in question (e.g. MLC).
IgE-Testing
Allergen-specific IgE
  Shellfish extract (potentially false negative or 
low titers in case of low abundant allergens or 
extract do not represent the specific shellfish 
species consumed by the patient (e.g. Southern 
hemisphere)
  Purified allergen (tropomyosin) from shrimps, 
house dust-mite and anisakis are available on the 
allergen microchip (ISAC, Thermo Fisher Scientific) 
and used to quantify allergen-specific IgE
Interpretation of SPT and IgE (sensitization tests) 
outcomes see also Fig. 4 and Table 5. For examples 
of currently available sIgE and SPT kits, see Table 6.
Results only clinically relevant in case of corresponding 
symptoms after shellfish ingestion or contact via 
inhalation or skin.
Challenge tests
(in case of doubtful relationship between shellfish 
ingestion and allergic reaction):
Oral double-blind, placebo-controlled food challenge 
in patients without moderate or severe anaphylactic 
reactions:
1. Preparing meal with whole seafood extract or the 
ground boiled of the offending seafood species 
(masked in fruit juice, chocolate or vanilla ice 
cream, or in a burger)
2. Accumulated doses of up to 24 g of seafood (e.g. 
1-2 large prawns)
Clinical management
Advices and avoidance
  Strict avoidance of all shellfish containing 
products, even with small amounts, regardless of 
the grade of shellfish processing.
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  Avoidance of inhalation of shellfish containing 
protein vapours
  Avoidance of touching or handling shellfish
Pharmacotherapy (emergency kit)
  Due to the risk of severe reactions after 
unintentional ingestion of shellfish containing 
products, emergency medication for self-
administered drug application required
  Symptomatic treatment is required
  Emergency medication optional (not mandatory)
Allergen-specific immunotherapy
At present commercially available products for 
allergen-specific immunotherapy of shellfish protein 
allergy are not available.
CLINICAL CASES
Case 1 (published (21))
History: 19-year-old Chinese male, developed hives, 
circumoral swelling and systemic symptoms – 
faintness, vomiting, diarrhea and abdominal cramp 
after running. He was bought into the Emergency 
Department (EMD). He had consumed a home-
cooked meal containing prawns prior to exercise. 
The patient also had rashes when ingesting clams.
SPT: Negative to extensive list of foods, including 
wheat, prawn but positive to Der p, Der f, Blo t
Diagnosis: Food-dependent exercise-induced 
gastrointestinal reactions and anaphylaxis to 
shellfish allergens
Recommendation: Oral administration of 
chlorpheniramine
Case 2 (published (22))
History: 22-months old Latin-American male with 
history of milk allergy, reactive airway disease, and 
eczema and no history of allergic rhinitis symptoms. 
On ingestion of one shrimp, there was immediate 
swelling of eyes and hives on his face without 
difficulty in breathing. Symptoms subsided within 
24 hours on administration of diphenhydramine.
In-vitro testing: Serum-specific IgE showed levels of 
12.6 kU/L to shrimp, 12.3 kU/L to milk, 0.55 kU/L 
Figure 4
Diagnostic algorithm for shellfish allergy.
ADVERSE REACTION TO 
SHELLFISH
Determination of history
+
_
Typical immediate Type 1 
symptoms
Delayed symptoms
• Delayed IgE reactions (e.g. Mollusks)
• Food intolerance
• Toxins
IgE quantification by 
ImmunoCAP  or in-
house prepared ELISA
Skin Prick Test
DBPCFC and 
overnight observation 
 if toxin not considered
Analysis of the 
offending shellfish for 
toxins (if available)
Recommendation 
of avoidance or oral 
food challenge 
(If available)
Skin 
Prick 
Test
Recommendation 
of avoidance or 
oral food challenge 
(If available)
IgE quantification by 
Immunocap and/or oral 
food challenge and/or 
recommendation of avoidance
  Consider toxins
  Food intolerance
  Review the history
 In-house 
prepared  
Skin Prick test
+_
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Table 5
Features and clinical pattern of three different developments of shellfish allergy
Ingestion Inhalation Contact
Routes of 
sensitiza-
tion
(IgE specific 
response)
1. Gastro-intestinal uptake and 
subsequent IgE sensitization to 
stable shellfish allergens
2. Gastro-intestinal uptake of shell-
fish allergens and subsequent IgE 
cross-reactivity to shellfish or fish 
parasite allergens
1. Inhalation of air-borne par-
ticulate shellfish matter and 
subsequent IgE sensitization 
to allergens tropomyosin and 
arginine kinase
2. Ingestion-induced IgE sensitiza-
tion and subsequent inhalation 
related cross-reactivity to dust 
mite or insect tropomyosin
1. Primary uptake and IgE sensi-
tization to shellfish allergens 
through IgE receptors on epi-
dermal Langerhans’ (dendritic) 
cells
2. IgE sensitization to shellfish pro-
teins via gastro-intestinal or in-
halational route and subsequent 
IgE reactivity on skin contact
Affected 
age group children/adolescents/ adults
adolescents / seafood processing 
workers/restaurant workers
children/ adolescents/ adults/ 
seafood processing workers/ 
restaurant workers
Shellfish 
allergens 
involved
TM (Pen m 1), AK (Pen m 2), MLC 
(Pen m 3), SCP (Pen m 4), TnC (Pen 
m 6), TIM (Pen m 8) 
Tropomyosin, Arginine kinase Not known
Allergen 
abundance
High in fresh and cooked meat and 
related products
Moderate to high in aerosol aller-
gen content of Pen m1 and Pen 
m2 near cooking stations
Not known
Thermal 
stability Very high stability High High
Prevalence 2% adults  0.9% children
4-36% among shellfish process 
workers
65% among shrimp workers (irri-
tant of allergic origin)
Elicitors
Fresh or cooked shellfish meat. 
Processed foods containing shell-
fish
Air-borne shellfish bio-matter and 
cooking vapours
Wet aerosols, splash on hands 
and face
Symptoms
Generalised reactions (anaphylax-
is), cutaneous (urticaria, angiode-
ma, atopic dermatitis), gastroin-
testinal (pain, nausea, diarrhoea, 
vomiting), oral allergy syndrome
Upper and lower respiratory tract 
symptoms: asthma. Ocular-nasal 
symptoms: rhinitis, conjunctivitis
Contact dermatitis, urticaria, 
eczema
Medical 
diagnosis
Moderate to severe food allergic 
reaction to shellfish proteins
Moderate to severe respiratory 
symptoms which may lead to 
ingestion induced food allergy to 
shellfish proteins
Contact dermatitis and urticaria 
due to primary sensitization to 
shellfish proteins
Type of 
food allergy Type I – immediate onset Type I – immediate onset Type IV – delayed onset 
Avoidance/
Technical 
solution
No oral intake of crustacean or 
mollusk products, even small 
amounts
Protection of nose and mouth 
using appropriate facemask, good 
ventilation in shellfish processing 
workplace, minimize aerosoliza-
tion of shellfish proteins 
Use of hand gloves and facemask 
for protection
Product 
declara-
tion
Mandatory on each shellfish 
containing protein. Separate for 
crustaceans and mollusks (EU 
legislation)
- -
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to egg white, 0.72 kU/L to wheat, 0.41 kU/L to 
soybean, 0.61 kU/L to peanut, and <0.35 kU/L to 
codfish.
Recommendations: Strict avoidance of shrimp and 
other shellfish in his diet. Autoinjector epinephrine 
was prescribed. No further episodes of angioedema 
or hives were observed.
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Farm animals provide a major part of the diet 
in many parts of the world
Sensitization to meat can be acquired 
through different routes (inhaled, oral, skin)
New forms of allergic reactions to meat have 
been recognized (cat-pork and red meat)
IgE assays including meat allergen sources 
and components will help identifying the 
patients
The only effective treatment is avoidance of 
relevant meat sources
THE ALLERGEN SOURCES
Meat derived from domesticated mammals has been 
an important part of the human diet for at least ten 
thousand years. The animal tissue sold and eaten 
as meat includes: blood, fat, innards and tendons 
as well as muscles. Sensitisation to serum proteins 
and milk proteins from the same animal is inevitable 
due to cross-reactivity. Milk is a relevant allergen 
source only for goats, sheep, and cows in the USA 
and Europe, but it is important to remember that 
camels and other animals are milked in some parts of 
the world. Further, although there is a limited range 
of animals that are sold commercially in the west, a 
much larger variety of wild animals may be hunted 
and eaten in rural communities worldwide.
Farm animals provide a major part of the diet in 
western societies and in many other parts of the 
world. These animals are prized for their meat and 
organs (Fig. 1). In addition, there are hundreds of forms 
of processed meat, including sausages, salami, bacon, 
etc. Meat also incorporates significant quantities of 
protein derived from serum, which includes many 
proteins that are recognized as allergens in cow’s 
milk. Other products derived from these mammals 
Marianne van Hage, Tilo Biedermann, 
Thomas A.E. Platts-Mills
ALLERGY TO 
MAMMALIAN MEAT 
 EAACI Molecular Allergology User´s GuideEAACI Molecular Allergology User´s Guide2016 Part  B:  Using Molecular Al lergology In The Cl inical  Practice 
194 Allergy to Mammalian Meat
include different forms of fat, paté, as well as gelatin, 
which is derived from tendons, cartilage, or skin.
MAJOR AND RELEVANT MINOR 
ALLERGENIC MOLECULES
Initially the identification of meat derived allergens 
focused on protein antigens recognized by patients 
who reported allergic reactions that occurred rapidly 
after exposure. Most of these cases presented in 
childhood and many of the allergens were species-
specific proteins (1, 2). However, it was already 
clear that some mammalian proteins showed cross-
reactivity between species, and this included both 
immunoglobulins and albumins (3, 4) (see also chapter 
A04). The major allergens from beef, Bos taurus, are 
serum albumin (Bos d 6) and immunoglobulin IgG 
(Bos d 7) (Table 1) (1, 3-5). Beef-allergic children have 
been reported to react to bovine serum albumin on 
SPT, but only some of them do so during challenge (1). 
Myoglobin has been identified as a clinically relevant 
and heat-resistant allergen in one case report (6). 
Actin was shown to bind IgE of meat-allergic patients, 
but skin prick tests were negative (4). More studies 
are needed to evaluate the importance of these 
allergens.
Despite the truly enormous quantities of meat 
eaten worldwide there are only a limited number 
of allergens defined (Table 1). Indeed despite the 
extensive consumption of meat from sheep, goats 
Figure 1
*Any of these products can include serum proteins including proteins present in cow’s milk (e.g., albumins, 
globulins and the mammalian oligosaccharide galactose-alpha-1,3-galactose (alpha-gal)).
$ Gelatin is made from tendons, cartilage or skin and is a protein with varying quantities of glycosylation, 
used widely in food.
Table 1
Major and minor meat allergenic molecules
Animals Milk Allergen molecules* #
Alpha-gal 
Reactions to 
meat intake
Bos domesticus  
(cow)
+++ eleven (9 ) 
Bos d 2-12
Yes
Sus domesticus 
(pig)
NA albumin (1) 
Sus s
Yes
Capra Aegagrus 
(goat)
++ 0 Yes
Ovis Aries 
(sheep)
++ 0 Yes
Odocoileus 
virginianus (deer)
NA 0 Yes
Equus caballus NA four (1) 
Equ c 1-4
Yes
Oryctolagus 
cuniculus (rabbit)
NA three (0)  
Ory c 1, 3-4
?
Cavia porcellus 
 (guinea pig)
NA five (0)  
Cav p 1-4, 6
?
NA=not applicable
*IUIS Allergen Nomenclature Sub-Committee
# Number in brackets indicates the number of allergens defined as 
food allergen. 
Meat*
Muscle meat Organ meat Processed meat Fat, tendons etc.
Steak, Leg, Chop, 
Ground Meat
Heart, Livers, Kidney, 
Intestine, Lungs
Sausage, Salami, Bacon, 
Smoked ham etc
Fat: Suet, Lard Tallow
Tendons: Gelatin$
Saudage casing (primary pork intestines)
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and deer as well as horses, there are no relevant 
allergens included in the IUIS database from these 
sources. Even for rabbit and guinea-pig, where there 
are 3 and 5 allergens respectively in the database, all 
of the defined allergens were recognized on the basis 
of inhalant symptoms. Single case reports show that 
serum albumin is responsible for clinical symptoms to 
rabbit or horsemeat (7, 8). Thus the only species with 
a significant number of food allergens recognized is 
the cow where nine of the allergenic proteins are 
recognized as food allergens. However, even in that 
case, most of the allergens were initially identified 
as allergens in cow’s milk. Indeed, the majority of 
reported reactions to beef in childhood have occurred 
in cow’s milk allergic children (1, 5, 9). The same can 
occur with reactions to goat or sheep meat, with 
goat’s milk or sheep milk as the primary sensitizer but 
this is much less common. It is difficult to access the 
world literature on reactions to meat, because a large 
proportion of the populations eating goat and sheep 
have only limited medical care. However, it is likely 
that the main meat proteins taken orally have very 
little allergenicity in man (10).
SENSITIZATION TO INDIVIDUAL 
MOLECULES AND ITS CLINICAL RELEVANCE
In the last fifteen years, two new forms of allergic 
reactions to meat have been recognized. In both 
of these syndromes, presentation is most often in 
adult life and in both cases the relevant antigens are 
characterized by extensive cross-reactivity between 
different mammals. First, it was recognized that some 
patients who had allergic reactions to pork, were 
reacting because of pre-existing IgE antibodies to 
cat albumin that cross-react with pork albumin (11, 
12). Secondly, an enigmatic allergic reaction to the 
monoclonal antibody cetuximab led to the recognition 
that a surprisingly large number of individuals in the 
South East of the United States had IgE antibodies 
to the oligosaccharide galactose alpha-1, 3-galactose 
(alpha-gal) (13). This oligosaccharide is a blood 
group substance of the non-primate mammals and 
is present on all forms of tissue including red meat 
(14, 15), organs such as kidney (16), gelatin (17) and 
cat IgA (18). These patients also present with a novel 
form of delayed food allergy where in general they 
feel no symptoms for 2-6 hours after eating meat (16, 
19-22).
Table 2
Routes of Sensitization for Allergens Related to 
Allergic Reactions to Meat
Inhaled: Cat albumins related to systemic rapid 
reactions to pork (cat pork syndrome)
Oral: Cow’s milk allergens related to allergic 
reactions to beef
Skin: Tick bites lead to alpha-gal sensitization, 
and ingestion of red meat may later trigger 
reactions
Routes of sensitization
Prior to the year 2000, it was generally assumed 
that sensitization to food antigens was induced by 
oral exposure. However, we now have at least two 
alternative routes of exposure (Table 2).
Sensitization to cat albumin occurs predominantly 
in patients who own cats and is assumed to occur 
by inhaling dander particles carrying this protein. 
Thus the route of sensitization to the cross-
reacting pork albumin reflects a sensitization that 
was initially established by inhaled exposure. The 
second alternative route is through the skin. For the 
oligosaccharide alpha-gal, the only established route 
for sensitization is by tick bites. Strikingly there are 
three different tick species that have been implicated: 
Amblyomma americanum in the USA; Ixodes holocyclus 
in Australia; and Ixodes ricinus in Europe. Moreover, 
Ixodes ricinus has been shown to contain alpha-gal (23). 
While it is certainly possible that other parasites can 
induce this response there is no clear evidence for that 
at present. On the other hand, there is good evidence 
that eating meat carrying this oligosaccharide does 
not induce IgE-mediated sensitization in children or 
adults to alpha-gal since these IgE antibodies are not 
present in the serum of children raised in arctic areas 
where the ticks are not present (24).
CLINICAL RELEVANCE, DIGANOSIS AND 
MANAGEMENT
The only effective form of treatment for allergic 
reactions to meat is to avoid the relevant source 
or sources. There are no consistent studies using 
immunotherapy for meat allergy, nor are there 
studies using anti-IgE as therapy. Thus, the main 
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parts of management are accurate diagnosis and 
education. Cofactors (for example, alcohol, ASA, 
physical exercise) can increase intestinal absorption 
and substitute for higher sensitivity to red meat (16).
Clinical diagnosis
Diagnosis is based on i) history, ii) skin test and/or IgE 
antibody assays, and iii) challenge protocols (Table 3).
The diagnosis of alpha-gal sensitivity may be obvious 
from the history and skin tests. However, it may be 
useful to have a panel of serum IgE assays to establish 
the diagnosis of meat reactions. This will need to include 
IgE to alpha-gal, beef and pork, as well as IgE antibodies 
to milk, cat and porcine albumin, and chicken, turkey 
and cod can be used as negative controls.
Clinical management
Discussion of avoidance may require written 
protocols, as well as discussion of the many forms 
in which proteins derived from meat are eaten. With 
meat sensitization in childhood it may be necessary 
to go dairy-free to establish a symptom-free 
condition. After that it should be possible to carry 
out challenge tests if necessary and to progressively 
modify details of the diet. For pork-cat syndrome it is 
usually sufficient to avoid pork and pork products. In 
some cases, the cross-reactivity with beef albumin is 
strong enough to give symptoms with beef products. 
As albumins are thermolabile proteins, well-cooked 
meat is often tolerated whereas ham and sausage are 
not. Challenges may be useful to assess the tolerance 
of well cooked beef in children.
Full avoidance of all products containing alpha-gal is 
not easy because this includes all products derived 
from mammals. However, most cases require a 
significant dose of red meat (i.e., ≥20 g of meat) to 
cause reactions, and over 80% of cases can tolerate 
milk and milk products. In many cases, the patients 
have already recognized what they can tolerate 
before they present to physicians. As in other IgE-
Table 3
Diagnosis of Meat Reactions
History SPT IgE Challenge
Primary meat sensitivity in childhood
Immediate reactions to meat 
often with pre- existing sen-
sitivity to cow’s milk.
Milk and relevant meat. Milk and meat.
Graded meat challenges in 
cases where doubt remains.
Pork-Cat Syndrome
Reactions to pork within one 
hour
In some case with additional 
reactions to beef and in most 
cases pre-existing sensitiza-
tion to cats.
Cat, dog and pork.
Pork, 
cat, beef, 
porcine 
and cat 
albumin
Graded challenge tests may 
be necessary in some cases 
where diagnosis remains 
unclear.
Delayed Anaphylaxis to Red Meat or the Alpha-gal syndrome
Urticaria and/or anaphylax-
is occurring 3-6 hours after 
eating beef,
Beef, lamb, pork, and cow’s milk 
negative or 2-4 mm in diameter.
Intradermal skin tests give much 
clearer results.
Gelatin-derived colloids can be 
used as alternative where test 
solutions for intracutaneous 
testing with meat-extracts is not 
available, some used cetuximab 
however with less sensitivity.
Alpha-gal, 
beef, lamb, 
pork, and
Challenge tests have been 
carried out in experimental 
protocols.
be necessary in some cases 
where diagnosis remains un-
clear, co-factors may need 
to be included to elucidate 
clinically overt reactions.
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mediated food allergies, mastocytosis increases the 
risk for severe reactions also for alpha-gal allergic 
individuals. Thus, measurement of serum tryptase in 
the investigation of red meat allergy is recommended.
CLINICAL CASES
Case 1
Clinical history: Patient, 56-year-old female, 
who previously had ingested red meat without 
experiencing symptoms, visited in early autumn 
the ER due to urticaria. The case history revealed 
that she had eaten a sausage five hours earlier. In 
November the same year she had an anaphylactic 
reaction six hours after eating a hamburger. She 
was referred to the Allergy Clinic for investigation 
of food allergy. The examination revealed that she 
had obtained several tick bites during the summer 
and noted prolonged redness and itching at the 
site of the tick bite.
In vitro testing: IgE negative to soybean, peanut, cod 
and wheat. IgE against beef was 14 kU/L, pork 7.6 
kU/L, milk 1.7 kU/L and alpha-gal 80 kU/L.
In vivo tests: SPT 3+ against birch. SPT negative to 
beef, lamb, pork and cow’s milk.
Diagnosis: Red meat allergy.
Recommendation: She was recommended to avoid 
red meat and became symptom-free.
Case 2
Clinical history: An 18-year-old male patient 
describes five, mostly nocturnal, anaphylactic 
reactions with hives, nausea, abdominal pain and 
dyspnea in the last ten years with unknown trigger. 
In four of five episodes, allergic reactions occurred 
3-5 hours after a meal containing pork meat, once 
with physical exercise (cycling) where cutaneous 
reactions occurred shortly (1h) after. The patient 
is otherwise healthy and has no history of atopy or 
other (food) allergies. No further episodes occurred 
since the patient had become a vegetarian. There 
is a history of tick bites in the patient’s childhood.
In vitro testing: Specific IgE to alpha-gal was highly 
positive (29.6 kU/l) and negative to pork (< 0.1 
kU/l), beef (< 0.1 kU/l), chicken (< 0.1 kU/l) and 
omega-5-gliadin (< 0.1 kU/l). The tryptase level 
was 2.13 µg/l (< 11.4 µg/l).
In vivo tests: Skin prick test was negative to beef, 
lamb, pork and cow’s milk, but prick-to-prick test 
revealed positive reactions to raw and cooked 
pork kidney. Intradermal testing was positive to 
Gelafundin® 4% (gelatin polysuccinate) diluted 
1:100.
An oral challenge was performed with cooked 
pork kidney (17g) under careful monitoring. The 
patient developed urticaria approx. 3 hours after 
challenge and was treated with antihistamines and 
corticosteroids.
Diagnosis: Late-onset anaphylaxis to red meat based 
on IgE recognizing alpha-gal
Recommendation: The patient was informed to avoid 
red meat especially in combination with co-factors 
such as alcohol, acetylsalicylic acid or exercise as 
well as oral ingestion of large amounts of gelatin. 
Furthermore, we handed out an allergy pass listing 
Cetuximab and gelatin-colloid plasma expander 
Gelafundin®.
It should be emphasised that skin prick test responses to 
beef, lamb, pork and cow’s milk can be very small in size 
or negative. In adults, intradermal skin tests may give 
much clearer results (Table 3).
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Allergies to fruits and vegetables can either 
be due to cross sensitization with pollen 
allergens or are due to “true” food allergens
The majority of plant food allergens can be 
assigned to a restricted number of protein 
families
Frequently observed IgE cross reactivity does 
not always coincide with clinical relevance
Prick to prick testing using raw plant foods is 
often superior to extract based testing
Food challenges are the method of choice to 
rule out clinically silent IgE cross reactivity 
THE ALLERGEN SOURCES
Plant food, especially fruits and vegetables are part of 
a healthy diet and their consumption is recommended 
for prevention of cardiovascular and metabolic 
disorders. However, in predisposed individuals food 
allergic reactions are caused/induced upon uptake of 
a range of fruits and vegetables.
Fruits
While the range of allergenic fruits is broad, the 
majority of frequent inducers of allergic reactions 
belong to the Rosaceae family. Therefore, this 
botanical family will be described in more detail. 
Among those, pyrenocarps and stone fruits but 
also nuts (almond) are able to induce food allergic 
symptoms in atopic patients.
Fruits are consumed raw or processed, and both, 
peel and pulp contain allergens. For example the 
non-specific lipid transfer proteins (nsLTPs) are 
accumulated in the outer layer of fruits, and by 
removing the peel the allergen exposure can be 
reduced. Also, certain apple cultivars are known to 
be low in their allergen content for the Pathogenesis-
related 10 (PR-10) proteins and nsLTPs, while others 
Barbara Ballmer-Weber, Karin Hoffmann-
Sommergruber
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are expressing higher amounts of these allergens (1, 
2). Unfortunately, the reduced levels of Mal d 1 do 
not always coincide with low levels of Mal d 3, thus 
an overall hypoallergenic apple is so far not available. 
Also postharvest treatment processes may impact on 
allergen levels, as storage under defined conditions 
has suggested for Mal d 1 and Mal d 3 levels (3).
Furthermore, fruits can be eaten in cakes, desserts, 
jams and jellies, as ingredients of dishes and as fruits 
juices either after pasteurization or without heat 
treatment.
In “biological cosmetics” fruit extracts are also used 
and may pose an unexpected risk in highly sensitized 
patients.
In addition, the kiwifruit will be presented as an 
example of a novel food, entering the European 
market in the late 70s of the 20th century, and thus 
eventually developing into a relevant allergen source, 
previously not anticipated as such.
In addition, citrus fruits, banana, melon, and grapes 
represent plant food allergen sources, affecting 
mostly Southern European patients/consumers.
The well-known latex fruit syndrome, comprising 
allergic reactions against latex products and fruits 
and vegetables containing cross reactive allergens 
will not be considered in this chapter, since this topic 
is covered in Section B22 by M. Raulf.
Vegetables
Also vegetables present a relevant source of allergens, 
with celery being an allergen food to be labelled on 
food products according to the EU allergen legislation 
(European Directive 2007/68/EC).
Celery and carrot, both belonging to the botanical 
Apiaceae family can be consumed raw as well as 
cooked, and several studies have investigated the 
impact on heat treatment on individual allergens, 
thus up- or downregulating their allergenic capacity. 
Especially in celery the bulb (tuber; celeriac) as well 
as the green parts (stalks) are eaten raw as well as 
cooked. In addition, celery seeds can be used as a 
spice as well and are offered either as “celery salt” 
alone or as a spice mixture to be used for various 
dishes. In the latter case the presence of celery 
derived proteins may not be that evident and 
may lead to unexpected reactions in predisposed 
individuals. Also celery seed oil is sometimes used as 
a food ingredient or in cosmetics.
In addition to celery and carrot also tomato and bell 
pepper are well known allergenic foods. In the recent 
past additional tomato allergens have been identified 
belonging to the seed storage proteins present in the 
seeds of the tomato fruit (4).
MAJOR AND RELEVANT MINOR 
ALLERGENIC MOLECULES
Fruits
Within the Rosaceae PR-10 protein family members 
have been identified as allergens in apple, peach, 
apricot, pear, raspberry, and strawberry. These 
proteins are major allergens in apple and peach, 
and are located in the pulp and skin of the fruits. In 
general, PR-10 proteins are labile proteins at extreme 
pH conditions and their structure is affected upon 
heat treatment. They are constitutively expressed in 
plant tissues. In addition they are upregulated upon 
environmental stress and pathogen attack. They 
are supposed to act as plant steroid carriers. PR-10 
proteins in fruits are supposed to induce mild local 
reactions in patients. Also heat treatment of fruits 
(e.g. pasteurized fruit juices and jams) affects PR-10 
allergenicity.
The nsLTPs are small proteins with a rigid tertiary 
structure formed by 4 disulfide bridges. Their 
function is to transport lipids across cell membranes. 
Allergens from this protein family are identified from 
apple, peach, apricot, cherry, plum, pear, raspberry, 
strawberry, and mulberry. They are major allergens 
and primarily located in the outer tissue layers (peel) 
of fruits. Upon pathogen attack they are upregulated 
and therefore classified as PR-14. In contrast to PR-
10 allergens they are stable proteins not affected by 
low pH environment and heat treatment. However, 
at neutral pH their resistance to heat treatment is 
much lower as compared at acidic pH (5). In general 
severe, generalized allergic symptoms are correlated 
with nsLTPs intake.
Profilins are small proteins with an ubiquitous 
expression throughout the plant kingdom. They 
are functional in various important cell-signaling 
pathways and bind actin. These small proteins are 
of intermediate to low stability when subjected to 
heat treatment. Sensitization to profilin is frequently 
observed in patients, however it often lacks clinical 
relevance. Allergens from the profilin family have 
been identified in apple, peach, pear, and strawberry.
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Thaumatin-like proteins share a common 3 
dimensional rigid structure defined by conserved 
cysteine residues forming 8 disulfide bridges. These 
proteins are expressed in ripening fruits and are 
upregulated upon biotic and abiotic stress (PR-5). 
They are regarded as minor allergens, based on data 
obtained from apple, peach, and cherry.
The gibberellin-regulated protein, peamaclein, 
was identified from peach. This is a small protein 
upregulated upon biotic stress and located in the 
peach peel (6).
In pear another allergen, an isoflavone reductase 
related protein was identified, which showed 
allergenic activity in a small group of patients allergic 
to pear (7).
The green kiwifruit contains PR-10, nsLTP, profilin, 
and thaumatin-like proteins with allergenic activity. 
The cysteine protease, actinidin, enzymatically 
degrades seed storage proteins and is upregulated 
in blossoms and fruits. In kiwifruit monosensitized 
allergic patients it is a major allergen. In addition, a 
number of minor allergens have been identified such 
as phytocystatin, kiwellin, pectin-methylesterase 
and its inhibitor and a major latex-protein, which 
belongs to the Bet v 1 superfamily. 2S albumins 
and 11S globulins localized in the seeds were also 
characterized as allergens.
While actinidin is abundantly expressed in green 
kiwifruits its expression level and allergenic activity 
is much lower in golden kiwifruits (8) and in certain 
kiwifruit cultivars (8).
Banana contains profilin, nsLTP and thaumatin-like 
proteins with allergenic activity. In addition, beta-1,3 
glucanase (PR-2) and class I chitinase (PR-3), both 
degrading fungal cell walls and the exoskeleton of 
insects, are banana allergens and contribute to the 
cross-reactivity with latex allergens.
In citrus fruits nsLTPs type 1 were identified, and 
germin-like proteins, as relevant allergens. In contrast 
to other fruits, profilins are regarded as major 
allergens in citrus fruits with clinical relevance (10).
From melon profilin, cucumisin, an alkaline serine 
protease, and a member of the PR-1 family are 
identified as allergens (Table 1 and Fig. 1).
Vegetables
In celery, the PR-10 protein is a major allergen, 
especially in Central Europe. Also, profilin is supposed 
to sensitize a relevant number of celeriac allergic 
patients. Less frequently, sensitization to the FAD-
containing oxidase, a glycoprotein, is observed. In 
this case, the carbohydrate moieties of this enzyme 
seem to be relevant for the IgE binding capacity (11). 
In the recent past, nsLTPs have been identified from 
celery. While the nsLTP type 1 is expressed in the 
stalks, the nsLTP type 2 is found in the tuber (12, 
13). Only limited IgE-cross-reactivity is observed 
between those two different proteins. Similarly to 
celery, the PR-10 protein is a major allergen in carrot. 
At least 2 isoforms of Dau c 1 seem to be responsible 
for sensitization and provide only partial cross-
reactivity. In addition, profilin has been identified as 
a minor allergen. Finally, the isoflavone-reductase-
like protein is the most recently characterized food 
allergen. However, neither data on the prevalence of 
sensitization are available nor the clinical relevance 
of this allergen is known to date.
Figure 1
Peach and kiwifruit as selected examples of fruit 
allergen sources.
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Table 1
Allergens in Fruits
Biochemical name Molecular mass (kDa) Allergen
Pathogenesis related protein 
10 (PR 10) 17 
Rosales: Mal d 1 (apple), Pru p 1 (peach), Pru ar 1 (apricot), Pru av 1 
(cherry), Pyr c 1 (pear), Rub i 1 (red raspberry), Fra a 1 (strawberry);
Ericales: Act d 8 (green kiwifruit), Act c 8 (golden kiwifriut);
Profilin 14 
Rosales: Mal d 4 (apple), Pru p 4 (peach), Pru av 4 (cherry), Pyr c 4 
(pear);
Ericales: Act d 9 (green kiwifruit);
Zingiberales: Mus a 1 (banana);
Sapindales: Cit s 2 (sweet orange), Lit c 1 (litchi);
Cucurbitales: Cuc m 2 (muskmelon); 
nsLTP (type 1) 9 
Rosales: Mal d 3 (apple), Pru p 3 (peach), Pru ar 3 (apricot), Pru av 3 
(cherry), Pru d 1 (plum), Pyr c 3 (pear), Rub i 3 (red raspberry), Fra a 
3 (strawberry), Mor n 3 (mulberry);
Ericales: Act d 10 (green kiwifruit), Act c 10 (golden kiwifruit);
Zingiberales: Mus a 3 (banana),
Sapindales: Cit l 3 (lemon), Cit r 3 (tangerine), Cit s 3 (sweet orange);
Vitales: Vit v 1 (grape);
Thaumatin-like protein 23 
Rosales: Mal d 2 (apple), Pru p 2 (peach), Pru av 2 (cherry);
Ericales: Act d 2 (green kiwifruit);
Zingiberales: Mus a 4 (banana); 
Giberellin regulated protein 69 Rosales: Pru p 7 (peach); 
Isoflavone reductase related 
protein 34 Rosales: Pyr c 5 (pear);
Class I chitinase 33 Zingiberales: Mus a 2 (banana); 
Beta 1,3 Glucanase 30 Zingiberales: Mus a 5 (banana); 
Germin like protein 23 Sapindales: Cit s 1 (sweet orange); 
Alkaline serine protease 67 Cucurbitales: Cuc m 1 (muskmelon); 
Pathogenesis-related protein 1 17 Cucurbitales: Cuc m 3 (muskmelon); 
Actinidin 30 Ericales: Act d 1 (green kiwifruit);
Phytocystatin 10 Ericales: Act d 4 (green kiwifruit);
Kiwellin 26 Ericales: Act d 5 (green kiwifruit); Act c 5 (golden kiwifruit); 
Major latex protein/ ripening 
related protein 17 Ericales: Act d 11 (green kiwifruit);
Cupin (11S globulin) 50 Ericales: Act d 12 (green kiwifruit);
2S albumin 11 Ericales: Act d 13 (green kiwifruit);
source: IUIS Allergen Database, March 2015
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From tomato, profilin was identified as a minor 
allergen. Additionally, beta-fructofuranosidase and 
cyclophilin are minor allergens and a member of the 
Bet v 1 superfamily. Recently nsLTPs, both, type 1 
and type 2 were characterized, however, little is 
Figure 2
Celery and tomato as selected examples of vegeta-
ble allergen sources.
Table 2
Allergens in Vegetables 
Biochemical name Molecular  mass (KDa) Allergen
Pathogenesis related protein 
PR- 10
15 Apiales: Api g 1 (celery), Dau c 1 (carrot);
Profilin 14 Apiales: Api g 4 (celery), Dau c 4 (carrot);
Solanales: Cap a 2 (bell pepper), Sola l 1 (tomato); 
nsLTP type 1 9 Apiales: Api g 2 (celery);
Solanales: Sola l 3 (tomato); 
nsLTP type 2 6-7 Apiales: Api g 6 (celery);
Solanales: Sola l 6 (tomato); 
Osmotin-like protein 
(thaumatin like protein) 
23 Solanales: Cap a 1 (bell pepper); 
Isoflavone reductase-like 
protein 
 33 Apiales: Dau c 5 (carrot); 
Beta-fructofuranosidase 50 Solanales: Sola l 2 (tomato);
PR protein, TSI-1 18 Solanales: Sola l 4 (tomato); 
Cyclophilin 19 Solanales: Sola l 5 (tomato);
FAD containing oxidase 58 Apiales: Api g 5 (celery); 
source: IUIS Allergen Database, March 2015
known about their prevalence in sensitization. For 
bell pepper profilin and the thaumatin-like protein 
- called osmotin-like protein – have been identified 
as allergens. However, data about their relevance for 
diagnosis is rather limited (Table 2 and Fig. 2).
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SENSITIZATION TO INDIVIDUAL 
MOLECULES AND THEIR CLINICAL 
RELEVANCE
Epidemiology and sensitization/cross reactivity 
rates
Prevalence data for plant food allergies are scarce and 
the available data so far originate from a few studies. 
In a systematic review by Zuidmeer et al. the overall 
prevalence for fruits ranged from 0.1 to 4.3% (14). 
Within a European Community Respiratory Health 
Table 3
Sensitization to individual fruit allergens
Allergen Allergenicity Risk Factor Sensitization rate
Mal d 1 High in BP allergic 
patients
Birch pollen, Bet v 1-related 
sensitization; Consumption of raw fruits; 
Living in Central and Northern Europe;
15 - 70% of apple allergic patients17 
Mal d 2 no data Consumption of raw and processed 
fruits?
5 - 18% of apple allergic patients17 
Mal d 3 High in Southern 
Europe
Consumption of raw and processed 
fruits, Southern Europe, multiple 
Rosaceae sensitization 
1 - 50% of apple allergic patients17 
Mal d 4 Predominantly GP 
and BP allergic 
patients 
Grass pollen, profilin-related sensitiz 
sensitization 
10 - 40% apple allergic patients17 
Pru p 1 High in BP allergic 
patients
Birch pollen, Bet v 1-related sensitization 
Consumption of raw fruits; Living in 
Central and Northern Europe
11 % in Spanish peach allergic 
children
7 – 31% in adults (ES, IT) 18-20 
Pru p 3 High in Southern 
Europe
Consumption of raw and processed 
fruits, Southern Europe, multiple 
Rosaceae sensitization
96% peach allergic children (ES) 19
62-96% peach allergic adults (IT, 
ES)520, 522
Pru p 4 GP-allergic patients Consumption of fruits 10% peach allergic children (7 – 34% 
adults (ES, IT) 19, 20
No data available for Pru p 2 and Pru p 7
Act d 1 Kiwifruit monosensitization 5 – 32 % (Central Europe – 
Iceland)21, 22 
Act d 2 2 – 18 %21 
Act d 5 2 – 18%21 
Act d 8 BP allergy Birch pollen, Bet v 1-related sensitization 7 – 58%21, 34
Act d 9 BP and GP allergy Birch pollen; Bet v 2-related sensitization 31 – 7%21
Act d 10 3 - 22%22 
No data available for Act d 3, Act d 4, Act d 6, Act d 7, Act d 11 – Act d 13
Survey (ECRHS) overall sensitization rates for fruits 
were assessed by Burney and colleagues in 2010 
and 2014. Peach was the most frequent inducer of 
sensitization increasing from 5.4% to 7.9% in 2014. 
Apple ranked second with a sensitization rate of 
4.2% and 6.5% followed by kiwifruit with 3.6% and 
5.2% sensitizing capacity (15, 16). Prevalence data on 
allergen specific sensitization have been generated 
by a few European wide studies. For apple the SAFE 
study provided data on Mal d 1- Mal d 4 (17), while 
the peach allergens were investigated in Spanish 
and Italian studies (18-20) reflecting the clear cut 
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Table 4
Sensitization to individual vegetable allergens
Allergen Allergenicity Risk Factor Sensitization rate
Api g 1 BP allergy Birch pollen, Bet v 1-related sensitization 75% 23, 37
Api g 4 BP allergy 42% 23, 37
Api g 5 45% 23
No data available for Api g 2 and Api g 6
Dau c 1 BP allergy Birch pollen, Bet v 1-related sensitization 58 – 100% 24 
Dau c 4 GP and BP allergy Pollen Profilin-related sensitization 18% 24
No data available for Dau c 5
difference in the frequency of LTP-sensitization 
predominant in the Southern European areas as 
compared to the PR-10 sensitization detected in 
areas with Fagales pollen exposure. Several kiwifruit 
studies were performed including a multicenter, 
within the Europrevall project and single center 
studies (21, 22) (Table 3).
Vegetables
In the systematic review the overall prevalence of food 
allergies caused by vegetables is around 1.4% (14). The 
sensitization rates for vegetables were assessed by 
Burney et al. within the ECRHS study. Sensitization to 
carrot was determined of 3.6% and increased in 2014 
to 5.0% while celeriac sensitization was observed in 
3.5% and 6,3% of the general population, respectively 
(15, 16). In celeriac allergy allergen-specific 
sensitization prevalence was investigated within the 
EuroPrevall project (23). For carrot allergy one study 
investigated the sensitization rate in Switzerland, 
Denmark and Spain (24) (Table 4).
CLINICAL RELEVANCE, DIAGNOSIS AND 
MANAGEMENT
To date limited components are available to facilitate 
the in vitro diagnosis in fruit and vegetable allergies 
(25). This comprises cross-reactive allergens derived 
from inhalant allergenic sources (Bet v 1 and Bet v 
2 from birch pollen and the latex allergens Hev b 
6.01,6.02 and 11) as well as food components from 
few Rosaceae fruits (Mal d 1,3; Pru p 1,3,4) (17, 19, 20), 
kiwifruit allergens (Act d 1,2,5,8) and some Apiaceae 
allergens (Dau c 1, Api g 1). The following section 
therefore concentrates on Rosaceae, Apiaceae, 
kiwifruit allergy and the latex-fruit-syndrome.
Clinical relevance and clinical pattern
Rosaceae fruit allergy
The Rosaceae family includes many edible fruits. 
Apple, cherry and peach are the best-studied species 
from an allergy point of view. Allergen components 
are available to date just from peach and apple. The 
allergens identified in the fruits of the Rosaceae 
family are 1) PR-10, (Bet v 1 family member), 2) 
profilin, 3), nsLTP type 1, and 4) thaumatin like protein. 
Additionally in peach a gibberellin-regulated protein 
has been detected. Due to high cross-reactivity 
between the PR-10 proteins, the profilins and the 
nsLTPs, the corresponding allergens derived from 
peach are usually applied for diagnostic approaches 
in all types of Rosaceae fruit allergies.
The sensitization pattern to these allergens is 
geographically influenced. Sensitization rates to the 
Bet v 1 homologous proteins are significantly higher 
in countries with high pollen exposure of the Fagales 
trees (birch, alder, hazel; see Sections B1 and C2), 
whereas sensitization to nsLTP is significantly higher 
in Mediterranean countries (see section C3) (16, 17, 
26). Sensitization to Rosaceae fruit profilins (see 
Section C1) is more evenly distributed but most likely 
higher in the Mediterranean area (17). Knowledge 
on sensitization to Thaumatin-like fruit proteins or 
gibberellin-regulated protein is restricted. The Bet v 
1-related food proteins, the profilin and the nsLTP 
are panallergens, depicting a high cross-reactivity 
across the plant kingdom and sensitization to these 
molecules is often not accompanied by clinical 
symptoms (27, 28). Therefore, determination of sIgE 
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to these molecules should not be used as a screening 
tool (no prophetic testing!) and sensitization without 
convincing case history should always be validated 
by food challenges (Fig. 3). All three protein families 
have been associated with the various types of clinical 
manifestation in Rosaceae fruit allergies ranging 
from contact urticaria of the oral mucosa (so called 
Oral Allergy Syndrome, OAS) up to anaphylaxis. The 
prevalence of systemic reactions in those patients 
with a confirmed fruit allergy is higher in nsLTP 
mediated fruit allergies than in the Bet v 1 or profilin 
mediated ones (17, 26, 29). In the following three 
typical patterns of Rosaceae fruit allergy are outlined.
A) Patient with a sensitization to Fagales tree pollen 
and IgE to Bet v 1 may develop cross-sensitisation 
to Bet v 1 homologous proteins from different 
Rosaceae fruits. Symptoms are elicited by 
unprocessed fruits. The usual manifestations are 
local oropharyngeal symptoms (OAS).
Cave: in selected cases Bet v 1 related fruit allergy 
can be associated with systemic reaction (30), i.e. 
in conjunction with co-factors (alcohol, exercise, 
ingestion into an empty stomach (31), high quantity 
of the ingested Bet v 1 homologues)
B) Patient with a sensitization to nsLTP mainly 
derived from peach (Pru p 3) may develop cross-
sensitization to other fruit nsLTPs. The clinical 
manifestations vary from local oropharyngeal 
symptoms up to anaphylaxis. The clinical pattern 
is influenced by co-factors (see under A, so called 
LTP syndrome (32). Symptoms are elicited by 
unprocessed and processed fruits.
C) Patients with a sensitization to profilin, frequently 
acquired via sensitization to grass pollen, might 
develop a cross-sensitisation to profilin in 
Rosaceae fruits (17). The usual manifestations 
are local oropharyngeal symptoms (OAS). The 
risk for a systemic reaction is low.
Cave: sensitisation to profilin is highly likely to be 
clinically silent (33).
Kiwifruit allergy
Allergy to kiwifruit is one of the most frequently 
observed fruit allergies in Europe (22). Thirteen kiwifruit 
allergens have been identified to date (Table 1 and 
3, Fig. 1). An allergy to kiwifruit can be acquired via 
gastrointestinal tract (primary food allergy) or via cross-
sensitization to birch or grass pollen and latex allergens. 
The allergic symptoms range from mild oropharyngeal 
symptoms to severe, generalized reactions.
Actinidin, Act d 1, is the major allergen of kiwifruit 
and correlates significantly with a kiwifruit 
monosensitization (21). Sensitization to Act d 8 and 
Act d 9 is specific for patients with pollen-kiwifruit 
allergies (21, 34). The sequence homology between 
kiwifruit nsLTP (Act d 10) and other nsLTP, particularly 
Pru p 3 from peach, is small and therefore there is a 
limited danger of cross-reactivity (35). Additionally, 
cross-reactivity between Hev b 11, a chitinase from 
latex, and a protein in kiwifruit has been identified. 
The sensitivity of IgE measurement to kiwifruit extract 
is low (17%) but could be increased by including 
different kiwifruit components (Act d 1–Act d 5 and 
Act d 8–Act d 9) to 77% (21). Sensitization to Act 
d 1 was associated with the severity of the reaction 
(22) in a pan-European study and sensitizations to 
Act d 1 and Act d 3 were significantly correlated with 
anaphylactic reactions of patients from Spain (36).
In the following four typical patterns of kiwifriut 
allergy are outlined.
a. Patient with a sensitization to Fagales tree pollen 
and IgE to Bet v 1 may develop cross-sensitisation 
to the Bet v 1 homologous protein Act d 8. The 
usual manifestations are local oropharyngeal 
symptoms (OAS).
b. Patient with a sensitization to profilin particularly 
from grass pollen may develop cross-sensitization 
to profilin in kiwifruit. The usual manifestations 
are local oropharyngeal symptoms (OAS)
c. Patient with a sensitization to latex proteins (i.e. 
Hev b 6 and 11) may develop cross-sensitisation 
to homologous proteins in kiwifruit. The clinical 
pattern varies from mild oropharyngeal symptoms 
up to anaphylaxis.
d. Patients with a sensitization (usually 
monosensitization) to Act d 1 may develop a 
primary kiwifruit allergy. The risk to develop 
systemic reaction up to anaphylaxis is increased.
Apiaceae vegetable allergy
The major representatives of the Apiaceae family in 
terms of food allergy are celeriac (Apium graveolens) 
and carrot. Celeriac allergy is highly associated 
with birch pollen and mugwort pollen sensitization 
referred to as birch-mugwort- celery-syndrome.
To date, five celeriac allergens have been identified 
in celeriac tuber Api g 1 (Bet v 1 homologue), Api 
g 6 (nsLTP type 2), Api g 3 (chlorophyll a-b binding 
protein), Api g 4 (profilin), Api g 5 (flavoprotein) and in 
celery stalk, additionally Api g 2 (nsLTP type 1).
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Use of Api g 1, 4, 5 increased the sensitivity from 
approximately 70% to 88% (75% rApi g 1, 42% rApi g 
4 and 42% to nApi g 5) (23).
Celeriac induced symptoms range from mild 
oropharyngeal symptoms (OAS) up to anaphylaxis 
(37). No marker allergen for prediction of severe 
reactions has yet been identified. Particular severe 
reactions to celeriac occur in mugwort-sensitised 
patients (23, 37). The culprit cross-reactive allergens 
between mugwort and celeriac have not been 
identified so far. The clinical significance of the 
nsLTPs derived either from celeriac tuber (Api g 6) or 
from celery stalk (Api g 2) has not been confirmed to 
date (12, 13).
Also carrot allergy is highly associated with a 
sensitization to birch and mugwort pollen (24). 
Allergens identified in carrot are Dau c 1 (Bet v 1 
homologue), Dau c 4 (profilin), Dau c 5 (isoflavone 
reductase), Dau c CyP (cyclophyllin) and Dau c 3 
(nsLTP). The diagnostic relevance of Dau c 5 and 
Dau c CyP has not been investigated and it is not 
clear whether Dau c 3 is indeed present in the edible 
parts of carrots. As for celeriac allergy carrot allergy 
induced symptoms range from mild oropharyngeal 
symptoms (OAS) up to anaphylaxis (24).
In the following two typical patterns of celeriac/
carrot allergy are outlined.
A) Patient with a sensitization to Fagales tree pollen 
and IgE to Bet v 1 may develop cross-sensitisation 
to Bet v 1 homologous proteins in Apiaceae 
vegetables such as carrot and celeriac. Symptoms 
are often elicited by unprocessed foods. The 
usual manifestations are local oropharyngeal 
symptoms (OAS).
Cave: Bet v 1 related allergy to carrot and celeriac 
can be associated with systemic reaction. Systemic 
reactions are more frequently observed in Bet v 1 
related celeriac and carrot allergy than in Bet v 1 
related allergy to Rosaceae fruits (37) and might 
be elicited also by processed foods (particularly in 
celeriac allergy) (26).
B. Patient with a sensitization to mugwort pollen 
may develop cross-sensitization to not yet defined 
allergens in celeriac and carrot. The clinical 
manifestation varies from local oropharyngeal 
symptoms up to anaphylaxis. Symptoms are 
elicited by unprocessed and processed vegetables. 
IgE determination and skin testing particularly to 
celeriac extract are often negative. Typical pattern: 
Sensitization to mugwort pollen, positive prick-
prick test with native food, negative testing using 
celeriac extract.
Latex-fruit-syndrome
In 30-70% of patients with a latex allergy associated 
food allergies have been observed, particularly to 
banana, avocado, chestnut, kiwifruit (see kiwifruit 
allergy) and many more (38). 11% of patients with a 
fruit allergy showed symptoms after latex challenge 
(39). Oropharyngeal symptoms are frequently 
observed, but in about 10% of latex associated food 
allergies anaphylactic reactions have been observed. 
As cross-reactive allergens beta-1,3-glucanase (Hev 
b 2), hevein (Hev b 6.02) and the hevein like domain 
of class I chitinases (Hev b 11) have been identified. 
However, further studies are needed since in a recent 
study the pathogenic role of Hev b 6 and Hev b 11 
have been questionned (40).
Clinical diagnosis of fruit and vegetable allergies
Allergies to fruits and vegetables are often initiated by 
a primary sensitization to pollen. Since the majority of 
fruit and vegetable allergens are part of few protein 
families and characterized by a high cross-reactivity 
the clinical relevance of a sensitization needs to be 
often established by food challenges.
Case history
Previous reaction(s) to the incriminated fruit/
vegetable or fruits and vegetables from the same 
plant family. Symptoms onset and course, elicitation 
by raw or processed food, co-factors (exercise, 
NSAID, alcohol etc.), allergies to pollen, latex.
Skin prick test (SPT)
  commercial fruit and vegetable extracts limited 
due to false negative results as a consequence 
of underrepresentation of Bet v 1 homologous 
proteins and in part also nsLTPs
  prick-prick test with offending fruits and 
vegetables increased sensitivity but limited to 
false positive results (irritation of the skin)
IgE-Testing
  Due to the low stability of the Bet v 1 homologous 
proteins, these allergens are in some but not all 
diagnostic food extracts underrepresented (low 
sensitivity) leading to false negative test results.
  IgE Bet v 1 or Bet v 1 homologous proteins in 
reaction pattern A (Pru p 1, Mal d 1, Act d 8, Api 
g 1, Dau c 1) indicative for a Bet v 1 related fruit/
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vegetable allergy but limited by low specificity.
  IgE to nsLTP (Pru p 3, Mal d 3) in reaction pattern 
B, might be associated with systemic reactions, 
limited by low specificity.
  IgE to Act d 1 risk factor for monosensitization 
and for systemic reactions to kiwifruit.
  IgE Hev b 6.02 and Hev b 11 hint for possible 
latex induced fruit allergy.
Challenge tests
  A/C: often not indicated if symptoms are limited 
to the oropharyngeal area, challenge with 
processed foods indicated in case of “unclear” 
history in terms of tolerance, i.e. in celeriac allergy
  B/D/E/F: titrated challenge indicated in cases 
where allergy is not supported by clear-cut case 
history
Clinical management
Advices and avoidance
  A/C: Avoidance of symptom eliciting raw fruits 
and raw vegetables (avoidance of processed foods 
only in patients with positive food challenges 
with the respective processed food)
  B/D/E/F: Avoidance of symptom eliciting raw 
and processed fruits and vegetables, for celeriac 
allergy also traces
Pharmacotherapy (emergency kit)
  A/C: Due to the small risk of systemic reactions 
or severe local reaction (angioedema lips, swelling 
oral mucosa) emergency medication for p.o. self-
administration (antihistamines, steroids)
  B/D/E/F: Emergency medication for p.o. self-
administration (antihistamines, steroids) and in 
case of systemic reaction epinephrine for self-
administration (pen)
Allergen-specific immunotherapy
  Immunotherapy with birch pollen extract in Bet 
v 1mediated fruit allergy showed contradictory 
results (41, 42).
  Oral tolerance induction was observed in Bet v 1 
related apple allergy (43) but results need to be 
confirmed
  Sublingual immunotherapy for patients with 
a nsLTP induced peach allergy using a Pru p 3 
quantified peach extract has shown promising 
results, but the beneficial effect needs to be 
confirmed in the future (44).
CLINICAL CASES
Case 1
History: 28-year-old female patient, with recurrent 
anaphylactic reactions. First anaphylaxis with four 
years after plum, in the following after apple, with 
9 years after peach.
Microarrayed specific IgE: Bet v 1 negative, Bet v 2 
1.2 ISU-E, Ara h 9 2.9 ISU-E, Cor a 8 3.6 ISU-E, Jug 
r 3 8.8 ISU-E, Pru p 3 12 ISU-E
Diagnosis: LTP syndrome with recurrent anaphylactic 
reactions after plum, peach, apple
Recommendation: strict elimination of symptom 
inducing fruits in raw and processed form. 
Emergency kit with antihistamines, steroids and 
adrenaline pen (SLIT with Pru p 3 quantified extract 
has been considered, but denied by the patient).
Case 2
History: Male, 48 years old. Rhinoconjunctivitis to 
birch pollen and oropharyngeal itch to raw apples 
since school age. Regular ingestion of apples 
despite oral symptoms. He gets up in the night 3 
am, ingests three apples into empty stomach and 
develops oral itch, slight swelling of the lips and 
collapses. Two weeks later he gets up again in the 
night, ingests several apples into empty stomach, 
develops severe itch of the oral mucosa, swelling of 
the lips and loses consciousness for few minutes. 
After 1 hour spontaneous regression of symptoms.
In-vitro testing: specific IgE to Bet v 1: 88 kUA/l, 
IgE to Bet v 2 < 0.35 kUA/l, IgE to Pru p 3 < 0.35 
kUA/l.
SPT: Birch pollen, raw apple strongly positive
Food provocation: No symptoms on provocation 
with cooked apple puree, contact urticarial with 
blisters of the oral mucosa and slight angioedema 
of the lips after one quarter of a raw apple
Diagnosis: Anaphylactic reaction with oral contact 
urticaria, angioedema of lips and collapse after 
ingestion of apples into empty stomach due to Bet 
v 1 related apple allergy
Recommendations: Strict avoidance of raw apples; 
cooked apples without dietary restriction (due to 
thermal instability of Bet v 1-related allergens).
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Case 3
History: Young female patient, 23 years old, no atopic 
background. Ingestion of kiwifruit, after 15 minutes 
nausea, abdominal cramps, emesis, diarrhea, drop 
of blood pressure. Emergency treatment.
SPT: negative skin test with birch and grass pollen, 
latex, isolated positive skin test with raw kiwifruit
In-vitro testing (ImmunoCAP): specific IgE Bet v 1 < 
0.35 kUA/l, IgE to Bet v 2< 0.35 kUA/l, IgE to latex 
< 0.35 kUA/l; IgE to kiwi extract < 0.35 kUA/l
Figure 3
Diagnostic work-up in Rosaceae fruit allergy. 
* Patients with sensitization to birch pollen or other Fagales tree pollen and history of Rosaceae fruit in-
duced oropharyngeal symptoms usually do not need further investigation; 
+ Sensitivity of skin test or in vitro IgE determination using fruit extracts might be low due to underrepre-
sentation of Bet v 1 homologues; 
$ In patients from Mediterranean countries: OAS can also be linked to LTP or profilin sensitization. In case 
of LTP mediated OAS strict elimination of fresh and processed food is recommended.
Microarrayed specific IgE: positive to Act d 1 and Act 
d 2
Oral challenge: mucosa challenge with kiwifruit: oral 
contact urticaria, flush face and nausea
Diagnosis: primary kiwifruit allergy with sensitization 
to Act d 1 and Act d 2-
Recommendation: strict elimination diet for raw 
and processed kiwifruit, emergency kit with 
antihistamines, steroids and adrenaline pen.
Positive case history of a Rosaceae 
fruit allergy
SPT birch pollen 
SPT with fresh fruits and/or 
fruit extracts*+
IgE Bet v 1$
IgE fruit extract *
Food challenge *
optional
Elimination diet 
 of fresh fruits
Oropharyngeal symptoms 
(OAS)
Oropharyngeal symptoms 
associated with systemic 
reaction
SPT birch pollen 
SPT with fresh fruits and/or 
fruit extracts+
IgE fruit extract *
IgE Bet v 1 
if available Bet v 1 
homologues in fruits  
(Mal d 1, Pru p 1)
IgE Pru p 3 
 if available nsLTP 
homologues in fruits  
(Mal d 3)
Optional  
IgE Bet v 2  
or homologues in fruits 
(Pru p 4)
Food challenge Food challenge  depending on symptoms Food challenge
Elimination diet 
 of fresh fruits
Elimination diet of fresh 
and processed fruits
Elimination diet 
 of fresh fruits
history
skin test
in vitro test 1
in vitro test 2
challenge
diet
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Wheat is related to several clinically different 
allergic diseases even in different organs 
including food allergy, wheat-dependent 
exercise-induced anaphylaxis, respiratory 
allergy and contact urticarial.
 due to cross-reactivity with other allergens 
including grasses, IgE measurement to whole 
wheat extract gives unreliable results with 
low specificity in diagnostics
 there are several well-characterized 
allergenic molecules such as gliadins 
glutenins and alpha-amylase inhibitors but 
it has been difficult to name single major 
allergens
 the sensitization to individual proteins is 
associated to disease manifestations but 
with a significant overlap
THE ALLERGEN SOURCES
Wheat (Triticum aestivum) may be considered the 
most important source of food globally. For example, 
world trade in wheat is greater than for all other crops 
combined. Most food cultures serve wheat as an 
important part of daily meals, including bread, pasta, 
breakfast cereal, semolina, bulgur and couscous, to 
name a few. Wheat has more vegetable protein than 
other two worldwide important cereals, corn or rice. 
There are several different classifications of wheat 
and a number of different species and sub-species 
have been described, not to mention more than 
25000 cultivars (1). However, there seem to be no 
clinically significant differences in allergenicity.
In most countries, allergy to milk and egg are the 
two most single-common allergies but wheat comes 
as third at least in Germany, Japan and Finland (2). 
Wheat allergy prevalence varies depending on the 
age and region from 0.4% to 4% (2, 3). The most 
typical clinical manifestations of wheat-induced food 
allergy include IgE-mediated food allergy and celiac 
disease. The latter is more an autoimmune disease, it 
is not included in allergy treatment algorithms in most 
countries and is often treated by gastroenterologists 
Mika Mäkelä
WHEAT 
ALLERGY 
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rather than allergists. Therefore, celiac disease is not 
covered in this chapter other than in the classification 
as shown in Fig. 1.
MAJOR AND RELEVANT MINOR 
ALLERGENIC MOLECULES
Basically, wheat is a grass from the Poaceae family. 
The measurement of wheat-specific IgE and its use 
for clinical diagnosis is problematic due to the low 
specificity when using whole wheat extract as a test 
allergen either in SPTs or in serum assays. Wheat-
specific IgE is common among atopic children at all 
ages without true food allergies--up to 65% of the 
patients with grass pollen allergy had false positive 
IgE-ab test results to wheat extracts (4). On the 
other hand, some allergens are underrepresented in 
whole wheat extract based tests due to their relative 
insolubility.
The list of the World Health Organization/
International Union of Immunological Societies 
Allergen Nomenclature Sub-committee lists 27 
wheat allergens (www.allergen.org). Wheat (Triticum 
aestivum) allergen numbers start with Tri a 12 (profilin) 
and end with Tri a 45 (Elongation factor 1). Many 
of the not yet clinically well-studied allergens are 
homologous to characterized grass pollen allergens 
or seedallergens from related cereals.
Wheat proteins have been broadly divided into 
watersoluble albumins, salt-soluble globulins, and 
insoluble prolamins, including the gliadins which are 
soluble in aqueous alcohols, and the glutenins (5) (Fig. 
1). The gliadins and glutenins arethe major storage 
proteins in the wheat grain, also making wheat flour 
suitable for baking. Each of these fractions contains 
allergenic proteins which have been associated with 
clinical symptoms but as yet, there is no concensus 
definition of major and minor allergens of wheat. 
Little is known also of the allergenicity as what comes 
to heating and processing of the fractions.
The best-characterized single component of wheat is 
omega-5-gliadin. Gliadin is a major allergen for wheat-
dependent, exercise-induced anaphylaxis (WDEIA, 
later in this document clinical form B) but also for the 
early childhood wheat allergy with symptoms of type 
I reaction and atopic eczema (later A type) (5-8) and 
baker’s asthma/allergy (type C) (10). Other relatively 
well-documented allergens include alpha-amylase 
inhibitors (AAI), the response to which is associated 
with both baker’s allergy and food allergy (5, 9, 10), 
wheat LTP has also obvious clinical relevance and it 
has been associated with Baker’s asthma (11) and 
food allergy (12).
So far, attempts to find single components predicting 
clinical reactivity have produced at best high 
sensitivity with the expense of low specificity. 
Although an early study showed up to 100% 
specificity for clinical response with sensitization to 
omega-5-gliadin (6), later larger studies recruiting 
more heterogeneous patient groups have produced 
much lower rates for both sensitivity and specificity 
(5, 8).
Figure 1
Classification of wheat-related allergic diseases. Modified from 1.
Pathogenesis
Allergic Autoimmune
Food 
allergy WDEIA
Respiratory 
allergy
Contact 
urticaria
Celiac 
disease
Dermatitis 
herpeti-formis
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SENSITIZATION TO INDIVIDUAL 
MOLECULES AND THEIR CLINICAL 
RELEVANCE
Epidemiology and sensitization/cross reactivity 
rates
Sensitization to wheat among children was < 1% in a 
systematic review taking into account a number of 
studies around the world (13). In a population-based 
study amongst six-year-old children in Britain, wheat 
sensitization rate was 0.4% and most of this was 
concluded to be result from grass sensitization based 
on the food challenges (14). No studies have examined 
response to single proteins at population level.
Cross-reactivity of wheat comes at least from 
sensitization to grass pollen. It varies, however, how 
much of the sensitization can be explained on this at 
different age groups and in different disease conditions. 
Wheat is also highly cross-reactive with other cereals, 
mainly rye and barley (10). Early studies showed that 
prolamins like gamma-70 and gamma-35 secalins in 
rye and gamma-3 hordein in barley cross-react with 
omega-5 gliadin (15) and there are several other proteins 
among these three cereals, which are highly cross-
reactive. Moreover, there is high sequence identity 
among many other proteins such as a-purothionins 
from wheat, rye, and barley ( >80%) (16). In a large study 
of baker’s allergy, rye flour inhibited binding of IgE to 
most wheat allergens at a significant level (9).
There are many more relevant sensitizations to single 
proteins other than gliadins, AAI or LTP. Two recent 
studies have demonstrated the role of sensitization 
to both low-molecular-weight (LMW) Tri a 36 and the 
high-molecular-weight (HMW) glutenin, Tri a 26 with 
most typical type of childhood wheat allergy (5, 8, 13, 
17). Moreover, omega-5-gliadin is not the only gliadin 
that seems to be of significance. Also alpha- beta- 
and gamma-gliadins present as important allergens 
in several studies (5, 8).
Recently, based on construction of T. aestivum 
cDNA library and screening it with serum IgE from 
patients suffering from respiratory wheat allergy 
five novel wheat allergens were characterized: a 
thioredoxin h isoform, glutathione transferase, 1-Cys-
peroxiredoxin, profilin and dehydrin (18). Particularly 
of these, a potential and emerging food allergen is 
alpha-purothionin Tri a 37 (16).
In the largest study of any wheat allergic patients, 19 
recombinant wheat flour proteins and 2 cross-reactive 
carbohydrate determinants were tested in sera of 101 
bakers from several European countries with wheat 
flour allergy. Not a single allergen emerged as major 
Figure 2
Allergenic molecules of wheat grouped according to their solubility.
Wheat protein solubility fractions
Alpha-amylase inhibitors
(AAI)
Lipid transfer protein
(LTP)
Avenin-like protein
Albumin/Globulin
Water/dilute saline Gluten
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one and each baker showed an individual IgE-binding 
profile with great interindividual variation (9).
Taken altogether, there is generally a significant 
overlap of the responses to individual proteins in 
different disease conditions.
CLINICAL RELEVANCE, DIAGNOSIS AND 
MANAGEMENT
Clinical relevance and clinical pattern
Due to different routes and amounts of exposure four 
scenarios can prompt IgE-mediated sensitizations 
and clinical symptoms of immediate hypersensitivity 
(1) (Table 3, A – D).
A) Typically, IgE-mediated form of food allergy to 
wheat is analogous to the symptoms seen in 
milk or egg allergy. Allergic individuals develop 
symptoms within minutes to 1–2 h after ingestion 
of a wheat. The symptoms include urticaria, 
angioedema, erythema, pruritus, vomiting, 
abdominal pain, persistent cough, hoarse voice, 
wheeze, stridor, respiratory distress, nasal 
congestion and, in most severe case, anaphylaxis. 
These may be associated also with delayed-type 
symptoms which include the worsening of atopic 
dermatitis and gastrointestinal symptoms such as 
Table 1
Allergenic molecules of wheat 
Allergen/
IUIS code Biochemical name
MW 
(kDa)
heat 
stability
Tri a 12 Profilin 14 low
Tri a 14 Non-specific lipid transfer protein 9 high
Tri a 15 Monomeric alpha-amylase inhibitor 0.29 high
Tri a 18 Agglutinin isolectin 1
Tri a 19 Omega-5-gliadin, seed storage protein 65 high
Tri a 20 Gamma gliadin 35-38
Tri a 21 Alpha-beta-gliadin 30-45 low
Tri a 25 Thioredoxin 13
Tri a 26 High molecular weight glutenin 88
Tri a 27 Thiol reductase homologue 27
Tri a 28 Dimeric alpha-amylase inhibitor 0.19 13 high
Tri a 29 Tetrameric alpha-amylase inhibitor CM1/CM2 13 high
Tri a 30 Tetrameric alpha-amylase inhibitor CM3 16 high
Tri a 31 Triosepohosphate-isomerase 26
Tri a 32 1-cys-peroxiredoxin
Tri a 33 Serpin 40
Tri a 34 Glyceraldehyde-3-phosphate-dehydrogenase 40-42
Tri a 35 Dehydrin
Tri a 36 Low molecular weight glutenin GluB3-23 40
Tri a 37 Alpha purothionin 12 high
Tri a 39 Serine protease inhibitor-like protein
based on www.allergen.org
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Table 2
Allergenic molecules of wheat 
Allergen Allergenicity Risk factor Clinical response rate
Tri a 12 Profilin inhaled flour baker's allergy, not significant in food allergy
Tri a 14 Non-specific lipid transfer protein
not cross-reactive 
with grass pollen
the allergenicity strengthened 
by activated tissue 
transglutaminase, 
mayh be important both in 
WDEIA and in some cases 
food allergy
Tri a 15
Monomeric 
alpha-amylase 
inhibitor 0.29
60% of the A type 
patients positive
Tri a 18 Agglutinin isolectin 1 ?
elevated general atopic risk 
for childhood food allergies, 
atopic eczema and exposure 
to wheat
mainly recognized by 
patients with baker's 
asthma?
Tri a 19 Omega-5-gliadin 50%-70% of wheat allergic patients
elevated general atopic risk 
for childhood food allergies, 
atopic eczema and exposure 
to wheat
>80%?, marker for severity 
and persistence ?
Tri a 20 Gamma gliadin 50%-70% of wheat allergic patients, 
elevated general atopic risk 
for childhood food allergies, 
atopic eczema and exposure 
to wheat
possibly best severity 
marker 
Tri a 21 Alpha-beta-gliadin
>50% of wheat 
allergic patients? >50%?
Tri a 25 Thioredoxin grass cross-reactivity inhaled flour
Tri a 26 High molecular weight glutenin
50%-70% of wheat 
allergic patients, all 
those with severe 
reaction
significant, testing in 
combination with other 
gluten-derived proteins 
Tri a 27 Thiol reductase homologue
frequently detected 
allergen among 
bakers
inhaled flour not significant in food allergy?
Tri a 28
Dimeric alpha-
amylase inhibitor 
0.19
50%-70% of wheat 
allergic patients
as a single allergen, optimal 
combination for sensitivity 
and specificity
Tri a 29
Tetrameric alpha-
amylase inhibitor 
CM1/CM2
37% of food allergic 
positive
Tri a 30
Tetrameric alpha-
amylase inhibitor 
CM3
high specificity for baker's 
asthma
Tri a 31 Triosephosphate-isomerase
rarely recognized by patients 
with baker's asthma, no data 
on food allergy
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Table 3
Clinical pattern of different types of wheat allergy
A B C D
Routes of sensitiza-
tion (development 
of an aller-gen-spe-
cific IgE immune 
response)
gastro-intestinal (or cuta-
neous) uptake of wheat 
proteins with subsequent or 
concomitant IgE- sensitiza-
tion to stable pro-teins
gastro-intestinal 
uptake of wheat 
proteins with sensi-
tization to especial-
ly omega-5-gliadin
inhalation of wheat flour 
and dust during grain 
processing and subse-
quent sensitization to 
water-soluble allergens
use of local 
cosmetics on 
the skin
Affected (age) group infants/children/rarely 
adults
adults/adolescents Exposed work-ers, typi-
cally bakers
adolescents/
adults
Wheat allergens 
involved
gliadins (ω-5-gliadin most 
important (?) 
ω-5-gliadin, LTP (Tri 
a 14)
combination of Tri a 
27,28,29,39,32 gives 
highest sensitivity and 
specificity
hydrolyzed 
wheat pro-
tein (HWP)/ 
gluten
HMW glutenins   
LMW-glutenins   
AAI's  sensitization to several 
other al-lergens includ-
ing AAI's (particularly 
Tri a 15 and 30), Tri a 21 
and 33 common
 
several others with varying 
sensitization rate
   
Table 2 (continued)
Allergenic molecules of wheat 
Allergen Allergenicity Risk factor Clinical response rate
Tri a 32 1-cys-
peroxiredoxin
? inhaled flour recognized by patients with 
baker's asthma
Tri a 33 Serpin inhaled flour recognized by patients with 
baker's asthma, no data on 
food allergy
Tri a 34 Glyceraldehyde-
3-phosphate-
dehydrogenase
low rarely recognized by patients 
with baker's asthma
Tri a 35 Dehydrin ? inhaled flour mainly recognized by patients 
with baker's asthma
Tri a 36 Low molecular 
weight glutenin 
GluB3-23
60%-80% of wheat 
allergic patients
>50%, testing in combination 
with other gluten-derived 
proteins 
Tri a 37 Alpha purothionin 16% of allergic 
patients with food 
allergy, patients with 
baker's asthma not 
sensitized
marker for severity with food 
allergy?
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Table 3 (continued)
Clinical pattern of different types of wheat allergy
A B C D
Allergen abundance   Not known common in cosmetics
Thermal stability high high low? high?
Digestive stability high high low?
Prevalence (North 
and Middle Europe)
high low low? low
Prevalence (South-
ern Europe)
moderate low low? low
Elicitators (prod-
ucts)
all wheat products  ingested wheat 
prior to exercise
wheat flour and dust 
in the air
hydrolyzed gluten in cos-
metics such as facial soap
Symptoms quick onset (minutes to 
2 hours) of potentially 
severy systemic reactions 
with various symptoms of 
anaphylaxis: 
quick onset urti-
caria, angioedema, 
and/or systemic 
symptoms of ana-
phylaxis
airway symptoms 
(i.e. allergic rhinocon-
junctivis and asthma 
symptoms) within few 
hours of exposure
mucosal (i.e. oro-pharyn-
geal), cutaneous (urticar-
ia, angioedema, eczema 
flaring), airway-related 
(upper and lower air-
ways), gastrointestinal 
and/or cardiovascular 
symptoms
typically urticaria after 
application of the cream/
soap. Ingestion of foods 
containing deami-dated 
gluten can cause systemic 
reactions including ana-
phylaxis
Additional clinical 
features
atopic eczema ( infants 
with wheat allergy), reac-
tions after other cereals 
including rye and barley, 
rarely oats
alcohol consump-
tion enhances 
responsiveness 
 usually patients do not 
have other types of wheat 
allergy
Medical diagnosis obvious and repeata-ble 
food allergic reaction to 
wheat (porridge, bread, 
pasta etc.)
symptoms and his-
tory, sensitiza-tion 
to omega-5-gliadin, 
in some cases chal-
lenge test
Allergic asthma and 
rhinoconjunctivitis 
due to wheat protein 
inhalation
obvious contact urticaria 
when using HWP con-
tain-ing products
Patients can also develop 
type A food allergy.
Type of food allergy class 1 class 1 primary inhalant 
allergy
class I
Avoidance No oral intake of wheat 
at significant amounts 
(milligram levels)
No ingestion of 
wheat
occupational avoid-
ance strategies in sit-
uations of large wheat 
protein exposure
cosmetics containing 
HWP, in those with 
sys-temic reactions avoid-
ance of HWP in food
Product declaration mandatory on each 
wheat-containing prod-
uct (EU law)
mandatory on each 
wheat-containing 
product (EU law)
- ?
Technical solution no general technical 
solution available 
no technical solu-
tions
dust extractor in oc-
cupational settings
?
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stomach pain and diarrhea or loose stools.
Early presumably gastro-intestinal or cutaneous 
sensitization to rather stable wheat allergens (for 
example, omega-5-gliadin, HMW glutenin, LMW 
glutenin, alpha-amylase inhibitor) in often atopic 
infants is the basis of most typical IgE-mediated 
wheat allergy, extending often until school-age 
and in rare cases, up to adulthood.
B) wheat-dependent, exercise-induced anaphylaxis 
(WDEIA) means the appearance of severe 
symptoms after ingestion of wheat followed by 
physical exercise typically among young adults 
and adult individuals. Symptoms vary from 
generalized urticaria to severe anaphylactic 
reaction. Sensitization to omega-5-gliadin is 
the most specific marker for the disease but the 
patients are sensitized also to a number of other 
wheat allergens. This is an important albeit not 
highly prevalent form of wheatallergy.
C) baker’s allergy or asthma comes from inhalation 
of the wheat flour. At the moment, the test 
allergen with most sensitivity but low specificity 
is whole-wheat flour (including all allergens). 
The specificity of testing can be improved by 
component-specific analysis (Table 3).
D) contact urticaria associated with use of cosmetics 
and also sometimes together with food allergy. 
Hydrolysis of wheat is carried out to overcome 
its insolubility in cosmetics and exposure to 
hydrolyzed wheat protein (HWP) can cause 
either contact urticaria or even anaphylaxis when 
consuming deamidated gluten containing food
Clinical diagnosis
Typical case history, careful anamnesis, proper 
interpretation of sensitization tests (i.e. SPT, IgE) and 
as the only golden standard, food challenge, form the 
basis of diagnosis for wheat allergy.
Case history
The most typical clinical picture of wheat-induced 
food allergy is similar to the other early childhood 
food allergies. The symptoms vary from eczema flares 
to anaphylaxis and the association of ingested food 
possibly containing wheat sometimes leads to the 
right direction. When the symptoms are vague and 
delayed the best way to proceed is to put the child 
on elimination diet for 1-2 weeks and monitor the 
response. It is, however, not recommended to test 
children with mild-to-moderate atopic eczema without 
other symptoms for wheat due to common skin prick 
test positivity at this age without clinical relevance.
WDEIA should be suspected when a patient 
has experienced severe urticaria attacks or even 
anaphylaxis associated recurrently with exercise and 
eating preceded the exercise (Fig. 3). Sometimes the 
level of exercise can be relatively light such as brisk 
walking. It is also important to inquire possible use 
of alcohol and/or of acetylsalicylic acid (ASA) at the 
time of the reaction (19).
Baker’s allergy is mainly seen in occupational settings 
and it should be suspected with patients suffering 
from chronic severe rhinitis and/or asthma symptoms.
Contact urticaria with use of cosmetics is relatively 
common and hydrolyzed wheat should always be 
thought as one possible inducer.
Skin prick test (SPT)
  comercial wheat extract or in-house solution 
employing wheat flour. Some authorities have 
claimed that this should not be used at all due 
to the very low specificity for all types of wheat 
allergy. Specificity can be improved by additional 
testing to omega-5 gliadin (dissolved in ethanol, 
in-house preparation) or other gliadins. For clinical 
pattern D, hydrolyzed wheat protein should be 
tested. There is little experience on SPT testing 
for other single proteins.
Figure 3
Severe urticaria on the whole body seen in a 
young woman after wheat ingestion and exer-
cise challenge.
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IgE-Testing
allergen-specific IgE (commercially available are 
whole wheat extract, Tri a 14, Tri a 19, gliadins)
  wheat extract (low specificity although high 
sensitivity) to clinical patterns A-C
  omega-5-gliadinand gliadins (alpha, beta, gamma) 
for clinical patterns A and B
  lipid transfer proteins (Tri a 14) for A and B, 
probably no cross-reactivity with grass pollen 
although there are not enough data to exclude 
this. Measuring sensitization may help in 
differentiating wheat sensitization from pollen 
allergy in patients with high levels of grass pollen-
specific IgE, not very sensitive
  AAI’s, particularly dimeric 0.19, LMW and HMW 
glutenins, Tri a 37 for A and C
  combination of Tri a 27,28,29,39,32 for C
Challenge tests
Clinical pattern A mainly: various protocols with 
whole wheat can be used, for example, challenge 
in children with wheat flakes containing porridge or 
bread (5). Start with low dose (1-50 mg) of wheat-
specific protein. A suitable time interval between 
the increasing doses should be an hour (digestion of 
wheat may be slower than milk and egg). Continue up 
to 500 mg-1 g of cumulative dose of wheat protein. 
Also double-blind placebo-controlled protocols have 
been published both for children and adults (5, 20).
Clinical patterns B and C: usually case history and 
IgE testing is enough for diagnosis. In uncertain 
cases, carefully monitored exercise challenge with 
high readiness for anaphylaxis after wheat ingestion 
may be considered. Some centers have used ASA or 
alcohol as additional provocating factor instead of 
exercise (19) (Fig. 3).
Pattern D: challenge on the skin with HWP containing 
cream
Clinical management
Advices and avoidance
Patients with severe wheat allergy should be 
discouraged to try different forms of wheat. There 
is no evidence of reduced allergenicity between 
different species of wheat such as spelt. Little is 
known of changes in allergenicity during processing.
A: Avoidance of all wheat containing products, the 
level of avoidance can be titrated according to 
symptoms. Those with anaphylaxis should avoid 
products even with small amounts of wheat. 
Those with delayed symptoms and IgE-negative 
to wheat should be encouraged to use maximal 
dose not eliciting symptoms.
B: Avoidance of all gluten containing wheat
C: Avoidance of inhalation of wheat containing 
proteins
D: Avoidance of cosmetics with hydrolyzed wheat 
protein
Pharmacotherapy (emergency kit)
A: For those with delayed reactions or mild systemic 
reactions, antihistamine at age-dependent 
dosages is enough. Because of the rapid absorption 
of cetirizine as compared to other antihistamines 
such as loratadine or desloratadine, it may be 
the antihistamine-of-choice. For those with a 
history of severe reactions in food challenge or 
after unintentional ingestion of wheat containing 
products, use of adrenaline autoinjector should 
be instructed carefully
B: Adrenaline autoinjector
C: Symptomatic treatment as required for rhinitis/
asthma
Allergen-specific immunotherapy
At present there are no commercially available 
products. Clinical studies are being done on oral 
immunotherapy for clinical pattern A but, as to 
date, there are not enough published data to draw 
conclusions about proper product to use or adequate 
protocols.
Prognosis
The studies on prognosis of wheat allergy have 
demonstrated a high rate of spontaneous resolution 
of the symptoms in children similar to that of milk or 
egg allergy (8, 21, 22, 23). In one study, sensitization 
to gliadins correlated best with persistent wheat 
hypersensitivity and the development of asthma in 
children (22). Generally, high levels of wheat-specific 
IgE predict slower resolution and those with IgE 
negative allergy are clinically tolerant by age three. 
Taken altogether, children should be challenged at 
certain intervals, in early childhood yearly, to test for 
development of tolerance.
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CLINICAL CASES
Case 1 (original)
History: 9-year old boy. Atopic dermatitis since early 
infancy. First obvious reactions to wheat (skin 
flares with eczema, urticaria) soon after start of 
wheat at 6 months. First anaphylactic reaction to 
wheat at 2 years of age with generalized urticaria, 
bronchial obstruction and vomiting. Strict 
avoidance and adrenalin autoinjector continued 
until now. Developed also birch allergy at 2 years 
of age and later other pollen sensitizations. Avoids 
some fresh vegetables such as cucumber, pea, 
nuts and banana due to oral allergy syndrome 
symptoms. The family wants to know whether to 
continue avoiding wheat or not.
SPT: whole wheat extract 9 mm, omega-5-gliadin 7 
mm, rye 5, barley 5, oat 0. Birch 7 mm, timothy 
grass 5 mm.
Specific serum IgE: wheat 390 kU/l, omega-5-gliadin 
18 kU/l, timothy grass 40 kU/l, birch 100 kU/l.
Oral challenge: wheat porridge 1ml (=13 mg wheat 
protein) as a starting dose: mild tickling in the mouth 
which resolves spontaneously. With doubling the 
dose, the boy starts vomiting, complains of nasal 
obstruction.
Diagnosis: wheat allergy.
Recommendation: complete avoidance of wheat, 
adrenalin autoinjector guidance for the boy and all 
caretakers.
Case 2 (original)
History: 30-year-old female nurse. Generally 
healthy and mild pollen allergy. During the last 
few years occasional urticaria which the patient 
has sometimes linked to wheat ingestion (bread, 
pasta). Occasionally urticarial appearance after 
brisk walk or jogging.
SPT: whole wheat extract 5 mm, omega-5-gliadin 7 
mm, rye 3, barley 3, oat 0.
Specific serum IgE: wheat 20 kU/l, omega-5-gliadin 
10 kU/l.
Challenge: large amount of pasta ingested. One hour 
later a nurse-controlled free field running test 
for 6 minutes was performed. During the last 2 
minutes patient starts complaining severe itching 
and develops rapidly massive generalized urticaria, 
no signs of bronchial obstruction or severe 
gastrointestinal symptoms. Receives adrenalin, 
which relieves urticaria (see Figure 3 after one 
adrenalin injection). The urticaria starts increasing 
again in 15 minutes, and the patient receives 
another adrenalin shot. After this, the urticaria is 
resolved, and the patient feels fine.
Diagnosis: wheat-dependent exercise-induced 
urticaria.
Recommendation: 4 hours after ingestion of wheat 
no exercise including brisk walking.
Case 3 (original)
History: 37-year-old female cook who later studied 
to become pastry chef/ baker. After 2 years of 
working as a baker the patient started experiencing 
nasal symptoms first from rye flour and later from 
wheat and malt flours. No asthmatic symptoms at 
any time.
SPT: whole wheat extract 0 mm as were the other 
cereals
specific serum IgE: in-house immunoassay with the 
working place dust from wheat flour and rye flour 
positive. Wheat IgE 2.1 kU/l, rye 0.8 kU/l.
Challenge: chamber challenge with wheat flour 
induced nasal symptoms and also increase in nasal 
resistance (acoustic rhinomanometry).
Textbox 1
Highlights
  wheat allergy can manifest as different clinical 
conditions including typical childhood food 
allergy, wheat-dependent exercise-induced 
food allergy and baker’s allergy/asthma
  The IgE response is diverse among patients 
and is directed against a number of allergens 
in all clinical conditions
  specific IgE to whole wheat extract is often 
positive without clinical significance in all 
age groups, not only due to heavy cross-
reactivity with grass pollen
  component-specific measurement of the 
response improves specificity but at the 
moment the only golden standard remains 
food challenge
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Diagnosis: occupational allergic rhinitis due to wheat 
and rye (baker’s allergy)
Recommendation: primarily a respiration filter and 
change of the station in the kitchen. This did not 
help this patient enough so she is considering to 
learn a new profession. 
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Soy allergens can induce food allergic 
reactions and occupational inhalant allergies
IgE sensitizations to stable seed storage 
proteins Gly m 5, 6 and 8, more common in 
infants, are associated with severe allergic 
reactions
In regions with birch pollen exposure Bet v 
1-crossreactive soy allergen Gly m 4 induces 
the most common soy allergy
Oropharyngeal and sometimes severe 
reactions to Gly m 4 are limited to fresh, 
hardly processed soy protein containing 
products
THE ALLERGEN SOURCES
Soybeans, a legume species native to East Asia, 
represent a rich and inexpensive source of proteins 
for animal feeds and foods, including textured 
vegetable protein (TVP) in many meat and diary 
analogues (Fig. 1).
Soybean is grouped within the “big eight” foods 
being responsible for 90% of all allergic reactions and 
an important allergen source due to the wide use in 
processed foods presenting a hidden allergen carrier 
(1). Fermented soy products such as soy sauce and 
miso are much less allergenic compared with tofu 
and soymilk (2, 3). Advising complete avoidance of 
all soy products impairs quality of life for soybean 
allergy patients.
Allergic reactions have been described after exposure 
to
A) highly processed soy (containing) products, 
including TVP (for review see (1, 4).
B) hardly processed (5-7) as well as
C) unprocessed soy beans (8-11).
Jörg Kleine-Tebbe, Kirsten Beyer, Motohiro 
Ebisawa
SOY 
ALLERGY 
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A) Since many decades, occasionally severe allergic 
reactions primarily in children have been 
attributed to processed soy containing foods 
(12), based on IgE to stabile, officially recognized 
soybean allergens (see Table 53, www.allergen.
org) and some suggested soy proteins (see www.
allergome.org; search for Gly m).
B) Since 2002 allergic reactions have increasingly 
been recognized in birch pollen allergic individuals 
after ingestion of hardly processed dietary soy 
powder containing or soy drink products (5, 6, 
13). These often oro-pharyngeal symptoms due 
to IgE-related cross reactivity present the most 
common type of soy allergy in the northern 
hemisphere, particularly in regions with relevant 
birch pollen exposure (13).
C) High exposure and inhalation of raw unprocessed 
soybeans during unloading of freight ships caused 
epidemic outbreaks of inhalant allergies in harbor 
workers as well as citizens in close vicinity (8-11).
MAJOR AND RELEVANT MINOR 
ALLERGENIC MOLECULES
At least 16 soybean allergens have been identified 
displaying metabolic, storage or protective functions 
(for review see (1). ). They belong to diverse protein 
families characterized by conserved three-dimensional 
structures leading to broad immunochemical IgE 
mediated cross-reactions among different members 
of the legume families or other plant foods. Due to 
complexity and heterogeneity of soybean proteins the 
relationship between their structure and subsequent 
allergenicity has only partly been addressed.
In the past numerous fractions of soybeans and 
various soy proteins with partial characterization were 
proposed to induce IgE-mediated hypersensitivity food 
reactions (for extensive review of older literature on soy 
allergy until 2000 see online repository http://www.
food-allergens.de and (4), newer literature until 2007 
see (1) or inhalant allergies (i.e. Gly m 1, Gly m 2).
Figure 1
Soybean foods and ingredients (figure modified from (1)).
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Table 1
Allergenic molecules of soy
Allergen Biochemical name MW Heat  stability Isoforms 
Gly m 1 hydrophobic protein (shell), LTP 7 ? 2
Gly m 2 defensin 8 low?
Gly m 3 profilin 14 low 2
Gly m 4 pathogenesis-related protein, PR-10, Bet v 1 
family member
17 low 1
Gly m 5 "beta-conglycinin (vicilin, 7S globulin)" 63-65 (α-s.u.)
48 (beta-subunit) high 2 (α-s.u.)
2 (beta-subunit)
Gly m 6 glycinin (legumin, 11S globulin) 52-61 (s.u.) high 5 (s.u.)
Gly m 7 seed biotinylated protein 76 ? 1
Gly m 8 2S albumin 28 high 1
Gly m 39kD, P39
Gly m Agglutinin Agglutinin, Lectin
Gly m Bd28K 7S vicilin-like globulins
Gly m 30kD cysteine protease
Gly m CPI cystatin
Gly m TI trypsin inhibitor
Figure 2
Major and relevant minor allergenic molecules of soy. Gly m xy: Gly m 39kD (P39), Gly m Agglutinin, Gly m 
Bd28K, Gly m 30kD, Gly m CPI, Gly m TI (soybean allergens without official designation, www.allergome.
org), boldface: available for allergen-specific IgE diagnostics.
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During the last 15 years additional soy allergens (Gly 
m 4 - 8) have been identified and officially accepted 
by the IUIS Allergen Nomenclature Sub-Committee 
(Table 1).
SENSITIZATION TO INDIVIDUAL 
MOLECULES AND THEIR CLINICAL 
RELEVANCE
Reliable data on sensitization rates are available only 
for Gly m 4, 5 and 6.
Epidemiology and sensitization/cross reactivity 
rates
Previous sensitization rates were mainly based 
on skin or IgE testing to whole soybean extracts 
(for recent review and summarized analysis of 
sensitization rates in children see (12): From 40 
studies identified weighted prevalence of soy allergy 
in children was reported, providing ranges and total 
means (in brackets) between 0 and 0.5 % (0.27%) for 
the general population, 0.4 to 3.1 % (1.9%) for the 
referred population, and 0 to 12.9 % (2.7%) for IgE-
sensitized children (12).
IgE testing in a large cohort of approx. 13,000 young 
German subjects between 3 to 17 years revealed 
allergen-specific IgE to soybean extract in 6.3% of 
the cohort (14). A similar approach in approx. 7,000 
German adults revealed sensitization rates of 3.7% to 
soybean extract and 10.3% to soybean allergen Gly 
m 4 (15).
Notably, conclusions on primary sensitization rates 
are hampered due to highly cross reactive, labile 
soybean allergens of low abundance:
  Bet v 1-homologue Gly m 4 and
  Soybean profilin Gly m 3 (i.e. presumably in 
regions with high grass pollen exposure and 
subsequent sensitization to i.e. grass profilin).
Gly m 4 (and possibly Gly m 3) are underrepresented in 
diagnostic soybean extracts leading to vast differences 
between extract and single allergen based IgE results 
(15). In addition, the (low) presence of Gly m 4 (and Gly 
m 3) in soybean extracts will obscure a differentiation 
of food reactions to stabile allergens (i.e. Gly 5 (16, 17), 
6 (16, 17), and 8 (18, 19), likely to be well represented 
in soybean extracts) and cross reactions to the Bet 
v 1-homologue in soy, as demonstrated in cohort 
studies with atopic children (20).
Sensitization rates to Gly m 1 - 3 and Gly m 5 - 8 are 
still lacking.
CLINICAL RELEVANCE, DIAGNOSIS AND 
MANAGEMENT
Clinical relevance and clinical pattern
Due to different routes and amounts of exposure, 
degree of soybean processing and physicochemical 
properties of the involved soybean protein allergens, 
three distinct scenarios (Table 3, A – C) can prompt 
IgE-mediated sensitizations and clinical symptoms of 
immediate hypersensitivity:
A) (Early) presumably gastro-intestinal (or 
cutaneous?) sensitization to rather stable soybean 
allergens (i.e. Gly 5 (16, 17), 6 (16, 17), and 8 (18, 
19), and many others) in atopic individuals are the 
basis of subsequent severe systemic reactions 
after ingestion of small amounts of (processed) 
soy products (1, 4), IgE-sensitizations (i.e. to 
seed storage proteins such as 7S globulins, 11S 
globulins and 2S albumins) could also evolve 
from exposure and subsequent IgE-sensitization 
to more than one legume (i.e. peanut and soy) 
prompting symptoms occasionally after ingestion 
of peanut as well as soy products. These reactions 
- considered rather rare - have mainly described in 
young infants (16, 18), and are hardly reported in 
adults (8, 17)
B) Exposure to fagales pollen in atopic individuals 
developing Bet v 1-specific IgE with variable 
degree of cross reactivity to soybean PR-10 
protein Gly m 4 (in >70% of Bet v 1-sensitized 
individuals), potentially inducing mainly oro-
pharyngeal and sometimes systemic allergic 
symptoms after consumption of mildly processed 
soy products (i.e. soy protein powder, soy drinks 
etc.) in approx. 10% of birch pollen sensitized 
subjects (5-7). These individuals are likely to have 
very high IgE to birch pollen (6, 21).
This type of soy allergy due to Bet v 
1-crossreactions is considered the most prevalent 
soy allergy in Northern and Middle Europe, 
presumably also in Northern parts of Asia, as well 
as in North America (Canada, Northern states of 
the US), depending on the degree of birch pollen 
exposure.
C) Massive exposure to unprocessed soybeans 
inducing IgE-mediated sensitizations to hull 
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Table 2
Clinical relevance of IgE sensitization to soy allergenic molecules
Allergen Allergenicity Risk factor Sensitization rate
Clinical 
response rate
Gly m 1 90% of exposed 
harbor workers
occupational massive exposure to soy beans ? ?
Gly m 2 ? ? ? ?
Gly m 3 ? high grass pollen exposure, individuals with 
broad pollen-specific IgE repertoire? ? ?
Gly m 4 70% serological 
Gly m 4 cross 
reactivity in Bet 
v 1-sensitized 
individuals
a) Birch pollen Bet v 1-related sensitization
b) high native Gly m 4 content in less 
processed soy products "
10.3% in a 
representative 
cohort of >7000 
German adults 
(583)
10(-20?)% clinical 
Gly m 4 cross 
reactivity in Bet 
v 1-sensitized 
individuals (575)
Gly m 5 ? elevated general atopic risk for infant (adult) 
food allergies, atopic eczema and exposure 
to seed storage proteins from soy 
? ?
Gly m 6 ? elevated general atopic risk for infant (adult) 
food allergies, atopic eczema and exposure 
to seed storage proteins from soy
? ?
Gly m 7 ? ? ? ?
Gly m 8 ? elevated general atopic risk for infant (adult) 
food allergies, atopic eczema and exposure 
to seed storage proteins from soy 
? ?
allergens (Gly m 1, Gly m 2) with subsequent 
inhalant allergies in exposed (newly or formerly 
nsLTP-sensitized) individuals (8-11).
Clinical diagnosis
Specific questions, proper interpretation of 
sensitization tests (i.e. SPT, IgE) and optional food 
challenges help to establish the diagnosis of soy 
allergy. Following work-up (Fig. 3) might facilitate 
proper diagnosis.
Case history (anamnesis)
Previous reaction(s) to soy, symptoms, affected 
organ system(s), onset and course (progression), 
soy containing food items (highly-, mildly-, non-
processed grade), co-factors (exercise, NSAID, 
alcohol etc.), previous reactions after other allergen 
sources (i.e. peanuts or Bet v 1-related plant foods 
in table 3, see Section C02 on Bet v 1-related cross 
reactivity), additional (allergic) features, i.e. birch 
pollen allergy, LTP sensitization (see Section C03 on 
LTP allergy syndrome), additional atopic diseases, i.e. 
atopic eczema, asthma.
Working hypothesis: based on soy-related clinical 
pattern A - C (Table 3).
Skin prick test (SPT)
  commercial soy extract (reasonable results in case 
of highly abundant allergens, i.e. seed storage 
proteins, limited value due to false negative 
responses in case of cross reactive labile soy 
allergen, i.e. Gly m 4 as elicitators),
  prick-prick test with offending soy product (in 
case of severe anaphylactic reaction, preferably 
titrated testing with diluted soy product or primary 
IgE-testing before SPT; potentially false negative, 
depending on the abundance and stability of the 
soy allergen in question, i.e. Gly m 4)
  prick-prick test with mildly processed soy drink 
or soy powder (if Gly m 4 is suspected)
IgE-Testing
total total IgE (for appropriate interpretation of 
allergen-specific IgE)
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Table 3
Features and clinical pattern of three different types of soy allergy
A B C
Routes of 
sensitization 
(development of 
an allergen-spe-
cific IgE immune 
response)
1. gastro-intestinal (or cuta-
neous) uptake of soybean 
proteins with subsequent 
IgE- sensitization to stable 
soybean proteins
or
2. gastro-intestinal (or cu-
taneous) sensitization of 
other legume proteins (i.e. 
peanut) with subsequent 
cross-reactivity to i.e. stable 
soybean proteins
1. inhalation of birch pollen 
allergens and subsequent 
IgE-sensitization to major 
allergen Bet v 1
or 
2. presumably inhalation of 
(grass) pollen allergens and 
subsequent sensitization to 
pollen profilin (i.e. from grass-
es, Phl p 12 from timothy)?
1. inhalation of (unprocessed) 
soybeans and subsequent 
sensitization to hull aller-
gens
or
2. previous sensitization to 
LTP-containing plant foods 
(i.e. peach) or LTP-contain-
ing pollen (mugwort, pari-
etaria, plane tree) with cross 
reactivity to soy LTP? 
Affected (age) 
group
infants/children
> adults
adults/adolescents
> children (occasoinally)
Exposed workers and citizens 
in close vincinity
Figure 3
Diagnostic work-up in soy-related allergic reactions (representing food allergy class 2 in left column and 
class 1 in right column). Arrows indicate potential diagnostic steps; dashed arrows indicate that mild as well 
as severe reactions can be associated with different clinical features (information from the allergy history).
With birch pollen allergy and/or 
broad crossreactivity to 
Bet v 1-related plant foods
(adults>adolescents>>infants)
Pos SPT to birch pollen
Pos SPT to unprocessed soy
Neg SPT to processed soy
(SPT to birch > soy extract)
Pos IgE to Bet v 1
Pos IgE to Gly m 4
Low (neg) IgE to soy extract
(IgE to Gly m 4 > soy extract
Food challenge (optional):
Mild (oro-pharyngeal) > 
systemic reactions 
No birch pollen allergy or 
broad crossreactivity to Bet v 
1-related plant foods
(infants>>adolescents/adults) 
Often neg SPT to birch pollen
Pos SPT to processed and 
unprocessed soy
(SPT to soy > birch extract)
Often neg IgE to Bet v 1
Pos IgE to Gly m 5, 6, 8
High IgE to soy extract
(IgE to soy > Gly m 4)
Food challenge (if needed):
Severe (systemic) > mild 
reactions 
Birch pollen (Bet v 1)-related soy allergy, 
avoid unprocessed soy products
Primary soy allergy confirmed, 
soy products avoidance and emergency kit 
Mild (oro-pharyngeal) reaction to soy Severe (systemic) reaction to soy
history
SPT
IgE
challenge
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Table 3 (continued)
Features and clinical pattern of three different types of soy allergy
A B C
Soybean allergens 
involved
Gly m 5; Gly m 6; Gly m 7? ;Gly m 8?
and others (without official IUIS-
name, see table 1)
Gly m 4; Gly m 3 (presumably) Gly m 1 (LTP); Gly m 2 
(defensin)
Allergen abun-
dance
moderate to high content (i.e. seed 
storage proteins Gly m 5, 6 and 8) in 
soy beans and related products
1. low content of Gly m 4 in soy 
beans and soy protein (0.01-
0.1%) and related, less pro-
cessed soy products
2. Gly m 3 content not known
Not known
Thermal stability high low moderate
Digestive stability high low moderate
Prevalence (North 
and Middle Eu-
rope)
low high ?
Prevalence 
(Southern Europe)
low low occasionally asthma 
outbreaks in the past
Elicitators (prod-
ucts)
Many soy products (including highly 
processed or refined soy products) 
Hardly processed soy products 
(soy drinks, soy protein powder, 
even after 1st consumption
Unprocessed soybeans 
(i.e. during unloading)
Symptoms quick onset (minutes to 2 hours) of 
potentially severy systemic reactions 
with various symptoms of anaphy-
laxis: mucosal (i.e. oro-pharyngeal), 
cutaneous (urticaria, angioedema, 
eczema flaring), airway-related (up-
per and lower airways), gastrointesti-
nal and/or cardiovascular symptoms
quick onset (2 - 30 minutes) 
mostly mild mucosal symptoms 
(oro-pharyngeal), occasionally 
severe reactions (angioedema, 
i.e. eyelid-, lip-, ear- and/or 
throat swelling) and/or rare sys-
temic symptoms of anaphylaxis 
(see left column)
airwary symptoms (i.e. 
allergic rhinoconjunctiv-
is and asthma symp-
toms) within few hours 
of exposure
Additional clinical 
features
atopic eczema (i.e. in infants with 
soy allergy), sometimes also (poten-
tially severe) reactions after other 
legumes, i.e. peanut, lupine (flour), 
seeds or tree nuts 
commonly additional (multiple) 
clinical cross reactivities to oth-
er Bev v 1-related plant foods, 
i.e. apple, hazelnut, cherry, 
plum, peach, carrot, celery
Medical diagnosis Risk of systemic food allergic reac-
tion to stable soybean proteins
Birch pollen/Bet v 1-related 
food allergy to cross reactive 
soy allergen Gly m 4
Allergic asthma and rhi-
noconjunctivitis due to 
soy protein inhalation
Type of food 
allergy
class A class B primary inhalant allergy
Avoidance Advising avoidance of allergenic soy 
products, in most cases soy sauce 
and miso can be consumed
No ingestion of large amounts 
of unprocessed soybean 
products
occupational avoidance 
strategies in situations 
of large soy protein 
exposure (unloading of 
soy shipments)
Product 
declaration
mandatory on each soy-containing 
product (EU law)
(voluntary) additional warning 
on hardly processed soy 
products particularly for birch 
pollen allergic individuals
- 
Technical 
solution
no general technical solution 
available 
thermic or pressure processing 
of soy to reduce content in 
labile soy proteins
dust extractor in 
occupational settings
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allergen-specific IgE:
  soy extract (22) (IgE potentially false negative or 
low titers in case of clinical pattern B),
  Gly m 5 (16, 17), 6 (16, 17) and 8 (18, 19) (if soy-
related clinical pattern A, Table 55)
  Gly m 4 and/or Bet v 1 (if soy-related clinical 
pattern B, Table 3)
Interpretation of SPT and IgE (sensitization tests) 
outcome see also Fig. 81:
Results only clinically relevant in case of corresponding 
symptoms after soy ingestion.
Challenge tests
(in case of doubtful relationship between soy 
ingestion and allergic reaction):
Depending on the clinical pattern (A – C) titrated 
(oral) provocation with
A) offending or another appropriate soy protein 
containing product (soy powder, tofu, soy drink)
B) preferably mildly processed soy protein containing 
product with soy allergens of low abundance (i.e. 
Gly m 4)
C) if needed, nasal/bronchial challenge with titrated 
soy extracts or the offending (unprocessed) soy 
products
Clinical management
Advices and avoidance
A) Avoidance of soy containing products depending 
on the symptom-eliciting-dose and the severity 
of the event (rule by thumb): in case of severe 
reactions after a small dose avoidance of 
small amounts, regardless of the grade of soy 
processing; in case of a mild reaction after a large 
dose less strict avoidance needed. Fermented 
soy products such as soy sauce and miso are 
much less allergenic compared with tofu and 
soymilk (2, 3) Advising complete avoidance of all 
soy products impairs quality of life for soybean 
allergy patients.
B) Avoidance of larger amounts of soy products, 
particularly if hardly or mildly processed (i.e. due 
to thermal processing, heating, like soy drinks, 
soy powders).
C) Avoidance of inhalation of soy containing (hull) 
proteins
Pharmacotherapy (emergency kit)
A) Due to the risk of severe reactions after 
unintentional ingestion of soy containing 
products emergency medication including self-
administered adrenaline required
B) Emergency medication optional (not mandatory)
C) Symptomatic treatment as required
Allergen-specific immunotherapy
At present commercially available products for 
allergen-specific immunotherapy of soybean protein 
allergy are not available.
CLINICAL CASES
Case 1 (published (23))
History: girl, 16 years old, atopic dermatitis: 
After 20 min. bike riding anaphylactic reaction 
(abdominal pain, dyspnea, semiconsciousness, 
generalized flushing and swelling, low blood 
pressure), subsequent emergency treatment and 
hospitalization (2 days). Two similar reactions 
during bike riding before. No food allergy to soy, 
peanut or other food item known so far.
SPT: Tofu, soy milk, boiled green soybean, soybean 
flour weakly positive (half histamine-equivalent), 
miso, soy sauce and soybean fibers negative.
In-vitro testing: Total IgE 542 kU/l, specific IgE to 
soybean 34 kUA/l, peanut 1.3 kUA/l, wheat, 
Omega-5-Gliadin, various pollen including birch 
pollen and Gly m 4 negative.
Microarrayed specific IgE: high to Gly m 5 
(ß-conglycinin); Gly m 6 (glycinin), Gly m 3, CCD 
negative.
Oral challenge: 30 minutes exercise after ingestion 
of 200 g tofu development of severe urticaria 
and face swelling. No reactions after boiled green 
soybeans, soy milk, without or with exercise.
Diagnosis: Food-dependent exercise-induced 
anaphylaxis (FDEIA) to soybean allergen Gly m 5.
Recommendation: 4 hours after ingestion of soybean 
products (particularly tofu) no exercise.
Case 2 (original)
History: Male, born 1954: Since 1996 severe birch 
pollen induced rhinoconjunctivitis; after ingestion 
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of raw apples, hazelnuts or strawberries oral itch. 
Adverse event after SCIT with non-modified birch 
pollen extract with severe systemic reaction.
In 2006 after soy dessert increasing local itch (after 5 
min: mouth, palate; after 15 min: eyes) and complete 
eyelid swelling within 20-30 min; subsequent 
emergency treatment and hospitalization overnight. 
In 2012 after 3 fresh apple pieces local itch (3 min: 
mouth, palate) and burning throat, after 15 min. 
almost complete eye lid swelling, itchy eyes, stuffy 
nose and after 30 min itchy hives at upper limbs; 
subsequent emergency treatment.
In-vitro testing: 2007: Total IgE 37 kU/l, specific IgE 
to Gly m 4: 2.3 kUA/l. 2012: Total IgE 48.5 kU/l, 
specific IgE to Bet v 1: 24 kUA/l (almost 50% of 
total IgE specific for Bet v 1 indicating a strong 
sensitization to Bet v 1 with cross reactivity to 
structurally related allergens).
Diagnosis: Angioedema after soymilk ingestion due 
to Gly m 4 (Bet v 1-cross reactive soy allergen)
Recommendations: Strict avoidance of mildly 
processed soy protein products and raw apples; 
great care with large amounts of raw, Bet v 1-cross 
reactive pome and stone fruits, tree nuts and 
legumes. Cooked plant products without dietary 
restriction (due to thermal instability of Bet v 
1-related allergens).
Case 3 (primary sensitization (18))
History: Male (2y 9m)
He had started to develop atopic eczema around his 
mouth at 4 months after birth. He first received 
blood examination at the age of 8 months and 
was already sensitized to egg white, wheat, and 
soybean (total IgE 250 IU/ml, egg white 21.40 kU/
ml, wheat 3.19 kU/ml, and soybean 0.99 kU/ml). 
He was advised to avoid those foods from diet by 
the doctor. He then visited a hospital at the age of 
2y 5m to receive oral food challenges.
In-vitro testing: His laboratory finding at the first visit 
was as follows; total IgE 5650 IU/ml, egg white 70 
kU/ml, wheat 3 kU/ml, and soybean 17.1 kUml 
(Gly m 8: 37.6 kU/ml, Gly m 5: 4.9 kU/ml, Gly m 
6: 1.1 kU/ml).
Diagnosis: He then received soy product (Tofu) 
challenge at the age of 2y 9m, and developed skin 
rash, and sneezing + coughing at the dose of 9 g 
of tofu.
Recommendations: Avoidance of tofu, soymilk but 
not soy sauce, miso, and natto was advised.
Prognosis: He has naturally outgrown from soybean 
allergy 1 year later with soybean IgE 1.90 kU/ml.
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Peanut allergens can induce severe food 
allergic reactions
IgE sensitizations to stable seed storage 
proteins (Ara h 2, less to Ara 1, 3 and 6), 
mainly developing in infancy and early 
childhood, are associated with severe allergic 
reactions
Depending on regional pollen or allergen 
exposures IgE sensitization to cross-reactive 
(pollen) allergens can occur in adolescents 
and adults being rarely responsible for severe 
reactions
Due to the incomplete panel of identified 
peanut allergens and the difficulties 
interpreting sensitization results diagnostics 
with peanut extract and oral peanut 
challenges are integral part of current allergy 
work-up
THE ALLERGEN SOURCES
The peanut (Arachis hypogaea) belongs to the legume 
family (Leguminosae). Peanuts are most commonly 
grown in China, followed by India and the United 
States of America. Many different cultivars are 
known. Peanuts are a common trigger of food-
induced anaphylaxis. In many parts of the world 
such as Europe or the US peanuts are primarily 
consumed in roasted form. They might be eaten 
as whole peanuts, peanut butter, peanut flips or 
as an ingredient in many products. Peanuts can be 
roasted in the shell and sold like this or they are 
shelled, blanched, oven roasted either dry or in oil, 
and ground for the production of peanut butter or 
to be sprayed on peanut flips. In other parts of the 
world such as Asia and Africa, raw peanuts are used 
more commonly as a cooking ingredient. Peanuts 
have a high protein content of 24%–29% and contain 
various allergens. The processing of peanuts seems 
to be important in regard to their allergenicity as 
roasting at high temperatures likely promotes the 
formation of compact globular protein aggregates 
that can increase the allergenicity of Ara h 1 and 2 
(1), whereas cooking might reduce their allergenicity. 
In addition peanut oil is commonly used and in its 
Jörg Kleine-Tebbe, Kirsten Beyer, Motohiro 
Ebisawa
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unrefined form, may contain sufficient amounts of 
allergens to trigger allergic reactions.
MAJOR AND RELEVANT MINOR ALLERGENS
A number of peanut allergens have been identified. 
Many of them have protective functions or are seed 
storage proteins. The peanut allergens belong to 
diverse protein families leading to immunochemical 
IgE-mediated cross-reactions among different 
members of the legume families but also other plant 
foods such as tree nuts (2). The identified peanut 
allergens are shown in Table 1.
SENSITIZATION TO INDIVIDUAL 
MOLECULES AND THEIR CLINICAL 
RELEVANCE
Epidemiology and sensitization/cross reactivity 
rates
Sensitization rates are mainly based on skin prick test or 
specific IgE measurement to whole peanut extracts. 
The sensitization rates vary widely depending on the 
age and co-morbidities and other (inhalant) allergies 
of the tested population. Irrelevant sensitization 
seems to be especially high in subjects with 
coexisting pollen allergy whereas clinically relevant 
sensitization is much higher in children with eczema. 
In an Australian study it has been shown that infants 
with eczema were 11-times more likely to develop 
peanut allergy than infants without eczema (3). 
Screening a non-selected cohort of 13,100 German 
children of the general population aged 3–17 years 
demonstrated that almost 11% of the children 
were sensitized to peanuts (4). However, this high 
prevalence of peanut sensitization predominantly 
results from cross-reactivity to pollen and does not 
reflect the rate of primary peanut allergy.
In a multicentre, multinational study on prevalence of 
sensitizations to foods in adults in Europe (EuroPrevall) 
(5), peanut extract sensitization rates showed high 
variability between 0.5 % in Reykjavik, 5 % in Zurich, 
1.6 % in Utrecht und 7.2 % in Madrid. Prevalence of 
IgE sensitization to seed storage proteins of peanut 
showed lower rates (6): No sensitizations were found 
in Sofia and Lodz, 0.1 % in Utrecht, 0.4 % in Zurich 
und 0.5 % in Madrid.
Interestingly, sensitizations to seed storage proteins 
seem to be only present, if peanut allergy started in 
childhood and therefore might serve as a marker for 
early onset peanut allergy. Data from the multicentre 
study on children and adults (EuroPrevall) indicate, 
that allergic subjects possess allergen-specific IgE to 
seed storage proteins, only if the allergy manifested 
before the age of 14 years (6).
In patients with clinically relevant peanut allergy it has 
been shown that 76-96% of peanut-allergic children and 
adolescents in the US and central and northern Europe 
possess specific IgE to Ara h 2 and Ara h 6, compared 
with only 42% in Spain (7, 8). The sensitization rates 
for Ara h 1 are between 63% and 80% and for Ara h 3 
somewhat lower, whilst the rate for Ara h 7 is only 43% 
(7, 8). Ara h 9 is considered a secondary food allergen 
particularly in Mediterranean countries. This secondary 
sensitization/cross-reaction is probably due to other 
nsLTPs (e.g., Pru p 3 in peach). Sensitizations to the 
Bet v 1-homologous PR-10 protein Ara h 8, the profilin 
Ara h 5 and glycoproteins (CCD) are usually caused by 
cross-reactions to pollen allergens. Sensitization rates 
vary depending on regional pollen exposure but also 
eating habits. The prevalence of sensitization to Ara h 
10/11 and Ara h 14/15 is not known and likely affects 
only a small number of peanut allergic sufferers. The 
fact that oleosins may be underrepresented or absent 
in aqueous peanut extracts represents a diagnostic gap 
hampering the identification of affected patients (9).
CLINICAL RELEVANCE, DIAGNOSIS AND 
MANAGEMENT
Clinical relevance and clinical pattern
Distinct scenarios can prompt sensitizations and 
potential clinical symptoms depending on different 
routes of exposure and physicochemical properties 
of the involved peanut proteins:
A) Early, presumably cutaneous sensitization to 
rather stable peanut allergens (i.e. Ara h 1, 2, 3, 6, 
7) in children with eczema (10) and an impaired 
skin barrier function is the basis of subsequent 
severe systemic reactions after ingestion of 
peanut products. Patients frequently react with 
immediate type symptoms involving the skin 
(e.g. urticaria), the gastrointestinal tract (e.g. 
vomiting), the respiratory system (e.g. wheezing) 
and/or the cardiovascular system (e.g. drop in 
blood pressure). This hazard is probably linked to 
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Table 1
Peanut allergens 
Allergen Biochemical name MW Heat stability
Ara h 1 Cupin (Vicillin-type, 7S globulin) 64 Yes
Ara h 2 Conglutin (2S albumin) 17 Yes
Ara h 3 Cupin (Legumin-type, 11S globulin, Glycinin) 60, 37 (fragment) Yes
Ara h 5 Profilin 15 No
Ara h 6 Conglutin (2S albumin) 15 Yes
Ara h 7 Conglutin (2S albumin) 15 Yes
Ara h 8 Pathogenesis-related protein, PR-10, Bet v 1 family 
member
17 No
Ara h 9 Nonspecific lipid-transfer protein type 1 9.8 Yes
Ara h 10 Oleosin 16 Yes
Ara h 11 Oleosin 14 Yes
Ara h 12 Defensins 8
Ara h 13 Defensins 8
Ara h 14 Oleosin 17.5 Yes
Ara h 15 Oleosin 17 Yes
Ara h 16 non-specific Lipid Transfer Protein 2 8.5 Yes
Ara h 17 non-specific Lipid Transfer Protein 1 11 Yes
www.allergen.org, 27-09-2015
Figure 1
Identified peanut allergens. Bold letters: allergens available for allergen-specific IgE testing (modified and 
updated from (13) with kind permission of Springer-Verlag, Heidelberg Berlin, Germany).
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the high stability of the allergens and their high 
proportion of the total protein content.
B) Sensitizations to the Bet v 1-homologous PR-
10 protein Ara h 8, the profilin Ara h 5 and 
glycoproteins (CCD) are usually caused by cross-
reactions to pollen allergens. Birch trees are 
responsible for a considerable north-south gradient 
in Europe in terms of cross-reactions to Ara h 8; in 
regions of higher grass pollen exposure, increased 
cross-reactive IgE to Ara h 5 and CCD-containing 
peanut extracts can be expected. The involved 
proteins are largely labile to heat and digestion. 
Since peanuts are generally not consumed raw but 
roasted or cooked, only mild and predominantly 
oropharyngeal symptoms develop.
C) Ara h 9 is considered a secondary food allergen 
particularly in Mediterranean countries. This 
secondary sensitization/cross-reaction is 
probably due to other nsLTPs (e.g., Pru p 3 in 
peach). Since Ara h 9 possesses thermal and 
digestive stability, affected patients can develop 
systemic symptoms (11).
Clinical diagnosis
Specific questions, proper interpretation of 
sensitization tests (i.e. SPT, IgE) and optional food 
challenges help to establish the diagnosis of peanut 
allergy.
Case history (anamnesis)
Previous reaction(s) to peanut, symptoms, affected 
organ system(s), onset and course (progression), 
co-factors (exercise, NSAID, alcohol etc.), previous 
reactions to other allergen sources (i.e. peach), 
additional (allergic) features, i.e. birch pollen allergy, 
additional atopic diseases (i.e. atopic eczema, asthma).
Working hypothesis: based on peanut-related clinical 
pattern A - C
Skin prick test (SPT)
  Commercial peanut extract (reasonable results 
in case of highly abundant allergens, i.e. seed 
storage proteins),
  Prick-prick test with peanuts or offending peanut 
product (in case of severe anaphylactic reaction 
primary IgE-testing before SPT)
IgE-Testing
Allergen-specific IgE:
  Peanut extract,
  Ara h 2 (Fig. 3)
Figure 2
Risk ramp for peanut allergens: increased risk for severe symptoms and anaphylactic reactions from left to 
right. Green: Pollen-related highly cross-reactive allergens, Yellow: Food allergens with increased thermal 
stability and digestive resistance.
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Ara h 2-specific IgE [kUA/l]
Comments:
a) Until now Ara h 2 and Ara h 6 specific IgE 
demonstrates the best association with systemic 
reactions to peanut based on controlled oral 
challenges (12, 14).
b) To predict a positive peanut challenge with 95% 
probability, Ara h 2-specific IgE had extensively 
been tested in controlled studies with different 
designs involving oral food challenges to a 
variable degree (15-18). Predictive values from 
<1 to 42 kUA/l demonstrate the broad range and 
subsequent limitations to use predefined cut-offs 
(Ara h 2-specific IgE) for the ultimate prediction of 
clinically relevant reactions to peanut. Based on 
vigorous challenges in all patients with suspected 
Figure 3
Study results regarding the risk of peanut allergy associated with allergen-specific IgE to the 2S-albumin 
seed storage protein Ara h 2. Shown is the S-shaped calculated probability for a positive oral peanut 
challenge in case of Ara h 2-specific serum IgE (blue line with confidence intervals). Resulting IgE con-
centration with predefined probabilities (5, 10, 20% and 80, 90, 95%) for a positive challenge above the 
figure. Calculated positive (left y-axis, red line with range) and negative (right y-axis, green line with range) 
prediction (PPV, NPV) with single values (empty dots). All single IgE measurements (+) depending on oral 
challenge outcome on top of the figure. Capitalized letters mark unexpected positive peanut challenges 
in a few cases (A – D) despite low Ara h 2-specific IgE-concentrations <0.03 kUA/l (see <10% probability 
range) or unexpected negative peanut challenges (cases E and F) despite high Ara h 2-specific IgE-con-
centrations >14.4 kUA/l (see >90% probability range). (reproduced from (12) with kind permission of John 
Wiley & Sons, Inc).
 EAACI Molecular Allergology User´s GuideEAACI Molecular Allergology User´s Guide2016 Part  B:  Using Molecular Al lergology In The Cl inical  Practice 
240 Peanut Allergy 
peanut allergy (12), Ara h 2-specific IgE has to 
exceed levels of 42 kUA/l – a rare finding and 
therefore only useful for clinical decisions in case 
of similar high IgE levels.
c) To predict a negative peanut challenge with 90% 
probability, Ara h 2-specific IgE has to be <0.03 
kUA/l – with some discordant exceptions (12).
d) An absolute (100%) prediction cannot be achieved 
with measurements of Ara h 2-specific IgE due to 
the before mentioned exceptions. Subsequently, 
the individual clinical relevance of allergen-
specific IgE concentrations (i.e. to single allergens 
of legumes) has to be determined on a case-by-
case basis by the physician in charge (13).
Challenge tests
(in case of a doubtful relationship between peanut 
ingestion and allergic reaction):
Depending on the patient’s history, titrated oral 
provocation with peanuts (e. g. whole peanuts or 
lightly roasted peanut flour) should be performed.
The following procedures (Fig. 4-6) might facilitate 
proper diagnosis.
Measurement of peanut-specific IgE is a good 
screening parameter in patients at risk for peanut 
allergy such as patients with atopic dermatitis (Fig. 4). 
However, the risk of peanut allergy in children with 
atopic dermatitis is not the same in all geographical 
areas: it is high in i.e. the USA, UK, Australia and low 
in the Mediterranean area for instance. Therefore, 
the need to test for peanut sensitisation is strikingly 
different depending on the country and global region. 
It is not needed in children with regular consumption 
of peanut showing general tolerance to peanut.
The absence of peanut-specific IgE has a high negative 
predictive value. Elevated peanut-specific IgE is only 
clinically relevant in the presence of corresponding 
symptoms. In the case of no detectable peanut-
specific IgE, an additional skin prick test with peanut 
serves to detect or exclude sensitization. If the 
screening is positive, an oral peanut challenge test 
should be considered.
Measurement of peanut- and Ara h 2-specific IgE 
plays an essential role in case of suspected primary 
peanut allergy. Elevated peanut- and Ara h 2-specific 
IgE and a clearly positive patient history are highly 
suggestive of a clinically relevant allergy (Fig. 5) Oral 
challenge is often not needed.
Peanut-specific IgE is detectable in around 10% 
of the population, especially in birch pollen areas. 
Therefore, unexpected findings of elevated IgE 
to peanut are often seen in the clinical practice. 
A stepwise approach (Fig. 6) takes the potential 
consequences into consideration. The most important 
initial question relates to the frequency (e.g., more 
than once a month) and time course (e.g., within the 
previous 6 weeks) of peanut consumption.
In general, the measurement of Ara h 1- and Ara h 
3-specific IgE is often not necessary, since there is high 
cross-reactivity between these seed storage proteins 
(19) and mono-sensitizations to Ara h 1 and/or 3 are 
rare. In doubt, an oral food challenge test can clarify 
cases of negative or low IgE to Ara h 2. If no specific IgE 
to any seed storage protein can be identified, a clinically 
relevant peanut allergy is unlikely, although it cannot be 
ruled out completely in the presence of sufficient clinical 
suspicion (diagnostic gap due to e.g., oleosins (Ara h 
10/11, 14/15(20)) and defensins (Ara h 12/13(21)). 
Specific IgE to the nsLTP Ara h 9 should be additionally 
determined in patients with systemic reactions but 
negative to the storage proteins of peanut.
Clinical management
Advices and avoidance
Strict avoidance of all peanut-containing products. 
Within the EU peanuts are required to be labeled in 
all pre-packed and non-pre-packed foodstuff. A great 
problem exists still with the “may contain” labels.
Pharmacotherapy (emergency kit)
Due to the risk of severe reactions after unintentional 
ingestion of peanut containing products emergency 
medication for self-administered drug application are 
recommended for all peanut allergic patients.
Allergen-specific immunotherapy
At present, commercial products for allergen-specific 
immunotherapy of peanut protein allergy are not 
available.
CLINICAL CASES
Case 1A
History: boy, 13 months of age with moderate atopic 
dermatitis. So far never eaten peanut or peanut 
containing products (Fig. 1).
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Figure 5
Allergic reaction following consumption of peanut. (modified from (13)).
Figure 4
Patients with atopic dermatitis or other food allergies have a high risk for peanut allergy and sensitization 
might be excluded prior to the consumption of peanut-containing products. Depending on the context, 
the signs plus (+) or minus (-) carry different meanings: either positive/negative, yes/no or observed ef-
fect/no effect. (modified from (13)).
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In-vitro testing: peanut- specific IgE 3.4 kUA/l, Ara h 
2-specific IgE 0.9 kUA/l.
Oral challenge: a titrated peanut challenge was 
performed up to 3 g of peanut protein. He 
passed the peanut challenge without any clinical 
symptoms.
Diagnosis: peanut sensitized but clinical tolerant.
Recommendation: Regular peanut product consumption 
suitable for young children (e.g. peanut butter).
Case 1B
History: girl, 11 months of age with moderate atopic 
dermatitis. So far never eaten peanut or peanut 
containing products (Figure 1).
In-vitro testing: peanut- specific IgE 89.1 kUA/l, Ara 
h 2-specific IgE 62.6 kUA/l.
Oral challenge: a titrated peanut challenge was not 
recommended as the predicted probability for 
peanut allergy was 95%.
Figure 6
Incidental finding of sensitization (e.g., elevated IgE to peanut in panel or screening tests). The algorithm 
refers to different geographical regions i.e. a) areas with many birch/fagales trees and prevalent pollen 
allergies initiated by Bet v 1, b) areas with high grass or weed pollen exposure and subsequent sensitiza-
tions to profilins, and c) the Mediterranean with prevalent LTP sensitizations. Clinicians should consider 
appropriate IgE testing depending on the geographical region where they are working.
Diagnosis: peanut allergy
Recommendation: Peanut avoidance, education 
from dietitian, emergency medication including 
adrenaline auto injector.
Case 2A
History: boy, 2 years of age. He ate a peanut snack 
at a friend’s house. He had never eaten peanuts 
before. After 30 minutes he developed urticaria 
and coughing, after 40 minutes wheezing (Figure 
2).
In-vitro testing: peanut- specific IgE 5.2 kUA/l, Ara h 
2-specific IgE 3.1 kUA/l.
Diagnosis: peanut allergy, an oral peanut challenge is 
not necessary.
Recommendation: Peanut avoidance, education 
from dietitian, emergency medication including 
adrenaline auto injector.
Incidental finding of peanut sensitization
Regular consumptiom without symptoms
IgE to Ara h 2
a) Birch pollen allergy? or 
b) Profilin sensitization? or
c) LTP sensitization?
IgE to a) Ara h 8 or b) Ara 
h 5 or c) Ara h 9 
Consider oral peanut 
challenge to confirm 
diagnosis
Relevant peanut allergy unlikely 
consider regular consumption
Peanut allergy confirmed, 
strict avoidance and emergency kit/drugs
in case of 
doubt
+ _
_
+(+) +
+ _
_+
+_
*
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Case 2B
History: boy, 9 years of age. He ate with his parents 
at a restaurant. His dish contained peanut sauce 
and the dessert various tree nuts. After 20 minutes 
he vomited, developed hives and wheezing. He 
had eaten peanuts in the past but infrequently and 
the last time he remembered was about 7 months 
ago (Figure 2).
In-vitro testing: peanut- specific IgE 4.1 kUA/l, Ara h 
2-specific IgE 1.1 kUA/l, and cashew nut-specific 
IgE 11.6 kUA/l.
Oral challenge: a titrated peanut challenge was 
performed up to 3 g of peanut protein. He 
passed the peanut challenge without any clinical 
symptoms but showed clear reaction to cashew 
upon food challenge
Diagnosis: cashew nut allergy, peanut sensitized but 
clinical tolerant.
Recommendation: Cashew avoidance, education 
from dietitian, emergency medication including 
adrenaline auto injector AND regular peanut 
product consumption
Case 3
History: boy, 14 years of age with allergic 
rhinoconjunctivitis in spring. On a panel test he 
showed sensitization against birch and peanut. He 
had eaten peanuts in the past without symptoms 
but infrequently (Figure 3).
In-vitro testing: birch-specific IgE >100 kUA/l, 
peanut-specific IgE 20.1 kUA/l, Ara h 2-specific 
IgE 0.1 kUA/l.
Diagnosis: Allergic rhinoconjunctivitis, relevant 
peanut allergy unlikely.
Recommendation: Consider regular consumption
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Tree nut and seed allergens largely belong to 
the pathogenesis-related,  seed storage, lipid 
transfer and oleosin protein families
Sensitization for tree nut and seed allergens 
is largely independent of birch pollen, with 
the exception of hazelnut
Analysis of IgE to molecular components 
in suspected nut or seed allergy may 
disentangle harmless allergy due to cross-
reactivity to pollens from potentially harmful 
allergy.
THE ALLERGEN SOURCES
Tree nuts, and seeds, but actually also legumes are in 
fact all seeds. Therefore, allergenic proteins in these 
food items are often shared. Such proteins belong to 
the families of seed storage proteins (2S albumins, 
legumins – 7S globulins and vicilins – 11S globulin), 
non-specific (ns) lipid transfer protein (nsLTP) and oil-
body associated oleosins. The degree of sequence 
homology of the same protein family between tree 
nuts and between seeds is largely dependent on the 
botanical relationship.
Consumption of tree nuts and seeds in individuals 
allergic to these food items is related to the majority of 
allergic reactions to foods. Such reactions may be fatal 
or almost fatal. Some nuts and seeds were uncommon 
in the diet some decades ago in many countries in 
the Western world. However, tree nuts and seeds 
have become increasingly popular in health foods, 
as single food items such as snacks, as ingredients 
in dishes such as in ragouts and salads, as well as in 
pastries, chocolate and candies. The current pattern 
of increased exposure to, and consumption of nuts 
and seeds is a likely explanation for the suggested 
increase of reported reactions to such food items (Fig. 
Edward Knol, Magnus Wickman
TREE NUT AND SEED 
ALLERGY 
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1) in addition to the general increased incidence of 
food allergies as such. In this chapter, we will discuss 
allergens of hazelnut, almond, cashew/pistachio, 
walnut/pecan nut and Brazil nut, as well as to lesser 
extent allergens of pine nut, coconut and the seeds of 
sunflower, pumpkin, poppy, mustard and buckwheat. 
Nuts or seeds not discussed herein have been excluded 
due to a lack of solid data.
In Europe, Canada and the United States, tree nuts, 
peanuts and seeds are listed as priority food allergens. 
Tree nuts and seeds are found in many food products, 
as listed below (Fig. 1). Today, many food items are 
labelled with “may contain (nuts/peanuts/seeds)” 
which causes substantial problems for tree nut or 
seed allergic individuals.
Allergic reactions have been described after exposure 
to all food items containing nuts or seeds. Oil made 
from these nuts and seeds have been found to contain 
potential allergenic proteins from these sources. 
However, the concentrations of these proteins are 
very low and should not present a risk of allergic 
reactions in the vast majority of allergic people (1). As 
the allergenic proteins, with the exception of profilin 
and pathogenesis-related 10 (PR-10) allergens, in tree 
nuts and seeds are heat stable, processing does not 
impact the allergenicity of such food products.
MAJOR AND RELEVANT MINOR 
ALLERGENIC MOLECULES
An overview of the allergenic proteins, described until 
May 2015, in tree nuts and seeds is depicted in Tables 
1 and 2. With regard to the tree nuts, it is clear that 
the allergens belong to a limited number of protein 
families. As discussed before, these protein families 
resemble digestion and heat stable proteins. In tree 
nuts, Table 1, the 2S albumin proteins allergens are 
well represented. Recent information has indicated 
that these can be potent allergens and are related to 
the more severe forms of allergy, such as Cor a 14 in 
hazelnut (2). The molecular mass of the 2S albumins 
ranges around 10-16 kDa, while the other prominent 
protein families 11S and 7S globulins have higher 
molecular mass of about around 50 kDa. In the tree 
nuts it is remarkable that the prominent PR-10/Bet v 1 
family is only described in the hazelnut as Cor a 1, but 
this allergen has not been described (yet) in the other 
tree nuts. Oral cavity symptoms to almond and walnut 
are often described by birch pollen allergic patients.
In nuts, most allergens have been described for 
hazelnut, which is most probably the direct result of 
more research in this food. In addition to the allergen 
families described above, hazelnut also contains 
Figure 1
Foods and ingredients containing tree nuts and seeds. Note: 
These lists are not complete and may change. Food and food 
products purchased from other countries, through mail-order 
or the Internet, are not always produced using the same manu-
facturing and labeling standards as in Europe.
Chocolate and pralines 
Nougat (sugar paste made with nuts), for 
example, Torrone
Dishes such as almond chicken, pad thai, 
chili and trout amandine 
Gianduja and giandula (chocolate blended 
with hazel nuts) 
Marzipan (almond paste)
Almond milk
Nut milk 
Tree nut oils 
Spreads, for example, almond paste-based 
spreads, cheese spreads, chocolate nut 
spreads 
Nutella (hazelnut) 
Tahini, halva (sesame)
Vegetarian dishes 
Various Indian curries and Asian dishes 
Industrial made Pesto 
Industrial made tomato sauce with cheese 
Industrial made pasta dishes 
Cereals
Baked goods 
Baking mixes, cereals, crackers and 
muesli
Barbecue and pesto sauces 
Dressings and gravies 
Flavoured coffees 
Frozen desserts 
Liqueurs, for example, amaretto, 
Frangelico 
Natural flavourings and extracts, for 
example, pure almond extract 
Salads, for example, Waldorf salad 
Snack foods, for example, trail mix
Bean bags, kick sacks/hacky sacks 
Bird seed 
Cosmetics, hair care products, sun 
screens 
Massage oils 
Pet food
Food and products that contain or often 
contain tree nuts and seeds Other possible sources of tree nuts Non-food sources of tree nuts
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allergens of the oleosin family and the LTPs. LTPs 
have also been described in almond (Pru du 3) and 
walnut (Jug r 3).
For the seed allergens, Table 2, the same protein 
families have been described like for tree nuts, with 
2S albumins and 7S and 11S globulins as the most 
frequently described. Many of the seed allergens 
show cross reactivity with their protein family 
counterparts in tree nuts and peanut (4). In sesame 
two proteins per protein family are demonstrated in 
11S globulin, 2S albumin and oleosin (5). Due to the 
fact that these three proteins show a high degree of 
heterogeneity, it is expected that there is more than 
one form present in the nut or seed. It has to be taken 
in account that the absence of some protein families 
in specific seeds might be due to the fact that many 
of these need to be discovered.
SENSITIZATION TO INDIVIDUAL 
MOLECULES AND THEIR CLINICAL 
RELEVANCE
Epidemiology and sensitization/cross reactivity 
rates
We have limited knowledge of sensitisation to tree 
nuts and seeds in the general population. Most reports 
on tree nut and seed allergy are based on clinical 
cases. However in a recent paper (6), the prevalence 
rates of sensitisation to two tree nuts and five seeds 
in an adult population from 13 different countries 
were presented (Table 3). Importantly, the authors 
reported prevalence rates of sensitisation to tree nuts 
and seeds irrespective of sensitisation to birch pollen, 
as well as sensitisation rates for tree nuts and seeds 
after excluding individuals sensitized to birch pollen. 
This is important because pathogenesis-related 10 
Table 1
 Tree nuts allergens. Overview of the different proteins per protein families for the tree nut allergens
Source
Storage proteins Pathogenesis- related proteins Oleo-
sin
Profi-
lin ??11S  
globulin
7S 
 globulin
2S  
albumin
PR10
Bet v 1-like
PR-14
nsLTP
Hazelnut
Corylus avellana Cor a 9 Cor a 11 Cor a 14 Cor a 1 Cor a 8
Cor a 12
Cor a 13 Cor a 2
Almond
Prunus dulcis Pru du 6
Pru du 
3 Pru du 4
Cashew
Anacardium occidentale Ana o 2 Ana o 1 Ana o 3
Pistachio
Pistacia vera
Pis v 2
Pis v 5? Pis v 3 Pis v 1
Walnut
Juglans regia Jug r 4 Jug r 2 Jug r 1 Jug r 3 Jug r 5?
Pecan
Carya illinoinensis Car i 2 Car i 1
Brazil nut
Bertholletia excelsa Ber e 2 Ber e 1
Pine nut
Pinus pinea Pin pi 1 Pin pi 6 kD? Pin pi 17 kD
Coconut
Cocos nucifera Coc n 4 Coc n 2 Coc n 5
Bold font indicates that these are available on commercial diagnostic platforms. LTP: Non-specific lipid transfer protein (3).
“?” = not yet established
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(PR-10) allergens may interfere with sensitization of 
tree nuts and seeds amongst birch allergic individuals. 
Interestingly, sensitisation to buckwheat was more 
commonly found than sensitisation to peanut (Table 3).
In an American paper from 2010, self-reported tree 
nut allergy in 1997, 2002 and 2008 was found in 
0.5%, 0.7% and 0.6% respectively, of the population. 
In contrast, only 0.1% reported sesame allergy (602). 
In the HealthNuts study from Melbourne it was 
recently shown that sesame allergy occurred in 0.7% 
of infants (8). Reports of hazelnut allergy have largely 
been limited to European countries. Notably, there 
is some geographical variation, with the hazelnut 
allergen, Cor a 1, and the homologous birch pollen, 
Bet v 1, protein being the targets of focus in Northern 
and Central Europe, and the hazelnut allergen Cor a 
8 sensitisation being the target of focus in reports 
in peach allergic individuals from Southern Europe. 
During the last decade, several papers have appeared 
on allergic reactions to cashew. In a recent review on 
cashew nut allergy (9), the authors concluded that an 
increase in cashew allergy in recent decades could 
not be clearly documented, despite the impression 
that this has been the case, particularly as exposure 
to cashew has increased in the population. Cashew 
is now used in industrial food as a replacement for 
more expensive pine nuts and for its properties of 
improving texture. In a recent population-based 
study of children admitted to emergency rooms due 
to reaction to foods in Stockholm during 2007, 5% 
had reacted to cashew, 3% to hazelnut, 2% to almond, 
walnut or pistachio, whereas 0.3-0.5% reported 
reactions to pecans, Brazils nut or coconut (10).
Cross reactivity rates of sensitization
As homologous proteins, such as the 2S albumins, 7S 
globulins, 11S globulins, oil-body associated oleosins 
and ns LTPs are all prevalent in nuts and seeds and 
have common epitopes within the same protein 
family, Immunoglobulin E (IgE) cross-reactivity is 
to be expected. This is particularly true if the amino 
acid sequence is similar, and the biological function 
and three-dimensional (3D) structure are the same, 
which usually is the case in botanically closely related 
plants. The (primary) structural similarity between 
different proteins of tree nuts and seeds, expressed 
Table 2
 Seed allergens Overview of the different proteins per protein families for the seed allergens
Source
Storage proteins Pathogenesis-relat-ed proteins Oleo-
sin
Profi-
lin ??11S  
globulin
7S 
 globulin
2S 
 albumin
PR10
Bet v 1-like
PR-14
nsLTP
Sesame
Sesamum indicum
Ses i 6
Ses i 7 Ses i 3
Ses i 1
Ses i 2
Ses i 4
Ses i 5 Ses i 8?
Mustard seed
Sinapis alba Sin a 2 Sin a 1 Sin a 3 Sin a 4
Sunflower seed
Helianthus annuus Hel a 2S Hel a 3 Hel a 2
Hel a 4, 
defensin
Pumpkin seeds
Cucurbita maxima
Cuc ma
Cuc ma 2
Cuc ma Cyp
Poppy seed
Papaver somniferum Pop s 1 Pop s 2 Pop s 34 kD
Buckwheat
Fagopyrum 
esculentum
Fag e 1 Fag e 3 Fag e 2
Bold font indicates that these are available on commercial diagnostic platforms. LTP: Non-specific lipid transfer protein (3).
“?” = not yet established
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as a percentage of amino acid sequence identity or by 
another measure, is a molecular basis for antibody or 
clinical cross-reactivity, but not at all a demonstration 
of such cross-reactivity. Generally speaking, the higher 
the structural similarity between two allergens, the 
higher is the probability of cross-reactivity between 
the two. However, as antibodies may bind to specific 
epitopes residing in regions that are more conserved 
(less variable) than the protein as a whole, cross-
reactivity may also occur to a higher extent than 
indicated by the overall percentage sequence identity.
Furthermore, patients’ specific sensitization profiles 
need to be taken into account when considering 
possible cross-reactions. For example, 11S globulin 
mediated IgE cross-reactivity between peanut and 
hazelnut cannot occur unless the patient displays 
IgE sensitization to Ara h 3 and Cor a 11 (11). In a 
very interesting paper by Maloney et al. (12), the 
use of serum-specific IgE measurements for the 
diagnosis of peanut, tree nut, and seed allergy serum 
IgE levels were investigated. The correlation of IgE 
levels between cashew and pistachio, and between 
walnut and pecan were 0.98 and 0.96, respectively. 
The corresponding correlations of IgE levels between 
hazelnut, peanut, almond and sesame were between 
0.6 and 0.7. Between cashew/pistachio and other 
nuts, the IgE level correlation ranged from 0.16 
to 0.55. The high correlations noted between IgE 
of cashew and pistachio and the high correlations 
between walnut and pecan are explained by 
very homologous proteins in botanically related 
plants. Cashew and pistachio, both belong to the 
Anacardiaceae family (Sumak trees) and walnut and 
pecan nut both to the Juglandaceae family (Walnut 
trees). Due to the close correlation between cashew 
and pistachio, an individual who reacts to cashew 
may have a similar reaction to pistachio or vice versa 
on equivalent doses. The same can be expected for 
an individual who is allergic to walnuts and who eats 
pecans, or vice versa.
CLINICAL RELEVANCE, DIAGNOSIS AND 
MANAGEMENT
Clinical pattern and relevance
Five clear patterns types of clinical patterns and 
relevance have been described amongst individuals 
sensitised or allergic to tree nuts, and seeds.
A)  Primary sensitization to one tree nut or seed 
allergen
B) Co-sensitization to at least two primary tree nut 
and/or seed allergens
C) Primary sensitization and allergy to at least one 
tree nut or seed and cross reactive IgE to another 
botanically-related tree nut or seed (high degree 
of sequence homology)
D) Primary sensitization and allergy to at least one 
tree nut or seed and cross reactive IgE to another 
botanically not closely related tree nut or seed 
(low to moderate degree of sequence homology)
E) Primary sensitization to pollen and cross-reactive 
IgE between PR-10 and LTP allergenic proteins in 
tree nuts and seeds.
  ad A. The patient is sensitized only to one tree 
nut or seed out of several tested. Irrespective of 
symptoms the IgE is relatively low. This patient is 
in general at younger age. At a very low age IgE 
levels below 0.35 kU/l can be found in children 
reacting to nuts, in particular cashew nut. This 
patient should avoid the culprit nut or seed but 
nothing else.
  ad B. This patient is often poly-sensitized to nuts 
and/or seeds with relatively high IgE levels to all 
tested relevant allergens. For a patient with nut-
seed allergy and polysensitised with high IgE in 
general, total restriction of tree nuts and avoidance 
of the seeds causing symptoms is recommended.
Table 3
Prevalence of sensitisation to tree nuts, peanut and 
seeds in adults of mostly Western Europe, Australia 
and the United States 
Overall (%) Overall, excluding birch pollen positive (%)
Hazelnut 7.2 3.1
Sesame 3.7 2.8
Buckwheat 2.8 2.2
Peanut 2.6 1.8
Walnut 2.2 1.8
Sunflower 2.1 1.8
Poppy seed 1.8 1.4
Mustard 0.9 0.8
Modified from (517)
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  ad C. The patient is sensitized to both, cashew 
and pistachio, or to walnut and pecan with 
rather equal IgE levels between the botanically 
related groups of nuts. Patients sensitized to only 
cashew and pistachio should only avoid theses 
nuts. No other restrictions should be made. The 
same recommendation would be appropriate for 
patients sensitised and allergic to only walnut and 
pecan.
   For patients sensitized to walnut, clinical cross-
reaction to hazelnut may occur and vice versa. 
Such cross-reactions usually result in milder 
reactions as compared to reactions attributed to 
the primary sensitizing nut.
   ad D. This is the most common patient with nut 
allergy: allergic to a few nuts with rather high IgE 
and with IgE to other nuts 10 times less or more. 
Usually those patients tolerate well other nuts.
  ad E. This patient is most likely birch pollen 
allergic (Bet v 1) if (s)he is resident in Northern 
Europe. If resident in Southern Europe, positive 
IgE to Artemisia, Parietaria or plane tree (LTP) 
may be present, but considered as markers of 
cross–reactivity between LTPs. Approximately 
80% of this Northern European population will 
experience “birch pollen related food allergy” 
to other PR-10 allergens. The PR-10 allergen, 
Cor a 1, is unstable to gastric digestion and is 
heat labile. Symptoms in the oral cavity may be 
unpleasant, but will not cause systemic reactions 
under normal circumstances. In most tree nuts 
and seeds PR-10 proteins are likely to be present, 
most notably in Fagales trees.
Clinical diagnosis
Specific questions, appropriate interpretation 
of sensitization test results and, under certain 
conditions, open- or blinded airborne or oral food 
challenges will help to establish the diagnosis of tree 
nut and seed allergy and the grade of severity. The 
following work-up might facilitate proper diagnosis, 
which will be beneficial for the patient (Fig. 2).
Detailed patient history
The following are examples of questions that will 
help establish a detailed patient history, followed by 
the questions in a bulleted list.
  Achieve information on previous reaction(s) to 
tree nuts and/or seeds or if this is first time of 
reaction?
  Did the patient previously tolerate the offending 
food?
  What were the symptoms and which were the 
affected organs?
  Were multiple foods ingested or multiple nuts?
  What was the dose causing the symptoms?
  What was the time for onset of symptoms after 
ingestion?
  What is the estimated duration of administration 
of the adrenalin autoinjector (AAI).
  What was the progression despite injection of 
adrenalin?
  Were one, two or more AAI used?
  Did the patient engage in concomitant exercise, 
take non-steroidal anti-inflammatories (NSAID), 
consume alcohol or other potentially aggravating 
factors?
  Is the patient birch pollen allergic or allergic to 
plants with pollen containing LTP?
Working hypothesis: based on tree nut-seed related 
clinical pattern A - E
Appropriate interpretation of sensitisation results
Skin prick test (SPT)
Commercial extracts of nuts or prick-to-prick test 
with fresh nuts has a very limited value due to false 
positive responses in case of cross-reactive labile nut 
allergen proteins, such as Cor a 1.
IgE-Testing
Total IgE has no added value in this context.
In clear cases, with exposure to a single tree nut or 
seed followed by a systemic reaction, one could ask 
if IgE testing is needed. However, the rationale for 
testing of sensitization is to examine the possibility 
of co-sensitisation or cross-reactive IgE to other nuts 
or seeds and assess the risk of reaction at exposure:
  in hazelnut or walnut allergic individuals Cor a 
14 and Jug r 1, both 2S albumins and sequence 
homology of 66% could be tested (clinical pattern 
A, B or D)
  for Cor a 9 and Cor a 14 at reaction to hazelnut 
and to disentangle from sensitisation to solely 
Cor a 1 (if nut-related clinical pattern A-D)
  for nut or seed extracts containing PR-10 protein 
or LTP: risk of false positive results (clinical 
pattern E),
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  for Cor a 1 and/or Bet v 1 or Cor a 8 and LTP 
containing pollens (if hazelnut-related clinical 
pattern E).
  for other tree nut and seed (sesame) allergen 
components there is to date little experience in 
clinical practice
For interpretation of sensitization test results see 
also Fig. 2.
Results only clinically relevant in case of corresponding 
symptoms after tree nut or seed ingestion.
Oral food challenges
Oral food challenges should be performed in cases 
of doubtful relationship between reported symptoms 
following ingestion and IgE test results and in patients 
who have avoided certain tree nuts, legumes/peanuts 
or seeds due to a previous reaction to these kind of 
foods and sensitisation to that particular food can be 
demonstrated:
  Depending on the clinical pattern (A – E), an 
oral food challenge with standardised increasing 
Figure 2
Diagnostic work-up in tree-nut, peanut and/or seed-related allergic reactions. Arrows indicate potential 
diagnostic steps; dashed arrows indicate that mild as well as severe reactions can be associated with dif-
ferent clinical features (based on information from the detailed patient history).
Mild oro-pharyngeal reac-tion 
to tree nuts or seeds 
Oro-pharyngeal reac-tion 
to tree nuts or seeds and in 
addition cough and nausea 
Anaphylaxis to a known tree 
nut and or seed
Underlying birch pollen allergy 
and IgE cross reactivity 
between PR-different 10 
proteins. All ages. Bet v IgE 
level dependent
IgE to birch pollen. IgE 
reactivity to tree nuts and 
orseeds 
IgE reactivity to offending tree 
nuts and or seeds. Magnitude 
of IgE levels are age 
dependent. IgE to birch pollen 
irrelevant.
SPT or serum IgE pos to birch 
pollen If high IgE to Bet v 1 > 
Cor a 1>Ara h 8>Gly m 4. IgE 
to other nuts may be present, 
but with low IgE levels. Cor a 
14, Cor a 9, Ara h 2 negative
When available, test for 25 
albumin, 7S and 11S globulins 
of tree nuts and/or seeds. 
Check with SPT or serum IgE 
pus to birch pollen
IgE reactivity to also to other 
tree nuts and/or seeds, but 
with significant lower IgE when 
cross reactive IgE
No oral challenge needed 
since symptoms are birch 
pollen allergy related only. In 
families with a high proportion 
of fear challenge may be a 
relief 
If present, risk indication 
of future systemic reaction 
at exposure. No oral food 
challenge needed to the 
eliciting food, but might be for 
related foods 
No oral food challenge needed 
to the offending tree nut seed. 
Challenge can be considered 
to other tree nuts seed when 
considerably lower IgE 
compared to the offending one
Personal decision on 
avoidance. No emergency kit
Avoidance of symptom eliciting 
nuts or seeds. Prescription of 
symptomaticometics
Primary severe tree nut 
or seed allergy confirmed. 
Emergency kit including 
training how to use it
When IgE to
storage 
proteins are 
negative
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doses of the offending food may be performed. 
It is important to not stop the challenge at a too 
low dose. Five to 10 nuts or an equivalent dose 
of seeds is mostly required for judgement of little 
risk at further exposure on not too high doses.
  Low dose challenge in nut/seed allergic 
individuals to reduce fear of products labelled 
with “may contain”
  Airborne blinded challenges for those with a fear 
being in an environment where nuts/seeds are 
present (restaurants, cafés, parties, travelling by air).
Clinical management
Advice and avoidance
1. Balanced avoidance of the offending tree nut, 
and/or seeds. If a patient is likely to experience a 
systemic reaction on a minor dose, a high degree 
of pre-cautious is required.
2. When a patient is likely to experience a mild 
reaction on relatively large dose, avoidance of 
larger doses should be avoided, especially when 
aggravating factors are present.
3. If reactions are due to PR-10 allergy, it is up to 
the patient to decide on amount of exposure.
Pharmacotherapy (emergency kit)
1. In patients with previously anaphylaxis or 
systemic reactions on a minor dose, emergency 
medication including AAI for self-administration 
is required accompanied with a personalized 
emergency treatment plan.
2. Tablets of corticosteroids and non-sedating 
antihistamines are optional, but not mandatory.
3. Symptomatic treatment as required.
Allergen-specific immunotherapy
At present, commercially available products for 
allergen-specific immunotherapy of tree nut or seed 
protein allergy are not available.
CLINICAL CASES
Case 1 (original)
Birch pollen allergy with symptoms to several PR-10 
protein family containing fruits
History: Boy, 13 years: Since he was 6 years old, birch 
pollen induced rhinoconjunctivitis; after having 
had consumed pieces of several raw fruits, but in 
particular raw apples, plums, cherries, peaches, 
pears, carrot or strawberries oral itch, feeling of 
swelling in the throat and breathing difficulties. 
Several emergency visits because of this. Does 
not dare to drink apple juice or eat an apple cake. 
He experiences oral itch after eating hazelnut 
and almond. He has been prescribed an adrenalin 
auto-injector which has been frequently used due 
to suspected anaphylaxis, but never urticarial, 
never facial oedema. Despite dyspnoea, rhonchi 
have never been verified and oxygen saturation 
has always been within normal range.
Micro array in-vitro testing: Most allergen molecules 
in the PR-10 family positive. All LTPs and storage 
proteins negative.
Interpretation: PR-10 family related symptoms only?
Oral challenge: Due to disabling anxiety an open 
oral challenge to apple juice is performed which 
he passes. At challenge with raw apple at the day 
care unit oral itch and dyspnoea, but not rhonchi, 
is demonstrated and oxygen saturation is within 
normal range. He is required to calm down and 
breathing gets back to normal.
Diagnosis: PR-10 induced OAS symptoms due to 
underlying birch pollen allergy. At follow up both 
mother and son confirm panic attacks of the son at 
start of OAS symptoms after having taken pieces 
of a fruit containing the PR-10 protein family.
Recommendations: Only avoidance of what he 
thinks is relevant for him. No need for adrenalin 
auto-injector. Since this challenge he has had no 
more emergency visits.
Case 2 (original)
Combined PR-10 and tree nut storage protein allergy
History: 7-year old boy with rather severe 
rhinoconjunctivitis both, to birch and timothy 
pollen. Eats Nutella and after some minutes gets 
oral itch, blisters on the tongue and lip oedema. 
Some swallowing difficulties and hyper salivation. 
Textbox 1
Oral food challenges
An oral challenge can tell what the patient should 
not eat, not what the patient can eat in the future 
without any risk
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Can eat raw fruits including apples and peaches. Is 
this a systemic reaction or just local reaction due 
to PR-10 protein family allergy?
In-vitro testing ImmunoCAP (kU/l): Birch, 33; 
Timothy, 14; Hazelnut, 22; Cor a 1, 38; Cor a 8, 
1.2; Cor a 9, 9; Cor a 14, 6.6; Almond, 3.5; Cashew, 
0.97; Walnut, 7.4; Jug r 1, <0.1; Jug r 3, 1.7; Peanut, 
4.5, but all peanut storage proteins negative
Interpretation: PR-10 driven nut allergy, but also 
combination with IgE to hazelnut storage protein 
IgE including nut LTP (Cor a 8 and Jug r 3).
Rational for oral challenge: What not to avoid
Oral challenge (peanut, cashew nut and walnut): 
Tolerates the maximum dose of 10 cashew nuts 
and 10 peanuts at 2 different occasions. At walnut 
challenge oral cavity symptoms which can be 
verified at 1 walnut.
Interpretation of challenge: Challenge to hazelnut is 
not necessary. Tolerates both, cashew and peanut, 
but reacts to walnut.
Diagnosis: Besides PR-10 protein family allergy 
also storage protein family allergy to hazelnut. 
Sensitisation to walnut and reaction to walnut 
indicates either co-sensitisation to walnut or 
serological and clinical cross reactivity between 
hazelnut and walnut proteins. To test for Jug r 4 
(11S globulin) had been of great value.
Recommendation: Since he tolerates cashew nuts 
he will also tolerate pistachio (close relationship). 
He is eating marzipan without problems. Thus, he 
tolerates almonds. He should maintain avoiding 
hazelnut and also to avoid walnut (see case below).
Case 3 (original)
Primary hazel nut allergy with clinical cross-reactions 
to walnut and buckwheat
History: Woman 20 years old with moderate asthma 
and mild eczema. No known pollen or food allergy. 
Eating chocolate with hazelnuts which she has 
done before. After some bites (5-10 minutes) 
she gets tingling feeling in her mouth. After an 
additional 5 minutes abdominal cramping followed 
by breathing difficulties and dizziness. At the 
emergency ward low blood pressure. Low oxygen 
saturation at arrival. Anaphylaxis grade II.
In-vitro testing, ImmunoCAP positives (kU/l): 
Hazelnut, 260; Cor a 8, 2.4; Cor a 9, 172; Cor a 14, 
60; Walnut, 72; Jug r 1, 2.8; Jug r 3, 15; Cashew, 
44; Almond, 2.3; pine nuts, 1.4; Brazil nut <0.1; 
Ara h 1, Ara h 2 and Ara h 3 all between 2.4-0.4.
Micro arrayed specific IgE: relatively high to all 
available 11S globulins, but low to 2S albumins.
Rational for oral challenge: what not to avoid
Oral challenge with cashew nut: Tolerates the 
maximum dose of 10 cashew nuts.
Interpretation of challenge: The sequence homology 
between the 2S albumin and 7S and 11S globulins 
vary from between 47%-60%.
Oral challenge with walnut: After 1 walnut she gets 
itch in her mouth and irritation in the throat. 
After 30 minutes she receives 1 more walnut. 
Now dermal itch and itch in the palms and scalp. 
Interpretation of challenge: in this patient it is 
obvious that walnut molecules for IgE testing are 
missing, which is likely to be the 11S globulin Jug r 
4 molecule. This molecule has a sequence identity 
to Cor a 9 of 76%. Hazelnut and walnut are from 
an evolutionary point of view located on sister 
branches.
Continued challenge at home: Peanut, almond and 
pine nut - without symptoms
Diagnosis: Multiple tree-nut allergy with anaphylaxis 
to hazelnut at a moderate dose. After three months 
anaphylaxis to buckwheat most likely 11S globulin 
driven. IgE buckwheat 29.
Recommendation: Avoidance of hazelnut, walnut, 
pecan nut and buckwheat.
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Bee venom allergy can cause severe and even 
fatal anaphylaxis
Specific immunotherapy is effective in 
inducing immunological tolerance and, 
therefore, protection in bee venom-allergic 
patients
Component-resolved diagnosis is able to 
discriminate between true sensitization and 
cross-reactivity and facilitates the choice of 
correct immunotherapy
Molecular analyses offer the potential 
for novel ways of therapy monitoring and 
prediction of therapy outcome
THE ALLERGEN SOURCES
Bees are flying insects of the order Hymenoptera with 
approximately 20000 known species closely related 
to wasps and ants. The most common elicitors of bee 
venom allergy are honeybees which are known for 
their outstanding role in pollination and for producing 
honey and beeswax. Only two honeybee species 
have been truly domesticated, whereby Apis mellifera 
(European, western or common honeybee) (Fig. 1) is 
the most common domesticated species and shows 
a world-wide distribution due to human-induced 
global dispersal. The other domesticated species Apis 
cerana (eastern honeybee) is native to southern and 
eastern Asia. Nowadays, also bumblebees (Bombus 
spp.) (Figure 1), the close relatives of honeybees, have 
gained some importance as elicitors of work related 
venom allergy since they are increasingly used for 
pollination in greenhouses (1).
Sensitization to bee venom occurs after a 
sting, whereby honeybees are the only stinging 
Hymenoptera that nearly always leave their stinger 
with adherent venom sac in the skin of the victim. 
Meanwhile the venom is continuously pumped 
into the skin until the venom sac is exhausted 
Markus Ollert, Simon Blank
BEE VENOM 
ALLERGY 
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or the stinger removed. Bee venom is a complex 
mixture of low molecular weight substances such 
as biogenic amines, basic peptides, toxins and of 
higher molecular weight proteins, many of them with 
enzymatic activity. The so far identified honeybee 
venom allergens are proteins or glycoproteins with a 
molecular mass ranging from 3 to 200 kDa (Table 1).
Figure 1
The honeybee and the bumblebee.
Figure 2
Schematic representation of the core glyco-
sylation of insects. The glycan carries an al-
pha-1,3-fucose residue which is not present in 
human carbohydrate structures and therefore 
is highly immunogenic. It can induce the gen-
eration of cross-reactive human IgE antibodies 
(GlcNAc, N-acetylglucosamine; man, mannose; 
fuc, fucose).
Apis mellifera
Apis spp.
Bombus terrestris
Bombus pennsylvanicus
Bombus spp.
α1,6-man
α1,3-man
α1,6-fuc
α1,4-man
β1,4-GlcNAc
β1,4-GlcNAc
α1,3-fucose
Asn
Venom allergy is one of the most frequent triggers of 
severe anaphylactic reactions in adults. Approximately 
9.2 to 28.7 % of the adult population shows a 
sensitization to Hymenoptera venom (including bees 
and vespids) and the prevalence of systemic sting 
reactions among adults ranges between 0.3 and 7.5 
% (2, 3). The prevalence of sensitization to honeybee 
venom is related to the degree of exposure. Thus, 
the frequency of honeybee venom allergy is higher 
in rural than in urban populations and especially 
beekeepers and their family members are at a high 
risk for honeybee venom allergy (4).
The venom allergens of different honeybee 
species are highly similar and also bumblebee 
venom closely resembles honeybee venom. Both 
venoms are reported to be highly cross-reactive. 
Cross-reactivity of honeybee and vespid venom 
at protein level is limited and largely contributed 
to homologous allergens present in both venoms 
such as hyaluronidases, dipeptidylpepdidases and 
vitellogenins. However, the majority of cross-
reactivities can be attributed to clinically irrelevant 
IgE antibodies that are directed against cross-reactive 
carbohydrate determinants (CCDs) (5) (Fig. 2). This is 
of particular importance, since most Hymenoptera 
venom allergens are glycoproteins with one or 
more of such carbohydrate structures (Table 1). In 
insects the relevant CCD epitope is defined by an 
alpha-1,3-linked fucose residue at the innermost 
N-acetylglucosamine of the carbohydrate core 
structure. Since both glycan modifications are not 
present on human carbohydrate structures, they are 
highly immunogenic and can induce the production 
of specific IgG and IgE antibodies. IgE antibodies 
with specificity for the alpha-1,3-fucose epitope 
are responsible for a significant proportion of sIgE 
double sensitizations to honeybee and wasp (known 
as yellow jacket in the Unites States) venom (6).
MAJOR AND RELEVANT MINOR 
ALLERGENIC MOLECULES
The venom of the honeybee Apis mellifera is certainly 
the best characterized Hymenoptera venom (for 
detailed reviews see Ollert and Blank 2015 (7) 
and Spillner et al., 2014 (8). Mainly by proteomic 
approaches in the last years much progress has 
been made in identifying important allergens of low 
abundance. Moreover, recombinant strategies have 
helped to characterize the allergenic potential of 
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several individual allergens in detail (Table 1). The 
allergenicity of most of the honeybee venom allergens 
seems to depend on correct threedimensional 
folding of the molecules (Figure 3). The role as major 
allergens to which more than 50 % of patients show 
IgE reactivity to, so far was demonstrated for the 
honeybee venom allergens Api m 1, Api m 2, Api m 
3, Api m 5 and Api m 10 (for references see Table 1).
Although, in recent years much progress has been 
made in the identification and characterization of 
honeybee venom allergens, the picture might be 
much more complex since more than 100proteins 
and peptides were identified in honeybee venom (9) 
Moreover, the complexity is increased by different 
glycosylation patterns and protein heterogeneity and 
even seasonal effects seem to influence the venom 
composition. Thus, the season of venom collection 
might also influence the composition of venom 
extracts for specific immunotherapy.
SENSITIZATION TO INDIVIDUAL 
MOLECULES AND ITS CLINICAL RELEVANCE
Previous analyses of the sensitization to individual 
allergens using native purified allergens or 
immunoblots with venom extracts are only partially 
reliable due to the interference of IgE antibodies 
Table 1
Important allergenic molecules of honeybee and bumblebee venom
Allergenic 
molecule Biochemical name IUIS code
MW 
(kDa)
Native aller-
gen contains 
CCDs
Prevalence among patients
Apis cerana (eastern honeybee)
Api c 1 Phospholipase A2 58 16 Yes ?
Apis mellifera (European, western or common honeybee)
Api m 1 Phospholipase A2 65 16 Yes 57-97%1-7
Api m 2 Hyaluronidase 67 45 Yes 46.3-52.2%2, 6-7
Api m 3 Acid phosphatase 68 49 Yes 50%7
Api m 4 Melittin 69 3 No 22.9-42.5%2, 6-7
Api m 5 Allergen C/DPP IV 70 100 Yes 58.3-60%7-8
Api m 10 CRP / Icarapin 66 55 Yes 51.5-61.8%7, 9
Api m 12 Vitellogenin 735 200 Yes 50%10
Bombus pennsylvanicus (American bumblebee)
Bom p 1 Phospholipase A2 156 16 Yes ?
Bom p 4 Protease 157 27 No ?
Bombus terrestris (Large earth bumblebee)
Bom t 1 Phospholipase A2 158 16 Yes ?
Bom t 4 Protease 159 27 Yes ?
CRP: carbohydrate-rich protein; DPP IV: dipeptidylpeptidase IV
1Jakob T et al. J Allergy Clin Immunol; 130:276-278; 2Hofmann SC et al. J Allergy Clin Immunol; 128:248; 3Hofmann SC et al. J Allergy Clin 
Immunol; 127:265-267; 4Korosec P et al. J Allergy Clin Immunol; 128:671-673; 5Müller UR et al. Allergy; 64:543-548; 6Sturm GJ et al. J Allergy 
Clin Immunol; 128:247-248; 7Köhler J et al. J Allergy Clin Immunol; 133:1383-1389; 8Blank S et al. J Immunol; 184:5403-5413; 9Blank S et al. 
Allergy; 66:1322-1329; 10Blank S et al. PLoS One; 8:e62009.
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directed against cross-reactive carbohydrate 
determinants (CCDs). Nowadays, advanced 
recombinant strategies allow the production of 
correctly folded allergens, devoid of carbohydrate-
based cross-reactivity, which allow the elucidation 
of the role of particular allergens beyond clinically 
irrelevant cross-reactivity (12). Thus, reliable data on 
sensitization rates are available for several honeybee 
venom allergens (Table 1). Major differences in 
sensitization rates have been observed for Api m 1 
in different studies. These differences are partially 
attributable to differential inclusion criteria of the 
patient population and partially to the preparation of 
the allergen Api m 1, which had been used in those 
studies in various ways – as natural purified allergen 
or as recombinant allergen from bacterial or insect 
cell expression systems.
Recently, it was demonstrated that not only Api m 
1, but also Api m 2, Api m 3, Api m 5 and Api m 10 
are major allergens, thus indicating that honeybee 
venom contains a higher number of clinically 
important allergens than formerly anticipated (13). 
Moreover, the combination of 6 allergens (Api m 1-5, 
10) showed a diagnostic sensitivity of approximately 
95 % for honeybee venom-allergic patients, whereby 
74 % of patients were sensitized to more than one 
allergen (39 different sensitization profiles).
It is not known whether certain sensitization profiles 
exist that are linked to the severity of the disease or 
that are predictive for the outcome of immunotherapy. 
Recently, it was shown that the allergens Api m 3 and 
Api m 10 (68 % of patients show sIgE reactivity with Api 
m 3 and/or Api m 10 and 4.8 % are sensitized to Api m 3 
and/or Api m 10 exclusively (13) are underrepresented 
or missing in several of the licensed preparations 
routinely used for honeybee venom immunotherapy 
(14), and moreover, that during immunotherapy there 
is minimal IgG4 induction against these two allergens 
in contrast to those that are present in high amounts 
in the extracts (13). It will remain an important topic 
of future clinical research to analyze the relationship 
between sIgE specific sensitization profiles and 
unwanted side effects and/or treatment failure during 
honeybee venom immunotherapy.
CLINICAL MANAGEMENT
Clinical diagnosis
The diagnosis of honeybee venom allergy comprises 
the patient history of a systemic sting reaction, a 
Textbox 1
Clinical relevance
  Molecular diagnostic approaches should aim 
to exclude sensitizations that are exclusively 
caused by clinically irrelevant cross-reactive 
carbohydrate determinants (CCDs)
  Impact of individual molecules on severity of 
symptoms is still unknown
  Patients exclusively sensitized to allergens 
that are underrepresented in therapeutic 
extracts might be at risk to respond less well 
to specific immunotherapy 
Figure 3
Structures of selected honeybee venom allergens. Structures were generated by either X-ray diffraction 
(10, 11) or structural modelling.
Api m 1 Api m 2 Api m 3 Api m 5
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positive skin test response and/or the detection 
of venom-specific IgE antibodies. Especially, when 
the patient was not able to definitely identify the 
culprit insect, the correct diagnosis is not always 
straightforward in clinical practice due to inherent 
problems and limitations of both diagnostic tests 
when using extract.
Patient history
One focus of taking the patient history should be 
the identification of the culprit insect. An important 
factor for the identification of honeybees is that they 
are the only stinging Hymenoptera species that nearly 
always leaves their stinger with adherent venom sac 
in the skin of the victim. However, several patients 
are not able to discriminate between honeybee and 
vespid stings, so that the results of patient’s history 
often remain inconclusive. Moreover, patient history 
should consider information on number and date of 
sting reactions, severity of symptoms and the time 
between sting and the onset of symptoms as well 
as the assessment of potential risk factors (such as 
medication, cardiovascular risks and other diseases).
Skin tests
Skin tests are performed as prick test or intradermal 
test with commercial honeybee venom and vespid 
venom extract at least 2 weeks after the sting reaction 
to avoid possible false-negative results during the 
refractory period (15). For more detailed information 
please refer to the vespid venom chapter.
Baseline serum tryptase
It is recommended to determine the tryptase 
concentration in all patients with a history of a severe 
reaction after a Hymenoptera sting. Adult patients 
with mastocytosis and/or elevated baseline serum 
tryptase are at risk for more-severe reactions following 
stings. In addition, proper diagnosis of venom allergy 
in mastocytosis patients can be affected since sIgE 
might be more often negative compared to venom 
allergic patients without mastocytosis.
IgE testing
Total IgE (tIgE):
Several studies investigated the specific/total IgE 
ratio in the context of atopy and of allergen-specific 
immunotherapy (reviewed in Hamilton et al. (16). In 
54% of Hymenoptera venom-sensitized individuals, 
the ratio of sIgE/tIgE was >4% (16). Thus, in the clinical 
management of bee venom allergy, the measurement 
of tIgE can provide guidance to the clinician in the 
context of the ratio sIgE/tIgE, although it is not 
generally recommended in the guidelines.
Allergen-specific IgE:
Honeybee venom and vespid venom extract: Specific 
IgE measurements to venom extracts might show 
multiple positive test results due to sensitization 
to multiple venoms or to cross-reactivity of 
cross-reactive carbohydrate determinants (CCD) 
or homologous allergens present in different 
venoms. Results might be negative due to the 
underrepresentation of particular allergens in the 
extract (for schematic representation of diagnostic 
problems associated with venom extracts see (Fig. 4).
Bumblebee venom extract: Although, allergy 
to bumblebee venom is rare, sIgE detection to 
bumblebee venom could be useful in patients heavily 
exposed to bumblebee stings since bumblebee 
venom contains proteins not found in honeybee 
venom. Although major allergens of bumblebee 
and honeybee venom are partially cross-reactive, 
additional species-specific epitopes are present due 
to an incomplete sequence identity.
Allergens Api m 1, Api m 2, Api m 10, Ves v 1, Ves v 5, 
Pol d 5 (and others not available yet for routine sIgE 
testing): A) In case of multiple positive test results 
with different venoms to discriminate between true 
sensitization and cross-reactivity. B) For differential 
diagnosis in patients with inconclusive patient 
history to identify the culprit insect(s). C) In case of 
negative test results with different venoms despite a 
convincing clinical history due to enhanced sensitivity 
of the component-resolved diagnostic approach. D) 
In patients with mastocytosis. 
Although Api m 2 seems to be an important allergen to 
diagnose honeybee venom allergy in certain patients, 
it might show cross-reactivity with vespid allergen 
Ves v 2, and thus is no specific marker allergen.
CCD markers (MUXF3, horseradish peroxidase, 
bromelain, ascorbate oxidase): To confirm the 
presence of CCD-specific IgE antibodies as reason of 
multiple positive test results. However, since specific 
IgE directed against both, CCD and protein epitopes 
might be present, the detection of CCD-specific IgE 
alone does not allow the exclusion of sensitization to 
protein epitopes of multiple venoms.
For the interpretation of specific IgE outcome see 
also (Fig. 4).
 EAACI Molecular Allergology User´s GuideEAACI Molecular Allergology User´s Guide2016 Part  B:  Using Molecular Al lergology In The Cl inical  Practice 
260 Bee Venom Allergy 
Cellular tests
When skin tests and specific IgE measurements 
yield negative results in patients with a systemic 
anaphylactic reaction, additional cellular tests, such 
as basophil activation, are recommended and have 
shown additional benefits when used together with 
allergen components (for more detailed information 
about cellular tests please refer to the chapter about 
vespid venom allergy).
Sting challenge
A sting challenge with a live insect is not 
recommended as diagnostic tool in untreated patients 
and should serve only as control of success of venom 
immunotherapy. For more detailed information refer 
to the vespid venom chapter.
Prevention and Therapy
Avoidance of honeybee stings
  Avoidance of perfumes.
  Avoidance of floral or bright colored clothing.
  Careful outdoor eating and drinking.
  Wearing shoes outside.
  Avoidance of swatting to bees.
  Keeping windows of the vehicle closed.
  Staying away from beehives.
Pharmacotherapy (emergency kit)
Due to the risk of severe reactions patients allergic to 
bee venom should carry an emergency kit including 
an adrenaline autoinjector for self-administration, 
especially during the bee season. Although, this is a 
highly debated issue, according to current guidelines, 
also patients who have successfully undergone 
immunotherapy are recommended to carry an 
emergency kit to eliminate a remaining risk.
Specific immunotherapy
Honeybee venom immunotherapy is indicated 
both in children and adults with a history of a 
severe systemic reaction including respiratory 
and cardiovascular symptoms and documented 
sensitization to honeybee venom with either skin 
test and/or specific serum IgE tests. Immunotherapy 
is not indicated when neither skin testing nor serum 
specific IgE indicate a sensitization as well as for large 
local reactions or unusual reactions (17).
Figure 4
Molecular sIgE diagnostics in venom allergy. Molecular diagnostics with recombinant marker allergens is 
able to exclude “false-positive” test results due to IgE directed against CCDs or homologous allergens 
present in venom extracts and to uncover IgE sensitizations to allergens that are underrepresented, labile, 
degraded or masked in venom extracts.
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Venom immunotherapy with honeybee venom also 
seems to be sufficient in nonprofessionally exposed 
bumblebee-allergic patients who most likely react 
on the basis of cross-reactivity and a primary 
sensitization to honeybee venom. Indeed, in heavily 
exposed greenhouse workers who are frequently 
stung by bumblebees an immunotherapy with 
Figure 5
Diagnostic algorithm in honeybee and vespid venom allergy. A red minus indicates a negative and a 
green plus a positive test result. Two red minus and two green plus indicate double-negative and dou-
ble-positive test results, respectively. Some centers additionally use CAP inhibition tests. However, due 
to the availability of the growing number of molecular components CAP inhibition becomes less and less 
important for the discrimination between bee and vespid venom allergy. Nevertheless, due to the lack 
of proper marker allergens, CAP inhibition can be useful to differentiate between Polistes and Vespula 
venom allergy. 1Not yet available for routine diagnosis. 2For individual patients perhaps low sensitivity. 
3For discrimination between Vespula and Polistes venom allergy refer to the vespid venom chapter. 4The 
basophil activation test (BAT) is not available for routine diagnosis in every clinic.
bumblebee venom would be preferable. However, 
bumblebee venom for routine therapeutic approaches 
is commercially not generally available and such 
approaches have only been reported in case reports.
The success of specific immunotherapy may be 
monitored by a sting challenge test with a live insect 
(see also chapter about vespid venom allergy).
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CLINICAL CASES
Case 1 (original)
History: Female, 40 years old, stung by unidentified 
insect in tip of the middle finger of the right hand. 
Within minutes generalized itching and urticaria, 
dyspnea and a feeling of tightness in the throat. 
Care by an emergency physician.
Skin prick test: Honeybee venom (100 µg/mL) and 
wasp (yellow jacket) venom (300 µg/mL) positive.
In vitro testing (conventional): tIgE 18.6 kU/L, sIgE to 
honeybee venom 6.9 kUA/L, sIgE to wasp (yellow 
jacket) venom 1.3 kUA/L, baseline tryptase 6.3 µg/L.
In vitro testing (molecular): sIgE to rApi m 1 5.7 
kUA/L, sIgE to rVes v 1 <0.1 kUA/L, sIgE to rVes 
v 5 <0.1 kUA/L, sIgE to CCD (MUXF3) 2.4 kUA/L.
Diagnosis: Honeybee venom allergy, cross-reactivity 
to wasp (yellow jacket) venom due to CCD-specific 
IgE.
Recommendation: Venom immunotherapy with 
honeybee venom extract, emergency kit with 
adrenaline autoinjector.
Case 2 (original)
History: Male, 52 years old, history of 3 episodes of 
severe anaphylactic reactions (1 after a honeybee 
sting and 2 after wasp/yellow jacket stings).
Intradermal skin test: Honeybee venom (0.001 µg/
mL) and wasp (yellow jacket) venom (0.01 µg/mL) 
positive.
In vitro testing (conventional): tIgE 15 kU/L, sIgE to 
honeybee venom <0.1 kUA/L, sIgE to wasp (yellow 
jacket) venom 1.1 kUA/L, baseline tryptase 18.9 
µg/L.
In vitro testing (molecular): sIgE to rApi m 1 <0.1 
kUA/L, sIgE to rApi m 2 <0.1 kUA/L, sIgE to rApi 
m 3 1.28 kUA/L, sIgE to sApi m 4 <0.1 kUA/L, 
sIgE to rVes v 1 1.99 kUA/L, sIgE to rVes v 5 
1.53 kUA/L, sIgE to CCD (MUXF3) <0.1 kUA/L 
(For the measurement of sIgE to rApi m 3 and 
rApi m 4 research prototype allergens were used 
which are not yet available for routine diagnosis, 
demonstrating the usefulness of additional 
allergens for diagnosis.)
Diagnosis: Honeybee and wasp (yellow jacket) venom 
allergy, mastocytosis.
Recommendation: Venom immunotherapy with 
honeybee venom and wasp (yellow jacket) 
venom extracts, emergency kit with adrenaline 
autoinjector.
Case 3 (original)
History: Male, 45 years old, stung by an unidentified 
insect in the neck, within minutes generalized 
itching, dyspnea, loss of consciousness. Care by an 
emergency physician.
Skin prick test: Honeybee venom (100 µg/mL) and 
wasp (yellow jacket) venom (100 µg/mL) positive.
In vitro testing (conventional): tIgE 360 kU/L, sIgE to 
honeybee venom 23.6 kUA/L, sIgE to wasp (yellow 
jacket) venom 4.3 kUA/L, baseline tryptase 3.1 
µg/L.
In vitro testing (molecular): sIgE to rApi m 1 10.9 
kUA/L, sIgE to rVes v 1 <0.1 kUA/L, sIgE to rVes 
v 5 7.4 kUA/L, sIgE to CCD (MUXF3) <0.1 kUA/L.
Diagnosis: Honeybee and wasp (yellow jacket) venom 
allergy.
Recommendation: Venom immunotherapy with 
honeybee venom and wasp (yellow jacket) 
venom extracts, emergency kit with adrenaline 
autoinjector.
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In wasp venom allergy CRD is a valuable 
tool since both rVes v 5 and rVes v 1 are 
commercially available.
There are currently no marker recombinant 
allergens available that allow a definite 
discrimination between Vespula and Polistes 
venom sensitization.
It is recommended to determine the baseline 
tryptase concentration in all patients 
with a history of a severe reaction after a 
Hymenoptera sting.
THE ALLERGEN SOURCES
The family Vespidae is divided into the Vespinae and 
Polistinae subfamilies. Vespula, Dolichovespula and 
Vespa make up the three genera of the Vespinae. 
Vespula (called wasps in Europe, yellow jackets in the 
USA) being the most important species in Europe.
The species Polistes dominula and Polistes gallicus are 
European paper wasps; P. dominula has also spread 
to the northeastern United States and also been 
reported in Australia. The species Polistes exclamans, 
Polistes annularis and Polistes fuscatus are indigenous 
to North America and not present in Europe.
Several of the European species of the vespid family 
differ from those found in the USA. Furthermore, 
popular names for vespids in the USA and Europe are 
different and may lead to confusion (Table 1) (1).
MAJOR AND RELEVANT MINOR ALLERGENS
Hymenoptera venoms are complex cocktails 
of low molecular weight substances such as 
biogenic amines, basic peptides, toxins and of 
M. Beatrice Bilò, Markus Ollert
VESPID 
ALLERGY
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higher molecular weight proteins, many of them 
with enzymatic activity, together with a variety 
of other components, all of which may contribute 
to sensitization, allergic symptoms and success of 
immunotherapy. The certainly best characterized 
venom is that of the honeybee Apis mellifera, which 
is due to the outstanding importance of beekeeping 
and thus of the honeybee venom (HBV) as elicitor 
of venom allergy all over the world and moreover, 
to the availability of detailed proteomic data of pure 
venom (2) and genomic information of the honeybee 
(3). Additionally, in the last years much progress has 
been made in the identification of new allergens of 
the common wasp (in USA known as yellow jacket) 
Vespula vulgaris. Prominent wasp/vespid venom 
(VV) allergens include phospholipase A1 (Ves v 1), 
hyaluronidase (Ves v 2.0101) and antigen 5 (Ves v 5), 
a protein of unknown function but high abundance in 
the venom (Table 2; Fig. 1) (4, 5). Recently, a second 
inactive hyaluronidase (Ves v 2.0201), carrying an 
inactivating mutation in the active site of the enzyme, 
was identified in VV which interestingly seems to 
be the predominant allergen (6, 7). In the last years 
significant progress has been achieved mainly by 
proteomic approaches in identifying important 
allergens of low abundance. The genes of the 100 
kDa dipeptidylpeptidases IV (DPP IV) from HBV (Api 
m 5) and YJV (Ves v 3), a new class of homologous and 
cross-reactive Hymenoptera venom enzymes, were 
identified (8). Additionally, the 200 kDa vitellogenins 
Api m 12 and Ves v 6 were described as novel pair of 
cross-reactive panallergens of HBV and VV (9). So far, 
only the major allergens Ves v 1 (phospholipase A1) 
and Ves v 5 (antigen 5) of VV and Pol d 5 (antigen 5) 
of Polistes dominula venom are available for routine 
molecular diagnostics.
SENSITIZATION TO INDIVIDUAL 
MOLECULES AND ITS CLINICAL RELEVANCE 
(VESPULA SPP. AND POLISTES SPP.)
Asymptomatic sensitization: The prevalence of 
sensitization (indicated by a positive skin test and/or 
the detection of serum specific IgE to whole venom 
extract in patients with no previous case history) is 
estimated at between 9.3% and 28.7% (12) in the 
adult population which is related to the degree of 
exposure to stings and to the insect distribution and 
behavior. Reliable data on asymptomatic sensitization 
rate are not available for Vespid venom recombinant 
allergens.
However, the risk for sensitized asymptomatic 
patients of developing a systemic reaction (SR) has 
been demonstrated to be low (5.3% in a recent study 
(13) and 10-15% in old studies (14). Moreover, an 
increase in serum specific IgE levels after a sting is not 
an indicator for conversion into a clinically relevant 
hypersensitivity (13).
Sensitization rate to individual molecules and clinical 
relevance
Reliable data on sensitization rates are available for 
many vespid allergens (Table 3 and 4).
Table 1
Vespid species in the USA and Europe 
Genus Europe USA
Species Popular name Species Popular name
Polistes gallicus
dominula
Wasp annularis
fuscatus
exclamans
Paper wasp
Vespula vulgaris
germanica
rufa
Wasp vulgaris
germanica
maculifronts
Yellow jacket
Dolichovespula media
saxonica
Wasp maculata
arenaria
Hornet
Vespa crabro
orientalis
Hornet crabro European hornet
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Table 2
Overview of the vespid venom allergens which are presently listed in the WHO/IUIS Allergen Nomencla-
ture official database. 
Allergen Name/Function MW (kDa) Potential N-glycosylation
American paper wasps (Polistes annularis, P. exclamans, P. fuscatus, P. metricus)
Pol a 1, Pol e 1 Phospholipase A1 34 0
Pol a 2 Hyaluronidase 38 2
Pol e 4 Protease ?
Pol a 5, Pol e 5, Pol f 5, Pol m 5 Antigen 5 23 0
European paper wasps (Polistes dominula, P. gallicus)
Pol d 1, Pol g 1 Phospholipase A1 34 1
Pol d 4 Protease 33 6
Pol d 5, Pol g 5 Antigen 5 23 0
Hornets (Vespa crabro, V. magnifica, V. mandarinia)
Vesp c 1, Vesp m 1 Phospholipase A1 34 0
Vesp ma 2 Hyaluronidase 35 4
Vesp c 5, Vesp ma 5, Vesp m 5 Antigen 5 23 0
Polybia wasp (Polybia paulista, P. scutellaris)
Poly p 1 Phospholipase A1 34 0
Poly s 5 Antigen 5 23 0
White-faced hornet, yellow hornet (Dolichovespula maculate, D. arenaria)
Dol m 1 Phospholipase A1 34 2
Dol m 2 Hyaluronidase 42 2
Dol m 5, Dol a 5 Antigen 5 23 0
Yellow jackets (Vespula vulgaris, V. flavopilosa, V. germanica, V. maculifrons, V. pensylvanica, V. squamosa, V. vidua)
Ves v 1*, Ves m 1, Ves s 1 Phospholipase A1 35 0, 0, 2
Ves v 2.0101, Ves m 2 Hyaluronidase 45 4
Ves v 2.0201 H y a l u r o n i d a s e 
(inactive)
45 2
Ves v 3 DPP IV 100 6
Ves v 5*, Ves f 5, Ves g 5, Ves m 5, 
Ves p 5, Ves s 5, Ves vi 5
Antigen 5 25 0
Ves v 6 Vitellogenin 200 4
Allergens which are available for routine molecular diagnostics in 2015 are printed bold.
*Marker allergens with experimental evidence to be able to discriminate each by itself between honeybee and yellow jacket venom allergy.
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Specific IgE determination against non-glycosylated 
recombinant species-specific major allergen Ves v 5 
alone showed a sensitivity between 84.5% and 100% 
(15-20).
Sensitization to rVes v 1 was found in 33.3-54% of 
yellow jacket venom (YJV) allergic patients (17-22). 
Sensitization to rVes v 2 was reported in 5-25% of 
YJV allergic patients, while sensitization to rVes v 3 in 
50-62.8% of YJV allergic patients (8, 20).
Wasp and bee vitellogenins (rApi m 12 and rVes v 
6) seem to play a relevant role as sensitizing venom 
components and as a novel cross-reactive class 
of homologous allergens responsible for double 
positive results with bee and YJ venoms apart from 
Table 3
Sensitization rates to individual yellow jacket venom allergens
Allergen Name/Function Sensitization Rate References
Ves v 1 Phospholipase A1B 33.3 – 54% 638, 639, 640, 641, 642
Ves v 2a (0101
Ves v 2b (0201)
Hyaluronidase
Hyaluronidase*
5%
20-25%
618
618
Ves v 3 Dipeptidylpeptidase IV 50-62.8% 630. 640
Ves v 4 CUB-protease ?
Ves v 5 Antigen 5 84.5 – 100% 636, 637, 638, 639, 640
Ves v 6 Vitellogenin 39% 631
* Inactive isoform of Ves v 2a without enzymatic activity
Figure 1
Structures of selected vespid venom allergens. Structures were generated by either X-ray diffraction (10) 
or structural modeling (11).
Ves v 1 Ves v 2 Ves v 3 Ves v 5
Pol d 1 Pol d 4 Pol d 5
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Table 4
Sensitization rates to individual Polistes dominula/annularis venom allergens
Allergen Name/Function Sensitization Rate References
Pol d 1 Phospholipase A1 87% (nPol d 1) 650
Pol d 4 Serine protease ?
Pol d 5 Antigen 5 69-72% (nPol d 5) 650
Pol a 5 Antigen 5 44% (r Pol a 5) 650
cross-reactive carbohydrate determinants (CCDs). 
In particular rVes v 6 was recognized by 39% of YJV 
allergic patients (9).
The diagnostic sensitivity of a combination of the YJV 
recombinant allergens rVes v 5 and rVes v 1 has been 
reported to be as high as 92-98% (17, 19, 21, 23-25). 
Since both rVes v 5 and rVes v 1 are commercially 
available, in wasp venom allergy CRD is valuable and 
can be used to exclude unspecific sensitization due 
to CCDs.
Nevertheless, rVes v 1 and 5 failed to diagnose 2-8% 
of subjects with established allergy, thus indicating 
the need to add more allergens (17).
Indeed, one recent study using a combination of ELISA 
assays and routine ImmunoCAPs suggested that the 
measurement of the combination of recombinant 
antigens (rVes v 1, 2, 3, 5) may further increase 
the sensitivity of routine assays to wasp venom up 
to 100% (20). In contrast, a following study using 
ImmunoCAP system for all allergens showed that 
none out of 27 patients with a convincing history of 
YJV anaphylaxis but sIgE level below 0.35 kUA/L to 
the currently available YJV ImmunoCAP (spiked with 
rVes v 5) displayed IgE reactivity above 0.35 kUA/L to 
rVes v 1, 2, or 5, and only one displayed IgE reactivity 
to rVes v 3, most likely due to cross reactivity to Api 
m 5 (26).
In patients with a documented history but negative 
tests results, several studies each collecting a limited 
number of patients demonstrated the chance to 
diagnose these cases by using recombinant Ves v 5 
as allergen (from 42.1% up to 84%) (16, 19, 20, 21, 
24, 25). Consequently the conventional extract was 
spiked with Ves v 5 which led to a higher sensitivity 
(19, 21). This rVes v 5 spiked YJV ImmunoCAP was 
introduced for routine diagnostics in autumn 2012 
and has replaced the previous YJV ImmunoCAP since 
then.
In the case of double positivity to honeybee (HB) and 
wasp venom extracts, IgE detection to recombinant 
allergens Api m 1, Ves v 1 and Ves v 5 is able to 
discriminate double sensitization from CCD related 
cross-reaction in venom allergic patients (15, 16). 
However, the discrimination between HBV and 
YJV sensitization is still difficult due to the limited 
sensitivity of the only available HBV allergen Api m 
1. While Ves v 1 and Ves v 5 negative results exclude 
YJV sensitization with a high likelihood, Api m 1 
negative results do not exclude HBV sensitization. 
Here additional HBV marker allergens are needed to 
optimize the diagnostic precision (see chapter on bee 
venom).
In the south of Europe double sensitization to either 
Vespula or Polistes species is more frequent than that 
of Vespula and honeybee (27-29). According to a 
recent study, the major allergens of Polistes dominula 
and Vespula vulgaris venoms, namely phopholipase A1 
and antigen 5, are required to identify the probable 
sensitizing species in vespid-allergic patients, while 
Vespula hyaluronidase was shown to have no additional 
value as regards the specificity of the assay (30).
Unlike YJV and HBV, venoms of different Polistes 
species have recently been demonstrated to be 
devoid of any a1,3-core-fucosylation and hence 
allow CCD interference free diagnostics (30).
The importance of rPol d 1 for a CRD of Polistes venom 
allergy in Europe was also underlined by a recent 
case report. One Spanish patient on immunotherapy 
with the American Polistes species venom mixture 
developed anaphylaxis following a sting challenge 
with Polistes dominula However, no reaction occurred 
with the same sting challenge when the treatment was 
switched to the Polistes dominula extract after a more 
sensitive diagnosis using rPol d 1 specific IgE (32).
So far, no data are available on the correlation 
between certain molecular sensitization profiles to 
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vespid allergens and severity of the sting reaction. 
In addition, there are currently no marker allergens 
available that allow a definite discrimination between 
YJ and Polistes venom sensitization.
CLINICAL MANAGEMENT
Clinical Diagnosis
The goal of vespid allergy diagnostics is to classify 
the type of reaction, to identify the culprit insect and 
to explain the pathomechanism. Currently it is based 
on clinical history, skin tests and measurement of 
specific IgE antibodies to vespid venom (33).
Since in vitro tests to whole venom extracts are 
negative in approximately 20% of positive skin tests 
and approximately 10% of negative skin tests yield 
a positive in vitro result, the European guidelines 
published ten years ago recommends skin testing as 
well as evaluation of venom-specific IgE as a standard 
procedure in all patients with a history of SRs (33).
Moreover, as venom sensitization is found in about 
10-30% of history-negative persons, only those with 
a history of a previous SR are in general eligible for 
diagnostic testing.
Patient history
The patient is asked to describe his/her symptoms 
and the course of the sting reaction, number of stings, 
clues as to the type of insect involved and individual 
risk factors for anaphylaxis. Uncertainty regarding 
the nature of the stinging insect (bee or wasp) is a 
common clinical conundrum except in the case of 
beekeepers, and sometimes gardeners and farmers.
Vespinae and Polistinae subfamilies are very similar, 
with differences at the junction of the thorax and 
abdomen. Vespinae have a truncated junction while 
Polistinae are more oval in shape. Vespidae are almost 
hairless and have black and yellow striped abdomens 
(33). Thus it is understandable that the laypersons 
often cannot differentiate between members of the 
Vespinae and Polistinae subfamily.
In patients with a history of severe systemic reaction 
dermatological evaluation is recommended to rule 
out a possible diagnosis of cutaneous mastocytosis. In 
patients with an unclear or suggestive psychosomatic 
reaction, scrutiny of emergency room and ambulance 
records is recommended.
Skin tests
The sensitivity of the skin prick test is lower than that 
of the intradermal test (up to 1.0 μg/ml), which has to 
be used in order to confirm the negative result (609). 
In a recent series of 301 patients with YJV allergy, the 
titrated skin prick correctly identified 49 % and the 
combination of prick test and intradermal tests 94% 
of the cases (19).
Standardised hymenoptera venom products, including 
YJ and Polistes wasp venoms, are commercially 
available in many countries, being mixtures of the 
clinically relevant species for YJ (Vespula vulgaris, V. 
flavopilosa, V. germanica, V. maculifrons, V. pensylvania, 
V, squamosa) as well as American Polistes (Polistes 
annularis, P. exclamans, P. fuscatus, P. metricus) venom 
extracts.
Contrary to the USA, dialyzed bee and yellow jacket 
venoms are used for diagnosis and therapy in some 
European countries, allowing different diagnostic 
accuracy with respect to the use of un-dialyzed 
extracts (34). In dialyzed venom, low molecular weight 
components (like histamine and components with 
histamine-releasing activity) smaller than 1000-3000 
Dalton are removed. In view of lower cross-reactivity 
between venoms of the European and American 
species of Polistes (35), commercial preparations of 
European Polistes dominula venom are now available 
(29).
No recombinant venom allergens are commercially 
available for skin testing.
Skin test results and severity of sting reaction
There is no correlation between the severity of sting 
reactions and skin-test reactivity to whole venom 
extracts (36). Indeed, the most positive skin tests 
occur in patients with LLRs only, while almost 25% 
of patients who are referred for evaluation of a sting-
induced SR have a negative SPT and show a positive 
intradermal test only at the highest concentration (1 
μg/ml) (33).
IgE-testing
Total IgE (tIgE)
Determination of tIgE may be useful for appropriate 
interpretation of allergen-specific IgE, especially in 
the case of very low level of sIgE.
Specific antibodies to hymenoptera venoms are 
frequently seen in asymptomatic individuals with 
high total IgE (37), and correlate with atopy status 
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(38), but appear to be largely irrelevant in clinical 
terms (37).
Allergen specific IgE
Venom specific IgE can be detected immediately 
after the sting, but the optimal time point will be 1-4 
weeks later (33), since the sting most likely will have 
induced a boost of the IgE production.
Sensitivity for YJV is usually lower than for HB venom. 
According to some recent studies, the conventional 
YJV sIgE assay using the whole extract yielded a 
sensitivity between 83.4 % and 91% (15, 19, 21).
In some studies (19, 21) it has been demonstrated 
that the newly developed YJV solid-phase assay 
complemented with rVes v 5 has a higher sensitivity 
than the traditional YJV test.
Honeybee venom and vespid venom extract: Specific 
IgE measurements to venom extracts might show 
multiple positive test results due to sensitization 
to multiple venoms or to cross-reactivity of CCDs 
or homologous allergens present in different 
venoms. Results might be negative due to the 
underrepresentation of particular allergens in the 
extract (for schematic representation of diagnostic 
problems associated with venom extracts see Fig. 
93 in the chapter on bee venom). Polistes species 
venom has been demonstrated to be devoid of CCD 
reactivity, thus avoiding the potential for CCD related 
cross-reactivity (31).
Vespula spp. and Polistes spp. / P. dominulavenom 
extracts: A double in vitro positivity to YJ and Polistes 
venom is common in Mediterranean countries (27-
29), where the species Polistes dominula and Polistes 
gallicus are the most common species. A incomplete 
cross-reactivity between European and American 
paper wasps was demonstrated (29, 35), leading to 
the need to introduce, at least in Europe, the Polistes 
gallicus or dominulus extract (the latter only being 
available in some European countries) into clinical 
practice for diagnostic and therapeutic purposes.
Total IgE, allergen specific IgE results and severity of 
sting reaction: There is no correlation between the 
severity of sting reactions and the concentration of 
venom sIgE to whole venom extracts (33, 39, 40), as 
some patients with minimal or absent venom-specific 
IgE antibodies can develop severe anaphylaxis (41). 
The influence of total IgE and venom specific IgE on 
the severity of hymenoptera sting reactions has been 
evaluated, with conflicting results. In a prospective 
study on a large population of patients with history of 
sting anaphylaxis, neither skin tests to insect venom 
nor venom specific IgE were significantly correlated 
with the reaction’s severity after in-hospital sting 
challenge, in accordance to previous prospective 
and retrospective studies (36). In another study, 
high specific IgE levels were related to high total 
IgE levels, but not to severe sting reactions, which 
occurred more frequently in patients with low total 
IgE (42). In a more recent study, an influence of total 
and specific IgE on severity of sting reactions could 
not be shown, except for honey bee venom specific 
IgE, which were significantly lower in patients with 
severe anaphylaxis (43).
For the use of species-specific marker allergens that 
help to differentiate between honeybee venom and 
vespid venom allergy, please refer to the chapter 
on bee venom allergy and the diagnostic algorithm 
depicted in (Fig. 2).
Cellular tests
Among cellular tests, basophil activation test 
(BAT) is the most useful one and can be used as a 
diagnostic tool in some specific cases. BAT allows the 
identification of approximately two thirds of patients 
with systemic sting reactions but negative venom-
specific IgE and skin test results (44).
BAT is also recommended in double positive patients 
with inconclusive recombinant or skin test double 
positive results, especially if the patient has had an 
anaphylactic reaction to only one insect45. Since 
results of BAT are influenced by the presence of CCDs 
in venoms, BAT together with a component-resolved 
diagnosis by means of CCDs-free recombinant 
allergens, may be useful to a better diagnostic 
approach to hymenoptera venom allergy (45, 46).
IgE-inhibition test
The IgE-inhibition test is of use when distinguishing 
between cross-reactivity and double sensitization. 
However, it is costly and results are sometimes 
difficult to interpret (33, 40).
Baseline serum tryptase
As outlined in the chapter on bee venom allergy, it 
is recommended to determine the baseline tryptase 
concentration in all patients with a history of a severe 
reaction after a Hymenoptera sting. For more details 
refer to the bee venom chapter.
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Sting challenge
As challenge test with subcutaneously or 
intracutaneously administered venom is not reliable, 
it should be performed using live insects (47). The 
outcome of sting challenge is influenced by a number 
of factors, including insect biology, indicating that 
bees yield more reliable sting challenge results than 
do vespids. However, sting challenge should not be 
used as a diagnostic tool in untreated patients, as a 
tolerated sting challenge does not fully predict the 
outcome of future stings in an individual patient 
and as untreated patients may develop very severe 
reactions to a sting challenge (47).
Prevention and Therapy
Preventive measures
A series of recommendations have been formulated 
Figure 2
Diagnostic algorithm in yellow jacket and paper wasp venom allergy. A red minus indicates a negative and 
a green plus a positive test results. 
aimed at substantially minimizing the risk of field 
re-sting, although as yet no evidence-based studies 
have been performed to support this.
Untreated patients with anaphylaxis should not be 
given β-blockers, except when the administration 
of these drugs is urgently required as in the case of 
certain cardiac arrhythmias. If possible, angiotensin 
converting enzyme inhibitors (ACEI) should also be 
avoided.
Pharmacotherapy (emergency kit)
A) Hymenoptera venom allergic patients should 
carry an emergency kit for self-administration at 
all times, especially during the insect season.
B) Self-injectable adrenaline should be considered 
for all patients with a history of a SR, particularly 
those who have experienced ‘moderate-severe’ 
Positive History
sIgE YJ venom
sIgE PW venom
sIgE Ves v1/5
sIgE Pol d5
BAT* YJ
BAT* PW
sIgE to other Pol d allergens
Skin test
NO VIT
YJ venom + PW venom PW venomYJ venom
CONSIDER VENOM SPECIFIC IMMUNOTHERAPY (VIT)
Tryptase
_
+
+
_
+
+
_
_
_
+
+
_
_
+
+
_
+
+
_
_
+
+
_
_
* BAT is not available for routine diagnosis in every clinic Yellow jacket: YJ – Paper wasp: PW
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episodes or those with increased risk of future 
exposure to stings (beekeepers, gardeners, waste 
management workers etc.), underlying mast cell 
disorders or raised baseline serum tryptase or 
other co-morbidities (48).
Venom specific immunotherapy (VIT)
The efficacy of subcutaneous venom immunotherapy 
has been confirmed by both sting challenge and in-
field sting in prospective controlled and uncontrolled 
studies, in one meta-analysis and systematic reviews 
demonstrating that the protection rate of vespid VIT 
is greater than that of honeybee VIT (39, 40, 48-50).
The repeatedly observed difference in the success 
rates in bee and vespid venom-allergic patients is not 
completely clear. The fact that the amount of venom 
delivered by a bee sting during a sting challenge is 
much larger and more consistent may partially explain 
this difference in the reaction rate to sting challenges, 
which has also been observed in untreated patients 
(668). The composition of bee venom, which is a 
mixture of proteins and other pharmacologically 
active molecules, including melittin, and/or the 
absence or underrepresentation of major allergens in 
commercially available venom preparations may be 
another alternative explanation (52).
Finally, venom-allergic patients with mast cell 
diseases will benefit from VIT, albeit to a lesser extent 
than patients without mastocytosis (53).
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USING 
MOLECULAR 
ALLERGOLOGY 
IN THE CLINICAL 
PRACTICE
PART B
B22
Implementation of low-allergen, powder-free 
latex gloves or latex-free devices decrease 
the prevalence of latex allergy
Several recombinant latex allergens (Hev 
b 1 -15) are available and useful for the 
determination of sensitization profiles 
and exclusion of glyco-epitopes (with low 
clinical relevance) responsible for IgE-binding 
to latex; the serological work-up for the 
diagnosis of latex type I-allergy is highly 
recommended;
With respect of the sensitivity of the IgE 
assays, the improved natural latex extract 
spiked with the recombinant Hev b 5 is 
a sensitive tool for the diagnosis of latex 
sensitization and superior compared to 
the available panel of recombinant latex 
allergens.
INTRODUCTION
Adverse reactions to latex include non-allergic 
contact dermatitis, delayed type IV and immediate 
type I hypersensitivity. Irritant contact dermatitis 
and type IV hypersensitivity are immediate or 
delayed (24-96 hours) responses to chemicals and 
additives in latex products. Type I hypersensitivity is 
the most serious response to latex proteins occurring 
minutes to hours after exposure and ranging from 
mild irritation to loss of life. Here the term “latex 
allergy” covers latex protein induced IgE-mediated 
hypersensitivity reactions.
THE ALLERGEN SOURCES
During the late 1980s and early 1990s natural 
rubber latex (NRL) allergy has become an important 
occupational health concern, particularly among 
hospital personnel especially health-care workers 
(HCW) and medical doctors and in dental clinics. 
Additionally, in children with spina bifida also a 
high prevalence of latex sensitization (up to 72%) 
was observed. The milky sap of the rubber tree 
Monika Raulf
LATEX 
ALLERGY
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Hevea brasiliensis is the source for the production of 
commercial natural rubber latex (NRL) devices and 
represents also a source of potent allergenic proteins 
(1, 2) (Fig. 1).
Most of Hevea brasiliensis grows commercially in 
a number of tropical countries, mainly in Thailand, 
Indochina, Malaysia and India. The milky sap is 
synthesized by specialized laticifer cells and collection 
of the latex is possible by scarifying the trunk of the 
Hevea brasiliensis tree. Ammonia treatment prevents 
coagulation resulting in hydrolysis of the latex 
proteins. The main constituent of Hevea latex is the 
polymeric hydrocarbon 1,4 cis-poly-isoprene and only 
1-2% of the fresh milky sap is made up of proteins. 
The proteins are heterogeneously distributed in the 
latex sap and they are involved in the biosynthesis of 
the polyisoprene, associated with the coagulation of 
latex and in the defense of the plant against various 
diseases. After ultra-centrifugation of the fresh latex 
sap basically three main fractions (rubber phase, the 
C-serum and the bottom fraction (B-serum) are easily 
discerned (Fig. 2).
The rubber phase comprises the rubber particles and 
two main, insoluble proteins, which are extractable 
from the surface of the rubber particles. Most of the 
C-serum and B-serum proteins are water-soluble. 
Latex C-serum contains various proteins (more than 
200 polypeptides) and some of them are enzymes 
associated with the rubber biosynthesis (3).
Allergic reactions have been described through direct 
skin/mucus membrane contact or via inhalation. 
For HCWs, there are numerous potential routes 
of exposure to NRL allergens. Skin exposure may 
Figure 1
From the sap of the latex tree Hevea brasiliensis to multiple latex devices.
Rubber tree
Hevea brasiliensis
Ammoniated latex sap
Medical devices Household devices
Manufacturing of
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occur from direct contact with many NRL products, 
such as latex gloves. In the case of latex gloves, 
lubricants that facilitate donning and removal, such 
as cornstarch, may be added by dipping the gloves 
into a powder-slurry. Proteins, liberated from the 
latex, attach to the powder as the slurry dries onto 
the gloves. This powder can act as a carrier for latex 
proteins and protein-loaded powder particles can 
become aeroallergens during donning and removal 
of the gloves. Inhalational exposure may occur when 
aerosolized glove powder coated with NRL allergens 
comes into contact with the mucous membranes of 
the nose, throat and airways of the lung.
Before initiating a primary NRL prophylaxis around 
and during surgery and anesthesia of all spina bifida 
patients and the introduction of powder-free gloves 
with reduced protein levels in hospitals, children with 
spina bifida, health care workers (HCW), and persons 
with a history of multiple surgeries belonged to a 
group with a higher risk to develop a NRL allergy. 
In addition, high risks were also described for non-
health care workers with exposure to latex such as 
hairdressers, cleaners and food-service workers, as 
well as workers in rubber industrial companies or 
subjects with food allergy and atopy.
MAJOR AND RELEVANT MINOR 
ALLERGENIC MOLECULES
Up to now about 250 different NRL polypeptides 
were identified. About 60 are capable to bind human 
IgE (3) and currently 15 allergens have been included 
in the latest nomenclature list of the International 
Nomenclature Committee of Allergens (IUIS) and 
assigned official numbers (Hev b 1-15) (http://www.
allergen.org) (Table 1, Fig. 2).
Hev b 1 together with Hev b 3 are rubber particle 
proteins. Hev b 5 is an acidic (pI 3.5) and heat-
stable 16-24 kDa protein, rich of glutamic acid as 
well as of proline residues. The first recombinant 
Hev b 5 (rHev b 5) was described by Slater et al. (4). 
Prohevein, assigned by the WHO/IUIS as Hev b 6.01, 
was isolated from the B-serum and posttranslational 
cleavage proceeds two further proteins, the 4.7 kDa 
hevein (Hev b 6.02) and the 14 kDa C-terminal domain 
Hev b 6.03 (5). All three allergens additionally exist in 
the plant and the ratio between Hev b 6.01 and Hev 
b 6.03 is about 30:1. Hev b 6.02 (hevein) comprises 
the most important part of IgE-binding epitopes in 
the prohevein molecule. In addition, hevein shows 
homology to several chitin-binding lectin domains (4) 
and may be responsible for certain cross-reactivity 
to several other plants and food. Most of the Hev 
b-proteins have been cloned and expressed as 
recombinant proteins. Sequencing demonstrated 
both unique epitopes and sequences commonly 
found in other plant proteins. Sequence homology 
helps to explain the cross-reactivity to a variety of 
foods experienced by latex allergic individuals.
SENSITIZATION TO INDIVIDUAL 
MOLECULES AND THEIR CLINICAL 
RELEVANCE
Depending on the definition of the study group and 
the methods for assessment of latex sensitization 
and/or allergy (mainly based on skin or IgE testing 
with latex extracts), the observed prevalence among 
health care workers ranges between 0-30%, whereas 
the prevalence among children with spina bifida 
ranges between 25-72% (5). Among adult blood 
donors showing latex-specific IgE antibodies two 
separate studies reported a sensitization frequency 
of about 6% (6). In contrast, the prevalence in the 
general population is between 0 and 2.3% (7). 
Individuals who are allergic to latex products may 
Protein content 
(percentage)
Gap space
Hev b 1
Hev b 3
Smaller rubber particles
Rubber phase
(∼ 27%)
Hev b 7.02
Hev b 5
Hev b 8
Hev b 9 C-serum
(∼ 48%)
B-serum
(∼ 25%)
Hev b 13
Hev b 11
Hev b 10Hev b 7.01
Hev b 6.01, 6.02, 6.03
Hev b 2, Hev b 4
Figure 2
Separation of the latex sap into three main frac-
tions after centrifugation and distribution of the 
latex allergens.
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experience allergic reactions due to cross-reactivity 
from a variety of fresh fruits, vegetables and nuts.
Latex allergy shows distinct patterns that can be 
predicted through component-resolved diagnosis 
including cross-reactive carbohydrate determinants 
to clarify if protein epitopes (with clinical relevance) 
or the glyco-epitopes (with low clinical relevance) 
are responsible for the IgE-binding to latex. Based 
on different exposure routes, different allergens are 
dominantly recognized by IgE of latex-sensitized 
patients. The recombinantly available latex allergens 
Hev b 5 and Hev b 6.01 are the major allergens 
involved in sensitizing HCW (8).
Hev b 1 and Hev b 3 are of minor relevance since <20% 
of the HCW have positive IgE antibody responses 
to these insoluble particle-bound allergens. Based 
on this insolubility, Hev b 1 and Hev b 3 are much 
harder to aerosolize, and their sensitization process 
thus seems to require contact to latex with blood or 
mucosal surfaces, which occurs during surgery. Hev b 
7.02 appears to be of an intermediate relevance and 
showed no association to the atopic status or the 
presence of latex-fruit syndrome. Hev b 11.0102, the 
Hevea latex class I chitinase derived from Hevea leaves 
displays minor relevance as allergen in HCW and is 
only recognized in sera with sIgE responses to rHev b 
6.01. Lee et al. described that hevamine (Hev b 14) and 
Hev b 1 are the major allergens in Taiwanese medical 
workers. Major allergens in spina bifida patients are 
Hev b 1, Hev b 3, Hev b 5 and Hev b 6.01 (8).
CLINICAL RELEVANCE, DIAGNOSIS AND 
MANAGEMENT
The latex epidemic hit its peak in the mid-1990s. 
Since then, the apparent prevalence of latex allergy 
has been steadily decreasing. The implementation of 
Table 1
Immunological and clinical properties of characterized latex allergens of the rubber tree Hevea brasiliensis 
Allergenic molecule Biochemical name Prevalence among patients* MW (in kDa)
Hev b 1 Rubber Elongation Factor (REF) 81%1 14
Hev b 2 β-1,3-Glucanase 70%1, 2, 3 34
Hev b 3 Small rubber particle proteins 58%1 24
Hev b 4 Lecithinase homologue - 53-55
Hev b 5 Acidic structural protein up to 60%2 16
Hev b 6 Prohevein (hevein precursor) up to 70%2 20
Hev b 7 Patatin-like protein (esterase) 
from latex-B- and C-serum
25%1, 2 44
Hev b 8 Profilin (actin-binding protein) 10%1, 2 14
Hev b 9 Enolase up to 3%2 51
Hev b 10 Manganese superoxide 
dismutase (MnSOD)
up to 3%2 26
Hev b 11 Chitinase class I up to 18%1, 2 30
Hev b 12 Non-specific Lipid Transfer 
Protein type 1 (nsLTP1)
- 9
Hev b 13 Esterase up to 80%1, 2, 3 42
Hev b 14 Hevamine - 30
Hev b 15 Serine protease inhibitor - 7.5
1among spina bifida patients, 2among health care workers, 3only testing with native Hev b 2 or Hev b 13, respectively, *all data published in (8)
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low-allergen, powder-free latex gloves in hospitals 
had shown a dramatic decrease in the prevalence of 
latex allergy.
About 30-50% of latex-allergic patients show allergic 
symptoms to plant-derived foods, especially fresh 
fruits (9). The association was called latex-fruit 
syndrome [review in (10), (11) and huge amounts of 
relevant fruits, constantly increasing, are described 
and the most commonly involved are avocado, 
banana, chestnut, and kiwi. Several latex allergens 
were discussed as responsible for the latex-fruit 
cross-reactivity (Fig. 3), such as Hev b 2 (12), Hev b 
6.02 (13-15) Hev b 7 (16), Hev b 8 (17) and Hev b 
12 (18). The time course of sensitization is a topic of 
discussion. In the literature there are some reports 
describing a symptomatic fruit allergy (banana) 
before symptoms of NRL allergy were noted (19) as 
well as NRL allergic symptoms preceded a banana 
allergy. In some cases the use of recombinant single 
latex allergens for latex-specific IgE mapping is 
helpful to discriminate between cross-reactivity and 
co-sensitization to latex and fruits (15, 17).
Diagnosis
The diagnostic approach for latex allergy starts with 
obtaining a detailed clinical history, including the 
history of risk factors and the temporal relationship 
between exposure to NRL devices and the 
symptoms. Specific questions concerning symptoms 
at the workplace, use of latex devices etc. proper 
interpretation of sensitization tests (i.e. skin prick 
test, IgE) and optional challenge test with powdered 
gloves and glove-wearing test help to establish the 
diagnosis of type I- latex allergy. In the past the 
diagnostic of a latex sensitization was rather difficult, 
because several studies demonstrated that IgE test 
systems gave false-negative results in more than 
25% of patients with allergic reactions based on NRL 
and skin test positive subjects (20). One reason for 
these discrepancies was a missing allergen. Indeed, 
by addition of rHev b 5 to the diagnostic repertoire 
of latex allergens, 8 out of 16 subjects with clear 
latex allergy and negative latex-specific IgE value 
using Thermo Fisher (Phadia) CAP system showed 
significantly elevated IgE levels to Hev b 5 (21). 
These findings demonstrate that latex allergen Hev b 
5 may play a special role in diagnostic tests showing 
false-negative IgE results. The addition of rHev b 5 in 
sufficient amounts improved the ImmunoCAP used 
for serological testing significantly (22, 23). These 
results indicate a new approach: if relevant allergens 
are too labile to survive all steps required for the 
production of a standardized allergen preparation 
they can be added as a stable recombinant protein to 
the allergen preparation during the production.
In contrast, false-positive latex-specific IgE results 
in subjects without clinical symptoms to latex and 
negative skin prick test most often base on IgE-binding 
to N-glycans and/or O-glycans which are often 
part of allergens of plant origin, like latex. In these 
cases e.g. application of CCD tools (like horseradish 
peroxidase (HRP) and/or inhibition studies with 
“cross-reactive carbohydrate determinants” (CCD) 
to clarify if protein epitopes (with clinical relevance) 
or the glyco-epitopes (with low clinical relevance) 
are responsible for the IgE-binding to latex (8) are 
helpful. In addition, component-resolved diagnosis 
using microarray (24) or single placed ImmunoCAP 
coupled with recombinant or native allergens (8) are 
reliable tools for diagnosing latex allergy. Following 
serological work-up (Fig. 4) might support proper 
diagnosis.
Clinical management
Studies have shown that economically feasible 
interventions to reduce NRL exposure can 
successfully allow latex-allergic individuals to 
continue working. Implementation of powder-free 
gloves with low or undetectable NRL allergen was 
a successful strategy to reduce the latex allergen 
concentration at the work site and allowed most 
Figure 3
Molecular background and association of la-
tex-fruit/vegetable syndrome –allergens with 
potential importance for cross-reactivity. (modi-
fied according to (26)).
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HCWs to remain on the job, and decreased the 
number of new cases of occupational latex allergy. 
The complete cessation of exposure was associated 
with a greater rate of asthma-related disability and 
loss of income; therefore, reduction of exposure 
to latex is safe and more economical alternative to 
complete removal from the workplace. The risk of 
re-sensitization by re-exposure to NRL has to be 
minimized. In some cases, when avoidance measures 
are not feasible or effective, specific immunotherapy 
with latex extracts can be offered (25).
CLINICAL CASE
Case 1 (published (15))
History: man, 37 years old, developed urticaria with 
skin redness, itching, dyspnea and tachycardia 
5 minutes after drinking a glass of apple juice 
supplemented with acerola (Malpighia glabra; 
Barbados cherry); no allergy to apple and apple 
juice was well tolerated; in the past seasonal hay 
fever symptoms caused by grass pollen and wild 
herbal pollen; since childhood, a significant contact 
urticaria induced by natural rubber latex products 
was well known; OAS after ingesting avocado, 
celery, walnut, and curry during pollen season.
SPT: wheal size same as for histamine – grass pollen 
mixture, latex, rye; weak reactions to plantain, 
hazel, birch pollen; limited reaction to mugwort 
and ragweed pollen and to curry; intracutaneous 
skin reaction with acerola pulp and with acerola-
containing apple juice; apple juice without acerola 
negative.
In-vitro testing: Total IgE 145 kU/L, specific IgE to 
latex 24.7 kU/L; acerola (RAST) 1.5 kU/L; CAP 
class 3 to grass pollen, CAP class 2 to plantain, 
peanut, tomato soy bean, CAP class 1 to hazelnut 
pollen, ragweed pollen, banana, green apple, herbal 
mixture and nut mixture; single recombinant latex 
allergens:  Hev b 6.01, 17.1 kU/L; Hev b 6.02, 18.7 
kU/L; Hev b 8, 0.7 kU/L; Hev b 1, 3, 5, 10 <0.35 
kU/L. Inhibition studies showed that IgE binding 
to acerola allergens was completely inhibited by 
latex and acerola extract, whereas preincubation 
of the patient’s serum with acerola showed nearly 
complete inhibition to latex (79%) and rHev b 
6.01 (85%). rHev b 8 as a solid-phase allergen 
and acerola as an inhibitor revealed no significant 
inhibition.
Oral challenge: open oral challenge tests with apple 
juice with and without acerola and diluted acerola 
pulp; negative for apple juice; exposure to acerola 
pulp with a latency period of 5 minutes induced 
itching and swelling lips
Diagnosis: Latex-acerola cross-reactivity based on 
Hev b 6.01/Hev b 6.02; Primary sensitization 
to latex led to cross-reactivity to acerola; (Pro-)
hevein is the important allergen and responsible 
for the cross-reactivity;
Allergologists should include acerola on the growing 
list of latex-cross-reactive food allergens and inform 
latex-allergic patients about cross-reacting allergens 
as the traces of acerola in apple juice.
TOOLS
For latex allergy diagnosis an improved latex 
ImmunoCAP spiked with rHev b 5 (ThermoFisher 
Scientific) is available and useful. In addition, 
recombinant single latex allergens are also 
Table 2
Improvement of NRL allergy diagnostics
Method Sensitivity Specificity Positive predic-tive value (PPV)
Negative predic-
tive value (NPV) Test efficacy
NRL (k82) 76% 98.3% 98.1% 78.7% 86.7%
k82 + „rHev b 5“ 90% 98.3% 98.4% 89.4% 93.75%
rHev b-mix* 83.6% 98.3% 98.2% 84.3% 90.6%
Spiking of the NRL extract with the rHev b 5 was a suitable method to improve the in vitro latex allergy diagnostic; *rHev b-mix include rHev b 1, 
rHev b 5, rHev b 6.01 and rHev b 8; data published in (8)
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Figure 4
Serological work-up for the diagnosis of latex type I-allergy; This approach is not useful in patients with 
contact dermatitis and or protein contact dermatitis, where additional patch tests including other rubber 
components (e.g. chemical additives) might be needed (modified according to (26)).
commercially available (rHev b 1, rHev b 3, rHev b 5, 
rHev b 6.01, rHev b 6.02, rHev b 8, rHev b 9, rHev b 11) 
for single testing (ImmunoCAP) and for screening in 
a multiplex system (ISAC allergen chip; ThermoFisher 
Scientific) and are useful for the determination of 
individual sensitization profiles, but in comparison 
to the rHev b 5-spiked latex extract their application 
achieves no better diagnostic sensitivity. Currently 
no latex skin test extract is commercially available 
e.g. in Germany.
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Laboratory animal allergy (LAA) is an 
important occupational disease and rodents 
like mice and rats frequently used in animal 
research are the most common causes of LAA.
Rodent allergens can be found in dander, hair, 
urine, saliva, and serum. Urine is the main source 
of allergenic proteins in both mice and rats. 
As common for the most mammalian inhalant 
allergens, the major allergens from mouse, rat, 
guinea pig, hamster and rabbit are lipocalins. 
Controlling of the airborne allergen 
exposure in animal facilities is possible 
by using commercially available sensitive 
immunoassays for mouse and rat allergens.
Specific IgE determination in the case of LAA 
based on extracts prepared from epithelia, 
serum-/urine protein as mixture or alone 
and is useful. Single LAA allergens are not 
commercially available so far for routine testing. 
THE ALLERGEN SOURCES
Laboratory animal allergy (LAA) is an important 
occupational disease (1). Rodents like mice and rats 
frequently used in animal research are the most 
common causes of LAA. Also rabbits, hamsters and 
guinea pigs are used for research. A study from 
Japan (2) showed that the frequencies of symptoms 
against different laboratory animals were similar 
and that mice and rats are not more allergenic than 
other animals, but they are used more often in 
research facilities. LAA is commonly observed among 
technicians, animal caretakers, physicians, and 
scientists who work in pharmaceutical industries, 
university laboratories, and animal breeding facilities 
(3). In occupational settings, the prevalence rates of 
rodent allergies vary from 11 to 44% depending on 
the diagnostic methods (questionnaire or laboratory 
testing) used (2). The prevalence of mouse and rat 
allergy is very similar. Sensitization and work-related 
symptoms occur at the latest, 2-3 years after the 
initial exposure to laboratory animals (4). Besides an 
atopic background, the most important risk factor for 
the development of an allergy to rodents is the level 
of exposure to laboratory animal allergens. Symptoms 
of occupational allergy against mice and rats are 
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comparable to symptoms induced by environmental 
allergens and consist of allergic rhinoconjunctivitis as 
well as allergic asthma.
Laboratory animal workers may also be exposed 
to other types of allergens in the workplace. These 
include allergens in animal or fish food (e.g. mealworm 
or corn cob), natural rubber latex (via using gloves), 
moulds, storage pests, mites, pollen, enzymes, 
antibiotics and several sensitizing chemicals.
MAJOR AND RELEVANT MINOR 
ALLERGENIC MOLECULES
Rodent allergens can be found in dander, hair, 
urine, saliva, and serum. Urine is the main source of 
allergenic proteins in both mice and rats. As common 
for the most mammalian inhalant allergens, the major 
allergens from mouse, rat, guinea pig, hamster and 
rabbit are lipocalins (Fig. 1, Table 1). Lipocalins (see 
chapter ‘lipocalin’) have a common tertiary structure 
composed of a central β-barrel formed of eight anti-
parallel β-strands (5). The major mouse (Mus musculus) 
allergen, Mus m 1 (about 17 kDa) is a prealbumin and 
lipocalin–odorant binding protein (6) belonging to 
the rodent family of major urinary proteins (MUP) 
(7) (Table 1). MUPs are produced in the liver and 
other exocrine glands under hormonal control and 
transported via blood and secreted in urine. Mouse 
MUPs are encoded by 35 genes, with 15 forms 
detectable in urine. The expression of MUPs varies 
according to species, strains, sexes, and individuals. 
MUPs seem to play a complex role in chemosensory 
signaling among rodents.
Analogous to mouse allergens, the major rat (Rattus 
norvegicus) allergen Rat n 1 (about 17 kDa) is a 
prealbumin or alpha-2u-globulin that belongs to the 
lipocalin group and to the family of MUPs (3, 5, 7, 
8). The amino acid identity between mouse and rat 
MUPs is approximately 65%. In contrast to the MUPs 
from mice, the MUPs from rats are glycosylated. 
Urine collected from male rats contains much larger 
quantities of Rat n 1 than urine from female rats.
Studies of particle size distribution revealed that 
airborne Mus m 1 is carried on particles with 
aerodynamic diameter ranging from 0.4 to >10 µm, 
with the majority on particles between 3.3 and 10 µm 
and that airborne Rat n 1 was detected on particles 
ranging from <0.5 to 20 µm with the majority on 
particles larger than 8 µm (9).
In addition to mice and rats, rabbits (Oryctolagus 
cuniculus) are also frequently used as laboratory animals 
or kept as domestic pets. Rabbit serum albumin, two 
lipocalins (Ory c 1 and Ory c 4) and a secretoglobin 
(Ory c 3) are described as allergens in saliva and dander 
(10). Members of the lipocalin-superfamily were also 
characterized as relevant allergens in guinea pig (Cavia 
porcellus) (5). Cav p 1 was identified in hair extracts 
and urine and can form both monomers (20 kDa) and 
dimers (40-42 kDa) (5). Cav p 2, a non-glycosylated 17 
kDa lipocalin, has 39% sequence identity with Bos d 
2, the major allergenic protein from cow dander. Cav 
p 3 and 6 are also lipocalins and Cav p 4 is the 66 kDa 
serum albumin.
Hamsters (Cricetinae) also belong to the group of 
domestic pets as well as to laboratory animals. So far 
allergic/anaphylactic reactions are described as case 
report. Although the Siberian or Djungarian hamsters 
(Phodopus sungorus) arebit easy to distinguish by 
a layperson from common hamsters such as the 
European (Cricetus cricetus) and Golden (Mesocricetus 
auratus) they belong to a different genus. The 
Figure 1
Characterized allergens in mice, rats, rabbits, 
guinea pig and hamster.
Mus m 1
Rat n 1
Ory c 3
Ory c 4
Ory c 1
Cav p 1
Cav p 3
Cav p 6
Cav p 2
Cav p 4
Pho s 21
Mes a 1
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Golden hamster is the main species used in animal 
research experiments. In the Golden hamster, male-
specific submaxillary gland protein (MSP), a lipocalin 
expressed in a sex- and tissue-specific manner in 
the submaxillary and lacrimal glands, is secreted in 
the saliva, tears and urine. The major allergen from 
the Siberian hamster, Pho s 21kDa, is also a lipocalin 
secreted by the submaxillary gland (11). It has a 
sequence identity of 40% with Mes a 1.
CLINICAL RELEVANCE, DIAGNOSIS AND 
MANAGEMENT
The major determinant of LAA is the exposure 
to rodent allergens but the exposure-response 
appears to be complex since at highest exposures 
to rats, there is attenuation of both sensitization 
and work-related symptoms. Additionally the effects 
of exposure seem to be modified importantly by 
individual susceptibility. A study of Jeal et al. (12) 
showed that high exposure to rats is associated 
with lower rates of specific IgE and symptoms but 
an increased frequency of high specific IgG and 
IgG4 production. Specific IgG4 produced together 
with specific IgE may reduce the risk of developing 
work-related chest symptoms compared with when 
specific IgE is produced alone (12-14).
Diagnosis
Specific occupational-related questions (working in 
laboratory animal facilities), proper interpretation 
of sensitization tests (i.e. SPT, IgE) and optional 
workplace-related, inhalant challenge tests help to 
establish the diagnosis of LAA.
Skin prick testing
Commercial allergen extracts of hair, epithelia and/
or dander from mouse, rat, rabbit and guinea pig are 
Table 1
Characterized inhalant animal allergens
Animal species Allergen Protein family MW 
(kDa)
Allergen source Sensitization 
rate (%)1
Mouse
(Mus musculus) Mus m 1
Lipocalin/ urinary 
prealbumin 17 Urine, Hair Dander 66
Rat
(Rattus norvegicus) Rat n 1 Lipocalin 17 Urine 73 - 87
Rabbit
(Oryctolagus cuniculus)
Ory c 1 Lipocalin 17-18 Saliva, Dander -
Ory c 3 Secretoglobin 19-21 Saliva, Dander 77
Ory c 4 Lipocalin 24 Saliva 46
Guinea pig
(Cavia porcellus)
Cav p 1 Lipocalin 20 Dander, Urine 70
Cav p 2 Lipocalin 17 Saliva, Dander, Tears 65
Cav p 3 Lipocalin 18 Saliva, Dander 54
Cav p 4 Serum albumin 66 Serum 52
Cav p 6 Lipocalin 18 Saliva -
Golden or Syrian hamster, 
(Mesocricetus auratus) Mes a 1 Lipocalin 20-30
Saliva, Tears, Urine 
Dander -
Siberian or Djungarian hamster 
(Phodopus roborovskii)
Pho s 
21kD2 Lipocalin
18, 
21, 23 Saliva, Dander 100
All allergens (with the exception of Phos s 21 kDa) are listed in the WHO/IUIS allergen data bank (www.allergen.org)
1Sensitization rates base on different studies with different patient groups and test systems (ELISA, Immunoblot, ImmunoCAP). They served as 
orientation points, no absolute numbers.
2Allergen listed in Allergome; this lipocalin had no cross-reactivity with common and golden hamster; MW: Molecular weight
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available and often used in the diagnosis procedure. 
Skin prick test extracts from hamster are based on 
Golden or Syrian hamster and sensitizations to 
Siberian or Djungarian hamster are not possible 
to determine accurately due to the lack of cross-
reactivity between the lipocalins Mes a 1 and Pho s 
21kD.
IgE-Testing
Total IgE (for appropriate interpretation of allergen-
specific IgE)
Allergen-specific IgE to the suspected animal allergen 
extracts is the common and recommended step. 
Specific IgE determination in the case of LAA is based 
on extracts prepared from epithelia, serum-/urine 
protein as mixture or alone (e71 = mice epithelia; e88 
= mice epithelia, serum/urine proteins; e76 = mice 
serum proteins; e76 = mice urine proteins; e73 = rat 
epithelia; e87 = rat epithelia, rat serum/urine proteins; 
e75 = rat serum proteins; e74 = rat urine proteins; e84 
= hamster epithelia; e6 = guinea pig epithelia; e82 = 
rabbit epithelia; e206 rabbit serum proteins; e211 
= rabbit urine proteins). It has to be considered that 
dual sensitization to rat and mouse urinary allergens 
reflects cross-reactive molecules rather than atopy 
(15) and therefore the determination of the primary 
sensitizer is difficult. In this case, information from 
the exposure assessment and the clinical history 
are helpful. There is not enough evidence to advice 
the use of single molecules for in-vitro diagnosis. 
Single animal allergens, relevant for LAA, are not 
commercially available so far for routine testing.
Clinical management
Results of the study published by Schmid et al. (16) 
confirmed the necessity of regular medical check-
ups for employees with contact to laboratory animal 
dust. The authors recommended that medical check-
ups must be part of a prevention strategy including 
education, engineering controls, administrative 
controls, use of personal protective equipment and 
vocational integration. Controlling of the airborne 
allergen exposure in animal facilities is possible by 
using commercially available sensitive immunoassays 
for mouse and rat allergens (3).
In the case of individuals with LAA and asthmatic 
symptoms (occupational asthma) there is good 
evidence that removal from exposure within the 
first year of work-related symptoms leads to a better 
prognosis than that of those who remain exposed. In 
general the aim of management of individuals with 
occupational asthma is to preserve their health and 
wealth, preferably to leave their employer in business; 
it is necessary also to prevent other workers from 
developing occupational asthma (17).
Although atopy is strongly associated with the 
development of LAA, its predictive value is low 
and most employees with atopy will not develop a 
specific sensitization. Thus, the exclusion of atopic 
subjects from working with laboratory animals seems 
to be insufficiently discriminatory when screening 
for susceptible individuals (1). Laboratory animal 
research shows no signs of becoming less common, 
and an increasingly susceptible (atopic) population is 
likely to be recruited into such work.
An essential prerequisite for the formulation of allergy 
vaccines for specific immunotherapy is the knowledge 
about and the good characterization of the relevant 
allergens. Production of recombinant allergens from 
the small mammalian species responsible for the most 
cases of LAA is also insufficient so far. Therefore, it is 
a broad range of these unmet needs in the case of 
LAA to improve diagnosis and therapy.
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Up to 50% of pollen allergic patients are 
sensitized to profilin.
Sensitization virtually always follows 
primary sensitization to a specific pollen 
source.
On SPT most pollen sources score positive.
Clinical relevance is variable but potentially 
present.
Up to 50% of sensitized patients may have 
food allergy, oral allergy syndrome in most 
cases
Raw tomato, melon, watermelon, and citrus 
fruits are typically associated with profilin.
Patients tolerate processed foods.
The spectrum of offending plant foods 
sometimes is very large.
THE PROTEIN
Profilin is a protein of 12-15 kDa in size present in all 
eukaryotic cells and involved in the organization of 
cytoskeleton as well as in signal transduction. It is a 
monomeric actin-binding protein and a key regulator 
of actin-filament dynamics during processes such 
as cells movement, cytokinesis, and signaling (1). In 
higher plants, it is identified as an allergen in monocot 
and dicot angiosperms.
THE PROTEIN FAMILY
Profilins from higher plants constitute a family 
of highly conserved proteins showing sequence 
identities of at least 75% even between members 
from distantly related organisms. In view of the 
high sequence homology, cross-reactivity between 
profilins is extremely common and involves virtually 
every plant source. Thus, profilin can be considered 
the archetypal pan-allergen (2).
Riccardo Asero, Domingo Barber
PROFILINS
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CLINICAL RELEVANCE OF PROFILIN
As an airborne allergen
Profilins are able to elicit IgE responses in 10-60% 
of pollen-allergic patients (2, 3). However, the 
sensitization prevalence seems to increase, as more 
and more allergic patients seen at allergy departments 
show sensitization to a large number of botanically 
unrelated plants (4).
As a rule, profilin sensitization follows sensitization 
to a primary, major allergenic pollen source. In 
most cases, grass pollen is responsible for profilin 
hypersensitivity but, depending on geographical 
differences, also birch pollen, ragweed pollen and 
mugwort pollen may act as primary sensitizers (3, 5).
Being a minor pollen allergen, profilin sensitization 
is almost always associated with the sensitization 
to major pollen allergens. Assessing the clinical 
relevance of profilin as an airborne allergen is quite 
complicated, and in effect it was seldom investigated. 
In a Spanish study, only profilin-sensitized, pollen-
allergic patients scored positive on a conjunctival 
provocation test with date palm profilin, thus 
suggesting that profilin may act as an aeroallergen (6). 
Another study based on nasal/bronchial provocation 
with date palm profilin in sensitized subjects 
confirmed this finding (7). However, in a field study 
the clinical impact of profilin hypersensitivity turned 
out to be rather limited, as most sensitized patients 
reported symptoms only in the specific season of the 
primary sensitizing pollen source (8). Nonetheless, 
for the only case of primary sensitization to profilin 
reported so far, the patient also suffered from long 
lasting seasonal symptoms (9).
Figure 1
Three-dimensional structures of Phl p 12 (grass 
pollen) and Cuc m 2 (melon). Identical amino 
acid residues are in red, conservative changes 
in orange and unrelated amino acids are in blue. 
The structure is highly conserved in all profilins, 
consisting of a central 6-stranded antiparallel 
β-sheet and two α-helices situated at the N and 
C terminal sides. The 3-D structure of Cuc m 2 
was modeled by using the Swiss-Model Protein 
Modelling Server,21 taking as templates the fol-
lowing crystal structures of plant profilins: (1) A 
thaliana pollen, Ara t 8, PDB code 1A0K (76.2% 
of sequence identity); (2) birch pollen, Bet v 2, 
PDB code 1CQA (78.9% identity); and (3) H 
brasiliensis, Hev b 8.0204, PDB code 1G5U 
(83.1% identity). Secondary structure was iden-
tified with the DSSP program.
Table 1
Basic protein characteristics of Phl p 12
Protein characteristics
Allergen source Phleum pratense,Timothy grass pollen
Protein family Profilin
UniProtKB accession No. P35079
Three dimensional 
structure available No
Molecular structure Central 6-stranded β sheet and two α-helices
Molecular weight 14,235 kDa
Length 131 amino acids
Ligand binding Actin, poly-L-proline
Dimerization No
Glycosylation No
Disulfide bonds Yes
Isoelectric point 5.07
Distribution Every plant cell
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As a plant food allergen
Although profilin is present in every plant-derived 
food, its relevance as a food allergen has long been 
underrated (10, 11). Nonetheless, its role as a plant 
food allergen in about 50% of sensitized subjects 
has recently emerged (12), with clinical allergy to 
certain foods such as melon, watermelon, citrus 
fruits, banana, pineapple, persimmon, zucchini, 
and tomato being characteristically associated 
with profilin hypersensitivity (12-20). Being highly 
pepsin-sensitive (14), the clinical expression of 
profilin-induced food allergy is in most cases the oral 
allergy syndrome, although cases of systemic allergic 
reactions have been recently reported as well in 
specific areas in Spain where the levels of grass pollen 
allergy are extremely high (Fig. 3). Oral provocation 
of food allergic patients with low doses of purified 
profilin has proven to induce severe reactions in grass 
pollen (GP) allergic patients resident in areas with high 
grass pollen exposure (21). This fact should be taken 
into account when evaluating severe food allergic 
reactions in areas where GP allergy is dominant.
Profilin and natural rubber latex allergy
The end of the last century and the beginning of the 
current one have been characterized by an impressive 
increase in the prevalence of allergy to natural rubber 
latex. NRL contains many allergenic proteins, including 
profilin (Hev b 8). Therefore, the crude extract of 
Hevea brasiliensis latex scores often positive in 
patients with multiple pollen sensitizations. This 
has frequently caused concern for the risk of intra-
operative anaphylactic reactions. However, most latex 
products have been replaced by synthetic products 
and therefore, the risk of allergic reactions due to latex 
allergens including profiling is no longer a health issue. 
Thus, patients who show uniquely IgE reactivity to 
profilin in NRL can undergo surgery and other medical 
procedures without any risk (22, 23).
Table 2
A selection of profilins from different pollen sources
Botanical 
family
Allergen source Allergen
Fagales
Birch (Betula pendula) Bet v 2
Hazel tree (Corylus avellana) Cor a 2
Alder (Alnus glutinosa) Aln g 2
Hornbeam (Carpinus betulus) Car b 2
Oak (Quercus alba) Que a 2
Beech (Fagus sylvatica) Fag s 2
Graminae
Timothy (Phleum pratense) Phl p 12
All other grass pollen 
species
Allergen 
12
Asteraceae
Mugwort (Artemisia vulgaris) Art v 4
Ragweed (Ambrosia 
artemisiifolia) Amb a 8
Urticaceae Pellitory (Parietaria judaica) Par j 3
Oleaceae
Olive (Olea europaea) Ole e 2
Ash (Fraxinus excelsior) Fra e 2
Cupressaceae Cypress (Cupressus sempervirens) Cup s 8
Euphorbiaceae
Annual mercury (Mercurialis 
annua) Mer a 1
Date palm (Phoenix 
dactylifera) Pho d 2
Table 3
Profilins from some plant foods
Botanical 
family
Allergen source Allergen
Rosaceae
Apple (Malus domestica) Mal d 4
Peach (Prunus persica) Pru p 4
Pear (Pyrus communis) Pyr p 4
Cucurbitaceae Melon (Cucumis melo) Cuc m 2
Actinidiaceae Kiwi (Actinidia deliciosa) Act d 9
Apiaceae
Celery (Apium graveolens) Api g 4
Carrot (Daucus carota) Dau c 4
Rutaceae Orange (Citrus sinensis) Cit s 2
Leguminosae
Peanut (Arachis hypogaea) Ara h 5
Soybean (Glycine maxima) Gly m 3
Solanaceae Tomato (Solanum lycopersicum) Sola l 1
Bromeliaceae Pineapple (Ananas comosus) Ana c 1
Corylaceae Hazelnut (Corylus avellana) Cor a 2
Brassicaceae Yellow mustard (Sinapis alba) Sin a 4
Asteraceae Sunflower (Helianthus annuus) Hel a 2
Moraceae Fig (Ficus carica) Fic c 4
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Figure 2
Cross-reactivity between profilins from different 
pollens and plant foods.
Figure 3
Areas of Spain characterized by a high preva-
lence of profilin sensitization (dots) where some 
cases of severe profilin-induced food allergy 
have been recorded.
CLINICAL MANAGEMENT
Profilin hypersensitivity can be diagnosed in-vivo by 
SPT using a commercial profilin-enriched date palm 
pollen extract currently available only in Italy, Spain 
and Austria (24) such extract for skin testing shows a 
sensitivity and specificity that is very close to that of 
the recombinant grass pollen profilin for in-vitro use 
(Phl p 12) (25).
Several recombinant profilins are currently 
available for the routine in-vitro diagnosis of IgE 
hypersensitivity. In the ImmunoCAP assay (Thermo 
Fischer Scientific) Phl p 12, Bet v 2, Pru p 4, and Hev b 
8, the profilins from grass pollen, birch pollen, peach, 
and natural rubber latex are the 4 profilins currently 
available. In the ImmunoCAP ISAC multiplex assay, 
Mer a 1 (from annual mercury) is present as well 
(in a former version of the assay Ole e 2, the olive 
pollen profilin has also been present, but is currently 
withdrawn due to its low sensitivity (26)). Regarding 
the clinical significance of profilin-specific IgE levels, 
their value in predicting an oral allergy syndrome 
seems extremely limited or absent (27).
Since profilins are extremely well conserved and 
cross-reacting and show an equivalent IgE binding 
potency (28, 29), one wonders if a representative 
marker allergen is sufficient to detect hypersensitive 
patients. In this sense, a recent study showed that 
one single marker protein is sufficient to diagnose 
or exclude sensitization (26). As for the homology 
between profilins from different sources, extracts 
from two pollens, namely pellitory and cypress, score 
frequently negative in profilin hypersensitive patients 
(18). Whether this depends on a more limited cross 
reactivity of profilins from these two plants with the 
other profilins (30, 31), or on a lower concentration 
of the protein in the extract (32) is still a matter of 
debate; further studies are needed to clarify this 
point.
Profilin hypersensitivity does not normally require 
special clinical measures. Although most pollen sources 
are probably able to induce profilin hypersensitivity 
(33), from a respiratory point of view the clinical 
impact of the inhaled protein is in most cases quite 
limited (8). Some studies have demonstrated the 
disappearance of profilin-associated food allergy in 
subjects submitted to injection immunotherapy with 
different pollen extracts (34, 35).
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CLINICAL CASES
Case 1
Clinical History - A 32-year-old woman resident in 
Extremadura, a heavily grass-exposed area, with 
pollen allergy and clinical history of oral allergy 
syndrome, urticaria, and asthma following the 
ingestion of Melon, Watermelon, Banana, Peach 
and Orange. Open challenge with melon was 
positive.
Tests with extracts - On SPT, with exception 
of cypress all pollens scored positive, and no 
reactivity to peach LTP was detected.
Tests with molecules - ISAC microarray scored 
positive for: Cyn d 1: 76.7, Phl p 1: 75, Phl p 2: 21, 
Phl p 4: 1.0, Phl p 5: 51.5, Phl p 6: 2.6, Phl p 11: 
0.73, Bet v 2: 6.39, Hev b 8: 5.14, Mer a 1: 8.94, 
Phl p 12: 1.64, Mux F3: 0.67, Ole e 1: 0.37.
Oral challenges - On DBPCFC, the administration 
of 74 µg of pure date palm pollen profilin induced 
OAS and FEV1 decline of 20% that were treated 
with antihistamine and bronchodilators.
Diagnosis - Grass pollen allergy with severe profilin-
mediated food allergy was eventually diagnosed.
Case 2
Clinical history – A 38-year-old man living in the 
surroundings of Milan, Italy. At the age of 32 starts 
having severe rhino-conjunctivitis from mid-
August to the end of September when he returns 
home from the summer holidays at the sea (where 
he is well). After 3 years, oral itching following the 
ingestion of melon, watermelon, tomato, banana, 
orange and peach appears.
Tests with extracts - SPT with pollen allergens score 
positive for grass, mugwort, ragweed, plantain, 
birch, hazel, plane and olive, and negative for 
pellitory and cypress. A SPT with profilin-enriched 
date palm pollen extracts scores intensely positive.
Tests with molecules - The ImmunoCAP assay scores 
strongly positive for Amb a 1 and Phl p 12, and 
negative for Phl p 1, Phl p 5, Phl p 7, Art v 1, Pla a 1, 
Pla l 1, Bet v 1, Cor a 1, Ole e 1, Par j 2, and Pru p 3.
Diagnosis - Respiratory allergy to ragweed and 
profilin-induced food allergy are eventually 
diagnosed.
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PART C
The major birch pollen allergen, Bet v 1, 
represents the prototype of all PR-10-like 
allergens and is the primary sensitizer in 
regions with birch pollen exposure
The presence of homologous allergens 
in Fagales tree pollen explains IgE cross-
reactivity between pollen from hazel, alder, 
beech, oak and hornbeam.
Minute amounts of PR-10-like allergens 
in raw fruits, nuts, vegetable and legumes 
can induce individual patterns of oro-
pharyngeal symptoms and sometimes 
severe allergic reactions in Bet v 
1-sensitized individuals.
Testing for Bet v 1-specific IgE is sufficient. 
The relevance of cross-reacting pollens or 
foods can be clinically clarified by seasonal 
and food related symptoms without further 
IgE-testing of Bet v 1-homologues.
THE PR-10 PROTEIN ARCHITECTURE
Bet v 1, the major allergen of birch pollen, was the 
first plant allergen and the first allergenic PR-10-like 
protein to be cloned and characterized (Table 1) (1).
The protein architecture of Bet v 1 comprises a highly 
curved seven-stranded anti-parallel beta-sheet that 
embraces a 25 residue-long C -terminal alpha-helix 
(2). The beta-sheet and the C-terminal part of the long 
alpha-helix are separated by two consecutive alpha 
helices that connect the beta1- and beta2-strands. All 
these structural elements contribute to the formation 
of a large hydrophobic cavity that penetrates the 
entire protein and whose presence suggests that Bet 
v 1 might function as a carrier for presumably multiple 
hydrophobic ligands. Structural information is available 
for various Bet v 1 -homologous allergens from plant 
foods (Fig. 1 shows some examples) and their overall 
similarity clearly illustrates the molecular basis for the 
cross-reactivity of these proteins.
Although Bet v 1 contains a variety of different T 
cell epitopes, a major T cell epitope located at the 
C-terminal amino acid residue positions 142-156 was 
recognized by T cells from 61% birch pollen allergic 
individuals studied (3). This part of the molecule shares 
Heimo Breiteneder, Jörg Kleine-Tebbe
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high sequence similarities with various Bet v 1-related 
tree pollen allergens. The extent of T cell cross-reactivity 
with Bet v 1-related food allergens also corresponded 
to the degree of sequence similarity of the food 
allergens’ C-termini to the Bet v 1 amino acid residues 
142-156 (3). The sensitizing capacity of different Bet 
v 1 homologues from plant foods seems to correlate 
with the presence of immunodominant T cell epitopes 
(4). The Bet v 1-specific IgE response is polyclonal, and 
epitopes are spread across the entire Bet v 1 surface. 
Furthermore, the IgE recognition profile of Bet v 1 is 
variable and highly patient specific (5).
THE PR-10-LIKE FAMILY OF ALLERGENIC 
PROTEINS
In 1980, pathogenesis-related proteins (PR proteins) 
were defined as “proteins encoded by the host plant 
but induced only in pathological or related situations” 
and subsequently grouped into families (6). Today, the 
list of PR proteins comprises 14 families (7). When the 
sequence of Bet v 1 was discovered in 1989, the PR-
10 family had not been defined yet but it was noted 
that Bet v 1 was homologous to a PR protein from 
pea (1). Bet v 1 is constitutively expressed in pollen 
at rather high concentrations. Hence, the term PR-10 
for the Bet v 1 homologous allergens is not entirely 
correct. These constitutively expressed proteins are 
referred to as PR-10 like proteins.
The cDNA sequence coding for Bet v 1.0101 was 
discovered on July 3, 1988, and published in 1989 
(1). Since then the number of sequences related to 
the Bet v 1 sequence has grown steadily and rapidly. 
At present, the version 29.0 of the Pfam database 
attributes 14,065 sequences from 1,452 species to 
the Bet v 1-like superfamily (http://pfam.xfam.org/
clan/CL0209). These proteins are found in all three 
domains of life, i.e. archaea, bacteria and eukaryotes, 
and all share the Bet v 1 architecture (8). The Bet v 
1-like superfamily of proteins comprises 14 families, 
one of which is the Bet v 1 family. The Bet v 1 family 
in turn is composed of 11 subfamilies. One of these 
subfamilies is the PR-10 group of proteins to which 
almost all of the Bet v 1 homologous allergens 
belong. There are only two examples of allergens that 
are members of other subfamilies, the kiwi allergen 
Act d 11 (9) from the RRP/MLP (= ripening related 
proteins/major latex proteins) subfamily, and the 
Table 1
Bet v 1.0101 datasheet
Protein characteristics
Allergen source Betula pendula (syn. B. verrucosa, B. alba), birch
Protein family Bet v 1
Protein subfamily PR-10
UniProt accession 
number P15494
Three dimensional 
structure available Yes
Molecular structure
Seven-stranded anti-parallel 
β-sheet flanked by three 
α-helices
Theoretical molecular 
weight 17439.63 Da
Molecular weight 
measured by MS 17439.6 +/- 0.3 Da
Length 159 amino acid residues
Ligand binding Yes
Oligomerization state Monomeric
Glycosylation No
Disulfide bonds 0
Isoelectric point 5.39
Synthesis In the cytoplasm of birch pollen
Distribution
Pollen is distributed intro 
the environment by wind 
dispersal and can enter the 
indoor environment.
Table 2
Characteristics of the PR-10 like family of allergen-
ic proteins
Common tertiary structure with seven-stranded 
antiparallel β-sheet with long C-terminal α-helix and 
two short α-helices
Sequences with high identities
Small cross-reactive molecules of around 17 kDa
Present in early flowering Fagales trees, fruits, 
vegetables, nuts and seeds
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mung bean allergen Vig r 6 (10) from the CSBP (= 
cytokinin specific binding proteins) subfamily.
Birch pollen is one of the most common causes of 
IgE-mediated allergy in Northern and Central Europe 
as well as in North America. The major sensitizing 
allergen present in birch pollen is Bet v 1 to which 
93% of individuals with birch pollen allergy produce 
specific IgE (11). Birch belongs to the botanical order 
Fagales, which comprises eight families. Allergies 
have been strongly associated with pollen produced 
by the early flowering trees of the families Betulaceae 
and the Fagaceae (Table 3).
In general, allergic reactions to Fagales pollen are 
initiated by independent sensitization to members of 
the Betuloideae or Coryloideae subfamilies. However, 
25% of the IgE epitopes of the Betuloideae and 
the Coryloideae pollen allergens are unique for the 
respective subfamily, whereas pollen allergens from 
the Fagaceae are generally cross-reactive (12).
Homologues of Bet v 1 have also been identified in a 
wide range of plant foods (13). The most frequently 
observed clinical entity is caused by IgE antibodies 
that cross-react between Bet v 1 and its homologues 
in fruits, nuts, seeds and vegetables. They induce 
predominantly oropharyngeal symptoms, coined oral 
Figure 1
Ribbon and solid surface representations of birch pollen Bet v 1 (PDB 1BV1) and homologues from cherry 
(Pru av 1; PDB 1E09), celeriac (Api g 1; PDB 2BK0) and peanut (Ara h 8; PDB 4M9B), rainbow-coloured 
from blue at the N-terminus to red at the C-terminus. The 3-D images were created with the molecular 
modelling system UCSF Chimera (http://www.cgl.ucsf.edu/chimera).
allergy syndrome (OAS) (14). Severe reactions to Gly 
m 4, the Bet v 1 homologue from soybean (see Section 
B17), have been observed in a subpopulation of Bet 
v 1-allergic individuals (15). Bet v 1-allergic patients 
are at risk to acquire various plant food allergies, and 
even to react to novel foods without prior exposure. 
In contrast to Bet v 1, Bet v 1-related food allergens 
are regarded as incapable of sensitizing predisposed 
individuals. The few exceptions that were described 
include Dau c 1 from carrot (16-18), and Cor a 1 from 
hazelnut (19).
The list of plant food allergens to which Bet v 1-allergic 
individuals may react is quite varied and most likely 
connected to the variation in the individual IgE 
epitope patterns described (5). Interestingly, most of 
the Bet v 1 cross-reactive allergens are found in fruits 
of the Rosaceae, vegetables of the Apiaceae, or seeds 
of the Fabaceae (Table 4).
Amino acid sequence identities between selected PR-
10 pollen and plant food allergens fall between 38 
and 88% (Table 5). There is also a range of plant foods 
that contain cross-reactive Bet v 1 homologues that 
have not yet received an official allergen nomenclature 
designation including plum, nectarine, fig, mango, 
persimmon, jackfruit, walnut, and chickpea.
Bet v1 Pru av 1 Api g 1 Ara h 8
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Table 4
Bet v 1 –homologous allergens from plant foods
Botanical family Allergen source Allergen
Rosaceae Strawberry (Fragaria ananassa) Fra a 1
Apple (Malus domestica) Mal d 1
Apricot (Prunus armeniaca) Pru ar 1
Cherry (Prunus avium) Pru av 1
Peach (Prunus persica) Pru p 1
Pear (Pyrus communis) Pyr c 1
Raspberry (Rubus idaeus) Rub i 1
Actinidiaceae Golden kiwifruit (Actinidia chinensis) Act c 8
Green kiwifruit (Actinidia deliciosa) Act d 8
Apiaceae Celery (Apium graveolens) Api g 1
Carrot (Daucus carota) Dau c 1
Fabaceae Peanut (Arachis hypogaea) Ara h 8
Soybean (Glycine max) Gly m 4
Mung bean (Vigna radiata) Vig r 1
Corylaceae Hazelnut (Corylus avellana) Cor a 1.04
Fagaceae Chestnut (Castanea sativa) Cas s 1
Solanaceae Tomato (Solanum lycopersicum) Sola l 4
Table 3
Bet v 1-homologous pollen allergens of Fagales pollen
Botanical 
family
Botanical 
subfamily Allergen source Allergen
Betulaceae
Betuloideae
Birch (Betula pendula) Bet v 1
Alder (Alnus glutinosa) Aln g 1
Coryloideae
Hazel (Corylus avellana) Cor a 1
Hornbeam (Carpinus betulus) Car b 1
Hop-hornbeam (Ostrya carpinifolia) Ost c 1
Fagaceae
Fagoideae Beech (Fagus silvatica) Fag s 1
Quercoideae Oak (Quercus alba) Que a 1
Castaneoideae Chestnut (Castanea sativa) Cas s 1
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Table 5
Amino acid identities (%) between PR-10 allergens
Bet v 1
Mal d 1 57
Pru av 1 60 88
Act d 8 49 50 53
Api g 1 39 39 40 47
Ara h 8 46 49 50 38 39
Gly m 4 48 53 54 44 38 70
Cor a 1.04 67 62 65 52 43 53 57
Que a 1 58 59 60 52 44 44 50 59
Bet v 1 Mal d 1 Pru av 1 Act d 8 Api g 1 Ara h 8 Gly m 4 Cor a 1.04 Que a 1
CLINICAL RELEVANCE
General importance
Bet v 1 is regarded as (i) a marker allergen for a 
primary sensitization to pollen of birch and other 
Fagales trees (e.g. alder, hazel, hornbeam, beech), 
and (ii) an indicator of cross-reactivity to a number of 
related major pollen and plant food allergens.
Clinically, Bet v 1 and its homologues (iii) represent 
important pollen allergens (after inhalant exposure), 
and (iv) are considered important inducers of birch 
pollen-associated plant food allergies.
Symptoms (inhalant allergy)
Typical mucosal symptoms of tree pollen allergy in 
Middle Europe occur during spring between February 
and May with maximums depending on the current 
climate and the region:
  itchiness, redness, tearing of the eyes
  itch in the nose, (repeated) sneezing, runny and/
or stuffy nose
   optional dry cough (particularly during or shortly 
after exercise), dyspnea, pressure sensation on the 
chest, wheezing, bronchial secretion and difficulty 
in breathing as indicators for increasingly affected 
lower airways (asthmatic lower airway inflammation)
Clinical diagnoses of intermittent (seasonal) 
rhinoconjunctivitis and allergic asthma due to 
birch (Fagales) pollen become very likely in case of 
repeated, sometimes increasing mucosal symptoms 
during the same season in subsequent years.
Despite being indirect, additional oropharyngeal 
symptoms that occur in approximately 2/3 of birch 
pollen allergic individuals after consumption of 
certain raw plant foods (Table 3) indirectly confirm 
a suspected birch pollen allergy. In a minority of 
birch pollen allergic individuals, ingestion of roasted 
hazelnuts or products containing roasted hazelnuts 
can induce OAS.
Epidemiology
According to the European Respiratory Health Survey, 
the prevalence of sensitization to birch pollen was on 
average 6.4% with a maximum of 22.4% in northern 
Europe (20). Sensitization was generally high in 
northern and mid-Europe and low in the south of 
Europe. A large nationwide study in Germany on a 
representative sample of children and adolescents 
revealed the presence of IgE specific for birch pollen 
allergens in 15% of the individuals in the age group of 
3 to 17 years (21). In the age group of 13 to 17 years, 
15.7% of the girls and 21.7% of the boys had IgE 
specific for birch pollen allergens. IgE-sensitization to 
birch pollen allergens in adults (age 19 to 79 years) 
was found to be 17.4% and sensitization to Bet v 
1 15.2% (22). Approximately half of all sensitized 
individuals will develop symptoms such as allergic 
rhinoconjunctivitis or allergic asthma.
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Figure 2
IgE Cross-reactivity between the birch pollen major allergen Bet v 1 (at 12 o’clock of the circle) and related 
allergens in tree pollen of the order Fagales, in pome and stone fruit, tree nuts, vegetables, and legumes. Ad-
ditional Bet v 1 homologues are present in plum, peach, apricot, nectarine, strawberries, fig, mango, persim-
mon, jackfruit, walnut, chickpea, potatoes, tomatoes and parsley. Bidirectional cross reactivity is illustrated by 
red double arrows and unidirectional cross reactivity with green arrows. Allergen sources and corresponding 
without listing in the IUIS data bank are given in grey letters (Figure: modified from http://www.allergome.org; 
O-ring dynamically created on March 3, 2015), with kind permission of Springer Verlag, Heidelberg, Berlin. 
Symptoms (oral exposure)
Minute amounts of Bet v 1-homologous proteins are able 
to induce various, transient, predominantly oropharyngeal 
symptoms (Table 5) with a quick onset (sometimes 
immediately and often within minutes) after consumption 
of raw plant foods (Table 3) in approximately 2/3 of birch 
pollen allergic individuals. These symptoms are often 
referred to as “oral allergy syndrome” (OAS), implicating a 
particular clinical entity. This is not the case, since
  oropharyngeal symptoms can occur quite variably 
including different degrees of severity (Table 6, 
symptom complex A)
  diffusion of inflammatory mediators (i.e. 
histamine) and/or neurogenic reflexes can 
prompt additional severe symptoms in the head 
area (Table 6, symptom complex B) or
  systemic, sometimes anaphylactic symptoms can 
occur in rare cases (Table 6, symptom complex C)
Noteworthy, oropharyngeal symptoms are not 
unique or specific for Bet v 1-induced cross reactions 
or certain food items, since other food allergens are 
able to induce similar symptoms:
  profilin-containing plant foods (see Section C01)
  nsLTP-containing plant foods (see Section C03)
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  animal derived food allergens (see Section C05, 
C08)
Thus, the so-called OAS does not represent a defined 
clinical entity (syndrome), but a rather variable symptom 
complex. The occurrence of only oropharyngeal 
symptoms reflects the physicochemical properties of 
the particular food allergens which in the case of the 
Bet v 1-homologues PR-10-like proteins are
  instability (rarely substantial intestinal absorption) 
and
  excellent aqueous solubility (quick onset of 
symptoms after mucosal exposure)
From a clinical point of view, a large and over the 
years increasing number of reported Bet v 1-related 
cross-reactive plant foods
  indicates a high level of Bet v 1-specific IgE based 
on a broad polyclonal IgE-repertoire
  is associated with more severe clinical reactions 
due to foods of the Bet v 1 cluster
The following variables are presumably involved in 
rare, severe clinical reactions to foods containing Bet 
v 1-homologues:
  strong Bet v 1-specific IgE response (high specific 
IgE/total IgE ratio)
  broad Bet v 1-specific IgE repertoire (indirectly 
reflected in a large panel of implicated plant 
foods)
  ingested amount of particular Bet v 1-homologue 
containing food
  differences in stability of Bet v 1-homologue in 
the respective food items (more often systemic 
reactions due to hazelnuts, soy, carrots and 
celeriac in comparison to e.g. apples)
  presumably matrix effects of certain food items 
(e.g. soy) with high protein content, protecting the 
immediate degradation of a Bet v 1-homologue 
containing food.
An increase of oropharyngeal symptoms during 
or shortly after the birch pollen season is generally 
observed. Natural birch pollen exposure might 
booster the Bet v 1-specific IgE response with a 
possibly broadened IgE repertoire.
Occasionally, subjects experience oropharyngeal 
symptoms (Table 6) after consumption of typical 
Bet v 1-related plant foods without suffering from 
inhalant symptoms during the tree pollen season. 
This observation, a (so far) clinically “silent” Bet v 1 
sensitization, can still prompt unexpected allergic 
reactions after the first consumption of Bet v 
1-related plant foods. Without knowledge of the 
molecular relationship both, the diagnosis of a birch 
pollen (Bet v 1)-associated plant food allergy, and 
proper consultation of the affected individuals might 
be unnecessarily delayed.
The most frequently observed allergy to soy in Central 
Europe is based on the serological cross-reactivity of 
Bet v 1-specific IgE (70%) with its homologue Gly m 
4 from soybean (Section B17). In general, reactions 
occur following the ingestion of large amounts of 
soy-based products that did not undergo major 
processing steps (e.g. soymilk, soy-based protein 
powders). Reactions can be systemic and severe and 
have been observed in about 10% of birch-pollen 
allergic individuals (15).
Conclusions on clinical relevance
  6.4 to 22.4% of the European population is 
sensitized to birch pollen
  Around half of all sensitized individuals will 
develop symptoms
  Around 70% of birch pollen allergic individuals 
suffer from associated plant food allergy
  Impact of IgE cross-reactivity on clinical 
symptoms of food allergy is still unknown
  Molecule-based therapeutic approaches are 
under investigation
CLINICAL MANAGEMENT
Diagnostic testing of Bet v 1-related allergies
IgE-sensitization to Bet v 1 can be assessed (Fig. 3) 
directly by allergen-specific IgE testing to Bet v 1, or 
indirectly by SPT with birch pollen extract (wheal >3 
mm or >5 mm) or allergen-specific IgE testing with 
birch pollen extract.
Convincing analytical specificity after birch pollen 
extract testing is only obtained in case of a limited 
sensitization profile (i.e. if only positive to pollen of 
Fagales trees). If a positive SPT result was already 
obtained with a birch pollen extract, allergen-specific 
IgE should rather be tested to Bet v 1, providing 
more (analytical) specificity than another birch pollen 
extract for in vitro diagnosis.
Commercial plant food extracts (for SPT as well as IgE-
testing) often show false negative results and should be 
avoided due to a low abundance and a lack of stability 
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of Bet v 1 homologous food allergens. Instead, Prick-
to-Prick tests can be performed with suspected, fresh, 
raw plant foods. Despite a lack of standardization, 
this approach can provide a qualitative, indirect 
demonstration of IgE-sensitization/cross reactivity.
No value of broad molecular testing of Bet v 
1-sensitized subjects
Is it worth it to demonstrate additional IgE-
sensitizations/cross reactions to Bet v 1-homologues 
such as allergen-specific IgE to Mal d 1, Cor a 1.04, Pru 
p 1 and many others? Presumably not, since numerous 
positive serological cross-reactions are to be expected 
when Bet v 1-specific IgE is present (23). Thus, such 
test results are not informative in terms of their 
clinical relevance without further clinical information. 
Only a clear-cut negative IgE result against a Bet v 
1-homologues single allergen (i.e. Dau c 1, Gly m 4, Pru 
p 1), obtained with a sensitive IgE test (cut-off at 0.1 
kUA/l; singleplex assay) could reliably rule out an IgE-
sensitization/cross-reactivity and subsequent clinically 
relevant food allergy due to Bet v 1-cross-reactivity. 
Unfortunately, this scenario does hardly exist in reality. 
Instead, rational and targeted testing (i.e. allergen-
specific IgE only to Bet v 1) is recommended. As a rule of 
thumb sensitization tests in case of Bet v 1-associated 
cross-reactions are only meaningful, if the results will 
potentially lead to clinical consequences.
Interpretation of Bet v 1-related IgE-
sensitizations
Interpretation of a test addressing the clinical 
relevance of a previously demonstrated Bet v 
1-sensitization can only be obtained with clinical 
information. Thus, a detailed anamnesis is so 
important in case of a birch pollen-associated food 
allergy in question. Following diagnostic work-up can 
facilitate a final interpretation of the clinical relevance 
of a sensitization test (i.e. positive birch pollen SPT, 
positive Bet v 1-specific IgE):
  The subject should be systematically asked 
again, whether oropharyngeal (or other) allergic 
symptoms (Table 6) occurred and after which 
ingested, raw plant foods they appeared or not. 
The list of foods should not only address the most 
common ones as apples and hazelnuts, but the 
whole panel of potentially Bet v 1-cross-reactive 
plant foods (Table 4).
Table 6
Potential symptoms due to Bet v 1-associated IgE cross-reactivity to plant foods
Symptom complex Symptoms Organ/localisation
A. Limited 
oropharyngeal 
symptoms 
(frequent)
itch  
("tingling", "tickling", "prickle")
lip mucosa, oral mucosa, palate
burning, stinging palate, throat
mild mucosal swelling lip mucosa, oral mucosa, palate, throat
B. Additional 
symptoms in 
the head area 
(isolated or with 
symptoms from 
A) (rare events)
itch, redness, tearing conjunctiva
itch, sneezing, runny nose, stuffy nose nose
itch ears (internally, Eustachian tubes)
tissue (skin) swelling (angioedema) eye lids, lips, cheeks, ears, face 
severe (internal) mucosal swelling, 
globus sensation, difficulty swallowing, 
hoarseness (indicating vocal cord or larynx 
edema), shortness of breath, stridor 
palate, throat, larynx 
C. systemic 
symptoms
(extremely rare)
itch, redness, hives, swelling (angioedema) localized, multifocal or generalized at the skin
nausea, vomiting, abdominal pain, diarrhea stomach, intestine
breathing difficulties, chest pressure, chest 
tightness, shortness of breath, wheezing, 
cough, sputum (optional) 
bronchi
dizziness, general weakness, 
unconsciousness, circulatory collapse
heart and circulation
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  Oral challenge tests can help - in case of missing 
clinical information or vague anamnesis - to prove 
or rule out clinical cross-reactions. They can also 
serve as a prospective test of a potentially cross-
reactive, but so far never eaten plant food.
Oral food challenges, however, are rarely routinely 
performed in case of Bet v 1-associated food allergies 
for following reasons:
  They are tedious to perform considering the 
number of potentially cross-reactive foods.
   There is no urgent indication in case of solely 
oropharyngeal symptoms.
   They are not easy to interpret due to 
predominantly subjective symptoms.
   There are almost no validated dose-dependent 
tests.
   There are only few proven published protocols for 
oral challenge procedures with Bet v 1-associated 
plant food (24, 25).
Finally, only those Bet v 1-related foods should be 
avoided in their raw form, which have induced typical 
allergic symptoms. Avoiding every potentially cross-
reactive food item of the Bet v 1-cluster would be 
exaggerated and clinically not justified. The same is 
true for plant foods, showing indirectly after Prick-to-
Prick tests or directly after serological analysis positive 
IgE-sensitizations: Even the entire panel of Bet v 
1-homologues employed for diagnostic purposes 
would not be able to separate silent from clinically 
relevant sensitizations in case of positive test results.
Diagnostic recommendations for Bet v 1-related 
allergy
   Bet v 1-homologues in tree pollen extracts for 
diagnostic purposes will induce positive SPT and 
IgE reactions to a number of Fagales trees (Table 
3), not necessarily being clinically relevant.
   Prick-to-Prick tests with fresh (raw) foods are 
superior diagnostic tools compared to commercial 
food extracts in case of birch pollen-associated 
plant food allergies due to low stability of Bet v 
1-homomlogues.
   After being spiked with recombinant Bet v 
1-homologues (e.g. Cor a 1) birch pollen-
Figure 3
Diagnostic algorithm in case of Fagales tree pollen and/or Bet v 1-homologue related food allergy to raw 
plant foods 
spring-related mucosal symptoms 
(ocular, nasal and/or bronchial) in 
subsequent years 
oropharyngeal symptoms to raw Bet 
v 1 homologue-containing plant foods 
(apple, hazelnut, Table 3)
Bet v 1  
specific IgE 
birch pollen 
specific IgE
birch pollen 
SPT and/or and/or
allergen immunotherapy
month? pollinating trees
(Bet v 1-homologue) 
Feb hazel (Cor a 1)
March alder (Aln g 1) 
April birch (Bet v 1)
April /May beech/oak   
(Fag s 1, Que a 1) 
Oropharyngeal symptoms?
  apple   hazelnut   carrot
  pear   almond   celeriac
  cherry   walnut   potato
  plum   kiwi   parsil
  apricot   figue   soy bean
  peach   rasperry   mung bean
allergen avoidance
suspected Bet v 1 allergy
extract and molecule-based 
sensitization test(s)
molecular-concept- based 
interpretation(anamnesis, 
optionalchallenge)
aggreement with history?
clinically relevant? 
allergy management 
 (consequences, advice)
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associated plant food extracts (i.e. hazelnut 
extract) can bind more IgE, increase assay 
sensitivity (lowered “limit of quantitation”, LoQ) 
and provide elevated allergen-specific IgE-values.
   At the same time “spiking” will unfold more positive 
(potentially clinically irrelevant) sensitizations, 
pointing to general drawbacks of extract-based 
diagnostics (i.e. high sensitization rates to peanut 
in Middle Europe due to cross-reactive natural Bet 
v 1-homologue Ara h 8 in peanut extracts).
   Bet v 1-specific IgE serves as a reliable marker for 
potential, serological cross-reactions to a number 
of plant foods (Table 3). Actual clinical relevance 
of potential cross-reactions is systematically 
addressed by the physician together with 
the patient based on the subject´s individual 
symptoms after consumption of raw foods 
containing Bet v 1-homologues.
   Positive specific IgE to Bet v 1-homologues 
plant food allergens (i.e. Pru p 1 from peach) 
demonstrates allergic sensitization, being 
clinically relevant in case of corresponding 
symptoms.
   A negative IgE results (i.e. to Gly m 4 from soy, 
approx. in only 25% of Bet v 1-sensitized subjects) 
would exclude serological cross-reactivity with 
certainty and clinically relevant cross-reactions 
as well.
The rule-of-thumb for the diagnostic work-up of 
Bet v 1-associated allergic reactions concludes: “The 
physician’s interpretation, based on the patient’s 
individual symptoms, and not the outcome of a 
sensitization test will establish the decision about 
the clinical relevance of previous diagnostic findings.”
Sensitization can be tested by skin prick testing, or 
in vitro extract- or molecule-based assays. IgE test 
results always have to be interpreted in the context 
of the anamnesis. At present, all Bet v 1-related 
allergens that are of relevance in Europe are available 
as recombinant proteins, but only few for diagnostic 
purposes. However, the Bet v 1–related allergens 
from mango, persimmon or jackfruit – all of them 
have been described as causing symptoms in birch 
pollen allergic individuals – are not yet available as 
recombinant proteins.
Extract composition for allergen-specific 
immunotherapy
Due to the high cross-reactivity of the major allergens 
Bet v 1, Cor a 1 and Aln g 1 of birch, hazel and alder 
pollen, respectively, birch pollen monoextracts as 
well as combined extracts from hazel, alder and birch 
pollen are suitable for specific immunotherapy of a 
tree pollen allergy. The selection will mainly depend 
on the time when symptoms occur (Fig. 3).
Whether immunotherapy with tree pollen extracts 
has a beneficial influence on associated plant food 
allergies is still under discussion. Most studies were 
performed on birch pollen associated apple allergy. As 
the apple allergen Mal d 1 has the highest sequence 
identity to Bet v 1, one might expect the best results 
from a birch pollen based immunotherapy. However, 
the results from several studies on birch pollen 
associated apple allergy are controversial (26-28). No 
clinical effect on a birch pollen associated hazelnut 
allergy was observed after one year of specific 
immunotherapy with a birch pollen extract (29).
Therefore, oral allergy syndrome to birch pollen 
associated plant foods in the absence of pollen 
induced respiratory symptoms should not be 
considered as a main criterion for selecting patients 
for birch pollen immunotherapy. Recombinant Bet v 1 
and variations of the molecule were tested in clinical 
trials for their efficacy as immunotherapy reagents 
but are not yet available on the market (30, 31).
CLINICAL CASES
Case 1 (original)
History: Female, 39 yrs: Since 2015 for the first 
time during spring time eye itch, tearing, swelling, 
sneezing, runny and blocked nose, later chest 
tightness, wheezing, coughing and white sputum. 
In addition, since spring 2015 itchy throat after 
eating raw fruits (apples, cherries, peaches).
In-vivo testing: SPT (wheal diameter [mm]): hazel 12, 
alder 5, birch 4, oak 6.
In-vitro testing: Total IgE 190 kU/l, specific IgE to Bet 
v 1: 91 kUA/l (>47% of total IgE indicating a strong 
sensitization).
Diagnosis: A) Allergic rhinoconjunctivitis due to 
Fagales tree pollen; B) Bet v 1-associated food- 
allergy (oropharyngeal symptoms to certain raw 
Rosaceae fruits)
Recommendations: Allergen-specific immunotherapy 
with birch pollen extract with caution during the 
escalation phase (high relative specific IgE to Bet 
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v 1 is associated with potential adverse events). 
Avoidance of raw Bet v 1-cross-reactive pome and 
stone fruits (see history); cooked, baked or roasted 
plant products without dietary restriction (due to 
thermal instability of Bet v 1-related allergens).
Comments: a) Strong Bet v 1-sensitization based on 
high absolute IgE values and high ratio between 
Bet v 1-specific IgE and total IgE; b) despite the 
short allergy history (1st allergy season!) strong 
indication for AIT due to the brisk disease 
development including lower airways and cross-
reactive oropharyngeal symptoms.
Case 2 (original)
History: Male, 35 yrs: Since 10 years Fagales tree 
pollen induced rhinoconjunctivitis with itchy 
eyes, sneezing, runny nose, sore throat, itch in 
the ears, general fatigue. After ingestion of raw 
apples, hazelnuts, cherries, peaches, apricots, 
strawberries, blueberries*, grapes* within 5 
minutes itchy and sore throat, itchy eyes and ears 
for 15 minutes, after soy products loose stool.
In-vivo testing: SPT (wheal diameter [mm]): hazel 6, 
alder 5, birch 10, oak 3, grass-mix 3, mugwort 3.
In-vitro testing: Total IgE 10 kUA/l, specific IgE to Bet 
v 1: 3.4 kUA/l (>1/3 of total IgE indicating strong 
sensitization), Phl p 1: 2.8 kUA/l, other allergen 
specificities Phl p 12 (profilin), Art v 1, mugwort, 
Pru p 3 (nsLTP) negative (<0.1 kUA/l).
Diagnosis: A) Allergic rhinoconjunctivitis due to 
Fagales tree pollen; B) Bet v 1-associated food- 
allergy (oropharyngeal symptoms to raw foods)
Recommendations: Allergen-specific immunotherapy 
with birch or hazel-alder-birch extract. Avoidance 
of raw Bet v 1-cross-reactive pome and stone 
fruits (see subject´s history).
Comments: a) absolute IgE values (total and allergen-
specific) are both low; b) relative relationship between 
Bet v 1-specific IgE and total IgE is high (pointing to 
the need to consider both, total and specific IgE, 
for proper interpretation); c) *certain fruits are not 
indicative as containing Bet v 1-homologues, but are 
nsLTP-containing foods; thus, due to negative IgE to 
Pru p 3 and profilin these reported reactions cannot 
be easily explained, i.e. Pru p 7 homologues.
Case 3 (original)
History: Female, 47 yrs: Since 15 years after 
consumption of raw plant foods like apples, 
cherries, hazelnuts, walnuts within 1 minute 
mild sore throat for 5 minutes. So far no allergic 
symptoms during spring.
In-vitro testing: Total IgE 174 kUA/l, specific IgE to 
Bet v 1: 34 kUA/l.
Diagnosis: Bet v 1-associated food allergy 
(oropharyngeal symptoms to raw foods) without 
allergic airway disease.
Recommendations: Avoidance of raw Bet v 1-cross-
reactive pome and stone fruits (see subject´s 
history). No indication for AIT due to missing 
Fagales tree pollen induced airway symptoms
Comments: Rare cases are suffering from 
oropharyngeal allergy symptoms due to plant 
foods containing Bet v 1-homologues without any 
allergic airway symptoms during the birch pollen 
season. Diagnosis is established by IgE-testing 
to Bet v 1. Potential clinical consequences are 
addressed “clinically” (without further IgE-testing 
to other Bet v 1-homologues).
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C03
nsLTPs are the most prevalent plant -food 
allergens in Southern Europe.
The clinical reactions can be systemic and 
severe, especially when not associated to 
birch pollinosis.
Pru p3, the major allergen of peach, plays a 
precursor role in the sensitization to other 
nsLTPs
Relevant nsLTPs containing plant-foods 
belong not only to Rosaceae family but also 
to the nut group and to cereals such as 
wheat, maize and rice.
THE PROTEIN
Pru p 3, the major allergen of peach, was the first nsLTP 
to be fully identified and characterized as a relevant 
food allergen (1, 2). It is the most broadly recognized 
allergen of the family although there are patients 
sensitized to other nsLTPs that might not develop 
IgE antibody reactive with Pru p 3. It is located in 
vascular tissue and in the outer cell layers of the plant 
organs. Importantly, it is concentrated in the pericarp 
of fruits, while the pulp contains levels approximately 
220-fold lower than the peel. Peach fuzz contains 
large amounts of Pru p 3. It is a small basic protein 
of 91 amino acids, with a molecular weight of 9,178 
kDa. Structurally, Pru p 3 contains a highly-conserved 
domain consisting of eight cysteine residues which is 
a distinctive sign of the Prolamin superfamily. They 
form a network of four disulphide bridges which 
makes the protein resistant to high temperature 
and pH changes. The main structural motif of Pru 
p 3 consists in a compact C-terminal alpha-helical 
domain and four helices that are connected by short 
loops. The four disulfide bridges are responsible for 
the nsLTPs compact folding which forms a tunnel-
like hydrophobic cavity that runs through the whole 
molecule and is able to accommodate ligands such 
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as phospholipids, acyl-coenzyme A and fatty acids 
(Figure 1). Three IgE-binding epitopes on the LTP 
molecule have been identified: Pru p 311-20, Pru 
p 331-40, Pru p 371-80. These peptides are shared 
with other fruits including apple, apricot, plum, 
cherry, orange, strawberry, grape, with a sequence 
identity ranging from 62 to 81% (3). Pastorello et 
al. (4) have also identified two immunodominant 
T-cell reactive regions that have been called Pru 
p312-27 and Pru p 357-72. These peptides have the 
ability to induce the production of IL-4 from Pru p 
3-specific T cells after allergen-specific stimulation 
which reflects a Th2-dominated response. The stable 
tertiary conformation of Pru p 3 provides resistance 
to thermal degradation. In vitro IgE-antibody binding 
ability is maintained after 30 min at 121°C and after 
160 min at 100°C (5, 6). Pru p 3 is also resistant to 
proteolytic digestion. After a proteolytic treatment 
with trypsin, 35% of the molecule remains intact 
and three high molecular weight (HMV) peptides are 
released in addition to the smaller peptide Pru p 357-
72. These peptides still show IgE antibody and T-cell 
binding ability and thus have the potential to either 
sensitize or induce an allergic reaction (6).
THE FAMILY
Pru p 3 belongs to the family of non-specific Lipid 
Transfer Proteins (nsLTPs), which are the allergens most 
frequently involved in food induced allergic reactions 
in the adult population from the Mediterranean area 
(7). sLTPs belong to the superfamily of Prolamins 
that includes several families of allergens including 
the alpha-amylase inhibitors, 2S albumins, and the 
non-specific lipid transfer proteins (nsLTPs). All the 
members of the Prolamin superfamily share the 
conserved amino acid pattern of eight cysteine 
residues. In contrast to the other members of the 
superfamily, nsLTPs are not restricted to seed tissues, 
but ubiquitously expressed throughout the plant. The 
concentration of nsLTPs is variable and depends on 
maturity, storage conditions, and cultivar of the fruit. 
nsLTPs have a role in the transport of hydrophobic 
molecules that comprise the cutin and suberin layers 
of plant tissues. Because of the suggestion that they 
could be involved in plant defense against bacterial 
and fungal infections, the nsLTPs have been classified 
as type 14 Pathogenesis-related Proteins. To date, 
the International Union of Immunological Societies 
Figure 1
Crystal structure of peach Pru p 3 (PDB 2ALG), 
the prototypic member of the family of plant 
non-specific lipid transfer protein pan-allergens. 
Protein chains are colored. The structure was 
generated using PyMOL Molecular Graphics 
System v1.6.
Table 1
Basic protein characteristics of Pru p 3
Protein characteristics
Allergen source Prunus persica, peach
Protein family Lipid Transfer Proteins
UniProtKB accession 
No. P81402
Three dimensional 
structure available Yes
Molecular structure mainly alpha-helix
Molecular weight 9,178 kDa
Length 91 amino acids
Ligand binding mainly hydrophobic ligands
Dimerization no
Glycosylation no
Disulfide bonds 4
Isoelectric point 9.25
Distribution seeds, fruits, leaves, roots, pollens
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Table 2
Representative Members of the nsLTP family and 
cross-reactivity between them
Botanical 
family
Allergen source Allergen
Plant foods
Rosaceae Peach (Prunus persica) Pru p 3
Apple (Malus domestica) Mal d 3
Cherry (Prunus avium) Pru av 3
Vitaceae Grape (Vitis vinifera) Vit v 1
Rutaceae Orange (Citrus sinensis) Cit s 3
Solanaceae Tomato (Lycopersicon 
esculentum)
Lyc e 3
Corylaceae Hazelnut (Corylus avellana) Cor a 8
Juglandaceae Walnut (Juglans regia) Jug r 3
Fabaceae Peanut (Arachis hypogaea) Ara h 9
Asteraceae Lettuce (Lactuca sativa) Lec s 1
Poaceae Maize (Zea mays) Zea m 14
Wheat (Triticum aestivum) Tri a 14
Occupational allergens
Euphorbiaceae Natural Rubber Latex 
(Hevea brasiliensis)
Heb b 12
Asparagaceae Asparagus (Asparagus 
officinalis)
Aspa o 1
Pollens
Urticaceae Parietaria (Parietaria 
Judaica)
Par j 1
Asteraceae Ragweed (Ambrosia 
artemisiifolia)
Amb a 6
Mugwort (Artemisia 
vulgaris)
Art v 3
Oleaceae Olive (Olea europoea) Ole e 7
Platanaceae Plane (Platanus acerifolia) Pla a 3
A high degree of IgE anti-nsLPT cross-reactivity has 
been observed within the Rosaceae family and with 
citrus fruits, grape, tomato, vegetables (asparagus, 
lettuce, etc.), nuts (hazelnut, walnut, peanut, etc.), 
maize, onion, carrot, rice spelt (partial cross-reactivity) 
(3). The Arg39/Thr40 epitope is well conserved in 
Rosaceae nsLTPs and only partly conserved in cereal 
nsLTPs. In addition, relevant allergens from Parietaria, 
Artemisia, Platanus and Olea pollen are also members 
of the nsLTP family, but show rather low (Artemisia 
and Platanus) or absent (Parietaria and Olea) cross-
reactivity with Pru p 3 as a consequence of the lower 
sequence identity (<35%), and different lengths (5). In 
conclusion, conserved as well as divergent residues 
exist between the Rosaceae and other nsLTPs, but the 
sequence identity between i.e. Pru p 3 and Art v 3 (9) 
or Ara h 9 (10) is somehow limited.
CLINICAL RELEVANCE
Clinically relevant nsLTPs have been described both 
in foods and pollens. The current prevalence of 
nsLTPs, sensitization in Europe is unknown; however, 
in an epidemiological survey performed in Spain (11, 
12) on pollen allergic patients, Pru p 3 sensitization 
affected 11% of the adults and 22% of the children 
tested. These data indicate that approximately 2% 
of adults and 4% of children manifest a positive sIgE 
to Pru p 3, assuming a 20% prevalence of pollen 
allergy. Approximately 50% of the patients that were 
sensitized to Pru p 3 were referred with a complaint of 
a possible food allergy. Considering the patients that 
are not pollen allergic and exclusively LTP-sensitized, 
the LTP-syndrome represents the most frequent type 
of food allergy in adults and adolescents in southern 
Mediterranean countries. In contrast, this nsLTP 
driven syndrome shows a low prevalence in Central 
and Northern Europe.
From a clinical point of view, the LTP-syndrome 
presents some peculiar aspects, which need to 
be appreciated when planning the appropriate 
management of nsLTP allergic patients.
Clinical Reactivity
LTP-induced allergic reactions can be mild but more 
often they are systemic and severe, as observed 
by several European investigators during the last 
decade. Different studies described the strong 
association between Pru p 3 positivity and the 
severity of systemic allergic symptoms (13-15).
Allergen Nomenclature Sub-committee lists 41 
allergenic nsLTPs that originate from fruits, pollen 
of trees and weeds, vegetables, nuts and seeds, and 
natural rubber latex. The most prominent members of 
the NsLTPs family are presented in Table 2. LTPs are the 
most important allergens of the Prunoideae subfamily 
which includes peach, apricot, plum and cherry (8). 
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Figure 2
Cross-reactivity due to nsLTP molecules between different allergenic sources: continous lines indicate a 
high degree of cross-reactivity amon the Rosaceae family. Dashed lines indicate partial cross-reactivity. 
Figure 3
Homology between members of the nsLTP fam-
ily.  A) Surface residues on Pru p 3 conserved 
among 8 Rosaceae fruit nsLTP proteins. Red: 
Residues conserved in 90% or more proteins. 
Orange: Residues conserved in 40-90% of the 
proteins (gradient); White: Residues conserves in 
less than 40% of the proteins B) Surface residues 
conserved among Pru p 3 and 4 isoforms of Art v 
3. Red: Residues in Pru p 3 conserved in 90% or 
more of Art v 3 allergen isoforms. Orange: Res-
idues conserved in 40-90% of Art v 3 allergen 
isoforms (gradient); White: Residues conserved 
in less than 40% of Art v 3 allergen isoforms; 
C) Surface residues conerved among Pru p 3 
and Ara h 9. Red: Residues in Pru p 3 conerved 
among Pru p 3 and Ara h 9. White: non-con-
served residues.
A
B
C
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Interestingly, Pru p 3 (and other nsLTPs) can induce 
symptoms that range from an Oral Allergy Syndrome 
(OAS), with oral pruritus, edema, vesicles and 
erythema localized in the oro-pharyngeal cavity (16), 
to anaphylaxis, with gastrointestinal involvement, 
nausea, vomiting and diarrhea, generalized urticaria, 
as well as contact urticaria, and severe asthma. In 
the majority of the cases, systemic symptoms are 
preceded by OAS. Isolated systemic symptoms are 
very rare (17, 18).
Geographical differences
Another peculiar aspect of the LTP-syndrome is the 
clear-cut geographical difference in sensitization. 
The severe LTP-induced clinical manifestations seen 
in Mediterranean populations are usually in stark 
contrast to the mild clinical manifestations of the 
oral allergy syndrome that are associated to Birch 
pollen allergy which is caused by Bet v 1 and Bet v 
2 sensitization in Central and Northern Europe. As 
regards the peach model, the concept of the inter-
dependence of the severity of the symptoms from 
Pru p 3 sensitization, especially in areas that are 
not exposed to Fagales, is now well accepted, as 
compared to mild Pru p 3 symptoms in subjects that 
are pollen-sensitized. These findings have also been 
confirmed by other investigators in the apple model 
(19).
In a European collaborative study on apple allergy, 
Mal d 3 sensitization was significantly more frequent 
in Spain, an almost birch-free area, as compared to 
birch-rich countries/regions such as The Netherlands, 
Austria and Northern Italy. These correlations suggest 
that the birch pollen exposure, typical of Central and 
Northern European populations, may confer a sort of 
“immune protection” to LTP sensitization.
Pediatric patients
Children sensitized to Pru p 3 present clinical 
symptoms earlier than those sensitized to the other 
pollen related allergens (20). In a clinical study carried 
out in Italian adults, 26 out of 48 subjects uniquely 
sensitized to Pru p 3 presented peach-related allergy 
symptoms between 2-15 years, earlier than subjects 
sensitized only to Pru p 1 and/or Pru p 4. Furthermore, 
in the same patients, Pru p 3-sensitization correlated 
with the development of allergic reactions to a 
higher number of plant-foods than Pru p 1 and 4 
sensitization alone.
Role of Pru p 3
Peach is the most frequent cause of nsLTP allergy, 
and Pru p 3 sensitization seems to play a precursor 
role in the sensitization to other nsLTPs. The most 
frequently involved plant-foods are the fruits 
belonging to the Rosaceae family, which include 
apple, plum, apricot, cherry and pear. However, 
there are also botanically unrelated nsLTP-containing 
plant foods that appear to be strongly associated 
with peach, particularly in the nut group. In fact, 
walnut, hazelnut and peanut have been described 
as foods eliciting not only OAS but also severe 
systemic reactions in LTP-sensitized subjects. Also, 
cereals such as wheat, maize and rice can cause 
systemic reactions of various degrees of severity, 
as confirmed by DBPCFC in LTP-allergic patients. In 
particular, wheat has been recently described as the 
cause of exercise-related anaphylaxis in three young 
LTP-sensitized patients. nsLTP allergens have been 
identified also in green bean, fennel, orange, kiwi and 
lentil using sera of allergic patients who have been 
sensitized to peach nsLTP. A large number of the 
aforementioned studies have demonstrated that Pru 
p 3 sensitization dominates the immune response to 
nsLTPs in other foods containing structurally similar 
nsLTPs and that peach is almost always the food that 
initiates the nsLTP allergy syndrome. Importantly, 
however, there are cases in which Pru p 3 cross-
reactive sIgE is present in individuals who experience 
no symptoms despite being positive for sIgE to nsLTP 
in other foods. In these individuals, the IgE anti-
nsLTP appears to have no clinical significance and 
should be considered as a risk factor for developing 
food allergies.
nsLTPs and respiratory allergens
As shown in table 2, nsLTPs have been identified 
as major and minor allergens in different tree and 
weed pollens. Interestingly, sensitization to inhaled 
pollen nsLTPs is associated with more severe clinical 
phenotypes. Pellitory pollen is the only pollen whose 
major allergen is an nsLTP. Accepted threshold pollen 
levels for sensitization are low and clinically, pellitory 
pollinosis is often linked to asthma. The presence of 
IgE antibody specific for Ole e 7, the nsLTP from Olive 
pollen, has been associated with a severe allergic 
olive pollen phenotype, with increased risk of asthma 
and concomitant-reactions during immunotherapy. 
In areas of heavy olive pollen exposure, this allergen 
can sensitize up to 50% of the pollen allergic 
population (11). Art v 3 and Pla a 3, are minor pollen 
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allergens that display partial cross-reactivity with Pru 
p 3 (Figure 2). As a consequence, sIgE to mugwort or 
Plane tree should always be evaluated for potential 
cross-reactivity with Pru p 3 and other pollen nsLTPs. 
In Areas with high Plane tree (as Barcelona) or 
mugwort (as Gran Canaria) exposure, sensitization to 
these pollen nsLTPs has been associated with a more 
complex recognition pattern in nsLTP food allergic 
patients (21).
Importantly, nsLTP from fruits and vegetables have 
been reported to induce respiratory symptoms. 
Pru p 3 monosensitizes up to 10% of patients 
with respiratory allergy in areas with extensive 
orchard tree cultivation (12). It is present in high 
concentration in peach tree leaves and has been 
shown to induce respiratory allergy symptoms in 
sensitized patients. Asparagus nsLTP has been 
described as an occupational allergen that is able to 
induce respiratory symptoms (22).
CLINICAL MANAGEMENT
Identification of clinically relevant allergens
The clinical history should provide evidence for 
those plant-foods that are most frequently involved 
in the typical allergic reactions related to the nsLTP 
syndrome, including peach, apple and other Rosaceae 
fruits. Other foods that frequently are linked to nsLTP 
induced allergy symptoms include walnut, hazelnut, 
peanut, maize, wheat, rice, or other seeds. However 
consideration should be given to the fact that nsLTPs 
are present in all vegetable tissues and they all might 
theoretically induce vegetable-mediated allergic 
symptoms.
Role of Cofactors
A second critical point in the diagnosis associates 
with cofactors such as exercise, alcohol intake, anti-
acids and NSAIDs that can promote severe reactions. 
Thus, their potential involvement should always 
be considered in nsLTP-hypersensitive subjects. 
Furthermore, severe nsLTP-associated clinical 
reactions can also frequently occur in patients who 
are not pollen allergic.
CRD Diagnosis
Positive skin tests and/or extract-specific IgE that 
confirm plant-food sensitization should be further 
investigated by CRD. Skin prick tests with the 
commercial extracts, and a prick-to-prick with fresh 
vegetable foods should be performed according 
to European guidelines. A prick-to-prick test with 
fresh fruits and vegetables has proven to be more 
diagnostically sensitive in confirming a history of food 
allergy to plant-foods than a SPT using commercial 
food extracts (23). In order to test for LTP sensitization, 
LTPs containing allergenic commercial extracts of 
apple and peach are now commercially available. They 
can be useful for the identification of large numbers of 
LTP-sensitized patients. Pru p 3 containing reagents 
in particular have proven vital in the diagnosis of 
the nsLTP syndrome. However, Pru p 3 cannot be 
considered a general marker of nsLTP induced clinical 
allergy. As indicated above, Pru p 3 has very limited 
homology with pollen nsLTPs, such as Par j 1 or Ole 
e 7, and this means the potential for a complete lack 
of cross-reactivity. Other LTPs such as Tri a 14 that is 
connected to Baker’s asthma, have proven to also be 
Pru p 3 independent sensitizers (24).
nsLTP-specific IgE antibody is an important marker 
for true food allergy with a high risk for severe 
systemic reactions. This is in contrast with the oral 
allergy syndrome-induced food allergy symptoms 
that are associated with sensitization to Bet v 1 and 
Bet v 2 homologues in birch allergic patients. As such, 
serological assays have been developed to detect 
anti-LTP specific IgE antibody (e.g., Thermofisher 
Scientific/Phadia ImmunoCAP) for use in the 
definitive diagnosis of plant-foods allergy.
In peach sensitized individuals, the simultaneous 
presence of both Pru p 3 and Pru p 1-specific IgE 
antibodies seems to lower the apparent risk of severe 
food allergic reactions, however similar data for other 
foods are still lacking. The availability of IgE antibody 
cut-off values that correlate with the severity of the 
symptoms could increase the efficacy of diagnosis. 
Recently (25) a proposed cut-off of 2.69 kUA/l has 
been reported for rPru p 3 specific IgE antibody values 
that identifies peach-allergic patients at a higher risk 
for severe symptoms after peach ingestion. Further 
studies are needed to identify possible thresholds 
for IgE antibody levels to other relevant food nsLTP 
allergens.
At present, nine different nsLTPs are available 
on the multiplex ImmunoSorbent Allergen Chip 
(Thermofisher Scientific/ Phadia: ISAC). The clinical 
relevance of IgE antibody test results generated with 
this panel of allergenic specificities for predicting 
nsLTP clinical reactivity is still a subject of active 
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research. In contrast to other pan-allergen allergen 
specificities, it may be necessary to incorporate a 
broader selection of nsLTP in the test panel to make 
a correct patient diagnosis. Pru p 3 seems to play a 
central role in nsLTP-mediated reactions. In vivo and 
in vitro diagnostic tools for Pru p 3 are commercially 
available and their inclusion in general patient 
screening is advisable, especially in geographic areas 
where the prevalence of nsLTPs sensitization is 
considerable.
DBPCFCs for LTP-containing plant-foods
The double-blind placebo-controlled food challenge 
(DBPCFC) is the gold standard for the diagnosis of 
food allergy. In routine clinical practice, DBPCFCs for 
LTP-containing plant-foods should be performed only 
for nutritionally relevant foods such as wheat, rice 
and maize. In some cases the challenge test should 
also be performed after exercise given that LTPs have 
been described as foods involved in food dependent 
exercise induced anaphylaxis (FDEIA) (26).
Figure 4
Diagnostic algorithms using component resolved diagnosis in the case of a positive serology or skin test 
to (a) peanut, (b) peach, (c) hazelnut, or (d) apple extracts (nsLTP allergens are displayed in bold).
Peanut
Ara h 9 +
Ara h 1/2/3 +/-
Ara h 8 -
Ara h 9 -
Ara h 1/2/3 +
Ara h 8 -
Ara h 9 -
Ara h 1/2/3 -
Ara h 8 +
Primary sensitization
Risk of severe reactions
Secondary sensitization- cross 
-reactivity with birch pollen
Local reactions (OAS)
Hazelnut
Cor a 8 +
Cor a 9/14 +/-
Cor a 1-
Cor a 8 +
Cor a 9/14 +
Cor a 1-
Cor a 8 -
Cor a 9/14 -
Cor a 1+
Primary sensitization
Risk of severe reactions
Secondary sensitization- cross 
-reactivity with birch pollen
Local reactions (OAS)
Apple
Mal d 3 +
Mal d 1 -
Mal d 4 +/-
Mal d 3 -
Mal d 1 +
Mal d 4 +/-
Primary sensitization
Risk of severe reactions
Secondary sensitization- cross 
-reactivity with birch pollen
Local reactions (OAS)
Peach
Pru p 3 +
Pru p 1 -
Pru 4 -
Pru p 3 +
Pru p 1 +
Pru 4 +/-
Pru p 3 -
Pru p 1 +
Pru 4 +/-
Primary sensitization
Risk of severe reactions
Secondary sensitization- cross 
-reactivity with birch pollen
Local reactions (OAS)
Co-sensitization
Protection agains severe 
systemic reactions
Diagnosis Algorithms
Figure 3 depicts diagnosis algorithms that can be 
used to evaluate a potential nsLTP mediated allergy.
Many patients show a progressive clinical recognition 
of nsLTPs. In some cases, they might be obliged to 
avoid almost any vegetable from the diet. How the 
complexity and intensity of the IgE antibody profile 
to the panel of nsLTPs might predict this evolution is 
subject of active research.
Treatment
The possibility of desensitization is being explored 
(27). In a recent congress communication (28), 90% 
of treated patients with a sublingual peach extract 
vaccine tolerated a whole peach after one year of 
treatment. In contrast to the published study (27), 
about 50% of the patients were included, in spite 
of having had a previous anaphylactic reaction. This 
suggests that immunotherapy might be a feasible 
option for the treatment of severe nsLTP allergy. 
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Currently there is only a peach-based sublingual 
vaccine commercially available in Spain.
CLINICAL CASES
Case 1 (published (26))
A 17 year-old male with a 12-years history of peach-
induced systemic symptoms (urticaria, angioedema) 
and sporadic anaphylaxis of unknown origin. Specific 
IgE antibody levels were strongly positive to rPru p 
3 (34.7 kUA/L), and moderately positive to wheat 
(1.56 kUA/L), maize (4.92 kUA/L) and rice (1.46 
kUA/L). sIgE to omega 5 gliadin was negative. 
IgE immunoblotting was positive for reactivity to 
nsLTPs in three cereals. Wheat Open Exercise Food 
Challenge (OEFC) induced an anaphylactic reaction 
that was treated with Epinephrine. Rice and maize 
OEFCs were negative. A wheat-free diet allowed the 
patient to perform agonistic physical activity without 
any symptoms. He did not need to eliminate rice and 
maize. Thus, LTP sensitization detected to rice and 
maize was due to cross-reactivity with Pru p 3. The 
message is that the challenge is mandatory in order 
to avoid unnecessary food elimination.
Case 2 (unpublished real case)
Female, 24 years old, with a recent episode of 
anaphylaxis (angioedema of lips and eyelids, 
abdominal pain and diarrhea), which occurred 15 
minutes after the ingestion of hazelnut ice cream. 
She also reported oral allergy syndrome (OAS) and 
gastrointestinal symptoms (abdominal pain, nausea 
and vomiting) with most of the Rosaceae fruits that 
were particularly severe with peach. In addition, 
she reported a 5-years history of grass and pellitory 
pollen allergy. Prick-to-prick tests were positive 
for hazelnut, walnut, maize, peach, apple, plum 
and cherry. Specific IgE antibody responses were 
positive to hazelnut (4.61 kUA/l), peach (14.7 kUA/l) 
and all the Rosaceae fruits and nuts. The levels of 
IgE antibodies to selected nsLTP components were 
10.9 kUA/L (rPru p 3) and 2.5 kUA/L (rCor a 8). IgE 
antibodies were negative to rPru p1, rCor a 1, rCor 
a 9, rCor a 14, milk, casein and eggs. In this patient, 
the rCor a 8 sensitization that caused an anaphylactic 
reaction following hazelnut exposure was shown to 
be secondary to Pru p 3 sensitization.
Case 3 (published (26))
Male, 15 year old boy with a history of atopic 
dermatitis, allergic asthma and OAS to Prunoideae 
fruits, and frequent episodes of severe anaphylaxis 
in the previous 2 years after eating any kind of 
cereal. A rice DBPCFC at rest was positive. The 
OEFCs with wheat and maize were positive and 
particularly severe with maize. The patient specific 
IgE antibody responses were positive to rPru p 3 
(6.94 kUA/L), wheat (5.70 kUA/L), rice (8.81 kUA/L) 
and maize (9.86 kUA/L) and they were negative for 
rϖ 5 gliadin. IgE immunoblotting was positive for 
nsLTPs present in all three cereals. In this patient, 
rPru p 3 sensitization was shown to be the cause of 
the observed sensitization to rice and maize nsLTPs 
that led to the rice induced anaphylaxis and the 
exercise-induced anaphylaxis (EIA) to maize. Both 
were much more severe than the allergic symptoms 
induced following wheat exposure. Importantly, the 
clinical effects of the cross-reactivity with Pru p 3 are 
virtually impossible to predict apriori.
TOOLS
Component resolved diagnosis by SPT is possible 
using peach extracts that have been highly enriched 
for Pru p 3 and have very low content of other 
allergens. As most of the patients with nsLTP 
mediated food allergic reactions will be positive 
to Pru p 3, this extract should be used in a general 
screening for respiratory as well as food-induced 
allergic disease.
Complex nsLTP syndrome patients will eventually 
react to multiple members of the nsLTP family. The 
ISAC-112 contains 9 different nsLTPs. In addition to 
the presence of Pru p 3, there are three nuts nsLTPs 
(Ara h 9, Cora a 8, Jug r 3), one cereal flour nsLTP (Tri 
a 14) and four pollen nsLTPs (Art v 3, Ole e 7, Pla a 3 
and Par j2).
The sIgE responses to the above mentioned nsLTP 
panel may reflect reactivity to a broader number of 
the nsLTP family recognition. IgE anti-nsLTP reactivity 
may be related to the severity of the LTP syndrome 
and the probability of future side reactions to new 
fruits and vegetables. However, to date, there is no 
validated approach or threshold limit values for sIgE 
anti-nsLTP levels. The individual allergens are also 
available in the singleplex ImmunoCAP.
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C04
Minor respiratory allergen of animal dander
Highly conserved sequences with strong 
amino acid identity
Allergen implicated in pork-cat and bird-
egg syndrome
Meat and milk allergen
May elicit severe symptoms upon ingestion 
of not cooked or boiled food
THE PROTEIN
Bos d 6 - Bovine serum albumin (BSA), is a well 
characterized protein (Table 1) (1). It is synthesized 
in the liver and constitutes a major component 
of plasma. It is widely used in biochemical and 
immunological assays, as cell culture ingredient and 
in vaccines.
The protein architecture of Bos d 6 was resolved 
in 2012 (1) and revealed an α-helical structure, 
composed of three structurally similar domains 
arranged into a heart-shaped from Fig. 1. The 
molecule is stabilized by seventeen disulfide bonds. 
Bos d 6 is denatured by heating above 50°C. Helices 
are partially disrupted and heat-induced aggregation 
takes place at 60°C.
Bos d 6 is a respiratory and food allergen as it is 
present in bovine dander, in milk and meat. It is 
classified as minor allergen in animal dander, but it 
is an important meat and milk allergen in the case 
of uncooked food ingestion. In fact Bos d 6 is a 
thermolabile protein, and well done meat or boiled 
milk are safe for allergic patients. There is currently 
no assay available for quantification of Bos d 6 in the 
environment.
Christiane Hilger
SERUM ALBUMINS
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THE FAMILY
Serum albumins are large globular proteins 
synthesized in the liver (2). They are abundant in 
plasma and contribute to the regulation of colloid 
osmotic pressure. Serum albumins transport a 
multitude of metabolites, nutrients, drugs and other 
molecules. They have an α-helical structure with 
three domains stabilized by several disulfide bridges. 
Serum albumins change their conformation in order 
to bind diverse ligands. They are present in dander, 
saliva, milk and meat. They are thermolabile and are 
easily denatured in food by cooking. Chicken serum 
albumin, formerly α-livetin, is an allergen of egg 
yolk. Seven allergens are officially recognized by the 
IUIS Allergen Nomenclature Subcommittee: Bos d 6 
(bovine), Can f 3 (dog), Cav p 4 (guinea-pig), Equ c 3 
(horse), Fel d 2 (cat), Sus s 1 (pig) and Gal d 5 (chicken) 
(Table 2). However, a number of serum albumins from 
different animals have been shown to bind IgE and 
to be cross-reactive: sheep, goat, rabbit, hamster and 
other mammals (3).
Serum albumins have a molecular weight of 65-69 
kDa. They are composed of 607-608 amino acids 
and during maturation, the signal peptide and a 
pro-peptide of 18 and 4 amino acids, respectively 
are cleaved off. Mammalian serum albumins have 
highly conserved amino acid sequences (2) and show 
sequence identities of 72-82% to human serum 
albumin (HSA) (Table 3). Avian serum albumins 
display lower identities (46-49%) to HSA and to other 
mammalian serum albumins (42-48%).
Table 3 displays two-by-two comparisons of amino 
acid identities between HSA and different serum 
albumins. The identity between HSA and mammalian 
serum albumins is very high. It was generally 
assumed that proteins with a sequence identity 
above 62% were rarely allergenic (4). Serum albumins 
constitute a remarkable exception to this rule. Other 
important animal allergen families like tropomyosins, 
β-parvalbumins and caseins lie below this threshold. 
IgE-cross-reactivity between mammalian serum 
albumins has been well documented (3). All pairs with 
a high sequence identity (>70%) are potentially cross-
Figure 1
Ribbon model of the three-dimensional struc-
ture of Bos d 6 (3V03). N-terminal end in red, 
C-terminal end in purple.
Table 1
Basic protein characteristics of Bos d 6
Protein characteristics
Allergen source Bos domesticus, domestic cattle
Protein family Serum albumin
UniProtKB accession 
No P02769
Three dimensional 
structure available Yes
Molecular structure mainly helical
Theoretical molecular 
weight 66.56 kDa
Length 607 amino acids; mature protein: 583 amino acids
Ligand binding Yes
Dimerization No
Glycosylation No
Disulfide bonds 17
Isoelectric point 5.6
Synthesis liver, secreted
Distribution Plasma, dander, saliva, milk, meat,
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reactive. It has been postulated that below 50%, 
cross-reactivity is rare (5). Cross-reactivity between 
mammalian and the less conserved avian serum 
albumins seems actually to be rare, but has been 
documented in single case reports (6). Molecules 
displaying a low level of overall sequence identity 
may nevertheless share single epitopes composed 
of short stretches of sequence identity leading to 
patient-dependent IgE-cross-reactivity.
A comparison of the surfaces of some important 
allergenic mammalian serum albumins visualizes 
potential cross-reactive B cell epitopes (Fig. 2). B- 
and T-cells recognizing HSA epitopes will be deleted 
during the immunological education process.
CLINICAL RELEVANCE
Serum albumins are respiratory allergens present in 
animal dander and fluids such as milk, serum, urine 
and saliva. They are considered minor allergens 
(7). Depending on the study population, about 14-
50% of cat and dog-allergic patients present IgE to 
cat or dog albumins. Monosensitization to cat or 
dog serum albumin seems to be extremely rare in a 
primary sensibilisation. IgE to Fel d 2 would usually 
be detected along with IgE directed to a major 
allergen e.g. Fel d 1. On the contrary, the presence 
of IgE to Can f 3 without any detectable IgE to other 
dog allergens (Can f 1, Can f 2) would be a marker of 
Textbox 1
Albumin Family Characteristics
  Common tertiary α-helical structure
  Highly conserved sequences with strong 
amino acid identity
  Large secreted molecules of 65 - 69 kDa
  Thermolabile
  Present in dander, secretions and meat
Table 2
Bos d 6-homologous allergens from animals
Animal family Allergen source Allergen
Bovidae Domestic cattle (Bos 
domesticus)
Bos d 6
Canidae Dog (Canis familiaris) Can f 3
Cavidae Guinea-pig (Cavia porcellus) Cav p 4
Equidae Domestic horse (Equus 
caballus)
Equ c 1
Felidae Cat (Felis domesticus) Fel d 2
Phasianidae Chicken (Gallus domesticus) Gal d 5
Suidae Domestic pig (Sus scrofa) Sus s 1
Table 3
Amino acid identities (%) between allergenic serum albumins and HSA (2)
Bos d 6
Can f 3 76
Cav p 4 70 73
Equ c 3 74 76 72
Fel d 2 78 87 76 78
Gal d 5 43 46 43 43 45
HSA 76 80 72 76 82 46
Sus s 1 79 78 72 76 79 42 75
Bos d 6 Can f 3 Cav p 4 Equ c 3 Fel d 2 Gal d 5 HSA Sus s 1
Dark blue shaded areas indicate sequence identities >80%, light shaded areas display identities between 70 and 80%. Figures in bold blue 
indicate documented IgE-cross-reactivity between albumins. HSA, human serum albumin.
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Figure 2
Surface representation of serum albumin comparisons. Comparison of the cross-reactive serum albumins 
from domestic cattle (Bos d 6), cat (Fel d 2), and pig (Sus s 1). Surface representation of Bos d 6 (3V03) 
colored by sequence conservation with Fel d 2 and Sus s 1, shown in 4 side views. Sequence conservation 
was calculated by Consurf (18). The highly variable sequence conservation was identified as deep blue, 
the average was in white and the conserved sequences are denoted in deep red (Figure provided by K 
Arumugam, Luxembourg Institute of Health).
Figure 3
Cross-reactivities among allergenic serum albumins. All mammalian serum albumins are potentially 
IgE-cross-reactive. Clinical cross-reactivity between mammalian serum albumins of cat and pork and Gal 
d 5 are rare and have been documented only from mammal to bird. Solid lines represent documented 
IgE-cross-reactivity, dashed lines hypothetical cross-reactivity.
Fel d 2
Can f 3
Equ c 3
Gal d 5
Cav p 4
Bos d 6
Sus s 1
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cross-reactivity and the primary sensitization source 
should be investigated. The clinical relevance of 
IgE to serum albumins is difficult to explore as IgE 
to other animal allergens are always present in the 
same patient. It is generally assumed that they are of 
low relevance. However, two cases of occupational 
asthma triggered by inhalation of Bos d 6 have been 
reported in a laboratory worker (8, 9). High levels of 
IgE-antibodies to Fel d 2 have been associated with 
atopic dermatitis in cat-allergic children (10).
In contrast to its role as respiratory allergen, serum 
albumin in food has been shown to elicit minor, 
moderate and severe clinical symptoms. Bos d 6 is a 
component of the milk whey fraction and constitutes 
about 1% of the total protein content of milk (0.1-0.4g/
l). In a series of 60 children with immediate reactions 
to milk confirmed by DBPCFC, 61.3 % had allergen-
specific IgE-antibodies to Bos d 6 (11). Boiling milk for 
10 min eliminated skin prick test responses in subjects 
reactive to BSA. Cross-reactivity has been described 
between different mammalian milks. Not only Bos d 
6, but also the major bovine milk allergens caseins and 
β-lactoglobulin have homologues in milk from other 
species. Serum albumins are also an important allergen 
of meat. A high percentage of milk-allergic children 
(13-20%) are also allergic to beef (12). In a series 
of 28 children diagnosed with beef allergy, 92.9% 
were diagnosed allergic to milk by skin prick test and 
DBPCFC. In children with beef allergy, sensitization to 
Bos d 6 is a marker of cow’s milk allergy (12). Because 
Bos d 6 is a thermolabile allergen, well-done meat is 
tolerated by most patients.
Albumins are also involved in cross-reactivity 
between animal dander and milk or meat. A patient 
allergic to horse developed a systemic reaction upon 
ingestion of mare’s milk (13). The association between 
allergy to cat dander and pork meat, known as pork-
cat syndrome was already described more than a 
decade ago in Europe (14). Among 2 groups of cat-
allergic patients, 14 and 23% had specific IgE to Fel 
d 2, 3-10% had cross-reacting IgE to porcine albumin 
(15). Among those, one out of three experienced 
clinical symptoms upon ingestion of pork meat. 
Thus, statistically 1-3% of cat-allergic patients could 
develop pork-cat syndrome. This syndrome has only 
recently been described in the US and should be 
differentiated from the delayed type of meat allergy 
based on IgE to alpha-gal (chapter B14) (16).
Chicken serum albumin (Gal d 5) is an inhalant and 
food allergen implicated in the bird-egg syndrome 
(17). It is present in egg yolk and it was also detected 
in domestic air samples. Bronchial challenges elicited 
asthmatic responses in 6 asthmatic patients. IgE-
reactivity was reduced to 88% after heating at 90°C 
for 30 min. Chicken serum albumin Gal d 5 does not 
share any sequence identity with ovalbumin Gal d 2, 
a storage protein and allergen of egg white.
The wide use of bovine serum albumin in cell culture 
media holds new risks. Several case reports have 
shown that Bos d 6, an ingredient of the culture 
medium of spermatozoids has provoked severe 
anaphylactic reactions upon artificial insemination 
(7). Some vaccines contain Bos d 6 but apparently no 
side effects have been described. Further studies are 
still needed.
As serum albumins are minor allergens, there 
is no current research on the development of 
hypoallergenic molecules. Current immunotherapies 
available contain animal dander extracts and albumin 
content may be variable.
CLINICAL MANAGEMENT
A careful record of the clinical history such as the 
presence of pets at home or regular pet contact is 
of great value. Skin prick test or allergen-specific IgE 
using animal dander will confirm animal sensitization. 
In order to define the primary sensitization source, 
specific IgE to major allergens such as Fel d 1, Can f 
1, 2 or 5 should be determined. Unfortunately, the 
number of components is still limited and no allergens 
are available for small furry pets. IgE-antibodies 
Textbox 2
Clinical relevance
  Minor respiratory allergen of animal dander
  Mean sensitization rates of 30% in patients 
allergic to furry animals
  Allergen implicated in pork-cat syndrome
  Meat and milk allergen
  May elicit severe symptoms upon ingestion 
of not cooked or boiled food
  Allergen implicated in bird-egg syndrome
  No molecule based therapeutic approach 
available
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Figure 4
Added value of the use of single allergens in the case of a positive IgE test to cat dander.
Cat dander
Fel d 1 +
Fel d 2/4 -
Fel d 1 +
Fel d 2/4 +
Fel d 1 -
Fel d 2/4 +
Primary sensitization to cat
Cross-sensitization to serum albumins  
and lipocalins, potential sensitization to food 
Check for primary source
Primary sensitization to cat, 
potentially cross-sensitization or co-
sensitization to other animal or food
Bos d 6 +
Sus s 1 +
Marker of milk and beef 
allergy
Potential clinical symp-
toms upon pork inges-
tion; pork-cat syndrome
Figure 5
Added value of the use of single allergens in the case of a positive IgE test to milk.
Milk
Bos d 4, 5, 8 +
Bos d 6 -
Bos d 4, 5, 8 +
Bos d 6 +
Bos d 4, 5, 8 -
Bos d 6 +
Primary sensitization to milk
Cross-sensitization to serum  
albumins, potential sensitization to food 
Check for primary source
Primary sensitization to milk, 
potentially cross-sensitization to meat 
or animal dander
Bos d 6 +
Sus s 1 +
Marker of milk and beef 
allergy
Potential clinical symp-
toms upon pork inges-
tion; pork-cat syndrome
Major allergens 
of cat, dog ... +
Primary sensitization to 
animal dander
Figure 6
Added value of the use of single allergens in the case of a positive IgE test to meat.
Alpha-gal +
Meat
Alpha-gal +
Bos d 6, Sus s 1-
Alpha-gal -
Bos d 6 + or Sus s 1+
Alpha-gal -
Bos d 6, Sus s 1-
Delayed allergic reaction to 
meat
Sensitization to other allergens or 
non-allergic reaction
Immediate type reaction
Sensitization to meat, potentially 
cross-sensitization to animal dander
Sensitization to red meat, 
possibly also to gelatin
Sensitization to Cetuximab
Sensitization to tick bites
Sensitization to milk
Additional clinical testing
Bos d 6 +
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directed to serum albumins are a marker of cross-
reactivity, but do not mandatorily imply clinical cross-
reactivity. Patients with IgE to serum albumins should 
be advised to avoid mammalian pets as they may 
experience clinical symptoms upon contact with any 
pet. As mammalian serum albumins are highly cross-
reactive, the choice of serum albumins included in 
the determination of allergen-specific IgE should be 
guided by the clinical history. Specific IgE are mostly 
positive to Can f 3 and Fel d 2 whereas IgE-reactivity 
against Bos d 6 and Sus s 1 are less frequent. Gal d 5 
should be considered as an independent allergen as 
homology to mammalian albumins is very low.
Patients with moderate to high levels of IgE to serum 
albumins are at risk to develop symptoms upon 
ingestion of unboiled milk and raw or medium cooked 
meat such as sausages, ham and steaks. IgE to Bos 
d 6 and Sus s 1 should be determined and patients 
should be carefully advised. As serum albumins are 
thermolabile, well-cooked meat and heated milk may 
be tolerated.
CLINICAL CASES
Case 1 (published (15))
Clinical history - A 17-year-old girl with a history 
of rhinitis and asthma when exposed to cat 
experienced anaphylactic reactions on two 
occasions when the only food consumed was pork 
(ham and sausage).
Test with extracts - The patient had positive skin prick 
tests to cat dander and pork. IgE were positive for 
cat dander (>100 kUA/L) and pork (22 kUA/L).
Test with molecules - Specific IgE to animal serum 
albumins were 165 kUA/L to Fel d 2, 37 kUA/L 
to Can f 3, 22 kUA/L to Sus s 1 and 2.5 kUA/L to 
Bos d 6. IgE to Sus s 1 could be totally inhibited by 
addition of Fel d 2, confirming primary sensitization 
to cat.
Conclusion – Results were consistent with pork-cat 
syndrome and the patient was advised to avoid 
eating pork.
Case 2 (published (16))
Clinical history – A 52-year-old man, experienced 
anaphylaxis 20 min after a meal of pork tenderloin, 
potatoes and green beans. As symptoms occurred 
quickly after the meal, the involvement of IgE 
directed to alpha-gal antibodies seemed unlikely.
Test with extracts – Skin prick tests were positive 
for pork, cat and dog dander. Allergen-specific 
IgE were positive for cat dander (3.74 kUA/L) and 
pork (0.65 kUA/L), negative to beef.
Test with molecules – The patient had specific IgE 
to Fel d 1 (1.58 kUA/L) and Fel d 2 (2.28 kUA/L). 
Specific IgE were negative for alpha-gal, and Bos 
d 6.
Conclusion - Results were consistent with pork-cat 
syndrome and the patient was advised to avoid 
eating pork.
Allergen nomenclature: Fel d 2, Bos d 6, Can f 3, Sus s 1, 
Gal d 5: cat, bovine, dog, porcine and chicken serum 
albumins.
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C05
Tropomyosins are highly allergenic cross-
reactive molecules from diverse sources 
(pan allergens) that can induce diverse 
symptoms including anaphylaxis.
Sensitization to tropomyosins can 
occur by ingestion (seafood), inhalation 
(mites, cockroaches) or parasite infection 
(ascariasis, anisakiasis).
The clinical impact of non-food allergenic 
tropomyosins may be greater than 
previously thought.
In vitro determination of IgE antibodies to 
tropomyosin could be more specific, with 
higher positive predictive value, than the 
whole extract in cases of shrimp allergy.
THE PROTEIN
The shrimp (Penaeus aztecus) major allergen, Pen 
a 1, is one of the most clinically relevant allergenic 
tropomyosins (1-3). Its basic characteristics are 
presented in Table 1. There is no three-dimensional 
structure available from any allergenic tropomyosin, 
but a predicted model of Ascaris lumbricoides 
tropomyosin (Asc l 3) is presented in Fig. 1. The 
secondary structure is a coiled-coil molecule formed 
by two parallel alpha-helices.
These proteins are heat-stable, which partially 
explains their high allergenicity. Together with actin 
and myosin play an important role in the contractile 
activity, as well as the regulation of cell morphology 
and motility. Shellfish allergenic tropomyosins were 
first described in shrimp (4-6) but they are important 
allergens in other sources. The relevance of 
sensitization to tropomyosins varies from low clinical 
impact to anaphylaxis.
Several IgE binding epitopes of shrimp tropomyosins 
have been reported. Ayuso et al. identified five major 
IgE binding sites on Pen a 1 that were cross-reactive 
epitopes among shrimp, lobster, house dust mite and 
cockroach (7, 8). The sites include eight IgE binding 
Luis Caraballo
TROPOMYOSINS
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epitopes: epitope 1 (residues 43 – 55) in region 1; 
epitope 2 (residues 87 – 101) in region 2; epitopes 
3a (residues 137 – 141) and 3b (residues 144 – 
151) in region 3; epitope 4 (residues 187 – 197) in 
region 4; and epitopes 5a (residues 249 – 259), 5b 
(residues 266 – 273) and 5c (residues 273 – 281) in 
region 5. The sequence identity of these regions to 
homologous regions of other tropomyosins varies 
from 56% (rabbit) to 98% (lobster).
Further analyses of these epitopes and comparing 
them with other related sequences suggested that 
they can be classified into three types: epitope 
5a that is highly conserved among crustaceans, 
mollusks, insects and mites. The second type is 
composed of epitopes 2, 3 and 4 that represent all 
arthropods but not mollusks. The third type includes 
epitope 1, 5b and 5c, which are specific to crustacean 
(9). Epitope mapping of other tropomyosins such as 
Pen j 1, Pen m 1 and Pan b 1 from shrimp, Tur c 1 
(snail), Cra g 1 (oyster) and Oct v 1 (octopus) have 
also been performed. The amino acid sequence of 
several tropomyosin epitopes is already known. In 
addition, T cell epitopes have been described. Ravkov 
E et al., using an in vitro MHC-peptide biding assay 
as well as ex vivo proliferation and cytokine release 
assays, identified and validated 17 T cell epitopes 
restricted to multiple MHC class II alleles. This finding 
is potentially useful for designing peptide-based 
immunotherapy of shrimp allergy. The challenge of 
further studies is to analyze which tropomyosins 
epitopes are species-specific markers.
THE FAMILY
Tropomyosin belongs to a family of proteins (Pfam 
PF00261) that includes a large number of cross 
reactive allergens, most of them from invertebrate 
sources, such as shrimp, lobster, crab, snail, abalone, 
whelk, clam, mussels, octopus, house dust mites, 
cockroaches and helminths (Table 2).
Around 40 IgE binding tropomyosins has been 
described, some of them cloned and expressed as 
recombinant proteins and tested for allergenicity. 
However, only few (Pen a 1, Pen m 1, Ani s 3, Bla g 
7 and Der p 10) have been included in commercial 
in vitro allergy testing. Tropomyosin amino acid 
sequence is highly conserved among shellfish and 
other invertebrates, where share over 70% identity; 
their comparison with vertebrate tropomyosins 
reveals 51 to 57% identity (1).
Leung P et al. have shown that serum IgE to shrimp 
also binds tropomyosin of other shellfish such as 
greasy back shrimp, spiny lobster and Indo-Pacific 
swamp crab, abalone, whelk, green mussel, pen shell, 
Figure 1
Molecular model of Ascaris lumbricoides tro-
pomyosin generated by Swiss-Model (template 
Sus scrofa PDB 1c1g). Epitopes visualized with 
PyMOL.
Table 1
Basic protein characteristic s of Pen a 1
Protein characteristics
Allergen source Shrimp
Protein family Tropomyosin
UniProtKB accession 
No Q3Y8M6
Three dimensional 
structure available No
Molecular structure Alpha-helical
Theoretical molecular 
weight 32.8 kDa
Length 284 amino acids
Ligand binding Yes
Dimerization Homodimer
Glycosylation No
Disulfide bonds No
Isoelectric point 4.72
Synthesis Several isoforms
Distribution Muscle and non-muscle cells
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Table 2
A list of clinically relevant tropomyosins
Family Allergen Source Allergen
Penaeoidea Brown shrimp (Penaeus aztecus) Pen a 1
Northern Red Shrimp (Pandalus borealis) Pan b 1
Giant tiger prawn (Penaeus monodon) Pen m 1
European Shrimp (Litopenaeus vannamei) Lit v 1
Common Shrimp (Crangon Crangon) Cra c 1
Palinuridae Spiny lobster (Panulirus stimpsoni) Pan s 1
Cancridae Common crab (Charybdis feriatus) Cha f 1
Hellixidae Brown garden snail (Helix aspersa) Hel as 1
Mytilidae Green mussel (Perna viridis) Per v 1
Octopodidae Common Octopus (Octopus vulgaris) Oct v 1
Ommastephidae Japanese flying squid (Todarodes pacificus) Tod p 1
Osteidae Pacific cupped oyster (Crassostrea gigas) Cra g 1
Haliotidea Abalone (Haliotis diversicolor) Hal d 1
Pyroglyphidae House dust mite (Dermatophagoides farinae) Der f 10
House dust mite (D. pteronyssinus) Der p 10
Echymiopodidae Storage mite (Blomia tropicalis) Blo t 10
Blattidae American cockroach (Periplaneta americana) Per a 7
Blattellidae German cockroach (Blattella germanica) Bla g 7
Anisakidae Anisakis (Anisakis simplex) Ani s 3
Ascaridae Roundworm (Ascaris lumbricoides) Asc l 3
Table 3
Amino acid identities (%) between some tropomyosins
Pen a 1
Pen s 1 100%
Cha f 1 100% 91%
Hel as 1 71% 63% 63%
Oct v 1 75% 63% 63% 83%
Per v 1 55% 55% 55% 70% 70%
Der p 10 71% 80% 82% 64% 63% 55%
Bla g 7 76% 82% 84% 63% 63% 56% 80%
Asc l 3 62% 72% 74% 64% 64% 57% 73% 70%
Pen a 1 Pen s 1 Cha f 1 Hel as 1 Oct v 1 Per v 1 Der p 10 Bla g 7 Asc l 3
Figures in bold blue indicate tropomyosin pairs with <70% amino acid sequence identity
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scallop, Pacific cupped oyster, cuttlefish, sword tip 
squid and octopus (10), which reflects the high cross 
reactivity of this family. Still, tropomyosins are not 
the only allergens of shellfish; other cross-reactive 
clinically relevant allergens have been reported (798).
For comparing the protein sequences of allergenic 
tropomyosins, Leung M et al. (9) conducted a 
phylogenetic analysis and found that arthropods 
tropomyosins share 91.7% homology (76.1 - 
100%) and mollusks share 77.2% (65.1 – 99.3%), 
which indicates that, at the whole sequence level, 
tropomyosins are not species-specific allergy 
markers. Homology between crustacean and mollusks 
tropomyosins is 56 – 68% and between vertebrate 
and invertebrate tropomyosins 53 -57% (1). Table 
3 displays two-by-two comparisons of amino acid 
identities between representative tropomyosins.
All pairs with a high sequence identity are potentially 
cross-reactive. Sequence alignments are good 
primary prediction tools for cross-reactivity, but most 
importantly, the use of IgE-inhibition studies with 
sera from clinically well characterized patients will 
allow defining clinically relevant cross-reactivity (Fig. 
2). A comprehensive phylogenetic tree of allergenic 
tropomyosins from various taxonomic groups can be 
found in reference (9).
Mite (group 10) and cockroach (group 7) tropomyosins 
cross react with shrimp tropomyosins and have 
also been described as clinically relevant allergens. 
Besides, preliminary data show that 33% of sera 
with positive IgE against mosquito extract reacted to 
natural tropomyosin purified from and also showed 
cross reactivity with the shrimp allergens nPen m 1 
and rLit v 1. The clinical impacts of these finding are 
currently under evaluation. The allergenicity and cross 
reactivity of Ascaris lumbricoides tropomyosin (Asc l 3) 
has been thoroughly analyzed (11-13); further studies 
have shown an important clinical impact by sensitizing 
the asthmatic populations in tropical underdeveloped 
countries, where helminthiases, together with 
perennial exposition to mite tropomyosins might 
increase asthma symptoms (14, 15).
Figure 2
Cross-reactivity among allergenic tropomyosins from several sources. Lines represent documented IgE- 
corss-reactivity. Dotted lines represent potential IgE-cross-reactivity based on high sequence identities.
Pen a 1
Der p 10
Bla g 7
Cha f 1
Per v 1
Hel as 1
Asc l 3
Oct v 1
Pan s 1
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Cross-reactivity between house dust mite (HDM) 
allergens and some shellfish has been described 
and there are reports suggesting that it is clinically 
significant. Subcutaneous HDM immunotherapy in 
patients sensitized to shrimp or snail could increase 
allergy symptoms after ingestion of these foods. 
Sensitization to shrimp tropomyosin in Orthodox 
Jews has been demonstrated in HDM allergic patient 
(803). Although cross-reactive tropomyosins are 
good candidates for explaining these observations, 
other allergens may be involved. In addition, other 
authors have obtained opposite results after 
immunotherapy, suggesting that the adverse side 
effects are not universal and could be influenced 
by the type of immunotherapy and genetic factors 
determining the susceptibility to get sensitized by 
other allergens. Therefore, more research is needed 
to define this controversial effect of cross reactivity 
among arthropods on immunotherapy.
CLINICAL RELEVANCE
Tropomyosins from invertebrates are allergenic 
for genetically susceptible individuals and due to 
their extensive cross reactivity, are considered pan 
allergens. Recently the vertebrate tropomyosin, Ore 
m 4, was described as a major allergen of tilapia 
(Oreochromis mossambicus) (17). Sensitization can 
occur by ingestion (seafood), inhalation (mites, 
cockroaches) or parasite infection (ascariasis, 
anisakiasis).
Most allergenic tropomyosins are major shellfish 
allergens. Symptoms may be induced by very low 
amounts of the offending food and sometimes 
by inhalation. They include immediate cutaneous 
reactions (urticaria, angioedema, rash) oral allergy 
syndrome (swelling in the lips and mouth), digestive 
symptoms (vomiting, abdominal cramping, and 
diarrhea), anaphylaxis and asthma. In Europe, 
sensitization to mite tropomyosin Der p 10 is low and 
has been considered an effect of cross reactivity but 
also a marker for broad sensitization among HDM 
allergy patients. Component resolved diagnosis of 
D. pteronyssinus allergens Der p 1, Der p 2 and Der 
p 10 has been suggested for selecting patients for 
HDM immunotherapy. In this study, the frequency of 
IgE to Der p 10 was low. However, the prevalence 
of sensitization to Der f 10 was found around 80% 
in Japan. In addition, sensitization to Der p 10 was 
found 55% in Zimbabwe and 34% in Colombia (14), 
probably because of perennial exposure to shellfish 
and helminth infections. Therefore, the clinical 
impact of non-food allergenic tropomyosins may be 
greater than previously thought. In fact, it has been 
suggested that sensitization to tropomyosin from 
mite (14), cockroach, Ascaris (14, 15) and mosquito 
(18) could influence the prevalence and severity 
of asthma in places where co exposition to several 
sources of tropomyosin occurs. The influence of 
Ascaris tropomyosin sensitization on the outcome 
of immunotherapy for mite allergy has not been 
evaluated.
The frequency of IgE sensitization to tropomyosins in 
shellfish allergic patients ranges from 50 to 100%. In 
addition, Pen a 1 binds up to 75% of all shrimp specific 
IgE antibodies (2), which is supported by histamine 
release experiments (1). Seafood allergy is one of 
the most common allergies and includes reaction 
to crustaceans, mollusks and fish. The prevalence 
of shellfish (crustacean and mollusks) allergy is 0.6% 
in the world population. In some regions of high 
consumption such as Singapore, the prevalence of 
seafood allergy in school children is around 5%.
CLINICAL MANAGEMENT
Clinical history of adverse reaction suggesting allergy 
after intake of shellfish is crucial for starting diagnosis 
procedures. Whole extracts are very useful for 
diagnosing shellfish allergy by ST, although Prick-prick 
procedure is also useful. Tropomyosin sensitization 
is very important when evaluating shellfish allergy 
but other allergens also play a role (9). It has been 
suggested that in vitro determination of IgE antibodies 
to tropomyosin is more specific and has a higher 
positive predictive value than the whole extract in 
Textbox 1
Tropomyosin Family Characteristics
  Secondary structure formed by two parallel 
alpha-helices
   High amino acid identitiy between sequences
   High degree of cross-reactivity
   Thermostable proteins, high allergenicity
   Considered panallergens
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cases of shrimp allergy. In addition, Thalayasingam et 
al. found that the presence of specific IgE to shrimp 
has diagnostic test sensitivity of 82% and specificity 
of 22.2% (19). This low specificity, mainly due to 
the high rate of false positives that in turn are a 
consequence of the high cross-reactivity between 
shrimp and other Arthropods allergens, explains 
why allergy to shellfish should be often diagnosed 
by challenge. Only two shellfish tropomyosins, Pen a 
1 and Pen m 1 (both from shrimp), are commercially 
available for in vitro testing. A possible diagnostic 
steps (Fig. 4) could be starting with ST with the whole 
extract, and detecting IgE antibodies to the extract, 
tropomyosin and other shellfish allergens, such as 
Pen m 2 (Arginine kinase) and Pen m 4 (Sarcoplasmic 
calcium binding protein).
Since most shellfish tropomyosins share sequences 
and epitopes (cross-sensitization) and there is a great 
diversity of seafood (co-sensitization), it is currently 
difficult to define the primary allergenic source using 
component resolved diagnosis. Then the added 
value using single allergens for distinguishing the 
sensitizing source is still limited because there are no 
species-specific markers of sensitization. However, 
a panel of tropomyosin plus other five shrimp (C. 
crangon) allergens could be useful for comparing 
sensitization patterns from patients with different 
symptoms or severity of symptoms and identify 
clinically useful biomarkers. More recently Pascal 
M et al. evaluated, in patients from USA, Brazil and 
Spain, the efficiency of several allergens to predict 
shrimp allergy. They found that tropomyosin and 
Figure 3
Diagnostic algorithm for shellfish allergy. In vitro tests for IgE to molecular allergens (CRD) include Pen a 
1, Pen m 2 and Pen m 4.
No Anaphylaxis
History & Symptoms of 
Shellfish allergy
Anaphylaxis
Skin test. Shellfish and 
mollusks extracts
Positive Negative
In vitro CRD
Positive: 
Avoidance Negative
Challenge
Positive: 
Avoidance Negative
In vitro diagnosis: 
extracts and CRD
Positive: 
Avoidance Negative
Skin test, 
Extracts
Positive: 
Avoidance Negative
Consider other 
Diagnosis
In vitro diagnosis: 
Extracts and CRD
Positive: 
Avoidance Negative
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sarcoplasmic-calcium-binding-protein sensitization 
is associated with clinical reactivity; in addition, the 
tropomyosin epitope p51-55 seems to be of good 
value as a diagnostic test to confirm allergy. The 
authors present a very interesting flow diagram for 
shrimp allergy diagnosis (20).
Still, the gold standard for food allergy diagnosis is 
the double-blind placebo-controlled food challenge. 
An important aspect of management is the detection 
of tropomyosin in food samples to prevent accidental 
ingestion and anaphylactic reactions. Several 
approaches and techniques have been proposed.
Management of shellfish allergy is based on strictly 
avoidance based on clinical reactions. In general, 
if a patient is allergic to shrimp, avoidance of all 
crustaceans is recommended, although it is possible 
that allergy be limited to particular crustacean 
member. Avoidance of mollusks is advised if allergy 
to it is demonstrated. However, patients with high 
IgE reactivity to tropomyosin might be advised to 
avoid all shellfish. No immunotherapy is currently 
available for seafood allergy but experimental 
approaches to obtain appropriate compounds for 
specific immunotherapy have been developed. 
Hypoallergenic Pen a 1, hypoallergenic peptides from 
Met e 1, periodate treatment of crab tropomyosin 
and simulated gastric digestion of the whole shrimp 
extract are under analysis. Animal models for 
sensitization will help to obtain better reagents for 
diagnosis and treatment.
CLINICAL CASES
Case 1 (published (21))
Clinical History: A 30-year-old man with a 10-year 
history of mild persistent asthma and allergy to 
house dust mites and pollen presented generalized 
urticaria, facial erythema, and pharyngeal pruritus 
after eating shellfish on 3 separate occasions during 
a 2-year period. He associated the most recent 
episode with lobster. Since then, he has tolerated 
some crustaceans, mollusks, and fish, although he 
has avoided eating shrimp and lobster. No other 
food or drug allergies were reported, and he has 
not received immunotherapy for house dust mites.
Test with extracts: The patient had positive results for 
D pteronyssinus (21.4 kU/L) and D farinae extracts 
(12.6 kU/L). Weak SPT positivity with shrimp. IgE 
to lobster extracts (2.9 kUA/l) and PPT to lobster 
were positive (6 mm).
Food challenge: the patient tolerated up to 8 g of 
cooked shrimp during the challenge (and normal 
servings have been tolerated several times 
since). The study performed with lobster gave 
positive results by CAP (2.9 kUA/l) and PPT (6 
mm). However, the patient refused the oral food 
challenge with lobster.
Test with molecules: The patient had positive results 
to Der p 1 (4.7 kUA/L), Der p 2 (60.9 kUA/L), Der 
f 1 (0.4 kUA/L) and Der f 2 (47.2 kUA/L). Purified 
tropomyosins from shrimp (Pen a 1, 0.04 kU/L) and 
D pteronyssinus (Der p 10, 0 kU/L) were negative.
Conclusion: Selective allergy to lobster in a patient 
with primary sensitization to house dust mite.
References
1. Reese G, Schicktanz S, Lauer I, Randow S, Lüttkopf D, 
Vogel L et al. Structural, immunological and functional 
properties of natural recombinant Pen a 1, the major 
allergen of Brown Shrimp, Penaeus aztecus. Clin Exp 
Allergy 2006;36:517-524.
2. Daul CB, Slattery M, Reese G, Lehrer SB. Identification 
of the major brown shrimp (Penaeus aztecus) allergen 
as the muscle protein tropomyosin. Int Arch Allergy 
Immunol 1994;105:49-55.
3. Reese G, Jeoung BJ, Daoul CB, Lehrer SB. 
Characterization of recombinant shrimp allergen Pen 
a 1 (tropomyosin). Int Arch Allergy Immunol 1997;113: 
240-242.
4. Hoffman DR, Day ED Jr, Miller JS. The major heat 
stable allergen of shrimp. Ann Allergy 1981;47:17-22.
5. Naqpal S, Rajappa L, Metcalfe DD, Rao PV. Isolation and 
characterization of heat-stable allergens from shrimp 
(Penaeus indicus). J Allergy Clin Immunol 1989;83:26-
36.
6. Leung PS, Chu KH, Chow WK, Ansari A, Bandea CI, 
Kwan HS et al. Cloning, expression, and primary 
structure of Metapenaeus ensis tropomyosin, the 
major heat-stable shrimp allergen. J Allergy Clin 
Immunol 1994;94:882-890.
7. Ayuso R, Lehrer SB, Reese G. Identification of 
continuous, allergenic regions of the major shrimp 
allergen Pen a 1 (tropomyosin). Int Arch Allergy 
Immunol 2002;127:27-37.
8. Ayuso R, Reese G, Leong-Kee S, Plante M, Lehrer SB. 
Molecular basis of arthropod cross-reactivity: IgE-
binding cross-reactive epitopes of shrimp, house dust 
mite and cockroach tropomyosins. Int Arch Allergy 
Immunol 2002;129:38-48.
EAACI Molecular Allergology User´s Guide2016 Part  C:  Cross-Reactive Molecules & their Cl inical  Relevance
336 Tropomyosins 
9. Leung NY, Wai CY, Shu S, Wang J, Kenny TP, Chu KH 
et al. Current immunological and molecular biological 
perspectives on seafood allergy: a comprehensive 
review. Clin Rev Allergy Immunol 2014;46:180-197.
10. Leung PS, Chow WK, Duffey S, Kwan HS, Gershwin 
ME, Chu KH. IgE reactivity against a cross-reactive 
allergen in crustacea and mollusca: evidence for 
tropomyosin as the common allergen. J Allergy Clin 
Immunol 1996;98:954-961.
11. Santos AB, Rocha GM, Oliver C, Ferriani VP, Lima RC, 
Palma MS et al. Cross-reactive IgE antibody responses 
to tropomyosins from Ascaris lumbricoides and 
cockroach. J Allergy Clin Immunol 2008;121:1040-
1046.
12. Acevedo N, Sánchez J, Erler A, Mercado D, Briza 
P, Kennedy M et al. IgE cross-reactivity between 
Ascaris and domestic mite allergens: the role of 
tropomyosin and the nematode polyprotein ABA-
1. Allergy 2009;64:1635-1643.
13. Acevedo N, Erler A, Briza P, Puccio F, Ferreira F, 
Caraballo L. Allergenicity of Ascaris lumbricoides 
tropomyosin and IgE sensitization among asthmatic 
patients in a tropical environment. Int Arch Allergy 
Immunol 2011;154:195-206.
14. Ahumada V, García E, Dennis R, Rojas MX, Rondón 
MA, Pérez A et al. IgE responses to Ascaris and mite 
tropomyosins are risk factors for asthma. Clin Exp 
Allergy 2015;45:1189-1200.
15. Buendía E, Zakzuk J, Mercado D, Alvarez A, Caraballo 
L. The IgE response to Ascaris molecular components 
is associated with clinical indicators of asthma 
severity. World Allergy Organo J 2015;8:8.
16. Fernandes J, Reshef A, Patton L, Ayuso R, Reese G, 
Lehrer SB. Immunoglobulin E antibody reactivity to 
the major shrimp allergen, tropomyosin, in unexposed 
Orthodox Jews. Clin Exp Allergy 2003;3:956-961.
17. Liu R, Holck AL, Yang E, Liu C, Xue W. Tropomyosin from 
tilapia (Oreochromis mossambicus) as an allergen. Clin 
Exp Allergy 2013;43:365-377.
18. Cantillo JF, Fernandez-Caldas E, Puerta L. 
Immunological aspects of the immune response 
induced by mosquito allergens. Int Arch Allergy 
Immunol 2014;165:271-282.
19. Thalayasingam M, Gerez IF, Yap GC, Llanora GV, Chia 
IP, Chua L et al. Clinical and immunochemical profiles of 
food challenge proven or anaphylactic shrimp allergy in 
tropical Singapore. Clin Exp Allergy 2015;45:687-697.
20. Pascal M, Grishina G, Yang AC, Sánchez-García S, Lin J, 
Towle D et al. Molecular Diagnosis of Shrimp Allergy: 
Efficiency of Several Allergens to Predict Clinical 
Reactivity. J Allergy Clin Immunol Pract 2015;3:521-
529.
21. Iparraguirre A, Rodrìguez- Pérez R, Juste S, Ledesma A, 
Moneo I, Caballero ML. Selective allergy to lobster in 
a case of primary sensitization to house dust mites. J 
Investig Allergol Clin Immunol 2009;19:409-413. 
EAACI Molecular Allergology User´s Guide
CROSS-REACTIVE 
MOLECULES & 
THEIR CLINICAL 
RELEVANCE
PART C
C06
Polcalcins are EF-hand calcium binding 
proteins only expressed in mature pollen
Extensive IgE cross-reactivity among pollen 
polcalcins
Specific IgE to polcalcins can be performed 
with any member of the family
Can be considered a marker of 
polysensitisation with unknown clinical 
relevance for respiratory symptoms
THE PROTEIN
The first cloned polcalcin was from birch pollen (Bet v 
4) (1). But the most representative pollen polcalcin (1) 
is Phl p 7 from Phleum pratense (Timothy grass). Phl 
p 7 belongs to a subfamily of two EF-hand calcium 
binding pollen allergens that are preferentially 
expressed in mature pollen of higher plants including 
monocotyledonic and dicotyledonic species.
Phl p 7 was detected only in pollen but not in root and 
leaf extracts. It seems that is completely eluted out of 
the pollen grains after a few minutes of hydration. It 
contains 78 amino acids with a molecular weight of 
8,677 Da. Summaries of biochemical characteristics 
of Phl p 7 are showed in Table 1.
The physiological role of Phl p 7 is likely related to the 
importance of regulating the calcium levels for pollen 
germination and pollen tube growth, as other calcium 
binding proteins contained in pollen.
rPhl p 7 exhibited a potent allergenic activity and 
is able to induced basophil histamine release and 
immediate type skin reactions. Phl p 7 has high 
stability (thermal and proteolysis) (1) and refolding 
capacity, a characteristic related to potent allergens. 
Joaquín Sastre
POLCALCINS
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It contains calcium-modulated conformational IgE 
epitopes, which become accessible only in the 
calcium-bound form (open conformation), suggesting 
that IgE recognition is only activated by the calcium-
bound conformation.
THE FAMILY
Polcalcins belong to two EF-hand calcium-binding 
proteins. To date, 40 members of this allergen family 
have been identified in grasses, trees, bushes, weeds, 
and other flowering plants (Table 2). The two EF-hand 
allergens share a high degree of sequence homology 
(average sequence identity of 77%), which explain 
the extensive cross-reactivity of allergic patients’ 
IgE Abs with the various members of the family 
(Fig. 2-5). Although they do not present a complete 
immunological equivalence the diagnosis of patients 
sensitized to polcalcins can be performed with any 
member of the family (809, 810). The IgE binding 
capacity to polcalcins depends on conformational 
epitopes (2-6) (Fig. 4). It has been demonstrated that 
the Phl p 7 and related two EF-hand allergens do not 
share epitopes with other EF-hand allergens (e.g., Bet 
v 3, parvalbumin).
Figure 1
(A) Ribbon model of the three-dimensional 
structure of Phl p 7 (PDB 1K9U) solved by X-ray 
crystallography using DENZO and SCALEPACK 
software. (B) Stereo ribbon representation of 
the intertwined Phl p 7 dimer. Chain A is colored 
in blue, chain B is shown in red and the calcium 
ions are highlighted in yellow.
Table 1
Basic protein characteristics of Phl p 7
Protein characteristics
Allergen source Phleum pratense (Timothy grass)
Protein family Polcalcin
UniProtKB accession 
No O82040
Three dimensional 
structure available yes
Molecular structure alpha-helical fold
Theoretical molecular 
weight 8,677 Da
Molecular weight 
measured by MS 14,22 kDa
Length 78 amino acids, mature protein 
Ligand binding EF-hand calcium-binding allergen
Dimerization Dimer
Glycosylation no
Disulfide bonds no
Isoelectric point 4.39
Synthesis Pollen grains
Function Pollen germination and pollen tube growth
Textbox 1
Polcalcin Family Characteristics
  Common tertiary structure with alpha-helical 
fold
  Calcium binding activity
  High sequence identity ( average 77%)
  Small molecules of 8 kDa
  Conformational IgE epitopes (calcium-
modulated)
  Extensive IgE cross-reactivity among pollen 
polcalcins
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Table 2
Polcalcins described from different pollen
Botanical 
family
Allergen source Allergen
Grasses Crested Wheatgrass, Agropyron cristatum Agr c 7
Anthoxanthum odoratum Ant o 7
Cultivated Oat, Avena sativa Ave s 7
Tall Windmill Grass, Chloris elata Chl el 7
Bermuda grass, Cynodon dactylon Cyn d 7
Cocksfoot Grass, Dactylis glomerata Dac g 7
Salt grass, Distichlis spicata Dis s 7
Festuca elatior Fes e 7
Barley, Hordeum sativum Hor v 7
Cogon Grass, Imperata cylindrica Imp c 7
Rye grass, Lolium perenne Lop p 7
Rice, Oryza sativa Orz s 7
Timothy Grass, Phleum pratense Phl p 7
Kentucky Blue grass, Poa pratensis Poa p 7
Wheat, Triticum aestivum Tri a 7
Sorghum, Sorghum bicolor & Sorghum halepense Sor b 7 & Sor h 7
Wild Cane, Saccharum speciossisimum Sac sp 7
Smut Grass, Sporobolus indicus Spo in 7
Corn, Zea mays Zea m 7
Fagales Alder, Alnus glutinosa Aln g 4
Birch, Betula verrucosa Bet v 3Bet v 4
Hornbeam, Carpinus betulus Car b 4
Beech, Fagus sylvatica Fag s 4
White Oak, Quercus alba Que a 4
 Asteraceae Short Ragweed, Ambrosia artemisiifolia Amb a 9, Amb a 10
English Mugwort, Artemisia vulgaris Art v 5
Brassicaceae Rapeseed, Brassica napus Bra n 4Bra n 7
Amaranthaceae Goosefoot, Chenopodium album Che a 3
Cupressaceae Japanese cedar, Cryptomeria japonica Cry j 4
Arizona Cypress, Cupressus arizonica Cup a 4
Cedar, Juniperus oxycedrus Jun o 4
Oleaceae Ash, Fraxinus excelsior Fra e 3
Olive, Olea europeae Ole e 3Ole e 8
Common Lilac, Syringa vulgaris Syr v 3
Solanaceae Tobacco, Nicotiana tabacum Nic t 3
Urticaceae Parietaria, Pellitory, Parietaria judaica Par j 4
Fabaceae Locust Tree, Robinia pseudoacacia Rob p 4
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Figure 2
Backbone ribbon-type representation of the three-dimensional structure of Che a 3 (PDB 2OPO) and of 
structural models of Ole e 3 and Syr v 3 determined by using the services of the Swiss-Model Protein 
Modelling Server (811).
Figure 3
Comparison of the amino acid sequences of different polcalcins (7).
Figure 4
3D-modeling of Fra e 3 (dimer) (bottom). In orange, highly variable region; red, calcium-binding site; and 
blue, calcium ion.
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Figure 5
Cross-reactivity among polcalcins of different allergenic sources.
CLINICAL RELEVANCE
The members of this protein family have been identified 
as potent allergens. However, it is considered a minor 
allergen in all populations studied, since the reported 
allergenic prevalence of this family of proteins varies 
between 5 and 46%. Che a 3, a polcalcin from 
Chenopodium album, common in semi-desert areas, 
is an atypical polcalcin because it showed reactivity 
up to 46% of sera from individuals with chenopod 
allergy (8). The high prevalence of this panallergen in 
these patients might have a relationship with their 
characteristic polysensitization. Moverare et al. (9) 
compared different European populations regarding 
the reactivity of Bet v 4, prevalence values between 5 
and 11% for patients from North and Central Europe, 
and 27% for Italian patients. All these data point to 
the existence of a certain correlation between the 
poly-sensitization degree and geographical area and 
Textbox 2
Clinical relevance
  Polcalcins are minor allergens in patients 
sensitised to grass, tree or weed pollen
  Are markers for cross-reactivity between 
pollen, but not present in plant foods.
  Unknown clinical relevance for respiratory 
symptoms
  Isolated polcalcins have extensive cross-
reactivity
  Diagnosis of patients sensitized to polcalcins 
can be performed with any member of the 
family
  Can be considered a marker of 
polysensitisation
Grasses Cupressaceae
Brassicaceae
Oleaceae
Solanaceae
FabaceaeAmaranthaceae
Urticaceae
Asteraceae
Fagales
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prevalence of sensitisation minor allergens. In Table 
87 are described the percentage of sensitisation to 
different polcalcins in patients with pollen allergy. 
Barber et al. (10) described that patients who were 
simultaneously sensitized to polcalcins and profilins, 
there was a duplication both in the number of 
sensitizations to major allergens and in the years of 
disease evolution. Similar findings were obtained 
by Orovitg et al. (11). Presence of IgE positivity to 
polcalcin in patients with pollen allergy is not a 
contraindication for AIT prescription. Otherwise, 
minimal quantity of polcalcin is present in commercial 
preparations for immunotherapy, thus making the 
treatment ineffective regarding this selected allergen.
Figure 5
Diagnostic algorithm for patients polysensitized to pollen
Polysensitization to 
pollen
Seek for:
- Allergens specific of primary 
sensitisation
- Panallergens (profilin & 
polcalcin)
+ to allergenes specific of primary 
sensitisation
+ to polcalcin: more intense and longer 
duration of sensitisation to pollen
Table 3
Prevalence of polcalcin sensitisation in patients with pollen allergy
Main Sensitisation 
of the Population 
Studied
Prevalence of sensitisation 
to Polcalcins Reference
Birch Bet v 4= 5% (1)
Chenopodium/Salsola Che a 3= 46%; Che a 3= 41% (8, 13)
Olive Ole e 3=20-30% (11, 14)
Grass Phl p 7= 2- 10% (11, 15, 16) 
Alnus Aln g 4= 18% (17)
Robinia pseudoacacia Che a 3= 33% (12)
Ash Fra a 3= 16% (7)
Cupresus/Cypress Cup a 4= 10% (18)
Polysensised to pollen Polcalcin= 31% (19)
CLINICAL MANAGEMENT
Polcalcins are only expressed in pollen, thus there is 
no connection with food allergy. It is considered as 
a panallergen and therefore could be a confounding 
factor in the diagnosis of polysensitized pollen-
allergic patients and may lead to a diagnosis of 
“allergy mirages” (12) (Fig. 5). Can also be considered 
a marker of a longer duration of sensitisation and of 
a more severe respiratory disease. Polcalcins are not 
commercially available for SPT, however, in some 
research articles an extract derived from palm pollen, 
which was prepared by ALK (Madrid, Spain) was used. 
For specific IgE determinations there are currently 
only two polcalcins available; Phl p 7 and Bet v 4.
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CLINICAL CASE
Case 1
Clinical History: Male, 26 years, with a 10-year 
history of rhinitis and asthma during spring. No 
complaint of adverse reaction to food.
Test with extracts: Skin prick test showed positive 
reaction to grass, olive, cypress, plantago. Due 
to extent polysensitisation to pollen a molecular 
diagnosis was performed before to give an 
indication for immunotherapy.
Test with molecules: Specific IgE was positive Phl p 
1, Phl p 5, Phl p 12, Phl p 7 and negative to Ole e 
1, Cup a 1, Pla l 1.
Conclusion: Results indicate a primary sensitisation 
only to grass pollen and panallergens (profilin 
and polcalcin), which confirm a longer duration 
of the respiratory symptoms and the severity of 
the disease. Immunotherapy with a grass pollen 
extract was prescribed.
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Common tertiary structure with low 
sequence identity among family members
Cross-reactive sub-group with high 
sequence identity
Airborne, easily spreading into indoor 
environment
Risk factor for respiratory symptoms and 
asthma
Impact of individual molecules on severity 
of symptoms is still unknown
THE PROTEIN
Equ c 1, the major allergen of horse, was one 
of the first lipocalins to be isolated, cloned and 
characterized (Table 1) (1). The determination of its 
three-dimensional structure classified it as lipocalin 
(Fig. 1) (2). Equ c 1 was found to have surfactant 
properties; it lowers the surface tension of liquids 
and could play a role in sweat evaporation. Equ c 
1 purified from horse sweat contains oleamide, an 
endogenous bioactive substance, as well as other 
small organic molecules. The physiological role of 
Equ c 1 is still under investigation.
Horse allergens are readily detectable in stables (3). 
However they disperse poorly in the air as allergens 
are not detectable beyond 50 m from the stable. 
They stick to clothes and are readily transported 
home or to public places. They are detectable in 
classrooms when many children have regular contact 
with horses.
The characterization of B and T cell epitopes is still 
under investigation and no strategies have been 
developed so far for immunotherapy.
Christiane Hilger
LIPOCALINS
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THE FAMILY
The majority of the mammalian allergens are 
lipocalins (4) (Table 2). Lipocalins are proteins that 
are ubiquitous; they are present also in arthropods, 
plants and bacteria, and have very diverse functions. 
They are characterized by a common tertiary 
structure composed of a central β-barrel formed of 
eight anti-parallel β-strands. The internal binding 
pocket carries small hydrophobic molecules such 
as retinol, steroids, pheromones and odorants. 
Mammalian allergens isolated so far are mostly 
odorant and pheromone binding lipocalins. Only few 
natural ligands have been characterized. Lipocalin 
Figure 1
Ribbon model of the three-dimensional struc-
ture of Equ c 1 (PDB 1EW3). N-terminal end in 
red, C-terminal end in purple.
Table 1
Basic protein characteristics of Equ c 1
Protein characteristics
Allergen source Equus caballus, horse
Protein family lipocalin
UniProtKB accession 
No Q95182
Three dimensional 
structure available yes
Molecular structure mainly beta-sheet
Theoretical molecular 
weight 20.097 kDa
Molecular weight 
measured by mass 
spectrometry
22.0 kDa
Length 187 amino acids, mature protein 172
Ligand binding yes
Dimerization homodimer
Glycosylation yes 
Disulfide bonds 1
Isoelectric point 4.51
Synthesis
Sublingual gland, low levels in 
submaxillary gland and liver, 
secreted
Distribution fur, saliva, urine
Textbox 1
Lipocalin Family Characteristics
  Common tertiary structure with central 
barrel
  Divergent sequences with low identity
  Sub-group with high sequence identity
  Small secreted molecules of 16-25 kDa
  Airborne, easily spreading into indoor 
environment allergens are present in dander, saliva and urine. 
They stick to particles and become easily airborne 
and transported to public places such as schools or 
day-care centres (3-5).
Lipocalins are small, secreted molecules of 150-250 
amino acids. Despite their highly conserved structure, 
they display little sequence identitiy, usually between 
20 and 30%. Therefore lipocalins were considered as 
species-specific allergy markers. The further isolation 
of new allergen molecules showed that some lipocalins 
have much higher sequence identities, which can be 
as high as 67%. In inhibition studies they were able 
to cross-react at low doses (6-8). Representatives of 
this cross-reactive group are Equ c 1, Fel d 4 and Can 
f 6. However, even between molecules of low general 
sequence identity such as Fel d 4 and Can f 2 (25% 
identity), single epitopes may have short stretches 
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of sequence identity and lead to patient-dependent 
IgE-cross-reactivity (9). Can f 4 has been reported to 
show some cross-reactivity with a putative bovine 
allergen with both molecules sharing only 37% of 
sequence identity (10).
Table 3 displays two-by-two comparisons of amino 
acid identities between a subgroup of lipocalins. All 
pairs with a high sequence identity are potentially 
cross-reactive. The challenge of further studies is 
to analyze which lipocalins are adequate species-
specific markers and which are markers of cross-
reactivity. Sequence alignments are good primary 
prediction tools for cross-reactivity, but most 
importantly the use of IgE-inhibition studies with 
sera from clinically well-characterized patients will 
allow defining clinically relevant cross-reactivity.
A comparison of the surfaces of some members 
of the cross-reactive lipocalin subgroup visualizes 
potential cross-reactive B cell epitopes (Fig. 2A). In 
contrast, an analogous surface representation of a 
non-cross-reactive group of lipocalins shows a very 
limited epitope cross-reactivity (Fig. 2B).
The objective of further studies will be the 
identification of marker molecules for each animal 
species in order to clearly identify the sensitizing 
allergen source. Fig. 3 shows documented as well as 
putative cross-reactive molecules.
Table 2
Bos d 5-homologous allergens from animals
Animal 
family Allergen source Allergen
Bovidae Domestic cattle  (Bos domesticus)
Bos d 2
Bos d 5
Canidae Dog (Canis familiaris)
Can f 1
Can f 2
Can f 4
Can f 6
Cavidae Guinea-pig (Cavia porcellus)
Cav p 1
Cav p 2
Cav p 3
Cav p 6
Cricetidae Golden hamster (Mesocricetus auratus) Mes a 1
Equidae Domestic horse (Equus caballus) Equ c 1Equ c 2
Felidae Cat (Felis domesticus) Fel d 4Fel d 7
Leporidae Rabbit (Oryctolagus cuniculus) Ory c 1Ory c 4
Muridae
Mouse (Mus musculus) Mus m 1
Rat (Rattus norvegicus) Rat n 1
Table 3
Amino acid identities (%) between lipocalins with high sequence identity
Equ c 1
Fel d 4 67
Fel d 7 26 20
Can f 1 28 26 62
Can f 6 57 67 25 26
Cav p 6 48 53 24 24 53
Mus m 1 46 49 22 21 47 45
Ory c 4 52 63 25 24 58 49 51
Rat n 1 47 55 24 23 52 50 64 54
Equ c 1 Fel d 4 Fel d 7 Can f 1 Can f 6 Cav p 6 Mus m 1 Ory c 4 Rat n 1
Blue shaded areas indicate lipocalin pairs with >50% amino acid sequence identity, figures in bold blue indicate documented IgE-cross-reactivity 
between lipocalins 
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CLINICAL RELEVANCE
All mammalian lipocalin allergens are respiratory 
allergens, with the exception of the β-lactoglobulins 
(e.g.Bos d 5), which are present in milk (4). They are 
major allergens of different furry pets and are shed 
into the environment by animal dander and secretions. 
They stick to clothes and human hair and are passively 
transferred to public places (3). Allergens quantified 
in airborne dust in schools have been shown to attain 
levels that are able to sensitize children or to even 
stimulate asthma exacerbations. Up to 50% of the 
households in industrialized countries have a pet. 
Twenty-four percent of European households have 
a cat, 25 % have a dog and about 6-8% own a small 
mammal. Particularly families with children more 
frequently own a pet.
Allergy to furry animals is considered a risk factor 
for development of asthma (12). The role of single 
allergen molecules as markers of severe or mild 
disease has not yet been investigated in detail. A 
multi-sensitization to several components (lipocalin, 
Figure 2
Surface representation of lipocalin comparisons A). Comparison of the cross-reactive lipocalin group from 
horse (Equ c 1), cat (Fel d 4), and dog (Can f 6). Surface representation of Equ c 1 (1EW3) colored by 
sequence conservation with Fel d 4, Can f 6. (figure kindly provided by Frontiers in Immunology (11) ) B) 
Comparison of non-cross-reactive lipocalins from dog (Can f 1, Can f 2, Can f 4). Surface representation 
of Can f 2 (3L4R) colored by sequence conservation with Can f 1 and Can f 4. Sequence conservation 
was calculated by Consurf (16). The highly variable sequence conservation was identified as deep blue, 
the average was in white and the conserved sequences are denoted in deep red (Figure provided by K 
Arumugam, Luxembourg Institute of Health).
Textbox 2
Clinical relevance
  Up to 50% of households have a pet
  Risk factor for respiratory symptoms and 
asthma
  Impact of individual molecules on severity of 
symptoms is still unknown
  No molecule based therapeutic approach 
available
kallikrein, secretoglobin) seems to be associated 
with increased bronchial inflammation in severe 
asthmatics. In cat-, dog- or horse-allergic children, 
sensitization to Can f 2 and Equ c 1 was more 
common in severe than in controlled asthma (13).
For the moment, the best treatment seems to be 
allergen avoidance. However this is not always 
feasible as it is often difficult to get accepted by 
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the patients. In addition, as pets are kept in many 
households, severely allergic patients might get 
socially excluded if trying to avoid allergens. The 
only immunotherapies currently available are made 
of animal dander extracts. Results of subcutaneous 
immunotherapy (SCIT) have shown a benefit in cat-
allergic patients with asthma and rhinoconjunctivitis. 
Results for dog SCIT are less convincing. A number of 
experimental therapies using peptides or recombinant 
designer molecules are being developed for Fel d 1 
(14). Before being able to develop analogous lipocalin 
vaccine reagents, much more research has to be 
done to determine the relevant molecules and their 
epitopes.
Figure 3
Cross-reactivities among allergenic lipocalins based on sequence identity. Lines represent documented 
IgE-cross-reactivity, dotted lines represent potential IgE-cross-reactivity based on high sequence identities.
CLINICAL MANAGEMENT
A careful record of the clinical history such as the 
presence of pets at home or regular pet contact is of 
great value. Skin prick test or specific IgE using animal 
dander will confirm animal sensitization. As animal 
dander contains cross-reactive molecules such as 
serum albumins, some of the cross-reactive lipocalins 
and potentially other cross-reactive molecules, it is 
important to define the primary allergenic source, 
especially if a specific immunotherapy is intended. 
Co-sensitization has to be distinguished from cross-
sensitization. It is important to acknowledge that IgE-
cross-reactivity may not always imply clinical cross-
reactivity.
Fel d 4
Fel d 7
Can f 1
Can f 6
Mus m 1
Rat n 1
Cav p 6
Ory c 4
Equ c 1
Bos d 2
Bos d 5
Mes a 1
Cav p 2
Cav p 3
Can f 2
Can f 4
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At the current state of the art, Fel d 1, Can f 1, Can 
f 2 and Can f 5 are commercially available species-
specific markers of sensitization. Equ c 1 may cross-
react with Fel d 4 and Can f 6, Mus m 1 may cross-
react with Rat n 1. If the clinical history does not allow 
a clear identification of the sensitizing animal, the 
following decision tree (Fig. 4-6) will help to orient 
the use of components. Unfortunately the number 
of commercially available components is still limited. 
The coverage is rather good for cat and dog, but only 
two cross-reactive molecules, Equ c 1 and Equ c 3, 
are available for horse and no molecules are available 
for component-resolved diagnosis of small furry pets.
CLINICAL CASES
Case 1 (published (15))
Clinical history: A 24-year-old man presented at the 
clinic with a 14-year history of rhinitis and asthma 
when exposed to horses and a 2 years history of 
rhinitis when exposed to dogs.
Test with extracts: Specific IgE to horse dander were 
elevated (92 kUA/L), they were moderate to dog 
(7.2 kUA/L).
Test with molecules: Specific IgE were detected to 
Equ c 1 (18 kUA/L). All commercially available dog 
allergens (Can f 1, 2, 3, 5) were negative. However 
IgE to Can f 6 were clearly positive (3.7 kUA/L). 
Inhibition assays showed that IgE-recognition of 
Can f 6 could be totally inhibited by low doses of 
Equ c 1.
Conclusion: In this particular case, clinical symptoms 
to dog were due to cross-reactivity of Can f 6 with 
Equ c 1.
Case 2 (published (7))
Clinical history: A 30-year-old women had asthma 
upon exposure to her cat.
Figure 4
Added value of the use of single allergens in the case of a positive IgE test to cat dander.
Figure 5
Added value of the use of single allergens in the case of a positive IgE test to dog dander.
Cat dander
Fel d 1 +
Fel d 2/4 -
Fel d 1 +
Fel d 2/4 +
Fel d 1 -
Fel d 2/4 +
Primary sensitization to cat
Cross-sensitization to cat
Check for primary source
Primary sensitization to cat, 
potentially cross-sensitization or co-
sensitization to other animal
Can f 1/2/5 -
Equ c 1+
Primary sensitization to dogCan f 1/2/5 +Equ c 1+/-
Primary sensitization to horse
Dog dander
Can f 1/2/5 +
Can f 3/6 -
Can f 1/2/5 +
Can f 3/6 +
Can f 1/2/5 -
Can f 3/6 +
Primary sensitization to dog
Cross-sensitization to dog
Check for primary source
Primary sensitization to dog, 
potentially cross-sensitization or co-
sensitization to other animal
Fel d 1-
Equ c 1 +
Primary sensitization to catFel d 1+Equ c 1 +/-
Primary sensitization to horse
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Figure 6
Added value of the use of single al-
lergens in the case of a positive IgE 
test to horse dander.
Figure 7
Diagnostic procedure for case 1.
Horse dander
Could be primary sensitization 
to horse or cross-reactivity to 
other animals
IgE to different horse allergen, but 
primary source or
Cross-reactive allergen in dander
Check for primary sensitization source
Equ c 1 +
Equ c 1 -
Primary sensitization to dogCan f 1/2/5 +
Primary sensitization to catFel d 1 +
Fel d 1 -
Can f 1/2/5 -
Primary sensitization to horse
Primary sensitization to dogCan f 1/2/5 +
Primary sensitization to catFel d 1 +
Fel d 1 -
Can f 1/2/5 -
Primary sensitization to horse
Horse dander 
92 KUA/L
Could be primary sensitization 
to horse or cross-recativity to 
other animals
Equ c 1 +
Equ c 1 -
Primary sensitization to dogCan f 1/2/5 +
Primary sensitization to catFel d 1 +Fel d 2/4 +
Fel d 1 -
Can f 1/2/5 - Primary sensitization to horseCross-sensitization to cat or dog
Can f 6 +
Test with extracts: Specific IgE were positive for cat 
(>100 kUA/L) and dog dander (9 kUA/L).
Test with molecules: The patient had specific IgE 
against Fel d 1 (51 kUA/L) and Fel d 4 (51 kUA/L), but 
Fel d 2, Can f 1, Can f 2 and Can f 3 were negative. 
Specific IgE to the cross-reactive Can f 6 were 18 
kUA/L. These could be completely inhibited by Fel 
d 4, suggesting cat as the primary allergen source.
Conclusion: Specific IgE were positive to cat and 
dog, but the presence of specific IgE to the marker 
allergen Fel d 1 as well as the absence of specific 
IgE to Can f 1 or Can f 2 confirmed that cat was 
the primary allergen source and that Can f 6 was a 
IgE-cross-reacting allergen in dog.
Figure 8
Diagnostic procedure for case 2.
Cat dander  
> 100 KUA/L
Fel d 1 +
Fel d 2/4 +
Primary sensitization to cat, 
potentially cross-sensitization 
to other animal. Check for co-
sensitization to dog. Can f 1/2/5 -
Can f 6 +
Co-sensitization to dogCan f 1/2/5 +
Cross-sensitization to dog
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Case 3 (published (830))
Clinical history: A 53-year-old man presents with 
respiratory symptoms upon exposure to cat and dog.
Test with extracts: Specific IgE were positive for cat 
(65 kUA/L) and dog dander (68 kUA/L)
Test with molecules: The patient had specific IgE 
against Fel d 1 (35.8 kUA/L), Fel d 2 (0.7 kUA/L), Fel 
d 4 (45 kUA/L), Can f 1 (26 kUA/L), Can f 2 (13.5 
kUA/L), Can f 3 (0.2 kUA/L) and Can f 6 (33 kUA/L).
Conclusion: The presence of IgE to the specific markers 
Fel d 1, Can f 1 and Can f 2 argues for co-sensitization 
of cat and dog. Inhibition and cross-inhibition studies 
with Can f 6 and Fel d 4 showed weak inhibition, 
confirming the hypothesis of co-sensitization. 
Allergen nomenclature: Fel d 1, cat uteroglobin; Can 
f 1, Can f 2, Can f 6, Equ c 1, Fel d 4, dog, horse and 
cat lipocalins; Can f 3, Fel d 2: dog and cat serum 
albumins; Can f 5, dog kallikrein.
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THE PROTEIN
In the early seventies, Gad c 1 was the first 
parvalbumin identified as major fish allergen in Baltic 
cod. Subsequent cloning and biomolecular studies 
were performed with the parvalbumin Gad m 1, the 
homologue allergen from Atlantic cod (Table 1) (1). 
Currently, two isoallergens are listed in the allergen 
nomenclature database, Gad m 1.01 and Gad m 1.02. 
Each isoform has been characterized as two isoforms 
of high sequence homology. The protein structure of 
cod parvalbumin was first modeled on the basis of 
the x-ray structure from carp parvalbumin. Recently, 
the NMR-based protein structure was published 
revealing important characteristics on the folding 
and stability of parvalbumins (2). Gad m 1 has a six 
α-helical protein fold which is a common feature of 
parvalbumins (Fig. 1).
Gad m 1 was identified as the major allergen in cod 
muscle. However, food allergy to codfish might be 
also caused by other allergens, such as Gad m 2 (cod 
enolase) and Gad m 3 (cod aldolase) (3).
Cod parvalbumin is mainly found in fish muscle. It is a 
highly stable protein of low molecular weight (10–12 
kDa) binding Ca2+-ions (or Mg2+-ions) via two peptide 
Parvalbumins are members of the Ca2+-binding 
EF-hand family.
Clinical cross-reactivity is explained by highly 
conserved parvalbumin IgE epitopes.
Monosensitized patients might have IgE to 
species-specific epitopes.
Parvalbumins are food and respiratory allergens.
Parvalbumins are fish panallergens.
Parvalbumins resist to food processing.
Perform skin testing with cod and salmon muscle
Be aware that a false negative result might be 
obtained with dark fish muscle!
Test specific IgE to cod and salmon extract
Test specific IgE to cod and carp parvalbumin
C08
Annette Kuehn, Lars K. Poulsen, Martine 
Morisset
PARVALBUMINS
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loops called EF-hand motifs (4). It is involved in the 
regulation of the intracellular calcium concentration 
during muscle relaxation.
As for all bony fishes, cod has two types of muscles, 
the light and dark tissue differing by their physiological 
function. Cod belongs to the whitefishes having mainly 
light muscle tissue and only a small strip of dark tissue 
under the fish skin. Parvalbumins are commonly found 
in the light muscles but not in the dark muscles such as 
described for tuna (5). The allergen level in cod is up to 
2 mg parvalbumin per g of muscle tissue (6).
B cell epitopes have been analyzed for cod parvalbumin 
(1, 7). Several regions seem to be involved in the 
antigen-antibody interaction. A correlation was found 
between the severity of the allergic reaction and the 
number of epitopes. Allergic patients recognizing 
ten IgE-binding peptides including an important 
C-terminal epitope had more severe reactions than 
others. It was concluded that the number of linear 
epitopes should serve as a marker for the severity of 
the allergic reaction. A strategy for immunotherapy 
using hypoallergenic parvalbumins, including cod 
parvalbumin, is under development but it is not yet 
available for clinical practice (8). So far, successful oral 
immuntherapy for allergy to cod has been reported for 
patients treated with boiled fish (9).
THE FAMILY
Based on their protein characteristics, parvalbumins 
are attributed to two different phylogenetic origins, 
the α- and the β-lineage (10). Both subtypes can be 
found in different organs (central nervous system, 
endocrine tissue) but the highest expression rates 
have been determined in muscles (11). Muscles from 
mammals and birds express α-parvalbumins, which 
are considered as non-allergenic proteins.
Parvalbumins of the β-subtype have been characterized 
as panallergens in fish muscle (10). They belong to 
the EF-hand protein family comprising important 
allergens from both animal and plant origin (see also 
chapter ‘Polcalcins’). These proteins share conserved 
domains consisting of Ca2+-binding peptide loops 
flanked on both sides by α-helices. These structures 
Figure 1
Three-dimensional structure of Gad m 1 (PDB 
2MBX). Two Ca2+-molecules are bound to two 
functional EF-hand motifs.
Table 1
Basic protein characteristics of Gad m 1.
Protein characteristics
Allergen source Gadus morhua, Atlantic cod 
Protein family parvalbumin
UniProtKB accession 
No Q904L0
Three dimensional 
structure available yes
Molecular structure alpha-helical structure
Theoretical molecular 
weight 11.55 kDa
Molecular weight 
measured by mass 
spectrometry
11.36 kDa
Length 109 amino acids
Ligand binding yes (Ca2+, Mg2+)
Dimerization dimer, oligomer
Glycosylation no
Disulfide bonds no
Isoelectric point 4.58
Synthesis muscle tissue, cytosolic protein
Distribution muscle, swimbladder
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are called EF-hand motif as both α-helices are 
arranged like the thumb and the forefinger of a hand. 
Fish parvalbumins have three EF-hand motifs (AB, CD, 
EF) whereas only the CD- and EF-sites are functional 
and bind divalent ions (Ca2+, Mg2+). Parvalbumin 
structures rearrange globally upon ion-binding and 
release. The ion-binding is essential for the stability 
of parvalbumins. Ca2+-depleted parvalbumins bind 
only weakly IgE-antibodies from fish-allergic patients 
(11, 12). Therefore, the functional calcium-binding 
motifs (CD, EF) have been suggested as important 
conformational B cell epitopes.
Allergens from the parvalbumin family have been 
identified and characterized in a number of fishes 
(1). Homologs from 12 species have been validated 
and included in the official allergen nomenclature 
database (www.allergen.org). Detailed data on 
molecular and allergenic properties are available 
for parvalbumins from fishes, which are commonly 
consumed in Europe such as cod, salmon, mackerel 
and tuna. The most important representatives of the 
parvalbumin family are summarized in Table 2.
Parvalbumins are small cytosolic molecules of 
107-110 amino acids (1). Several but mostly two 
isoallergens can be found in the same fish muscle 
such as for salmon, cod and carp. These allergens 
were named β1- and β2-parvalbumins sharing 
a sequence identity of 64 %, 72 % and 84 %, 
respectively. Not all isoforms are necessarily included 
in the official allergen nomenclature database. Table 
3 illustrates pairwise comparisons of amino acid 
identities between parvalbumins from different 
fishes, which are commonly consumed in Europe. 
Identities highlighted in blue have been shown to be 
IgE cross-reactive molecules in in-vitro studies. This 
comparison shows that sequence homologies vary 
over a broad range. However, IgE cross-reactivity 
has not been only reported for highly similar (98 
% identity) but even more distantly related fish 
parvalbumins (63 % identity). This complies with 
Table 2
Gad m 1-homologous allergens from fishes. 
Taxonomic order Allergen source Allergen
Clupeiformes
Herring (Clupea harengus) Clu h 1*
Pilchard (Sardinops sagax) Sar sa 1*
Cypriniformes
Carp (Cyprinus carpio) Cyp c 1*
Anchovy (Engraulis encrasicolus) Eng e 1
Gadiformes
Atlantic/Baltic cod (Gadus morhua/callarias) Gad m 1/Gad c 1*
Hake (Merluccius merluccius) Mer mr 1
Pollock (Theragra chalcogramma) The ch 1
Perciformes
Barramundi (Lates calcarifer) Lat c 1*
Mackerel (Scomber scombrus) Sco s 1
Swordfish (Xiphias gladius) Xip g 1*
Tuna (Thunnus albacares) Thu a 1*
Pleuronectiformes
Megrim (Lepidorhombus whiffiagonis) Lep w 1*
Sole (Solea solea) Sol so 1
Salmoniformes
Char (Salvelinus fontinalis) Sal f 1
Rainbow trout (Oncorhynchus mykiss) Onc m 1*
Salmon (Salmo salar) Sal s 1*
Scorpaeniformes Redfish (Sebastes marinus) Seb m 1*
*www.allergen.org
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the fact that the global protein structures are highly 
conserved and argues for common conformational 
B-cell epitopes (11).
Fish parvalbumins are highly cross-reactive 
molecules, anti-parvalbumin IgE-antibodies recognize 
often homologs from different fishes supporting 
the fact that fish-allergic patients often react to 
multiple fishes (see chapter ‘Fish allergy’) (12). The 
molecular basis for this high IgE cross-reactivity is 
the remarkable structural homology, especially in 
the ion-binding regions. The surface comparison 
of selected cross-reactive fish allergens visualizes 
potential conformational B cell epitopes common 
to most parvalbumins (Fig. 2). However, a number 
of patients react only to specific or single fishes. 
Tolerance of single species might be explained by very 
low allergen contents such as for tuna (6). Another 
reason for this clinical mono-/oligo-sensitivity are 
species-specific IgE-binding epitopes present on 
parvalbumins (13, 14). Studies on monosensitivity to 
salmon/trout confirmed the presence of a salmonid-
Table 3
Amino acid identities (%) between parvalbumins from cod, carp, salmon, trout, herring, mackerel, tuna and 
whiff
Gad m 1*
Cyp c 1* 80
Sal s 1* 64 64
Onc m 1* 65 65 98
Clu h 1* 75 72 72 73
Sco s 1 72 76 64 65 75
Thu a 1 77 88 67 68 74 70
Lep w 1 63 68 63 65 63 69 69
Gad m 1* Cyp c 1* Sal s 1* Onc m 1* Clu h 1* Sco s 1 Thu a 1 Lep w 1
blue, documented IgE cross-reactivity; bold, > 80 % amino acid sequence identity; * β1-isoform used for comparison
Figure 2
Surface comparisons of three different cross-reactive parvalbumins (based on PDB 2MBX, sequence con-
servation determined using ConSurf tool). A. cod Gad m 1, B. salmon Sal s 1, C. tuna Thu a 1; colors 
according to protein identity between depicted parvalbumin and the two others: blue, variable; white, 
average; red, conserved.
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specific parvalbumin epitope, which is unique for 
these fish allergens (Fig. 3).
Fig. 4 represents documented and putative cross-
reactivities among known fish parvalbumins. 
Recently, new fish allergens have been characterized 
(see chapter ‘Fish allergy’). Fish beta-enolases and 
aldolases were identified as food allergens in cod 
(Gad m 2, Gad m 3), salmon (Sal s 2, Sal s 3) and tuna 
(Thu a 2, Thu a 3) (Fig. 4) (3). Future studies will have 
to address the characterization of selective marker 
molecules, parvalbumins and the new fish allergens, 
for IgE-based diagnosis to discriminate between 
patients with clinical cross-reactivity and fish species-
specific sensitization.
Figure 3
Surface comparisons of non cross-reactive parvalbumins in salmonid-monosensitized patients (based on 
PDB 2MBX, sequence conservation determined using ConSurf tool). A. cod Gad m 1, B. salmon Sal s 1, 
C. trout Onc m 1. Yellow, Ca2+-binding sites; red, species-specific epitope.
Figure 4
Cross-reactivities among allergenic fish parvalbumins. All parvalbumins have a high potential for cross-re-
activity based on high sequence homology. Lines represent documented IgE-cross-reactivity. Clockwise: 
cod, salmon, trout, pollack, tuna, carp, mackerel, herring, whiff, sole.
Gad m 1
Sol so 1
Lep w 1
Clu h 1
Sco s 1
Cyp c 1
Thu a 1
The c 1
Onc m 1
Sal s 1
Gad m 2
Gad m 3
Sal s 2
Sal s 3
Thu a 1
Thu a 3
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CLINICAL RELEVANCE
Beta-parvalbumins are present in the fish muscle and 
skin but they become airborne upon handling and 
processing of fish (1). As such, they are both food and 
respiratory allergens. Fish allergy is both important 
in the domestic and occupational environment. 
Incidental episodes might occur upon inhalation 
of volatile allergens during fish preparation in the 
domestic environment. These allergenic molecules 
can even be found in unexpected environments 
such as mattress dust. Respiratory problems of the 
upper and lower airway tract have been reported in 
the occupational context among workers processing 
fish (15). A clear correlation has been shown for 
the development of work-related asthma and fish 
allergy as explained by high atmospheric fish allergen 
concentrations in the workplace.
Studies estimated that less than 1 % of the general 
population suffers from an allergy to fish (see chapter 
‘Fish allergy’) (11). Children often maintain their 
sensitization to fish during adolescence. Fish allergy 
is more frequent in countries with large coastal 
regions characterized by frequent fish consumption 
and settling of fish-processing industries. Concerning 
the prevalence of specific IgE to parvalbumins in fish-
allergic patients, it was stated for a long time that 
more than 90 % are sensitized to this panallergen. 
According to results of recent studies, this prevalence 
seems to be considerably lower but it still requires 
further investigations for a better understanding (3).
The main route of sensitization to fish parvalbumins 
is by oral ingestion, thus by uptake through the 
gastrointestinal tract. Common clinical manifestations 
include mild (oral allergy syndrome, erythema) to 
moderate (urticaria, vomiting) or severe (angioedema, 
asthma, anaphylaxis) symptoms (1, 11). Sensitized 
patients with antacid medication are at higher risk to 
develop severe reactions than others.
A key feature of potent food allergens is their 
stability to thermal treatment. Fish parvalbumins 
are extremely heat-stable and therefore, they are 
still detectable in products processed by cooking, 
frying or in pickeled food (6). This emphasizes their 
undiminished allergenicity upon various preparation 
methods. Fish parvalbumins become glycosylated 
by heating in the presence of glucose through the 
Maillard reaction (16). However, the resulting effects 
on their allergenic potency, be it cumulative or 
diminishing, still require further investigations.
Currently, there is no causal therapy available to 
treat allergic sensitization to fish parvalbumins. The 
therapeutic desensibilization with increasing doses of 
fish is disadvised as the risk for anaphylactic reactions 
is important. A strict avoidance diet is recommended 
to fish-sensitized patients. According to established 
EU-labeling regulations, fish has to be indicated 
specifically with an allergy hazards note on the 
product of each commercial food product (guideline 
2007/68/EG). Caution is advised with loose items 
and products from fish origin (fish gelatin), which 
might be contaminated with fish allergens. Another 
perspective for the future treatment of fish allergy is 
the development of hypoallergenic parvalbumins (8). 
Low IgE-bindings mutants have been first identified 
for carp parvalbumin and later on, further developed 
for homologue allergens from commonly consumed 
fish allergens. This therapeutic strategy is currently 
under investigation by an EU-funded project 
targeting the immunemodulatory efficiency of these 
hypoallergenic mutants.
CLINICAL MANAGEMENT
The mainstay for the diagnosis of fish allergy are the 
record of the patient’s medical history, the analysis 
of the skin reactivity using fish extracts or authentic 
food, the quantification of serum IgE-antibodies and 
in some cases, oral food challenges (see Section B12 
‘Fish allergy’). IgE-quantification assays are available 
for approx. 30 extracts from different fish species as 
well as two parvalbumins, Gad c 1 from cod and Cyp 
c 1 from carp. Newly identified fish allergens such as 
enolases (cod Gad m 2, salmon Sal s 2, tuna Thu a 2), 
aldolases (cod Gad m 3, salmon Sal s 3, tuna Thu a 3) 
or fish gelatin are still missing for IgE-testing.
Highly sensitized patients often react to various 
fishes. First, they should be tested for skin reactivity 
to cod and salmon native muscle followed by analysis 
of specific IgE-binding to cod and salmon extract. 
Second, a polysensitization to fish can be confirmed 
by detecting specific IgE to the cross-reactive 
parvalbumins from cod (Gad m 1) and carp (Cyp c 
1). Future IgE-testing for other allergens will entail a 
more specific diagnosis of these patients (Fig. 5).
However, a number of fish-allergic individuals react 
to specific fishes only (3). The challenge of future 
studies will be the identification of marker allergens 
for IgE-tests to discriminate between these poly- and 
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oligo-/mono-sensitized patients. As for now, the 
discriminative significance of anti-parvalbumin IgE-
antibodies seems to be low because they are often 
cross-reacting with various homologs which does not 
necessariliy imply a clinical reactivity. An exception 
has been reported for a subgroup of patients with 
monosensitivity to salmonid fishes. They might be 
diagnosed efficiently by determination of specific IgE 
to salmon and trout parvalbumin (see ‘Clinical case 2’) 
(13, 14). However, the positive predictive value (PPV) 
for single parvalbumins in the diagnosis of allergy to 
single fishes still needs to be defined.
Overall, allergens different from parvalbumins might 
be elicitors for fish allergy. Cod enolases and aldolases 
have been identified as responsible allergens in three 
clinical cases of monosensitivity to cod (see chapter 
‘Fish allergy’) (17). Even other allergens such as 
fish gelatin might play a role in this context (Fig. 6) 
(18). Anyway, diagnostic conclusions from in vitro 
IgE-results, especially negative results, should be 
confirmed by further oral provocation tests in case of 
a strong suspicion of a fish allergy.
CLINICAL CASES
In the clinical cases presented in this paragraph, 
following parvalbumins been included in IgE-based 
diagnostic procedures during research studies: 
salmon Sal s 1, carp Cyp c 1, cod Gad m 1, tuna Thu 
a 1, trout Onc m 1, pangasius Pan h 1, catfish Sil g 1.
Case 1 (published (3))
Clinical History: A male child, 12 years, with a 
clinical history of fish allergy since early childhood 
presenting with angioedema and respiratory 
problems upon ingestion of different fishes as well 
as with acute urticaria when touching fish.
Test with extracts: Skin tests performed with 
commercial extracts were positive for cod, salmon 
and tuna. IgE to cod, salmon and tuna extract 
were positive (16 kUA/L, 32 kUA/L and 65 kUA/L, 
respectively).
Food challenge: The parents of the child refused a 
food challenge.
Figure 5
Added value of the use of single allergens in the case of a positive IgE test to cod extract.
Figure 6
 Added value of the use of single allergens in the case of a positive IgE test to tuna extract.
Cod extract
Potentially cross-/co-
sensitization to other fishesGad m 1+
Gad m 1-
Gad m 2, Gad m 3 +
Allergy to various fishesCyp c 1, Sal s 1, Thu a 1+
Potentially primary sensitization and 
clinical monosensitivity to cod
Tuna extract
Potentially cross-/co-
sensitization to other fishesThu a 1 +
Thu a 1 -
Fish gelatin +
Allergy to various fishesCyp c 1, Gad m 1, Sal s 1+
Potentially cross-/co-sensitiza-
tion to other fishes
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Test with molecules: Cod, salmon and tuna 
parvalbumins were positive in IgE ELISA (20 
kUA/L, 18 kUA/L and 30 kUA/L, respectively).
Conclusion: The polysensitization to unlimited 
fishes was confirmed in this case by revealing 
cross-reactive IgE-antibodies to homologue 
parvalbumins from different fishes (Fig. 7).
Case 2 (published (13))
Clinical History: A female patient, 21 years, with 
a clinical history of fish allergy since childhood 
presenting with swellling of the tongue and oral 
mucosa, facial edema and vomiting minutes after 
ingestion of salmon or trout.
Figure 7
Diagnostic procedure case 1.
Figure 8
Diagnostic procedure case 2.
Figure 9
Diagnostic procedure case 3.
Cod extract
Potentially cross-/co-
sensitization to other fishesGad m 1+
Gad m 1-
Gad m 2, Gad m 3 +
Allergy to various fishesSal s 1, Thu a 1+
Potentially primary sensitization 
and clinical monosensitivity to cod
Potentially cross-/co-
sensitization to other fishes
Cyp c 1, Gad m 1, Thu a 1-
Primary sensitization and clinical 
monosensitivity to salmonoid fishesOnc m 1 +
Allergy to various fishes
Salmon extact
Sal s 1 +
Sal s 1-
Potentially cross-/co-
sensitization to other fishes
Cyp c 1
Specific sensitivity to fishes 
from the order Siluriformes
Cyp c 1 -
Sil g 1 +
Allergy to various fishes
Catfish extact
Pan h 1 +
Pan h 1 - IgE to other allergens
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Test with extracts: Skin tests performed with 
commercial extracts were positive for salmon and 
trout but negative for other fishes. Only IgE to 
salmon extract was slightly positive (0.4 kUA/L).
Food challenge: As the patient experienced 
repeatedly symptoms with salmonid fishes, she 
refused to be tested by oral provocation.
Test with molecules: As determined by IgE ELISA, 
salmon and trout parvalbumins were positive 
at 0.2-0.4 kUA/L. No inhibition assays were 
performed with other fish parvalbumins as IgE-
binding was negative for cod, carp, mackerel, 
redfish and herring homologs.
Conclusion: In this case, clinical species-specific 
sensitivity to salmonid fishes was confirmed by 
specific IgE to salmon and trout parvalbumin (Fig. 
8).
Case 3 (published (19))
Clinical History: Female patient, 36 years, presenting 
with anaphylaxis (oral itch, urticaria, angioedema, 
dizziness, hypotension) after eating a pangasius.
Test with extracts: All skin tests were negative. 
Specific IgE was not available for pangasius extract 
but it was positive for wels catfish extract (0.5 
kUA/L), a closely related species.
Food challenge: The patient refused to be tested by 
oral provocation.
Test with molecules: IgE binding was found for 
parvalbumins from pangasius, wels catfish and 
angler which could not be abolished in IgE 
immunoblot cross-inhibition assays.
Conclusion: The species-specific sensitization to 
closely related fishes from the order Siluriformes 
was confirmed by component-based IgE-testing 
using parvalbumins from this fish family (Fig. 9).
TOOLS
Fish allergens validated by the World Health 
Organization and International Union of 
Immunological Societies (WHO/IUIS) Allergen 
Nomenclature Sub-committee can be checked at 
www.allergen.org. Informations about allergen 
families such as the EF-hand family can be obtained 
from the homepage of the AllFam database (www.
meduniwien.ac.at/allergens/allfam/). Details about 
the new food labeling regulation are available at 
http://ec.europa.eu/food/food/labellingnutrition/
foodlabelling/index_ en.htm. Progress of the EU-
project FAST on hypoallergenic carp parvalbumin 
Cyp c 1 can be found at the project homepage (www.
allergome.org:8080/fast/index.jsp).
Fish allergens can be detected in authentic food 
samples using a DNA-based kit from R-Biopharm 
(http://www.r-biopharm.com/products/food-feed-
analysis/allergens/fish/item/surefood-allergen-fish).
Two books might be useful for further reading about 
clinical features of fish allergy and biomolecular 
properties of food, including fish, proteins: ‘Food 
allergy’ by James JM, Burks W, Eigenmann PA, Elsevier 
2012) and ‘Chemical and biological properties of 
food allergens’ by Jedrychowski L, Wichers HJ, CRC 
Press 2010.
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IMPORTANT 
ALLERGENIC 
MOLECULES 
AND THEIR 
CHARACTERISTICS D01
Nr Allergen Source Description Chapter
1 Act d 1 Green kiwifruit 
(Actinidia deliciosa)
This cysteine protease, actinidin is a major allergen from 
kiwifruit and points towards kiwifruit monosensitization
B15
2 Act d 8 Green kiwifruit 
(Actinidia deliciosa) 
This allergen is a PR-10 molecule (Bet v 1 homologue) from 
kiwifruit, thus cross-sensitization may occur. 
B15
C02
3 Act d 9 Green kiwifruit 
(Actinidia deliciosa) 
This allergen is a Profilin from kiwifruit. Sensitization to Act 
d 9 (and to Act d 8) is a specific condition of patients with 
pollen-kiwifruit allergies.
 B15 
C01
4 Amb a 1 Ragweed  
(Ambrosia 
artemisiifolia) 
This allergen is a marker of ragweed sensitization. Its 
biological function is that of a pectase lyase and it shows 
cross-reactivity with Art v 6 from Mugwort. 
B03
5 Amb a 6 Ragweed (Ambrosia 
artemisiifolia) 
Amb a 6, a non-specific Lipid Transfer Protein (nsLTP), is a 
specific marker for sensitization to ragweed. 
B03
C03
6 Api g 1 Celery  
(Apium graveolens)
This allergen is a PR-10 molecule (Bet v 1 homologue) from 
celery, thus cross-sensitization (up to 75%) may occur in areas 
where birch pollen is abundant. 
B15
7 Api m 1 European, western 
or common honey-
bee (Apis mellifera) 
This major bee venom allergen is recognized by up to 97% of 
the patients who show a reaction to a sting of the common 
honeybee.
B20
8 Api m 2 European, western 
or common honey-
bee (Apis mellifera) 
IgE antibodies to this hyaluronidase may cross-react with Ves 
v 2 in vespid venom, due to an identical CCD structure. 
B20
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Nr Allergen Source Description Chapter
9 Api m 10 European, western 
or common honey-
bee (Apis mellifera) 
This allergenic molecule is a specific marker protein for 
honeybee venom allergy. 
B20
10 Ara h 1 Peanut  
(Arachis hypogaea) 
Ara h 1 is a major peanut allergen with sensitization rates 
between 63% and 80%. This heat stable molecule is a Cupin 
(Vicillin-type, 7S globulin)
 B18
11 Ara h 2 Peanut  
(Arachis hypogaea) 
The heat stable peanut allergen Ara h 2 is a Conglutin (2S 
albumin). An association between sensitization to Ara h 
2 and Ara h 6 and systemic reactions to peanuts has been 
demonstrated. 
B18 
12 Ara h 3 Peanut  
(Arachis hypogaea) 
The 11S (Cupin) is a heat stable and relevant food allergen 
from peanut. Frequent cross-reactivity between Ara h 1 and 
Ara h 3 is observed.
B18
13 Ara h 6 Peanut  
(Arachis hypogaea) 
Just as Ara h 2, also Ara h 6 is a heat stable Conglutin (2S 
albumin). In the US and Northern Europe 76-96% of the 
patients with clinically relevant peanut allergy possess specific 
IgE to Ara h 2 and Ara h 6. 
B18
14 Ara h 8 Peanut 
 (Arachis hypogaea) 
This peanut allergen is a PR.10-like molecule (Bet v 1 
homologue), which is not stable to heat. IgE sensitization to 
Ara h 8, Ara h 5 and glycoproteins (CCD) are usually caused by 
cross-reactions to pollen allergens. 
B18
C02
15 Art v 1 Mugwort 
(Artemisia vulgaris) 
Art v 1 is a marker of sensitization to mugwort. It is a defensin-
like protein and shows a partial cross-reactivity with Amb a 4 
from ragweed. 
B03
16 Art v 6 Mugwort 
(Artemisia vulgaris) 
This molecule is a Pectase lyase, which shows cross-reactivity 
with Amb a 1 from Ragweed. 
B03
17 Asp f 1 Fungus 
(Aspergillus 
fumigatus) 
This Ribotoxin is the major secreted allergen causing ABPA. 
The spectrum of allergens produced by the fungus spans 
a wide variety of different molecular structures covering 
enzymes, secreted, intracellular, and structural proteins. 
B07
18 Asp f 2 Fungus 
(Aspergillus 
fumigatus) 
Asp f 2 is an ABPA-related intracellular allergen of unknown 
function. Even if further confirmatory studies are needed, it 
seems that Asp f 2 is exclusively recognized by patients with 
ABPA both, in asthma and CF. 
B07
19 Asp f 6 Fungus  
(Aspergillus fumigatus)
This phylogenetically highly conserved intracellular allergen 
shows a high degree of cross-reactivity with other fungal proteins.
B07
B08
20 Bet v 1 Birch pollen 
(Betula verrucosa) 
93% of the birch allergic individuals produce specific IgE-
antibodies to this major birch pollen allergen. Homologues 
of Bet v 1 are present in pollens from related early flowering 
trees and have also been identified in a wide range of plant 
foods. Through cross-reactivity, patients may not only suffer 
from respiratory, but also from oropharyngeal symptoms, 
coined oral allergy syndrome (OAS). 
B01
C02
21 Bet v 2 Birch  
(Betula verrucosa) 
This allergenic molecule belongs to the profilin-like 
superfamily. Profilins represent a major cause of cross-
reactivity among most plant sources due to their highly 
conserved structure and ubiquitous distribution. 
B01
C01
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22 Bla g 1 German 
Cockroach 
(Blattella 
germanica) 
The presence of Bla g 1 in fecal particles makes this molecule, 
together with Bla g 2, a good marker of cockroach allergen 
exposure. Cross-reactivity has been described between Bla g 
1 and homologous proteins (such as Per a 1, Per f 1 and Bla 
o 1) from other cockroach species, as well as allergens from 
other insects. 
B05
23 Bla g 5 German 
Cockroach 
(Blattella 
germanica) 
Bla g 5 is a sigma class glutathione S-transferase (GST), a 
major cockroach allergen, which elicits high levels in IgE 
responses among cockroach-sensitized individuals. Cross-
reactivity with GSTs of several sources has been described. 
B05
24 Bla g 7 German 
Cockroach 
(Blattella 
germanica) 
Bla g 7 belongs to the invertebrate tropomyosins, which are 
important pan-allergens among dust mites, chironomids, 
silverfish, crustaceans, nematodes and mollusks. IgE binding 
frequency to cockroach tropomyosins are very different 
in some populations, which may reflect differences in the 
environmental conditions. 
B05
C05
25 Blo t 1 Mite 
(Blomia tropicalis) 
This molecule is a mite group 1 allergen (Cysteine protease). 
Blo t 1 is a major marker of sensitization to the storage mite 
Blomia tropicalis. 
B04 
26 Blo t 2 Mite 
(Blomia tropicalis)
This molecule is a mite group 2 allergen (NPC2 protein family). 
Blo t 2 is a major marker of sensitization to the storage mite 
Blomia tropicalis.
B04
27 Blo t 10 Mite 
(Blomia tropicalis) 
Blo t 10 is a Tropomyosin from the storage mite Blomia 
tropicalis. Especially its cross-reactivity with other 
tropomyosins can be clinically relevant.
B04
C05
28 Bos d 4 Cow´s milk (whey) 
(Bos domesticus)
This alpha-lactalbumin is a major allergen from whey. B10
29 Bos d 5 Cow´s milk (whey) 
(Bos domesticus) 
This Beta-lactoglobulin belongs to the group of lipocalins. 
Therefore it may show cross-reactivity to a variety of 
respiratory allergens. It is the only cow´s milk protein that is 
not present in human breast milk. 
B10
C07
30 Bos d 6 Cow´s milk (whey) 
(Bos domesticus) 
Bos d 6 is a respiratory and food allergen as it is present in 
bovine dander, in milk and meat. Also known as Bovine Serum 
Albumin (BSA) it is classified as minor allergen in animal 
dander, but is an important meat and milk allergen in the case 
of uncooked food ingestion.
B10/
B14
C04
31 Bos d 8 Cow´s milk (curd) 
(Bos domesticus) 
IgE to Casein (Bos d 8) can be found in 53% of the patients 
reactive to cow´s milk. High levels of specific IgE antibodies 
directed against casein are predictive of clinical reactivity to 
baked milk as it is more resistant to extensive heating than 
other allergenic proteins. Due to the heterogeneity to the 
casein fraction it has been further split into Bos d 9 – Bos d 12. 
B10
32 Bos d 9 Cow´s milk (curd) 
(Bos domesticus) 
This allergen represents the alphaS1- casein fraction from 
whey and is regarded as a major food allergen. 
B10
33 Bos d 10 Cow´s milk (curd) 
(Bos domesticus) 
This allergen represents the alphaS2-casein fraction from 
whey and is regarded as a major food allergen. 
B10
 EAACI Molecular Allergology User´s GuideEAACI Molecular Allergology User´s Guide2016 Appendices
368 Important Allergenic Molecules and their Characteristics
Nr Allergen Source Description Chapter
34 Bos d 11 Cow´s milk (curd) 
(Bos domesticus) 
This allergen represents the beta-casein fraction from whey 
and is regarded as a major food allergen. 
B10
35 Bos d 12 Cow´s milk (curd) 
(Bos domesticus) 
This allergen represents the kappa-casein fraction from whey 
and is regarded as a major food allergen. 
B10
36 Can f 1 Dog 
(Canis familiaris) 
This major dog allergen (sensitization rate: 50-76%) is a 
species-specific marker of sensitization. Moreover, the 
sensitization during childhood has been shown to be a 
predictive marker of dog allergy in adolescence. Can f 1 is 
a Lipocalin, synthesized in the salivary glands and dispersed 
into the environment by saliva and dander. It has a moderate 
risk of cross-reactivity with Fel d 7. 
B06
C07
37 Can f 3 Dog 
(Canis familiaris) 
This thermolabile protein is a serum albumin that has a high 
risk of cross-reactivity with other serum albumins. 
B06
C04
38 Can f 6 Dog 
(Canis familiaris) 
This major dog allergen is a Lipocalin, synthesized in salivary 
glands and dispersed into the environment by saliva and 
dander. It has a moderate risk of cross-reactivity with Fel d 
4 and Equ c 1. 
B06
C07
39 Che a 1 Goosefoot 
(Chenopodium 
album) 
This Ole e 1-like protein is a marker of sensitization to 
goosefoot. It shows cross-reactivity with Sal k 5 of the 
Russian Thistle. 
B03
40 Cor a 1 Hazel (pollen and 
nuts) 
(Corylus avellana) 
This Bet v 1-related food allergen belongs to the PR-10-like 
proteins and is the major allergen in hazelnut allergy. One 
isoform is mainly found in hazel pollen (Cor a 1.01), the other 
mainly in the nut (Cor a 1.04).
B01/
B19
C02
41 Cor a 8 Hazelnut 
 (Corylus avellana) 
Cor a 8 is a non-specific Lipid Transfer Protein (nsLTP). Patients 
with a sensitization to nsLTP mainly derived from peach (Pru p 3) 
may develop cross-sensitization to other nsLTPs, such as Cor a 8.
B19
C03
42 Cor a 9 Hazelnut 
 (Corylus avellana) 
Cor a 9 is an abundant seed storage protein (11S globulin). 
IgE antibodies against this allergen are linked with objective 
symptoms for hazelnut allergy and a positive DBPCF for due 
to hazelnut 
B19
43 Cor a 14 Hazelnut 
 (Corylus avellana) 
Cor a 14 is a 2S -albumin, which belongs to the seed storage 
proteins. Severe allergic reactions to this allergenic molecule 
have been reported in children and adults. Nevertheless it 
doesn´t qualify as major allergen, as most of the hazelnut 
allergies are related to birch pollen (See Cor a 1)
 B19
44 Cross-reac-
tive carbo-
hydrate de-
terminants 
(CCDs)
Variable 
 (Plant derived) 
Cross-reactive carbohydrate determinants do not behave as 
allergens in vivo and are therefore clinically insignificant, but 
the presence of IgE to CCDs could lead to a misleading in vitro 
reactivity also in the case of extract-based testing or when 
using CCD-containing natural purified glycoproteins 
B01
45 Cup a 1 Cypress 
(Cupressus 
arizonica) 
Cup a 1 is a specific marker allergen for a sensitization to 
pollen of trees of the Cupressaceae family. The high sequence 
identity, and therefore high degree of cross-reactivity among 
Cupressaceae family members, suggests the use of Cup a 
1 as a representative marker of the entire family for both 
diagnostic testing and therapeutic approaches
 B01
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46 Cyn d 1 Bermuda grass 
(Cynodon dactylon) 
This major beta expansin group 1 allergen is a marker of 
sensitization to the subtropical Bermuda grass. 
B02
47 Cyp c 1 Common Carp 
(Cyprinus carpio) 
This major allergen in fish muscle is a parvalbumin. 
Parvalbumins are small muscle proteins of remarkable stability 
towards physicochemical effects by food processing. During 
fish preparation, they can even become airborne. Most fish-
allergic patients have specific IgE to these allergens. 
B12
C08
48 Der p 1 House Dust Mite 
(Dermatophagoides 
pteronyssinus) 
Der p 1 is a major mite allergen (Prevalence among patients: 
70-100%). As an active cysteine protease, it has been 
identified in fecal particles and is strongly associated with 
asthma. Its important role for the symptoms of rhinitis and 
asthma has been evidenced. 
B04
49 Der p 2 House dust mite 
(Dermatophagoides 
pteronyssinus) 
Der p 2 is a major mite allergen (Prevalence among patients: 
80-100%). It has been identified in fecal particles and is 
strongly associated with asthma. This molecule has activity 
comparable to MD2. 
B04
50 Der p 10 House dust mite 
(Dermatophagoides 
pteronyssinus) 
Der p 10 is a Tropomyosin from house dust mite, present in 
muscle and non-muscle cells. The tropomyosin amino acid 
sequence is highly conserved among shellfish and other 
invertebrates, which explains the high level of cross-reactivity. 
Symptoms, which may depend on ingestion or inhalation, range 
from milder reactions to anaphylaxis. HDM allergic patients in 
Europe do not show high prevalences of IgE sensitization to Der 
p 10. The observed sensitizations can be considered an effect 
of cross-reactivity, but also a marker for broad sensitization.
B04
C05
51 Der p 23 House dust mite 
(Dermatophagoides 
pteronyssinus) 
Der p 23 is a house dust mite allergen identified in the fecal 
particles and in the peritrophic lining of the gut. This recently 
described molecule is a Peritrophin like protein that appears 
to be associated with asthma. 
B04
52 Equ c 1 Horse 
(Equus Caballus) 
This major horse allergen is a species-specific marker of 
sensitization. It is a Lipocalin, synthesized in salivary glands 
and dispersed into the environment by saliva and dander. It 
has a moderate risk of cross-reactivity with Fel d 4 and Can f 
6 and is known to have surfactant properties. 
B06
C07 
53 Equ c 3 Horse 
(Equus Caballus) 
Equ c 3 is a serum albumin, a thermolabile protein synthesized 
in the liver. This allergen is present in horse dander, secretions 
and meat. It shows a high risk of cross-reactivity with other 
serum albumins. 
B06
C04
54 Fel d 1 Cat 
(Felis domesticus) 
Fel d 1, the major cat allergen, is a species-specific marker 
of sensitization. Moreover, the sensitization during childhood 
has been shown to be a predictive marker of cat allergy in 
adolescence. This molecule, whose synthesis is related to 
sexual hormones, is an uteroglobin expressed in skin and 
salivary glands. 
B06 
55 Fel d 4 Cat 
(Felis Domesticus) 
This major cat allergen is a Lipocalin, synthesized in salivary 
glands and dispersed into the environment by saliva and 
dander. It has a moderate risk of cross-reactivity with Can f 6 
and Equ c 1. 
B06
C07
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56 Gad c 1 Codfish 
 (Gadus callarias) 
The dominating major allergen in fish muscle is parvalbumin 
of which Gad c 1 was the first to be identified. Parvalbumins 
are small muscle proteins of remarkable stability towards 
physicochemical effects by food processing. During fish 
preparation, they can even become airborne. Parvalbumin 
levels vary considerably in different fish tissues and species. 
Most fish-allergic patients have specific IgE to these allergens. 
B12
C08
57 Gal d 1 Hen´s egg 
 (Gallus domesticus) 
Ovomucoid is a heat-stable and highly allergenic egg white 
protein.1 IgE responses to Gal d 1 indicate a risk for reaction 
to all forms of egg High levels of specific IgE may indicate 
sustained egg allergy. 
B11
58 Gal d 2 Hen´s egg  
(Gallus domesticus) 
Ovalbumin is the most abundant egg white protein. As it is 
heat-labile, IgE responses to Gal d 2 indicate a risk for clinical 
reaction to raw or slightly heated egg as well as certain vaccines. 
B11
59 Gal d 3 Hen´s egg 
 (Gallus domesticus) 
Ovotransferrin or conalbumin is a heat-labile egg white 
protein with iron-binding capacity and antimicrobial activity. 
IgE antibodies against Gal d 3 increase the risk for a clinical 
reaction to raw or slightly heated egg. 
B11
60 Gad m 1 Atlantic Codfish 
(Gadus morhua) 
This molecule is a parvalbumin, the dominating major allergen 
in fish muscle. Parvalbumins are small muscle proteins of 
remarkable stability towards physicochemical effects by food 
processing. Parvalbumin levels vary considerably in different 
fish tissues and species. Most fish-allergic patients have 
specific IgE to these allergens. 
B12
C08
61 Gly m 1 Soy 
 (Glycine max) 
Gly m 1 is a major respiratory allergen from soybean shells, to 
which subjects are exposed through the inhalation of soybean 
dust. Sensitization rates are still lacking. 
B17
62 Gly m 4 Soy 
 (Glycine max) 
Gly m 4, an allergen from soy, is a PR-10-like protein (Bet 
v 1 homologue) that has low thermal and digestive stability. 
Soy allergy due to Bet v 1-cross-reactions is considered the 
most prevalent soy allergy in Northern and Middle Europe, 
presumably also in the Northern parts of Asia, as well as 
in North America (Canada, Northern states of the US), 
depending on the degree of birch pollen exposure. 
B17
C02
63 Gly m 5 Soy 
 (Glycine max) 
Sensitization to Gly m 5, a vicilin (7S globulin) from soy points 
towards an increased risk for atopic dermatitis and (severe) 
food allergy to soy and related plant foods in children. 
Prevalence rates are still unknown.
B17 
64 Gly m 6 Soy 
 (Glycine max) 
Sensitization to Gly m 6, a legumin (11S globulin) from soy 
points towards an increased risk for atopic dermatitis and 
(severe) food allergy to soy and related plant foods in children. 
Prevalence rates are still unknown.
B17 
65 Hev b 1 Rubber tree 
(Hevea brasiliensis) 
Hev b 1 is a rubber elongation factor (REF) that is hard 
to aerosolize because of its insolubility. Therefore, the 
sensitization to this molecule seems to require contact with 
blood or mucosal surfaces. Sensitization to Hev b 1 is less 
common in health care workers, but it represents a major 
allergen in spina bifida patients. 
B22
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66 Hev b 3 Rubber tree 
(Hevea brasiliensis) 
Hev b 3 is a small rubber particle protein that is hard 
to aerosolize because of its insolubility. Therefore, the 
sensitization to this molecule seems to require contact with 
blood or mucosal surfaces. Sensitization to Hev b 3 is less 
common in health care workers, but it represents a major 
allergen in spina bifida patients. 
B22
67 Hev b 5 Rubber tree 
(Hevea brasiliensis) 
Hev b 5 is an acidic and heat- stable protein from rubber tree. 
Currently rHev b 5, together with rHev b 6.01, is a major allergen 
among health care workers sensitized to latex. Apart from this, 
it is represents a pajor allergen for spina bifida patients. 
B22
68 Hev b 
6.01
Rubber tree 
(Hevea brasiliensis) 
This rubber tree allergen is a Prohevein, that with 
posttranslational cleavage proceeds in two further proteins: 
Hev b 6.02 (hevein) and Hev b 6.03. Currently rHev b 6.01, 
together with rHev b 5, is a major allergen among health care 
workers sensitized to latex. Apart from this, it also represents 
a major allergen for spina bifida patients. 
B22
69 Hev b 8 Rubber tree 
(Hevea brasiliensis) 
This rubber tree allergen is a profilin (Actin –binding protein), 
that has been discussed as responsible for the latex –fruit 
cross-reactivity. 
B22
C01
70 Jug r 1 Walnut  
(Juglans regia) 
Jug r 1 is a 2S albumin and sensitization to 2S albumins from 
tree nuts including walnut can be related with more severe 
fodo allergic reactions.
B19
71 Jug r 3 Walnut  
(Juglans regia) 
Jug r 3 is a non-specific lipid transfer protein (nsLTP). Patients 
with a sensitization to nsLTP mainly derived from peach (Pru 
p 3) may develop cross-sensitization to Walnut. 
B19
C03
72 Mal d 1 Apple  
(Malus domestica) 
This allergen is a PR.10-like molecule (Bet v 1 homologue) 
from apple, thus cross-reactivity between pollen and food may 
occur. 
B15
C02
73 Mal d 3 Apple  
(Malus domestica) 
Mal d 3 is a non-specific Lipid Transfer Protein, a small 
stable protein not affected by low pH environment and 
heat treatment. Patient with a sensitization to nsLTP mainly 
derived from peach (Pru p 3) may develop cross-sensitization 
to other fruit nsLTPs. The clinical manifestations vary from 
local oropharyngeal symptoms up to anaphylaxis. The clinical 
pattern is influenced by cofactors. 
B15
C03
74 Mala s 6 Fungus 
(Malassezia 
sympodialis)
This allergen of Malassezia sympodialis is a Cyclophilin, 
recognized by the 92% of the sensitized patients affected by 
atopic dermatitis.
B08
75 Mala s 11 Fungus 
(Malassezia 
sympodialis) 
This allergen of Malassezia sympodialis is a Manganese 
Superoxide Dismutase. In patients affected by atopic 
dermatitis, the sensitization to this allergen correlates to 
disease severity. It is highly cross-reacting with Asp f 6. 
B08
76 Mus m 1 Mouse urine 
 (Mus musculus) 
This major mouse allergen is a prealbumin and lipocalin–
odorant-binding protein belonging to the rodent family of 
major urinary proteins (MUP). MUPs are produced in the 
liver and other exocrine glands under hormonal control 
and secreted in urine. They seem to play a complex role in 
chemosensory signaling among rodents. 
B23
C07
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77 Ole e 1 Olive tree,  
Plane tree  
(Olea europaea) 
Ole e 1 is the most common sensitizing molecule in olive 
pollen. It is utilized in both diagnostic and therapeutic 
extracts for standardization purposes and can determine 
immunological changes after olive pollen AIT 
B01 
78 Par j 1 Pellitory 
(Parietaria judaica) 
Parietaria pollen is the only pollen whose major allergen, Par 
j 1, is a non-specific lipid transfer (nsLTP) protein. Accepted 
threshold pollen levels for sensitization are low and clinically, 
Parietaria pollinosis is often linked to asthma. 
B03
C03
79 Par j 2 Pellitory 
(Parietaria judaica) 
Par j 2, a non-specific lipid Transfer Protein, is a highly specific 
marker for sensitization to pellitory. 
B03
80 Pen a 1 Brown Shrimp 
(Penaeus aztecus) 
The shrimp major allergen, Pen a 1, is one of the most clinically 
relevant allergenic tropomyosins. Five major IgE binding sites on 
Pen a 1 have been identified that were cross-reactive epitopes 
among shrimp, lobster, house dust mite and cockroach. Its 
heat-stability partially explains its high allergenicity.
B13
C05
81 Per a 1 American Cockroach 
(Periplaneta ameri-
cana) 
Per a 1 is a midgut microvilli protein homologue from the 
American Cockroach It shows cross-reactivity with the 
homologous protein Bla o 1 from the German Cockroach. 
B05 
82 Per a 2 American 
Cockroach 
(Periplaneta 
americana) 
Per a 2 is an Aspartic protease-like from American Cockroach. 
Sensitization to Per a 2 has been recognized more frequently 
in patients with persistent asthma than in patients with 
rhinitis only, suggesting that this allergen could be a marker 
for more severe airway disease. 
B05
83 Per a 7 American 
Cockroach 
(Periplaneta 
americana) 
Per a 7 is a Tropomyosin from the American Cockroach. IgE 
binding frequency to cockroach and mite tropomyosins are 
very different according to different populations. Higher 
values in tropical Countries and lower in the US and Europe 
may reflect differences in environmental conditions. 
B05
C05
84 Phl p 1 Timothy grass 
(Phleum pratense) 
This major timothy grass pollen allergen is a marker of 
genuine, species-specific, sensitization. It shares epitopes 
with group 1 allergens from other grasses and shows IgE 
cross-reactivity to most other group 1 allergens from grasses, 
corns and monocots. Sensitization to Phl p 1 usually precedes 
other grass pollen sensitizations and its specific IgE response 
is the most prevalent in grass pollen allergic patients. 
B02
85 Phl p 4 Timothy grass 
(Phleum pratense) 
Phl p 4 is a tryptase-resistant glycoprotein. It can be classified 
as a major allergen. It shows IgE cross-reactivity with other 
group 4 grass pollen allergens. Moreover, cross-reactivity 
to the major ragweed allergen Amb a 1 and to Oilseed Rape 
pollen has been demonstrated. Natural Phl p 4 contains CCD, 
which may lead to IgE cross-reactivity with a wide range of 
plants and plant products. 
B02
86 Phl p 5 Timothy grass 
(Phleum pratense) 
Phl p 5 is another major pollen allergen of temperate grasses 
with a lower sensitization prevalence, but often with high IgE-
levels. Phl p 5 is a cytoplasmatic ribonuclease, important in 
the enzymatic degradation of RNA. It shows broad IgE cross- 
reactivity with other group 5 allergens from the Pooideae 
subfamily of temperate grasses. 
B02
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87 Phl p 7 Timothy grass 
(Phleum pratense) 
Phl p 7 and Phl p 12 are minor allergens, representing 
pan-allergens from the plant world. Phl p 7, polcalcin, is a 
calcium binding protein present in many different pollen, 
hence representing a broad cross-reacting allergen. Phl p 
7-sensitization can be used as a marker for a more general 
pollen sensitization. 
B02
C06
88 Phl p 12 Timothy grass 
Profilin 
(Phleum pratense) 
Phl p 12 is a member of the profilin family, an actin-binding 
protein that is present throughout the whole plant world. As 
profilins are ubiquitous in plant cells, profilin sensitization 
gives rise to a long range of cross-reacting plants and plant 
products as birch, soybean, corn, latex and plant foods. 
B02
C01
89 Pla a 1 Plane tree 
(Platanus 
acerifolia) 
Pla a 1 and Pla a 2 may serve as a marker of primary 
sensitization to plane tree pollen, therefore it is useful for 
AIT selection, whilst the nsLTP Pla a 3 has been linked with 
sensitization to plant-food LTPs 
B01 
90 Pla l 1 English plantain 
(Plantago 
lanceolata) 
Pla l 1, an Ole e 1-like protein, is a highly specific marker 
allergen for English plantain because of the limited cross-
reactivity with the other protein family members. 
B03
91 Pru p 3 Peach 
 (Prunus persica) 
Pru p 3 is the major allergen from peach. This molecule is a 
non-specific lipid transfer protein, a small protein stable at 
pH extremes, heat treatment and proteolytic digestion. It is 
concentrated in the pericarp of fruits, while the pulp contains 
levels approximately 220-fold lower than the peel. It shows 
from 62 to 81% of identity sequence with analogue protein 
from apple, apricot, plum, cherry, orange, strawberry, grape. 
Peach is the most frequent cause of nsLTP allergy, and 
Pru p 3-sensitization seems to play a precursor role in the 
sensitization to other nsLTPs. 
B15
C03
92 Pru p 4 Peach 
(Prunus persica) 
Pru p 4 is a Profilin from peach. Profilins are small proteins with 
ubiquitous expression throughout the plant kingdom. They 
are functional in various important cell-signalling pathways 
and bind actin. These small proteins are of intermediate to 
low stability when subjected to heat treatment. Sensitization 
to profilin is frequently observed in patients, however it often 
lacks clinical relevance. Allergens from the profilin family have 
been identified also in apple, pear, cherry and strawberry. 
B15
C01
93 Rat n 1 Rat urine 
(Rattus norvegicus) 
Analogous to mouse allergens, the major rat (Rattus 
norvegicus) allergen Rat n 1 is a prealbumin or alpha-2u-
globulin that belongs to the lipocalin group and to the family 
of MUPs (major urinary proteins). The amino acid identity 
between mouse and rat MUPs is approximately 65%. Urine 
collected from male rats contains much larger quantities of 
Rat n 1 than urine from female rats. 
B23
C07
94 Sal k 1 Russian thistle 
(Salsola kali) 
Sal k 1, a Pectin Methylesterase, is a marker of sensitization 
to Salsola. This allergen contains N-glycans, thus result might 
be false positive if the patient is CCD positive. 
B03
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95 Sal s 1 Atlantic Salmon 
(Salmo salar) 
The dominating major allergen in fish muscle is parvalbumin. 
Parvalbumins are small muscle proteins of remarkable 
stability towards physicochemical effects by food processing. 
During fish preparation, they can even become airborne. 
Parvalbumin levels vary considerably in different fish tissues 
and species. Most fish-allergic patients have specific IgE to 
these allergens. 
B12
C08
96 Sus s 1 Pig (Sus scrofa 
domestica) 
Sus s 1 is the pork albumin. Its cross-reactivity with cat 
albumin characterizes the cat pork syndrome. 
B14
97 Tri a 14 Wheat  
(Triticum aestivum) 
This molecule is a non-specific lipid transfer protein that has 
high heat stability and probably does not cross-react with 
grass pollen. It may be important both in wheat-dependent, 
exercise-induced anaphylaxis (WDEIA) and in some cases of 
food allergy. 
B16
C03
98 Tri a 19 Wheat  
(Triticum aestivum) 
Tri a 19 is a wheat seed storage protein. This molecule is 
an ω-5-gliadine not well represented in wheat extracts 
because of its poor aqueous solubility. 50%-70% of wheat 
allergic patients are sensitized to this allergen. Tri a 19 is 
often responsible for wheat-dependent, exercise-induced 
anaphylaxis (WDEIA). 
B16
99 Ves v 1 Yellow Jacket 
(Wasp)  
(Vespula vulgaris) 
This Phospholipase A1 is the major allergen and therefore 
marker protein in vespid venom allergy.
B21
100 Ves v 5 Yellow Jacket 
(Wasp) 
 (Vespula vulgaris) 
Ves v 5 is a marker protein for vespid venom allergy. It is a 
protein of unknown function but high abundance in the 
venom. With sensitization rates of 84.5 to 100% it is a major 
allergen. 
B21 
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affinity in immunology, a measure of the attraction 
or force of association between a single antigenic 
site and a single antibody to that site (Ka).
allergen extract a mixture of molecules (some 
allergens and others not allergens), typically 
composed of proteins, glycoproteins, lipoproteins, 
or protein-conjugated chemicals/drugs that have 
been solubilized from a defined (usually biological) 
source and that a portion of which can elicit an 
immunoglobulin E antibody response in exposed 
persons; 
Note: Allergen extracts have historically been referred to 
as “allergens” by diagnostic reagent manufacturers. This 
common practice should be replaced by the use of “allergen 
extract” to distinguish it from an allergen molecule.
allergen molecule individual native or recombinant 
allergen that has unique molecular and structural 
properties, including a defined molecular weight, 
isoelectric point, carbohydrate composition, 
nucleotide and/or amino acid sequence, and 
reactivity to a monospecific or monoclonal 
antibody. In addition, the allergenic property 
of the “major allergens” of a given allergen 
specificity needs to be verified by its ability 
to bind to immunoglobulin E antibody and/or 
induce a positive skin test or histamine release 
from basophils from individuals who are clinically 
allergic to that allergen specificity.
allergen source (raw) material the starting raw 
material from which allergenic extracts are 
obtained; 
Note: This material may or may not have been physically 
processed to remove extraneous, nonbiological materials, 
and it is typified by materials such as raw pollen, animal hair, 
mold cultures, drugs, venoms, foodstuffs, or recombinant 
expressed proteins.
allergenic epitope a submolecular structure or 
surface on the allergenic molecule that is primarily 
responsible for IgE antibody binding.
allergosorbent a solid phase material to which 
allergen extracts (mixtures of allergens) or 
individual native or recombinant allergen 
molecules are attached by covalent coupling 
methods or adsorption.
Taken with permission from [59]
Note: this list is not exhaustive and has not yet been agreed on by all 
authors. A complete glossary will be provided in the future editions of 
this manuscript
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antigen in immunology, any substance that can 
stimulate the production of antibodies by an 
organism and combine specifically with them.
analytical sensitivity quotient of the change in an 
indication and the corresponding change in the 
value of a quantity being measured (ISO 15193 );
Note 1: The term “analytical sensitivity” has been historically 
used to describe the lowest amount of a given substance in 
a biological specimen that is detectable in an assay system;
analytical specificity/selectivity ability of a 
measurement procedure to determine solely the 
quantity it purports to measure (ISO 1519323); 
Note 1: Analytical specificity (selectivity) refers in general to 
the ability of an assay to measure one particular substance, 
rather than others, in a sample. Applied to immunoglobulin E 
(IgE) assays with single allergens, “one particular substance” 
would indicate the repertoire of allergen-specific IgE to “one 
particular allergen molecule”; 
Note 2: In the previous editions of I/LA20, analytical 
specificity of IgE-detecting assays was solely linked to 
the capability to selectively measure IgE, instead of other 
immunoglobulin classes or subclasses (eg, immunoglobulin 
G, immunoglobulin M). This definition refers to the 
“antibody-related analytical specificity (selectivity)” of 
IgE-detecting assays and is still an important definition for 
modern immunoassays; 
Note 3: Allergen molecules for quantifying allergen-specific 
IgE will limit the detected IgE repertoire. Only antibodies 
binding to the selected molecule (eg, major cat allergen Fel 
d 1) will be detected instead of all allergen source-specific 
(eg, cat-specific) antibodies. Thus, the use of allergen 
molecules increases analytical specificity compared to 
the broad allergen-specific IgE repertoire directed toward 
a complex mixture of proteins in an extract (eg, from cat 
dander). This new definition refers to the “allergen-related 
analytical specificity (selectivity)” of IgE-detecting assays; 
Note 4: The term “allergen-related analytical specificity 
(selectivity)” is particularly useful to understand and 
justify the concept of species-specific vs cross-reactive 
IgE antibodies toward defined allergen molecules. In 
case of particular physicochemical properties of certain 
allergen molecules (eg, high pH and digestion stability, 
high abundance in an allergen source), IgE detection with 
these molecules might be helpful to identify risk-associated 
allergen-specific IgE responses.
component resolved diagnosis [see: Molecular-
based allergy diagnosis]  Due to the misleading 
definitions of component, “Component resolved 
diagnosis” has been relabeled as “Molecular-based 
allergy (MA) diagnostics.”
cross-reactivity in immunology, the reaction of an 
antibody with an antigen other than that which 
elicited its formation, as a result of shared, similar, 
or identical antigenic determinants; 
Note1: Within the context of this document, cross-
reactivity has two meanings. First, it refers to a human 
immunoglobulin E (IgE) antibody that binds to an allergenic 
epitope that is structurally similar to, but not identical 
with, the molecule that elicited its formation. Cross-
reactivity results from shared, similar, or identical allergenic 
determinants (allergen-related cross-reactivity). There are 
many illustrations of cross-reactive allergen molecules—
for example, among the Hymenoptera (vespid) venoms. 
Clinical cross-reactivity refers to the degree (percentage) 
of clinical reactions after exposure to taxonomically related 
allergen sources (eg, allergic reactions to goat’s milk in 
case of clinically proven IgE-mediated allergy to cow’s milk 
proteins). 
Note 2: Second, cross-reactivity can refer to the degree to 
which the monoclonal or polyclonal antihuman IgE detection 
reagents bind to other human immunoglobulin isotypes 
(immunoglobulin G, immunoglobulin A, immunoglobulin M, 
immunoglobulin D)) (antibody-related cross-reactivity).
epitope/determinant the minimum molecular 
structure of the antigenic site that will react with 
a monoclonal antibody; any site on an antigen 
molecule at which an antibody can bind; the 
chemical structure of the site determining the 
specific combining antibody; 
Note: In the context of immunoglobulin E (IgE) assays, 
allergenic epitopes are regions on allergens that bind directly 
to the IgE antibody binding site. They can be detected by 
monoclonal antibodies to 1) determine the level of allergens 
of a particular specificity in an environmental specimen (eg, 
Der p 1 and Der f 1 in house dust); and 2) demonstrate 
identity and qualify extracts during the manufacturing of 
allergen-containing reagents.
free immunoglobulin E (IgE) human IgE that 
circulates in blood in an unbound state, free 
of therapeutically administered humanized 
immunoglobulin G anti-IgE, soluble IgE receptors, 
or other binding factors; 
Note 1: Research assays for free IgE that use the alpha 
chain of the high affinity FcεR1 (fragment crystallizable-
epsilon receptor 1) as the IgE detection reagent have been 
studied but they are not commercially available; 
Note 2: See immunoglobulin E.
immunoglobulin E (IgE) human IgE is an 
immunoglobulin of the approximate molecular 
weight of 190 000, which exists normally in 
monomeric form and constitutes approximately 
0.0005% of the total serum immunoglobulins; 
Note: It binds with high affinity to FcεR1 (fragment 
crystallisable-epsilon receptor 1) mainly expressed on mast 
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cells and basophils and low affinity FcεR2 receptors on a 
number of other cells. IgE mediates the production and 
release of vasoactive mediators following the binding of 
allergen.
immunoglobulin a glycoprotein composed of two 
heavy and two light chains that functions as an 
antibody; 
Note 1: Human immunoglobulins have been subdivided 
into different classes or isotypes (immunoglobulin M, 
immunoglobulin G (IgG)1, IgG2, immunoglobulin G3, 
immunoglobulin G4, immunoglobulin A (IgA)1, IgA2, 
immunoglobulin D, immunoglobulin E [IgE]), each of which 
possesses a unique set of antigenic markers, physiochemical 
properties, and each of which produce a different pattern of 
effector functions (receptor binding, complement activation, 
opsonization). All antibodies are immunoglobulins, but it 
is not certain that all immunoglobulins possess antibody 
function;
isoallergens proteins (allergens) that are essentially 
identical except for minor differences in their 
primary amino acid composition or substituted 
side chains
Limit of detection (LoD)/minimum detectable 
dose lowest amount of analyte in a sample that 
can be detected with (stated) probability and 
defined accuracy (see also definition of analytical 
sensitivity)
Limits of Blank, Limits of Quantitation (LoQ) lowest 
amount of a measurand in a material that can be 
quantitatively determined with stated accuracy 
(as total error or as independent requirements 
for bias and precision), under stated experimental 
conditions.
major allergen generally regarded as an allergenic 
molecule to which >50% of clinically allergic 
patients with an allergy to its source react.
minor allergen generally regarded as an allergenic 
molecule to which <50% of clinically allergic 
patients with an allergy to its source react.
molecule-based allergy diagnosis (previously referred 
to as “Component resolved diagnosis”) diagnosis 
of human allergy risks by evaluation of 
immunoglobulin E antibody−based sensitization 
profiles to individual allergen molecules (eg, Amb 
a 1, first identified major allergen in common 
ragweed pollen); 
Note 1: Molecule-based allergy diagnosis allows distinction 
of sensitization to primary (genuine) sensitizing allergens (eg, 
Bet v 1, major allergen from birch pollen) from secondary or 
cross-reactivity sensitization produced by panallergens (eg, 
Bet v 2, profilin from birch pollen; Bet v 4, polcalcin from 
birch pollen) ; 
Note 2: Due to the misleading definitions of “component,” 
“component resolved diagnosis” has been relabeled as 
molecule-based allergy diagnosis.
multiplex assay a test delivering more than one test 
result based on a single addition of a test specimen; 
Note: Multiplex assays can be discriminated from 
singleplex assays where one addition of a specimen 
results in immunoglobulin E (IgE) antibody measurement 
to one allergen specificity. A multi-allergen screen is not 
a multiplex assay despite the fact that it has been shown 
by the manufacturer to detect IgE antibody to each of 
the individual allergens in a mixture with a single serum 
addition. This is because the multiple allergens are in one 
allergen-containing reagent and the multi-allergen screen 
generates a single result, which defines it as a singleplex 
assay.
native allergenic molecules allergenic proteins, 
glycoproteins, and lipoproteins that have 
been purified by chemical, chromatographic, 
electrophoretic and/or immunoaffinity techniques 
from allergen extracts of natural biological 
materials and that can elicit an IgE antibody 
response.
omalizumab for asthma and allergy patients who 
receive subcutaneous injections of omalizumab, 
which is a humanized immunoglobulin G1-kappa 
antihuman immunoglobulin E (IgE) fragment 
crystallizable (Fc) therapy, their IgE will exist in 
two states: free IgE (unbound with omalizumab) 
and complexed omalizumab-bound IgE, which 
is blocked by the anti-IgE from binding to the 
alpha chain of the high affinity FcεR1 (Fc-epsilon 
receptor 1); 
Note: Caution should be exercised when analyzing blood 
from allergy patients receiving omalizumab, since the 
therapeutically administered anti-IgE can alter the accuracy 
of some total and allergen-specific IgE assays.
qualitative assay an assay system that produces an 
indication of the presence or absence of an analyte 
but does not provide a precise estimate of the 
concentration of that analyte; a positive test result 
implies only that the assay signal exceeds the 
analytical threshold or positive cutoff point that 
has been set to obtain an arbitrary combination of 
diagnostic sensitivity and specificity; 
Note: A positive assay signal should relate to a certain 
presence of immunoglobulin E antibody specific to the 
allergen tested in the subject’s blood.
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quantitative assay an assay system that produces 
an accurate and reproducible estimate of the 
concentration of an analyte, such as immunoglobulin 
E (IgE) antibody, in the test specimen; its analysis 
can use homologous or heterologous interpolation 
from a calibration curve, which is referenced to a 
readily available standard reference preparation;
radioallergosorbent test (RAST) the acronym 
“RAST” should now be considered a historic term, 
because radioisotopes are rarely used today in 
clinical assays for immunoglobulin E (IgE) antibody; 
Note: In 1967, the RAST was developed as the first 
immunoassay system available for the measurement of 
human IgE antibodies to defined allergen specificities in 
human serum. In its original form, the RAST used a paper 
disc solid phase to which allergen was covalently attached 
(allergosorbent) to bind allergen-specific antibodies of all 
isotypes (primarily IgE, immunoglobulin G, immunoglobulin 
A) from serum. Following a buffer wash to remove unbound 
serum proteins, bound IgE was detected with I125-labeled 
polyclonal antihuman IgE. Results were reported in log-
related classes or in arbitrary units by interpolation from 
a heterologous IgE antibirch pollen reference curve. Many 
minor modifications of this original assay format have been 
commercialized and they are discussed in the text. When 
referring to serological IgE antibody assays, the term RAST 
should no longer be used as a generic descriptor to refer 
to an IgE antibody assay unless it describes a radioisotopic 
allergosorbent assay for human IgE antibody.
recombinant allergen molecules an allergenic 
molecule is produced in a heterologous cell system 
using a recombinant gene construct encoding the 
allergenic protein; 
Note: A description of the process of cloning, sequencing, 
transfecting expression vectors, and expressing allergenic 
peptides and proteins is beyond the scope of I/LA20. 
Some immunoglobulin E antibody assays currently use 
recombinant allergens to supplement natural allergen 
extracts and replace labile, low abundance, or absent 
allergens (eg, rHev b 5 in the Hevea brasiliensis latex–
containing reagent).
semi-quantitative assay a semiquantitative assay 
system provides an additional option over the 
qualitative assay in terms of defining the magnitude 
of the response. The variations in the positive signal 
detected by the assay are commonly presented in 
terms of a series of increasing grades or classes 
(eg, I to VI, low to high); in arbitrarily defined units 
per milliliter determined relative to a supplier-
specific heterologous dose-response curve or 
an end-point dilution at which the assay signal 
becomes negative (eg, titer); or in comparison to a 
qualitative grading scheme (eg, color chart); 
Note: Allergen-specific immunoglobulin E assays that 
use normalized counts generated in two-point calibrated, 
modified, or alternative scoring systems are considered 
semiquantitative assays unless demonstrated otherwise. 
Classes, grades, or modified scoring units are considered 
historical reporting schemes that are out of date and should 
thus not be used.
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AAI Adrenalin Autoinjector
AAI Alpha-Amylase Inhibitors
ABPA Allergic Bronchopulmonary 
Aspergillosis
ACEI Angiotensin Converting Enzyme 
Inhibitors
AD Atopic Dermatitis
AEC Absolute Eosinophil Count
aGAL Alpha-GAL
AIT Allergen Specific Immunotherapy
AK Arginine kinase
AllFam Allergen protein Families
AR Allergic Rhinitis
ASA Acetylsalicylic Acid
BAMSE Swedish abbreviation for Children, 
Allergy, Milieu, Stockholm, 
Epidemiology
BAT Basophil Activation Test
BHR Bronchial Hyper-Reactivity
BP Birch Pollen
BSA Bovine Serum Albumin
Bt Blomia tropicalis
CCD(s) Cross-reactive Carbohydrate 
Determinant(s)
CF Cystic Fibrosis
CLSI Clinical Laboratory Standards Institute
CM Cow’s milk
CMA Cow’s Milk Allergy 
CRD Component Resolved Diagnostics
CRP Carbohydrate-Rich Protein
CSBP Cytokinin-Specific Binding Proteins
CT Computed Tomography
CXCL Chemokine (C-X-C motif) Ligand 8
DBPCFC Double-Blind Placebo Controlled Oral 
Food Challenge
Df Dermatophagoides farinae
Dp Dermatophagoides pteronyssinus
DPBB Double-Psi Beta-Barrel
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DPP IV Dipeptidylpeptidases IV
EAACI European Academy of Allergy and 
Clinical Immunology
EASI Eczema Area and Severity Index
EC Environmental Control
ECRHS European Community Respiratory 
Health Survey
EF-hand Conserved domain consisting of a 12 
residue calcium-binding loop flanked 
on both sides by α-helices of 12 
residues in length
EIA Exercise-Induced Anaphylaxis
ELISA Enzyme-Linked Immunosorbent Assay
EMD Emergency Department
EoE Eosinophilic Esophagitis
EPIT Epicutaneous Immunotherapy
ER Emergency Room
FA Food Allergy
FAST Food Allergy Specific ImmunoTherapy 
Here:
Title of an EU-project that aims at the 
development of safe and effective 
treatment of food allergies
FcεRI High affinity receptor for the Fc part 
of IgE
FDEIA Food-Dependent Exercise-Induced 
Anaphylaxis
FPIES Food Protein-induced Enterocolitis 
Syndrome
fuc Fucose
GA2LEN Global Allergy and Asthma European 
Network
GCP Good Clinical Practices
GlcNAc N-acetylglucosamine
GMP Good Manufacturing Practices
GP Grass Pollen
GST Glutathione-S-Transferase
HB Honeybee
HBV Honeybee Venom
HCW Health-Care Workers
HDM House Dust Mite
HEPA High-Efficiency Particulate Arrestance
HMW High Molecular Weight
HRP horseradish peroxidase
HSA Human Serum Albumin
HWP Hydrolyzed Wheat Protein
Ig Immunoglobulin
IL (4….) Interleukin (4…)
ISAC Immune Solid phase Allergen Chip
ISU ISAC Standardized Units
IT Immunotherapy
IU International Unit
IUIS International Union of Immunological 
Societies
LAA Laboratory animal allergy
LAR Local Allergic Rhinitis
LLR Local reaction?
LMW Low Molecular Weight
LoB Limit of Blank
LoD Limit of Detection
LoQ Limit of Quantitation
LS lactose synthase
LTP Lipid Transfer Protein
MA Molecular based Allergy
man Mannose
MD2 Myeloid Differentiation Factor 2
MeDALL Mechanisms of the Development of 
ALLergy
MHC Major Histocompatibility Complex 
MLC Myosin light chain
MLC Myosin Light Chain
MLP Major Latex Proteins
MnSOD Manganese-dependent Superoxide 
Dismutase
MSP Male-specific Submaxillary Gland 
Protein
MUP Major Urinary Proteins
MUXF3 Carbohydrate epitope which is found 
in many plant proteins (see “Glossary” 
for more information)
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MW Molecular Weight
MYA Million Years Ago
N.A. Not Applicable
NCBI National Center for Biotechnology 
Information
ND Not Determined
NMR Nuclear Magnetic Resonance 
NPC2 Niemann-Pick disease, type C2
NPV Negative Predictive Value
NRL Natural Rubber Latex
NSAID Nonsteroidal Anti-Inflammatory Drugs
NSB Non-Specific Binding
nsLTP Non-specific Lipid Transfer Protein
OAS Oral Allergy Syndrome
OEFC Open Exercise Food Challenge
OFC Oral Food Challenge
OIT Oral Immunotherapy
PAMPS Pathogen Associated Molecular 
Patterns
PAR Protease-Activated Receptor
PBMC Peripheral Blood Mononuclear Cell
PDB Protein Databank 
Pfam Protein family
POCT Point-Of-Care Testing
PPT Prick by Prick Test
PPV Positive Predictive Value
PR-10 (2, 
3, 5, 14)
Pathogenesis Related Protein Group 
10 (2,3,5,14)
PSA Porcine Serum Albumin
PW Paper Wasp
RAST Radioallergosorbent Test
REF Rubber Elongation Factor
ROC Receiver Operating Characteristics
RRP Ripening-Related Proteins
SAFE European Study on Plant Food 
Allergies (Full title: ‘Plant food 
allergies: field to table strategies for 
reducing their incidence in Europe’)
SCBP Sarcoplasmic calcium binding protein
SCIT Subcutaneous Injection 
immunotherapy
SDAP Structural Database of Allergenic 
Proteins
SIT Specific Immunotherapy
slgE Specific Immunoglobulin E
SLIT Sublingual Immunotherapy
SOB Shortness Of Breath
SOTI Specific Oral Tolerance Induction 
SPT Skin Prick Tests
SR Systemic Reaction
TH1 T Helper 1 Cell
TH2 T Helper 2 Cell
TIM Triose phosphate isomerase
tlgE total Immunoglobulin E
TLR Toll-Like Receptor
TM Tropomyosin
TnC Troponin C
TNF Tumor Necrosis Factor
TVP Textured Vegetable Protein
UCSF University of California, San Francisco
UV Ultraviolet
VIT Venom Specific Immunotherapy
VV Vespid Venom
WDEIA Wheat-Dependent, Exercise-Induced 
Anaphylaxis
WHO World Health Organization
YJ Yellow Jacket 
YJV Yellow Jacket Venom
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